PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Eliopoulos, AG; Stack, M; Dawson, CW; Kaye, KM; Hodgkin, L; Sihota, S; Rowe, M; Young, LS				Eliopoulos, AG; Stack, M; Dawson, CW; Kaye, KM; Hodgkin, L; Sihota, S; Rowe, M; Young, LS			Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappa B pathway involving TNF receptor-associated factors	ONCOGENE			English	Article						LMP1; CD40; TRAF; IL6; NF-kappa B; keratinocytes	LATENT MEMBRANE-PROTEIN; ZINC-FINGER PROTEIN; TRANSFORMING PROTEIN; TRANSCRIPTION FACTOR; ACTIVATION MOLECULE; CYTOPLASMIC DOMAIN; INTERLEUKIN-6 GENE; T-LYMPHOCYTES; UP-REGULATION; IN-VITRO	Expression of the Epstein-Barr virus (EBV) transforming LMP1 in B cells activates the transcription factor NF-kappa B and induces phenotypic changes through two distinct domains in the cytoplasmic C-terminus of the protein, The aa 187-231 domain of LMP1, which is important for growth transformation, binds tumour necrosis factor (TNF) receptor associated factor (TRAF) 1 and TRAF3 and this interaction mediates subsequent signalling events, The TRAFs also associate with CD40, a member of the TNFR family, which upon ligation activates NF-kappa B and induces phenotypic changes similar to those mediated by LMP1. This study demonstrates that LMP1 expression in carcinoma cell lines and SV40-transformed keratinocytes results in induction of the pleiotropic cytokine interleukin 6 (IL6), an effect which is also observed upon CD40 Ligation. The mechanism by which either LMP1 expression or CD40 ligation induces IL6 production was found to be NF-kappa B-dependent. Mutational analysis identified domains in the C-terminus of LMP1 which are important for NF-KB activation and IL6 secretion, LMP1 and CD40 share a common PxQxT core TRAF binding motif and mutations in or adjacent to this sequence impaired the ability of LMP1 or CD40 to induce NF-kappa B activation and IL6 secretion, The importance of TRAF interactions in mediating these effects was confirmed using dominant negative TRAF2 and TRAF3 mutants which also identified differences in the signalling events mediated by the two NF-kappa B activating domains of LMP1. A20, an anti-apoptotic protein which interacts with TRAF2 and blocks CD40-mediated NF-kappa B activity, also blocked NF-kappa B and IL6 secretion in LMP1-transfected epithelial cells, These results suggest that LMP1 regulates IL6 production in epithelial cells in a manner similar to CD40 ligation and implicate TRAFs as common mediators in the transduction of signals generated via the CD40 and LMP1 pathways, As a role for IL6 in regulating epithelial cell growth has previously been suggested, the control of IL6 secretion via the CD4O and LMP1 pathways may have implications for the growth of both normal and transformed epithelial cells.	UNIV BIRMINGHAM,SCH MED,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	University of Birmingham; Cardiff University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			ELIOPOULOS, ARISTIDES/ABI-6632-2020; Rowe, Martin/B-2880-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; Young, Lawrence S/B-7213-2009	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1990, J IMMUNOL, V145, P1400; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; GAJEWSKI TF, 1995, J IMMUNOL, V154, P5637; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENDERSON SA, 1994, SEMIN VIROL, V5, P391, DOI 10.1006/smvy.1994.1043; HESS S, 1995, J IMMUNOL, V155, P4588; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Jaattela M, 1996, J IMMUNOL, V156, P1166; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KATIRA A, 1995, LEUKOCYTE TYPING, V5; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liebowitz David, 1993, P107; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; STADNYK AW, 1994, FASEB J, V8, P1041, DOI 10.1096/fasebj.8.13.7926369; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TAKIZAWA H, 1993, CANCER RES, V53, P4175; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; Young L S, 1992, Semin Cancer Biol, V3, P273; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	65	225	230	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2899	2916		10.1038/sj.onc.1201258	http://dx.doi.org/10.1038/sj.onc.1201258			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205097				2022-12-28	WOS:A1997XF55500004
J	Yang, TT; Namba, H; Hara, T; Takmura, N; Nagayama, Y; Fukata, S; Ishikawa, N; Kuma, K; Ito, K; Yamashita, S				Yang, TT; Namba, H; Hara, T; Takmura, N; Nagayama, Y; Fukata, S; Ishikawa, N; Kuma, K; Ito, K; Yamashita, S			p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells	ONCOGENE			English	Article						ionizing radiation; p53; DNA end-jointing; apoptosis; thyroid cell; thyroid carcinoma	WILD-TYPE P53; SEQUENCE SIMILARITY; ONCOGENE ACTIVATION; HIGH PREVALENCE; CYCLE CONTROL; EARLY EVENT; GENE; DEATH; BCL-2; EXPRESSION	To understand the effects of ionizing radiation on thyroid cells, we investigated the role of p53 in mediating apoptosis and in DNA repair following in vivo and in vitro irradiation of thyroid cells, In vitro exposure of human thyroid cells to ionizing radiation of up to 5-8 Gy failed to induce apoptosis in primary cells, The same results were obtained when the thyroid gland was irradiated in the intact rat, To explore the mechanism of failure of the wild-type p53 in inducing apoptosis in thyroid cells, we investigated the expression of apoptosis-related genes, bar, bcl-2 and fas/APO-1 following irradiation or induction of temperature-sensitive p53. The expression of Bar, Bcl-2 and Fas/APO-1 in human primary cultured thyroid cells did not change after irradiation, To further confirm the results, we established a clonal cell line (tsFRO) in which a temperature sensitive p53 (Val138) expression vector was stably transfected to a thyroid carcinoma cell line lacking endogenous p53, Incubation of tsFRO cells at the permissive temperature for three days, however, did not induce apoptosis although G(1) arrest was noted, Although enhanced expression of the bar mRNA level was observed, the expression of Bar, Bcl-2 and Fas/APO-1 protein did not change by shifting tsFRO cells to permissive temperature as well as irradiated primary cells, Furthermore, DNA end-jointing ability was examined by transfection of linearized luciferase plasmid into tsFRO cells, Increased luciferase activity occurred when the cells were cultured at the permissive temperature, indicating that the mild-type p53 enhances DNA end-jointing activity, Our results indicate that the wild-type p53 does not lead to apoptosis but facilitates DNA end-jointing in thyroid cells, These results may reflect specific responses in thyroid cells following irradiation.	NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT CELL PHYSIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; ITO HOSP,TOKYO 150,JAPAN; KUMA HOSP,KOBE 650,JAPAN	Nagasaki University; Nagasaki University; Kuma Hospital			Ting-Ting, YANG/E-6009-2010; Yamashita, Shunichi/GVS-9508-2022	Ting-Ting, YANG/0000-0001-5975-8359; Yamashita, Shunichi/0000-0001-6399-6261				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRIER F, 1994, J BIOL CHEM, V269, P32672; DEGROOT LJ, 1986, CURRENT THERAPY ENDO, P92; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; Fagin JA, 1996, CANCER RES, V56, P765; FAGIN JA, 1994, ANNU REV MED, V45, P45; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GORCZYCA W, 1992, CANCER RES, V52, P3491; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1992, CANCER RES, V52, P1369; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWABE Y, 1989, J CLIN ENDOCR METAB, V68, P1174, DOI 10.1210/jcem-68-6-1174; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitada S, 1996, ONCOGENE, V12, P187; Klugbauer S, 1995, ONCOGENE, V11, P2459; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEMOINE NR, 1989, ONCOGENE, V4, P159; LIN EY, 1993, J IMMUNOL, V151, P1979; LOWE SW, 1993, NATURE, V362, P786; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MIKIFOROV YE, 1996, ONCOGENE, V13, P687; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAGATAKI S, 1989, LANCET, V2, P385; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NAMBA H, 1993, ENDOCRINOLOGY, V132, P839, DOI 10.1210/en.132.2.839; NAMBA H, 1995, CANCER RES, V55, P2075; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Santoro M, 1996, ONCOGENE, V12, P1821; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER AB, 1985, MEDICINE, V64, P1; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMATO K, 1995, ONCOGENE, V11, P1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1994, ONCOGENE, V9, P3743	69	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1511	1519		10.1038/sj.onc.1200979	http://dx.doi.org/10.1038/sj.onc.1200979			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129141				2022-12-28	WOS:A1997WQ54800001
J	Chen, WD; Otterson, GA; Lipkowitz, S; Khleif, SN; Coxon, AB; Kaye, FJ				Chen, WD; Otterson, GA; Lipkowitz, S; Khleif, SN; Coxon, AB; Kaye, FJ			Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding	ONCOGENE			English	Article						apoptosis; chemotherapy; cysteine protease; FAS; retinoblastoma protein	RETINOBLASTOMA GENE-PRODUCT; LUNG-CANCER; GROWTH SUPPRESSION; CELL-LINES; PROTEIN; IDENTIFICATION; DOMAIN; CLONING; MEMBER; FAMILY	Dephosphorylation of the RE protein has been reported to be associated with apoptosis, In contrast, we show that treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial cells with alpha-FAS is associated with the cleavage of a 5 kDa fragment from the C-terminus of RE, resulting in a truncated product that we have designated as p100cl. This cleavage event coincides with the activation of cysteine proteases at the onset of apoptosis, is blocked by the addition of iodoacetamide to cells prior to the onset of apoptosis, and results in the expression of faster migrating protein species which can mimic dephosphorylated RE. The free 5 kDa fragment is detected only during apoptosis, predicts a cleavage site that we have mapped to a unique CPP32-like recognition sequence which is present at the C-terminus of all reported RE homologues, and results in a truncated RE protein with enhanced E2F binding affinity, While the causality for this cleavage event in the apoptotic process is still under investigation, our findings suggest distinct post-translational pathways for the RE product between cells examined during growth arrest (p105 hypophosphorylated RE) or apoptosis (p100cl).	USN,NCI,MED ONCOL BRANCH,DIV CLIN SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			CHEN, WEI-DONG/F-4521-2014; kaye, frederic/E-2437-2011	CHEN, WEI-DONG/0000-0003-2264-5515; 				BING A, 1996, CANCER RES, V56, P438; CARNEY DN, 1985, CANCER RES, V45, P2913; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAYOL X, 1993, ONCOGENE, V8, P2561; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEVINS JR, 1992, SCIENCE, V258, P424; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837	24	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1243	1248		10.1038/sj.onc.1201096	http://dx.doi.org/10.1038/sj.onc.1201096			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121775				2022-12-28	WOS:A1997WM78200015
J	Taniguchi, T; Okamoto, K; Reeve, AE				Taniguchi, T; Okamoto, K; Reeve, AE			Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour	ONCOGENE			English	Article						Wilms tumour; genomic imprinting; H19; IGF2; p57(KIP2)	GROWTH-FACTOR-II; DEPENDENT KINASE INHIBITOR; H19 GENE; MOUSE; RELAXATION; LOCUS; HETEROZYGOSITY; DELETION; DISRUPTION; CARCINOMA	Mouse p57(Kip2) arrests cells in G(1) by functioning as a strong inhibitor of several G(1) cyclin/Cdk complexes (Lee et al., 1995; Matsuoka et al., 1995; Sherr and Roberts, 1995), Human p57(K1P2) has been suggested to be a tumour suppressor gene because of its location at 11p15.5 which frequently undergoes maternal allele LOH in several types of cancer (Matsuoka et al., 1995; Sherr and Roberts, 1995; Hatada and Mukai, 1995), This suggestion was supported by the discovery that mouse p57(Kip2) is imprinted with expression from only the maternally inherited allele (Hatada and Mukai, 1995), Interestingly, p57(K1P2) is several hundred kilobases from the imprinted H19 and IGF2 genes which are involved in growth regulation (Hoovers et al., 1995), Here we show that human p57(K1P2) is imprinted with expression from the maternal allele, However, unlike the mouse, the imprinting is incomplete with significant expression from the paternal allele depending on the tissue examined, We have also shown that the imprinting of p57(K1P2) occurs independently of the H19/IGF2 domain and thus there must be at least two imprinted domains in 11p15.5. Finally, by examining Wilms tumours we have shown that following maternal 11p LOH, p57(K1P2) was expressed from the paternal allele, Therefore, p57(K1P2) cannot function as an imprinted tumour suppressor gene, at least in Wilms tumour.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND	University of Otago								BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BYRNE JA, 1993, GENE CHROMOSOME CANC, V7, P1; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOOVERS JMN, 1995, P NATL ACAD SCI USA, V92, P12346; JEN J, 1994, CANCER RES, V54, P6353; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; Orlow I, 1996, CANCER RES, V56, P1219; PAL N, 1990, ONCOGENE, V5, P1665; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reid LH, 1996, CANCER RES, V56, P1214; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	39	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1201	1206		10.1038/sj.onc.1200934	http://dx.doi.org/10.1038/sj.onc.1200934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121769	Bronze			2022-12-28	WOS:A1997WM78200009
J	Cohen, S; Regev, A; Lavi, S				Cohen, S; Regev, A; Lavi, S			Small polydispersed circular DNA (spcDNA) in human cells: Association with genomic instability	ONCOGENE			English	Article						genomic instability; spcDNA; two dimensional electrophoresis gene amplification; cancer; mutator phenotype	HAMSTER EMBRYO CELLS; GENE AMPLIFICATION; MITOCHONDRIAL-DNA; EXTRACHROMOSOMAL DNA; MOUSE 3T6-CELLS; HELA-CELLS; SEQUENCES; ELEMENT; MECHANISMS; SATELLITE	Small Polydispersed Circular DNA (spcDNA) was suggested to be associated with genetically unstable cells. However, until now, qualitative and quantitative research has been limited due to the lack of efficient methods for detection and analysis. We developed a two-dimensional (2-D) neutral-neutral gel electrophoresis assay for the identification, characterisation and quantitation of spcDNA. Using this method, we established the relation of spcDNA to genetic and induced genomic instability in human cells, both in vitro and in vivo. Enhanced amounts of spcDNA were found in genetically unstable cells and tissues. spcDNA was detected in a tumor cell-line (HeLa) and in tumor tissue (colon carcinoma) as well as in fibroblasts derived from patients suffering from the genomic instability disease, Fanconi's Anemia. We failed to detect spcDNA in the genetically stable normal human fibroblasts. However, following treatment with the initiating carcinogen MNNG, an induction of spcDNA was observed. The level of spcDNA was quantified according to mitochondrial DNA (mtDNA) standards. In light of these findings, we discuss the possible role of spcDNA as a marker and an enhancer of genomic instability.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ASSUM G, 1993, HUM GENET, V91, P489; BERKOFLINT Y, 1990, MOL CELL BIOL, V10, P75, DOI 10.1128/MCB.10.1.75; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen S, 1996, MOL CELL BIOL, V16, P2002; DELAP RJ, 1978, PLASMID, V1, P508, DOI 10.1016/0147-619X(78)90008-2; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FLORES SC, 1988, NUCLEIC ACIDS RES, V16, P3889, DOI 10.1093/nar/16.9.3889; FRIEDBERG EC, 1995, DNA REPAIR; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GAUBATZ JW, 1990, MUTAT RES, V237, P29, DOI 10.1016/0921-8734(90)90029-Q; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; GOLDSTEIN S, 1984, MOL CELL BIOCHEM, V64, P15, DOI 10.1007/BF00420924; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLIS M, 1986, GENE, V46, P153, DOI 10.1016/0378-1119(86)90399-9; JONES RS, 1985, NUCLEIC ACIDS RES, V13, P1027, DOI 10.1093/nar/13.3.1027; KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; KOWALD A, 1993, MUTAT RES, V295, P93, DOI 10.1016/0921-8734(93)90011-Q; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; KUNISADA T, 1984, GENE, V31, P213, DOI 10.1016/0378-1119(84)90212-9; KUNISADA T, 1987, J MOL BIOL, V198, P557, DOI 10.1016/0022-2836(87)90199-9; KUNISADA T, 1985, MECH AGEING DEV, V29, P89, DOI 10.1016/0047-6374(85)90050-8; KUNISADA T, 1983, PLASMID, V9, P8, DOI 10.1016/0147-619X(83)90027-6; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LAVI S, 1981, CARCINOGENESIS, V2, P417, DOI 10.1093/carcin/2.5.417; LAVI S, 1982, GENE AMPLIFICATION, P225; LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6; LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732; MISRA R, 1989, NUCLEIC ACIDS RES, V17, P8327, DOI 10.1093/nar/17.20.8327; MISRA R, 1987, J MOL BIOL, V196, P233, DOI 10.1016/0022-2836(87)90687-5; MOTEJLEK K, 1993, MUTAT RES, V293, P205, DOI 10.1016/0921-8777(93)90071-N; NEIDLINGER C, 1988, HUM GENET, V79, P286, DOI 10.1007/BF00366254; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; RIABOWOL K, 1985, NUCLEIC ACIDS RES, V3, P5563; RIO DC, 1990, ANNU REV GENET, V24, P543; RUIZ JC, 1989, MOL CELL BIOL, V9, P109, DOI 10.1128/MCB.9.1.109; RUSH MG, 1985, PLASMID, V14, P177, DOI 10.1016/0147-619X(85)90001-0; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SMITH CA, 1972, J MOL BIOL, V69, P163, DOI 10.1016/0022-2836(72)90222-7; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUNNERHAGEN P, 1986, NUCLEIC ACIDS RES, V14, P7823, DOI 10.1093/nar/14.20.7823; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; TLSTY T, 1982, GENE AMPLIFICATION, P231; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; WAHL GM, 1989, CANCER RES, V49, P1333; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YAMAGISHI H, 1985, MECH AGEING DEV, V29, P101, DOI 10.1016/0047-6374(85)90051-X; YAMAGISHI H, 1986, BIOESSAYS, V4, P218, DOI 10.1002/bies.950040508	56	80	85	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					977	985		10.1038/sj.onc.1200917	http://dx.doi.org/10.1038/sj.onc.1200917			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050997				2022-12-28	WOS:A1997WK34400011
J	Olshan, AF; Weissler, MC; Pei, H; Conway, K; Anderson, S; Fried, DB; Yarbrough, WG				Olshan, AF; Weissler, MC; Pei, H; Conway, K; Anderson, S; Fried, DB; Yarbrough, WG			Alterations of the p16 gene in head and neck cancer: Frequency and association with p53, PRAD-1 and HPV	ONCOGENE			English	Article						head and neck neoplasms; mutation; p53; p16INK44; HPV; PRAD-1	SQUAMOUS-CELL CARCINOMA; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; HOMOZYGOUS DELETIONS; ALTERED EXPRESSION; FAMILIAL MELANOMA; SUPPRESSOR GENES; INHIBITOR GENE; MTS1 GENE; TUMORS	Alterations, especially homozygous deletions, of the putative tumor suppressor gene, p16 (p16(INK4A), MTS1, CDKN2) have been found in tumor cell lines from a variety of neoplasms. Recent studies have reported frequent p16 gene deletions in cell lines from squamous cell carcinomas of the head and neck (SCCHN), although the prevalence of alterations was variable in primary tumors. This study determined the prevalence of point mutations and deletions of the p16 gene in 33 SCCHN. In addition, the association of p16 gene alterations and abnormalities of p53, PRAD-1 (cyclin D1), and the presence of human papillomavirus (HPV) was examined. We found an overall prevalence of p16 alterations of 36% (nine deletions, three single base substitutions, including one polymorphism). Seven tumors (of 29, 24%) had an alteration of p16 and p53; five (of 33, 15%) had alterations of p16 and PRAD-1; three (of 29, 10%) had alterations of all three genes. In addition, of the five tumors with human papillomavirus detected, only one also had a p16 gene alteration. The results indicate a potentially important role for the p16 gene in head and neck tumorigenesis. In addition, the presence of tumors with multiple somatic gene alterations suggest a possible interaction in the dysregulation of the cell cycle.	UNIV N CAROLINA,SCH MED,DIV OTOLARYNGOL HEAD & NECK SURG,CHAPEL HILL,NC 27599; LAB CORP AMER,DEPT MOL BIOL & PATHOL,RES TRIANGLE PK,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Olshan, AF (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC, USA.							AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Bauer HM, 1992, DIAGNOSTIC MOL PATHO, V2, P131; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; GRANA X, 1995, ONCOGENE, V11, P211; GRUIS NA, 1995, AM J PATHOL, V146, P1199; HANNON GJ, 1994, NATURE, V371, P357; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIU ET, 1993, SEMIN CANCER BIOL, V4, P47; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAWROZ H, 1994, CANCER RES, V54, P1152; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Yeudall WA, 1995, ORAL ONCOL, V31B, P291, DOI 10.1016/0964-1955(95)00028-3; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; YOO GH, 1994, CANCER RES, V54, P4603; ZHANG SY, 1994, CANCER RES, V54, P50; ZHOU XL, 1994, ONCOGENE, V9, P3737	49	79	79	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					811	818		10.1038/sj.onc.1200892	http://dx.doi.org/10.1038/sj.onc.1200892			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047388				2022-12-28	WOS:A1997WJ11200007
J	Cosgaya, JM; Perona, R; Aranda, A				Cosgaya, JM; Perona, R; Aranda, A			Retinoic acid induces secretion of transforming growth factors by PC12 pheochromocytoma cells	ONCOGENE			English	Article						retinoic acid; PC12 conditioned medium; TGF-beta 1	FACTOR-BETA; EXPRESSION; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1; DIFFERENTIATION; INDUCTION; RECEPTORS; PROMOTER; LINES; SUPERFAMILY	Conditioned medium from PC12 cells incubated with retinoic acid (RA) increases [H-3]thymidine incorporation in normal rat kidney (NRK) fibroblasts and 3D9 epithelial cells. The medium also causes anchorage-independent growth of NRK cells, which is strongly potentiated either in the presence of EGF or after activation of latent forms of transforming growth factors (TGFs) by acidification. These results suggest that RA regulates the release of more than one growth factor by PC12 cells. Conditioned media from control or NGF-treated PC12 cells causes growth of NRK cells in soft agar only after acidification. An increase in expression of the TGF-beta 1 gene is coincident with NGF-induced neuronal differentiation of PC12 cells. In addition, RA also causes a dose- and time-dependent increase in content of TGF-beta 1 transcripts. This increase is, at least in part, secondary to transcriptional activation. Sequences responsible for the effect of RA and NGF are located in the 5'-flanking region of the TGF-beta 1 gene. The TFG-beta 1 gene has two promoters and in transient transfection assays RA and NGF significantly enhance the activity of constructs containing the second promoter, High-affinity TGF-beta 1 receptors were undetectable in PC12 cells both before and after NGF or RA treatment. RA and NGF decrease PC12 cell proliferation and a neutralizing anti-TGF-beta 1 antibody does not reverse this inhibition. In summary, an increase in expression and secretion of TGF-beta 1 accompanies RA and NGF-induced PC12 cell growth arrest, but TGF-beta 1 does not play an autocrine role in this inhibition.	CSIC, INST INVEST BIOMED, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916				ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN PS, 1995, CANCER RES, V55, P2380; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cosgaya JM, 1996, J NEUROCHEM, V66, P89; COSGAYA JM, 1995, J NEUROCHEM, V65, P2484; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; FALK LA, 1991, BLOOD, V77, P1248; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUSUHARA M, 1992, CANCER RES, V52, P3011; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; MONIER S, 1994, CLIN EXP RHEUMATOL, V12, P595; PETERSON EP, 1994, J CELL PHYSIOL, V159, P551, DOI 10.1002/jcp.1041590319; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANZOELEN EJJ, 1993, GROWTH FACTORS, V9, P329, DOI 10.3109/08977199308991593; VANZOELEN EJJ, 1986, J BIOL CHEM, V261, P5003	35	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					579	587		10.1038/sj.onc.1200865	http://dx.doi.org/10.1038/sj.onc.1200865			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053856				2022-12-28	WOS:A1997WF52400009
J	Leverrier, Y; Thomas, J; Perkins, GR; Mangeney, M; Collins, MKL; Marvel, J				Leverrier, Y; Thomas, J; Perkins, GR; Mangeney, M; Collins, MKL; Marvel, J			In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways	ONCOGENE			English	Article						apoptosis; Bcl-X; survival; IL-3; MAP-kinase	HEMATOPOIETIC-CELLS; CALCIUM IONOPHORES; BCL-2 PROTECTION; C-MYC; DEATH; GROWTH; INTERLEUKIN-3; SUPPRESSION; ACTIVATION; EXPRESSION	The inhibition of cell death by growth factors plays a key role in the maintenance of the haematopoietic system homeostasis. However the mechanisms involved in this inhibition are still poorly understood. In order to determine if inhibition of apoptosis by growth factors is dependent only on the expression of survival genes, we have studied that process in the bone marrow derived IL-3 dependent cell line Baf-3. We show that, following IL-3 starvation, mRNA and protein levels of Bcl-X but not Bcl-2 decrease rapidly preceeding the onset of death. The death of IL-3 starved cells is asynchronous, starting between 6 to 8 h with 50% death being reached after 10 to 12 h. At any time point, apoptosis can be rapidly inhibited by growth factor re-addition, This has allowed us to determine that the inhibition of apoptosis by growth factor takes place at two levels. The first one, which we have called short term inhibition, is independent of mRNA and protein synthesis i.e. it takes place in the absence of survival gene neosynthesis and can be demonstrated during the first 6 h following growth factor re-addition. The second one corresponds to long-term survival-more than 24 h survival-and is strongly correlated with the induction of Bcl-X but not Bcl-2 gene expression. This induction of Bcl-X by IL3 is shown to be dependent on MAP-kinase activation.	ECOLE NORMALE SUPER LYON,LBMC,CNRS UMR49,INRA LA 913,F-69364 LYON 07,FRANCE; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			LEVERRIER, Yann/M-3767-2014; marvel, jacqueline/H-8638-2014	LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; Mangeney, Marianne/0000-0002-9102-191X; Thomas, Joelle/0000-0002-0461-6131				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LIENHARD GE, 1994, NATURE, V372, P128, DOI 10.1038/372128a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTANI H, 1993, J BIOL CHEM, V268, P22733; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	35	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					425	430		10.1038/sj.onc.1200845	http://dx.doi.org/10.1038/sj.onc.1200845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053839				2022-12-28	WOS:A1997WE36400005
J	Waridel, F; Estreicher, A; Bron, L; Flaman, JM; Fontolliet, C; Monnier, P; Frebourg, T; Iggo, R				Waridel, F; Estreicher, A; Bron, L; Flaman, JM; Fontolliet, C; Monnier, P; Frebourg, T; Iggo, R			Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract	ONCOGENE			English	Article						p53 functional assay; head and neck cancer; preneoplastic lesions	SQUAMOUS-CELL CARCINOMA; GENE-MUTATIONS; FUNCTIONAL ASSAY; NECK-CANCER; HEAD; DIAGNOSIS; TUMORS	Field cancerisation of the aerodigestive tract is caused by chronic exposure to alcohol and tobacco, but the nature of the genetic alterations preceding overt malignancy is unknown. To identify potential field changes we have used a functional assay which tests the transcriptional competence of human p53 expressed in yeast, To increase the sensitivity and reliability of the technique for samples containing under 20% mutant p53, the 5' and 3'-ends of the p53 cDNA were examined separately. With this split form of the assay the tissue p53 mRNA acts as its own control for RNA quality. Mutations were detected in 87% (46/53) of tumours, reflecting the high sensitivity of the technique, Multiple biopsies of histologically normal tissue from the upper aero-digestive tract were tested and clonal p53 mutations were identified in 76% (38/50) of biopsies from patients presenting with multiple tumours compared with 32% (38/117) of biopsies from patients presenting with single tumours (P<0.000001). AU patients (16/16) presenting with multiple tumours had at least one positive biopsy, compared with only 53% (19/36) of patients presenting with single tumours (P<0.001), This defines expansion of multiple clones of mutant p53-containing cells as an important biological mechanism of field cancerisation, and provides a means to identify patients likely to benefit from intensive screening for the development of new head and neck tumours.	SWISS INST EXPT CANC RES,ONCOGENE GRP,ISREC,CH-1066 EPALINGES,SWITZERLAND; CHU VAUDOIS,UNIV HOSP,SERV OTORHINOLARYNGOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,UNIV HOSP,PATHOL SERV,CH-1011 LAUSANNE,SWITZERLAND; CHU ROUEN,MOL GENET UNIT,F-76031 ROUEN,FRANCE	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Rouen			Flaman, Jean-Michel/K-8415-2018; Frebourg, Thierry/AAK-8390-2020; Iggo, Richard/G-3546-2014	Flaman, Jean-Michel/0000-0003-3544-0199; Estreicher, Anne/0000-0001-6828-2508				BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHUNG KY, 1993, CANCER RES, V53, P1676; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; Flaman JM, 1996, ONCOGENE, V12, P813; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; MAO L, 1994, CANCER RES, V54, P1634; NEES M, 1993, CANCER RES, V53, P4189; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; SAVARY M, 1991, ADV OTO-RHINO-LARYNG, V46, P165; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306	18	148	150	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					163	169		10.1038/sj.onc.1200812	http://dx.doi.org/10.1038/sj.onc.1200812			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010218				2022-12-28	WOS:A1997WC81800004
J	Marks, JR; Huper, G; Vaughn, JP; Davis, PL; Norris, J; McDonnell, DP; Wiseman, RW; Futreal, PA; Iglehart, JD				Marks, JR; Huper, G; Vaughn, JP; Davis, PL; Norris, J; McDonnell, DP; Wiseman, RW; Futreal, PA; Iglehart, JD			BRCA1 expression is not directly responsive to estrogen	ONCOGENE			English	Article						BRCA1; estrogen response; cell cycle; antiestrogen; proliferation	BREAST-CANCER-CELLS; GROWTH-FACTOR; GENE; RECEPTOR; MUTATIONS; TISSUES; DIFFERENTIATION; TRANSCRIPTION; ANTIESTROGENS; CULTURE	Expression of the breast cancer susceptibility gene, BRCA1, is induced by 17-beta estradiol (E(2)) in estrogen receptor containing breast cancer cell lines, Our previous studies have shown that BRCA1 transcription is also regulated with the cell cycle, reaching maximal levels just before the onset of DNA synthesis, In this study, we have examined whether the estrogen induction of BRCA1 is direct or is a result of the mitogenic activity of the hormone, Four lines of evidence lead us to conclude that E(2) induces BRCA1 primarily through an increase in DNA synthesis: (1) The kinetics and magnitude of induction are different from the directly E(2) inducible gene, pS2; (2) Induction of BRCA1, but not pS2, is blocked by cycloheximide indicating that de novo protein synthesis is required; (3) Other hormonal and growth factor treatments that induce DNA synthesis have a similar effect, including IGF-1, EGF and DNA synthetic flares induced by tamoxifen and retinoic acid; (4) BRCA1 genomic fragments near the 5' end of the gene containing putative estrogen response elements fail to respond to E(2) when transfected into breast cancer cell lines, The most consistent explanation for these findings and other published studies is that BRCA1 transcription is induced as a result of the mitogenic activity of E(2) in estrogen receptor positive cells.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; NIEHS, MOL CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA; DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Marks, JR (corresponding author), DUKE UNIV, MED CTR, DEPT SURG, BOX 3873, DURHAM, NC 27710 USA.			Norris, John/0000-0001-6553-8053	NATIONAL CANCER INSTITUTE [P50CA068438, R01CA061218] Funding Source: NIH RePORTER; NCI NIH HHS [CA68438, CA63786, CA61218] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; FORD D, 1995, AM J HUM GENET, V57, P1457; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; IMAI Y, 1982, CANCER RES, V42, P4394; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARKS JR, 1989, J VIROL, V63, P790, DOI 10.1128/JVI.63.2.790-797.1989; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; RAMKUMAR T, 1995, ENDOCRINOLOGY, V136, P536, DOI 10.1210/en.136.2.536; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; ZEIMET AG, 1994, J STEROID BIOCHEM, V49, P365, DOI 10.1016/0960-0760(94)90281-X	37	99	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					115	121		10.1038/sj.onc.1200808	http://dx.doi.org/10.1038/sj.onc.1200808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010238				2022-12-28	WOS:A1997WB76000011
J	Aprelikova, O; Kuthiala, A; Bessho, M; Ethier, S; Liu, ET				Aprelikova, O; Kuthiala, A; Bessho, M; Ethier, S; Liu, ET			BRCA1 protein level is not affected by peptide growth factors in MCF1OA cell line	ONCOGENE			English	Article						breast cancer; BRCA1 protein; cell cycle; EGF; NDF	OVARIAN-CANCER; BREAST-CANCER; MUTATIONS; FAMILIES; GENE; LOCALIZATION; EXPRESSION	The breast cancer susceptibility gene (BRCA1) has been identified as a putative tumor suppressor on chromosome 17. We raised antibody against Ring-finger domain of BRCA1, The antibody recognizes a specific BRCA1 protein doublet of about 220 kD, The majority of BRCA1 protein is localized to the nuclear fraction of untreated MCF10A cells. Though BRCA1 is thought to be a growth suppressor gene, no change in BRCA1 protein level was found when MCF10A cells were arrested by growth factor deprivation or stimulation of cell proliferation by re-addition of growth factors, Furthermore the subcellular localization of the BRCA1 protein does not change throughout the cell cycle, These results suggest that BRCA1 may not be directly involved in the regulation of the cell cycle of breast cancer cell line.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,DIV RADIAT & CANC BIOL,ANN ARBOR,MI 48109	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan			Liu, Edison/C-4141-2008					CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDAS JM, 1995, CANCER RES, V55, P4561; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P444; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	17	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2487	2491						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957093				2022-12-28	WOS:A1996VX10800024
J	Florenes, VA; Bhattacharya, N; Bani, MR; BenDavid, Y; Kerbel, RS; Slingerland, JM				Florenes, VA; Bhattacharya, N; Bani, MR; BenDavid, Y; Kerbel, RS; Slingerland, JM			TGF-beta mediated G(1) arrest in a human melanoma cell line lacking p15(INK4B): Evidence for cooperation between p21(Cip1/WAF1) and p27	ONCOGENE			English	Article						G(1) arrest; TGF-beta; p15(INK4B)-negative; p27(Kip1); p21(Cip1/WAF1); melanoma	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE-PRODUCT; CYCLE ARREST; CDK INHIBITOR; DNA-REPLICATION; MAMMALIAN-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; EPITHELIAL-CELLS; PROTEIN	We have studied TGF-beta mediated G(1) arrest in WM35, an early stage human melanoma cell line. These cells have lost p15(INK4B) expression through loss of one chromosome 9 and rearrangement of the other. In asynchronously growing WM35, TGF-beta caused reductions in cyclin D1, cyclin A and cdk4 proteins and their associated kinase activities and an increase in both p21(Cip1/WAF1) and p27(Kip1). These findings were confirmed in cells released from quiescence in the presence of TGF-beta, in which TGF-beta inhibited or delayed the reduction in the cdk inhibitors that normally occurs in late G(1). In contrast to observations in other cell types, there was an increased association of both p21(Cip1/WAF1) and p27(Kip1) with cyclin D1/cdk4 and with cyclin E/cdk2 during TGF-beta mediated arrest of asynchronously growing cells. Upregulation of p21(Cip1/WAF1) preceded that of p27(Kip1). Furthermore, p21(Cip1/WAF1) and p27(Kip1) were not present in the same cdk complexes but bound distinct populations of target cdk molecules. Both p21(Cip1/WAF1) and p27(Kip1) immunoprecipitates from asynchronously growing cells contained active kinase complexes. These KIP-associated kinase activities were reduced in TGF-beta arrested cells. It has been proposed that in TGF-beta arrested epithelial cells, up-regulation of p15(INK4B) and of p15(INK4B) binding to cdk4 serves to destabilize the association of p27(Kip1) with cyclin D1/cdk4, promoting p27(Kip1) binding and inhibition of cyclin E/cdk2. Our findings demonstrate that this is not a universal mechanism of G(1) arrest by TGF-beta, In TGF-beta arrested WM35, which lack p15(INK4B), the increased p21(Cip1/WAF1) may serve a similar function to that of p15(INK4B): initiating kinase inhibition and providing an additional mechanism to supplement the effect of p27(Kip1) on G(1) cyclin/cdks.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED BIOPHYS, DIV CANC BIOL, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center					NCI NIH HHS [CA41233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Bani MR, 1996, CANCER RES, V56, P3075; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; Enders GH, 1996, ONCOGENE, V12, P1239; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAMER IM, 1994, J CELL SCI, V107, P3469; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIU L, 1995, ONCOGENE, V11, P405; LIU L, 1995, UNPUB ONCOGENE; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MAELANDSMO GM, IN PRESS AM J PATHOL; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEI WQ, 1996, CANCER RES, V56, P264; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Petrocelli T, 1996, ONCOGENE, V12, P1387; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODECK U, 1994, CANCER RES, V54, P575; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND J, 1996, UNPUB; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Welch DR, 1996, MOL CELL DIFFER, V4, P91; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	80	84	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2447	2457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957087				2022-12-28	WOS:A1996VX10800018
J	Hardiman, G; Rock, FL; Balasubramanian, S; Kastelein, RA; Bazan, JF				Hardiman, G; Rock, FL; Balasubramanian, S; Kastelein, RA; Bazan, JF			Molecular characterization and modular analysis of human MyD88	ONCOGENE			English	Article						MyD88; death domain; dendritic cells; interleukin-1 receptor; Toll; cloning	PROTEIN SECONDARY STRUCTURE; MESSENGER-RNA DEGRADATION; IMMEDIATE EARLY RESPONSE; DROSOPHILA TOLL PROTEIN; FACTOR TNF RECEPTOR; RESISTANCE GENE-N; DEATH DOMAIN; SIGNAL-TRANSDUCTION; CELL-DEATH; TERMINAL DIFFERENTIATION	MyD88 was first characterized as a myeloid differentiation primary response gene in mice, activated in M1 myeloleukemic cells following interleukin-6 (IL-6) induced growth arrest and terminal differentiation. Analysis of expressed sequence tags (ESTs) from activated dendritic cell libraries led to the indentification of cDNAs encoding the human homolog (hMyD88). The original description of MyD88 as a 243 aa protein may reflect a truncated mouse cDNA since the 2682 nt hMyD88 cDNA predicts a 296 aa cytoplasmic protein. Consistent with this proposal is the detection of a 33 kDa protein in human heart, kidney and liver tissue. The expression pattern of MyD88 is also more widespread than originally believed: a 2.6 kb hMyD88 mRNA species was found to be constitutively expressed in many adult human tissues; in addition MyD88 expression was observed in monocyte, T, B, NK and dendritic cells. The MyD88 protein has a modular structure composed of an N-terminal 'death domain' (DD) similar to the intracellular segments of TNF receptor 1 (TNFR1) and FAS and a C-terminal region related to the signaling domains of vertebrate interleukin-1 receptors (IL-1R) and the Drosophila morphogen Toll. This intriguing structural framework may endow MyD88 with unique signaling capabilities	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Bazan, J. Fernando/B-4562-2010	Hardiman, Gary/0000-0003-4558-0400				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Bazan JF, 1996, PROTEINS, V24, P1; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROOKS JW, 1994, EUR CYTOKINE NETW, V5, P547; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CAOPONE MC, 1996, J IMMUNOL, V157, P969; CAUX C, 1995, J IMMUNOL, V155, P5427; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; CHIANG C, 1994, MECH DEVELOP, V47, P225; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; ELDON E, 1994, DEVELOPMENT, V120, P885; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ITOH N, 1993, J BIOL CHEM, V268, P10932; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOVENBERG TL, 1996, IN PRESS J NEUROIMMU; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Parnet P, 1996, J BIOL CHEM, V271, P3967; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1909, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STINGL G, 1995, IMMUNOL TODAY, V16, P330, DOI 10.1016/0167-5699(95)80148-0; STJOHNSTON D, 1992, CELL, V68, P201; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9	63	98	109	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2467	2475						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957090				2022-12-28	WOS:A1996VX10800021
J	Shu, JY; Hitomi, M; Stacey, D				Shu, JY; Hitomi, M; Stacey, D			Activation of JNK/SAPK pathway is not directly inhibitory for cell cycle progression in NIH3T3 cells	ONCOGENE			English	Article						JNK; SAPK; kinase; cell cycle; growth inhibition; c-jun	NERVE GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; DNA-DAMAGING AGENTS; C-JUN; TYROSINE KINASE; PC12 CELLS; TRANSCRIPTION FACTOR; RAS ACTIVITY; MITOGEN	In this study the induction of stress activated protein kinase (SAPK) activity by protein synthesis inhibitors was shown not to inhibit cellular proliferation. Anisomycin induced strong SAPK activity at non-inhibitory concentrations for either protein or DNA synthesis, while the other two inhibitors, emetine and cycloheximide, blocked cell cycle progression without strong SAPK induction. With all three inhibitors, the induction of SAPK activity was always accompanied by protein synthesis inhibition to some extent. Stimulation of mRNA expression of the genes c-jun, c-fos and c-myc correlated well with SAPK induction, but not with cell cycle inhibition. With concentrations of each inhibitor able to block DNA synthesis, no induction of message for the cyclin dependent kinase inhibitor waf-1 was observed;,while induction of gadd45 message indicated that the cells might be responding to growth-arrest or DNA damage. The inability of microinjected E2F/DP1 transcription factor proteins to overcome the inhibition of DNA synthesis induced by protein synthesis inhibitors indicate that blockage of an early event in cell cycle progression had occurred. These results indicate that the SAPK induction by protein synthesis inhibitors has no proliferative consequences.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BIRD TA, 1994, J BIOL CHEM, V269, P31836; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Franklin CC, 1995, ONCOGENE, V11, P2365; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; HARPER JW, 1993, CELL, V75, P805; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHU JY, 1994, CELL IMMUNOL, V159, P170, DOI 10.1006/cimm.1994.1305; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	74	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2421	2430						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957084				2022-12-28	WOS:A1996VX10800015
J	Lutz, W; Schwab, M				Lutz, W; Schwab, M			In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; N-myc; amplification; gene regulation; E2F; Spl	HUMAN NEURO-BLASTOMA; GROWTH-FACTOR RECEPTOR; LIGATION-MEDIATED PCR; ZINC-FINGER PROTEIN; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO; GENE AMPLIFICATION; BINDING-PROTEIN; NUCLEAR FACTOR	Amplification with subsequent overexpression of N-myc is a recurrent genomic alteration of neuroblastoma cells, DMS-in-vivo-footprinting of the basal promoter of the human N-myc gene (positions -221 to +21) revealed three changes in promoter architecture that are clustered in a 50 bp region and included (1) protein binding to two overlapping E2F-sites, (2) extreme hypersensitivity of guanine -159, and (3) a short stretch of single stranded DNA with a single protected guanine. While in transient assays the basal promoter activated gene expression in all cell lines analysed, the changes at the endogenous promoter were restricted to neuroblastoma cells with strong N-myc expression. The hypersensitivity of guanine -159 could result from protein binding to a flanking, evolutionary conserved 5'-CCTCCC-3'-element, referred to as CT-box, that was bound in vitro in a Zn2+-requiring manner by a protein from nuclear extracts of neuroblastoma cells. Four copies of the CT-box in front of an N-myc minimal promoter (-60 to +18) activated expression of a reporter gene in transient transfections whereas four copies of the mutant element did not. Our data add N-myc to a growing list of mammalian genes with CT-boxes that bind proteins in a Zn2+-dependent manner. Moreover, the data suggest that a common mechanism controls N-myc expression in neuroblastomas irrespective of N-myc copy number, and that in cell lines with amplification all gene copies contribute to N-myc expression.			Lutz, W (corresponding author), GERMAN CANC RES CTR, DEPT CYTOGENET 0825, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							AMBER LC, 1989, MOL CELL BIOL, V9, P4903; AMBER LC, 1990, GENE CHROMOSOME CANC, V1, P181; Arts J, 1997, NUCLEIC ACIDS RES, V25, P311, DOI 10.1093/nar/25.2.311; ASSELIN C, 1989, ONCOGENE, V4, P549; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bennett JD, 1996, ONCOGENE, V13, P1073; Bosher JM, 1996, ONCOGENE, V13, P1701; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Brodeur G M, 1985, Prog Clin Biol Res, V175, P105; BUONO P, 1993, FEBS LETT, V328, P243, DOI 10.1016/0014-5793(93)80936-O; CHEN CJ, 1995, CANCER RES, V55, P3873; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HALL DJ, 1990, ONCOGENE, V5, P47; HARA E, 1993, ONCOGENE, V8, P1023; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILLER S, 1991, ONCOGENE, V6, P969; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; IBSON JM, 1988, ONCOGENE, V2, P399; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; Ince TA, 1996, CANCER RES, V56, P2021; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI RS, 1994, J BIOL CHEM, V269, P7941; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lutz W, 1996, ONCOGENE, V13, P803; MAJELLO B, 1995, ONCOGENE, V10, P1841; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Minucci S, 1996, EMBO J, V15, P888, DOI 10.1002/j.1460-2075.1996.tb00423.x; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PLET A, 1992, ONCOGENE, V7, P1847; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SADEE W, 1987, CANCER RES, V47, P5207; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; Shi YG, 1996, BIOCHEMISTRY-US, V35, P3845, DOI 10.1021/bi952384p; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WADA RK, 1992, ONCOGENE, V7, P711; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; XU L, 1995, ONCOGENE, V11, P1865; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	93	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					303	315		10.1038/sj.onc.1201195	http://dx.doi.org/10.1038/sj.onc.1201195			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233765	Bronze			2022-12-28	WOS:A1997XK99900007
J	Friedman, SL; Shaulian, E; Littlewood, T; Resnitzky, D; Oren, M				Friedman, SL; Shaulian, E; Littlewood, T; Resnitzky, D; Oren, M			Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells	ONCOGENE			English	Article						p53 tumor suppressor; pRb; hepatocellular carcinoma; apoptosis; differentiation	WILD-TYPE P53; HUMAN HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA GENE-PRODUCT; HEPATITIS-B VIRUS; MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL ANALYSIS; ERYTHROLEUKEMIA-CELLS; SUPPRESSOR GENES; PROTEIN; EXPRESSION	Mutations in the tumor suppressor p53 are a common event in hepatocellular carcinoma (HCC), Because HCCs typically occur in livers with chronic injury and impaired function, we have explored the role of mild-type p53 in regulating the growth and differentiation of Hep 3B hepatoma cells, a p53-negative line derived from a liver cancer, Stable Hep 3B cell lines were generated in which inducible p53 was introduced using either a temperature-sensitive mutant (p53val135) or a tamoxifen-regulated p53-estrogen receptor chimera (p53mER(tm)-pBabepuro), In both cell lines, induction of transcriptionally active p53 was confirmed by assessing several p53 targets: Mdm2 protein, p21(waf1) mRNA and protein, and the cyclin G promoter, Despite marked induction of p21(waf1), cells with active p53 failed to undergo growth arrest, which is probably due to the presence of a non-functional retinoblastoma protein (pRb) in these cells, Apoptosis also was not observed, even after prolonged (48 h) serum starvation or exposure to cisplatinum. Lack of apoptosis was correlated with unchanged bax mRNA levels following p53 induction, Additionally, albumin mRNA levels remained unchanged, and there was no change in basal transactivation of a reporter containing the promoter of the haptoglobin gene, encoding an acute phase protein, This suggests that growth arrest may be required to promote liver-specific gene expression, Overall, our data demonstrate that introduction of transcriptionally active p53 does not alter the malignant, dedifferentiated phenotype of Hep 3B hepatoma cells, Hence, not all cancer cells are equally responsive to the re-activation of wild-type 53, The ability of a cancer cell to undergo p53-mediated phenotypic alterations may depend on the retention of functional downstream effector pathways.	IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Friedman, SL (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.				NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline; NIDDK NIH HHS [R01 DK37340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chojkier M, 1995, Prog Liver Dis, V13, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Constance CM, 1996, MOL CELL BIOL, V16, P3878; DOERR R, 1989, CANCER RES, V49, P384; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOSONO S, 1993, ONCOGENE, V8, P491; HSIA CC, 1994, J MED VIROL, V44, P67, DOI 10.1002/jmv.1890440113; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEVINS JR, 1992, SCIENCE, V258, P424; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PUISIEUX A, 1993, ONCOGENE, V8, P487; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RAMSEY WH, 1995, DIGEST DIS, V13, P81, DOI 10.1159/000171490; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SEKI S, 1995, HUM PATHOL, V26, P366, DOI 10.1016/0046-8177(95)90135-3; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; TABOR E, 1994, J MED VIROL, V42, P357, DOI 10.1002/jmv.1890420406; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Vater CA, 1996, ONCOGENE, V13, P739; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG X, 1994, CANCER RES, V54, P4177	61	46	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					63	70		10.1038/sj.onc.1201149	http://dx.doi.org/10.1038/sj.onc.1201149			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233778	Bronze			2022-12-28	WOS:A1997XH58600007
J	Cappellen, D; deMedina, SGD; Chopin, D; Thiery, JP; Radvanyi, F				Cappellen, D; deMedina, SGD; Chopin, D; Thiery, JP; Radvanyi, F			Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder	ONCOGENE			English	Article						bladder; human; transitional cell carcinoma; tumour progression; chromosome 10; loss of heterozygosity	SUPPRESSOR LOCI; ALLELIC LOSS; PROSTATE-CANCER; MXI1 GENE; LONG ARM; DELETION; IDENTIFICATION; PROGRESSION; REGION; HYBRIDIZATION	Loss of heterozygosity (LOH) on chromosome 10 has been observed in several human cancers including glioblastomas, meningiomas, melanomas and endometrial and prostate carcinomas, We have investigated the incidence of LOH on chromosome 10 in 36 human transitional cell carcinomas (TCCs) of the bladder, three upper urinary tract TCCs and one lymph node metastasis, using a panel of 27 highly polymorphic markers spanning 10p (short arm) and 10q (long arm), Fourteen bladder tumours (39%), the three upper urinary tract tumours and the lymph node metastasis showed LOH for at least one locus on chromosome 10, Remarkably, LOH on chromosome 10 was observed mainly in muscle-invasive (P=0.01) and high grade tumours (P=0.03). For five tumours and the lymph node metastasis, LOH was found at all informative loci, indicating monosomy or isodisomy of chromosome 10, The deletion mapping of the tumours with partial loss delineated two minimal regions of loss on chromosome 10q, One region, the most telomeric, was bounded by markers D10S214 and D10S169 and the other, the most proximal, was bounded by markers D10S222 and D10S531, Our results demonstrate that chromosome 10q LOH is common in muscle-invasive bladder cancers and that two potential tumour suppressor loci, at 10q24.1-q24.3 and 10q26.1-q26.2, may contribute to the malignant progression of these tumours. Localization of the smallest common regions of loss in bladder tumours provides a starting point for the identification of the genes involved.	INST CURIE,CNRS,UMR 144,SECT RECH,F-75248 PARIS 05,FRANCE; CHU HENRI MONDOR,GRP ETUD TUMEURS UROL,F-94010 CRETEIL,FRANCE; CHU HENRI MONDOR,UROL SERV,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP			Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAROSA R, 1995, HUM GENET, V95, P709; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1991, ONCOGENE, V6, P2305; CHANG WYH, 1995, CANCER RES, V55, P3246; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIBAS Z, 1984, CANCER RES, V44, P1257; GRAY IC, 1995, CANCER RES, V55, P4800; HABUCHI T, 1995, ONCOGENE, V11, P1671; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mostofi FK, 1973, INT HISTOLOGICAL CLA; OLUMI AF, 1990, CANCER RES, V50, P7081; PEIFFER SL, 1995, CANCER RES, V55, P1922; POLASCIK TJ, 1995, CANCER RES, V55, P5396; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; ROSIN MP, 1995, CANCER RES, V55, P5213; RUPPERT JM, 1993, CANCER RES, V53, P5093; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SIMON M, 1995, CANCER RES, V55, P4696; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SPIESSL B, 1992, TNM ATLAS ILLUSTRATE, P214; SPRUCK CH, 1994, CANCER RES, V54, P784; Trybus TM, 1996, CANCER RES, V56, P2263; TSAI YC, 1990, CANCER RES, V50, P44; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	47	99	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3059	3066		10.1038/sj.onc.1201154	http://dx.doi.org/10.1038/sj.onc.1201154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223669				2022-12-28	WOS:A1997XG10000008
J	Berner, JM; MezaZepeda, LA; Kools, PFJ; Forus, A; Schoenmakers, EFPM; VandeVen, WJM; Fodstad, O; Myklebost, O				Berner, JM; MezaZepeda, LA; Kools, PFJ; Forus, A; Schoenmakers, EFPM; VandeVen, WJM; Fodstad, O; Myklebost, O			HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas	ONCOGENE			English	Article						chromosome 12q13-15; amplicon; MAR; MDM2; HMGIC	GENOMIC HYBRIDIZATION ANALYSIS; MULTIPLE-ABERRATION REGION; SOFT-TISSUE SARCOMAS; MESSENGER-RNA; SOLID TUMORS; AMPLIFICATION; PROTEIN; MDM2; EXPRESSION; GLI	Amplified segments of the long arm of chromosome 12 are frequently observed in human sarcomas, In most cases there are separate amplified regions around the MDM2 and CDK4 genes, Here we show recurrent amplification of a third region encompassing HMGIC, a human architectural transcription factor gene, Reduced amplification frequency of sequences flanking the gene was observed, indicating that inclusion of this third region in the amplicons is also selected for, In three samples only the 5' part of HMGIC was amplified, suggesting preferential loss of the 3' part of the gene preceding or during amplification, In several other samples rearrangement of the gene was observed, Expression analysis showed transcripts of aberrant sizes, lacking 3' sequences, and 3' RACE of one sample revealed replacement of exons 4 and 5 with ectopic sequences, This truncation of HMGIC resembles that reported for translocations of HMGIC in benign tumors, including Lipomas, and it is striking that the gene was frequently amplified or rearranged in web differentiated Liposarcomas, the malignant counterpart of lipomas, It seems conceivable that high levels of either full length or truncated hmgic could be relevant for the etiology of these tumors.	NORWEGIAN RADIUM HOSP, DEPT TUMOR BIOL, B-3000 OSLO, NORWAY; CATHOLIC UNIV LEUVEN VIB, CTR HUMAN GENET, MOL ONCOL LAB, LOUVAIN, BELGIUM	Flanders Institute for Biotechnology (VIB); KU Leuven			Meza-Zepeda, Leonardo Andres/CAG-5229-2022; Myklebost, Ola/E-9335-2010	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Myklebost, Ola/0000-0002-2866-3223				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; FORUS A, 1994, CANCER GENET CYTOGEN, V78, P165, DOI 10.1016/0165-4608(94)90085-X; FORUS A, 1991, CYTOGENET CELL GENET, V58, P1977; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kazmierczak B, 1996, ONCOGENE, V12, P515; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kools PFJ, 1996, CANCER GENET CYTOGEN, V91, P1, DOI 10.1016/S0165-4608(96)00109-4; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROBERTS WM, 1989, CANCER RES, V49, P5407; SCHAJOWICH F, 1993, HISTOLOGICAL TYPING; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SMITH SH, 1992, CANCER RES, V52, P3746; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; WANSCHURA S, 1995, GENE CHROMOSOME CANC, V14, P68, DOI 10.1002/gcc.2870140112; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	35	86	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2935	2941		10.1038/sj.onc.1201135	http://dx.doi.org/10.1038/sj.onc.1201135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205100				2022-12-28	WOS:A1997XF55500007
J	Makino, K; Kuwahara, H; Masuko, N; Nishiyama, Y; Morisaki, T; Sasaki, J; Nakao, M; Kuwano, A; Nakata, M; Ushio, Y; Saya, H				Makino, K; Kuwahara, H; Masuko, N; Nishiyama, Y; Morisaki, T; Sasaki, J; Nakao, M; Kuwano, A; Nakata, M; Ushio, Y; Saya, H			Cloning and characterization of NE-dlg: A novel human homolog of the Drosophila discs large (dlg) tumor suppressor protein interacts with the APC protein	ONCOGENE			English	Article						tumor suppressor genes; two-hybrid screening; chromosome Xq13; EST	MOLECULAR CHARACTERIZATION; GENE-PRODUCT; HUMAN GENOME; TIGHT; ZO-1; ASSOCIATION; JUNCTIONS; SEPTATE; SAP90	We have cloned a cDNA for a novel human homolog of the Dvosophila discs large (dig) tumor suppressor protein, termed NE-dlg (neuronal and endocrine dig). Northern blot analysis revealed that the gene is highly expressed in neuronal and endocrine tissues. Fluorescence in situ hybridization (FISH) and radiation hybrid mapping studies localized the NE-dlg gene to chromosome Xq13. We also found that the NE-dlg gene encoded a 100 kDa protein. Immunolocalization studies using an NE-dlg antibody showed that the protein tended to be expressed in non-proliferating cells, such as neurons, cells in Langerhans islets of the pancreas, myocytes of the heart muscles, and the prickle and functional layer cells of the esophageal epithelium. Proliferative cells, including various cultured cancer cell lines and basal cells in the esophageal epithelium, showed little expression of the NE-dlg protein. In addition, yeast true-hybrid screening and in vitro binding assays revealed that the NE-dlg interacted with the carboxyl-terminal region of the APC tumor suppressor protein. These data suggest that NE-dlg negatively regulates cell proliferation through its interaction with the APC protein.	KUMAMOTO UNIV, SCH MED, DEPT TUMOR GENET & BIOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT NEUROSURG, KUMAMOTO 860, JAPAN; EHIME UNIV, SCH MED, DEPT HYG EHIME, SHIGENOBU, EHIME 79102, JAPAN; SUMITOMO ELECT IND LTD, BIOMED R&D DEPT, YOKOHAMA, KANAGAWA 244, JAPAN	Kumamoto University; Kumamoto University; Ehime University; Sumitomo Electric Industries			Saya, Hideyuki/J-4325-2013					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUWANO A, 1991, AM J HUM GENET, V49, P707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MONROE KR, 1995, NAT MED, V1, P827, DOI 10.1038/nm0895-827; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; WATSON KL, 1994, J CELL SCI, P19; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	34	53	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2425	2433		10.1038/sj.onc.1201087	http://dx.doi.org/10.1038/sj.onc.1201087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188857				2022-12-28	WOS:A1997WZ68000006
J	Kalikin, LM; Frank, TS; SvobodaNewman, SM; Wetzel, JC; Cooney, KA; Petty, EM				Kalikin, LM; Frank, TS; SvobodaNewman, SM; Wetzel, JC; Cooney, KA; Petty, EM			A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors	ONCOGENE			English	Article						loss of heterozygosity; ovarian; breast; prostate; tumor suppressor; chromosome 17q25	CANCER; CHROMOSOME-17Q; MUTATIONS; DELETION; DISTAL; LOCUS; GENE	Chromosomal regions of allelic imbalance in tumors are predicted to define the general location of tumor suppressor genes, We previously localized a putative breast tumor suppressor gene to a 3 cM region on 17q25 by deletion mapping of microsatellite markers in breast tumors, To determine if the same 17q25 region of loss is important in the genesis of other tumor types, 32 ovarian tumors and 24 prostate tumors, as well as 33 additional breast tumors, were analysed with 17q25 polymorphic microsatellite markers, While no significant loss was observed in prostate tumors, greater than half of ovarian tumors exhibited loss coincident with the candidate region previously defined in breast tumors. These results suggest that one or more novel tumor suppressor genes exist on 17q25 within a concordant region of interstitial loss defined in both breast and ovarian neoplasms.	UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT SURG, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Cooney, Kathleen/0000-0003-3831-6943	NATIONAL CANCER INSTITUTE [K08CA066613, F32CA071166, P50CA069568] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA71166-01, P50CA69568, K08CA66613-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; Cooney KA, 1996, CANCER RES, V56, P1142; Cooney KA, 1996, CANCER RES, V56, P4150; ECCLES DM, 1992, ONCOGENE, V7, P2069; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; Foster JW, 1996, GENOMICS, V33, P185, DOI 10.1006/geno.1996.0182; Frank TS, 1996, DIAGN MOL PATHOL, V5, P220, DOI 10.1097/00019606-199609000-00012; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN MF, 1987, CANCER RES, V47, P5518; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; Schultz DC, 1996, CANCER RES, V56, P1997; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SKUSE GR, 1995, LANCET, V345, P902, DOI 10.1016/S0140-6736(95)90015-2; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Wertheim I, 1996, ONCOGENE, V12, P2147	24	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1991	1994		10.1038/sj.onc.1201013	http://dx.doi.org/10.1038/sj.onc.1201013			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150366				2022-12-28	WOS:A1997WV80400012
J	Toki, T; Itoh, J; Kitazawa, J; Arai, K; Hatakeyama, K; Akasaka, J; Igarashi, K; Nomura, N; Yokoyama, M; Yamamoto, M; Ito, E				Toki, T; Itoh, J; Kitazawa, J; Arai, K; Hatakeyama, K; Akasaka, J; Igarashi, K; Nomura, N; Yokoyama, M; Yamamoto, M; Ito, E			Human small Maf proteins form heterodimers with CNC family transcription factors and recognize the NF-E2 motif	ONCOGENE			English	Article						NF-E2; small Maf; MafK; MafG; Nrf1; Nrf2	DOMINANT CONTROL REGION; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; GLOBIN GENE; EXPRESSION; CLONING; ONCOGENE; SUBUNIT; COMPLEX; DOMAIN	The transcription factor NF-E2, a heterodimeric protein complex composed of p45 and small Maf family proteins, is considered crucial for the regulation of erythroid gene expression and platelet formation. To facilitate the characterization of NF-E2 functions in human cells, we isolated cDNAs encoding two members of the small Maf family, MafK and MafG. The human mafK and mafG genes encode proteins of 156 and 162 amino acid residues, respectively, whose deduced amino acid sequences show approximately 95% identity to their respective chicken counterparts. Expression of mafK mRNA is high in heart, skeletal muscle and placenta, whereas mafG mRNA is abundant in skeletal muscle and is moderately expressed in heart and brain. Both are expressed in all hematopoietic cell lines, including those of erythroid and megakaryocytic lineages. In electrophoretic gel mobility shift assays binding to NF-E2 sites was found to depend on formation of homodimers or heterodimers with p45 and p45-related CNC family proteins. The results suggest that the small Maf family proteins function in human cells through interaction with various basic-leucine zipper-type transcription factors.	HIROSAKI UNIV,SCH MED,DEPT PEDIAT,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,SCH MED,DEPT MED,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,FAC SCI,DEPT BIOL,HIROSAKI,AOMORI 036,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 98077,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,CTR TARA,TSUKUBA,IBARAKI 305,JAPAN; KAZUSA DNA INST,KISARAZU 292,JAPAN	Hirosaki University; Hirosaki University; Hirosaki University; Tohoku University; University of Tsukuba; University of Tsukuba; Kazusa DNA Research Institute			Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Ito, Etsuro/0000-0002-0168-2475; Igarashi, Kazuhiko/0000-0002-2470-2475				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KOMATSU N, 1991, CANCER RES, V51, P341; KOTLOW KJ, 1995, MOL CELL BIOL, V15, P4640; KOTLOW KJ, 1996, P NATL ACAD SCI USA, V93, P3514; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Toki T, 1996, BIOCHEM BIOPH RES CO, V219, P760, DOI 10.1006/bbrc.1996.0307; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384	30	99	104	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1901	1910		10.1038/sj.onc.1201024	http://dx.doi.org/10.1038/sj.onc.1201024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150357				2022-12-28	WOS:A1997WV80400003
J	Mohanam, S; Chintala, SK; Go, Y; Bhattacharya, A; Venkaiah, B; Boyd, D; Gokaslan, ZL; Sawaya, R; Rao, JS				Mohanam, S; Chintala, SK; Go, Y; Bhattacharya, A; Venkaiah, B; Boyd, D; Gokaslan, ZL; Sawaya, R; Rao, JS			In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor	ONCOGENE			English	Article						plasminogen activators; receptors; glioblastoma; invasiveness	PLASMINOGEN-ACTIVATOR RECEPTOR; TRANSFORMED HUMAN FIBROBLASTS; HUMAN GLIOMA-CELLS; UROKINASE RECEPTOR; MATRIX METALLOPROTEINASES; BREAST-CANCER; TUMOR-CELLS; IN-VITRO; INVASION; EXPRESSION	The cell surface urokinase-type plasminogen activator receptor (uPAR) has been shown to be a key molecule in regulating plasminogen-mediated extracellular proteolysis, To investigate the role of uPAR in invasion of brain tumors, human glioblastoma cell line SNB19 was stably transfected with a vector capable of expressing an antisense transcript complementary to the 300 base pair of the 5' end of the uPAR mRNA, Parental and stably transfected (vector, sense, and antisense) cell lines were analysed for uPAR mRNA transcript by Northern blot analysis, and receptor protein levels were measured by radioreceptor assays and Western blotting. Significant reduction of uPAR sites was observed in the antisense transfected cell lines, The levels of uPAR mRNA were significantly decreased in antisense clones compared to control, vector and sense clones, The invasive potential of the cell lines in vitro was measured by Matrigel invasion assay and migration of cells from spheroids to monolayers. The antisense transfected cells showed a markedly lower level of invasion and migration than the controls, The antisense clones were more adhesive to the ECM components compared to parental, vector and sense clones, All transfected (vector, sense and antisense) clones and parental cells produced similar levels of uPA activity without any significant difference however, MMP-2 activity was decreased in antisense clones compared to controls, These results demonstrate that uPAR expression is critical for the invasiveness of human gliomas and down regulation of uPAR expression may be a feasible approach to decrease invasiveness.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROSURG, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA058311, R01CA056792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58311, CA56792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; ANDERSSON C, 1993, INT J DEV NEUROSCI, V11, P555, DOI 10.1016/0736-5748(93)90045-F; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BIANCHI E, 1994, CANCER RES, V54, P861; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN RL, 1991, BLOOD, V78, P479; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; GLADSON CL, 1995, AM J PATHOL, V146, P1150; KARIKO K, 1993, CANCER RES, V53, P3109; KOBAYASHI H, 1993, BRIT J CANCER, V67, P537, DOI 10.1038/bjc.1993.99; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1992, CANCER RES, V52, P1018; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LUNDJOHANSEN M, 1990, SPHEROID CULTURE CAN, P3; MOHANAM S, 1993, CANCER RES, V53, P4143; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEDERSEN PH, 1993, CANCER RES, V53, P5158; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; POLLANEN J, 1991, ADV CANCER RES, V57, P273; QUATTRONE A, 1995, CANCER RES, V55, P90; QUATTRONE A, 1995, ANTI-CANCER DRUG DES, V10, P97; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUSSEL DC, 1989, PATHOL TUMOURS NER, P42; Saleh M, 1996, CANCER RES, V56, P393; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; STAHL A, 1994, CANCER RES, V54, P3066; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656	45	100	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1351	1359		10.1038/sj.onc.1200963	http://dx.doi.org/10.1038/sj.onc.1200963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178895				2022-12-28	WOS:A1997WP10900010
J	vanPuijenbroek, AAFL; vanWeering, DHJ; vandenBrink, CE; Bos, JL; vanderSaag, PT; deLaat, SW; denHertog, J				vanPuijenbroek, AAFL; vanWeering, DHJ; vandenBrink, CE; Bos, JL; vanderSaag, PT; deLaat, SW; denHertog, J			Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation	ONCOGENE			English	Article						Ret; ERK2; signal transduction; transcription; cell scattering; growth inhibition	NEURO-BLASTOMA CELLS; TRANSFORMING GENE; NEUROBLASTOMA-CELLS; RET/PTC ONCOGENE; PROTOONCOGENE; PROTEIN; EXPRESSION; MUTATIONS; GROWTH; SPECIFICITY	The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in kidney and enteric nervous system development. Germline mutations in c-ret are responsible for the dominantly inherited cancer syndromes, multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma as well as the developmental disorder Hirschsprung's disease. Using SK-N-MC neuroepithelioma cells stably transfected with an EGFR/Ret chimeric receptor, we have studied cellular consequences and signalling events following activation of exogenous EGFR/Ret and endogenous FGF and PDGF receptor tyrosine kinases in cells of neuroectodermal origin. Here we report that Ret activation led to cell scattering, growth inhibition and loss of anchorage-independent growth. Basic FGF, but not PDGF, evoked similar responses in those cells. Nevertheless, activation of all three receptor tyrosine kinases led to ERK2 activation. Analysis of the kinetics of ERK2 activation and downstream events revealed that Ret and FGF receptor activation led to sustained ERK2 activation and SRE transactivation, while PDGF treatment led to transient ERK2 activation and failed to induce SRE transactivation. Our results suggest that sustained, but not transient ERK2 activation may be involved in cell scattering.	UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3508 TA UTRECHT,NETHERLANDS	Utrecht University	vanPuijenbroek, AAFL (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,NL-3584 CT UTRECHT,NETHERLANDS.							ASAI N, 1995, MOL CELL BIOL, V15, P1613; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CALIFANO D, 1995, ONCOGENE, V11, P107; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DEHNER LP, 1986, ARCH PATHOL LAB MED, V110, P997; Duband JL, 1995, ACTA ANAT, V154, P63; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; SACHS A, 1996, J CELL BIOL, V133, P1095; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	59	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1147	1157		10.1038/sj.onc.1200911	http://dx.doi.org/10.1038/sj.onc.1200911			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121763				2022-12-28	WOS:A1997WM78200003
J	Bertrand, P; Rouillard, D; Boulet, A; Levalois, C; Soussi, T; Lopez, BS				Bertrand, P; Rouillard, D; Boulet, A; Levalois, C; Soussi, T; Lopez, BS			Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein	ONCOGENE			English	Article						homologous recombination; p53; genetic instability; tumoral progression	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; GENE AMPLIFICATION; CYCLE CHECKPOINT; DNA; INSTABILITY; ARREST; MUTATIONS; SEQUENCE	Homologous recombination plays an essential role in processes involved in genome stability/instability, such as molecular evolution, gene diversification, meiotic chromosome segregation, DNA repair and chromosomal rearrangements, p53 devoid cells exhibit predisposition to neoplasia, defects in G(1) checkpoint and high genetic instability but a normal rate of point mutations, We investigated the effect of a p53 mutation, on spontaneous homologous recombination between intrachromosomal direct repeat sequences, in mouse L cells. In these cells, wild type for the p53 gene, we have overexpressed the mutant p53(175)(Arg>His) protein leading to a p53 mutant phenotype, as verified by the absence of a G(1) arrest after gamma-irradiation. We show that the rate of spontaneous recombination is increased from five- to 20-fold in the mutant p53 lines, Moreover, this increase is observed in gene conversion as well as in deletion events, Our results provide new insights into the molecular mechanisms of genetic instability due to a defect of p53.	CEA,UMR 217 CNRS,DSV,DRR,F-92265 FONTENAY ROSES,FRANCE; INST CURIE,SECT RECH,F-75231 PARIS 05,FRANCE; INST CURIE,UMR 218 CNRS,SECT RECH,F-75231 PARIS 05,FRANCE	CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; soussi, thierry/0000-0001-8184-3293; BERTRAND, Pascale/0000-0002-9019-742X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, P783; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOLLAG RJ, 1992, MOL CELL BIOL, V12, P1546, DOI 10.1128/MCB.12.4.1546; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P6225, DOI 10.1073/pnas.93.13.6225; FINN GK, 1989, MOL CELL BIOL, V9, P4009, DOI 10.1128/MCB.9.9.4009; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P5643, DOI 10.1093/nar/15.14.5643; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luo CM, 1996, J BIOL CHEM, V271, P4497; Luria SE, 1943, GENETICS, V28, P491; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAGASAWA H, 1995, CANCER RES, V55, P1842; NISHINO H, 1995, ONCOGENE, V11, P263; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; STRUZBECHER HW, 1996, EMBO J, V15, P1992; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TYLER J, 1996, NATURE, V381, P643; WALDMAN AS, 1991, NUCLEIC ACIDS RES, V19, P5943, DOI 10.1093/nar/19.21.5943; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	47	135	138	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1117	1122		10.1038/sj.onc.1200931	http://dx.doi.org/10.1038/sj.onc.1200931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070661				2022-12-28	WOS:A1997WM07000014
J	Roberts, T; Cowell, JK				Roberts, T; Cowell, JK			Cloning of the human Gfi-1 gene and its mapping to chromosome region 1p22	ONCOGENE			English	Article						human Gfi gene; cDNA sequence; chromosome 1p22	TRANSLOCATION; PROTEIN	Recently the rat and mouse Growth Factor Independence (Gfi-1) genes have been cloned (Gilks et al., 1993; Zoring ed al; 1996), This gene allows cells in culture to overcome the depletion of growth factors in the culture medium and maintain their proliferative potential, As part of a cloning strategy to isolated genes from human chromosome 1p22 which are associated with a constitutional chromosome translocation from a patient with stage 4S neuroblastoma, we have identified the human homologue of the Gfi gene and defined a 50 Kb map position within a well characterised YAC contig from the region, The full length cDNA sequence is 81% homologous with the rodent counterparts and, at the protein level, is even more highly conserved.	CLEVELAND CLIN FDN,DEPT NEUROSCI,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Roberts, Terry/A-8211-2014	Cowell, John/0000-0002-2079-5950				BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BRODEUR GM, 1983, CANCER GENET CYTOGEN, V8, P93, DOI 10.1016/0165-4608(83)90041-9; CARBONE P, 1988, CANCER GENET CYTOGEN, V32, P143, DOI 10.1016/0165-4608(88)90321-4; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308; KOOLS PFJ, 1995, CANCER GENET CYTOGEN, V79, P1, DOI 10.1016/0165-4608(94)00137-Z; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; Zornig M, 1996, ONCOGENE, V12, P1789	10	19	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					1003	1005		10.1038/sj.onc.1200910	http://dx.doi.org/10.1038/sj.onc.1200910			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9051000				2022-12-28	WOS:A1997WK34400014
J	Tung, RM; Blenis, J				Tung, RM; Blenis, J			A novel human SPS1/STE20 homologue, KHS, activates jun N-terminal kinase	ONCOGENE			English	Article						STE20; JNK; GC kinase; MAP kinase signalling	PROTEIN-KINASE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; C-JUN; SH3 DOMAINS; BINDING DOMAINS; YEAST; IDENTIFICATION; PATHWAYS; FAMILY	STE20-homologous proteins have been implicated in mammalian MAP kinase pathways as important transducers of signals from p21 family GTPases. We have cloned a novel STE20 family member, which we call KHS for kinase homologous to SPS1/STE20, that encodes a kinase of 95 kD which is expressed in a variety of tissues. Transiently expressed fusion protein GST-KHS exhibits phosphotransferase activity toward a panel of test substrates, including myelin basic protein (MBP), which is phosphorylated by all known STE20 homologues, KHS is most closely related to another human STE20, GC kinase (74% similar in the catalytic domain), which has recently been placed upstream of the stress-activated MAP kinases (SAPKs/JNKs. KHS also activates JNK in transient coexpression experiments, suggesting a role for KHS in the stress response of fibroblasts. Characterization and comparison of the regulation of these two kinases mill be important in elucidating MAP kinase signalling cascades.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEMOTO T, 1994, J STEROID BIOCHEM, V50, P225, DOI 10.1016/0960-0760(94)90126-0; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; PLATH K, 1994, BIOCHEM BIOPH RES CO, V203, P1188, DOI 10.1006/bbrc.1994.2308; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	56	68	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					653	659		10.1038/sj.onc.1200877	http://dx.doi.org/10.1038/sj.onc.1200877			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038372				2022-12-28	WOS:A1997WG43000003
J	Jiang, HP; Lin, JJ; Tao, J; Fisher, PB				Jiang, HP; Lin, JJ; Tao, J; Fisher, PB			Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta	ONCOGENE			English	Article						interferon-beta; melanoma differentiation associated gene-20 (mda-20); ribosomal protein L23a; cell growth inhibition; antisense transcripts	BOVINE SEMINAL RIBONUCLEASE; DOUBLE-STRANDED-RNA; C-MYC GENE; MESSENGER-RNAS; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; 2-5A-DEPENDENT RNASE; DIFFERENTIATION; CLEAVAGE; SITE	Interferons inhibit cell growth in normal and tumor-derived cells. The molecular basis of interferons antiproliferative activity remains to be defined. Using subtraction hybridization, a human melanoma differentiation associated gene, mda-20, has been identified that is down-regulated by treatment with interferon. Sequence analysis indicates that mda-20 is human ribosomal protein L23a (rp L23a). The mRNA levels of rp L23a and growth are diminished in a variety of human tumor cell lines following treatment with human fibroblast interferon, interferon-beta (IFN-beta). Expression of rp L23a is also reduced in human melanoma cells treated with human leukocyte (IFN-alpha) and immune (IFN-gamma) interferons, but not by growth inhibition resulting from serum starvation. These findings suggest that growth suppression alone is not sufficient to reduce rp L23a expression. Instead, reduced rp L23a mRNA results from biochemical changes mediated by interferons. Ectopic expression of an antisense rp L23a sequence in human HeLa cervical carcinoma cells results in a reduction in colony formation indicating a direct antiproliferative effect by inhibiting rp L23a expression. The mechanism underlying inhibition in rp L23a expression in IFN-beta-treated cells may involve antisense rp L23a RNA. These results suggest that rp L23a may be one of the target molecules involved in mediating growth inhibition by interferon.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN MED CTR,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN MED CTR,DEPT UROL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital					NCI NIH HHS [CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BIRNBAUM M, 1990, DIFFERENTIATION, V45, P138, DOI 10.1111/j.1432-0436.1990.tb00467.x; CAFFARELLI E, 1984, EMBO J, V6, P3493; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHAN YL, 1995, BBA-GENE STRUCT EXPR, V1260, P113, DOI 10.1016/0167-4781(94)00193-7; CHATTERJEE D, 1992, CANCER CHEMOTH PHARM, V30, P12, DOI 10.1007/BF00686479; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELBARADI TTAL, 1985, EMBO J, V4, P2101, DOI 10.1002/j.1460-2075.1985.tb03898.x; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARBE C, 1993, J INVEST DERMATOL, V100, pS239; *GEN COMP GROUP, 1991, PROGR MAN; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GREINER JW, 1985, PHARMACOL THERAPEUT, V31, P209, DOI 10.1016/0163-7258(85)90023-3; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; JACOBS FA, 1985, EUR J BIOCHEM, V150, P255, DOI 10.1111/j.1432-1033.1985.tb09015.x; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LEGHA SS, 1989, SEMIN ONCOL, V16, P34; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; OVERMAN PF, 1993, SOMAT CELL MOLEC GEN, V19, P347, DOI 10.1007/BF01232747; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; SCHEIN CH, 1995, BIOCHEM J, V307, P123, DOI 10.1042/bj3070123; SCHEIN CH, 1990, FEBS LETT, V270, P229, DOI 10.1016/0014-5793(90)81275-S; SEKAR V, 1983, BIOCHEM BIOPH RES CO, V114, P950, DOI 10.1016/0006-291X(83)90652-6; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; SREEVALSAN T, 1980, J CELL PHYSIOL, V104, P1, DOI 10.1002/jcp.1041040102; SUZUKI K, 1993, J BIOL CHEM, V268, P2755; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; VESTER B, 1984, J MOL BIOL, V179, P431, DOI 10.1016/0022-2836(84)90074-3; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZOON KC, 1986, P NATL ACAD SCI USA, V83, P8226, DOI 10.1073/pnas.83.21.8226	55	31	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					473	480		10.1038/sj.onc.1200858	http://dx.doi.org/10.1038/sj.onc.1200858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053844				2022-12-28	WOS:A1997WE36400010
J	Williams, KJ; Boyle, JM; Birch, JM; Norton, JD; Scott, D				Williams, KJ; Boyle, JM; Birch, JM; Norton, JD; Scott, D			Cell cycle arrest defect in Li-Fraumeni Syndrome: A mechanism of cancer predisposition?	ONCOGENE			English	Article						Li-Fraumeni; p53; transgenic; G(1) arrest	WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PRONE FAMILY; G(1) ARREST; RADIOSENSITIVITY; CHECKPOINT; MUTATIONS; FIBROBLASTS; REPAIR	Cancer predisposition in approximately 60% of Li-Fraumeni Syndrome (LPS) families is associated with germline mutation of the TP53 gene. The p53 protein has been shown to mediate G(1) arrest following DNA damage, We have investigated gamma-irradiation-induced transient and permanent G(1) arrest in normal and LFS fibroblasts. The duration of transient G(1) arrest varied between strains, but there was no difference in the range between normal (2-12 h) and LFS (1-13 h) cells. However, the extent of permanent G(1) arrest was greatly reduced in LFS fibroblasts (mean 33 +/- 8% of the cell population) compared with normals (mean 67 +/- 9%) and correlated with their increased radiation survival (r = 0.97, P<0.001). This phenotype was observed in LFS fibroblasts both with (seven cases) and without (two cases) TP53 mutation. Parallel studies with fibroblasts derived from cancer-prone, p53-deficient mice revealed no radiation-induced G(1) cell cycle arrest in p53 null (-/-) cells, The p53 +/- cells were comparable to the wt p53 cells in transient G(1) arrest capacity, but showed a diminished permanent G(1) arrest. These data clearly implicate p53 function in permanent G(1) arrest, The reduced capacity for DNA damage-induced, permanent G(1) arrest in LFS may contribute significantly to cancer predisposition in this familial syndrome.	CHRISTIE HOSP NHS TRUST,CRC,PAEDIAT & FAMILIAL CANC RES GRP,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP NHS TRUST,CRC,DEPT GENE REGULAT,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Williams, KJ (corresponding author), CHRISTIE HOSP NHS TRUST,CRC,DEPT CANC GENET,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND.							BECHHANSEN NT, 1981, LANCET, V1, P1335; BIRCH JM, 1994, CANCER RES, V54, P1298; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BURNET NG, 1994, RADIOTHER ONCOL, V33, P228, DOI 10.1016/0167-8140(94)90358-1; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALLE P, 1995, ONCOGENE, V10, P2447; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI CY, 1995, ONCOGENE, V11, P1885; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; NAGASAWA H, 1995, CANCER RES, V55, P1842; OCONNOR PM, 1993, CANCER RES, V53, P4776; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; PAULES RS, 1995, CANCER RES, V55, P1763; POOT M, 1990, FLOW CYTOMETRY PRACT, P105; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Sproston ARM, 1996, INT J RADIAT BIOL, V70, P145, DOI 10.1080/095530096145139; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART N, 1995, ONCOGENE, V10, P109; WEEKS DE, 1991, RADIAT RES, V128, P90, DOI 10.2307/3578071; Williams KJ, 1996, BRIT J CANCER, V74, P698, DOI 10.1038/bjc.1996.424; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	35	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					277	282		10.1038/sj.onc.1200838	http://dx.doi.org/10.1038/sj.onc.1200838			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018113				2022-12-28	WOS:A1997WD51600003
J	Gopalakrishnan, S; Fischer, RS; Quinlan, MP				Gopalakrishnan, S; Fischer, RS; Quinlan, MP			Induction of a complex between rasGAP and a novel 110 kD protein is required for immortalization of primary epithelial cells by the E1A 12S oncoprotein of adenovirus	ONCOGENE			English	Article						immortalization; adenovirus E1A 12S; protein complexes	GTPASE-ACTIVATING PROTEIN; EFFICIENT NUCLEAR-LOCALIZATION; GROWTH-FACTOR INDUCTION; C-TERMINAL REGION; TYROSINE PHOSPHORYLATION; COOPERATING ONCOGENES; CELLULAR PROTEIN; E1A-12S PROTEIN; TUMOR-ANTIGEN; EMBRYO CELLS	Although established cell lines can be transformed with oncogenic ras, primary epithelial cells cannot, but require the coexpression of an immortalizing oncogene, such as the E1A region of adenovirus. We have previously shown that immortalization of primary epithelial cells by E1A 12S requires the expression of five regions encoded by both the first and second exons of the gene, However, only three of these regions, located in the first exon, are required for cotransformation of primary cells with an activated ras oncogene, Thus, the expression of oncogenic ras is able to abrogate the need for the E1A function(s) encoded by the second exon that are required for immortalization, This suggested the possibility that the functions encoded by the second exon of E1A may involve or interact with the normal ras signal transduction pathway, The results described herein demonstrate that immortalization-competent 12S gene products induce the expression of a novel 110 kD protein, p110, that forms a stable complex with rasGAP. Failure to induce the p110-rasGAP complex results in the concomitant loss of ability of 12S to immortalize primary epithelial cells, The appearance of this complex parallels the expression of the 12S protein and is sensitive to the levels of E1A 12S, p110 induction is independent of the ability of 12S to activate the cell cycle and of the presence of adenovirus E1B and is not observed in the presence of the large T antigen of SV40, Thus, it is not a general response to proliferation or tumorigenic transformation, but rather seems to be specific to the immortalization function(s) of E1A 12S.	UNIV TENNESSEE, CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center				Fischer, Robert/0000-0003-0650-2696	NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER; NCI NIH HHS [CA50540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLS BLMC, 1991, CANCER RES, V51, P1177; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1994, CELL GROWTH DIFFER, V5, P475; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flint S. J, 1981, DNA TUMOR VIRUSES; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOTOH A, 1994, LEUKEMIA, V8, P115; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GSCHWENDT M, 1993, BIOCHEM BIOPH RES CO, V194, P571, DOI 10.1006/bbrc.1993.1858; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; PRONK GJ, 1993, ONCOGENE, V8, P2773; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1994, ONCOGENE, V9, P2639; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; QUINLAN MP, 1993, ONCOGENE, V8, P257; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHENK T, 1991, ADV CANCER RES, V57, P47; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	75	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2659	2669						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000140				2022-12-28	WOS:A1996VZ65400016
J	Huang, SY; Luca, M; Gutman, M; McConkey, DJ; Langley, KE; Lyman, SD; BarEli, M				Huang, SY; Luca, M; Gutman, M; McConkey, DJ; Langley, KE; Lyman, SD; BarEli, M			Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential	ONCOGENE			English	Article						c-KIT; tumor metastasis; melanoma; apoptosis	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; TUMOR NECROSIS FACTOR; W-MUTANT MICE; NUDE-MICE; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; DNA FRAGMENTATION; HUMAN PIEBALDISM; RNA EXPRESSION	Expression of the tyrosine-kinase receptor encoded by the c-KIT proto-oncogene progressively decreases during local tumor growth and invasion of human melanomas, To provide direct evidence that c-KIT plays a role in metastasis of human melanoma, we transfected the c-KIT gene into the c-KIT negative highly metastatic human melanoma cell line A375SM and subsequently analysed its tumorigenic and metastatic potential, A375SM parental cells, A375SM-NOT (neo, control), and A375SM-KIT-positive cells were injected s.c. and i.v. into nude mice, A375SM-KIT cells produced significantly slower growing s.c. tumors and fewer lung metastases than control cells. Exposure of c-KIT-positive melanoma cells in vitro and in vivo to stem cell factor (SCF), the ligand for c-KIT, triggered apoptosis of these cells but not of c-KIT-negative melanoma cells or normal melanocytes. Since SCF is produced by keratinocytes and other dermal cells in the skin, these results suggest that the loss of c-KIT receptor expression may allow malignant melanoma cells to escape SCF/c-KIT-mediated apoptosis, hence contributing to tumor growth and eventually metastasis, The antitumor and antimetastatic properties of SCF may be useful in treating human melanomas in early stages.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; AMGEN INC,THOUSAND OAKS,CA 91320; IMMUNEX RES & DEV CORP,SEATTLE,WA 98103	University of Texas System; UTMD Anderson Cancer Center; Amgen					NCI NIH HHS [CA64137, CA 41524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041524, R21CA064137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P3775; ALBELDA SM, 1990, CANCER RES, V50, P6757; ALBINO AP, 1991, CANCER RES, V51, P4815; ANDRE C, 1989, ONCOGENE, V4, P1047; ARMSTRONG CA, 1994, J INVEST DERMATOL, V102, P278, DOI 10.1111/1523-1747.ep12371782; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FIDLER IJ, 1990, CANCER RES, V50, P6130; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; HUANG SY, 1994, CANCER IMMUNOL IMMUN, V39, P231, DOI 10.1007/BF01525986; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; LASSAM N, 1992, ONCOGENE, V7, P51; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1993, INT J ONCOL, V3, P19; LUCA M, 1995, ONCOGENE, V11, P1399; MCGREGOR BC, 1989, AM J CLIN PATHOL, V92, P495, DOI 10.1093/ajcp/92.4.495; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORITA E, 1994, ARCH DERMATOL RES, V286, P273, DOI 10.1007/BF00387600; NATALI P, 1990, CANCER RES, V50, P1271; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RADINSKY R, 1994, ONCOGENE, V9, P1977; RADIZADEH S, 1993, SCIENCE, V261, P345; REAL FX, 1986, CANCER RES, V46, P4726; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SINGH RK, 1995, CANCER RES, V55, P3669; SINGH RK, 1994, CANCER RES, V54, P3242; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VERSCHRAEGEN CF, 1991, ANTICANCER RES, V11, P529; VILE RG, 1994, CANCER RES, V54, P6228; WILKS AF, 1993, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3342; ZAKUT R, 1993, ONCOGENE, V8, P2221; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	63	130	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2339	2347						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957075				2022-12-28	WOS:A1996VX10800006
J	Gaben, AM; Saucier, C; Bedin, M; Barbu, V; Courilleau, D; BonHoa, DH; Mester, J				Gaben, AM; Saucier, C; Bedin, M; Barbu, V; Courilleau, D; BonHoa, DH; Mester, J			Activation of p21ras is not sufficient to ensure a complete G(1) phase of the cell division cycle in mouse fibroblasts	ONCOGENE			English	Article						p21ras; cell cycle; growth factor requirement; SRE-dependent transcription; insulin signalling	EPIDERMAL GROWTH-FACTOR; MITOGENIC SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE FACTOR; SERUM-RESPONSE ELEMENT; NIH 3T3 CELLS; FACTOR-I; C-FOS; TYPE-1 NEUROFIBROMATOSIS; GUANINE-NUCLEOTIDES; GENE-EXPRESSION	In the mouse BP-A31 fibroblasts, mRNAs coding the three isoforms (Ha, Ki, N) of ras are expressed, and there are no activating mutations in the codons 12, 13 or 61. We have produced a subline (Ras2) expressing an oestrogen-inducible v-Ha-ras gene. The contribution of v-Ha-ras to the overall p21ras-GTP content was evaluated by metabolic labelling with P-32. Surprisingly, p21ras-GTP complexes were predominant in the serum-deprived BP-A31 cells as well as in the Ras2 cells. The excess of p21ras-GTP was not due to the lack of the GTPase activating protein. In transient transfection experiments, the serum response element (SRE)-directed CAT was expressed in serum-deprived BP-A31 cells, and insulin caused a further two- to threefold increase in CAT activity. A dominant negative ras mutant (Ha-Ras Asn-17) cancelled both the basal and insulin-induced CAT expression in the BP-A31 but not in the Ras2 cells. Expression of v-Ha-ras in Ras2 cells did not relax their growth factor-dependence and oestradiol had only a minor mitogenic effect. We conclude that p21ras activation does not ensure a complete cell division cycle in these cells, and does not entirely account for the transduction of the mitogenic signal initiated by insulin.	UNIV PARIS 06,FAC MED,F-75012 PARIS,FRANCE	UDICE-French Research Universities; Sorbonne Universite	Gaben, AM (corresponding author), HOP ST ANTOINE,INSERM U55,184 RUE FAUBOURG ST ANTOINE,F-75012 PARIS,FRANCE.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BRUNET A, 1994, ONCOGENE, V9, P3379; BUCHOU T, 1989, EXP CELL RES, V182, P129, DOI 10.1016/0014-4827(89)90285-1; BUCHOU T, 1990, J CELL PHYSIOL, V142, P559, DOI 10.1002/jcp.1041420315; BuquetFagot C, 1996, J CELL PHYSIOL, V166, P631, DOI 10.1002/(SICI)1097-4652(199603)166:3<631::AID-JCP18>3.0.CO;2-9; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHAROLLAIS RH, 1990, J CELL PHYSIOL, V145, P46, DOI 10.1002/jcp.1041450108; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAGOT D, 1991, ENDOCRINOLOGY, V129, P1033, DOI 10.1210/endo-129-2-1033; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAMBROOK J, 1989, MOL CLONING LAB HDB; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; Yenush L, 1996, MOL CELL BIOL, V16, P2509	52	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950978				2022-12-28	WOS:A1996VV14500008
J	MuellerPillasch, F; Lacher, U; Wallrapp, C; Micha, A; Zimmerhackl, F; Hameister, H; Varga, G; Friess, H; Buchler, M; Beger, HG; Vila, MR; Adler, G; Gress, TM				MuellerPillasch, F; Lacher, U; Wallrapp, C; Micha, A; Zimmerhackl, F; Hameister, H; Varga, G; Friess, H; Buchler, M; Beger, HG; Vila, MR; Adler, G; Gress, TM			Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein	ONCOGENE			English	Article						pancreatic cancer; KH-domain; RNA-binding; overexpression	RNA-BINDING PROTEINS; IN-VITRO; IDENTIFICATION; STABILITY; PANCREAS; COMPLEX	In a previous large scale screen for differentially expressed genes in pancreatic cancer, we identified a gene highly overexpressed in cancer encoding a novel protein with four K-homologous (KH) domains, KH-domains are found in a subset of RNA-binding proteins, including pre-mRNA-binding (hnRNP)K protein and the fragile X mental retardation gene product (FMR1). By fluorescence in situ hybridization (FISH) the identified gene named koc (KH domain containing protein overexpressed in cancer) was assigned to chromosome 7p11.5, Two pseudogenes were localised on chromosome 6 and 11, The cloned koc cDNA has a 250 bp 5'-UTR, a 1740 bp ORF and a 2168 bp 3'-UTR, The AU-rich 3'-untranslated region of koc contains eight AUUUA and four AUUUUUA reiterated motifs, The deduced koc protein with 580 amino-acids has a relative molecular mass (M-r) of approximately 65 000 (65 K), The koc transcript is highly overexpressed in pancreatic cancer cell lines and in pancreatic cancer tissue as compared to both, normal pancreas and chronic pancreatitis tissue, High levels of expression were as well found in tissue samples of other human tumours, As the KH domain has been shown to be involved in the regulation of RNA synthesis and metabolism, we speculate that koc may assume a role in the regulation of tumour cell proliferation by interfering with transcriptional and or posttranscriptional processes, However, the precise role of koc in human tumour cells is unknown and remains to be elucidated.	UNIV ULM,DEPT MED GENET,ULM,GERMANY; HUNGARIAN ACAD SCI,INST EXPT MED,BUDAPEST,HUNGARY; UNIV BERN,INSELSPITAL,DEPT VISZERAL & TRANSPLANTAT SURG,CH-3010 BERN,SWITZERLAND; UNIV ULM,DEPT SURG,ULM,GERMANY; UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,E-08193 BARCELONA,SPAIN	Ulm University; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Bern; University Hospital of Bern; Ulm University; Autonomous University of Barcelona	MuellerPillasch, F (corresponding author), UNIV ULM,DEPT INTERNAL MED 1,ROBERT KOCH STR 8,D-89081 ULM,GERMANY.		Varga, Gábor/O-8858-2017	Varga, Gabor/0000-0002-5506-8198; Gress, Thomas/0000-0002-9333-5461				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Gordis Leon, 1993, P837; Gress TM, 1996, ONCOGENE, V13, P1819; GRESS TM, 1994, EUR J CANCER, V30A, P1391, DOI 10.1016/0959-8049(94)90191-0; HAHM K, 1993, NUCLEIC ACIDS RES, V21, P3894, DOI 10.1093/nar/21.16.3894; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; SCHUSSLER MH, 1992, AM J PATHOL, V140, P559; SIMOI H, 1994, CELL, V77, P33; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VILA MR, 1994, LAB INVEST, V71, P423; WANG XM, 1995, MOL CELL BIOL, V15, P1769	21	220	243	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2729	2733		10.1038/sj.onc.1201110	http://dx.doi.org/10.1038/sj.onc.1201110			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178771				2022-12-28	WOS:A1997XB97800012
J	Shin, DY; Ishibashi, T; Choi, TS; Chung, EM; Chung, IY; Aaronson, SA; Bottaro, DP				Shin, DY; Ishibashi, T; Choi, TS; Chung, EM; Chung, IY; Aaronson, SA; Bottaro, DP			A novel human ERK phosphatase regulates H-ras and v-raf signal transduction	ONCOGENE			English	Article						protein tyrosine phosphatase; map kinase phosphatase; protein dephosphorylation	DUAL-SPECIFICITY PHOSPHATASE; ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; TYROSINE-PHOSPHATASE; VACCINIA VIRUS; CLONING SYSTEM; EXPRESSION; GROWTH; DEPHOSPHORYLATES	A cDNA encoding a novel human extracellularly regulated kinase (ERK) phosphatase, designated B59, was isolated from a B5/589 human mammary epithelial cell cDNA library, The 1104 nucleotide open reading frame encodes 368 amino acids including the highly conserved catalytic site sequence of protein phosphotyrosine phosphatases (PTPs), VXVHCXXGXXR, at amino acid position 276-287, The predicted 70 amino acid stretch surrounding the HC motif shares significant sequence identity with other human dual specificity PTPs (dsPTPs), including the known ERK PTPs CL100, PAC1, B23, as well as the dsPTPs VH-1 and VHR, B59 protein synthesized in vitro in a rabbit reticulocyte lysate dephosphorylated rat ERK1 and ERK2 proteins whose phosphorylation had been stimulated by v-mos kinase added to the lysate, Ectopic expression of B59 in NIH3T3 fibroblasts inhibited the induction of an oncogene-responsive promoter by the dominant-activating paf mutant, raf-BXB, Moreover, cotransfection of NIH3T3 cells with B59 inhibited morphological transformation by H-ras and v-raf oncogenes. These results suggest that B59 suppresses the transforming activity of H-ras or v-raf oncogenes through ERK dephosphorylation and inactivation.	NCI, CELLULAR & MOL BIOL LAB, DIV BASIC SCI, BETHESDA, MD 20892 USA; MT SINAI MED CTR, DERALD H RUTTENBERG CANC CTR, NEW YORK, NY 10029 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DEVEREAUX J, 1992, GCG PROCEDURE LIB VE; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KRAUS MH, 1991, METHOD ENZYMOL, V200, P547; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; PHAM CD, 1995, ONCOGENE, V10, P1683; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	50	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2633	2639		10.1038/sj.onc.1201106	http://dx.doi.org/10.1038/sj.onc.1201106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178761	Bronze			2022-12-28	WOS:A1997XB97800002
J	Tai, YT; Gould, MN				Tai, YT; Gould, MN			The genetic penetrance of the activated neu oncogene for the induction of mammary cancer in vivo	ONCOGENE			English	Article						neu; rat; mammary cancer; retroviral vector	SINGLE-STEP INDUCTION; TRANSGENIC MICE; EPITHELIAL-CELLS; COMPETITIVE PCR; FREQUENCY; CARCINOGENESIS; SUPPRESSION; INITIATION; NEOPLASIA; INVIVO	Carcinogeneis is most often viewed as a multistage disease process, An exception to this was suggested for neu transformation of mammary cells in a transgenic model (Muller et al., 1988); however, this interpretation is controversial (Bouchard et al., 1989), In order to better define nea mammary transformation in vivo, we directly measured the genetic penetrance of the nea oncogene, Mammary cells in situ were infected with replication-defective retroviral vectors carrying the activated nea oncogene (pJRneu). A limiting dilution in vivo transplantation assay was used to measure the percentage of mammary clonogenic (stem-like) cells that stably and functionally integrated this vector, Based on this, the percentage of clonogens integrating and expressing neu that could progress to mammary carcinomas was quantified to estimate the penetrance of this gene in mammary carcinogenesis, The genetic penetrance of neu was 3.6% (95% confidence interval 2.2%-5.8%), This high degree of genetic penetrance is compatible with the observations that certain neu-transgenic mice develop a very great number of mammary carcinomas (Muller et al., 1988), However, whether these data are compatible with a single-step transformation model (100% penetrance) is uncertain and is discussed.	UNIV WISCONSIN,DEPT HUMAN ONCOL,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NCI NIH HHS [CA58328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1995, BRAIN RES, V683, P251, DOI 10.1016/0006-8993(95)00272-R; Bauer G, 1996, HISTOL HISTOPATHOL, V11, P237; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Clifton K. H., 1985, CELL CLONES MANUAL M, P128; CLIFTON KH, 1986, CANCER RES, V46, P2390; DOMANN FE, 1994, RADIAT RES, V137, P330, DOI 10.2307/3578707; GOULD MN, 1977, RADIAT RES, V72, P343, DOI 10.2307/3574704; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; KAMIYA K, 1995, P NATL ACAD SCI USA, V92, P1332, DOI 10.1073/pnas.92.5.1332; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Langer C, 1996, EXP CELL RES, V222, P117, DOI 10.1006/excr.1996.0015; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; Lenahan MK, 1996, ONCOGENE, V12, P1847; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCCULLOCH RK, 1995, PCR METH APPL, V4, P219; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; SHEMESH J, 1993, J BIOL CHEM, V268, P15704; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAI YT, 1995, CARCINOGENESIS, V16, P1455, DOI 10.1093/carcin/16.7.1455; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649	25	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2701	2707		10.1038/sj.onc.1201101	http://dx.doi.org/10.1038/sj.onc.1201101			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178768				2022-12-28	WOS:A1997XB97800009
J	Flick, MB; Sapi, E; Perrotta, PL; Maher, MG; Halaban, R; Carter, D; Kacinski, BM				Flick, MB; Sapi, E; Perrotta, PL; Maher, MG; Halaban, R; Carter, D; Kacinski, BM			Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody	ONCOGENE			English	Article						c-fms proto-oncogene; phosphotyrosine; immunohistochemistry; tyrosine kinase; breast carcinoma	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; MACROPHAGE CELL-LINE; FMS PROTO-ONCOGENE; SIGNAL-TRANSDUCTION; PHOSPHORYLATED PROTEINS; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN MELANOCYTES	The macrophage colony stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, plays an important role in regulating the normal proliferation and differentiation of macrophages and trophoblasts. However, the abnormal expression of CSF-1R transcripts and protein by human breast carcinomas has been shown to correlate with advanced stage and poor prognosis. Ligand activated CSF-1R dimers transphosphorylate several tyrosines in their cytoplasmic domains which provide recognition sites for various effector proteins in multiple signal transduction pathways. In cells transformed by the c-fms oncogene, one of the major CSF-1R phosphotyrosines, pTyr723 is important for phenotypic expression of anchorage-independent growth and metastasis. In order to investigate the relationship between receptor activation/phosphorylation and cellular phenotypes in vitro and in vivo, we prepared a CSF-1R phosphorylation-state specific antibody raised against a specific phosphopeptide of CSF-1R, which included phosphorylated tyrosine 723. On immunoblots of lysates from cells expressing CSF-1R, this antibody recognizes phosphorylated CSF-1R in CSF-1 stimulated cells but not in unstimulated cells. As an immunohistochemical reagent, this antibody stained 52% of invasive human breast tumors (72% of CSF-1R positive cases) in a sample of 114 cases and 38% of carcinoma in situ. This data represents the first direct evidence of in vivo phosphorylation of CSF-1R in human breast carcinomas.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT OBSTET & GYNECOL, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University	Flick, MB (corresponding author), YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.				PHS HHS [CF47292] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Bacus SS, 1996, AM J PATHOL, V148, P549; BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; BRUCKNER A, 1992, CANCER RES, V52, P3043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMBERS SK, 1995, CANCER RES, V55, P1578; COMOGLIO PM, 1990, AM REV RESPIR DIS, V142, pS16, DOI 10.1164/ajrccm/142.6_Pt_2.S16; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; HALABAN R, 1992, ONCOGENE, V7, P2195; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1989, CANCER CEL, V7, P333; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KACINSKI BM, 1990, MOL CELLULAR BIOL CY, P393; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEATING MT, 1988, J BIOL CHEM, V263, P12805; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MARCUSSEN J, 1991, ANAL BIOCHEM, V198, P318, DOI 10.1016/0003-2697(91)90432-S; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PANNEERSELVAM K, 1995, J BIOL CHEM, V270, P7975, DOI 10.1074/jbc.270.14.7975; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROHRSCHNEIDER LR, 1994, GUIDEBOOK CYTOKINES, P168; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; Sapi E, 1996, CANCER RES, V56, P5704; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STERN DF, 1991, METHOD ENZYMOL, V198, P494; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WANG JYJ, 1988, ANAL BIOCHEM, V172, P1, DOI 10.1016/0003-2697(88)90403-4; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	39	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2553	2561		10.1038/sj.onc.1201092	http://dx.doi.org/10.1038/sj.onc.1201092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191055				2022-12-28	WOS:A1997XA94900007
J	Lengyel, E; Wang, H; Gum, R; Simon, C; Wang, Y; Boyd, D				Lengyel, E; Wang, H; Gum, R; Simon, C; Wang, Y; Boyd, D			Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade	ONCOGENE			English	Article						urokinase receptor; extracellular signal regulated kinase; mitogen activated protein kinase; invasion	FIBROBLAST GROWTH-FACTOR; VASCULAR ENDOTHELIAL-CELLS; MAP KINASE-KINASE; PROTEIN-KINASE; C-JUN; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; MATRIX INVASION; STROMAL CELLS; MUSCLE CELLS	The urokinase-type plasminogen activator receptor (u-PAR) facilitates extracellular matrix degradation in part by accelerating plasmin formation at the cell surface. We previously reported that u-PAR expression is elevated in colon cancer cell lines characterized by their in vitro invasive capacity. Since, u-PAR expression is increased by a variety of growth factors, which signal through the extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2), we determined if these mitogen-activated protein kinases (MAPKs) regulate u-PAR expression in two cultured colon cancer cell lines, An in-gel kinase assay showed that ERK1 activity was considerably higher in RKO cells, which display greater than or equal to 10(4) receptors/cell, than the GEO cells which have similar or equal to 10(4) urokinase receptors per cell. The expression of either an ERK-inactivating phosphatase (CL100), or a kinase-defective ERK1, decreased the activity of a u-PAR promoter-driven CAT reporter in RKO cells. Immune complex kinase assays indicated that the constitutive ERK1 activity in RKO cells was largely a result of an activated MEK1. Further, treatment of RKO cells with a specific inhibitor (PD 098059) of MEK1 activation, which diminished ERK1 activity, reduced the amount of urokinase specifically bound to the cell surface and this was associated with reduced laminin degradation. The expression of a dominant negative c-Raf-l also reduced u-PAR promoter activity suggesting that MEK1 activation involved an activator at, or upstream, of this serine-threonine kinase, Transfection of the u-PAR-deficient GEO cells with a constitutively activated MEK1 expression construct upregulated u-PAR promoter activity. Similarly treatment of GEO cells,vith a phosphatase inhibitor (sodium vanadate) caused a dose-dependent increase in ERK1 activity which paralleled increased cell surface binding of urokinase. Taken together, these data suggest that elevated u-PAR expression, in at least a sub-population of colon cancer, is partly a consequence of a constitutively activated ERK-1-dependent signaling cascade.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL HEAD & NECK SURG,HOUSTON,TX; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV MOL MED,MUCOSAL INFLAMMAT & CANC GRP,CANBERRA,ACT 2601,AUSTRALIA	University of Texas System; UTMD Anderson Cancer Center; Australian National University; John Curtin School of Medical Research			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGARWAL S, 1995, ONCOGENE, V11, P427; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOS JL, 1989, CANCER RES, V49, P4682; BOYD D, 1988, CANCER RES, V48, P3112; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CASEY JR, 1994, BLOOD, V84, P1151; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HOLLAS W, 1991, CANCER RES, V51, P3690; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKUN J, 1991, CANCER RES, V51, P1221; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JONES LG, 1994, J BIOL CHEM, V269, P23790; KARIKO K, 1993, CANCER RES, V53, P3109; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Muda M, 1996, J BIOL CHEM, V271, P4319; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; OHagan RC, 1996, ONCOGENE, V13, P1323; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; RAO VN, 1993, CANCER RES, V53, P3449; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, INT J CANCER, V57, P553, DOI 10.1002/ijc.2910570419; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHIRAKABE K, 1992, J BIOL CHEM, V207, P16685; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; SOZERI O, 1992, ONCOGENE, V7, P2259; STACEY DW, 1991, ONCOGENE, V6, P2297; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TSAI PS, 1995, ENDOCRINOLOGY, V136, P3831, DOI 10.1210/en.136.9.3831; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI J, 1982, J CELL BIOL, V100, P86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	86	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2563	2573		10.1038/sj.onc.1201098	http://dx.doi.org/10.1038/sj.onc.1201098			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191056				2022-12-28	WOS:A1997XA94900008
J	Craig, C; Wersto, R; Kim, M; Ohri, E; Li, ZW; Katayose, D; Lee, SJ; Trepel, J; Cowan, K; Seth, P				Craig, C; Wersto, R; Kim, M; Ohri, E; Li, ZW; Katayose, D; Lee, SJ; Trepel, J; Cowan, K; Seth, P			A recombinant adenovirus expressing p27(Kip1) induces cell cycle arrest and lass of cyclin-Cdk activity in human breast cancer cells	ONCOGENE			English	Article						cyclin kinase inhibitors; cell growth; cell cycle; G(1)/S arrest	DEPENDENT KINASE INHIBITOR; POTENTIAL MEDIATOR; P21; P16; GROWTH	In order to elucidate the biochemical mechanisms by which the universal cyclin kinase inhibitor p27(Kip1) regulates cell cycle progression in human breast cancer cells, a recombinant adenovirus expressing human p27 was constructed (Adp27). Upon infection of human breast cancer cells MDA-MB-231 and MCF-7 with Adp27, a high level of p27 expression was observed, and this resulted in a marked decrease in the proportion of cells in S-phase, In multiple cell lines, comparison of the cytotoxicity of Adp27 with another adenovirus vector expressing the related universal cyclin kinase inhibitor WAF1/Cip1 (AdWAF1), showed Adp27 to be markedly more (up to 56-fold) toxic than AdWAF1, DNA histograms showed Adp27 to cause a G(1)/S arrest at lower viral doses than AdWAF1, Analysis of cyclin dependent kinase activity following Adp27 infections showed decreased Cdk2 and cyclin B1-Cdc2 activity at lower viral doses when compared with AdWAF1, Adp27 is therefore potentially useful for studies of growth regulation and for gene therapy when growth inhibition is desired.	NCI,MED BRANCH,NIH,BETHESDA,MD 20892; NCI,PATHOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GINSBERG HS, 1988, VIROLOGY, P147; GOTTESMAN MM, 1994, J NATL CANCER I, V86, P1277, DOI 10.1093/jnci/86.17.1277; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; Gudas JM, 1996, CARCINOGENESIS, V17, P1417, DOI 10.1093/carcin/17.7.1417; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose D, 1995, CLIN CANCER RES, V1, P889; Kopp WC, 1992, MANUAL CLIN LABORATO, P933; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHUTTE B, 1987, CYTOMETRY, V8, P372, DOI 10.1002/cyto.990080405; SETH P, 1984, MOL CELL BIOL, V4, P1528, DOI 10.1128/MCB.4.8.1528; SETH P, 1986, VIRUS ATTACHMENT ENT, P191; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	28	190	196	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2283	2289		10.1038/sj.onc.1201064	http://dx.doi.org/10.1038/sj.onc.1201064			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178904				2022-12-28	WOS:A1997WY88300005
J	Thien, CBF; Langdon, WY				Thien, CBF; Langdon, WY			EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene	ONCOGENE			English	Article						growth factor; oncogene; receptor; signal transduction; tyrosine kinase	GROWTH-FACTOR RECEPTOR; PRODUCT C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PROTEIN PRODUCT; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; JURKAT CELLS; ONCOGENE	The 120 kD product of the c-cbl oncogene is rapidly tyrosine phosphorylated and recruited to the EGF receptor following ligand binding. Cbl's oncogenic potential is activated by a large carboxy-terminal truncation that generated v-cbl and removes the Ring finger and proline-rich SH3-binding domains. Here we show that this truncation reveals a novel and highly conserved domain that can interact directly with the EGF receptor in a phosphorylation dependent manner. Furthermore we demonstrate that the v-cbl domain is not utilized by c-cbl for recruitment to the receptor since this binding property is not evident in c-cbl constructs with proline domain deletions, and it is only revealed following deletion of the Ring finger. We also analyse a loss-of-function mutation from the C. elegans homologue, sli-1, and show that the corresponding mutation in v-cbl ablates transformation and EGF receptor association. Thus our findings provide further evidence that v-cbl possesses a novel and evolutionarily conserved phospho-tyrosine binding domain and that the dual capability of EGF receptor binding by cbl involves two distinct mechanisms. In addition these findings raise the possibility that v-cbl may transform by competing with c-cbl for phosphorylated binding sites on activated receptor complexes.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6907,AUSTRALIA	University of Western Australia			Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20241; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEANE MM, 1995, ONCOGENE, V10, P2367; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kontani K, 1996, J BIOL CHEM, V271, P1534; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	49	68	69	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2239	2249		10.1038/sj.onc.1201193	http://dx.doi.org/10.1038/sj.onc.1201193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174060				2022-12-28	WOS:A1997WX93800013
J	Alemi, M; Lucas, SD; Sallstrom, JF; Bergholm, U; Akerstrom, G; Wilander, E				Alemi, M; Lucas, SD; Sallstrom, JF; Bergholm, U; Akerstrom, G; Wilander, E			A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma	ONCOGENE			English	Article						RET proto-oncogene; deletion; medullary thyroid carcinoma	MULTIPLE ENDOCRINE NEOPLASIA; PROTOONCOGENE MUTATIONS; TYROSINE KINASE; MEN 2A; FMTC; ACTIVATION; CANCER; GENE	Genetic alteration of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B), familial medullary thyroid carcinoma (FMTC) and Hirschprung's disease. Oncogenically activated RET has also been demonstrated in sporadic medullary thyroid tumors, which in some cases show somatic missense mutations, We have recently described a complex 9 bp deletion in RET exon 11 in a single case of sporadic MTC, In order to determine the prevalence of this mutation among sporadic MTC tumors, we have now analysed 15 cases and five normal controls by PCR-based nonradioactive single-strand conformational polymorphism analysis (PCR-SSCP) and fragment size analysis of exon 11, DNA was extracted from microdissected tumor tissue or normal cells and subjected to nested PCR prior to analysis, A markedly divergent SSCP pattern and a PCR fragment 9 bp shorter than normal were demonstrated in 14 of the 15 MTC tumors. Sequencing revealed the deletion of nine bases encompassing a key cysteine at codon 634, often altered in MEN 2A, Four lymphocyte controls and normal thyroid tissue from one patient failed to show the deletion, Several factors in the DNA sequence environment immediately surrounding the deletions, including an extended inverted repeat, several direct repeats and a so-called symmetric element suggest that the deletional events may be non-random.	UNIV UPPSALA HOSP,DEPT SURG,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	Alemi, M (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.			Lucas, Steven/0000-0002-3409-2033				ALBERTINI AM, 1982, CELL, V29, P3189; Alemi M, 1996, ANTICANCER RES, V16, P2619; BOLINO A, 1995, ONCOGENE, V10, P2415; BRUNIER D, 1988, CELL, V52, P883, DOI 10.1016/0092-8674(88)90430-8; CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P739, DOI 10.1016/0030-4220(76)90187-0; DASGUPTA U, 1987, GENETICS, V115, P41; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DONISKELLER H, 1995, J INTERN MED, V238, P319, DOI 10.1111/j.1365-2796.1995.tb01205.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GALAS DJ, 1978, J MOL BIOL, V126, P858, DOI 10.1016/0022-2836(78)90024-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jackson C E, 1989, Henry Ford Hosp Med J, V37, P116; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KIMURA T, 1995, ENDOCR J, V42, P517, DOI 10.1507/endocrj.42.517; KRAWCZAK M, 1991, HUM GENET, V86, P425; LAIRMORE TC, 1993, BRIT J SURG, V80, P1092, DOI 10.1002/bjs.1800800904; LLOYD RV, 1995, AM J PATHOL, V147, P1539; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHAAPER RM, 1986, J MOL BIOL, V189, P272; SCHIMKE RN, 1968, NEW ENGL J MED, V279, P1, DOI 10.1056/NEJM196807042790101; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SINGER BS, 1988, J MOL BIOL, V202, P233, DOI 10.1016/0022-2836(88)90454-8; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; YAMAKAWAKOBAYASHI K, 1994, HUM GENET, V93, P625	30	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2041	2045		10.1038/sj.onc.1201042	http://dx.doi.org/10.1038/sj.onc.1201042			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160884				2022-12-28	WOS:A1997WW80900006
J	Takahashi, T; Shibuya, M				Takahashi, T; Shibuya, M			The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts	ONCOGENE			English	Article						vascular endothelial growth factor; tyrosine kinase receptor; signal transduction; MAP kinase	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; HEMATOPOIETIC-CELLS; BIOLOGICAL-ACTIVITY; EXPRESSION; ANGIOGENESIS; GENE; VASCULOGENESIS; BINDING	KDR/Flk-1 tyrosine kinase, one of the two receptors for Vascular Endothelial Growth Factor (VEGF) has been shown to generate the major part of mitotic signals in endothelial cells, although the mechanisms are poorly understood, Here we examined the processing and signal transduction of KDR/Flk-1. Both in endothelial cells and in NIH3T3 cells expressing KDR/Flk-1, an immature form of KDR/Flk-1 with a molecular mass of about 150 kDa was glycosylated to create a 200 kDa intermediate, and after further glycosylation a mature 230 kDa was expressed on the cell surface, Only this 230 kDa form was rapidly and transiently phosphorylated on tyrosine residues in the presence of VEGF, As a major substrate of KDR/FLk-1, PLC-gamma was found to be rapidly tyrosine-phosphorylated and associated with KDR/Flk-1 both in endothelial cells and NIH3T3 cells, Interestingly, however, a prompt activation of MAP kinase and subsequent strong mitotic signaling were generated only in the endothelial cell background, Activation of MAP kinase in NIH3T3 cells overexpressing KDR/Flk-1 showed a slower response as maximum levels were only attained after 20 min compared to 5 min in sinusoidal endothelial cells. These results suggest that the KDR/Flk-1 utilizes cell type-specific signal transduction pathway(s) for MAP kinase activation and the mitotic response in endothelial cells.	UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								APRELIKOVA O, 1992, CANCER RES, V52, P746; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; CLAUSS HSM, 1993, BLOOD, V81, P2767; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNINGHAM SA, 1995, J BIOL CHEM, V270, P20254; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GALLAND F, 1993, ONCOGENE, V8, P1233; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P309; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; LAROCHELLE WJ, 1986, J IMMUNOL METHODS, V92, P65, DOI 10.1016/0022-1759(86)90504-1; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MICAELSON IC, 1948, T OPHTHAL SOC UK, V68, P137; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RISAU W, 1988, DEVELOPMENT, V102, P471; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAMANE A, 1994, ONCOGENE, V9, P2682	50	267	288	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2079	2089		10.1038/sj.onc.1201047	http://dx.doi.org/10.1038/sj.onc.1201047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160888				2022-12-28	WOS:A1997WW80900010
J	Burke, CL; Lemmon, MA; Coren, BA; Engelman, DM; Stern, DF				Burke, CL; Lemmon, MA; Coren, BA; Engelman, DM; Stern, DF			Dimerization of the p185(neu) transmembrane domain is necessary but not sufficient for transformation	ONCOGENE			English	Article						receptor tyrosine kinase; dimerization; transmembrane domain; neu/HERZ/erbB-2	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; NEU-ONCOGENE; POINT MUTATION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; PROTO-ONCOGENE; CROSS-LINKING	The neu proto-oncogene encodes a receptor tyrosine kinase (RTK). The oncogenic allele neu* (p185*) bears a glutamic acid for valine substitution at position 664 within the predicted transmembrane domain. We have used this mutant to explore the role of the transmembrane domain in signal transduction by RTKs. Analysis of a panel of neu* proteins with second-site mutations in the transmembrane domain revealed a strong correlation of dimerization with transformation. Both dimerization and transformation are dependent on a domain formed by the amino acids Val663-Glu664-Gly665 (VEG). However, movement of the VEG elsewhere within the transmembrane domain promoted weak dimerization but not transformation, Epidermal growth factor receptor (EGFR)/neu chimeras were used to determine if mutations that disrupt activation by Glu664 affect hormone-regulated signal transduction as well. These mutations (of Val663 and Gly665) did not affect regulation by EGF, Introduction of the known transmembrane dimerization domain from Glycophorin A (GpA) stimulated dimerization, but was not sufficient for transformation. These results indicate that dimerization is necessary but not sufficient for transforming activity. The homologous wild-type domain, VVG, is not required for hormone-regulated signaling.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; UNIV PENN, SCH MED, DEPT BIOPHYS & BIOCHEM, PHILADELPHIA, PA 19104 USA	Yale University; Yale University; Yale University; University of Pennsylvania				Lemmon, Mark/0000-0002-3379-5319	NCI NIH HHS [R01CA45708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, IN PRESS; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; CAO HN, 1992, J BIOL CHEM, V267, P20489; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LONGO N, 1992, J BIOL CHEM, V267, P12416; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKAHSHI M, 1987, J BIOL CHEM, V263, P3400; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	72	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					687	696		10.1038/sj.onc.1200873	http://dx.doi.org/10.1038/sj.onc.1200873			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038376				2022-12-28	WOS:A1997WG43000007
J	Nielsen, NH; Emdin, SO; Cajander, J; Landberg, G				Nielsen, NH; Emdin, SO; Cajander, J; Landberg, G			Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein	ONCOGENE			English	Article						breast cancer; cell cycle; retinoblastoma tumour suppressor protein; cyclins and p16	TUMOR-SUPPRESSOR PROTEIN; D-CDK COMPLEXES; GENE-EXPRESSION; GROWTH-FACTOR; ECTOPIC EXPRESSION; MAMMARY CARCINOMAS; PHASE-TRANSITION; TRANSGENIC MICE; POOR PROGNOSIS; G(1) CONTROL	Inactivation of the retinoblastoma protein (pRB) by mutations or abnormal phosphorylation is a mechanism by which tumour cells can subdue normal growth control. Among molecules involved in control of pRB phosphorylation, cyclin D1 and E have been found to be deregulated and overexpressed in various types of cancers. In order to study the cell cycle regulatory mechanisms in breast cancer, we have analysed the protein expression of cyclin D1 and E in 114 tumour specimens from patients with primary breast cancer using Western blotting. Twenty-five out of 34 tumours with overexpression of cyclin E showed uniform low cyclin D1 expression, and by immunohistochemical analysis of pRB we present evidence for the existence of pRB defects in approximately 40% of these tumours in contrast to no PRE defects in the other group of tumours. This result was supported by a high protein expression of the cyclin-dependent kinase inhibitor p16 in 44% of the tumours with high cyclin E and low D1 expression, and all immunohistochemical pRB defect tumours showed a high p16 protein level. Additionally, an abnormal low pRB phosphorylation in relation to a high proliferative activity and loss of heterozygosity of the retinoblastoma susceptibility gene locus were found in all but one tumour with immunohistochemical defect pRB. Interestingly, tumours with high cyclin E and low D1 expression were generally oestrogen receptor negative suggesting a role for cell cycle regulators in the mechanisms leading to oestrogen independent tumour growth. Furthermore, the prognosis differed markedly for the patients in the various groups of tumours, indicating that the heterogeneous nature of breast cancer pathogenesis and the clinical course in part could be explained by different and distinctive sets of cell cycle defects.	UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT ONCOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT SURG,S-90187 UMEA,SWEDEN	Umea University; Umea University; Umea University								ADNANE J, 1989, ONCOGENE, V4, P1389; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; BATES S, 1994, ONCOGENE, V9, P1633; BOOKSTEIN R, 1990, NUCLEIC ACIDS RES, V18, P1666, DOI 10.1093/nar/18.6.1666; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BOYNTON RF, 1991, CANCER RES, V51, P5766; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Geng Y, 1996, ONCOGENE, V12, P1173; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HE J, 1994, CANCER RES, V54, P5804; HENRY JA, 1993, INT J CANCER, V53, P774, DOI 10.1002/ijc.2910530512; HERMAN ME, 1994, CANCER RES, V54, P5867; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JIANG W, 1993, ONCOGENE, V8, P3447; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, CANCER RES, V55, P4818; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NEVINS JR, 1992, SCIENCE, V258, P424; NIELSEN NH, 1996, IN PRESS BR J CANC; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; RENNER WA, 1995, BIOTECHNOL BIOENG, V47, P476, DOI 10.1002/bit.260470409; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SCHOTT DR, 1994, CANCER RES, V54, P1393; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; Ueki K, 1996, CANCER RES, V56, P150; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG NP, 1993, ONCOGENE, V8, P279; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU HJ, 1991, ONCOGENE, V6, P1139; YANDELL DW, 1989, AM J HUM GENET, V45, P547; ZHOU P, 1995, ONCOGENE, V11, P517; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	73	128	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					295	304		10.1038/sj.onc.1200833	http://dx.doi.org/10.1038/sj.onc.1200833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018115				2022-12-28	WOS:A1997WD51600005
J	Rossel, M; Pasini, A; Chappuis, S; Geneste, O; Fournier, L; Schuffenecker, I; Takahashi, M; vanGrunsven, LA; Urdiales, JL; Rudkin, BB; Lenoir, GM; Billaud, M				Rossel, M; Pasini, A; Chappuis, S; Geneste, O; Fournier, L; Schuffenecker, I; Takahashi, M; vanGrunsven, LA; Urdiales, JL; Rudkin, BB; Lenoir, GM; Billaud, M			Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations	ONCOGENE			English	Article						MEN 2; RET proto-oncogene; tyrosine kinase; isoforms	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE; PROTOONCOGENE MUTATIONS; CELL-LINE; FMTC; EXPRESSION; RECEPTOR; DISEASE; GENE; SPECIFICITY	Germline mutations of the RET proto-oncogene, which codes for a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. The RET gene encodes several isoforms whose biological properties, when altered by MEN 2 mutations, have not been thoroughly addressed yet. In this study, we have introduced a MEN 2A mutation (Cys634-->Arg) and the unique MEN 2B mutation (Met918-->Thr) in two RET isoforms of 1114 and 1072 amino acids which differ in the carboxy-terminus part, Herein, we report that each RET isoform activated by MEN 2A or MEN 2B mutation was transforming in fibroblasts and induced neuronal differentiation of pheochromocytoma PC12 cells. However, among the different RET-MEN 2 mutants, the long RET isoform activated by the MEN 2B mutation stimulated the most prominent neurite outgrowth in PC12 cells, while the short RET isoform counterpart elicited a very weak differentiation effect in PC12 cells. We further demonstrate that the morphological changes of PC12 cells caused by constitutively activated RET oncoproteins involved the engagement of a Ras-dependent pathway. These findings provide evidence that the biological properties of RET-MEN 2 mutants depend on the interplay between the RET isoforms and the nature of the activating MEN 2 mutation.	UNIV LYON 1,GENET LAB,UMR 5641 CNRS,F-69373 LYON 08,FRANCE; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,UMR 49 CNRS,F-69364 LYON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Nagoya University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			TAKAHASHI, Masahide/I-7244-2014; Urdiales, José Luis/K-1125-2014; van Grunsven, Leo/E-5839-2010; Takahashi, Masahide/AAN-4770-2020; Billaud, Marc N/M-6954-2013	Urdiales, José Luis/0000-0002-2519-9293; van Grunsven, Leo/0000-0002-0990-7034; Takahashi, Masahide/0000-0002-2803-2683; RUDKIN, Brian B./0000-0003-3700-1982; Rossel, Mireille/0000-0003-2275-0817				ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BOLINO A, 1995, ONCOGENE, V10, P2415; BORELLO MG, 1995, ONCOGENE, V11, P2419; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELELLIS RA, 1995, LAB INVEST, V72, P494; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1994, HUM MOL GENET, V3, P234; FOURNIER E, 1995, ONCOGENE, V11, P921; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSSEL M, 1995, HUM GENET, V95, P403; RUSSO AF, IN PRESS GENETIC MEC; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	55	78	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					265	275		10.1038/sj.onc.1200831	http://dx.doi.org/10.1038/sj.onc.1200831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018112				2022-12-28	WOS:A1997WD51600002
J	Zarkowska, T; U, S; Harlow, E; Mittnacht, S				Zarkowska, T; U, S; Harlow, E; Mittnacht, S			Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs	ONCOGENE			English	Article						pRB; epitope mapping; cyclin D1-CDK4 kinase; phosphorylation site; cell cycle	SUSCEPTIBILITY GENE-PRODUCT; MAP KINASE; PROGRESSION; PHOSPHATASE; FAMILY	The growth suppressive activity of the retinoblastoma tumour suppressor protein is controlled by cell cycle dependent phosphorylation, However, while many in vivo phosphorylation sites have been mapped, the identities of those residues whose phosphorylation is regulated remain elusive, We have mapped the epitopes of three independent monoclonal antibodies that recognise a distinction between differentially phosphorylated pRB sub-populations. All three antibodies recognise an identical epitope which encompasses an essential serine positioned within a consensus site for proline directed kinase phosphorylation, We provide evidence that this residue, serine 608 of pRB, is an authentic phosphorylation site that can be phosphorylated in vitro by cyclin A-CDK2 and cyclin D1-CDK4 kinases but not by cyclin E-CDK2 kinase or the mitogen activated kinase ERK2. Phosphorylation at this residue seems to be cell cycle regulated, occurring prior to entry into the S phase.	INST CANC RES,DEPT CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND; MASSACHUSETTS GEN HOSP,ONCOL MOL LAB,CHARLESTOWN,MA 02129	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Harvard University; Massachusetts General Hospital								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Belbrahem A, 1996, EXP CELL RES, V225, P286, DOI 10.1006/excr.1996.0178; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; HAMEL PA, 1992, ONCOGENE, V7, P693; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Possee RD., 1992, BACULOVIRUS EXPRESSI; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	22	55	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					249	254		10.1038/sj.onc.1200824	http://dx.doi.org/10.1038/sj.onc.1200824			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010227				2022-12-28	WOS:A1997WC81800013
J	Broome, MA; Hunter, T				Broome, MA; Hunter, T			The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding	ONCOGENE			English	Article						PDGF receptors; c-Src; SH3 domain; tyrosine phosphorylation	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; PROLINE-RICH PEPTIDES; MUTANT MICE; BACULOVIRUS EXPRESSION; CRYSTAL-STRUCTURE; SARCOMA VIRUS; BETA-RECEPTOR; CELL-CYCLE; 3T3 CELLS	Treatment of quiescent NIH3T3 cells with PDGF BE results in the transient activation and hyperphosphorylation of the protein-tyrosine kinase, c-Src. These effects correlate with novel serine and tyrosine phosphorylations in the N-terminal non-catalytic region of the molecule, which contains an SH3 and SH2 domain. In this study, a site of PDGF-induced tyrosine phosphorylation was mapped to Tyr 138 in the SH3 domain; Tyr 138 is exposed on the SH3 peptide binding surface. This same site is phosphorylated in vitro by the PDGF receptor when purified baculovirus-expressed c-Src is complexed with the activated receptor. Phosphorylation of Tyr 138 required association of c-Src with the PDGF receptor via its SH2 domain. When a c-Src Phe 138 mutant was stably expressed in Src(-) mouse fibroblasts, it was activated to the same extent as wild type c-Src following PDGF stimulation, indicating that phosphorylation of this site is not required for PDGF-mediated activation. However, Tyr 138 phosphorylation was found to diminish SH3 domain peptide ligand binding ability in vitro.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GARTNER T, 1992, EUR J BIOCHEM, V208, P91, DOI 10.1111/j.1432-1033.1992.tb17162.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Ishino M, 1995, ONCOGENE, V11, P2331; KARN J, 1989, ONCOGENE, V4, P773; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LIU XQ, 1993, ONCOGENE, V8, P1119; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSTELIN T, 1994, SRC FAMILY TYROSINE; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OKADA M, 1993, J BIOL CHEM, V268, P18070; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENG ZY, 1995, ONCOGENE, V11, P1955; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Possee RD., 1992, BACULOVIRUS EXPRESSI; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Summers MD, 1987, MANUAL METHODS BACUL; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALKER F, 1993, J BIOL CHEM, V268, P19552; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU KT, 1985, J BIOL CHEM, V260, P5838; ZHANG S, 1991, Cellular Physiology and Biochemistry, V1, P24, DOI 10.1159/000154590	83	41	41	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					17	34		10.1038/sj.onc.1200798	http://dx.doi.org/10.1038/sj.onc.1200798			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010229				2022-12-28	WOS:A1997WB76000002
J	Costello, PS; Turner, M; Walters, AE; Cunningham, CN; Bauer, PH; Downward, J; Tybulewicz, VLJ				Costello, PS; Turner, M; Walters, AE; Cunningham, CN; Bauer, PH; Downward, J; Tybulewicz, VLJ			Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells	ONCOGENE			English	Article						Syk; Fc epsilon RI; mast cell; signal transduction; allergy	BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-E RECEPTOR; ANTIGEN RECEPTOR; MICE LACKING; TRANSCRIPTION FACTOR; GAMMA-CHAIN; T-CELLS; PHOSPHOLIPASE C-GAMMA-1	Activation of the high affinity IgE receptor (Fc epsilon RI) of mast cells, a member of the antigen receptor family, leads to the release of allergic mediators, a critical event in the onset of immediate hypersensitivity. Stimulation of Fc epsilon RI results in the rapid association and activation of the Syk tyrosine kinase. Using Syk-deficient mast cells we show that they fail to degranulate, synthesize leukotrienes and secrete cytokines when stimulated through Fc epsilon RI, conclusively demonstrating an essential role for Syk in Fc epsilon Phi RI signalling, Furthermore, our data strongly supports a model of Fc epsilon RI engagement leading to the sequential activation of the tyrosine kinases Lyn and then Syk, A similar mechanism is likely to apply to signal transduction through all members of the antigen receptor family.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Turner, Martin/N-9976-2014	Turner, Martin/0000-0002-3801-9896; Downward, Julian/0000-0002-2331-4729				Adachi M, 1996, CELL, V85, P15; ALBER G, 1991, J BIOL CHEM, V266, P22613; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; Choi OH, 1996, NATURE, V380, P634; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DAI TN, 1995, ONCOGENE, V10, P849; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EISEMAN E, 1992, NATURE, V355, P78; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GRAND DG, 1994, J EXP MED, V180, P673; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HO AM, 1994, J BIOL CHEM, V269, P28181; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kimura T, 1996, MOL CELL BIOL, V16, P1471; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OHNO H, 1994, J EXP MED, V179, P365, DOI 10.1084/jem.179.1.365; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; ORTEGA E, 1989, EUR J IMMUNOL, V19, P2251, DOI 10.1002/eji.1830191211; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Schultz Leonard D., 1993, Cell, V73, P1445; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WADHWA M, 1991, QUANTITATIVE BIOL AS, P309; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	73	263	269	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2595	2605						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000133				2022-12-28	WOS:A1996VZ65400009
J	Buttice, G; DuterqueCoquillaud, M; Basuyaux, JP; Carrere, S; Kurkinen, M; Stehelin, D				Buttice, G; DuterqueCoquillaud, M; Basuyaux, JP; Carrere, S; Kurkinen, M; Stehelin, D			Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex	ONCOGENE			English	Article						extracellular matrix; metalloproteinases; oncogenes; gene regulation	SERUM RESPONSE ELEMENT; DNA-BINDING MOTIF; TRANSCRIPTION FACTORS; C-FOS; EXTRACELLULAR-MATRIX; DOMAIN PROTEINS; AP-1 SITE; ACTIVATION; ENHANCER; PROMOTER	Collagenase1 (MMP1) and stromelysin1 (MMP3) are extracellular proteolytic enzymes that degrade connective tissue macromolecules and basement membranes. Both genes are regulated by the Ets and Fos/Jun families of transcription factors/oncoproteins. Here, we show that two members of the Ets-family, Ets2 and Erg and their combinations differentially regulate collagenase1 and stromelysin1 promoter activity. In transiently transfected cells, Ets2 activates both promoters whereas Erg induces collagenase1 but not stromelysin1 promoter activity. Moreover, Erg completely inhibits stromelysin1 promoter activation by Ets2. In gel shift assays however, the Erg protein bound little or not to the collagenase1 promoter, whereas it bound to the stromelysin1 promoter. By site-specific mutagenesis, we identified one major site at -88 that abolished collagenase1 promoter activation by Erg. Surprisingly, mutation of the collagenase1 AP1 site at -73 also abolished the activation by Erg suggesting that Erg cooperates with Fos/Jun in collagenase1 promoter regulation. Indeed, gel shift and in vitro protein interaction studies showed that Erg binds to the Fos/Jun complex. Thus, Erg represents the first example of a transcription factor that can distinguish between the collagenase1 and stromelysin1 promoters in that when Erg is recruited by Fos/Jun at the promoter, it transcriptionally activates collagenase1 gene but not stromelysin1 expression.	WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, CTR MOL MED GENET, DETROIT, MI 48202 USA	Wayne State University; Wayne State University	Buttice, G (corresponding author), INST PASTEUR, CNRS URA 1160, MOL ONCOL LAB, 1 RUE CALMETTE, BP 245, F-59019 LILLE, FRANCE.			Duterque-Coquillaud, Martine/0000-0003-3943-5629; Buttice', Giovanna/0000-0001-6550-5585				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BUTTICE G, 1990, NUCLEIC ACIDS RES, V18, P3079, DOI 10.1093/nar/18.10.3079; BUTTICE G, 1994, CONTRIB NEPHROL, V107, P101; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NERLOV C, 1991, ONCOGENE, V6, P1583; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERB Z, 1994, PROTEINASES MATRIX D; WERNERT N, 1992, AM J PATHOL, V140, P119; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	57	140	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2297	2306						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957070				2022-12-28	WOS:A1996VX10800001
J	Smith, ML; Kontny, HU; Zhan, QM; Sreenath, A; OConnor, PM; Fornace, AJ				Smith, ML; Kontny, HU; Zhan, QM; Sreenath, A; OConnor, PM; Fornace, AJ			Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to uv-irradiation or cisplatin	ONCOGENE			English	Article						p53; GADD45; repair	NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL DOMAIN; NUCLEAR ANTIGEN; GROWTH ARREST; G1 CHECKPOINT; P53; DAMAGE; PROTEIN; INHIBITION; REPLICATION	Loss of p53 function in cancer cells commonly results in a condition of genomic instability. This is believed to emanate from a loss of the G(1) checkpoint response to DNA damage. While the role of p53 in the induction of a G(1) arrest is well-accepted, additional p53 functions are being discovered. Cell cycle checkpoints presumably function to allow additional time for DNA repair after damage is incurred, however, genetic studies in yeast suggest that components of the checkpoint pathway may also be involved in DNA lesion processing (Lydall and Weinert, 1995). Recent evidence suggests that this may also be the case for p53, as suggested by numerous reports linking p53 function to DNA repair. Thus, loss of p53 function might contribute to genomic instability independent of G(1)-arrest. In the present study, we explored the effect of p53 disruption and consequences of antisense GADD45 expression on the DNA repair capacity of human colon carcinoma RKO cells. DNA repair was assayed using host-cell reactivation of u.v.-damaged reporter plasmids and unscheduled DNA synthesis experiments in transiently-transfected cells. We show that a number of transfected genes that suppress p53 function reduce the ability of cells to repair u.v.-induced DNA damage. Moreover, cells in which expression of the p53-regulated gene GADD45 was blocked by antisense vectors, also showed altered levels of DNA repair. Blocking Gadd45 expression by constitutive antisense expression sensitized cells to killing by u.v.-radiation or by cis-platinum (II) diamine-dichloride (CDDP, or cisplatin), a cancer chemotherapy drug which produces DNA cross-links. These findings suggest the involvement of downstream effecters of the p53 pathway in the coordination of cell cycle arrest and DNA repair.			Smith, ML (corresponding author), NCI,DIV CANC TREATMENT,MOL PHARMACOL LAB,DEV THERAPEUT PROGRAM,NIH,BLDG 37,ROOM 5C09,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bae I, 1996, CANCER RES, V56, P840; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BURK PG, 1971, J LAB CLIN MED, V77, P759; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN IT, 1995, ONCOGENE, V11, P1931; COFFER PJ, 1995, ONCOGENE, V11, P561; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FAN SJ, 1995, CANCER RES, V55, P1649; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDBERG EC, 1995, DNA REPAIR; HALL PA, 1995, ONCOGENE, V10, P2427; HAVRE PA, 1995, CANCER RES, V55, P4420; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KLOCKER H, 1985, European Journal of Cell Biology, V39, P346; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Li G, 1996, AM J PATHOL, V148, P1113; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; McDonald E, 1996, CANCER RES, V56, P2250; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; Smith ML, 1996, AM J PATHOL, V148, P1019; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vairapandi M, 1996, ONCOGENE, V12, P2579; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	144	153	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2255	2263						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950993				2022-12-28	WOS:A1996VV14500023
J	Guenal, I; SidotideFraisse, C; Gaumer, S; Mignotte, B				Guenal, I; SidotideFraisse, C; Gaumer, S; Mignotte, B			Bcl-2 and Hsp27 act at different levels to suppress programmed cell death	ONCOGENE			English	Article						apoptosis; p53; simian virus 40; Bcl-2; Hsp27; necrosis	TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; SUBCELLULAR-LOCALIZATION; MITOCHONDRIAL-MEMBRANES; OUTER-MEMBRANE; IN-VIVO; APOPTOSIS; EXPRESSION	Apoptosis and necrosis, two morphologically distinct forms of cell death, can be induced by common stimuli depending on the doses and the cell type, This study compares the protective effect of oncoprotein Bcl-2 and of the small stress protein Hsp27 on these two types of cell death, We use rat embryo fibroblasts conditionally immortalized by the tsA58 mutant of SV40 large T antigen as parental cells to develop cell lines carrying inducible bcl-2 or hsp27 genes. Two apoptotic stimuli were used: shift to the restrictive temperature that induced p53-mediated apoptosis and treatment with low doses of hydrogen peroxide, Necrosis was induced by high doses of hydrogen peroxide. Although Bcl-2 and Hsp27 protect these cells from necrotic death, only Bcl-2 appears capable of preventing apoptotic death, Bcl-2 protection is not mediated by a negative effect on the induction of the p53 responsive genes bax or waf1 but it slows down at least two stages of apoptosis: decrease of mitochondrial membrane potential and subsequent morphological changes, In contrast, although Hsp27 has been recently shown to inhibit apoptosis induced by various stimuli, its overexpression has no effect on apoptosis in this cell system. It should be also noticed that the apoptotic stimuli (temperature shift or hydrogen peroxide treatment) induce Hsp27, but not Bcl-2 accumulation suggesting that, in parental cells, Hsp27 might already provide some protection, However, taken together these results suggest that Hsp27, as well as Bcl-2, acts at several levels to inhibit cell death, but that their protective functions only partially overlap.	CNRS,CTR GENET MOL,UPR 9061,F-91198 GIF SUR YVETTE,FRANCE; UNIV VERSAILLES,F-78035 VERSAILLES,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay			Guenal, Isabelle/F-3415-2019; Mignotte, Bernard/A-3499-2009	Guenal, Isabelle/0000-0003-1186-1458; Mignotte, Bernard/0000-0002-8512-8518				AKAO Y, 1994, CANCER RES, V54, P2468; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; DEJONG D, 1994, CANCER RES, V54, P256; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUOT J, 1991, CANCER RES, V51, P5245; ITOH N, 1993, J IMMUNOL, V151, P621; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; KORCHAK HM, 1982, BIOCHEM BIOPH RES CO, V108, P1495, DOI 10.1016/S0006-291X(82)80076-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LASTER SM, 1988, J IMMUNOL, V141, P2629; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LU QL, 1994, J CELL SCI, V107, P363; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; NAKAI M, 1993, BIOCHEM BIOPH RES CO, V196, P233, DOI 10.1006/bbrc.1993.2239; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SUSIN SA, 1996, J EXP MED, V184, P1; SUZUKI K, 1994, EUR J CELL BIOL, V63, P280; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UPADHYAY S, 1995, CANCER RES, V55, P4520; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZHENG DQ, 1994, ONCOGENE, V9, P3345; ZHENG LT, 1993, P NATL ACAD SCI USA, V90, P4533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; [No title captured]	78	88	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					347	360		10.1038/sj.onc.1201182	http://dx.doi.org/10.1038/sj.onc.1201182			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233769	Bronze			2022-12-28	WOS:A1997XK99900011
J	Lavender, P; Vandel, L; Bannister, AJ; Kouzarides, T				Lavender, P; Vandel, L; Bannister, AJ; Kouzarides, T			The HMG-box transcription factor HBP1 is targeted by the pocket proteins and E1A	ONCOGENE			English	Article						HMG-box; retinoblastoma; E1A	RETINOBLASTOMA PROTEIN; FUNCTIONAL INTERACTION; ACTIVATION DOMAIN; CELL-CYCLE; RB; BINDING; FOS; E2F; REPRESSION; EXPRESSION	A yeast two-hybrid screen has identified HBP1 as a transcription factor capable of interacting with the pocket protein family. We show that HBP1 can interact with one of these, RE, both in vitro and in mammalian cells. Two distinct RE binding sites are present within HBP1 - a high affinity binding site, mediated by an LXCXE motif and a separate low affinity binding site present within an activation domain. GAL4-fusion experiments indicate that HBP1 contains a masked activation domain. Deletion of two independent N- and C-terminal inhibitor domains unmasks an activation domain which is 100-fold more active than the full length protein. The released activation capacity is repressed by RE, p130 and p107. In addition, E1A can repress the activity of HBP1 via conserved region 1 sequences in a manner independent of the CBP coactivator. We show by stable expression in NIH3T3 cells that HBP1 has the capacity to induce morphological transformation of cells in culture.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge; University of Cambridge				Kouzarides, Tony/0000-0002-8918-4162; Lavender, Paul/0000-0001-8710-0263; Vandel, Laurence/0000-0002-3692-2942; Bannister, Andrew/0000-0002-6312-4436	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P228; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NEVINS JR, 1992, SCIENCE, V258, P424; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	34	59	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2721	2728		10.1038/sj.onc.1201243	http://dx.doi.org/10.1038/sj.onc.1201243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178770				2022-12-28	WOS:A1997XB97800011
J	Warbrick, E; Lane, DP; Glover, DM; Cox, LS				Warbrick, E; Lane, DP; Glover, DM; Cox, LS			Homologous regions of Fen1 and p21(Cip1) compete for binding to the same site on PCNA: A potential mechanism to co-ordinate DNA replication and repair	ONCOGENE			English	Article						Fen1; p21(Cip1); PCNA; DNA replication; DNA repair	CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; SCHIZOSACCHAROMYCES-POMBE; MOLECULAR-CLONING; AUXILIARY PROTEIN; ESCHERICHIA-COLI; RAD2 GENE	Following genomic damage, the cessation of DNA replication is co-ordinated with onset of DNA repair; this co-ordination is essential to avoid mutation and genomic instability, To investigate these phenomena, we have analysed proteins that interact with PCNA, which is required for both DNA replication and repair, One such protein is p21(Cip1), which inhibits DNA replication through its interaction with PCNA, while allowing repair to continue, We have identified an interaction between PCNA and the structure specific nuclease, Fen1, which is involved in DNA replication, Deletion analysis suggests that p21(Cip1) and Fen1 bind to the same region of PCNA, Within Fen1 and its homologues a small region (10 amino acids) is sufficient for PCNA binding, which contains an 8 amino acid conserved PCNA-binding motif, This motif shares critical residues with the PCNA-binding region of p21(Cip1), A PCNA binding peptide from p21(Cip1) competes with Fen1 peptides for binding to PCNA, disrupts the Fen1-PCNA complex in replicating cell extracts, and concomitantly inhibits DNA synthesis, Competition between homologous regions of Fen1 and p21(Cip1) for binding to the same site on PCNA may provide a mechanism to co-ordinate the functions of PCNA in DNA replication and repair.	UNIV DUNDEE,DEPT BIOCHEM,CRC LABS,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,CRC LABS,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Cox, Lynne/AAT-2047-2021; Warbrick, Emma/C-6424-2008; Lane, David P/C-4920-2008	Cox, Lynne/0000-0002-5306-285X; Lane, David/0000-0003-0551-3545; Glover, David/0000-0003-0956-0103				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORES RH, 1994, P NATL ACAD SCI USA, V91, P8655; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GULBIS JM, 1996, CELL, V87, P1; HALL PA, 1995, ONCOGENE, V10, P2427; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUPPI K, 1994, ONCOGENE, V9, P3017; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; Savio M, 1996, ONCOGENE, V13, P1591; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WASEEM NH, 1990, J CELL SCI, V96, P121; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XIONG Y, 1992, CELL, V71, P504	54	139	141	16	126	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2313	2321		10.1038/sj.onc.1201072	http://dx.doi.org/10.1038/sj.onc.1201072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178907				2022-12-28	WOS:A1997WY88300008
J	Rothenberger, S; Bachmann, E; Berger, C; McQuain, C; Odermatt, BF; Knecht, H				Rothenberger, S; Bachmann, E; Berger, C; McQuain, C; Odermatt, BF; Knecht, H			Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NF-kappa B-mediated transcription	ONCOGENE			English	Article						Epstein-Barr virus; latent membrane protein 1 (LMP1); NF-kappa B; ICAM-1; lymphoproliferative disorders	EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; CELLS; EXPRESSION; TRANSFORMATION; GENE; ACTIVATION; INDUCTION	An increasing number of reports shows a link between the Epstein-Barr virus (EBV) and lymphoid neoplasia. The latent membrane protein 1 (LMP1) is likely to play a determinant role in this process since this EBV encoded protein has oncogenic properties and is usually expressed in EBV-associated lymphoproliferative diseases (LPD), except Burkitt's lymphoma, We previously identified in LPD patients mutational hot spots and a 30 bp or 69 bp deletion in the LMP1 gene region coding for the C-terminal domain, These deletions are located in an area shown to be important for the activation of the transcription factor NF-kappa B. These findings lead us to test whether these natural deletion variants may have a functional effect, We measured the stimulation of their activity using a luciferase reporter plasmid containing NF-kappa B responsive elements, We tested the NF-kappa B inducing activity of four naturally occurring LMP1 deletion variants, Our results show that these deletion variants activate NF-kappa B to the same level as the wildtype form, indicating that the crucial residues for NF-kappa B activation are conserved among the variants isolated and lie within the last 32 amino acids of the C-terminal domain of the LMP1 oncogene.	UNIV MASSACHUSETTS, MED CTR, CTR CANC, LINK LABS, WORCESTER, MA USA; UNIV ZURICH HOSP, IMMUNOPATHOL LAB, CH-8091 ZURICH, SWITZERLAND; UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Massachusetts System; University of Massachusetts Worcester; University of Zurich; University Zurich Hospital; University of Lausanne				Rothenberger, Sylvia/0000-0001-8633-2994				BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; KLEIN C, 1995, BRIT J HAEMATOL, V91, P938, DOI 10.1111/j.1365-2141.1995.tb05416.x; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, LEUKEMIA, V7, P580; Knecht H, 1996, ONCOGENE, V13, P947; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Li SN, 1996, ONCOGENE, V12, P2129; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MILLER G, 1990, VIROLOGY, P1921; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988	35	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2123	2126		10.1038/sj.onc.1201032	http://dx.doi.org/10.1038/sj.onc.1201032			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160892				2022-12-28	WOS:A1997WW80900014
J	Ivanchuk, SM; Eng, C; Cavenee, WK; Mulligan, LM				Ivanchuk, SM; Eng, C; Cavenee, WK; Mulligan, LM			The expression of RET and its multiple splice forms in developing human kidney	ONCOGENE			English	Article						RET; kidney; alternative splicing	GROWTH-FACTOR RECEPTORS; ADULT-RAT TISSUES; TYROSINE KINASE; PROTO-ONCOGENE; PROTOONCOGENE PRODUCT; MESSENGER-RNA; CELL-LINE; VARIANTS; TRANSFORMATION; SPECIFICITY	A series of inductive events between two different cell groups, the ureteric bud epithelium and metanephric mesenchyme, gives rise to the functional mammalian kidney, These reciprocal inductive interactions involve a number of molecules, one of which is the RET receptor tyrosine kinase, The phenotype of mice lacking functional RET includes kidney agenesis or severe dysgenesis, indicating a requirement for RET in kidney organogenesis, To investigate RET expression in human kidney development, we used a semi-quantitative RT-PCR-based strategy to examine a panel of kidney RNA samples ranging from 8-24 weeks gestational age, We found RET expression was highest earlier in development (14 weeks) with expression decreasing through to 24 weeks gestation, While three alternative RET transcripts generated by exon skipping at the 5' end of the gene were all detected throughout kidney development, expression of one transcript, RET2/6, where exon 2 was spliced to exon 6, varied relative to full length RET during this period, Levels of RET2/6 were highest at the earliest age of fetal kidney examined (8 weeks) and decreased relative to all other RET transcripts to low adult levels, The period of high expression coincides with a period of rapid bud bifurcation, Thus, it is possible that RET2/6 has a role in the early growth and differentiation of the human kidney.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; HARVARD UNIV,SCH MED,DEPT MED,DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTRO,BOSTON,MA 02115; LUDWIG INST CANC RES,SAN DIEGO BRANCH,LA JOLLA,CA 92093	Queens University - Canada; Queens University - Canada; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Ludwig Institute for Cancer Research				Eng, Charis/0000-0002-3693-5145				ASAI N, 1995, MOL CELL BIOL, V15, P1613; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BARD JBL, 1994, MECH DEVELOP, V48, P3, DOI 10.1016/0925-4773(94)00273-8; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; BRACEY LT, 1987, P NATL ACAD SCI USA, V84, P9020, DOI 10.1073/pnas.84.24.9020; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CALIFANO D, 1995, ONCOGENE, V11, P107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Durbec PL, 1996, DEVELOPMENT, V122, P349; ENG C, 1997, IN PRESS HUM MUTAT; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LEONG SS, 1983, ADV THYROID NEOPLASI, P95; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORRISON C, 1994, BBA-GENE STRUCT EXPR, V1219, P493, DOI 10.1016/0167-4781(94)90076-0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POTTER EL, 1972, NORMAL ABNORMAL DEV, V1; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	43	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1811	1818		10.1038/sj.onc.1201016	http://dx.doi.org/10.1038/sj.onc.1201016			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150387				2022-12-28	WOS:A1997WW16600007
J	Isaacs, JS; Chen, PC; Garza, A; Hansen, MF; Barrett, JC; Weissman, BE				Isaacs, JS; Chen, PC; Garza, A; Hansen, MF; Barrett, JC; Weissman, BE			Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids	ONCOGENE			English	Article						p53; E6; tumor suppressor genes	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; MAMMARY EPITHELIAL-CELLS; GENE-MUTATIONS; HUMAN KERATINOCYTES; IN-VITRO; PROTEIN; EXPRESSION; UBIQUITIN; TUMOR	The ability of the E6 protein from high risk human papillomaviruses (HPVs) to degrade p53 via the ubiquitin pathway plays a major role in the development of cervical carcinomas. We have previously generated cell hybrids between a p53 null peripheral neuroepithelioma (PNET) cell line and a cervical carcinoma HeLa cell line which exhibits efficient E6-mediated degradation of p53. All of the resulting hybrids expressed HPV 18 E6 from the HeLa parent and some of the hybrids additionally expressed HPV 16 E6. Surprisingly, in spite of abundant E6 expression, the hybrids expressed relatively high steady-state levels of the wild-type p53 protein. We then examined the hybrids to determine whether other components of the E6-mediated degradation pathway were missing or nonfunctional. Specifically, we determined that the E6-associated protein (E6-AP), essential for E6-mediated degradation, was expressed. We further verified that these hybrids had a functional ubiquitination pathway, which suggests that this phenomenon is not due to a general defect in this pathway. We therefore conclude that other unidentified, possibly cell-specific factors can play a role in the E6-mediated degradative process and may act to inhibit this process.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; BOSTON UNIV,SCH MED,CTR HUMAN GENET,BOSTON,MA 02118; NATL INST ENVIRONM HLTH SCI,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NATIONAL CANCER INSTITUTE [R03CA053318, R01CA053318, U01CA060122, R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60122, CA 53318, CA 44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Bernard Bruno A., 1993, P207; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; CHEN TM, 1992, ONCOGENE, V7, P1541; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONNEHOWER L, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FOURET P, 1995, AM J PATHOL, V146, P599; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HALL IJ, 1996, IN PRESS GENES CHROM; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANDESMAN Y, 1994, ONCOGENE, V9, P1241; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE KA, 1994, ANN ONCOL         S1, V5, P85; LI Y, 1994, ONCOGENE, V9, P2261; LIANG XH, 1993, ONCOGENE, V8, P2645; LOWRY DR, 1994, P NATL ACAD SCI USA, V91, P2436; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SPANDAU DF, 1994, ONCOGENE, V9, P1861; TERVAHAUTA AI, 1994, CYTOPATHOLOGY, V5, P282, DOI 10.1111/j.1365-2303.1994.tb00432.x; THOMAS M, 1995, ONCOGENE, V10, P261; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VILLUENDAS R, 1993, BLOOD, V82, P3151; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1990, CANCER SURV, V9, P475; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	67	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1669	1678		10.1038/sj.onc.1201001	http://dx.doi.org/10.1038/sj.onc.1201001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135068				2022-12-28	WOS:A1997WR89300005
J	Hall, AR; Milner, J				Hall, AR; Milner, J			Specific p53-DNA complexes contain an mdm2-related protein	ONCOGENE			English	Article						p53; mdm-2; specific DNA binding	P53 QUATERNARY STRUCTURE; DNA-BINDING; WILD-TYPE; TUMOR-SUPPRESSOR; ONCOPROTEIN MDM2; GENE; IDENTIFICATION; EXPRESSION; ACTIVATION; ONCOGENE	The mdm2 gene encodes a family of proteins, a subset of which bind p53 and negatively regulate its function as a transcription factor. We now show that an anti-mdm-2 monoclonal antibody, 2A10, recognises a protein present in rabbit reticulocyte lysate which binds murine p53 translated in vitro. Deletion of p53 residues 10-35, which encompass the mdm-2 binding site, abolished binding of this 2A10-reactive protein. Binding was also dependent upon p53 protein conformation and may require nascent p53 polypeptide since binding was lost following conformational shifting of the temperature-sensitive mutant: A135V. Previous studies have shown that mdm-2-p53 complexes fail to exhibit detectable sequence-specific DNA binding. However, our present results demonstrate that p53 in complex with an mdm-2-related protein in vitro retained sequence-specific DNA binding capacity. Non-transformed (but not transformed) 3T3 cells were also found to express a similar 2A10-reactive protein, detectable by gel shift analysis of cellular p53 in complex with a specific DNA target. Mdm-2 in rabbit reticulocyte lysate and in normal, nontransformed 3T3 cells may represent constitutively expressed protein. Our results raise the possibility that constitutive mdm-2 may enhance and/or suppress functions of p53 as yet unidentified.	UNIV YORK,DEPT BIOL,YCRC P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARAK Y, 1993, EMBO J, V12, P2799; BUESORAMOS CE, 1995, LEUKEMIA LYMPHOMA, V17, P13, DOI 10.3109/10428199509051698; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HAINAUT P, 1994, ONCOGENE, V9, P299; HAINAUT P, 1993, CANCER RES, V53, P4463; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1993, ONCOGENE, V8, P2001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZERRAHN J, 1992, ONCOGENE, V7, P1371	36	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1371	1376		10.1038/sj.onc.1200962	http://dx.doi.org/10.1038/sj.onc.1200962			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178897				2022-12-28	WOS:A1997WP10900012
J	Francastel, C; AugeryBourget, Y; Prenant, M; Walters, M; Martin, DIK; RobertLezenes, J				Francastel, C; AugeryBourget, Y; Prenant, M; Walters, M; Martin, DIK; RobertLezenes, J			c-Jun inhibits NF-E2 transcriptional activity in association with p18/maf in Friend erythroleukemia cells	ONCOGENE			English	Article						c-Jun; NF-E2; transactivation; globin regulation; erythroleukemia	PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; SMALL MAF PROTEINS; ERYTHROID-CELLS; TRANSGENIC MICE; DIFFERENTIATION; EXPRESSION; FOS; ENHANCER	We have reported previously that antisense c-jun overcomes a block of Friend erythroleukemia cells to differentiation suggesting that the factor c-Jun may be an important negative regulator of erythroid differentiation, The recently described erythroid transcription factor NF-E2 plays an important role in the regulation of the transcription of globin genes and recognizes a sequence containing an AP-1 site, NF-E2 is a complex of two bZip proteins, p45 and p18/Maf. In order to determine whether c-Jun can interact with NF-E2/AP-1 sites to regulate transcriptional activation from them, we have compared the activity of AP-1 and NF-E2 in transient transcriptional assays, in erythroid and nonerythroid cells in the presence of c-jan sense and antisense expression vectors. In non-erythroid cells, c-Jun activates and NF-E2p18 inhibits both AP-1 and NF-E2 activities, suggesting that NF-E2/AP-1 sites function as AP-1 binding sites in these cells, In contrast, NF-E2p18 is a positive regulator of NF-E2 activity in erythroid cells. c-Jun alone is also a positive regulator of NF-E2 activity in erythroid cells but in association with NF-E2p18 inhibits this activity, Moreover antisense c-jun increases endogenous NF-E2 activity in erythroid cells. These results suggest that c-Jun could act as a repressor of NF-E2 transcriptional activity by forming inactive c-Jun/NF-E2p18 heterocomplexes which interfer with the transcription of globin genes in Friend erythroleukemia cells.	HOP PAUL BROUSSE,INSERM U268,F-94800 VILLEJUIF,FRANCE; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Fred Hutchinson Cancer Center			Francastel, Claire/AAI-4798-2021	Francastel, Claire/0000-0002-6353-4320				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHARNAY P, 1984, CELL, V55, P17; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PROFOUSJUCHELKA HR, 1983, MOL CELL BIOL, V3, P229, DOI 10.1128/MCB.3.2.229; ROBERTLEZENES J, 1988, CANCER RES, V48, P3972; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444	26	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					873	877		10.1038/sj.onc.1200902	http://dx.doi.org/10.1038/sj.onc.1200902			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047395				2022-12-28	WOS:A1997WJ11200014
J	Douglas, AM; Goss, GA; Sutherland, RL; Hilton, DJ; Berndt, MC; Nicola, NA; Begley, CG				Douglas, AM; Goss, GA; Sutherland, RL; Hilton, DJ; Berndt, MC; Nicola, NA; Begley, CG			Expression and function of members of the cytokine receptor superfamily on breast cancer cells	ONCOGENE			English	Article						breast cancer; cytokines; receptors; cell growth; growth factors	LEUKEMIA INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; MAMMARY EPITHELIAL-CELLS; IL-6 SIGNAL TRANSDUCER; CARCINOMA CELLS; PROLACTIN RECEPTORS; MESSENGER-RNAS; EGF RECEPTOR; GM-CSF; INTERLEUKIN-6	Receptors for the cytokines leukemia inhibitory factor (LIF), interleukin-6 (IL-6), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and interleukin-11 (IL-11) are members of the structurally conserved hemopoietin receptor superfamily, In addition, they all share the transmembrane signalling protein gp130, In this paper the expression and function of this family of receptors in breast cancer cells was examined, RT-PCR analyses demonstrated that gp130 was expressed in 12/12 breast cell lines and the specific receptor alpha-chains for IL-6, LIF, IL-11 and CNTF were expressed in the majority of these cell lines, This was in contrast to other hemopoitin receptors, Examination of 50 clinical samples of malignant breast tissue by RT-PCR showed a similar pattern of expression of gp130 associated receptors, Treatment of breast cancer cell lines with OSM resulted in changes in cellular morphology. Cellular proliferation was inhibited following exposure to OSM (3/4 cell lines), IL-11 (2/4 cell lines), and by IL-6 and LIF (1/4 cell lines), Cell surface binding of LIF and OSM was also documented, The expression of these receptors in 12/12 cell lines and greater than 95% of clinical samples suggests that these molecules may be important in regulating the growth of breast cells.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA; BAKER MED RES INST, PRAHRAN, VIC 3181, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR GROWTH FACTORS, PARKVILLE, VIC 3050, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Baker Heart and Diabetes Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Douglas, AM (corresponding author), ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LABS, PARKVILLE, VIC 3050, AUSTRALIA.		Sutherland, Robert L/A-8378-2008; Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013; Berndt, Michael C/D-5580-2012	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; 				ABE O, 1992, LANCET, V339, P71; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BONNETERRE J, 1986, EUR J CANCER CLIN ON, V22, P1331, DOI 10.1016/0277-5379(86)90141-0; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DANFORTH DN, 1993, CANCER RES, V53, P1538; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DICKSON RB, 1992, SEMIN ONCOL, V19, P286; EMERMAN JT, 1994, BONE MARROW TRANSPL, V13, P285; ETHIER SP, 1993, CANCER RES, V53, P627; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARRIS AL, 1994, BREAST CANCER RES TR, V29, P1, DOI 10.1007/BF00666176; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KACINSKI BM, 1991, ONCOGENE, V6, P941; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOEHORST SGA, 1993, J STEROID BIOCHEM, V45, P227, DOI 10.1016/0960-0760(93)90336-U; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; LASFARGUES EY, 1958, J NATL CANCER I, V21, P1131; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MCQUIRE WL, 1986, CANC SURVEYS, V5, P527; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURPHY LJ, 1984, J CLIN ENDOCR METAB, V58, P149, DOI 10.1210/jcem-58-1-149; MURPHY LJ, 1984, CANCER RES, V44, P1963; Nandurkar HH, 1996, ONCOGENE, V12, P585; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STAMPFER MR, 1993, CANCER SURV, V18, P7; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; TAMM I, 1994, P NATL ACAD SCI USA, V91, P3329, DOI 10.1073/pnas.91.8.3329; TAMM I, 1994, P NATL ACAD SCI USA, V91, P4338, DOI 10.1073/pnas.91.10.4338; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TREMPE G, 1973, IN VITRO CELL DEV B, V8, P433; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	65	89	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					661	669		10.1038/sj.onc.1200882	http://dx.doi.org/10.1038/sj.onc.1200882			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038373				2022-12-28	WOS:A1997WG43000004
J	BeerRomero, P; Glass, S; Rolfe, M				BeerRomero, P; Glass, S; Rolfe, M			Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells	ONCOGENE			English	Article						E6; p53; E6AP; papillomavirus; antisense	HUMAN PAPILLOMAVIRUS TYPE-16; UBIQUITIN-CONJUGATING ENZYME; TUMOR-SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS; IN-VIVO; PROTEIN; ASSOCIATION; ONCOPROTEIN; E6-AP; DEFICIENCY	Invasive cervical cancer is very highly correlated with the presence of high-risk human papillomavirus (HPV) types 16 and 18, Two viral proteins, E6 and E7, act in concert to subvert growth control of infected cells by inactivating the tumor suppressor proteins, p53 and Rb, respectively. E6 is thought to abrogate p53 function by stimulating its degradation via ubiquitin-mediated proteolysis in reaction requiring E6AP (EB-Associated Protein), Here we evaluate the in vivo role of E6AP in p53 degradation in normal and HPV-infected cell types using antisense phosphorothioate oligodeoxynucleotides (S-ODNs). This study shows that reduction of E6AP in viva in high-risk HPV-infected cells leads to an elevation of p53, confirming the function of E6AP predicted by in vitro experiments. Further, we demonstrate that reduction of E6AP in normal cells has no effect on p53 levels, indicative of an E6AP-indpendent mechanism for p53 degradation. These experiments show that inhibition of intermediate proteins in the ubiquitin-mediated proteolysis pathway (ubiquitin-conjugating enzymes or associated recognition proteins) can result in specific inhibition of substrate degradation. We propose that modulation of p53 levels by elimination of E6AP function may have therapeutic potential for cervical cancer.			BeerRomero, P (corresponding author), MITOTIX INC,1 KENDALL SQ,BLDG 600,CAMBRIDGE,MA 02139, USA.							Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LANDANYI M, 1993, CANCER RES, V53, P16; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maki CG, 1996, CANCER RES, V56, P2649; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENES DEV, V9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1993, ONCOGENE, V8, P1407; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STREMLAU A, 1985, NATURE, V314, P111; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEE C, 1985, AM J PATHOL, V119, P361; zur Hausen H, 1987, Appl Pathol, V5, P19	40	92	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					595	602		10.1038/sj.onc.1200872	http://dx.doi.org/10.1038/sj.onc.1200872			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053858				2022-12-28	WOS:A1997WF52400011
J	Cacace, AM; Ueffing, M; Philipp, A; Han, EKH; Kolch, W; Weinstein, IB				Cacace, AM; Ueffing, M; Philipp, A; Han, EKH; Kolch, W; Weinstein, IB			PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase	ONCOGENE			English	Article						PKC epsilon; Raf; oncogene	MITOGENIC SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAP KINASE; IN-VITRO; C FAMILY; TYROSINE PHOSPHORYLATION; 3T3 CELLS; GROWTH; FIBROBLASTS; PATHWAY	Previous studies have indicated that PKC epsilon behaves as an oncogene when overproduced in rodent fibroblasts (Cacace ef al., 1993; Mishak et al., 1993), In the present study, Western blot analysis revealed that the hyperphosphorylated form of Raf kinase was present at a high level in PKC epsilon overproducing R6 rat fibroblasts but not in R6 fibroblasts overproducing PKC alpha or beta 1. Extracts from the PKC epsilon overproducing cells also exhibited a marked increase in Raf-l kinase and MAP-kinase activity, To investigate the significance of these findings, dominant negative mutants of ras (N17) or raf (301-1) were stably expressed in early passage control and PKC epsilon-transformed R6 fibroblasts, by transduction using retrovirus-derived constructs, Dominant negative mf expressing clones exhibited a flat morphology, a decreased saturation density, and decreased growth in soft agar, In addition, these reverted clones exhibited decreased Raf kinase activity, In contrast, dominant negative ras expressing clones remained highly transformed, In addition, PKC epsilon was detected in Raf-l immunoprecipitates indicating that PKC epsilon forms a complex with Raf-l in vivo, Taken together, these results suggest that PKC epsilon functions as an oncogene in R6 cells by enhancing activation of the Raf-l kinase.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; GSF MUNICH,INST KLIN MOL BIOL & TUMORGENET,HAMATOLOGIKUM,D-81377 MUNICH,GERMANY	Columbia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Kolch, Walter/0000-0001-5777-5016	NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE KS, 1993, MCB, V13, P3167; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU X, 1993, CELL, V73, P571; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; RAPP UR, 1991, ONCOGENE, V6, P495; SOZERI O, 1992, ONCOGENE, V7, P2259; SZEBERENYI J, 1990, MOL CELL BIOL, V12, P5329; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARNER LC, 1993, ONCOGENE, V8, P3249; WEINSTEIN IB, 1990, ORIGINS HUMAN CANC C, P113; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	144	145	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2517	2526						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000126				2022-12-28	WOS:A1996VZ65400002
J	Buettner, VL; Hill, KA; Nishino, H; Schaid, DJ; Frisk, CS; Sommer, SS				Buettner, VL; Hill, KA; Nishino, H; Schaid, DJ; Frisk, CS; Sommer, SS			Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53 Big Blue double transgenic mice	ONCOGENE			English	Article						point mutations; Big Blue; mutator phenotype; transitions; deletions with insertions; inversions	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR DEFICIENCY; COLON-CANCER; MICROSATELLITE INSTABILITY; SUPPRESSOR GENE; GASTRIC-CANCER; LACI GENE; HOMOLOG; CARCINOGENESIS; CARCINOMA	p53 (-/-), lacI (+/-) double transgenic (p53/Big Blue(R)) mice provide an opportunity to examine the relationship in vivo between somatic mutation and tumorigenesis, Previously, the frequency and spectra of Cad mutations were found to be similar in normal tissues of 6 week old p53 (-/-) lacI (+/-) and p53 (+/+) lacI (+/-) mice, Herein, p53 (-/-), lacI (+/-) mice were used to examine the frequency and spectrum of spontaneous mutation in thymic lymphomas, Four mice with thymic lymphomas were sacrificed at 2.5, 3, 4 and 4.5 months of age, Normal thymus harvested from two p53 (+/+) lacI (+/-) mice and two p53 (-/-) lacI (+/-) mice served as controls, The mutation frequency in tumor 108 (6.8 x 10(-5)) was elevated 2.3-fold relative to the p53 (-/-) control (P<0.0001; chi(2) test), The mutation spectra were also different (P=0.0009; Fisher exact test); in particular, A:T-->G:C transitions were prominently overrepresented in tumor 108, In addition, there were two examples of unusual deletions with inversions, In tumors 44 and 115, but not 110, there were trends toward increased mutation frequencies and altered spectra, but, within the constraints of present sample sizes, the results are not statistically significant, In conclusion, these findings suggest that altered frequencies and spectra exist in a subset of thymic lymphomas, perhaps due to somatic mutation in one or more DNA repair genes.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT VET MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A., 1994, Cancer Bulletin (Houston), V46, P161; DOUGLAS GR, 1994, MUTAGENESIS, V9, P451, DOI 10.1093/mutage/9.5.451; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gartenhaus R, 1996, BLOOD, V87, P38; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1994, MUTAT RES-FUND MOL M, V310, P125, DOI 10.1016/0027-5107(94)90016-7; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINE AJ, 1992, CANCER SURV, V12, P59; LI FP, 1988, CANCER RES, V48, P5358; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIRONOV NM, 1994, CANCER RES, V54, P41; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHINO H, 1995, ONCOGENE, V11, P263; NISHINO H, 1995, BIOTECHNIQUES, V19, P587; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	40	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2407	2413						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957082				2022-12-28	WOS:A1996VX10800013
J	Martincic, D; Whitlock, JA				Martincic, D; Whitlock, JA			Improved detection of p53 point mutations by dideoxyfingerprinting (ddF)	ONCOGENE			English	Article						p53; point mutations; single strand conformational polymorphism; dideoxyfingerprinting	SINGLE BASE SUBSTITUTIONS; CONFORMATION POLYMORPHISM ANALYSIS; POTENTIAL GROWTH-REGULATORS; POLYMERASE CHAIN-REACTION; AUTOCRINE HYPOTHESIS; MALIGNANT GLIOMAS; SENSITIVE METHOD; GENOMIC DNA; PCR-SSCP; GENE	Two screening techniques for identifying point mutations (single-strand conformational polymorphism (SSCP) and dideoxyfingerprinting (ddF)) were compared to sequencing to determine their efficiency in detecting mutations in exons 5-8 of the p53 tumor suppressor gene. Twelve human glioblastoma cell Lines were studied by each of the three methods, Ten mutations were identified by sequencing; of these, 10/10 were detected by ddF, while SSCP detected 6/10 true mutations and falsely identified two presumed mutations not confirmed by sequencing. We examined the impact of parameters which influence DNA conformation (gel temperature, gel composition, and PCR product size) on the ability of SSCP and ddF to detect mutations. The sensitivity of SSCP varied with both gel temperature and the size of the PCR product; in contrast, ddF was not influenced by either gel temperature or product length (up to 460 nucleotides), We conclude that the increased sensitivity of ddF, together with its greater ease of application due to the lack of need for optimization, provides significant advantages over SSCP in screening DNA sequences for the presence of point mutations, Our results also suggest that the incidence of p53 mutations may be underestimated in studies of human cancers which utilize SSCP as the method of mutational screening.	VANDERBILT UNIV,SCH MED,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,NASHVILLE,TN 37232	Vanderbilt University				Whitlock, James/0000-0002-7887-0634	NICHD NIH HHS [HD28819] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028819] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAZYK H, 1995, BIOTECHNIQUES, V18, P256; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JENNINGS MT, 1994, HUM PATHOL, V25, P464, DOI 10.1016/0046-8177(94)90118-X; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Liu Q, 1994, PCR Methods Appl, V4, P97; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MOHABEER AJ, 1991, NUCLEIC ACIDS RES, V19, P3154, DOI 10.1093/nar/19.11.3154; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Scriver C.R., 1995, METABOLIC MOL BASES, P1; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; STRAUSS WM, 1991, CURRENT PROTOCOLS MO; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2039	2044						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934553				2022-12-28	WOS:A1996VR79500026
J	Nicholson, LJ; Hopwood, P; Johannessen, I; Salisbury, JR; Codd, J; ThorleyLawson, D; Crawford, DH				Nicholson, LJ; Hopwood, P; Johannessen, I; Salisbury, JR; Codd, J; ThorleyLawson, D; Crawford, DH			Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells	ONCOGENE			English	Article						EBV; LMP; epithelial cells; differentiation; tumorigenesis	NASOPHARYNGEAL CARCINOMA-CELLS; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; GROWTH TRANSFORMATION; DECREASED EXPRESSION; P53 MUTATIONS; KAPPA-B; LMP1; GENE; TRANSCRIPTS	Latent membrane protein (LMP) is a latent Epstein-Barr virus (EBV) protein expressed in the EBV associated malignancy, nasopharyngeal carcinoma (NPC). Properties ascribed to this protein include inhibition of epithelial cell differentiation and deregulation of epithelial cellular gene expression, and are believed to contribute to the development of NPC, Studies to evaluate the oncogenic potential of LMP in epithelial cells have not been conclusive, We carried out studies to determine the tumorigenic activity of LMP in two human epithelial cell lines, SCC12F and HaCaT; while SCC12F LMP transfectants were non-tumorigenic in severe combined immunodeficient mice, HaCaT LMP transfectants were strongly oncogenic, The tumours produced were well differentiated, keratinising squamous cell carcinomas suggesting that LMP does not inhibit epithelial cell differentiation which conflicts with a previous report by Dawson et al. (1990), To resolve this discrepancy we examined the ability of HaCaT and SCC12F LMP transfectants to differentiate in a suspension culture assay, Both lines were able to differentiate to a similar extent as parental lines and control transfectants. Our results indicate that LMP is strongly oncogenic in human epithelial cells but that inhibition of differentiation is not necessarily a mechanism by which LMP contributes to the pathogenesis of NPC.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111	University of London; London School of Hygiene & Tropical Medicine; Tufts University	Nicholson, LJ (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT HISTOPATHOL,LONDON SE5 9PJ,ENGLAND.			Salisbury, Jonathan/0000-0002-5889-4276	NCI NIH HHS [CA31893] Funding Source: Medline; NIAID NIH HHS [AI18757] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031893, R01CA031893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; CHEN ML, 1992, ONCOGENE, V7, P2131; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1992, INT J CANCER, V52, P834, DOI 10.1002/ijc.2910520527; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GOLDEN HD, 1973, J INFECT DIS, V127, P471, DOI 10.1093/infdis/127.4.471; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; KARIMI L, 1995, J GEN VIROL, V76, P759, DOI 10.1099/0022-1317-76-4-759; KARRAN L, 1992, P NATL ACAD SCI USA, V89, P8058, DOI 10.1073/pnas.89.17.8058; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEG G, 1993, J CLIN PATHOL, V46, P1080; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li SN, 1996, ONCOGENE, V12, P2129; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; LOUVIDOU C, 1995, J CLIN PATHOL MOL PA, V48, P717; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; NIEDERMAN JC, 1970, NEW ENGL J MED, V282, P361, DOI 10.1056/NEJM197002122820704; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RICKINSON AB, 1996, FIELDS VIROLOGY, V2; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SCULLEY TB, 1997, IN PRESS J VIROL; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	55	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					275	283		10.1038/sj.onc.1201187	http://dx.doi.org/10.1038/sj.onc.1201187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233762				2022-12-28	WOS:A1997XK99900004
J	Takahashi, K; Suzuki, K; Tsukatani, Y				Takahashi, K; Suzuki, K; Tsukatani, Y			Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence	ONCOGENE			English	Article						tyrosine phosphorylated beta-catenin; EGF receptor; tryptic digestion; dissociation of alpha-catenin; dysfunction of E-cadherin; normal human breast epithelial cells	EPIDERMAL GROWTH-FACTOR; E-CADHERIN EXPRESSION; ADHESION MOLECULE UVOMORULIN; BREAST EPITHELIAL-CELLS; HUMAN CARCINOMA-CELLS; ALPHA-CATENIN; CYTOPLASMIC DOMAIN; COMPLEX; PROTEIN; CANCER	Normal human breast epithelial (HBE) cells which reached confluence ceased growth and tightly adhered to each other, forming a monolayer, In quiescent cells thus arrested by density, E-cadherin colocalized and coimmunoprecipitated with alpha- and beta-catenins in the boundary region between adjacent cells, By contrast, immunocytostaining and Western blot analyses revealed that E-cadherin colocalized and coprecipitated with beta-catenin but not with alpha-catenin in exponentially growing cells at low density. As a comparable amount of alpha-catenin was detected in the total cell lysate of cells at different densities, it is suggested that alpha-catenin is present but dissociates from the E-cadherin-beta-catenin complex in growing cells, beta-Catenin was tyrosine phosphorylated in growing cells at low density but not in quiescent cells at confluence, Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin, Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of beta-catenin from E-cadherin was not, The results suggest that tyrosine phosphorylation of beta-catenin is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from E-cadherin, beta-Catenin thus phosphorylated at tyrosine is suggested to play the role in preventing alpha-catenin once dissociated from reassociating with E-cadherin until cells reach confluence.			Takahashi, K (corresponding author), KANAGAWA CANC CTR,RES INST,DEPT BIOCHEM,ASAHI KU,1-1-2 NAKAO,YOKOHAMA,KANAGAWA 241,JAPAN.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KADOWAKI T, 1994, CANCER RES, V54, P291; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LINDBLOM A, 1993, CANCER RES, V53, P3707; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1994, DEV GROWTH DIFFER, V36, P59; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PERCEALL WE, 1995, ONCOGENE, V11, P1319; SATO T, 1990, CANCER RES, V50, P7184; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	43	77	78	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					71	78		10.1038/sj.onc.1201160	http://dx.doi.org/10.1038/sj.onc.1201160			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233779				2022-12-28	WOS:A1997XH58600008
J	Roschke, V; Kopantzev, E; Dertzbaugh, M; Rudikoff, S				Roschke, V; Kopantzev, E; Dertzbaugh, M; Rudikoff, S			Chromosomal translocations deregulating c-myc are associated with normal immune responses	ONCOGENE			English	Article						c-myc; chromosomal translocation; B cell malignancy; tumor susceptibility	MURINE PLASMACYTOMAS; MOLECULAR ANALYSIS; CHOLERA-TOXIN; CELLS; LYMPHOMA; MICE; ONCOGENE; SUSCEPTIBILITY; DNA; DIFFERENTIATION	Plasmacytomas induced in BALB/c mice by pristane consistently evidence chromosomal translocations involving the c-myc gene and one of the Ig loci. This obervation has lead to the suggestion that c-myc deregulation is a critical event in the generation of such tumors, However, it is not clear whether c-myc translocation is related to pristane treatment or occurs in normal lymphocyte populations nor whether such translocations occur normally, and at similar frequencies, in strains genetically resistant to plasmacytoma development, such as DBA/2, In order to address these questions, a Long Distance PCR assay with single copy sensitivity was employed to assess the frequency of c-myc/IgA translocations in normal and immunized mice of both plasmacytoma resistant and susceptible lineages in the absence of pristane treatment. Our data demonstrate that spontaneous translocations occur in normal DBA/2 and BALB/c mice with no significant differences in frequency, A 3-5-fold increase in translocation frequency was observed in mice immunized with cholera toxin, a strong stimulator of IgA responses, We conclude that c-myc deregulation by chromosomal translocation is associated with normal physiological processes of B-cell differentiation and, as such, can not be the determining factor leading to malignancy.	NCI,GENET LAB,NIH,BETHESDA,MD 20892; USA,MED RES INST INFECT DIS,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; CHENG S, 1994, NATURE, V369, P684, DOI 10.1038/369684a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; GARBE C, 1991, J AM ACAD DERMATOL, V24, P584, DOI 10.1016/0190-9622(91)70088-J; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; HILBERT DM, 1993, ONCOGENE, V8, P1993; Husband A J, 1977, Ciba Found Symp, P29; HUSBAND AJ, 1978, J EXP MED, V148, P1146, DOI 10.1084/jem.148.5.1146; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1993, TOXICOL LETT, V67, P237, DOI 10.1016/0378-4274(93)90059-7; JI WZ, 1995, CANCER RES, V55, P2876; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; LYCKE N, 1989, J IMMUNOL, V142, P3781; LYCKE N, 1986, IMMUNOLOGY, V59, P301; Magrath I, 1992, Semin Cancer Biol, V3, P285; MOCK BA, 1993, P NATL ACAD SCI USA, V90, P9499, DOI 10.1073/pnas.90.20.9499; Muller JR, 1996, CANCER RES, V56, P419; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; PAVLIDIS NA, 1992, MED PEDIATR ONCOL, V20, P279, DOI 10.1002/mpo.2950200403; POTTER M, 1994, J NATL CANCER I, V86, P1058, DOI 10.1093/jnci/86.14.1058; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1994, CANCER RES, V54, P969; POTTER M, 1984, CANCER SURV, V3, P247; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Sokal RR, 1995, BIOMETRY; SOULIER J, 1995, BLOOD, V86, P1131; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STROBER W, 1991, IMMUNOL RES, V10, P386, DOI 10.1007/BF02919726; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904	43	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3011	3016		10.1038/sj.onc.1201156	http://dx.doi.org/10.1038/sj.onc.1201156			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223664				2022-12-28	WOS:A1997XG10000003
J	Takaoka, A; Adachi, M; Okuda, H; Sato, S; Yawata, A; Hinoda, Y; Takayama, S; Reed, JC; Imai, K				Takaoka, A; Adachi, M; Okuda, H; Sato, S; Yawata, A; Hinoda, Y; Takayama, S; Reed, JC; Imai, K			Anti-cell death activity promotes pulmonary metastasis of melanoma cells	ONCOGENE			English	Article						BCL-2; BAG-1; melanoma; pulmonary metastasis	HUMAN FOLLICULAR LYMPHOMA; CANCER METASTASIS; BCL-2; PROTEIN; APOPTOSIS; EXPRESSION; LECTINS; MATRIX; GENE	Bcl-2 inhibits apoptosis from a variety of stimuli, and a Bcl-2-binding protein BAG-1 also functions in protection from apoptosis in concert with Bcl-2, Here, we provide evidence that prolonged cell survival introduced by overexpression of Bcl-2 or BAG-1 proteins strongly promotes experimental pulmonary metastasis of melanoma B16-BL6 cells, In murine melanoma cell line B16-BL6, gene transfer-mediated expression of the Bcl-2 or BAG-1 led to prolonged cell survival against serum-starved apoptosis in vitro, The Bcl-2-expressing B16 cells, B16-Bcl-2 and the BAG-1-expressing B16 cells, B16-BAG-1 strongly enhanced pulmonary metastasis in allogenic BALB/c nude mice and whole lung weights were increased by 2.4-fold and 1.4-fold, respectively, compared with control transfectants, suggesting that Bcl-2 is a stronger positive modulator of metastasis, When the viable B16-Bcl-2 and control transfectants were injected subcutaneously into BALB/c nude mice, the colony numbers of pulmonary metastasis of the B16-Bcl-2 transfectant increased by 5.6-fold compared with the control transfectants, These enhanced metastatic potentials in the B16-Bcl-2 and the B16-BAG-1 transfectants were well correlated with anti-cell death activity against serum-starvation and enhanced cell viability on limiting dilution, Analysis of the transfectants however revealed that their growth rates, invasive ability and cell motility were not significantly altered by overexpression of either Bcl-2 or BAG-1 proteins, Taken together, these studies demonstrate that prolonged cell survival is a crucial factor to promote metastasis of melanoma, thereby contributing to tumor progression.	SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,HOKKAIDO 060,JAPAN; BURNHAM INST,CTR CANC RES,LA JOLLA,CA 92037	Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; ALBRECHTBUEHLER G, 1977, CELL, V11, P359; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; COLLINS KA, 1995, AM J DERMATOPATH, V17, P429, DOI 10.1097/00000372-199510000-00001; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIDLER IJ, 1990, CANCER RES, V50, P6130; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEROMSKY L, 1986, CANCER RES, V46, P5270; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; POSTE G, 1980, CANCER RES, V40, P1636; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAENZSANTAMARIA MC, 1994, J CUTAN PATHOL, V21, P393; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TRON VA, 1995, AM J PATHOL, V146, P643; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	29	109	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2971	2977		10.1038/sj.onc.1201147	http://dx.doi.org/10.1038/sj.onc.1201147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205104				2022-12-28	WOS:A1997XF55500011
J	Zhang, HT; Zhang, X; Zhao, HZ; Kajino, Y; Weber, BL; Davis, JG; Wang, Q; ORourke, DM; Zhang, HB; Kajino, K; Greene, MI				Zhang, HT; Zhang, X; Zhao, HZ; Kajino, Y; Weber, BL; Davis, JG; Wang, Q; ORourke, DM; Zhang, HB; Kajino, K; Greene, MI			Relationship of p215(BRCA1) to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells	ONCOGENE			English	Article						BRCA1; neu; EGFR; transformation	BREAST-CANCER; GROWTH-FACTOR; DNA-BINDING; BRCA1; PROTEIN; PHOSPHORYLATION; COMMON; LOCALIZATION; EXPRESSION; ONCOGENE	We have analysed the relationship of the products of two genes, neu and BRCA1, known to be important in human breast cancer, Highly specific antibodies that recognized both the rodent and human form of the BRCA1 gene product (M-r 215 kDa, p215(BRCA1)) were developed to facilitate these efforts, p215(BRCA1) was identified as a tyrosine phosphorylated protein primarily localized in the nucleus of several breast cancer cell lines, In transformed murine and human cells, levels of p215(BRCA1) tyrosine phosphorylation were inversely correlated with the activity of the erbB family receptor-tyrosine-kinases and with the transformed growth features of these cells, Regulation of p215(BRCA1) tyrosine phosphorylation was also related to events in the cell cycle, Increased levels of p215(BRCA1) phosphotyrosine content were observed in NIH3T3 cells arrested at the G(2)/M transition, These findings indicate that the products of BRCA1, neu, and erbB breast cancer genes participate in a common or shared signaling pathway important in cell growth and its regulation.	UNIV PENN,SCH MED,DEPT PATHOL & LAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Kajino, Kiichi/F-6873-2012; O'Rourke, Donald/AAC-3376-2021; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049; O'Rourke, Donald/0000-0002-8479-7314				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; ALTSCHUL SF, 1990, J MOL BIOL, V215, P195; Bennett L. M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P514; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis JG, 1997, P NATL ACAD SCI USA, V94, P707, DOI 10.1073/pnas.94.2.707; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1995, AM J HUM GENET, V56, P265; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Ormerod M.G., 1994, FLOW CYTOMETRY PRACT, P119; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1996, ONCOGENE, V13, P2149; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rao VN, 1996, ONCOGENE, V12, P523; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924	35	24	24	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2863	2869		10.1038/sj.onc.1201140	http://dx.doi.org/10.1038/sj.onc.1201140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205094				2022-12-28	WOS:A1997XF55500001
J	Wang, D; Mayo, MW; Baldwin, AS				Wang, D; Mayo, MW; Baldwin, AS			Basic fibroblast growth factor transcriptional autoregulation requires EGR-1	ONCOGENE			English	Article						basic fibroblast growth factor; Egr-1; autoregulation	VASCULAR ENDOTHELIAL-CELLS; FACTOR GENE-EXPRESSION; TUMOR-NECROSIS-FACTOR; AP-1 BINDING-ACTIVITY; C-FOS; HUMAN GLIOMAS; 3T3 CELLS; IN-VIVO; JUN-B; PROMOTER	Basic fibroblast growth factor (bFGF) is an important growth factor for neuroectoderm- and mesoderm-derived cells. In addition bFGF is an important angiogenic factor and appears to contribute to tumorigenesis. This is exemplified by the fact that bFGF is expressed in a large majority of human gliomas and that bFGF expression is critical for the growth and tumorigenesis of these cells. It has been shown previously that bFGF can induce its own expression through an increase in bFGF mRNA. In this report, we show that bFGF leads to its own synthesis through an autoregulated transcriptional response that requires the transcription factor Egr-1 (also known as Krox24, Zif268 and NGFI-A). Egr-1 binds to two DNA elements in the bFGF promoter and positively regulates transcription. Mutation of these sites blocks the ability of bFGF to transcriptionally regulate the bFGF promoter. These data indicate a mechanism to explain how bFGF functions to autoregulate its expression and demonstrate that Egr-1 is as an essential transcription factor in this process.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARENANDER AT, 1989, J NEUROSCI RES, V24, P107, DOI 10.1002/jnr.490240115; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; CAO XM, 1993, J BIOL CHEM, V268, P16949; Care A, 1996, MOL CELL BIOL, V16, P4842; COGSWELL P, 1997, IN PRESS J EXP MED; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUKS Z, 1994, CANCER RES, V54, P2582; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; Gospodarowicz D, 1990, CLIN ORTHOP RELAT R, V257, P231; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HALL SH, 1991, ENDOCRINOLOGY, V129, P1243, DOI 10.1210/endo-129-3-1243; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; ITO E, 1990, ONCOGENE, V5, P1755; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LOBB R, 1986, J BIOL CHEM, V261, P1924; MAASS A, 1994, BIOCHEM BIOPH RES CO, V202, P1337, DOI 10.1006/bbrc.1994.2077; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; NAKAMOTO T, 1992, CANCER RES, V52, P571; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHIMOYAMA Y, 1991, JPN J CANCER RES, V82, P1263, DOI 10.1111/j.1349-7006.1991.tb01791.x; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; STAN AC, 1995, J NEUROSURG, V82, P1044, DOI 10.3171/jns.1995.82.6.1044; STEFANIK DF, 1991, CANCER RES, V51, P5760; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; UEBA T, 1994, NEUROSURGERY, V34, P221, DOI 10.1227/00006123-199402000-00003; WEICH HA, 1991, J CELL BIOCHEM, V47, P158, DOI 10.1002/jcb.240470209; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZUCK B, 1992, J STEROID BIOCHEM, V41, P659, DOI 10.1016/0960-0760(92)90400-D	62	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2291	2299		10.1038/sj.onc.1201069	http://dx.doi.org/10.1038/sj.onc.1201069			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178905				2022-12-28	WOS:A1997WY88300006
J	Zeng, WR; Scherer, SW; Koutsilieris, M; Huizenga, JJ; Filteau, F; Tsui, LC; Nepveu, A				Zeng, WR; Scherer, SW; Koutsilieris, M; Huizenga, JJ; Filteau, F; Tsui, LC; Nepveu, A			Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas	ONCOGENE			English	Article						uterine leiomyoma; tumor suppressor gene; chromosome 7q22; CUTL1; human Cut homeobox gene; loss of heterozygosity	HUMAN ERYTHROPOIETIN GENE; CCAAT DISPLACEMENT PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; IN-SITU HYBRIDIZATION; MOLECULAR-CLONING; ABNORMALITIES; CHROMOSOME-7; ENHANCER; HYPOXIA; 7Q22	Cytogenetic analyses has revealed deletions and/or rearrangments at several chromosomal positions in approximately half of uterine leiomyomas. The most frequent genetic alteration, deletion of 7q22, was found in approximately 35% of studied cases with cytogenetic abnormalities (128/366=35%), The same chromosomal band was also found to be deleted in a fraction of acute myeloid leukemias and myelodysplastic syndromes, The frequent deletion of 7q22 in some tumors suggest that a tumor suppressor gene may be located in this region, The human Cut-like homeobox gene, CUTL1, is one of the genes localized to 7q22 and it was shown previously to encode a transcriptional repressor that down-modulates the expression of c-Myc, Activation of the c-Myc oncogenic potential has been shown in many cancers to result from alterations in one or the other of its several mechanisms of regulation, These observations led us to hypothesize that CUTL1 could act as a tumor suppressor gene, In the present study, we have identified polymorphic markers within and directly adjacent to CUTL1 at 7q22 and demonstrated that these markers are present in a commonly deleted region in seven out of 50 uterine leiomyomas samples examined, Furthermore, Northern blot analysis revealed that CUTL1 mRNA levels were reduced in eight tumors out of 13. These results suggest that CUTL1 may act as a tumor suppressor gene whose inactivation could be of pathological importance in the etiology of uterine leiomyomas.	HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ,CANADA; UNIV LAVAL,CHU LAVAL,CTR RECH,MOL ENDOCRINOL LAB,ST FOY,PQ G1K 7P4,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; McGill University; McGill University; Laval University; University of Toronto			Koutsilieris, Michael/AAD-3648-2019; Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010; /AAB-8315-2020	Scherer, Stephen W./0000-0002-8326-1999; 				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALCIN P, 1995, GENE CHROMOSOME CANC, V13, P219; DALCIN P, 1995, CANCER RES, V55, P1565; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; FENAUX P, 1989, BRIT J HAEMATOL, V73, P61, DOI 10.1111/j.1365-2141.1989.tb00221.x; FU P, 1993, MOL CELL ENDOCRINOL, V93, P107, DOI 10.1016/0303-7207(93)90113-X; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HEIM S, 1992, LEUKEMIA RES, V16, P43, DOI 10.1016/0145-2126(92)90098-R; HONN KV, 1992, CANCER METAST REV, V11, P353, DOI 10.1007/BF01307187; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JOHANNING GL, 1992, P NATL ACAD SCI USA, V89, P10964, DOI 10.1073/pnas.89.22.10964; LEMIEUX N, 1994, GENOMICS, V24, P191, DOI 10.1006/geno.1994.1603; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LITT M, 1993, BIOTECHNIQUES, V15, P280; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NILBERT M, 1989, CANCER GENET CYTOGEN, V42, P51, DOI 10.1016/0165-4608(89)90007-1; NILBERT M, 1990, HUM GENET, V85, P605; NILBERT M, 1988, CYTOGENET CELL GENET, V49, P300, DOI 10.1159/000132682; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; OZISIK YY, 1993, CANCER GENET CYTOGEN, V67, P59, DOI 10.1016/0165-4608(93)90045-N; PANDIS N, 1990, GENE CHROMOSOME CANC, V2, P311, DOI 10.1002/gcc.2870020409; PANDIS N, 1991, CANCER GENET CYTOGEN, V55, P11, DOI 10.1016/0165-4608(91)90229-N; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; REIN MS, 1991, OBSTET GYNECOL, V77, P923; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAIT SNJ, 1989, CANCER GENET CYTOGEN, V37, P157; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SCHERER S, 1991, P33; SCHERER SW, 1993, HUM MOL GENET, V2, P751, DOI 10.1093/hmg/2.6.751; SCHERER SW, 1993, GENOMICS, V15, P695, DOI 10.1006/geno.1993.1130; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; SOLBERG R, 1992, GENOMICS, V14, P63, DOI 10.1016/S0888-7543(05)80284-8; Sourla A, 1996, CANCER RES, V56, P3123; SWANSBURY GJ, 1994, CANCER GENET CYTOGEN, V73, P1, DOI 10.1016/0165-4608(94)90174-0; TAGUCHI T, 1994, GENOMICS, V20, P146, DOI 10.1006/geno.1994.1148; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VANNI R, 1991, CANCER GENET CYTOGEN, V53, P247, DOI 10.1016/0165-4608(91)90101-Y; WILCOX LS, 1994, OBSTET GYNECOL, V83, P549, DOI 10.1097/00006250-199404000-00011; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YUNIS JJ, 1988, BRIT J HAEMATOL, V68, P189, DOI 10.1111/j.1365-2141.1988.tb06188.x	58	72	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2355	2365		10.1038/sj.onc.1201076	http://dx.doi.org/10.1038/sj.onc.1201076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178912				2022-12-28	WOS:A1997WY88300013
J	Shridhar, V; Rivard, S; Wang, XH; Shridhar, R; Paisley, C; Mullins, C; Beirnat, L; Dugan, M; Sarkar, F; Miller, OJ; Vaitkevicius, VK; Smith, DI				Shridhar, V; Rivard, S; Wang, XH; Shridhar, R; Paisley, C; Mullins, C; Beirnat, L; Dugan, M; Sarkar, F; Miller, OJ; Vaitkevicius, VK; Smith, DI			Mutations in the arginine-rich protein gene (ARP) in pancreatic cancer	ONCOGENE			English	Article						pancreatic adenocarcinoma; ARP gene; recurring mutations	RENAL-CELL CARCINOMA; LUNG-CANCER; ADENOCARCINOMA; CHROMOSOME-3; ALLELOTYPE; DELETION; HETEROZYGOSITY	The ARP gene encodes a highly conserved arginine-rich protein from chromosomal band 3p21.1. At the cytogenetic level this region is frequently deleted in a variety of different solid tumors, although not in pancreatic cancer. We have reported the presence of a specific mutation (ATG(50)-->AGG) or deletion of codon 50 of the ARP gene in different tumor types (Shridhar et al., 1996, 1996a). In the present study, we have observed mutations involving codon 50 in II of 37 pancreatic tumors. The frequency of codon 50 mutation is roughly the same in pancreatic tumors as in the other types of tumors previously examined, In addition, we have detected mutations at codon 51 in multiple PCR subclones in two other pancreatic tumors, Mutations in the ARP gene are thus commonly observed in pancreatic cancer, as web as many other cancers.	WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University					NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; GRIFFIN CA, 1995, CANCER RES, V55, P2394; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHN SA, 1995, CANCER RES, V55, P4670; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MORITA R, 1991, CANCER RES, V51, P820; MUIRA I, 1990, GENES CHROM CANC, V2, P328; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; SCHRIDHAR R, 1996, CANCER RES, V56, P4475; SCHRIDHAR V, 1996, ONCOGENE, V12, P1931; SEYMOUR AB, 1994, CANCER RES, V54, P2761; Shridhar R, 1996, CANCER RES, V56, P5576; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	22	16	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2213	2216		10.1038/sj.onc.1201054	http://dx.doi.org/10.1038/sj.onc.1201054			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174057				2022-12-28	WOS:A1997WX93800010
J	Doherty, J; Freund, R				Doherty, J; Freund, R			Polyomavirus large T antigen overcomes p53 dependent growth arrest	ONCOGENE			English	Article						polyomavirus; large T antigen; p53; cell cycle arrest	RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; P53-DEPENDENT G(1) ARREST; TUMOR SUPPRESSOR GENE; CELL-CYCLE CONTROL; MIDDLE-T; SUSCEPTIBILITY GENE; DNA-DAMAGE; C-MYC; TRANSCRIPTIONAL ACTIVATION	Polyomavirus transforms cells in culture and induces tumors in mice without apparent interaction with or inactivation of the p53 tumor suppressor protein. In this report we investigate the ability of polyomavirus T antigens to overcome the growth suppression function of p53. A temperature sensitive p53 gene was introduced into mouse embryo fibroblasts derived from a p53 null mouse, resulting in expression of a protein with a mutant conformation at 37 degrees C and a functionally wild-type conformation at 32 degrees C. We found that expression of p53 at 32 degrees C induced the cyclin-dependent kinase inhibitor p21/WAF1 and arrested cell growth in the G(1)/G(0) phase of the cell cycle. Only the under-phosphorylated form of the retinoblastoma tumor suppressor protein (pRB) was detected in these growth arrested cells. We introduced both polyomavirus large T (LT) and middle T (MT) antigens into this cell line and showed that LT overcame p53-dependent growth arrest, while MT did not. In cells grown at 32 degrees C, LT expession led to cell proliferation and phosphorylation of pRB in the presence of p21. A mutant LT containing a defective pRB binding domain failed to overcome the growth arrest, indicating that interaction of LT with RE proteins is required to override p53 function. Although the polyomavirus T antigens do not interact with p53 directly, our results indicate that the virus, through LT, is able to interfere with the growth suppressive activity of p53.	UNIV MARYLAND,CELL & MOL BIOL PROGRAM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Doherty, Joanne/AAU-3288-2020	Doherty, Joanne/0000-0003-2705-5194	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BENJAMIN T, 1990, VIROLOGY, P347; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Flint S. J, 1981, DNA TUMOR VIRUSES; FRANCKE B, 1973, VIROLOGY, V55, P127, DOI 10.1016/S0042-6822(73)81014-1; FREUND R, 1994, J VIROL, V68, P7227, DOI 10.1128/JVI.68.11.7227-7234.1994; FREUND R, 1992, ONCOGENE, V7, P1979; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; Gray J W, 1979, Methods Enzymol, V58, P233; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLSTEIN M, 1991, SCIENCE, V75, P839; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V80, P4345; Sambrook J., 2002, MOL CLONING LAB MANU; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	96	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1923	1931		10.1038/sj.onc.1201025	http://dx.doi.org/10.1038/sj.onc.1201025			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150359				2022-12-28	WOS:A1997WV80400005
J	Sabe, H; Hamaguchi, M; Hanafusa, H				Sabe, H; Hamaguchi, M; Hanafusa, H			Cell to substratum adhesion is involved in v-Src-induced cellular protein tyrosine phosphorylation: Implication for the adhesion-regulated protein tyrosine phosphatase activity	ONCOGENE			English	Article						v-Src; cell substratum adhesion; transformation; protein tyrosine phosphatase; tyrosine phosphorylation	ROUS-SARCOMA VIRUS; GTPASE-ACTIVATING PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; PHOSPHOTYROSINE PHOSPHATASE; SURFACE PROTEIN; MONOCLONAL-ANTIBODIES; STABLE ASSOCIATION	Protein tyrosine phosphorylation accompanies the integrin-mediated cell to substratum adhesion, and is essential for the progression of G(1)/S phase of the cell-cycle in normal fibroblasts, To examine how cellular protein tyrosine phosphatase (PTPase) activity is involved in regulating the adhesion-dependent protein tyrosine phosphorylation, we employed fibroblast cells bearing an active form of a protein tyrosine kinase (PTK), v-Src. We found that the v-Src induced tyrosine phosphorylation in certain proteins such as tensin, talin, p120, p80/85 (cortactin) and paxillin was greatly reduced when the cell to substratum adhesion was lost. Re-adhesion of the cells onto fibronectin restored these phosphorylation events, while this was inhibited by the addition of RGD peptide. The kinase activity of the v-Src was unchanged by the loss of cell to substratum adhesion. On the other hand, treatment with a protein tyrosine phosphatase inhibitor vanadate caused much the same increase in the v-Src-mediated cellular tyrosine phosphorylation between cells adhered to the culture environments and cells kept in suspension. These data suggest that PTPase(s) appears to be more critical than the v-Src PTK in determining the cell adhesion-dependent protein tyrosine phosphorylation, Moreover, most of the protein tyrosine phosphorylations that are mediated by the v-Src but still dependent on the cell adhesion were indeed greatly reduced during an anchorage-independent growth of v-Src cells, Thus our data collectively indicate that the v-Src induced high level of tyrosine phosphorylation in certain types of proteins are still under the control of the integrin(s) or the cell adhesion to culture substratum, and most of these adhesion-regulated high levels of tyrosine phosphorylations are not essential for the transformed phenotype.	ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA; NAGOYA UNIV, SCH MED, SYOWA KU, NAGOYA, AICHI 466, JAPAN; JAPAN SCI & TECHNOL CORP, PRECURSORY RES EMBRYON SCI & TECHNOL, SAKYO KU, KYOTO 606, JAPAN	Rockefeller University; Nagoya University; Japan Science & Technology Agency (JST)	Sabe, H (corresponding author), KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN.		Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022		NCI NIH HHS [CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHEN WT, 1984, J CELL BIOL, V98, P1546, DOI 10.1083/jcb.98.4.1546; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAIRBAIRN S, 1985, J CELL BIOL, V101, P1790, DOI 10.1083/jcb.101.5.1790; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYMAN EG, 1982, J CELL BIOL, V94, P28, DOI 10.1083/jcb.94.1.28; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; HYNES RO, 1975, VIROLOGY, V64, P492, DOI 10.1016/0042-6822(75)90126-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TAPLEY P, 1989, ONCOGENE, V4, P325; TAVOLONI N, 1994, J CELL BIOL, V126, P475, DOI 10.1083/jcb.126.2.475; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	59	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1779	1788		10.1038/sj.onc.1201022	http://dx.doi.org/10.1038/sj.onc.1201022			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150383				2022-12-28	WOS:A1997WW16600003
J	Bol, DK; Kiguchi, K; GimenezConti, I; Rupp, T; DiGiovanni, J				Bol, DK; Kiguchi, K; GimenezConti, I; Rupp, T; DiGiovanni, J			Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice	ONCOGENE			English	Article						insulin-like growth factor-1; skin; tumor promotion; hyperplasia	FACTOR-I RECEPTOR; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; SKIN TUMORIGENESIS; MOUSE SKIN; PAPILLOMAS; EPIDERMIS; INDUCTION; CELLS	Transgenic animals were developed to assess the role of insulin-like growth factor 1 (IGF-1) in skin growth, differentiation and organization, as well as its importance in tumor formation. Expression of a human IGF-1 cDNA was targeted to the interfollicular epidermis of transgenic mice using a human keratin 1 promoter construct (HK1). Transgenic animals (HK1.IGF-1 mice) could be identified at birth by early ear unfolding and excessive ear and skin growth compared to nontransgenic littermates. Further examination of the skin from these mice showed epidermal hyperplasia and hyperkeratosis, marked thickening of the dermis and hypodermis, and early hair follicle generation in newborns. The severity of this phenotype correlated with transgene expression both of which subsided,vith age. Adult HK1.IGF-1 mice developed spontaneous tumors following treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) alone and exhibited an exaggerated epidermal proliferative response following treatment with the tumor promoter compared to non transgenic littermates. Additionally, HK1.IGF-1 transgenic mice developed papillomas faster and in markedly greater numbers compared to non-transgenic littermates in standard initiation-promotion experiments. The data presented suggest an important role for IGF-I in the process of multistage carcinogenesis in mouse skin.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV CARCINOGENESIS,DIV RES,SMITHVILLE,TX 78957	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA037111, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA37111] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDO Y, 1993, J INVEST DERMATOL, V100, P633, DOI 10.1111/1523-1747.ep12472297; BASERGA R, 1995, CANCER RES, V55, P249; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAWSON TP, 1995, CANCER RES, V55, P915; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; ELDRIDGE SR, 1990, CARCINOGENESIS, V11, P2245, DOI 10.1093/carcin/11.12.2245; EWING MW, 1988, CANCER RES, V48, P7048; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GREENHALGH D, 1994, KERATINOCYTE HDB, P471; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MATTHEWS L S, 1988, Endocrinology, V123, P2827; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINUTO F, 1986, CANCER RES, V46, P985; NAITO M, 1987, CARCINOGENESIS, V8, P1807, DOI 10.1093/carcin/8.12.1807; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; RESNICOFF M, 1995, CANCER RES, V55, P3739; Rho O, 1996, MOL CARCINOGEN, V17, P62, DOI 10.1002/(SICI)1098-2744(199610)17:2<62::AID-MC2>3.0.CO;2-V; ROGLER CE, 1994, J BIOL CHEM, V269, P1379; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V94, P573; ROTWEIN P, 1993, MOL REPROD DEV, V35, P358, DOI 10.1002/mrd.1080350407; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; TRICOLI JV, 1986, CANCER RES, V46, P6169; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	46	115	122	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1725	1734		10.1038/sj.onc.1201011	http://dx.doi.org/10.1038/sj.onc.1201011			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135074				2022-12-28	WOS:A1997WR89300011
J	Hart, KC; Donoghue, DJ				Hart, KC; Donoghue, DJ			Derivatives of activated H-ras lacking C-terminal lipid modifications retain transforming ability if targeted to the correct subcellular location	ONCOGENE			English	Article						ras; subcellular localization; transformation	GUANINE-NUCLEOTIDE-BINDING; MURINE SARCOMA-VIRUS; SRC-GENE-PRODUCT; PLASMA-MEMBRANE; POSTTRANSLATIONAL MODIFICATION; ONCOGENE PROTEIN; GOLGI-COMPLEX; P21; DOMAIN; SIGNAL	To examine the ability of uas to activate signal transduction pathways in the absence of lipid modifications, fusion proteins were constructed that target ras(WT) or activated ras(61L) to cellular membranes as integral membrane proteins, using the first transmembrane domain of the El protein of avian infectious bronchitis virus (IBV), which contains a cis-Golgi targeting signal. Golgi-targeted derivatives of activated ras were completely inactive in transformation assays. However, when examined in focus formation assays, transformation of NIH3T3 cells were seen with derivatives of vas(61L) containing a mutated El targeting sequence that results in plasma membrane localization. Removal of the lipid modification sites in and upstream of the CAAX motif did not abrogate the transforming activity of plasma membrane-localized ras(61L) derivatives, indicating that these lipid modifications are not essential for ras activity, as long as the protein is correctly localized to the plasma membrane. Interestingly, the activity of integral membrane versions of vas(61L) was strictly dependent on a minimum distance between the transmembrane domain anchor region and the coding sequence of vas. Derivatives with only a 3-amino acid linker were inactive, while linkers of either 11- or 22-amino acids were sufficient to restore transforming activity. These results demonstrate that: (1) activated ras targeted to Golgi membranes is unable to cause transformation; (2) lipid modifications at the C-terminus are not required for the transforming activity of plasma membrane-anchored ras(61L) derivatives, and serve primarily a targeting function; (3) a transmembrane domain can effectively substitute for C-terminal modifications that would normally target uas to the inner surface of the plasma membrane, indicating that ras(61L) does not need to reversibly dissociate from the membrane as might be allowed by the normal lipidation; and (4) in order to function properly, there exists a critical distance that the ras protein must reside from the plasma membrane.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,CTR GENET MOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,MOL PATHOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hart K C, 1995, Genet Eng (N Y), V17, P181; HART KC, 1994, J CELL BIOL, V127, P1843, DOI 10.1083/jcb.127.6.1843; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOHN J, 1989, J BIOL CHEM, V264, P13086; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LACAL PM, 1988, ONCOGENE, V2, P533; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1986, CANCER SURV, V5, P275; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Okada T, 1996, J BIOL CHEM, V271, P4671; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1984, CANCER INVEST, V2, P109, DOI 10.3109/07357908409020294; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; XU YF, 1993, J CELL BIOL, V123, P549, DOI 10.1083/jcb.123.3.549; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	50	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					945	953		10.1038/sj.onc.1200908	http://dx.doi.org/10.1038/sj.onc.1200908			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050994	Green Published, Bronze			2022-12-28	WOS:A1997WK34400008
J	MarcosGutierrez, CV; Wilson, SW; Holder, N; Pachnis, V				MarcosGutierrez, CV; Wilson, SW; Holder, N; Pachnis, V			The zebrafish homologue of the ret receptor and its pattern of expression during embryogenesis	ONCOGENE			English	Article						tyrosine kinase receptor; zebrafish; c-ret proto-oncogene; nervous system; excretory system	TYROSINE KINASE; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; RETICULOSPINAL NEURONS; AXONAL OUTGROWTH; PROTOONCOGENE; MUTATIONS; ACTIVATION; CADHERIN; EMBRYOS	The c-ret proto-oncogene, a member of the receptor tyrosine kinase gene superfamily, plays a critical role in the development of the excretory system and the enteric and autonomic nervous systems of mammalian embryos. To study the potential function of the c-vet locus in lower vertebrates, we have isolated its zebrafish homologue, ret1 and established its expression pattern during embryogenesis. Ret1 mRNA first appears during early somitogenesis in the presumptive brain, spinal cord and excretory system. Within the CNS, expression of ret1 is detected in primary motor and sensory (Rohon-Beard) neurons. Ret1 transcripts are also expressed in subsets of neural crest cells and cranial ganglia as well as in the enteric nervous system. In the excretory system, expression is detected in the developing nephric duct and the pronephros. Our findings reveal a remarkable similarity in the expression pattern of c-ret between higher and lower vertebrates, suggesting that the function of this locus has been conserved throughout vertebrate evolution. Furthermore, the conservation of ret1 expression in cell types which remain unaffected by the mammalian c-vet mutations, such as motor and sensory neurons, suggests a function of this receptor in these cell lineages.	NATL INST MED RES, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; UNIV LONDON KINGS COLL, RANDALL INST, DIV BIOMED SCI, RES CTR, LONDON WC2B 5RL, ENGLAND	MRC National Institute for Medical Research; University of London; King's College London			Wilson, Stephen W/B-9404-2008	Wilson, Stephen W/0000-0002-8557-5940; Pachnis, Vassilis/0000-0001-9733-7686				Appel B, 1995, DEVELOPMENT, V121, P4117; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EISEN JS, 1990, J NEUROSCI, V10, P34; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Green MC., 1989, GENETIC VARIANTS STR, P12; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1990, ADV SEC MESS PHOSPH, V24, P260; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KORZH V, 1993, DEVELOPMENT, V118, P417; MASLAND RH, 1993, J NEUROSCI, V13, P5194, DOI 10.1523/JNEUROSCI.13-12-05194.1993; MENDELSON B, 1986, J COMP NEUROL, V251, P160, DOI 10.1002/cne.902510203; MENDELSON B, 1986, J COMP NEUROL, V251, P172, DOI 10.1002/cne.902510204; METCALFE WK, 1990, DEVELOPMENT, V110, P491; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS PZ, 1986, J NEUROSCI, V6, P2278; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; ROBERTSON K, 1995, MECH DEVELOP, V53, P329, DOI 10.1016/0925-4773(95)00449-1; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weinberg E.S., 1992, Results and Problems in Cell Differentiation, V18, P91; Westerfield M, 1994, ZEBRAFISH BOOK; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XU QL, 1994, DEVELOPMENT, V120, P287	52	54	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					879	889		10.1038/sj.onc.1201048	http://dx.doi.org/10.1038/sj.onc.1201048			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050987				2022-12-28	WOS:A1997WK34400001
J	Gallagher, WM; Cairney, M; Schott, B; Roninson, IB; Brown, R				Gallagher, WM; Cairney, M; Schott, B; Roninson, IB; Brown, R			Identification of p53 genetic suppressor elements which confer resistance to cisplatin	ONCOGENE			English	Article						cisplatin; resistance; p53; cell cycle arrest; apoptosis	DNA-BINDING FUNCTION; CELL-LINES; ANTISENSE RNA; EXPRESSION SELECTION; STRUCTURAL ASPECTS; DRUG-RESISTANCE; OVARIAN-CANCER; PROTEIN; DEPENDENCE; SEQUENCES	Loss of p53 function is associated with the acquisition of cisplatin resistance in the human ovarian adenocarcinoma A2780 cell line, Selection for cisplatin resistance of A2780 cells was used to isolate genetic suppressor elements (GSEs) from a retroviral library expressing random fragments of human or murine TP53 cDNA. Six GSEs were identified, encoding either dominant negative mutant peptides or antisense RNA molecules which corresponded to various regions within the TP53 gene, Both types of GSE induced cisplatin resistance when introduced individually into A2780 cells, Expression of antisense GSEs led to decreased intracellular levels of p53 protein, One sense GSE induced loss of p53-mediated activities such as DNA damage induced cell cycle arrest and apoptosis, A synthetic peptide, representing the predicted amino acid sequence of this GSE, conferred resistance to cisplatin when introduced into A2780 cells and inhibited the sequence specific DNA binding activity of p53 protein in vitro. Overall, these results directly indicate that inactivation of p53 function confers cisplatin resistance in these human ovarian tumour cells. We have identified short structural domains of p53 which are capable of independent functional interactions and highlighted the efficacy of this approach to discriminate biologically active GSEs from a random fragment library.	CRC, BEATSON LABS, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND; UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA	Beatson Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327; Gallagher, William/0000-0002-4307-5999	NATIONAL CANCER INSTITUTE [R01CA056736, R01CA062099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56736, R01 CA62099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; Anthoney DA, 1996, CANCER RES, V56, P1374; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BAYEVER E, 1994, LEUKEMIA LYMPHOMA, V12, P223, DOI 10.3109/10428199409059593; BI SC, 1994, CANCER RES, V54, P582; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BROWN R, 1993, ANN ONCOL, V4, P623, DOI 10.1093/oxfordjournals.annonc.a058614; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Coffin J. M., 1990, VIROLOGY, P1437; DENHARDT DT, 1992, ANN NY ACAD SCI, V660, P70, DOI 10.1111/j.1749-6632.1992.tb21059.x; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FAN SJ, 1995, CANCER RES, V55, P1649; GORCZYCA W, 1993, CANCER RES, V53, P3186; GUDKOV AV, 1993, P NATL ACAD SCI USA, V90, P3231, DOI 10.1073/pnas.90.8.3231; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLZMAYER TA, 1992, NUCLEIC ACIDS RES, V20, P711, DOI 10.1093/nar/20.4.711; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MCLAUGHLIN K, 1991, CANCER RES, V51, P2242; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OSSOVSKAYA V, IN PRESS P NATL ACAD; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PLUMB JA, 1989, CANCER RES, V49, P4435; RONINSON IB, 1995, CANCER RES, V55, P4023; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; Shimamura A, 1996, CLIN CANCER RES, V2, P435; SORENSON CM, 1988, CANCER RES, V48, P4484; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VASEY PA, 1996, IN PRESS MOL PHARM; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	49	78	82	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					185	193						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010220				2022-12-28	WOS:A1997WC81800006
J	Qin, XQ; Barsoum, J				Qin, XQ; Barsoum, J			Differential cell cycle effects induced by E2F1 mutants	ONCOGENE			English	Article						restriction point; cell cycle withdrawal; E2F1; mutants; cell survival	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F-1; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; S-PHASE; DOWNSTREAM TARGET; FIBROBLASTS LEADS; BINDING PROTEIN; DNA-SYNTHESIS; EXPRESSION	Expression of two types of transactivation-defective E2F1 mutants in human Rb--/- tumor cells led to an increase in the proportion of cells in the G(1) phase of the cell cycle as determined by FAGS analysis. Experiments revealed two different mechanisms of action. One mutant type induced a G(1) arrest after the restriction point, with cells phenotypically at a cell cycle stage later than G(1). The action of this mutant was, at least in part, dependent on specific DNA binding and was over-ridden by coexpression of its wild-type counterpart. The other mutant type, which is defective in DNA binding, slowed the G(1) progression and restored a checkpoint for cell cycle withdrawal. The G(1) phase withdrawal of these tumor cells allowed the initiation of skeletal muscle cell differentiation. Thus, E2F1 appears to have two different functions before and after the cell cycle restriction point. This report also may provide a basis for a gene therapy approach for certain human cancers.			Qin, XQ (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANERJEE A, 1992, CANCER RES, V5, P6297; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3028; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KOFF A, 1992, SCIENCE, V257, P1989; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1995, TRANSCRIPTIONAL CONT; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU HJ, 1991, CANCER RES, V51, P4481; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	8	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					53	62		10.1038/sj.onc.1200809	http://dx.doi.org/10.1038/sj.onc.1200809			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010232				2022-12-28	WOS:A1997WB76000005
J	Lei, JY; Zou, TT; Shi, YQ; Zhou, XL; Smolinski, KN; Yin, J; Souza, RF; Appel, R; Wang, S; Cymes, K; Chan, O; Abraham, JM; Harpaz, N; Meltzer, SJ				Lei, JY; Zou, TT; Shi, YQ; Zhou, XL; Smolinski, KN; Yin, J; Souza, RF; Appel, R; Wang, S; Cymes, K; Chan, O; Abraham, JM; Harpaz, N; Meltzer, SJ			Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms	ONCOGENE			English	Article						DPC4; mutation; tumor suppressor gene; esophageal cancer; gastric cancer; DNA sequencing	TUMOR-SUPPRESSOR GENE; ADENOMATOUS POLYPOSIS; DROSOPHILA; DYSPLASIAS; ALLELOTYPE; DELETIONS; CARCINOMA; BETA; P53	Homozygously Deleted in Pancreatic Cancer 4 (DPC4), a recently identified candidate tumor suppressor gene, was previously shown to be altered in human pancreatic cancers, We examined DPC4 mutation in 30 examples of three other types of gastrointestinal malignancy: 10 esophageal cancers, 10 gastric cancers and 10 colorectal cancers occurring in the preneoplastic condition, ulcerative colitis, The entire coding region of DPC4 (including all 11 exons) was analysed by either direct sequencing of PCR product or the in vitro synthesized protein assay. No coding region mutations of DPC4 were found in any of the samples examined, Our results suggest that inactivation of DPC4 may not be important in the majority of these types of gastrointestinal cancer.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201; MT SINAI UNIV,SCH MED,DEPT PATHOL,NEW YORK,NY	University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai			Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HURSH DA, 1993, DEVELOPMENT, V117, P1211; Kim SK, 1996, CANCER RES, V56, P2519; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1990, CANCER RES, V50, P3627; Nagatake M, 1996, CANCER RES, V56, P2718; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHUTTE M, 1996, CANCER RES, V56, P2527; TARMIN L, 1995, CANCER RES, V55, P2035; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TOYOOKA M, 1995, CANCER RES, V55, P3165; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; XIAO S, 1995, CANCER RES, V55, P2968	20	70	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2459	2462						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957088				2022-12-28	WOS:A1996VX10800019
J	BaierBitterlich, G; Baier, G; Fuchs, D; Bock, G; Hausen, A; Utermann, G; Pavelka, M; Wachter, H				BaierBitterlich, G; Baier, G; Fuchs, D; Bock, G; Hausen, A; Utermann, G; Pavelka, M; Wachter, H			Role of 7,8-dihydroneopterin in T-cell apoptosis and HTLV-1 transcription in vitro	ONCOGENE			English	Article						HTLV infection; apoptosis; neopterin; 7,8-dihydroneopterin; HTLV LTR; reactive oxygen intermediates	VIRUS TYPE-I; NF-KAPPA-B; LUMINOL-DEPENDENT CHEMILUMINESCENCE; INTERFERON-GAMMA; OXIDATIVE STRESS; REACTIVE OXYGEN; TRANSACTIVATOR TAX; HIV-INFECTION; NEOPTERIN; LEUKEMIA	Adult T-cell leukemia is associated with high levels of neopterin, released in large amounts from human macrophages upon stimulation with interferon-gamma. Recent data suggested a potential role of neopterin-derivatives in oxygen radical-mediated processes, and evidence accumulates that oxidative stress is involved in the pathogenesis of viral diseases. We now report that increased concentrations of 7,8-dihydroneopterin may lead to enhanced apoptosis and disturbance of the redox-balance of human leukemic Jurkat T cells. Additionally, we demonstrate that 7,8-dihydroneopterin and hydrogen peroxide activate the type 1 human T-cell leukemia virus (HTLV-1) long terminal repeat (LTR). Furthermore, we found that the activity of the HTLV-1 transactivator protein Tax is amplified by an elevated concentration of 7,8-dihydroneopterin. Tax did not significantly augment 7,8-dihydroneopterin mediated apoptosis. Based on our data we propose that 7,8-dihydroneopterin may be involved in the progression to higher stages of HTLV-1 associated disease.	UNIV INNSBRUCK, LUDWIG BOLTZMANN INST AIDS RES, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST EXPT PATHOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST HISTOL & EMBRYOL, A-6020 INNSBRUCK, AUSTRIA	Ludwig Boltzmann Institute; University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	BaierBitterlich, G (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.		Fuchs, Dietmar/AAL-8011-2021; Baier, Gottfried/E-8755-2012	Fuchs, Dietmar/0000-0003-1627-9563; Baier, Gottfried/0000-0002-2085-8325				BAIERBITTERELIC.G, IN PRESS AIDS RES HU; BAIERBITTERLICH G, 1995, FEBS LETT, V364, P234, DOI 10.1016/0014-5793(95)00403-V; BAIERBITTERLICH G, 1994, ONCOGENE, V9, P319; BAIERBITTERLICH G, IN PRESS AIDS RES HU; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BILLIAU A, 1990, BIOCHEM PHARMACOL, V40, P1433, DOI 10.1016/0006-2952(90)90437-P; BITTERLICH G, 1988, IMMUNOBIOLOGY, V176, P228, DOI 10.1016/S0171-2985(88)80055-X; CHLICHLIA K, 1995, ONCOGENE, V10, P269; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAEFLER S, 1991, MOL F ONCOLOGY, P229; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0; FUCHS D, 1989, CLIN CHEM, V35, P2305; FUCHS D, 1994, IMMUNOL TODAY, V15, P496, DOI 10.1016/0167-5699(94)90197-X; FUJII N, 1992, MICROBIOL IMMUNOL, V36, P425, DOI 10.1111/j.1348-0421.1992.tb02041.x; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENSPAN HC, 1994, IMMUNOL TODAY, V15, P209, DOI 10.1016/0167-5699(94)90245-3; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P; MERL S, 1984, BLOOD, V64, P967; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MURR C, 1994, FEBS LETT, V338, P223, DOI 10.1016/0014-5793(94)80369-2; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; REIBNEGGER G, 1995, FREE RADICAL BIO MED, V18, P515, DOI 10.1016/0891-5849(94)00164-F; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; UBERALL F, 1994, FEBS LETT, V352, P11, DOI 10.1016/0014-5793(94)00899-X; WACHTER H, 1989, ADV CLIN CHEM, V27, P81, DOI 10.1016/S0065-2423(08)60182-1; WACHTER H, 1979, H-S Z PHYSIOL CHEM, V360, P1957; Wachter H, 1992, NEOPTERIN BIOCH METH, V10, P289; WEISS G, 1993, FEBS LETT, V321, P89, DOI 10.1016/0014-5793(93)80627-7; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2281	2285						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950996				2022-12-28	WOS:A1996VV14500026
J	Yayon, A; Ma, YS; Safran, M; Klagsbrun, M; Halaban, R				Yayon, A; Ma, YS; Safran, M; Klagsbrun, M; Halaban, R			Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: Evidence for the involvement of Src-family kinases	ONCOGENE			English	Article						FGF2; dominant-negative receptor; receptor tyrosine kinase; melanocytes	ACTIVATED PROTEIN-KINASE; HUMAN-MALIGNANT MELANOMA; MULTIPLE HUMAN CANCERS; TYROSINE KINASES; HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; C-SRC; FACTORS STIMULATE; CYCLE REGULATOR; EXPRESSION	Basic Fibroblast Growth Factor (bFGF/FGF2) is thought to play a decisive role in malignant progression. Aberrant expression of bFGF causes constitutive autocrine activation of its cognate receptor and autonomous growth of human melanoma cells or bFGF transformed fibroblasts in culture, It remains to be determined, however, whether the endogenous bFGF confers growth advantage to tumors and what are the downstream targets of the activated FGF receptor critical for its transforming capacity, We therefore transfected metastatic melanoma cells and bFGF transformed mouse fibroblasts with a dominant-negative mutant of the murine FGF receptor 1 (fgfr1/flg), comprising the extracellular and transmembrane domains but lacking the intracellular kinase domain (dnflg), Reverse transcriptase-PCR, I-125-bFGF binding and affinity labeling analyses show that the truncated receptor is targeted to the membrane and is expressed at much higher levels than the endogenous receptor in all of the selected clones, Expression of the dnflg dramatically reduces the basal as well as bFGF induced growth of these cells in vitro and also suppresses their tumorigenic potential in nude mice, The expression of the dnflg does not significantly alter the general level of tyrosyl-phosphorylated proteins in the transduced melanoma cells. Rather, a major downstream affected target is a Src-family kinase, whose activity, determined by an in vitro immune kinase assay, is stimulated in normal melanocytes by exogenous bFGF, and is markedly reduced in the dnflg-expressing melanoma cells, The present study demonstrates that direct interference with the activity of FGF receptors has a deleterious effect on cell proliferation and survival in vitro and in vivo leading to the suppression of melanoma tumor progression possibly through the inactivation of a Src-family kinase.	YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Yale University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Yayon, A (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.		Fu, Da/GXF-2656-2022		NCI NIH HHS [CA44542] Funding Source: Medline; NIAMS NIH HHS [AR39848, AR41942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044542, R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942, R01AR039848] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1991, CANCER RES, V51, P4815; AMAYA E, 1993, DEVELOPMENT, V118, P477; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; COWAN JM, 1991, MELANOMA RES GENETIC, V3; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, CANCER RES, V55, P2528; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1992, BIOLOGY OF THE EPIDERMIS : MOLECULAR AND FUNCTIONAL ASPECTS, P133; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HALABAN R, 1993, EPIDERMAL GROWTH FAC, P273; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAMB A, 1994, COLD SPRING HARB SYM, V59, P39, DOI 10.1101/SQB.1994.059.01.007; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LIU L, 1995, ONCOGENE, V11, P405; LOGANZO F, 1993, ONCOGENE, V8, P2637; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REED JA, 1994, AM J PATHOL, V144, P329; REYMOND A, 1995, ONCOGENE, V11, P1173; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1992, J BIOL CHEM, V267, P1470; WALKER GJ, 1994, ONCOGENE, V9, P819; WELLBROCK C, 1995, ONCOGENE, V10, P2135; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360; ZAKUT R, 1993, ONCOGENE, V8, P2221; ZHAN X, 1994, J BIOL CHEM, V269, P20221	65	66	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					2999	3009		10.1038/sj.onc.1201159	http://dx.doi.org/10.1038/sj.onc.1201159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223663				2022-12-28	WOS:A1997XG10000002
J	Wang, MS; Liu, YLE; Greene, J; Sheng, SJ; Fuchs, A; Rosen, EM; Shi, YE				Wang, MS; Liu, YLE; Greene, J; Sheng, SJ; Fuchs, A; Rosen, EM; Shi, YE			Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4	ONCOGENE			English	Article						TIMP; MMP; mammary carcinoma; nude mice; angiogenesis	INVASIVE TUMORS; IV COLLAGENASES; MESSENGER-RNAS; STROMAL CELLS; UP-REGULATION; CHICK-EMBRYO; IN-VIVO; EXPRESSION; TIMP-2; ANGIOGENESIS	We recently identified, cloned, and characterized a novel human tissue inhibitor of metalloproteinases-4, TIMP-4 (Greene et al., 1996), To determine if TIMP-4 can modulate the in vivo growth of human breast cancers, Ne transfected a full-length TIMP-4 cDNA into MDA-MB-435 human breast cancer cells and studied the orthotopic growth of TIMP-4-transfected (TIMP4-435) versus control (neo-435) clones in the mammary fat pad of athymic nude mice, TIMP4-435 clones expressed TIMP-4 mRNA and produced anti-metalloproteinase (MMP) activity, while neo-435 clones did not express TIMP-4 mRNA or produce detectable anti-MMP activity. Overexpression of TIMP-4 inhibited the invasion potential of the cells in the in vitro invasion assay, When injected orthotopically into nude mice, TIMP-4 transfectants were significantly inhibited in tumor growth by 4-10-fold in primary tumor volumes; and in an axillary lymph node and lung metastasis as compared with controls. These results suggest the therapeutic potential of TIMP-4 in treating cancer malignant progression.	LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT RADIAT ONCOL,NEW HYDE PK,NY 11040; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; GlaxoSmithKline; Human Genome Sciences Inc; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BARSKY SH, 1983, LAB INVEST, V49, P140; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERRETTONI BA, 1986, J BONE JOINT SURG AM, V68A, P308, DOI 10.2106/00004623-198668020-00021; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HARAN EF, 1994, CANCER RES, V54, P5511; Heppner KJ, 1996, AM J PATHOL, V149, P273; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HLATKY L, 1994, CANCER RES, V54, P6083; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Imren S, 1996, CANCER RES, V56, P2891; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KHOKHA R, 1992, CLIN EXP METASTAS, V10, P365, DOI 10.1007/BF00133464; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LAMSZUS K, 1997, IN PRESS LAB INVEST; Lund LR, 1996, DEVELOPMENT, V122, P181; MATSUZAWA K, 1996, NEUROPATHOL EXP NEUR, V55, P88; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi Y. E., 1995, V74, P215; SHI YE, 1993, CANCER RES, V53, P1409; SHI YE, 1993, CLIN EXP METASTAS, V11, P251, DOI 10.1007/BF00121168; SPYRATOS F, 1989, LANCET, V2, P1115; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WOLFF JEA, 1993, BRAIN RES, V604, P79, DOI 10.1016/0006-8993(93)90354-P	47	132	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2767	2774		10.1038/sj.onc.1201245	http://dx.doi.org/10.1038/sj.onc.1201245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190892				2022-12-28	WOS:A1997XD64300004
J	Ivanov, VN; Lee, RK; Podack, ER; Malek, TR				Ivanov, VN; Lee, RK; Podack, ER; Malek, TR			Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: A potential role for transcription factor NF-kappa B	ONCOGENE			English	Article						apoptosis; T lymphocyte; NF-kappa B; Fas ligand	PROTEIN-KINASE-A; IMMUNE-SYSTEM; REL FAMILY; C-MYC; DEATH; INHIBITION; EXPRESSION; BCL-2; HYBRIDOMAS; LIGAND	TCR-mediated activation of T cell hybridomas induces programmed cell death by a Fas-dependent pathway. We now show that costimulation of 2B4 cells, in the absence or presence of transgenic Bcl-2, with anti-CD3 epsilon and forskolin, an activator of cAMP signaling, resulted in antagonism of Fas-dependent activation-induced cell death that was always accompanied by selective down-regulation of the nuclear levels of NF-kappa B p65-p50 (RelA-p50) transcription factor. Forskolin not only inhibited activation-induced cell death and NF-kappa B activation, but also suppressed expression of Fas and Fas ligand (Fast). Furthermore, NF-kappa B p65 antisense oligonucleotide down-regulated nuclear levels of NF-kappa B, inhibited cell surface expression of Fas-L and apoptosis of 2B4. Collectively, these finding demonstrate a potential role of NF-kappa B in the regulation of activation-induced apoptosis in T lymphocytes.	UNIV MIAMI, SCH MED, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33101 USA; RUSSIAN ACAD SCI, INST GENE BIOL, MOSCOW, RUSSIA	University of Miami; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NCI NIH HHS [R01-CA4609] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1994, HDB B T LYMPHOCYTES, P63; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BRIDLE PK, 1992, CURR OPIN GENET DEV, V2, P199; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CODIAS EK, 1990, J IMMUNOL, V145, P1407; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; IVANOV V, 1994, J IMMUNOL, V153, P2394; IVANOV V, 1993, J IMMUNOL, V151, P4694; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JONDAL M, 1995, APOPTOSIS IMMUNOLOGY, P67; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEE MR, 1993, J IMMUNOL, V151, P5208; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams MS, 1996, J IMMUNOL, V157, P2395; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WU HY, 1994, J BIOL CHEM, V269, P20067; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	59	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2455	2464		10.1038/sj.onc.1201088	http://dx.doi.org/10.1038/sj.onc.1201088			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188860	Green Published			2022-12-28	WOS:A1997WZ68000009
J	Loughran, O; Clark, LJ; Bond, J; Baker, A; Berry, IJ; Edington, KG; Ly, IS; Simmons, R; Haw, R; Black, DM; Newbold, RF; Parkinson, EK				Loughran, O; Clark, LJ; Bond, J; Baker, A; Berry, IJ; Edington, KG; Ly, IS; Simmons, R; Haw, R; Black, DM; Newbold, RF; Parkinson, EK			Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes	ONCOGENE			English	Article						keratinocyte; senescence; immortality; telomerase; squamous; cancer	HUMAN-DIPLOID FIBROBLASTS; INDEFINITE DIVISION; TELOMERASE ACTIVITY; SUPPRESSOR GENE; SENESCENCE; LINES; HEAD; NECK; P53; CANCER	Human keratinocyte immortality is genetically recessive to the normal phenotype of limited replicative lifespan and appears to require the dysfunction of p53 and the cyclin D-Cdk inhibitor p16. In order to test for the inactivation of other candidate replicative lifespan genes in the immortal cells of human tumors, we developed a series of mortal and immortal keratinocyte cultures derived from neoplastic lesions of the head and neck which were amenable to molecular genetic analysis by the loss of heterozygosity (LOH) technique. The results indicate that keratinocyte immortalization in head and neck squamous cell carcinoma (SCC-HN) development involves the inactivation of at least two further pathways to senescence and four in all. Chromosomes 1, 4 and 7 carry genes representing immortality complementation groups C, B and D respectively and immortal keratinocytes showed LOH at either 4q32-q34 between D4S1554 and D4S171 (group B) or 7q31 (group D) but never 1q25 (group C). These results tentatively suggest that the genes responsible for the immortality complementation groups encode proteins on the same pathway to senescence. In addition, all of the immortal keratinocyte lines possessed high levels of telomerase activity and a suppressor of telomerase activity has been mapped to the short arm of chromosome 3p. Five out of eight lines showed LOH at 3p21.2-p21.3, a region which may carry a gene capable of suppressing SCC-HN telomerase. However, alternative mechanisms of telomerase reactivation were also suggested by our results. None of the above genetic alterations were seen in seven senescent neoplastic keratinocyte cultures, Other loci harbouring antiproliferative genes implicated in replicative lifespan showed few or no alterations and any alterations seen were additional to those described above.	BEATSON INST CANC RES,CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; BRUNEL UNIV,DEPT BIOCHEM,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; BRUNEL UNIV,DEPT BIOL,UXBRIDGE UB8 3PH,MIDDX,ENGLAND	Beatson Institute; Brunel University; Brunel University			Haw, Robin/D-1393-2009	Haw, Robin/0000-0002-2013-7835				BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; BURNS JE, 1994, BRIT J CANCER, V70, P591, DOI 10.1038/bjc.1994.356; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CAVANEE WK, 1983, NATURE, V305, P779; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EASTY DM, 1981, BRIT J CANCER, V43, P772, DOI 10.1038/bjc.1981.115; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; EDINGTON KG, 1996, IN PRESS CULTURE TUM, V4; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Karlsson C, 1996, CANCER RES, V56, P241; KAUFMANN WK, 1995, CANCER RES, V55, P7; KAUL SC, 1995, FEBS LETT, V361, P269, DOI 10.1016/0014-5793(95)00177-B; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; MAESTRO R, 1993, CANCER RES, V53, P5775; NAWROZ H, 1994, CANCER RES, V54, P1152; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	48	67	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1955	1964		10.1038/sj.onc.1201028	http://dx.doi.org/10.1038/sj.onc.1201028			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150362				2022-12-28	WOS:A1997WV80400008
J	Yu, YJ; Li, CY; Little, JB				Yu, YJ; Li, CY; Little, JB			Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells	ONCOGENE			English	Article						p53; HPV16 E6; radiosensitivity; apoptosis; mutability	WILD-TYPE P53; INDUCED G(1) ARREST; SV40 T-ANTIGEN; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CYCLE PROGRESSION; X-IRRADIATION; SINGLE-DONOR	In order to gain a better understanding of the role of p53 in radiation-induced mitotic failure, apoptosis and mutagenesis, we introduced the HPV16 E6 gene via a retroviral vector into the TK6 human lymphoblast cell line which expresses wild type p53. Abrogation of p53 function by E6 resulted in a delayed and reduced apoptotic response and a moderate increase in the frequency of mutations at the thymidine kinase (tk) locus following gamma-irradiation, but failed to alter radiosensitivity. The apoptotic response of the E6-transduced line was intermediate between that of wild type TK6 and the WTK1 cell line. WTK1 is derived from the same parental cell line as TK6 but expresses mutant p53. The spontaneous and gamma-ray-induced mutation frequencies in E6-transduced TK6 cells, although higher than that of the parental TK6 cell line, were still much lower than that of the WTK1 line. No effect on apoptosis, radiosensitivity or mutability was observed when the HPV16 E6 gene was introduced into the WTK1 cells. These results indicate that p53 does not regulate the radiosensitivity of TK6 cells through the apoptotic pathway. Furthermore, the previously observed enhanced radioresistance and mutability in WTK1 cells must be attributed to a more complex mechanism than p53 status alone.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Li, Chuan-Yuan/H-4148-2013		NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47542, CA-09078] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMUNDSON SA, 1993, MUTAT RES, V286, P233, DOI 10.1016/0027-5107(93)90188-L; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUANG H, 1996, IN PRESS INT J RAD B; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1995, ONCOGENE, V10, P2001; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVY JA, 1968, CANCER-AM CANCER SOC, V22, P517, DOI 10.1002/1097-0142(196809)22:3<517::AID-CNCR2820220305>3.0.CO;2-A; LI CY, 1995, ONCOGENE, V11, P1885; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI CY, 1995, INT J ONCOL, V7, P223; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIVINGSTONE LR, 1992, CELL, V70, P925; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACILWRATH AJ, 1994, CANCER RES, V54, P3718; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; MURNANE JP, 1993, NATURE, V365, P22, DOI 10.1038/365022a0; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ JL, 1995, MUTAGENESIS, V10, P227, DOI 10.1093/mutage/10.3.227; SLICHENMYER WJ, 1993, CANCER RES, V53, P5164; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SU LN, 1992, INT J RADIAT BIOL, V62, P201, DOI 10.1080/09553009214552021; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; TSANG NM, 1995, ONCOGENE, V10, P2403; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS AC, 1995, ONCOGENE, V11, P141; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHEN W, 1995, MUTAT RES LETT, V346, P85, DOI 10.1016/0165-7992(95)90055-1; Zhen W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P602	52	77	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1661	1667		10.1038/sj.onc.1201026	http://dx.doi.org/10.1038/sj.onc.1201026			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135067				2022-12-28	WOS:A1997WR89300004
J	Peter, M; Couturier, J; Pacquement, H; Michon, J; Thomas, G; Magdelenat, H; Delattre, O				Peter, M; Couturier, J; Pacquement, H; Michon, J; Thomas, G; Magdelenat, H; Delattre, O			A new member of the ETS family fused to EWS in Ewing tumors	ONCOGENE			English	Article						ETS family; Ewing tumor; EWS; transcription; fusion	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; GENE FUSION; CHROMOSOMAL TRANSLOCATION; SARCOMA TRANSLOCATION; CHIMERIC TRANSCRIPTS; TRANSFORMING GENE; TEL GENE; PROTEIN	As a result of chromosome translocations, the EWS gene is fused to a variety of transcription factors in human solid neoplasia. In Ewing tumors EWS can be fused to four different members of the ETS family, namely FLI-1, ERG, ETV1 and E1AF We have identified a new member of the ETS family, called FEV, which is fused to EWS in a subset of Ewing tumors, FEV encodes a 238 amino acid protein which contains an ETS DNA binding domain closely related to that of FLI-1 and ERG, However, the N-terminal portion of FEV is only 42 amino acids long which suggests that FEV is lacking important transcription regulatory domains contained in FLI-1 and ERG N-terminal parts. The C-terminal end of FEV is rich in alanine residues which may indicate that FEV is a transcription repressor. The FEV gene is encoded by three exons and is located on chromosome 2. I;EV expression was only detected in adult prostate and small intestine but not in other adult nor in fetal tissues, thus indicating that FEV has a restricted expression pattern, Following a scheme similar to previously described translocations in Ewing tumors, a t(2;22) chromosome translocation fuses the N-terminal domain of EWS to the ETS DNA binding domain of FEV.	INST CURIE,LAB GENET TUMEURS,INSERM U434,F-75231 PARIS 05,FRANCE; INST CURIE,LAB TRANSFERT,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PATHOL,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PEDIAT ONCOL,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				delattre, olivier/0000-0002-8730-2276				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BUIJS A, 1995, ONCOGENE, V10, P1511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Maniatis T., 1989, MOL CLONING LAB MAN; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	290	301	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1159	1164		10.1038/sj.onc.1200933	http://dx.doi.org/10.1038/sj.onc.1200933			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121764				2022-12-28	WOS:A1997WM78200004
J	Lutterbach, B; Hann, SR				Lutterbach, B; Hann, SR			Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation	ONCOGENE			English	Article						c-Myc; phosphorylation; immortalization; transactivation	CASEIN KINASE-II; TRANSFORMING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; NEOPLASTIC-CELLS; POINT MUTATIONS; GENE-EXPRESSION; PROTEIN; SITE; VIRUS	Using an extensive series of deletion and site-specific mutation constructs, we have identified five new phosphorylation sites in c-Myc in the N-terminal transactivation domain and near the C-terminal DNA binding/heterodimerization domain. We have also found that Thr-58 phosphorylation is regulated by specific cellular events. When c-Myc is overexpressed in cells Thr-58 phosphorylation was greatly enhanced in the overexpressed, exogenous c-Myc as compared with the endogenous protein. In contrast, an inhibition of Thr-58 phosphorylation and an enhancement of Serine 62 phosphorylation was observed in c-Myc from immortalized cells compared with primary cells. No significant changes in c-Myc phosphorylation were found when transformed and nontransformed cells were compared. Finally, mutations at these phosphorylation sites, either individually or in combination with previously described sites, did not affect the ability of c-Myc to transactivate through the CACGTG Myc/Max DNA binding sites. These results further suggest that either the molecular role for c-Myc phosphorylation does not involve modulating transcriptional activity of c-Myc or that the CACGTG site does not represent a physiological promoter element.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NCI NIH HHS [CA-47399, CA-48799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047399, P01CA048799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FILARDO EJ, 1991, J VIROL, V65, P6621, DOI 10.1128/JVI.65.12.6621-6629.1991; FRYKBERG L, 1987, ONCOGENE, V1, P415; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PULVERER BJ, 1994, ONCOGENE, V9, P59; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SYMONDS G, 1989, ONCOGENE, V4, P285; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	46	29	29	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					967	975		10.1038/sj.onc.1200920	http://dx.doi.org/10.1038/sj.onc.1200920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050996				2022-12-28	WOS:A1997WK34400010
J	Saito, H; Nakatsuru, S; Inazawa, J; Nishihira, T; Park, JG; Nakamura, Y				Saito, H; Nakatsuru, S; Inazawa, J; Nishihira, T; Park, JG; Nakamura, Y			Frequent association of alternative splicing of NER, a nuclear hormone receptor gene in cancer tissues	ONCOGENE			English	Article						nuclear hormone receptor; alternative splicing; cancer cell lines and primary cancers; NER	ACTIVATION	We have detected frequent alternative splicing of a gene that encodes NER, a protein homologous to the retinoic acid receptors, in cancer cells, Western and immunohistochemical analyses disclosed accumulation of a large amount of the aberrant NER product, generated by alternative splicing that caused skipping of an exon corresponding to the DNA-binding domain, in the nucleoli of cells of cancer cell lines and primary cancer tissues, The aberrant protein was detected in 116 of 228 primary cancers developed in various tissues including breast and colon, but was absent in the corresponding normal tissues; it was also detected in 31 of 39 cancer cell lines, This observation may imply that the aberrant NER product has some relation to the development and/or progression of cancers in a variety of human tissues.	JAPANESE FDN CANC RES,INST CANC,DEPT HUMAN GENOME ANAL,TOSHIMA KU,TOKYO 170,JAPAN; UNIV TOKYO,INST MED SCI,MOL MED LAB,MINATO KU,TOKYO 108,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN; TOHOKU UNIV,DEPT SURG 2,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; SEOUL NATL UNIV,SCH MED,SEOUL 110744,SOUTH KOREA	Japanese Foundation for Cancer Research; University of Tokyo; Kyoto Prefectural University of Medicine; Tohoku University; Seoul National University (SNU)			Park, Jae-Gahb/J-5494-2012					BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GRIFFIOEN AW, 1994, CELL ADHES COMMUN, V2, P195, DOI 10.3109/15419069409004437; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SUDO K, 1994, GENOMICS, V24, P276, DOI 10.1006/geno.1994.1616; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3	11	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					617	621		10.1038/sj.onc.1200859	http://dx.doi.org/10.1038/sj.onc.1200859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053861				2022-12-28	WOS:A1997WF52400014
J	Kashanchi, F; Araujo, J; Doniger, J; Muralidhar, S; Hoch, R; Khleif, S; Mendelson, E; Thompson, J; Azumi, N; Brady, JN; Luppi, M; Torelli, G; Rosenthal, LJ				Kashanchi, F; Araujo, J; Doniger, J; Muralidhar, S; Hoch, R; Khleif, S; Mendelson, E; Thompson, J; Azumi, N; Brady, JN; Luppi, M; Torelli, G; Rosenthal, LJ			Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53	ONCOGENE			English	Article						p53 binding; p53-activated transcription; HHV-6 transformation gene	POLYMERASE CHAIN-REACTION; VIRUS HUMAN HERPESVIRUS-6; EXANTHEM-SUBITUM; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; HUMAN CYTOMEGALOVIRUS; TRANSGENIC MICE; HUMAN LYMPHOMAS; LYMPHOCYTES-T; CELL-LINES	The 357 amino acid open reading frame 1 (OFF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication (Kashanchi et al., Virology, 201, 95-106, 1994). Tn the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment, Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV, Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic, Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the OFF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated OFF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed OFF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of OFF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that OFF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.	GEORGETOWN UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20007; NCI,MOL VIROL LAB,NIH,BETHESDA,MD 20892; NCI,NAVY MED ONCOL BRANCH,BETHESDA,MD 20892; UNIV MODENA,CTR EXPT HEMATOL,I-41100 MODENA,ITALY	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universita di Modena e Reggio Emilia			Luppi, Mario/J-3668-2016	Luppi, Mario/0000-0002-0373-1154; Hoch, Renee/0000-0003-0042-3751	NATIONAL CANCER INSTITUTE [R55CA060577, R01CA060577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ABLASHI DV, 1988, INT J CANCER, V42, P787, DOI 10.1002/ijc.2910420526; ABLASHI DV, 1995, TRENDS MICROBIOL, V3, P324, DOI 10.1016/S0966-842X(00)88964-7; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; BERTRAM G, 1991, In Vivo (Attiki), V5, P271; BLAZQUEZ MV, 1995, J ACQ IMMUN DEF SYND, V9, P389; BOVENZI P, 1993, LANCET, V341, P1288, DOI 10.1016/0140-6736(93)91198-U; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; CLANTON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P3826, DOI 10.1073/pnas.80.12.3826; CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; FUJITA M, 1995, ONCOGENE, V11, P15; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Hansen R, 1995, ONCOGENE, V11, P2535; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; KASHANCHI F, 1994, VIROLOGY, V201, P95, DOI 10.1006/viro.1994.1269; KASHANCHI F, 1993, J VIROL, V67, P2894, DOI 10.1128/JVI.67.5.2894-2902.1993; Kikuchi M, 1992, HUMAN HERPESVIRUS, VDV, P175; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Krueger G R, 1991, In Vivo, V5, P217; Krueger G R, 1994, In Vivo, V8, P501; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE PH, 1992, J INFECT DIS, V166, P291, DOI 10.1093/infdis/166.2.291; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LUPPI M, 1993, J INFECT DIS, V168, P1074, DOI 10.1093/infdis/168.4.1074; LUPPI M, 1995, J MED VIROL, V47, P105, DOI 10.1002/jmv.1890470119; LUPPI M, 1993, LEUKEMIA RES, V17, P1003, DOI 10.1016/0145-2126(93)90049-Q; LUSSO P, 1995, J EXP MED, V181, P1303, DOI 10.1084/jem.181.4.1303; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MANSUR CP, 1995, ONCOGENE, V10, P457; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; NIEDERMAN JC, 1988, LANCET, V2, P817; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PELLETT PE, 1996, FIELDS VIROLOGY, P2587; QAVI HB, 1995, INVEST OPHTH VIS SCI, V36, P2040; RAZZAQUE A, 1993, VIROLOGY, V195, P113, DOI 10.1006/viro.1993.1351; RAZZAQUE A, 1990, ONCOGENE, V5, P1365; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SAITO Y, 1995, J NEUROVIROL, V1, P30, DOI 10.3109/13550289509111008; SIECZKOWSKI L, 1995, VIROLOGY, V211, P544, DOI 10.1006/viro.1995.1436; SOUSSI T, 1990, ONCOGENE, V5, P945; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1988, LANCET, V1, P1463; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; Target Lusso P, 1992, HUMAN HERPESVIRUS, P25; THOMPSON J, 1994, ONCOGENE, V9, P1167; TLSTY TD, 1994, COLD SPRING HARB SYM, V59, P265, DOI 10.1101/SQB.1994.059.01.031; TORELLI G, 1995, J MED VIROL, V46, P178, DOI 10.1002/jmv.1890460303; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; YAMANISHI K, 1988, LANCET, V1, P1065	68	70	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					359	367		10.1038/sj.onc.1200840	http://dx.doi.org/10.1038/sj.onc.1200840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018122				2022-12-28	WOS:A1997WD51600012
J	Guillot, C; Falette, N; Paperin, MP; Courtois, S; GentilPerret, A; Treilleux, I; Ozturk, M; Puisieux, A				Guillot, C; Falette, N; Paperin, MP; Courtois, S; GentilPerret, A; Treilleux, I; Ozturk, M; Puisieux, A			P21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours	ONCOGENE			English	Article						breast cancer; p53; functional inactivation; p21(WAF1/CIP1)	P53-MEDIATED G(1) ARREST; P53 MUTATIONS; P53-INDEPENDENT PATHWAY; MONOCLONAL-ANTIBODIES; SUPPRESSOR GENE; HUMAN CANCER; CELL-LINES; PROTEIN; TUMORS; P21	Functional inactivation of the wild-type p53 protein has been described in different human cancers. Since a significant proportion of breast tumours express wildtype TP53, the p53 antiproliferative activity could be inactivated in transformed mammary epithelial cells by a mechanism independent on structural alteration of the gene, To test this hypothesis, we analysed the p53 activity in primary breast tumour cells. As a preliminary study, we demonstrated in breast adenocarcinoma cell lines that the nuclear accumulation of the inhibitor of cyclin dependent kinase p21(WAF1/CIP1), in response to adriamycin treatment, specifically reflected the activity of a functional wild-type p53 protein. Then, we used this strategy to study the p53 activity in 23 primary breast tumours. p21(WAF1/CIP1) accumulation was detected in all tumours expressing wild-type TP53. In contrast, no p21(WAF1/CIP1) response was detected in cells harboring a mutant TP53 gene. This report is the first functional study of p53 in primary breast tumours. The results demonstrate that TP53 mutation represents the only common mechanism leading to an irreversible inactivation of p53 functions in this cancer type.	INSERM U453,F-69008 LYON,FRANCE; CTR LEON BERARD,DEPT ANAT & CYTOL PATHOL,F-69008 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard			OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798				BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DIELLA F, 1993, LIFE SCI ADV BIOCH, V12, P47; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOMAGALA W, 1993, AM J PATHOL, V142, P669; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; GUILLOT C, IN PRESS CLIN CANC R; Hecker D, 1996, ONCOGENE, V12, P953; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEGROS Y, 1993, B CANCER, V80, P102; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MAZARS R, 1992, CANCER RES, V52, P3918; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ozcelik H, 1995, CLIN CANCER RES, V1, P907; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SOULE HD, 1990, CANCER RES, V50, P6075; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					45	52		10.1038/sj.onc.1200803	http://dx.doi.org/10.1038/sj.onc.1200803			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010231				2022-12-28	WOS:A1997WB76000004
J	Verkerk, AJMH; Ariel, I; Dekker, MC; Schneider, T; vanGurp, RJHLM; deGroot, N; Gillis, AJM; Oosterhuis, JW; Hochberg, AA; Looijenga, LHJ				Verkerk, AJMH; Ariel, I; Dekker, MC; Schneider, T; vanGurp, RJHLM; deGroot, N; Gillis, AJM; Oosterhuis, JW; Hochberg, AA; Looijenga, LHJ			Unique expression patterns of H19 in human testicular cancers of different etiology	ONCOGENE			English	Article						testis; germ cell tumors; non-germ cell tumors; H19 expression; genomic imprinting; germ cell development	GERM-CELL TUMORS; SPERMATOCYTIC SEMINOMA; IMPRINTED GENES; WILMS-TUMOR; IMMUNOHISTOCHEMICAL MARKERS; BIALLELIC EXPRESSION; ALLELIC METHYLATION; BLADDER-CARCINOMA; IGF2 EXPRESSION; HUMAN-DISEASES	The expression pattern of the imprinted human H19 gene was investigated in testicular cancers of different etiology, as well as in normal testicular parenchyma, parenchyma without germ cells, and adjacent to testicular germ cell tumors of adolescents and adults (TGCTs), using RNase protection analysis, mRNA in situ hybridization and reverse-transcription polymerase chain reaction. While different total expression levels were detected in spermatocytic seminomas, lymphomas, a Sertoli cell tumor and Leydig cell tumors, none showed a disturbance of monoallelic expression. Strikingly, the majority of invasive TGCTs revealed expression of both parental alleles. The total level of expression highly correlated with differentiation lineage and stage of maturation, similar to that as reported during early normal embryogenesis. Biallelic expression could also be determined specifically in testis parenchyma containing the preinvasive lesion of this cancer. We therefore conclude that within the adult testis, biallelic H19 expression is specific for TGCTs, and that the level of expression is dependent on differentiation lineage and maturation stage. This is in agreement with the proposed primordial germ cell-origin of this cancer, and might be related to retention of embryonic characteristics in TGCTs. In addition, our data argue against H19 being a tumor suppressor gene.	UNIV ROTTERDAM HOSP,LAB EXPT PATHOONCOL,DR DANIEL DEN HOED CANC CTR,ROTTERDAM,NETHERLANDS; HADASSAH UNIV HOSP,DEPT PATHOL,MT SCOPUS,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Hebrew University of Jerusalem; Hebrew University of Jerusalem			Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTON SC, 1991, DEVELOPMENT, V113, P679; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BOSMAN FT, 1993, INT J DEV BIOL, V37, P203; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; Burke A, 1993, J UROL PATHOL, V1, P21; COOPER MJ, 1996, IN PRESS J UROL; CUMMINGS OW, 1994, HUM PATHOL, V25, P54, DOI 10.1016/0046-8177(94)90171-6; DEGROOT N, 1993, MOL REPROD DEV, V36, P390, DOI 10.1002/mrd.1080360316; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; Donjacour A A, 1991, Cancer Treat Res, V53, P335; DoucRasy S, 1996, ONCOGENE, V12, P423; DUGIMONT T, 1995, MOL CELL, V85, P117; EBLE JN, 1994, HUM PATHOL, V25, P1035, DOI 10.1016/0046-8177(94)90062-0; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUNDELE RH, 1994, DEV GENET, V15, P515, DOI 10.1002/dvg.1020150610; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GOODFELLOW PN, 1982, NATURE, V300, P107, DOI 10.1038/300107a0; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hibi K, 1996, CANCER RES, V56, P480; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; JORGENSEN N, 1995, LAB INVEST, V72, P223; JORGENSEN N, 1993, HISTOPATHOLOGY, V22, P373; KONDO M, 1995, ONCOGENE, V10, P1193; Latham KE, 1995, DIFFERENTIATION, V59, P269; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Meyts E. Rajpert-De, 1994, International Journal of Andrology, V17, P85, DOI 10.1111/j.1365-2605.1994.tb01225.x; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOSTOFI FK, 1987, SEMIN DIAGN PATHOL, V4, P320; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; NAKASHIMA N, 1988, HUM PATHOL, V19, P1144, DOI 10.1016/S0046-8177(88)80145-X; OHLSSON R, 1994, DEVELOPMENT, V120, P361; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; ROMANENKO AM, 1983, VOP ONKOL, V19, P61; ROSENBERG SA, 1982, CANCER, V49, P2112; ROSSANT J, 1993, CURR BIOL, V3, P47, DOI 10.1016/0960-9822(93)90148-H; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SOLTER D, 1988, ANNU REV GENET, V22, P127; Solter Davor, 1992, Current Opinion in Biotechnology, V3, P632, DOI 10.1016/0958-1669(92)90007-6; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SVENSSON K, 1995, MECH DEVELOP, V51, P31, DOI 10.1016/0925-4773(94)00345-N; SZABO P, 1994, DEVELOPMENT, V120, P1651; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; TALERMAN A, 1984, LAB INVEST, V51, P343; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; WALSH C, 1995, CANCER RES, V55, P1111; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	68	58	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					95	107		10.1038/sj.onc.1200802	http://dx.doi.org/10.1038/sj.onc.1200802			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010236				2022-12-28	WOS:A1997WB76000009
J	Hall, CL; Lange, LA; Prober, DA; Zhang, S; Turley, EA				Hall, CL; Lange, LA; Prober, DA; Zhang, S; Turley, EA			pp60(c-src) is required for cell locomotion regulated by the hyaluronan receptor RHAMM	ONCOGENE			English	Article						migration; focal adhesions; cytoskeleton; tyrosine phosphorylation	ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; C-SRC; V-SRC; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; MEMBRANE INTERACTIONS; PP60C-SRC EXPRESSION	The tyrosine kinase pp60(c-src) has been implicated as a regulator of focal adhesion formation and cell spreading. Here we show that c-src also regulates cell motility and is a key component in the signaling pathway triggered by the motogenic hyaluronan receptor RHAMM, which has been shown to regulate focal adhesion turnover and to regulate ras. Fibroblasts derived from mice lacking src, (src (-/-), have a random locomotion rate that is significantly slower than the corresponding wild-type fibroblasts. Cell locomotion in these mutant cells is restored by the expression of c-src containing a functional kinase domain, but not by the expression of a kinase-deficient src or by a truncated src containing only functional SH2 and SH3 domains. RHAMM is also required for the restoration of src (-/-) cell locomotion. Thus, the motility of cells expressing c-src is reduced to src (-/-) levels by anti-RHAMM blocking antibodies while the cell locomotion of src (-/-) fibroblasts remains unaffected by anti-RHAMM antibodies. We predict that src acts downstream of RHAMM in the regulation of motility, since the expression of a dominant negative src significantly inhibits RHAMM-dependent ras and serum regulated cell locomotion, the expression of v-src enhances cell motility in a RHAMM independent fashion, and there is a physical and functional association between src and RHAMM in ras-transformed cells. However, we suggest that RHAMM regulates focal adhesion turnover via additional src-independent mechanisms. Thus, v-src is unable to turnover focal adhesions in the absence of RHAMM. These results directly demonstrate for the first time a role for src in the regulation of cell locomotion and confirm a key and complex role for src in the regulation of the actin cycle.	HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV MANITOBA, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PEDIAT, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG, MB R3E 0V9, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba; University of Manitoba; University of Manitoba								Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BOCKHOLT SM, 1993, MOL BIOL CELL S, V4; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ENTWISTLE J, 1995, GENE, V163, P233, DOI 10.1016/0378-1119(95)00398-P; ENTWISTLE J, 1996, IN PRESS J CELL BIOC; FLY CM, 1994, J NEUROCHEM, V62, P923; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KUNDRA V, 1994, ONCOGENE, V9, P1429; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCarthy J., 1993, Critical Reviews in Oral Biology and Medicine, V4, P619; NAKAMURA N, 1993, J CELL SCI, V106, P1057; NEET K, 1995, MOL CELL BIOL, V15, P4908; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCHIENG J, 1991, INVAS METAST, V11, P38; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARTIN AW, 1988, CANCER RES, V48, P6050; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1990, ONCOGENE, V5, P1437; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SANKAR S, 1995, AM J PATHOL, V147, P601; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Savani RC, 1995, INT J TISSUE REACT, V17, P141; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; THOMAS JE, 1993, ONCOGENE, V8, P2521; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOOLE BP, 1989, BIOL HYAL CIB FDN S, V143, P150; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TURLEY E, 1989, EXP CELL RES, V182, P340, DOI 10.1016/0014-4827(89)90239-5; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; TURLEY EA, 1989, CIBA F SYMP, V143, P121; VALLES AM, 1990, CELL REGUL, V1, P975, DOI 10.1091/mbc.1.13.975; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANG B, 1993, UNPUB	87	127	134	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2213	2224						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950989				2022-12-28	WOS:A1996VV14500019
J	Leonardsen, L; DeClue, JE; Lybaek, H; Lowy, DR; Willumsen, BM				Leonardsen, L; DeClue, JE; Lybaek, H; Lowy, DR; Willumsen, BM			Rasp21 sequences opposite the nucleotide binding pocket are required for GRF-mediated nucleotide release	ONCOGENE			English	Article						Rasp21-mutants; GRF; GNEF; Ras-loop 7; nucleotide-exchange	MURINE SARCOMA-VIRUS; GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; GUANINE-NUCLEOTIDE; SACCHAROMYCES-CEREVISIAE; EXCHANGE FACTOR; CATALYTIC DOMAIN; SIGNAL TRANSDUCTION; TERMINAL DOMAIN; TYROSINE KINASE	The substrate requirements for the catalytic activity of the mouse Cdc25 homolog Guanine nucleotide Release Factor, GRF, were determined using the catalytic domain of GRF expressed in insect cells and E. coli expressed H-Ras mutants. We found a requirement for the loop 7 residues in Ras (amino acids 102 to 105) for stimulation of guanine nucleotide release. The dependence on the switch I and II regions of Rasp21 (encompassing the residues that shift position in the GTP- versus GDP-bound protein), which had been seen with Sdc25-mediated exchange, was also found for GRF. In addition, the sensitivity of H-Ras to GRF was abolished when residues 130-139 were replaced by proline-aspartic acid-glutamine, whereas substitution of the entire loop 8 (residues 123-130 replaced by leucine-isoleucine-arginine) had no effect on the stimulation of guanine nucleotide release by GRF. Substrate activity of Ras proteins were independent of their post-translational processing, GDP release was stimulated threefold more effectively by GRF than was GTP release, and no major differences were found between the mammalian N-, H- and K-Ras proteins. Examining the responsiveness of the Ras protein from S. pombe and the human Ras like proteins RhoA, Rap1A, Rad and G25K revealed a strict Ras specificity; of these only S. pombe Ras was GRF sensitive.	UNIV COPENHAGEN, DEPT MOL CELL BIOL, DK-1353 COPENHAGEN, DENMARK; NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA	University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAPAGEORGE AG, 1989, J VIROL, V44, P509; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; REDDY EP, 1985, J VIROL, V53, P984, DOI 10.1128/JVI.53.3.984-987.1985; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WANG XZ, 1991, GENE, V100, P131, DOI 10.1016/0378-1119(91)90358-I; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269	54	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2177	2187						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950985				2022-12-28	WOS:A1996VV14500015
J	Suy, S; Anderson, WB; Dent, P; Chang, E; Kasid, U				Suy, S; Anderson, WB; Dent, P; Chang, E; Kasid, U			Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells	ONCOGENE			English	Article						ionizing radiation; Grb2; Sos; Ras; Raf; MAPK; breast cancer	GUANINE-NUCLEOTIDE EXCHANGE; MAP KINASE-KINASE; SIGNAL-TRANSDUCTION PATHWAY; SERINE-THREONINE KINASE; NIH 3T3 CELLS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ONCOGENIC P21(RAS); INDUCED ACTIVATION; MAMMALIAN-CELLS	Raf-1 protein serine/threonine kinase has been implicated in growth and damage-responsive signal transduction pathways. Several reports indicate an important role of Ras protein in the growth factor-induced activation of Raf-1. Here we investigated the possible involvement of Ras in ionizing radiation-induced activation of Raf-1. Irradiation of MDA-MB 231 human breast cancer cells caused an increase in GTP-binding and hydrolysis on Ras, and co-immunoprecipitations of endogenous Grb2 with Sos and Raf-1 with Ras. An increase in the level of membrane-bound Raf-1, and tyrosine-phosphorylation of Raf-1 were observed after irradiation. Consistent with these changes, irradiation of cells stimulated the catalytic activity of Raf-1, Finally, radiation treatment of breast cancer cells led to an increase in the phosphorylation and activity of the mitogen-activated protein kinase. Based on these biochemical modifications in vivo, me conclude that Raf-1 functions as an effector of Ras in the radiation-responsive signal transduction pathway leading to the activities of Raf-1 and mitogen-activated protein kinase.	GEORGETOWN UNIV,DEPT RADIAT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,WASHINGTON,DC 20007; GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT MED,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R55CA068322, P30CA051008, R01CA058984] Funding Source: NIH RePORTER; NCI NIH HHS [CA58984, CA68322, P30 CA51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bernhard EJ, 1996, CANCER RES, V56, P1727; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLCH W, 1991, NATURE, V349, P536; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARIAS R, 1993, CELL, V73, P381; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, SCIENCE, V363, P15; MCKENNA WG, 1990, CANCER RES, V50, P97; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PIROLLO KF, 1989, INT J RADIAT BIOL, V55, P783, DOI 10.1080/09553008914550831; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; Reed J C, 1993, Semin Immunol, V5, P327, DOI 10.1006/smim.1993.1039; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	47	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					53	61		10.1038/sj.onc.1201165	http://dx.doi.org/10.1038/sj.onc.1201165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233777				2022-12-28	WOS:A1997XH58600006
J	Marhin, WW; Chen, SJ; Facchini, LM; Fornace, AJ; Penn, LZ				Marhin, WW; Chen, SJ; Facchini, LM; Fornace, AJ; Penn, LZ			Myc represses the growth arrest gene gadd45	ONCOGENE			English	Article						gadd45; Myc; cell cycle; p53; growth arrest	HUMAN C-MYC; ENHANCER-BINDING-PROTEIN; DNA-DAMAGING AGENTS; CELL-CYCLE ARREST; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; MAMMALIAN-CELLS; IN-VIVO; EXPRESSION	The c-Myc protein strongly stimulates cellular proliferation, inducing cells to exit G0/G1 and enter the cell cycle. At a molecular level, Myc prevents growth arrest and drives cell cycle progression through the transcriptional regulation of Myc-target genes. Expression of the growth arrest and DNA damage inducible gene 45 (gadd45) is elevated in response to DNA damaging agents, such as ionizing radiation via a p53-dependent mechanism, upon nutrient deprivation, or during differentiation. Gadd35 holds a vital role in growth arrest as ectopic expression confers a strong block to proliferation. Exposure of quiescent cells to mitogen stimulates a rapid increase in c-Myc expression which is followed by the subsequent reduction in gadd45 expression. The kinetics of these two regulatory events suggest that Myc suppresses the expression of gadd45, contributing to G0/G1 phase exit of the cell cycle. Indeed, ectopic Myc expression in primary and immortalized fibroblasts results in the suppression of gadd45 mRNA levels, by a mechanism which is independent of cell cycle progression. Using an inducible MycER(TM) system, rapid suppression of gadd45 mRNA is first evident approximately 0.5 h following Myc activation. The reduction in gadd45 mRNA. expression occurs at the transcriptional level and is mediated by a p53-independent pathway. Moreover, Myc suppression and p53 induction of gadd45 following exposure to ionizing radiation are noncompetitive co-regulatory events. Myc suppression of gadd45 defines a novel pathway through which Myc promotes cell cycle entry and prevents growth arrest of transformed cells.	UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Penn, Linda/0000-0001-8133-5459				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHEN IT, 1995, ONCOGENE, V11, P1931; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Constance CM, 1996, MOL CELL BIOL, V16, P3878; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEAN M, 1986, J BIOL CHEM, V261, P9161; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALL PA, 1995, ONCOGENE, V10, P2427; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JACKMAN J, 1994, CANCER RES, V54, P5656; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG D, 1993, ONCOGENE, V8, P2805; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANIA L, 1980, VIROLOGY, V101, P217, DOI 10.1016/0042-6822(80)90497-3; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lenahan MK, 1996, ONCOGENE, V12, P1847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUCAS JM, 1993, BIOCHEM BIOPH RES CO, V194, P1446, DOI 10.1006/bbrc.1993.1987; MARHIN MW, 1996, ONCOGENE, V12, P43; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Papathanasiou M A, 1991, Cancer Treat Res, V57, P13; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; Vairapandi M, 1996, ONCOGENE, V12, P2579; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATERS CM, 1991, ONCOGENE, V6, P797; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	83	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2825	2834		10.1038/sj.onc.1201138	http://dx.doi.org/10.1038/sj.onc.1201138			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190899				2022-12-28	WOS:A1997XD64300011
J	Sachdev, S; Diehl, JA; McKinsey, TA; Hans, A; Hannink, M				Sachdev, S; Diehl, JA; McKinsey, TA; Hans, A; Hannink, M			A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes	ONCOGENE			English	Article						Rel/NF-kappa B transcription factors; I kappa B; nuclear import; nuclear export; oncogenesis	NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-NECROSIS-FACTOR; CHICKEN SPLEEN-CELLS; TATA-BINDING PROTEIN; RETICULOENDOTHELIOSIS VIRUS; DNA-BINDING; C-REL; TRANSCRIPTIONAL ACTIVATION; CYTOPLASMIC RETENTION	The net distribution of eukaryotic transcription factors between the cytoplasm and the nucleus provides an effective mechanism for controlling gene expression. We have utilized cis-acting signals for both nuclear import and nuclear export to experimentally manipulate the distribution of the v-Rel oncoprotein between the nucleus and the cytoplasm. The respective abilities of the v-Rel oncoprotein to localize to the nucleus in chicken embryo fibroblasts, to activate kappa B-dependent transcription in yeast, and to transform avian lymphoid cells were each markedly reduced by the fusion of a cis-acting nuclear export signal onto v-Rel. Our results demonstrate that a threshold nuclear function of v-Rel is required for manifestation of its oncogenic properties. In contrast, while increased expression of the avian I kappa B-alpha protein was able to prevent nuclear localization of v-Rel in chicken embryo fibroblasts, coexpression of I kappa B-alpha with v-Rel in the target cell for v-Rel mediated transformation did not reduce the ability of v-Rel to transform avian lymphoid cells or alter the distribution of v-Rel between the nucleus and the cytoplasm in v-Rel-transformed cells. Our results suggest that the ability of I kappa B-alpha to inhibit nuclear localization of v-Rel is affected by cell-type specific differences between fibroblasts and lymphoid cells.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NCI NIH HHS [CA55027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GELINAS C, 1988, ONCOGENE, V3, P349; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1996, IN PRESS ONCOGENE; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MICHAEL WM, 1995, CELL, V83, P415; MILLER CK, 1988, J VIROL, V62, P1219, DOI 10.1128/JVI.62.4.1219-1226.1988; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; SACHDEV S, 1995, ONCOGENE, V11, P811; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TZEN CY, 1994, EXP CELL RES, V211, P6; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	66	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2585	2594		10.1038/sj.onc.1201108	http://dx.doi.org/10.1038/sj.onc.1201108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191058				2022-12-28	WOS:A1997XA94900010
J	Shtivelman, E				Shtivelman, E			A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma	ONCOGENE			English	Article						metastasis; apoptosis; SCLC	L-DOPA DECARBOXYLASE; C-MYC; DNA FRAGMENTATION; CANCER; EXPRESSION; GENE; IDENTIFICATION; AMPLIFICATION; CHROMOGRANIN; ENDOCRINE	A novel human gene CC3 with properties of a metastasis suppresor gene for small cell lung carcinoma (SCLC) is described. CC3 is an evolutionary conserved gene that is expressed ubiquitously in human tissues. CC3 RNA is absent in a subset of SCLC cell lines known as variant (V-SCLC) that are derived from tumors characterized by highly aggressive metastatic behavior. Introduction of CC3 into a variant SCLC line results in significant suppression of its metastasis in vivo. When deprived of growth factors in vitro, v-SCLC cells modified to express CC3 undergo rapid and massive cell death that at least partially could be ascribed to the activation of the apoptotic pathway. In addition, expression of CC3 in v-SCLC cells increases induction of apoptosis by chemoterapeutic drugs. Loss of CC3 in highly metastatic cells such as SCLC might render them resistant to death-inducing signals and thus help to ensure their survival under unfavorable conditions encountered in the metastatic process.			Shtivelman, E (corresponding author), CALIF PACIFIC MED CTR,GERALDINE BRUSH CANC RES INST,2330 CLAY ST,ROOM 201,SAN FRANCISCO,CA 94115, USA.				NATIONAL CANCER INSTITUTE [R01CA071422] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA71422-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISNER SC, 1990, J CLIN ONCOL, V8, P402, DOI 10.1200/JCO.1990.8.3.402; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BISONETTE RP, 1992, NATURE, V359, P552; BUNN PA, 1985, BLOOD, V65, P764; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CARNEY DN, 1983, CANCER RES, V43, P2806; CARNEY DN, 1985, CANCER RES, V45, P2913; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1988, CANCER RES, V48, P4078; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IKEGAKI N, 1994, CANCER RES, V54, P6; JENSEN SM, 1990, CANCER RES, V50, P6068; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MORSTYN G, 1984, JNCI-J NATL CANCER I, V73, P801; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; SIEFFER EJ, 1988, SEMIN ONCOL, V15, P278; WEIDENMANN B, 1986, P NATL ACAD SCI USA, V83, P3500	31	101	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2167	2173		10.1038/sj.onc.1201059	http://dx.doi.org/10.1038/sj.onc.1201059			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174052				2022-12-28	WOS:A1997WX93800005
J	Akagi, T; Ono, H; Nyunoya, H; Shimotohno, K				Akagi, T; Ono, H; Nyunoya, H; Shimotohno, K			Characterization of peripheral blood T-lymphocytes transduced with HTLV-I Tax mutants with different trans-activating phenotypes	ONCOGENE			English	Article						HTLV-I; Tax; CD4; CD8; NF-kappa B; CREB/ATF	VIRUS TYPE-I; HUMAN INTERLEUKIN-6 GENE; CELL LEUKEMIA; RETROVIRAL VECTORS; EXPRESSION; TRANSCRIPTION; INFECTION; PROTEIN; GROWTH; MECHANISMS	Tax1, a transcriptional trans-activator of the Human T-cell leukemia virus type I (HTLV-I), induces the expression of many cellular genes through interaction with at least three distinct cellular transcription factors; CREB/ATF, NF-kappa B, and SRF. This Tax1-induced activation of cellular genes is considered to be a critical event in T-cell transformation by HTLV-I. To elucidate the role of each Taxi-inducible transcriptional pathway in T-cell transformation, we introduced Tax1 mutants with different trans-activating phenotypes into peripheral blood lymphocytes (PBL) by retroviral vectors. Analysis of these PBLs revealed that activation of the NF-kappa B pathway is sufficient to promote the growth response to IL-2. However, for the clonal expansion of CD4+ T-cells, which is a characteristic result of HTLV-I infection, activation of the CREB/ATF and SRF pathways is also required.	NATL CANC CTR,RES INST,DIV VIROL,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan			Nyunoya, Hiroshi/C-9705-2013	Nyunoya, Hiroshi/0000-0002-3237-9639				ABE Y, 1993, LYMPHOKINE CYTOK RES, V12, P279; AKAGI T, 1991, GENE, V106, P255, DOI 10.1016/0378-1119(91)90207-R; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; ASANO M, 1994, J IMMUNOL, V153, P5373; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DEROSSI A, 1985, VIROLOGY, V143, P640, DOI 10.1016/0042-6822(85)90405-2; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; Hahn B, 1984, Mol Biol Med, V2, P29; HARPER ME, 1986, NEW ENGL J MED, V315, P1073, DOI 10.1056/NEJM198610233151707; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HIMES SR, 1993, ONCOGENE, V8, P3189; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; LEE HM, 1993, J IMMUNOL, V151, P668; MARKHAM PD, 1984, INT J CANCER, V33, P13, DOI 10.1002/ijc.2910330104; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; MORI N, 1994, BLOOD, V84, P350; MORI N, 1994, BLOOD, V84, P2904; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1995, GENE DEV, V9, P2324; SOLDAINI E, 1992, EUR J IMMUNOL, V22, P1707, DOI 10.1002/eji.1830220707; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAM SW, 1994, CANCER RES, V54, P5816; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; TATEWAKI M, 1995, BLOOD, V86, P3109; vanBergen CAM, 1996, ANN HEMATOL, V72, P245, DOI 10.1007/s002770050167; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAMASHITA I, 1994, BLOOD, V84, P1573; YANG SC, 1990, CANCER RES, V50, P3526; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D	47	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2071	2078		10.1038/sj.onc.1201045	http://dx.doi.org/10.1038/sj.onc.1201045			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160887				2022-12-28	WOS:A1997WW80900009
J	Gallahan, D; Callahan, R				Gallahan, D; Callahan, R			The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4)	ONCOGENE			English	Article						INT3; NOTCH4; mammary tumor gene	OF-SPLIT COMPLEX; DROSOPHILA NOTCH; NEUROGENIC LOCUS; MAMMALIAN NOTCH; HUMAN HOMOLOG; PROTEIN GENE; ENHANCER; RECEPTOR; EXPRESSION; SEQUENCE	The INT3 gene is frequently rearranged in mouse mammary tumor virus (MMTV)-induced mammary tumors of the CzechII mouse strain, We have completed the nucleotide sequence of the normal 6.5 Kb INT3 RNA and defined the intron/exon boundaries of the gene, The open reading frame of INT3 RNA should encode a 200 kd protein which shares 60% homology with the mouse homologue of Drosophila NOTCH, INT3 is unique among other members of the NOTCH family by containing 29 instead of 36 EGF-like repeats in the extracellular domain of the gene product. Five novel EGF-like repeats have been created as consequence of apparent small deletions which have occurred within the coding region for the extracellular domain during evolution. Nucleotide sequence analysis of host-viral junction fragments from nine independent MMTV-induced mammary tumors containing a rearranged INT3 gene reveals that all of the integration events occur within a 174 bp region 3' of the sequences encoding the LIN12 repeats in the INT3 extracellular domain and 5' of the sequences encoding the transmembrane domain. Therefore, the only tumorigenic INT3 mutations resulting from MMTV proviral insertions are those which results in the expression of the intracellular domain. This strongly suggests that MMTV-induced activation of INT3 is manifest in the absence of the regulatory action of the extracellular domain, including the LIN12 repeat sequences, leaving the expressed intracellular domain constitutively free to function in its role in mammary tumorigenesis.	NCI, TUMOR IMMUNOL & BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BURDON T, 1991, J BIOL CHEM, V266, P6909; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; DELIDAKIS C, 1991, GENETICS, V129, P803; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Heitzler P, 1996, DEVELOPMENT, V122, P161; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KNUST E, 1992, GENETICS, V132, P505; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Lardelli M, 1995, INT J DEV BIOL, V39, P769; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NYE JS, 1994, DEVELOPMENT, V120, P2421; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SCHRONS H, 1992, GENETICS, V132, P481; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SIMPSON P, 1994, NOTCH RECEPTORS, P10; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	50	160	174	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1883	1890		10.1038/sj.onc.1201035	http://dx.doi.org/10.1038/sj.onc.1201035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150355				2022-12-28	WOS:A1997WV80400001
J	Higuchi, O; Amano, T; Yang, N; Mizuno, K				Higuchi, O; Amano, T; Yang, N; Mizuno, K			Inhibition of activated Ras-induced neuronal differentiation of PC12 cells by the LIM domain of LIM-kinase 1	ONCOGENE			English	Article						LIM protein; LIM motif; protein kinase; MAP kinase; neurite outgrowth	ZINC-FINGER MOTIF; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MAP KINASE; TRANSFORMATION; IDENTIFICATION; THREONINE; INDUCTION; PAXILLIN; LEUKEMIA	LIM-kinase 1 and 2 (LIMK1 and LIMK2) are members of a novel class of protein kinases with structures composed of two LIM motifs at the N-terminus and an unusual protein kinase domain at the C-terminus. The cellular functions of the LIMK family proteins have remained unknown, In the present study, we examined effects of LIMKs on neuronal differentiation of PC12 pheochromocytoma cells. Transient expression analyses revealed that LIMK1, in itself, had no apparent effect on PC12 cells, but the oncogenic Ras-induced differentiation of PC12 cells was notably inhibited by co-expression with LIMK1 or LIMK2. A mutant of LIMK1 lacking a protein kinase domain (Delta K) similarly inhibited Ras-induced differentiation of PC12 cells, but a mutant lacking a LIM domain (Delta LIM) failed to do so, indicating that a LIM domain but not a protein kinase domain is required for the inhibitory activity. This notion was further supported by the finding that mutation, changing conserved cysteines involved in zinc coordination to glycines in both of two LIM motifs, abolished the inhibitory activity of Delta K. Additionally, we also found that the constitutively activated MAP kinase kinase (MAPKK)-induced differentiation of PC12 cells was inhibited by co-expression with Delta K. Furthermore, Delta K did not inhibit the kinase activity of MAP kinase (MAPK) stimulated by MAPKK, when co-expressed in COS7 cells. These findings suggest that LIMK1 inhibits neuronal differentiation of PC12 cells, through its LIM domain and by interfering with events downstream of MAPK activation.	KYUSHU UNIV,FAC SCI,DEPT BIOL,HAKOZAKI,FUKUOKA 81281,JAPAN; JAPAN SCI & TECHNOL CORP,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN	Kyushu University; Japan Science & Technology Agency (JST)			Mizuno, Kensaku/G-8631-2015					BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; FUKUDA M, 1995, ONCOGENE, V11, P239; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; ITO A, 1990, BIOCHEM INT, V22, P235; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORI T, 1996, IN PRESS MOL BRAIN R; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1994, J BIOCH, V111, P636; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PROSCHEL C, 1995, ONCOGENE, V11, P1271; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WU RY, 1994, J BIOL CHEM, V269, P25085	42	17	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1819	1825		10.1038/sj.onc.1201020	http://dx.doi.org/10.1038/sj.onc.1201020			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150388				2022-12-28	WOS:A1997WW16600008
J	Aasheim, HC; Pedeutour, F; Smeland, EB				Aasheim, HC; Pedeutour, F; Smeland, EB			Characterization, expression and chromosomal localization of a human gene homologous to the mouse Lsc oncogene, with strongest expression in hematopoetic tissues	ONCOGENE			English	Article						Lsc homologue; Rho GEF; Dbl-family; hematopoetic expression	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; CELL POLARITY; LYMPHOCYTES-B; RHO; CDC42; RAS; CLONING; YEAST; REGULATORS	A human cDNA clone, denoted sub1.5, was isolated from cDNA library generated from human T cells, The sub1.5 cDNA sequence was novel and was not identical to any known cDNA sequences in the GenBank. Recently, however, a mouse cDNA (Lsc) with high homology to sub1.5 was identified, indicating that the sub1.5 sequence may represent the human homologue of the mouse Lsc gene. The sub1.5 cDNA includes an open reading frame of 875 amino acids, predicting a protein with molecular weight of 97 kDa. Like Lsc, sub1.5 shows homology to the previous described oncogene Lbc, in particular to two functional domains in the Lbc protein; the Dbl protooncogene homology domain and the pleckstrin homology domain. Lsc is proposed to be an oncogene and is a member of a growing family of proteins that may function as activators of the Rho family GTPases. Members of the Rho family regulates the polymerization of actin to produce stress fibers. Activation of Rho GTPases by sub1.5 is also indicated by our studies, as stress fiber formation is observed in serum-starved stable NIH3T3 sub1.5 transfectants. Sub1.5 cDNA hybridizes to two major transcripts of 3.5 and 5 kb size and the strongest expression is seen in hematopoietic tissues like thymus, lymph nodes, peripheral blood leukocytes and spleen. We also show that both purified B and T cells express sub1.5. In addition, our data indicate that sub1.5 mRNA is abundantly expressed in CD34(+) human progenitor cells. Fluorescent in situ hybridisation, using sub1.5 cDNA as a probe on human metaphases, shows that the sub1.5 gene is localized to chromosome 19q13.13.	FAC MED,URA CNRS 1462,NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	Aasheim, HC (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT IMMUNOL,N-0310 OSLO,NORWAY.		Smeland, Erlend/AAO-3214-2020					AASHEIM HC, 1994, BIOTECHNIQUES, V16, P716; AASHEIM HC, 1969, METHODS MOL BIOL CDN, V69; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAN AML, 1994, ONCOGENE, V9, P1057; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEDEUTOUR F, 1994, GENOMICS, V19, P31, DOI 10.1006/geno.1994.1008; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUSTEN LS, 1994, BLOOD, V84, P1473; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TOKSOZ D, 1994, ONCOGENE, V9, P621; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	36	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1747	1752		10.1038/sj.onc.1200994	http://dx.doi.org/10.1038/sj.onc.1200994			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135076				2022-12-28	WOS:A1997WR89300013
J	Oberst, C; Weiskirchen, R; Hartl, M; Bister, K				Oberst, C; Weiskirchen, R; Hartl, M; Bister, K			Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits	ONCOGENE			English	Article						cell transformation; oncogenes; differential gene expression; membrane proteins; potassium channels	CHICKEN-EMBRYO FIBROBLASTS; CYSTEINE-RICH PROTEIN; GATED K+ CHANNELS; DNA-BINDING; C-MYC; BETA-SUBUNIT; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; JUN ONCOGENE; CELL-CYCLE	Gene expression patterns in normal and v-myc-transformed quail embryo fibroblasts were compared by mRNA differential display, Displaying approximately 2500 mRNA species by reverse transcription/PCR, reamplification of 73 differential cDNA fragments and rescreening by Northern analysis led to the isolation of a clone, termed CO6, that hybridized to an mRNA species present only in the normal but not in the transformed fibroblasts. Further analyses revealed that the 0.95-kb CO6 mRNA was present in all normal quail and chicken embryo fibroblasts tested, but that it was undetectable in a variety of established quail cell lines transformed by the v-myc, v-myc/v-mil, v-jun/junD or v-src oncogenes or by a chemical carcinogen, Furthermore, CO6 mRNA was not detectable in fibroblasts newly transformed by retroviral constructs carrying v-myc or v-jun alleles or by the avian sarcoma virus ASV17. In fibroblasts transformed by a temperature-sensitive v-src mutant, expression of CO6 was strongly induced at the non-permissive temperature and reduced at the permissive temperature. Nucleotide sequence analysis of quail CO6 cDNA indicated that the corresponding gene encodes a 200-amino acid protein with 46 to 48% amino acid sequence identity to the regulatory beta subunits (K-vCa)beta of the bovine, human and canine high conductance Ca2+- activated K+ channels. No sequence homology to other ion channel subunits or to any other proteins in the databases was found, Like the K(vCa)beta subunits, the CO6 protein contains two putative transmembrane segments, Based on the relationship to mammalian K(VCa)beta both in primary structure and domain topology, the CO6 protein may represent the regulatory subunit of a yet unidentified avian Ca2+-activated potassium channel or a related membrane protein possibly involved in the regulation of cell proliferation.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Hartl, Markus/O-4655-2014; Weiskirchen, Ralf/O-1734-2018; Bister, Klaus/AFA-9400-2022	Hartl, Markus/0000-0001-7447-5920; Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Doonan J, 1996, NATURE, V380, P481, DOI 10.1038/380481a0; DRAHEIM H, 1994, PFLUG ARCH EUR J PHY, V427, P17, DOI 10.1007/BF00585937; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HUANG Y, 1994, J BIOL CHEM, V269, P31183; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KNAUS HG, 1994, CELL SIGNAL, V6, P861, DOI 10.1016/0898-6568(94)90019-1; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0	52	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	1997	14	9					1109	1116		10.1038/sj.onc.1200930	http://dx.doi.org/10.1038/sj.onc.1200930			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070660				2022-12-28	WOS:A1997WM07000013
J	Varley, JM; Thorncroft, M; McGown, G; Appleby, J; Kelsey, AM; Tricker, KJ; Evans, DGR; Birch, JM				Varley, JM; Thorncroft, M; McGown, G; Appleby, J; Kelsey, AM; Tricker, KJ; Evans, DGR; Birch, JM			A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene	ONCOGENE			English	Article						chromosome 17; LOH; Li-Fraumeni; tumours	GERMLINE P53 MUTATIONS; CANCER FAMILY SYNDROME; BREAST-OVARIAN CANCER; WILD-TYPE CHROMOSOME; SUPPRESSOR GENE; SPLICING MUTATION; BRAIN-TUMORS; YOUNG-ADULTS; PRONE FAMILY; ALLELE LOSS	We have studied a total of 36 tumours from 28 patients with germline mutations to the TP53 gene for loss of heterozygosity at TP53 using techniques of both direct sequencing and restriction fragment length polymorphism analysis. All patients were from families conforming to the definition of classical Li-Fraumeni syndrome (LFS) or were Li-Frammeni-like (LFL). The data we have obtained show that loss of the wild-type TP53 gene is observed in under half (44%) of all tumours, and that the pattern of LOH at TP53 may be mutation specific, LOH has been observed in premalignant as web as invasive tumours. Two tumours (6%) show loss of the mutant allele and retention of the wild-type, To confirm that TP53 is indeed the target for LOH events on chromosome 17, we have used additional microsatellite repeats to examine patterns of allelic imbalance along the length of chromosome 17. Data from this analysis indicate that TP53 is the target of loss, but reveal some other interesting patterns of allelic imbalance at other loci on chromosome 17.	ROYAL MANCHESTER CHILDRENS HOSP,CRC,PAEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M27 4HA,LANCS,ENGLAND	Royal Manchester Children's Hospital	Varley, JM (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784				BIRCH JM, 1994, CANCER RES, V54, P1298; BIRCH JM, 1990, J PATHOL, V161, P1, DOI 10.1002/path.1711610102; BORRESEN AL, 1992, CANCER RES, V52, P3234; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; BRUGIERES L, 1993, CANCER RES, V53, P452; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1990, GENETIC BASIS FOR CARCINOGENESIS, P33; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EELES RA, 1993, ONCOGENE, V8, P1269; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; FELIX CA, 1993, ONCOGENE, V8, P1203; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FREBOURG T, 1995, AM J HUM GENET, V56, P608; GARBER JE, 1991, CANCER RES, V51, P6094; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GRAYSON GH, 1994, AM J PEDIAT HEMATOL, V16, P341; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; GUTIERREZ MI, 1994, HUM MOL GENET, V3, P2247, DOI 10.1093/hmg/3.12.2247; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMELIN R, 1994, HUM GENET, V94, P88, DOI 10.1007/BF02272849; Heim S, 1995, CANC CYTOGENETICS; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIO Y, 1994, ONCOGENE, V9, P1231; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JOLLY KW, 1994, ONCOGENE, V9, P97; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOVAR H, 1992, ONCOGENE, V7, P2169; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SCOTT RJ, 1993, SCHWEIZ MED WSCHR, V123, P1287; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; Varley JM, 1996, ONCOGENE, V12, P2437; VARLEY JM, 1997, UNPUB MANUSCRIPT; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WILLIAMS KJ, 1996, IN PRESS ONCOGENE; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	66	84	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					865	871		10.1038/sj.onc.1201041	http://dx.doi.org/10.1038/sj.onc.1201041			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047394				2022-12-28	WOS:A1997WJ11200013
J	Venkatachalam, S; Denissenko, M; Wani, AA				Venkatachalam, S; Denissenko, M; Wani, AA			Modulation of (+/-)-anti-BPDE mediated p53 accumulation by inhibitors of protein kinase C and poly(ADP-ribose) polymerase	ONCOGENE			English	Article						DNA damage; p53 induction; apoptosis; cell cycle arrest	PERIPHERAL-BLOOD LYMPHOCYTES; DNA-DAMAGING AGENTS; ATAXIA-TELANGIECTASIA; HUMAN-CELLS; IONIZING-RADIATION; MOLECULAR CONTROLS; HUMAN FIBROBLASTS; SUPPRESSOR GENES; STRAND BREAKS; G(1) ARREST	The rapid accumulation of the p53 gene product is considered to be an important component of the cellular response to a variety of genotoxins, In order to gain insights on the biochemical pathways leading to p53 stabilization, the effect of (+/-) 7,8-dihydroxy-anti-9, 10-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyrene [(+/-)-anti-BPDE] induced DNA damage on p53 protein levels was investigated in various repair-proficient and repair-deficient human cells, Brief exposure of normal human fibroblasts to 0.05-1 mu M (+/-)-anti-BPDE resulted in elevated p53 protein levels as compared to the constitutive levels of control sells, The rapid induction response, detectable within a few hours, was sustained up to a period of at least 24 h, Repair-proficient and repair-deficient (XPA) human lymphoblastoid cells showed a similar response, The poly(ADP-ribose) polymerase inhibitor, 3-aminobenzamide (3-AB), diminished the p53 induction response by concomitantly decreasing the extent of (+/-)-anti-BPDE induced DNA damage in cells pretreated with the inhibitor, However, the direct involvement of poly ADP-ribosylation was also apparent as 3-AB was able to attenuate (similar to 50%) the p53 response by post-damage inhibitor treatment of the cells, Inhibition:of cellular DNA replication by hydroxyurea and AraC, in the presence or absence of DNA damage, also resulted in rapid p53 accumulation in repair-deficient cells, On the contrary, inhibition of protein kinase C (PKC) by calphostin-C led to an abrogation of (+/-)-anti-BPDE mediated p53 induction, Analysis of the downstream effects of carcinogen treatment showed that the lymphoblastoid cells undergo DNA fragmentation indicative of apoptosis while fibroblasts exhibit cell cycle arrest at the G(1)-S boundary.	OHIO STATE UNIV,DEPT RADIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,BIOCHEM PROGRAM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006074, R01ES002388] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES6074, ES2388] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BAE IS, 1995, CANCER RES, V55, P2387; BERGER NA, 1981, BIOCHEMISTRY-US, V20, P3610, DOI 10.1021/bi00515a047; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BJELOGRLIC NM, 1994, CARCINOGENESIS, V15, P771, DOI 10.1093/carcin/15.4.771; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHATTERJEE S, 1994, MOL CELL BIOCHEM, V138, P61, DOI 10.1007/BF00928444; CONNEY AH, 1982, CANCER RES, V42, P4875; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAN SJ, 1994, CANCER RES, V54, P5824; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GIBSONDAMBROSIO RE, 1986, IN VITRO CELL DEV B, V22, P529; GRANA X, 1995, ONCOGENE, V11, P211; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1991, CANCER RES, V51, pS5023; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASPIN LC, 1996, IN PRESS PAH; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUMAR M, 1995, BIOCHEM BIOPH RES CO, V214, P744, DOI 10.1006/bbrc.1995.2348; KURIAN P, 1992, CARCINOGENESIS, V13, P489, DOI 10.1093/carcin/13.3.489; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIU M, 1995, ONCOGENE, V10, P1955; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MOLINARI M, 1995, ONCOGENE, V10, P1849; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OSBORNE MR, 1981, CARCINOGENESIS, V2, P553, DOI 10.1093/carcin/2.6.553; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Price BD, 1996, CANCER RES, V56, P246; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1993, ONCOGENE, V8, P3055; PRICE BD, 1993, ONCOGENE, V8, P305; Sancar A, 1995, ANNU REV GENET, V29, P69, DOI 10.1146/annurev.ge.29.120195.000441; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STIERUM RH, 1995, CARCINOGENESIS, V16, P2765, DOI 10.1093/carcin/16.11.2765; STIERUM RH, 1994, CARCINOGENESIS, V15, P745, DOI 10.1093/carcin/15.4.745; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VENKATACHALAM S, 1993, BIOCHEM BIOPH RES CO, V197, P722, DOI 10.1006/bbrc.1993.2539; VENKATACHALAM S, 1994, CARCINOGENESIS, V15, P565, DOI 10.1093/carcin/15.4.565; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; WHITACRE CM, 1995, CANCER RES, V55, P3697; ZHANG W, 1994, CANCER RES, V54, P4448	60	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					801	809		10.1038/sj.onc.1200890	http://dx.doi.org/10.1038/sj.onc.1200890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047387				2022-12-28	WOS:A1997WJ11200006
J	Seitz, S; Rohde, K; Bender, E; Nothnagel, A; Kolble, K; Schlag, PM; Scherneck, S				Seitz, S; Rohde, K; Bender, E; Nothnagel, A; Kolble, K; Schlag, PM; Scherneck, S			Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: Linkage analysis in German breast cancer families	ONCOGENE			English	Article						breast cancer gene; loss of heterozygosity; linkage analysis; chromosome 8p	HETEROZYGOSITY; CARCINOMA; ALLELOTYPE; DISEASE; ONSET; LOCI; 8P	Chromosomal losses involving the short arm of chromosome 8 are frequent in a variety of tumor types, including breast cancer, suggesting the presence of one or more tumor suppressor genes in this region, Previous linkage analysis and studies of loss of heterozygosity (LOH) have suggested the presence of a putative third breast cancer susceptibility gene around D8S505 at 8p12-p22, We have performed linkage analysis in two German breast cancer families, showing negative lod scores with 17q and 13q markers, using seven adjacent microsatellite markers from 8p12-p22, Incorporating LOH data from tumors of the affected family members a maximum cumulative three-point lod score of 3.30 at Theta = 0.00 was obtained with D8S137 and D8S131, Our findings considerably strengthen the evidence for a third breast cancer susceptibility locus (BRCA3) mapping to the short arm of human chromosome 8.	MAX DELBRUCK CTR MOL MED,DEPT TUMOR GENET,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT BIOINFORMAT,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,DEPT PATHOL,D-10117 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,ROBERT ROESSLE CLIN,DEPT SURG ONCOL,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Humboldt University of Berlin								CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLIBY W, 1993, CANCER RES, V53, P2393; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEVILEE P, 1991, ONCOGENE, V6, P1705; EMI M, 1992, CANCER RES, V52, P5368; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KNOWLES MA, 1993, ONCOGENE, V8, P1357; MACOSKA JA, 1995, CANCER RES, V55, P5390; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; ROHDE K, 1995, HUM HERED, V45, P337, DOI 10.1159/000154302; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; WASYLYSHYN ML, 1991, SURGERY, V110, P268; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZIMMERMANN W, 1993, AM J HUM GENET, V52, P789; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	21	99	101	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					741	743		10.1038/sj.onc.1200881	http://dx.doi.org/10.1038/sj.onc.1200881			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038382				2022-12-28	WOS:A1997WG43000013
J	Zhong, WX; Oberley, LW; Oberley, TD; StClair, DK				Zhong, WX; Oberley, LW; Oberley, TD; StClair, DK			Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase	ONCOGENE			English	Article						MnSOD; tumor suppressor gene; gene transfection; glioma; antioxidant enzymes; reactive oxygen species	GLUTATHIONE-PEROXIDASE-ACTIVITY; ANTIOXIDANT ENZYMES; EXPRESSION VECTOR; MAMMALIAN-CELLS; GENE; MELANOMA; DIFFERENTIATION; CHROMOSOME-6; METASTASIS; INDUCTION	Manganese superoxide dismutase (MnSOD) has been previously shown to suppress the malignant phenotype of human melanoma and breast cancer cells, To test the possible role of MnSOD in glioma malignancy, MnSOD was overexpressed in wild type human glioma U118 cells and subcloned U118-9 cells by transfection of human MnSOD cDNA, The MnSOD-transfected cell lines demonstrated expression of exogenous (plasmid) MnSOD mRNA, increase in MnSOD immunoreactive protein, and a three- to eightfold increase in MnSOD enzymatic activity, The MnSOD overexpressing cell lines became less malignant as demonstrated by requiring a higher serum concentration to grow in vitro and much slower tumor growth in nude mice than the parental and neo control cell lines, These findings further support the hypothesis that MnSOD may be a tumor suppressor gene in a aide variety of human tumors.	UNIV IOWA, RADIAT RES LAB, MED LABS 77, IOWA CITY, IA 52242 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL SERV, MADISON, WI 53705 USA; UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53705 USA; UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40536 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Kentucky					NATIONAL CANCER INSTITUTE [R29CA049797, R01CA041267, R01CA049797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010758] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN BS, 1989, J CELL PHYSIOL, V139, P370, DOI 10.1002/jcp.1041390220; BULLARD DE, 1981, J NEUROPATH EXP NEUR, V40, P410, DOI 10.1097/00005072-198107000-00005; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LI JJ, 1995, ONCOGENE, V10, P1989; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miele ME, 1995, ANTICANCER RES, V15, P2065; MILLIKIN D, 1991, CANCER RES, V51, P5449; MURAMATSU H, 1995, CANCER RES, V55, P6210; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; Oberley LW, 1986, FREE RADICALS AGING, P352; OBERLEY TD, 1990, AM J PATHOL, V137, P199; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI DOI 10.1074/jbc.RA117.001068; SAFFORD SE, 1994, CANCER RES, V54, P4261; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; SUN Y, 1993, CARCINOGENESIS, V14, P1457, DOI 10.1093/carcin/14.7.1457; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YOSHIZAKI N, 1994, INT J CANCER, V57, P287, DOI 10.1002/ijc.2910570226; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	38	203	217	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					481	490		10.1038/sj.onc.1200852	http://dx.doi.org/10.1038/sj.onc.1200852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053845				2022-12-28	WOS:A1997WE36400011
J	Mukhopadhyay, T; Roth, JA				Mukhopadhyay, T; Roth, JA			Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol	ONCOGENE			English	Article						p53; lung cancer; apoptosis; methoxyestradiol; gene expression	TUMOR-SUPPRESSOR PROTEIN; BINDING-SITE; CYCLE; EXPRESSION; ESTROGEN; METABOLITE; CARCINOMA; GROWTH; DEATH; MCF-7	2-methoxyestradiol (2-MeOE(2)) treatment caused significant growth inhibition of H460 and A549 human lung cancer cell lines which contain wild-type p53, However, 2-MeOE(2) had a little effect on the p53 negative H358 and p53 mutated H322 cell lines, Western blot analysis indicated that 2-MeOE(2) treatment resulted in an eightfold increase in the endogenous wild-type p53 protein, while the level of the mutant p53 protein remained unchanged, TdT staining indicated that following 2-MeOE(2)-mediated increases in wildtype p53 protein, cells bypass the G(1)-S checkpoint of the cell cycle with 30 to 40% undergoing apoptosis. Introduction of anti-sense wt-p53 into wt-p53 cells abrogated the 2-MeOE(2) effect, A significant portion of lung cancer retains the wild-type p53 gene therefore, 2-MeOE(2) may have therapeutic application.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,SECT THORAC MOL ONCOL,DEPT THORAC & CARDIOVASC SURG,BOX 109,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZUYOKOTA E, 1995, CANCER RES, V55, P1863; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CANVER CC, 1994, J THORAC CARDIOV SUR, V108, P153; CUSHMAN M, 1995, J MED CHEM, V38, P2041, DOI 10.1021/jm00012a003; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HERMEKING H, 1995, CELL BIOL INT, V19, P705; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOTTERING ML, 1992, CANCER RES, V52, P5926; MAXWELL SA, 1996, IN PRESS ELECTROPHOR; MILNER J, 1990, ONCOGENE, V5, P1683; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; THOMPSON AM, 1990, BRIT J CANCER, V62, P78, DOI 10.1038/bjc.1990.233; TISHLER RB, 1995, CANCER RES, V55, P6021; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG TTY, 1995, CANCER RES, V55, P2487; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; Zamai L, 1996, CYTOMETRY, V23, P303, DOI 10.1002/(SICI)1097-0320(19960401)23:4<303::AID-CYTO6>3.3.CO;2-B	27	133	144	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					379	384		10.1038/sj.onc.1200835	http://dx.doi.org/10.1038/sj.onc.1200835			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018125				2022-12-28	WOS:A1997WD51600015
J	Pu, MY; Akhand, AA; Kato, M; Hamaguchi, M; Koike, T; Iwata, H; Sabe, H; Suzuki, H; Nakashima, I				Pu, MY; Akhand, AA; Kato, M; Hamaguchi, M; Koike, T; Iwata, H; Sabe, H; Suzuki, H; Nakashima, I			Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation	ONCOGENE			English	Article						Src kinase; redox regulation; Hg2+ (Mercuric ions)	HERBIMYCIN-A; T-CELLS; V-SRC; PHOSPHORYLATION; PP60C-SRC; BINDING; SITE; IDENTIFICATION; AUTOIMMUNITY; ASSOCIATION	The kinase activity of p60(c-src) has been shown to be basically regulated through phosphorylation and dephosphorylation of Y527. We found that catalytic activity of the immunoprecipitated c-Src kinase from NIH3T3 cells was elevated several folds by exposure to 0.5-50 mu M of sulfhydryl-reactive Hg2+. V-max of the kinase was increased whereas K-m was decreased. N-acetylcysteine neutralized this Hg2+ effect, suggesting a critical role of the Hg2+-mediated sulfhydryl modification of the kinase in the mechanism. Addition of protein tyrosine phosphatase inhibitor Na3VO4 into the reaction mixture did not inhibit the Hg2+-mediated activation. Further study revealed that Hg2+ was capable of activating the v-Src kinase lacking Y527 and the c-Src kinase from mutant cells defective of the Y527-phosphorylating Csk kinase. Cyanogen bromide cleavage maps of radiolabeled Src proteins showed that Hg2+ selectively promoted the autophosphorylation at Y416 and that the previously in vivo radiolabeled phosphorous on Y527 was not deleted during the promotion of Y416 autophosphorylation by Hg2+, Phosphoamino acid analysis demonstrated selective promotion of phosphorylation at tyrosine but not at serine/threonine. Not like bivalent Hg2+, monovalent p-chloromercuribenzenesulfonic acid was incapable of activating c-Src kinase. These results suggest a novel Y416 phosphorylation-linked activation pathway for Src kinases which is initially triggered independent of Y527-mediated or serine/threonine phosphorylation-linked regulation, possibly through sulfhydryl-based protein structural modification for functional alteration.	NAGOYA UNIV, SCH MED, DEPT IMMUNOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DIS MECHANISM & CONTROL RES INST, SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DIV MED, RADIOISOTOPE CTR, SHOWA KU, NAGOYA, AICHI 466, JAPAN; KYOTO UNIV, JRDC, PRESTO, INST VIRUS RES, KYOTO 60601, JAPAN	Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Kyoto University			KATO, Masashi/I-7250-2014; Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ATEN J, 1991, EUR J IMMUNOL, V21, P611, DOI 10.1002/eji.1830210312; ATKINSON TP, 1993, J IMMUNOL, V151, P1448; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAWSON DC, 1995, HANDB EXP PHARMACOL, V115, P53; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; GEORGE RJ, 1990, J CELL BIOCHEM, V42, P71, DOI 10.1002/jcb.240420203; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; LANDER HM, 1993, J IMMUNOL, V150, P1509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; OKADA M, 1989, J BIOL CHEM, V264, P20886; RAHMAN SMJ, 1993, FEBS LETT, V317, P35, DOI 10.1016/0014-5793(93)81486-J; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SCHUHMANN D, 1990, J IMMUNOL, V145, P2132; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; SPERLING R, 1969, BIOCHEMISTRY-US, V8, P3810, DOI 10.1021/bi00837a047; STEER ML, 1974, BIOCHIM BIOPHYS ACTA, V334, P389, DOI 10.1016/0005-2744(74)90182-X; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; TAKAFUJI S, 1989, CIBA F SYMP, V147, P188; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	42	65	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2615	2622						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000135				2022-12-28	WOS:A1996VZ65400011
J	Rader, JS; Kamarasova, T; Huettner, PC; Li, L; Li, Y; Gerhard, DS				Rader, JS; Kamarasova, T; Huettner, PC; Li, L; Li, Y; Gerhard, DS			Allelotyping of all chromosomal arms in invasive cervical cancer	ONCOGENE			English	Article						cervical cancer; allelotyping; chromosomes; tumor suppressor genes; loss of heterozygosity	COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; CELL-LINE SIHA; MICROSATELLITE POLYMORPHISMS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX; CARCINOMA; HETEROZYGOSITY; DELETION	The best characterized factor in the development of cervical cancer is the integration, of human papillomavirus into cervical cell chromosomes, Tn addition to HPV integration, the neoplastic process probably requires the activation of cellular protooncogenes and loss of tumor suppressor gene function, Loss of heterozygosity analysis in a large sample is used to identify regions which harbor putative tumor suppressor genes (TSG) since the deletion of normal alleles unmask mutated alleles, We evaluated tumor tissue from invasive cervical carcinomas, carefully microdissected to eliminate normal stroma and lymphocytes, for LOH at all 41 chromosomal arms with 50 polymorphic markers, We have evaluated tumor and normal DNA pairs from 48 invasive cervical cancers of which 85% of the tumors are confined to the cervix, The mean loss for all chromosomal arms was 12%. Three regions exhibited LOH two standard deviations above the mean: 3p14.1-12 (40%), 11q23.3 (36%), and 6p22-21.3 (32%), Three regions showed loss one standard deviation above the mean: 19q13.4 (30%), 6q21-23.33 (25%), and 2q33-37 (24%). Our results indicate that a significant number of invasive cervical cancers have lost specific chromsomal regions, thereby suggesting that genes involved in the cell cycle regulation or the suppression of tumor development are located in these regions.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rader, JS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA.							APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; BENTZ M, 1995, BLOOD, V85, P3610, DOI 10.1182/blood.V85.12.3610.bloodjournal85123610; CHUNG GTY, 1992, ANTICANCER RES, V12, P1485; *FOG, 1987, INT J GYNECOL OBSTET, V25, P87; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HANADA R, 1995, ONCOGENE, V11, P1829; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JONES MH, 1992, ONCOGENE, V7, P1631; JONES MH, 1994, GENE CHROMOSOME CANC, V9, P119, DOI 10.1002/gcc.2870090207; Kirkwood B., 1988, BR K ESSENTIALS MED; KLITZ W, 1994, AM J HUM GENET, V54, P497; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; KOHNO T, 1993, ONCOGENE, V8, P1825; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; Muliokandov MR, 1996, CANCER RES, V56, P197; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; PETRO R, 1986, VIRAL ETIOLOGY CERVI, P3; RADFORD DM, 1990, CANCER RES, V50, P6529; RUBIO MP, 1994, CANCER RES, V54, P4760; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHENGJING L, 1990, NATURE, V346, P470; SHIBATA D, 1992, AM J PATHOL, V141, P539; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOOK AK, 1991, AM J PREV MED, V7, P208; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; SYRJANEN K, 1990, SCAND J INFECT DIS, P7; TARKKANEN M, 1995, CANCER RES, V55, P1334; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; WALKER GJ, 1994, INT J CANCER, V59, P771, DOI 10.1002/ijc.2910590611; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; YOKOTA J, 1989, CANCER RES, V49, P3598	43	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2737	2741						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000149				2022-12-28	WOS:A1996VZ65400025
J	Halachmy, S; Bern, O; Schreiber, L; Carmel, M; Sharabi, Y; Shoham, J; Nir, U				Halachmy, S; Bern, O; Schreiber, L; Carmel, M; Sharabi, Y; Shoham, J; Nir, U			p94(fer) facilitates cellular recovery of gamma irradiated pre-T cells	ONCOGENE			English	Article						ionizing-radiation; nuclear; p94(fer); T cell; tyrosine kinase	PROTEIN-TYROSINE KINASE; FES-ENCODED PROTEIN; ABL MESSENGER-RNAS; C-ABL; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAY; TRANSCRIPT FERT; TRANSGENIC MICE; LYMPHOID-CELLS; MOUSE-TISSUES	p94(fer) is a ubiquitous, nuclear and cytoplasmic tyrosine kinase, whose accumulation has been demonstrated in all mammalian cell Lines analysed. In the present work, the p94(fer) expression profile was determined in cell lines which were not tested before. While being present in several hematopoietic and non hematopoietic cell lines including thymic stromal cells, the p94(fer) kinase could not be detected in pre-T and T cell lines. p94(fer) was also absent in pre-B line, but accumulated in these cells upon their induced development to antibody producing cells. This is in agreement with the absence of p94(fer) in primary th,mic and splenic T lymphocytes and its induced accumulation in stimulated B cells. Relatively high p94(fer) levels were detected in primary thymic and splenic stromal cells. Ectopic expression of p94(fer) in pre-T cells slightly affected their cell cycle profile but it did not affect their apoptotic death which was induced by ionizing radiation. However, p94(fer) facilitated dramatically, the cellular recovery of gamma irradiated pre-T cells which have escaped the apoptotic death. The enhanced recovery of the irradiated, p94(fer) expressing pre-T cells, resulted most probably from their increased survival, rather than from a prominent change in their proliferation rate. The absence of p94(fer) from pre-B and pre-T cells, may thus contribute to the relative sensitivity of these cells to ionizing radiation and to their dependence on the functioning of other nuclear tyrosine kinasese.	BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL	Bar Ilan University								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; CARE A, 1994, ONCOGENE, V9, P739; COFFER PJ, 1995, ONCOGENE, V11, P561; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESHEL I, 1990, J IMMUNOL, V144, P1554; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; GLIMCHER LH, 1983, SCAND J IMMUNOL, V17, P1, DOI 10.1111/j.1365-3083.1983.tb00759.x; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; IRLIN Y, 1992, IMMUNOL LETT, V33, P233, DOI 10.1016/0165-2478(92)90067-X; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM L, 1995, MOL CELL BIOL, V15, P4553; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LETWIN K, 1988, ONCOGENE, V3, P621; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARKS PA, 1983, P NATL ACAD SCI-BIOL, V80, P2281, DOI 10.1073/pnas.80.8.2281; MCWHIRTER JR, 1993, EMBO J, V12, P1523; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAMBROOK J, 1989, MOL CLONE LAB MANUAL; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SCHREIBER L, 1996, IN PRESS SCAND J IMM; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SOKAGUCHI N, 1980, J IMMUNOL, V125, P2654; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WADSWORTH SA, 1995, J IMMUNOL, V154, P2125; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WILKS AF, 1988, ONCOGENE, V3, P289; YAFFE A, 1996, IN PRESS CELL GROWTH; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YATES KE, 1995, ONCOGENE, V10, P1239	52	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2871	2880		10.1038/sj.onc.1201145	http://dx.doi.org/10.1038/sj.onc.1201145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205095				2022-12-28	WOS:A1997XF55500002
J	McConnell, MJ; Cunliffe, HE; Chua, LJ; Ward, TA; Eccles, MR				McConnell, MJ; Cunliffe, HE; Chua, LJ; Ward, TA; Eccles, MR			Differential regulation of the human Wilms tumour suppressor gene (WTI) promoter by two isoforms of PAX2	ONCOGENE			English	Article						PAX2; WT1; transcription factor; tumour suppressor; kidney development	HUMAN FETAL KIDNEY; PAIRED DOMAIN; DNA-BINDING; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION PROPERTIES; SEQUENCE RECOGNITION; PROTEIN WT1; EXPRESSION; MUTATION; ACTIVATION	PAX2 is a member of the paired box family of genes with an important role in kidney, genital tract and eye development. Another gene essential for kidney and genital tract development is the Wilms tumour gene, WT1. PAX2 and WT1 encode transcription factors expressed during fetal kidney development in patterns that overlap both spatially and temporally. The overlap of PAX2 and WT1 expression in fetal kidney prompted us to determine whether PAX2 regulates the WT1 gene. To investigate this possibility, the WT1 promoter and a series of WT1 promoter deletion fragments were cloned into a luciferase reporter vector, and used in cotransfection experiments with PAX2 expression constructs. PAX2 transactivated the WT1 promoter up to 35-fold in CHO-K1 cells, and from four- to sevenfold in 293 cells. Two regions of the WT1 promoter were required in the same promoter construct for efficient transactivation by PAX2 in CHO-K1 cells, and purified recombinant PAX2 protein was found to bind to two sites in the WT1 promoter, at -205/-230 and +377/ +402. Removal of WT1 promoter sequences containing the -205/-230, or + 377/ + 402 binding sites abolished transactivation of the WT1 promoter by PAX2 in CHO-K1 cells, and had a differential effect on transactivation of the WT1 promoter in 293 cells, depending on the PAX2 isoform used. A fragment containing the -205/ -230 site alone could be transactivated by PAX2. These findings suggest that PAX2 is a tissue-specific modulator of WT1 expression, and is involved in cell growth control via WT1.	UNIV OTAGO, DEPT BIOCHEM, CANC GENET LAB, DUNEDIN, NEW ZEALAND	University of Otago				McConnell, Melanie J./0000-0003-3840-1347				ANANT S, 1994, ONCOGENE, V9, P3113; BARD JBL, 1994, MECH DEVELOP, V48, P3, DOI 10.1016/0925-4773(94)00273-8; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1994, ONCOGENE, V9, P2059; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hildebrandt Friedhelm, 1995, Current Opinion in Pediatrics, V7, P182, DOI 10.1097/00008480-199504000-00012; HOFMANN W, 1993, ONCOGENE, V8, P3123; HOLST BD, 1994, J BIOL CHEM, V269, P22245; JACKSON P, 1993, ONCOGENE, V8, P589; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MATSUNAGA E, 1981, HUM GENET, V57, P231; NISEN PD, 1986, CANCER RES, V46, P6217; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P29976; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Sanyanusin P, 1996, GENOMICS, V35, P258, DOI 10.1006/geno.1996.0350; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SANYANUSIN P, 1995, HUM MOL GENET, V4, P2183, DOI 10.1093/hmg/4.11.2183; Saxen L., 1987, ORGANOGENESIS KIDNEY; SHAW APW, 1988, ONCOGENE, V3, P143; Song DL, 1996, DEVELOPMENT, V122, P627; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; Torban E, 1996, J AM SOC NEPHROL, V7, pA1785; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	66	56	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2689	2700		10.1038/sj.onc.1201114	http://dx.doi.org/10.1038/sj.onc.1201114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178767				2022-12-28	WOS:A1997XB97800008
J	Chernov, MV; Stark, GR				Chernov, MV; Stark, GR			The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate	ONCOGENE			English	Article						p53 accumulation; transcriptional activation; DNA binding; mouse (12)1/CA cells; DNA damaging agents	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NF-KAPPA-B; BINDING FUNCTION; IN-VITRO; GAMMA-IRRADIATION; SODIUM-SALICYLATE; GENE-EXPRESSION; KINASE-C	Treatment of mouse (12)1/CA cells with adriamycin or irradiation with U.V.C. induces p53-dependent transcription of a beta-galactosidase reporter and the endogenous p21/Waf1/Cip1 gene. Despite the induction of Waf1, the cells arrest only transiently in G(1) or G(2), then resume growth and eventually undergo apoptosis. In situ analysis of beta-galactosidase activity in U.V.C.-irradiated cells revealed a much higher level of p53-dependent transcription in cells undergoing apoptosis compared to transiently arrested cells. Incubation of the treated cells with salicylate, which inhibits the activation of protein kinases and transcription factors involved in stress responses, inhibits both p53-dependent transcription and apoptosis. The inhibition of transcription is due mainly to impairment of the ability of p53 to bind to DNA. The treated cells resume their p53-dependent programs whenever the salicylate is removed, even after as long as 60 h after the DNA has been damaged. Therefore, the p53-activating signals generated by adriamycin or U.V.C. are very long lived. The resumption of p53-dependent transcription is not accompanied by additional accumulation of the p53 protein, indicating that the activation of p53 is regulated by a separate pathway.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOMAROVA EA, 1996, IN PRESS EMBO J; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maki CG, 1996, CANCER RES, V56, P2649; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRICE BD, 1995, ONCOGENE, V11, P73; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Soddu S, 1996, MOL CELL BIOL, V16, P487; STEWART N, 1995, ONCOGENE, V10, P109; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TISCHLER RB, 1993, CANCER RES, V53, P2212; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHAN QM, 1994, ONCOGENE, V9, P3743	61	42	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2503	2510		10.1038/sj.onc.1201104	http://dx.doi.org/10.1038/sj.onc.1201104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191050				2022-12-28	WOS:A1997XA94900002
J	Jones, TL; Karavanova, I; Chong, L; Zhou, RP; Daar, IO				Jones, TL; Karavanova, I; Chong, L; Zhou, RP; Daar, IO			Identification of XLerk, an Eph family ligand regulated during mesoderm induction and neurogenesis in Xenopus laevis	ONCOGENE			English	Article						Eph ligand; xenopus development; nervous system	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; NEURAL CREST; MOLECULAR-CLONING; CDNA CLONING; EXPRESSION; PROTEIN; EMBRYOS; GENES; TRANSITION	We have isolated and characterized the first Xenopus transmembrane Eph ligand, XLerk (Xenopus Ligand for Eph Receptor Tyrosine Kinases). While this ligand has 72% identity with the closest mammalian family member, Lerk-2, it is the cytoplasmic domain of this molecule that is the most conserved domain with 95% identity, XLerk exists as a maternally expressed mRNA, however, expression of transcripts and protein increase during gastrulation and again in the late swimming tadpole stage. In the adult, XLerk is expressed at low levels in mast adult tissues with increased levels observed in the kidney, oocytes, ovary and testis. While low levels of XLerk expression are observed in the adult brain, ill situ hybridization analysis demonstrates prominent expression in the developing olfactory system, retina, hindbrain, cranial ganglia, and somites, Furthermore, we have shown that XLerk transcripts are significantly elevated during mesoderm induction caused by activin and FGF, but not during noggin-induced neuralization. These results suggest a role for XLerk in the developing mesenchymal and nervous tissue.	NCI,FREDERICK CANC RES & DEV CTR,LAB LEUKOCYTE BIOL,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; RUTGERS STATE UNIV,CANC RES LAB,PISCATAWAY,NJ 08855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Rutgers State University New Brunswick				Daar, Ira/0000-0003-2657-526X				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BRANDLI AW, 1995, DEV DYNAM, V203, P119; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Doniach T, 1995, CELL, V83, P1067, DOI 10.1016/0092-8674(95)90133-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; FLETCHER FA, 1994, ONCOGENE, V9, P3241; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HENS MD, 1995, DEV BIOL, V170, P274, DOI 10.1006/dbio.1995.1214; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HOLLAND PWH, 1988, DEVELOPMENT, V102, P150; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; JONES TL, 1995, ONCOGENE, V10, P1111; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KROTOSKI D, 1990, J EXP ZOOL, V253, P139, DOI 10.1002/jez.1402530204; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEFCORT F, 1992, DEVELOPMENT, V116, P767; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP PD, 1976, NORMAL TABLE XENOPUS, P252; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; RANSOM DG, 1993, DEV BIOL, V160, P265, DOI 10.1006/dbio.1993.1304; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SIMONNEAU L, 1992, DEV DYNAM, V194, P247, DOI 10.1002/aja.1001940402; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOMASELLI KJ, 1989, ASSEMBLY NERVOUS SYS, P81; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; Weinstein DC, 1996, MECH DEVELOP, V57, P133, DOI 10.1016/0925-4773(96)00536-9; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005	57	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2159	2166		10.1038/sj.onc.1201082	http://dx.doi.org/10.1038/sj.onc.1201082			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174051				2022-12-28	WOS:A1997WX93800004
J	Kirkpatrick, H; Waber, P; HoaThai, T; Barnes, R; OsborneLawrence, S; Truelson, J; Nisen, P; Bowcock, A				Kirkpatrick, H; Waber, P; HoaThai, T; Barnes, R; OsborneLawrence, S; Truelson, J; Nisen, P; Bowcock, A			Infrequency of BRCA2 alterations in head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; chromosome 13; BRCA2; mutational analysis	CANCER SUSCEPTIBILITY GENE; FREQUENT LOSS; MUTATIONS; RETINOBLASTOMA; POLYMORPHISMS; ALLELOTYPE; DELETION; TUMORS; P53; 13Q	Alterations of BRCA2 result in increased susceptibility to breast cancer in both men and women (relative lifetime risks of 0.06 and 0.8 respectively). BRCA2 maps to 13q12-q13 and encodes a transcript of 10157 bp. Other cancers that have been described in BRCA2 mutation carriers include those of the larynx. Human chromosome 13q has been shown previously by LOH studies to harbor several tumor suppressor genes for head and neck squamous cell carcinoma (HNSCCs). We therefore examined the role of BRCA2 in the development of these cancers. Only 6/22 (27%) of the laryngeal cancers we examined demonstrated LOH of the BRCA2-containing region. These and 10 other HNSCCs of different origins that were demonstrated by LOH studies to have lost the region of chromosome 13 containing BRCA2 were examined for alterations in this gene. SSCP analysis failed to reveal any alterations leading us to conclude that BRCA2 alterations are not frequently involved in the pathogenesis of HNSCCs and that the observed LOH of chromosome 13 loci is due to other, as yet, unidentified tumor suppressor gene(s). Interestingly tumors with LOH in this region (proximal to D13S118) were far more likely to be derived from women than men. This is unusual since HNSCCs are usually fourfold more common in men than in women.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DIV HEMATOL ONCOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OTOLARYNGOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JIN YS, 1993, CANCER RES, V53, P2140; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LEE NK, 1992, HEAD NECK-J SCI SPEC, V14, P235, DOI 10.1002/hed.2880140312; LEE NK, 1992, HEAD NECK-J SCI SPEC, V14, P407, DOI 10.1002/hed.2880140513; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Maestro R, 1996, CANCER RES, V56, P1146; MAESTRO R, 1993, CANCER RES, V53, P5775; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; NAWROZ H, 1994, CANCER RES, V54, P1152; Nylander K, 1996, BRIT J CANCER, V73, P1381, DOI 10.1038/bjc.1996.262; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; Reed AL, 1996, CANCER RES, V56, P3630; Rowley H, 1996, ARCH OTOLARYNGOL, V122, P497; SOMERS KD, 1992, CANCER RES, V52, P5997; Stratton MR, 1996, HUM MOL GENET, V5, P1515, DOI 10.1093/hmg/5.Supplement_1.1515; VANDERRIET P, 1994, CANCER RES, V54, P1156; Weber BHF, 1996, AM J HUM GENET, V59, P962; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WU CL, 1994, CANCER RES, V54, P6484; YOO GH, 1994, CANCER RES, V54, P4603	33	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	1997	14	18					2189	2193		10.1038/sj.onc.1201060	http://dx.doi.org/10.1038/sj.onc.1201060			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174054				2022-12-28	WOS:A1997WX93800007
J	Jiang, Z; Zacksenhaus, E; Gallie, BL; Phillips, RA				Jiang, Z; Zacksenhaus, E; Gallie, BL; Phillips, RA			The retinoblastoma gene family is differentially expressed during embryogenesis	ONCOGENE			English	Article						tumor suppressor genes; pRb; mouse development; in situ hybridization	MOLECULAR-CLONING; CHIMERIC MICE; PROTEIN; MOUSE; CYCLINS; MUTATION; RESCUE; CELLS; P107	We report differential expression of the RBI tumor suppressor gene and the homologous genes p107 and p130 during embryogenesis. Abundant RBI transcripts were detected during neurogenesis, hematopoiesis, myogenesis, lens development and in the ganglion cell layer of the embryonic retina, prior to and during differentiation, The expression pattern of RBI mirrored the defects in RBI mutant mice (RB-/-), In the heart, lung, kidney and intestine, p107, but not RBI, was expressed, In the liver and the central nervous system p107 and RBI were co-expressed, consistent with the accelerated cell death observed in RB-/-; p107(-/-) double knock-out mice, In the central nervous system, p107 expression was restricted to proliferating cells surrounding the ventricles, while RBI was expressed in areas of both proliferating and differentiating cells, In contrast to RBI and p107, expression of p130 was low throughout embryogenesis. In situ hybridization and Western blot analyses showed that the expression of p107 and p130 was not markedly altered in RB-/- embryos compared to control litter-mates, Our results suggest that members of RBI gene family have distinct, but overlapping roles in embryogenesis, with p107 and RBI possibly having redundant functions in the central nervous system and liver.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT MOL & MED GENET,RES INST,DIV IMMUNOL & CANC RES,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DIV HEMATOL & ONCOL,ONCOL RES LABS,BREAST CANC PREVENT PROGRAM,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Zacksenhaus, Eldad/AAD-3584-2020	Gallie, Brenda/0000-0002-9697-9211				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	30	116	123	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1789	1797		10.1038/sj.onc.1201014	http://dx.doi.org/10.1038/sj.onc.1201014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150384				2022-12-28	WOS:A1997WW16600004
J	Kotani, H; Takaishi, K; Sasaki, T; Takai, Y				Kotani, H; Takaishi, K; Sasaki, T; Takai, Y			Rho regulates association of both the ERM family and vinculin with the plasma membrane in MDCK cells	ONCOGENE			English	Article						Rho; ERM family; vinculin; peripheral bundle; cortical bundle; focal adhesion	GTP-BINDING PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; GDP DISSOCIATION INHIBITOR; SACCHAROMYCES-CEREVISIAE; FOCAL ADHESIONS; GENE-PRODUCT; EXCHANGE PROTEIN; BRAIN CYTOSOL; BUD FORMATION; KINASE-C	Rho small G protein regulates various actin-dependent cell functions. As to the functioning sites of Rho, Rho regulates formation of stress fibers and focal adhesions in many types of cultured cells, whereas we have shown that the association sites of actin filaments with the plasma membrane controlled by the ERM (Ezrin, Radixin, Moesin) family are the functioning sites of Rho in MDCK cells stably expressing myc-RhoA. We have investigated here the effect of microinjection of Rho GDI, a negative regulator of Rho which inhibits activation of Rho, C3, an exoenzyme of Clostridium botulinum which ADP-ribosylates Rho and inhibits its functions, or guanosine 5'-(3-O-thio) triphosphate-bound active form of Rho on the intracellular localization of both the ERM family and vinculin, which is one of the structural proteins of focal adhesions, in wild type MDCK cells. The ERM family was preferentially localized at peripheral bundles of actin filaments which are localized at the outer edge of colonies of the cells, microvilli and low Gaze-induced cortical bundles of actin filaments in wild type MDCK cells. Microinjection of Rho GDI or C3 inhibited the localization of the ERM family at both the peripheral bundles and the low Ca2+-induced cortical bundles. On the other hand, vinculin was localized at both focal adhesions and basal edges of the colonies of the cells, and microinjection of Rho GDI or C3 inhibited the localization of vinculin at both of these sites. These results indicate that activation of Rho is necessary for the association of both the ERM family and vinculin with the plasma membrane in wild type MDCK cells. Microinjection of the guanosine 5'-(3-O-thio) triphosphate-bound form of Rho induced an increase in the localization of vinculin at focal adhesions, but did not induce an increase in the localization of the ERM family at the plasma membrane, indicating that activation of Rho itself is sufficient only for the association of vinculin with the plasma membrane at focal adhesions.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V35, P809, DOI 10.1177/35.8.3298422; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO N, 1992, J CELL SCI, V103, P131; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UEDA T, 1990, J BIOL CHEM, V265, P9373; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	47	67	69	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1705	1713		10.1038/sj.onc.1200998	http://dx.doi.org/10.1038/sj.onc.1200998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135072				2022-12-28	WOS:A1997WR89300009
J	Pirollo, KF; Hao, ZM; Rait, A; Jang, YJ; Fee, WE; Ryan, P; Chiang, YW; Chang, EH				Pirollo, KF; Hao, ZM; Rait, A; Jang, YJ; Fee, WE; Ryan, P; Chiang, YW; Chang, EH			p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy	ONCOGENE			English	Article						p53; adenovirus; head and neck; cancer; radiosensitization	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; IN-VIVO; RECOMBINANT ADENOVIRUS; RADIATION-RESISTANT; IONIZING-RADIATION; CANCER-THERAPY; APOPTOSIS; EXPRESSION; GROWTH	Radiation resistant squamous cell carcinoma of the head and neck cell line JSQ-3 carries a mutant form of tumor suppressor gene p53. Treatment of these cells with an adenoviral vector containing wild-type p53 (Av1p53) was able to inhibit their growth in vitro and in vivo while having no effect on normal cells. More significantly, introduction of wtp53 also reduced the radiation-resistance level of this cell line in vitro, in a viral dose-dependent manner, Furthermore, this radiosensitization also carried over to the in vivo situation where the response of JSQ-3 cell-induced mouse xenografts to radiotherapy was markedly enhanced after treatment with Av1p53, Complete, long-term regression of the tumors for up to 162 days was observed when a single dose of Av1p53 was administered in combination with ionizing radiation, demonstrating the effectiveness of this combination of gene therapy and conventional radiotherapy, This sensitization of tumors to radiation therapy by replacement of wtp53 could significantly decrease the rate of recurrence after radiation treatment. Since radiation is one of the most prevalent forms of adjunctive therapy for a variety of cancers, these results have great relevance in moving toward an improved cancer therapy.	STANFORD UNIV,DEPT SURG,DIV OTOLARYNGOL,STANFORD,CA 94305; GENET THERAPY INC,NOVARTIS,GAITHERSBURG,MD 20878	Stanford University; Novartis					NCI NIH HHS [R01 CA45158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; *AM CANC SOC, 1993, PUB AM CANC SOC; *AM JOINT COMM CAN, 1983, MAN STAG CANC, P25; AWAN AM, 1991, HEMATOL ONCOL CLIN N, V5, P635, DOI 10.1016/S0889-8588(18)30406-4; BLAU HM, 1995, NEW ENGL J MED, V333, P1204, DOI 10.1056/NEJM199511023331808; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; BRAMSON JL, 1995, CURR OPIN BIOTECH, V6, P590, DOI 10.1016/0958-1669(95)80097-2; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLAYMAN GL, 1995, CANCER RES, V55, P1; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIMERY IW, 1993, JNCI-J NATL CANCER I, V85, P95, DOI 10.1093/jnci/85.2.95; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELSTNER E, 1995, CANCER RES, V55, P2822; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, CANCER RES, V54, P2287; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; Janat M. Fouad, 1994, Molecular and Cellular Differentiation, V2, P241; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG M, 1992, CANCER RES, V52, P6390; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KOECHLI OR, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90447-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, COLD SPRING HARB SYM, V59, P419, DOI 10.1101/SQB.1994.059.01.047; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MITTEREDER N, 1994, HUM GENE THER, V5, P717, DOI 10.1089/hum.1994.5.6-717; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PITTS JD, 1994, MOL CARCINOGEN, V11, P127, DOI 10.1002/mc.2940110302; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SEACHRIST L, 1994, J NATL CANCER I, V86, P82, DOI 10.1093/jnci/86.2.82; SETOGUCHI Y, 1994, J RESPIR CELL MOL BI, V10, P369; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shin DM, 1996, J NATL CANCER I, V88, P519, DOI 10.1093/jnci/88.8.519; SILBER R, 1994, BLOOD, V84, P3440; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; STEWART FM, 1995, J CELL BIOCHEM, V58, P416, DOI 10.1002/jcb.240580404; STEWART N, 1995, ONCOGENE, V10, P109; TRAPNELL BC, 1993, ADV DRUG DELIVER REV, V12, P185, DOI 10.1016/0169-409X(93)90059-D; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; WU SG, 1996, NAT MED, V2, P255; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	69	112	133	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1735	1746		10.1038/sj.onc.1201116	http://dx.doi.org/10.1038/sj.onc.1201116			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135075				2022-12-28	WOS:A1997WR89300012
J	Xu, X; Gelinas, C				Xu, X; Gelinas, C			A mutant Rel-homology domain promotes transcription by p50/NF kappa B1	ONCOGENE			English	Article						c-Rel; p50; NF kappa B; transcription; protein conformation	NF-KAPPA-B; DNA-BINDING SUBUNIT; C-REL; V-REL; ONCOGENIC TRANSFORMATION; MAMMALIAN-CELLS; GENE ACTIVATION; FAMILY PROTEINS; NUCLEAR FACTOR; P50 SUBUNIT	Previous studies showed that the binding of p50/NF kappa B1 to particular kappa B DNA sites altered its conformation in a way that correlated with transcriptional activation. Here, we investigated the effects of protein-protein interactions on the transcriptional activity of p50. We show that the association of p50 with a mutant Rel-homology domain (RHD) defective for DNA binding led to synergistic activation of kappa B site-dependent transcription, whereas neither protein alone had any effect. Partial proteolytic analysis showed that the conformation of p50 in these complexes differed from that in wild-type c-Rel-RHD/p50 complexes, and correlated with activated transcription. These results suggest that the Rel-homology domain can act as an allosteric effector to promote transcription by p50/NF kappa B1 and that the configuration of p50 is important for its activity. This also suggests that Rel proteins can promote transcription by other Rel-family members without binding to their DNA recognition site. These studies emphasize the important role of protein-protein interactions in Rel and NF kappa B-mediated transcription.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,GRAD PROGRAM BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; INST CANC RES,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [CA54999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; White DW, 1996, MOL CELL BIOL, V16, P1169; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	60	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1521	1530		10.1038/sj.onc.1200985	http://dx.doi.org/10.1038/sj.onc.1200985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129142				2022-12-28	WOS:A1997WQ54800002
J	DAdamo, DR; Novick, S; Kahn, JM; Leonardi, P; Pellicer, A				DAdamo, DR; Novick, S; Kahn, JM; Leonardi, P; Pellicer, A			rsc: A novel oncogene with structural and functional homology with the gene family of exchange factors for Ral	ONCOGENE			English	Article						oncogene; exchange factors; Ral; Ral-GDS; gene transfer	NUCLEOTIDE DISSOCIATION STIMULATOR; H-RAS; MOLECULAR-CLONING; CEREVISIAE CDC25; ACTIVATION; IDENTIFICATION; INVOLVEMENT; PROTEIN; GTPASE; MODEL	A novel oncogene, rsc (rabbit squamous cell carcinoma), has been identified from a DMBA-induced rabbit squamous cell carcinoma using gene transfer and the nude mouse tumorigenesis assay. A full-length cDNA has been isolated and sequenced. use has potent tumorigenic activity in nude mice (latency <4 weeks), but does not induce focus formation or anchorage independent growth. The oncogene resulted from the fusion of rHR 23A (a rabbit homologue of yeast Rad 23) with a member of the ral-GDS family which we named rgr (ral-GDS related). Deletion analysis demonstrated that the oncogenic potential resides in the Rgr portion of the gene. Rgr is 40% identical overall to Ral-GDS, with identity increasing to 72% over a 100 amino acid region of the catalytic domain. Biochemical experiments indicate that Rgr has GTP/GDP exchange activity for Ral, providing evidence that this pathway is associated with tumorigenesis. The linkage between the Ral pathway and tumorigenesis by a molecule in the Ral-GDS gene family (Ral-GDS being a known effector for Ras) will open the way for the characterization of this pathway and provide an important tool to understand its biological function.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA50434] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALTINGMEES M, 1992, STRAT MOL BIOL, V5, P58; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEALE AJ, 1963, LANCET, V2, P640; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bouck N, 1979, Methods Enzymol, V58, P296; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHENG JF, 1984, J MOL BIOL, V176, P1, DOI 10.1016/0022-2836(84)90379-6; COROMINAS M, 1991, ONCOGENE, V6, P645; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Fogh J, 1978, NUDE MOUSE EXPT CLIN; Ghadially F.N., 1988, GHADIALLYS ULTRASTRU, V3rd; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; Leon J., 1993, RAS SUPERFAMILY GTPA, P3; Mangues R, 1992, Semin Cancer Biol, V3, P229; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NOVICK SC, 1994, THESIS; Park SH, 1995, ONCOGENE, V11, P2349; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WATKINS D, 1994, CANCER GENET CYTOGEN, V72, P130, DOI 10.1016/0165-4608(94)90128-7; WEI W, 1993, CLONING ANAL FULL LE; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1996, ONCOGENE, V13, P353	49	47	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1295	1305		10.1038/sj.onc.1200950	http://dx.doi.org/10.1038/sj.onc.1200950			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178890				2022-12-28	WOS:A1997WP10900005
J	Leeds, P; Kren, BT; Boylan, JM; Betz, NA; Steer, CJ; Gruppuso, PA; Ross, J				Leeds, P; Kren, BT; Boylan, JM; Betz, NA; Steer, CJ; Gruppuso, PA; Ross, J			Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro	ONCOGENE			English	Article						mRNA stability; coding region determinant; fetal development	MOUSE-LIVER REGENERATION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; CODING REGION; CELL-DIFFERENTIATION; BOUND POLYSOMES; UNDEGRADED FREE; XENOPUS LIVER; HALF-LIFE; RAT-LIVER	We previously isolated and characterized a coding region determinant-binding protein (CRD-BP) that might regulate c-myc mRNA post-transcriptionally. CRD-BP binds specifically to the coding region of c-myc mRNA and might stabilize c-myc mRNA in vitro by protecting it from endonucleolytic cleavage, Since c-myc abundance is regulated during embryonic development and cell replication, we investigated whether CRD-BP is also regulated in animal tissues. We focused on CRD-BP expression during rat liver development and liver regeneration, because c-myc mRNA is regulated post-transcriptionally in both cases, CRD-BP expression parallels c-myc expression during liver development; the protein is present in fetal and neonatal liver but is absent or in low abundance in adult liver, In contrast, the up-regulation of c-myc mRNA following partial hepatectomy is not accompanied by upregulation of CRD-BP, To our knowledge, CRD-BP is the first example of a putative mammalian mRNA-binding protein that is abundant in a fetal tissue but either absent from or scarce in adult tissues, Its expression in fetal liver and in transformed cell lines suggests CRD-BP is an oncofetal protein.	UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PATHOL, MADISON, WI 53706 USA; RHODE ISL HOSP, DEPT PEDIAT, PROVIDENCE, RI 02903 USA; BROWN UNIV, SCH MED, PROVIDENCE, RI 02903 USA; UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT CELL BIOL, MINNEAPOLIS, MN 55455 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA007175, R01CA063676] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA63676] Funding Source: Medline; NICHD NIH HHS [HD24455] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fausto Nelson, 1994, P1059; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GRUPPUSO PA, 1996, IN PRESS IN VITRO CE; Gruppuso Philip A., 1993, Pediatric Research, V33, p49A; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Higgins GM, 1931, ARCH PATHOL, V12, P186; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; Kren BT, 1996, FASEB J, V10, P559, DOI 10.1096/fasebj.10.5.8621056; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RAMSEY JC, 1976, BIOCHEMISTRY-US, V15, P1704, DOI 10.1021/bi00653a018; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKIGUCHI M, 1985, J BIOCHEM, V97, P1447, DOI 10.1093/oxfordjournals.jbchem.a135199; Tiffany HL, 1996, J BIOL CHEM, V271, P12387, DOI 10.1074/jbc.271.21.12387; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Zelus BD, 1996, J VIROL, V70, P2411, DOI 10.1128/JVI.70.4.2411-2419.1996	43	93	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1279	1286		10.1038/sj.onc.1201093	http://dx.doi.org/10.1038/sj.onc.1201093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178888				2022-12-28	WOS:A1997WP10900003
J	Kamano, H; Klempnauer, KH				Kamano, H; Klempnauer, KH			B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter	ONCOGENE			English	Article						B-Myb; heat shock element; HSP70 promoter; cyclin D1	DNA-BINDING ACTIVITY; A-MYB; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATOR; RETINOBLASTOMA PROTEIN; V-MYB; C-MYB; HEMATOPOIETIC-CELLS; GENE-TRANSCRIPTION; REGULATORY DOMAINS	Previous studies have shown that B-Myb, a conserved member of the Myb transcription factor family, is a potent activator of the promoter of the human HSP70 gene but does not activate promoters containing Myb binding sites. We have now investigated the transactivation properties of B-Myb in more detail. We here report that B-Myb activates the HSP70 promoter by a novel mechanism which involves the heat shock element (HSE). Deletion analysis of B-Myb shows that a specific domain in the center of B-Myb, but not the DNA-binding domain is required for HSE-dependent transactivation. We also show that deletion of the C-terminal domain of B-Myb does not affect HSE-dependent transactivation but allows the protein to activate a promoter containing Myb binding sites. This suggests that the ability to activate Myb binding site containing promoters is repressed in the context of full length B-Myb and that HSE dependent and Myb binding site dependent transactivation are distinct functions of B-Myb. Finally, we report that cyclin D1 like B-Myb strongly activates the HSP70 promoter via the HSE. HSE-dependent transactivation is a novel activity of cyclin D1 and appears to be independent of the phosphorylation of the Rb protein. Our results reveal an interesting and unexpected connection between HSE-dependent gene activation and proteins expressed during the G1/S-transition of the cell cycle.	MAX PLANCK INST IMMUNOBIOL, HANS SPEMANN LAB, D-79108 FREIBURG, GERMANY	Max Planck Society								AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; ARSURA M, 1992, BLOOD, V79, P2708; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Kamano H, 1995, ONCOGENE, V11, P2575; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; KATO J, 1993, GENE DEV, V7, P331; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NEVINS JR, 1992, SCIENCE, V258, P424; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Sitzmann J, 1996, ONCOGENE, V12, P1889; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	52	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1223	1229		10.1038/sj.onc.1200945	http://dx.doi.org/10.1038/sj.onc.1200945			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121772				2022-12-28	WOS:A1997WM78200012
J	Ligon, AH; Pershouse, MA; Jasser, SA; Yung, WKA; Steck, PA				Ligon, AH; Pershouse, MA; Jasser, SA; Yung, WKA; Steck, PA			Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma	ONCOGENE			English	Article						glioblastoma; chromosome 11; differential expression	TUMOR-SUPPRESSOR GENES; HETEROZYGOSITY; ASTROCYTOMAS; LOCI; RNA; AMPLIFICATION; CHROMOSOME-17; TRANSCRIPTS; EXPRESSION; DELETIONS	Genetic deletions to chromosome 10 have been extensively documented for human glioblastomas (GBMs). To identify gene products that may be involved in malignant progression, a subtractive hybridization was performed between GEM cells and hybrid cells suppressed for tumorigenicity following microcell transfer of chromosome 10. One novel cDNA isolated from this subtraction showed consistent upregulation (similar to 4 to 10-fold) that correlated with the nontumorigenic phenotype of the hybrid cells. Subsequent analysis resulted in the identification of a full length cDNA (2,569 bp) termed RIG (regulated in glioma). RIG expression was either not detected or detected only at low levels in cultured glioma cells and primary glioblastoma specimens compared to normal brain cells. The 2.6 kb RIG mRNA was expressed predominantly in normal brain with lower levels in heart and lung. Sequence analysis showed no significant homology to known gene products, Genomic alterations of RIG were present in similar to 25% of glioma cell lines examined. Also, RIG mapped to chromosome 11p15.1, a region that is known to be altered in malignant astrocytomas. The differential expression pattern, tissue distribution and chromosomal location of RIG suggests it serves as a molecular marker for or may play a role in the malignant progression of GBMs.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BRAIN TUMOR CTR,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [R01 CA51148, R01 CA56041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051148, R01CA056041] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BIGNER SH, 1988, CANCER RES, V88, P405; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1989, CANCER RES, V49, P6572; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HUTCHINS JT, 1991, CANCER RES, V51, P1418; JABER M, 1994, NEUROSCIENCE, V61, P245, DOI 10.1016/0306-4522(94)90228-3; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P348, DOI 10.1002/gcc.2870050411; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Sambrook J., 1989, MOL CLONING; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SONODA Y, 1995, CANCER RES, V55, P2166; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WINGVIST R, 1993, CANCER RES, V52, P6646; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YUNG WKA, 1989, CANCER RES, V49, P1014; [No title captured]	36	8	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1075	1081		10.1038/sj.onc.1200925	http://dx.doi.org/10.1038/sj.onc.1200925			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070656				2022-12-28	WOS:A1997WM07000009
J	Bartholomew, C; Kilbey, A; Clark, AM; Walker, M				Bartholomew, C; Kilbey, A; Clark, AM; Walker, M			The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation	ONCOGENE			English	Article						Evi-1; repression; leukaemogenesis; development	ZINC-FINGER PROTEIN; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; MYELODYSPLASTIC SYNDROMES; RETROVIRAL INSERTIONS; CONSENSUS SEQUENCE; MAMMALIAN-CELLS; GENE-EXPRESSION; ACTIVATION; IDENTIFICATION	The myeloid transforming gene Evi-1 encodes a protein with two zinc finger domains, designated ZF1 and ZF2, with distinct DNA binding specificities. For the first time we demonstrate that Evi-1 has transcriptional repressor activity which is directly proportional to the amount of Evi-1 protein in cells. Repression has been observed with two distinct promoters: the minimal HSV-1 tk promoter and a VP16 inducible adenovirus E1b minimal promoter. Optimal repression is DNA binding dependent and is mediated by either ZF1 or a heterologous GAL4 DNA binding domain (GAL4DBD) but is significantly less efficient through the ZF2 binding site. Both GAL4DBD/Evi-1 fusion and non-fusion proteins have been used to map the repressor activity to a proline-rich region located within amino acids 514-724 between the ZF1 and ZF2 domains. Constitutive expression of mutant proteins lacking the repressor domain are defective for transformation of Rat1 fibroblasts demonstrating that this region is required for the oncogenic activity of the Evi-1 protein. These studies show that the Evi-1 gene encodes a transcriptional repressor and has important implications for the mechanism of action of the Evi-1 protein both in development and in the progression of some myeloid leukaemias.			Bartholomew, C (corresponding author), BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, LANARK, SCOTLAND.							BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DREYFUS F, 1995, LEUKEMIA, V9, P203; FUNABIKI T, 1994, ONCOGENE, V9, P1575; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAMA T, 1995, BLOOD, V86, P841; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LEVY ER, 1994, BLOOD, V83, P1348; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUGI T, 1995, ONCOGENE, V11, P191; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERKINS AS, 1991, DEVELOPMENT, V111, P479; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	46	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					569	577		10.1038/sj.onc.1200864	http://dx.doi.org/10.1038/sj.onc.1200864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053855				2022-12-28	WOS:A1997WF52400008
J	Huang, DCS; Cory, S; Strasser, A				Huang, DCS; Cory, S; Strasser, A			Bcl-2, Bcl-x(L) and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death	ONCOGENE			English	Article						apoptosis; Bcl-2; Bcl-x(L); E1B19kD adenovirus protein; Fas/APO-1 (CD95); TNF	TUMOR-NECROSIS-FACTOR; ANTI-FAS ANTIBODY; TRANSGENIC MICE; CAENORHABDITIS-ELEGANS; PROTOONCOGENE BCL-2; NEGATIVE SELECTION; INDUCED APOPTOSIS; MULTIPLE FORMS; LYMPHOID-CELLS; T-CELLS	Apoptosis is the physiological process by which unwanted cells in an organism are killed. Bcl-2, a membrane-bound cytoplasmic protein, is an effective inhibitor of apoptotic cell death induced by many cytotoxic agents. Survival-promoting homologues of Bcl-2 include its close relative, Bcl-x(L) and the 19 kD protein encoded by the E1B gene of adenoviruses. Whether these proteins are functionally equivalent and whether they can antagonise all or only some pathways to apoptosis is unresolved. We have carried out a systematic comparison of Bcl-2, Bcl-x(L) and adenovirus E1B19kD activity, using several cell lines and a range of cytotoxic conditions. High levels of expression of each of these proteins inhibited apoptosis induced by growth factor deprivation or treatment with gamma-radiation, glucocorticoid and various cytotoxic drugs. In contrast, none of them could effectively counter apoptosis induced via the TNF receptor or Fas/APO-1 (CD95). Biochemical analysis revealed that all three proteins can associate with Bar and Bah, members of the Bcl-2 protein subfamily that can facilitate apoptosis. The results provide evidence that Bcl-2, Bcl-x(L), and adenovirus protein E1B19kD are indistinguishable in their ability to regulate the cell death effector machinery.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Huang, David C. S./C-7586-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Strasser, Andreas/0000-0002-5020-4891				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gibson L, 1996, ONCOGENE, V13, P665; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEBRUN DP, 1993, AM J PATHOL, V142, P743; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REAP EA, 1995, J IMMUNOL, V154, P936; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P799; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	81	227	235	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					405	414		10.1038/sj.onc.1200848	http://dx.doi.org/10.1038/sj.onc.1200848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053837				2022-12-28	WOS:A1997WE36400003
J	Kerangueven, F; Eisinger, F; Noguchi, T; Allione, F; Wargniez, V; Eng, C; Padberg, G; Theillet, C; Jacquemier, J; Longy, M; Sobol, H; Birnbaum, D				Kerangueven, F; Eisinger, F; Noguchi, T; Allione, F; Wargniez, V; Eng, C; Padberg, G; Theillet, C; Jacquemier, J; Longy, M; Sobol, H; Birnbaum, D			Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions	ONCOGENE			English	Article						ataxia telangiectasia; BRCA1; breast cancer; chromosome 10; chromosome 11; chromosome 17	SUSCEPTIBILITY GENE; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; CHROMOSOME 11Q23; CANCER; TUMORS; IDENTIFICATION; AMPLIFICATION; INVOLVEMENT; LOCUS	To appreciate the involvement of known or potential susceptibility genes in sporadic breast tumors, we have searched for chromosomal deletions by studying loss of heterozygosity (LOH) at 43 microsatellite (CA)(n) markers from human chromosomes 10, 11 and 17, in 115 unselected consecutive samples of breast carcinoma with particular emphasis on specific regions. No site of consistent LOH was identified on chromosome 10. Five regions of LOH were contained within bands q22-24 of chromosome 11 for which nearly 50% of the tumors had LOH at at least one marker. This region is thus a major site of deletion in breast cancer and several tumor suppressor genes seem to be involved. One of them may be the ataxia telangiectasia (ATM) gene which is located in one of the affected regions. Five regions of LOH, one of which is within the BRCA1 gene area, were recognized along chromosome 17. LOH at three of these regions were found in highly proliferative tumors, When combined with a previous study of chromosome 13 with emphasis on BRCA2 and Rb1 genes, this work allowed to distinguish a total of 12 regions of LOH, variably affected in breast tumors and correlated with prognostic parameters.	INST J PAOLI I CALMETTES,LAB BIOL TUMEURS,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT ONCOGENET,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT NUCL MED,F-13009 MARSEILLE,FRANCE; UNIV NIJMEGEN HOSP,NIJMEGEN,NETHERLANDS; IGGM,CNRS URA 9942,MONTPELLIER,FRANCE; INST J PAOLI I CALMETTES,DEPT PATHOL ANAT,F-13009 MARSEILLE,FRANCE; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Radboud University Nijmegen; Universite de Montpellier; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm)			Padberg, G.W.A.M./H-8079-2014; Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Eisinger, Francois/0000-0002-8794-0681; Eng, Charis/0000-0002-3693-5145				AGRESTI A, 1990, J AM STAT ASSOC, V85, P543; Baffa R, 1996, CANCER RES, V56, P268; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARTER SL, 1994, CANCER RES, V54, P6270; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; CROPP CS, 1993, CANCER RES, V53, P5617; Davis M, 1996, CANCER RES, V56, P741; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eisinger F, 1996, CANCER RES, V56, P471; FERTIPASSANTONOPOULOU A, 1991, CANCER GENET CYTOGEN, V51, P183, DOI 10.1016/0165-4608(91)90130-M; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GRAY IC, 1995, CANCER RES, V55, P4800; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; Hollander M., 1973, NONPARAMETRIC STAT M, P115; HUI A, 1996, ONCOGENE, V56, P3225; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Ittmann M, 1996, CANCER RES, V56, P2143; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kerangueven F, 1996, INT J ONCOL, V8, P1155; KERANGUEVEN F, 1995, ONCOL REP, V2, P89; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P271; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; LINDBLOM A, 1994, AM J HUM GENET, V54, P871; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; NAGAI MA, 1995, ONCOLOGY, V52, P448; NEGRINI M, 1995, CANCER RES, V55, P3003; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Phillips KK, 1996, CANCER RES, V56, P1222; RASIO D, 1995, CANCER RES, V55, P3988; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SANCHEZ Y, 1996, CANCER RES, V93, P2551; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schultz DC, 1996, CANCER RES, V56, P1997; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; STARINK TM, 1986, CLIN GENET, V29, P222; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; THEILLET C, 1989, ONCOGENE, V4, P915; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; WINQVIST R, 1995, CANCER RES, V55, P2660; ZHUANG ZP, 1995, CANCER RES, V55, P467	54	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					339	347		10.1038/sj.onc.1200818	http://dx.doi.org/10.1038/sj.onc.1200818			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018120	Green Published			2022-12-28	WOS:A1997WD51600010
J	Huff, SY; Quilliam, LA; Cox, AD; Der, CJ				Huff, SY; Quilliam, LA; Cox, AD; Der, CJ			R-Ras is regulated by activators and effectors distinct from those that control Ras function	ONCOGENE			English	Article						GDP; GTP regulation; Raf kinases; dominant negative mutants	NUCLEOTIDE EXCHANGE FACTORS; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE KINASE; PROTEIN-KINASE; TYPE-1 NEUROFIBROMATOSIS; CELL-TRANSFORMATION; MAMMALIAN-CELLS; GENE-PRODUCT; GROWTH; EXPRESSION	Like Ras, constitutively activated mutants of the Ras-related protein R-Ras cause tumorigenic transformation of NIH3T3 cells. However, since R-Ras causes a transformed phenotype distinct from that induced by Ras, it is likely that R-Ras controls signaling pathways and cellular processes distinct from those regulated by Ras. To address this possibility, we determined if R-Ras is regulated by activators and effecters distinct from those that regulate Ras function, We observed that Ras guanine nucleotide exchange factors failed to activate R-Ras in vivo, indicating that R-Ras is activated by distinct GEFs. Consistent with this, mutants of R-Ras with mutations analogous to the Ras(15A)/(17N) dominant negative proteins did not antagonize Ras GEF function and lacked the growth inhibitory activity seen with these mutant Ras proteins, Thus, R-Ras, but not Ras, is dispensable for the viability of MIH3T3 cells. Finally, whereas constitutively activated Ras can overcome the growth inhibitory action of the Ras(17N) dominant negative protein via Raf-dependent and -independent activities, transforming mutants of R-Ras failed to do so. This inability was consistent with our observation that Ras-, but not R-Ras-transformed, NIH3T3 cells possessed constitutively upregulated Raf kinase activities. Thus, R-Ras and Ras are regulators of distinct signaling pathways and cellular processes.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT RADIAT ONCOL, CHAPEL HILL, NC 27599 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHEN SY, 1994, ONCOGENE, V9, P2691; Clark GJ, 1996, ONCOGENE, V12, P169; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GRAHAM SM, 1996, IN PRESS MOL CELL BI; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MOODIE SA, 1994, TRENDS GENET, V10, P14; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	77	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					133	143		10.1038/sj.onc.1200815	http://dx.doi.org/10.1038/sj.onc.1200815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010215				2022-12-28	WOS:A1997WC81800001
J	ElRouby, S; Newcomb, EW				ElRouby, S; Newcomb, EW			Identification of Bcd a novel proto-oncogene expressed in B-cells	ONCOGENE			English	Article						transfection; transforming activity; chronic lymphocytic leukemia; B-cell differentiation	CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; TRANSFORMING GENES; SEQUENCES; VAV; DNA; ACTIVATION; LYMPHOMAS; CLONING; DOMAINS	A novel B-cell derived (Bcd) oncogene has been isolated from the peripheral blood lymphocytes of one B-cell chronic lymphocytic leukemia (B-CLL) patient using DNA transfer and a mouse tumorigenicity assay. The Bcd proto-oncogene was activated by a truncation in the 5' UTR, It predicts for two open reading frames (ORFs). ORF1 consists of 240 bp that would encode 80 amino acids, while the major ORF2 consists of 648 bp capable of coding for 216 amino acids, Predicted peptide sequence of ORF2 contained a zinc finger domain which showed significant homology to GC box binding proteins BTEB2 and SP1. Transfection of an expression vector containing ORF2 but not full length cDNA was able to transform NIH3T3 cells and induce tumors in nude mice. Bcd mRNA transcripts of less than or equal to 2.6 kb were selectively expressed in PBL and testis of healthy individuals. Within the PBL, Bcd gene expression was restricted to CD19(+) B-cells and absent from CD14(+) monocytes and T-cells. Bcd transcripts were detected in all normal PBL samples tested but not in several malignant human B-cell lines and not in 50% of B-cells from B-CLL patients, However, stimulation of B-cells from B-CLL patients under conditions which induced differentiation into plasma cells was associated with induction of Bcd gene expression, The Bcd gene may therefore play an important role in B-cell growth and development.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; KAPLAN CANC CTR,NEW YORK,NY 10016	New York University					NCI NIH HHS [P30-CA16087, CA53572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087, R01CA053572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNSTEIN JM, 1994, HDB MUCOSAL IMMUNOLO, P625; BLAIR DG, 1982, SCIENCE, V28, P1122; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; ELROUBY S, 1993, BLOOD, V82, P3452; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORDON J, 1984, J IMMUNOL, V132, P541; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIPPS TJ, 1988, BLOOD, V72, P422; KODONAGA JT, 1987, CELL, V51, P1079; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEWCOMB EW, 1988, CANCER RES, V48, P5514; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	34	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2623	2630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000136				2022-12-28	WOS:A1996VZ65400012
J	Yatsula, BA; Plachy, J; Mikhailik, A; DavidPfeuty, T; Lecoq, O; Yatsula, V; Geryk, J; Svoboda, J; Calothy, G; Dezelee, P				Yatsula, BA; Plachy, J; Mikhailik, A; DavidPfeuty, T; Lecoq, O; Yatsula, V; Geryk, J; Svoboda, J; Calothy, G; Dezelee, P			Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations	ONCOGENE			English	Article						c-src; avian sarcoma virus; oncogene activation; neuroretina	ROUS-SARCOMA VIRUS; NEURORETINAL CELL-PROLIFERATION; NIH 3T3 CELLS; TRANSFORMATION DEFECTIVE MUTANT; TYROSINE KINASE-ACTIVITY; V-SRC; TRANSFECTED DNA; GROWTH-FACTOR; PP60C-SRC; ACTIVATION	We previously reported the isolation of PR2257, a novel avian sarcoma retrovirus which transduced the c-src protooncogene. The v-src gene of PR2257 differs from the c-src gene by a sequence change after amino acid 525, resulting in the replacement of tyrosine 527 by a valine, and an extension of the open reading frame into the non coding region of c-src. We investigated the respective roles of Tyr527 mutation and of the C-terminal extension in activating the oncogenic properties of c-src. Therefore we overexpressed the wild type c-src gene and c-src variants, carrying either a substitution of tyrosine 527 or an extension of the C-terminus or both modifications in combination, in chicken embryo fibroblasts and post mitotic neuroretina (NR) cells, using replication defective retroviruses. We also used in vivo inoculation of plasmid DNA to assess the tumorigenicity of the various c-src genes, We report that, in contrast to previous results, overexpression of c-src is sufficient to induce NR cell division, While mutation of tyrosine 527 alone significantly activates c-src transforming and tumorigenic properties, its combination with the C-terminal extension of PR2257 confers to this gene full oncogenic properties and increased metastatic potential as compared to the v-src of Rous sarcoma virus strains.	INST CURIE,UMR 146 CNRS,F-91405 ORSAY,FRANCE; ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences			Josef, Geryk/I-8729-2014; Plachy, Jiri/G-4381-2014; Geryk, Josef/G-3548-2014	Josef, Geryk/0000-0002-3992-2980; 				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEZELEE P, 1992, VIROLOGY, V189, P556, DOI 10.1016/0042-6822(92)90579-E; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GERYK J, 1989, J VIROL, V63, P481, DOI 10.1128/JVI.63.2.481-492.1989; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IBA H, 1985, MOL CELL BIOL, V5, P2856, DOI 10.1128/MCB.5.10.2856; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEBKOWSKI JS, 1984, MOL CELL BIOL, V4, P1951, DOI 10.1128/MCB.4.10.1951; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIN PH, 1995, ONCOGENE, V10, P401; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLACHY J, 1994, IMMUNOGENETICS, V40, P257, DOI 10.1007/BF00189970; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REDDY S, 1988, MOL CELL BIOL, V8, P704, DOI 10.1128/MCB.8.2.704; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SVOBODA J, 1992, IMMUNOGENETICS, V35, P309, DOI 10.1007/BF00189893; SVOBODA J, 1984, FOLIA BIOL-PRAGUE, V31, P135; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; YATSULA BA, 1994, BBA-GENE STRUCT EXPR, V1218, P473, DOI 10.1016/0167-4781(94)90210-0; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	45	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2717	2725						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000146				2022-12-28	WOS:A1996VZ65400022
J	SoferLevi, Y; Resnitzky, D				SoferLevi, Y; Resnitzky, D			Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E	ONCOGENE			English	Article						cyclin D1; apoptosis; cell cycle	S-PHASE ENTRY; CELL-CYCLE; PROTEIN; GENE; RB; TRANSITION; LEADS; G(1); RETINOBLASTOMA; FIBROBLASTS	Deregulation of the pRb/E2F pathway leads to disruption of the normal control of the G(1)/S transition, and is associated with transformation. However, recent accumulated evidence suggest that under certain circumstances deregulation of the pRb/E2F pathway can also lead to apoptotic cell death. Apoptosis was shown to be induced by expression of DNA tumor virus oncoproteins, knockout of the rb gene, and expression of E2F from heterologous promoter. Since phosphorylation of pRb by G(1) cyclin-dependent kinases (Cdks) causes its inactivation, we examined whether deregulation of G(1) Cdks, also drives apoptosis. We have used rat fibroblast cell lines capable of expressing cyclin E, cyclin D1, or both, in an inducible manner, through a tetracycline responsive promoter. We show here that ectopic expression of cyclins D1 and E in rat fibroblasts under serum starvation, leads to deregulated entry into S phase, and subsequently to apoptotic cell death. Furthermore, expression of cyclin D1 alone is sufficient to provoke apoptosis, whereas expression of cyclin E alone during serum starvation does not. Moreover, expression of either cyclins D1 and E, and cyclin D1 alone, under serum starvation led to a significant increase in the fraction of hyper-phosphorylated pRb whereas cyclin E expression alone did not. These results demonstrate that expression of cyclin D1 from heterologous promoter leads to apoptosis in serum starved cells, which may be mediated by phosphorylation of pRb.	WEIZMANN INST SCI,DEPT MOL & CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RENZING J, 1995, ONCOGENE, V10, P1865; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	43	104	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2431	2437						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957085				2022-12-28	WOS:A1996VX10800016
J	Ryan, KM; Birnie, GD				Ryan, KM; Birnie, GD			Cell-cycle progression is not essential for c-Myc to block differentiation	ONCOGENE			English	Article						cell-cycle progression; DNA binding; Max; c-Myc; myeloid differentiation; ornithine decarboxylase	NERVE GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; TRANSCRIPTIONAL ACTIVATION; HL-60 CELLS; DNA-BINDING; EXPRESSION; PROTEIN; MAX; PROLIFERATION; APOPTOSIS	The c-myc proto-oncogene has been shown to cause blockages to differentiation in many cell lineages, Although the mechanism by which c-Myc affects this process remains unknown, it is considered that it might result indirectly as an outcome of the continued cell-cycle progression invoked by c-Myc in cells which must growth arrest in order to differentiate, However, as there is little evidence to support this hypothesis, it is equally possible that a differentiation blockage occurs through a mechanism independent of c-Myc's involvement in cell-cycle progression, To explore this possibility me utilised a differentiation-defective variant of the U937 cell line, which still responds to the differentiation inducer by undergoing rapid growth Analysis of this line during growth arrest revealed that, although the expression of the Myc target gene, ornithine decarboxylase (ODC) was down-regulated, the cells differed from those of the parental line in that they continued to express high levels of c-Myc protein, did not but maintain levels of expression of the Myc antagonists, mad1 and mxi1. Moreover, antisense down-regulation of the c-Myc protein levels in these growth-arrested cells revealed that this continued c-Myc expression was essential for their differentiation blockage, These data therefore indicate that c-Myc can block differentiation by a mechanism dissociated from its ability to direct cell-cycle progression or the expression of ODC.	BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute				Ryan, Kevin M./0000-0002-1059-9681				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BACON TA, 1991, ONCOGENE RES, V6, P21; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CHAVANY C, 1995, MOL PHARMACOL, V48, P738; CROUCH DH, 1993, ONCOGENE, V8, P1849; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELD JK, 1990, ANTICANCER RES, V10, P1; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LARSSON LG, 1994, ONCOGENE, V9, P1247; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUK GD, 1982, SCIENCE, V216, P75, DOI 10.1126/science.6950518; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARUYAMA K, 1987, ONCOGENE, V1, P361; MITCHELL LS, 1992, DIFFERENTIATION, V49, P119, DOI 10.1111/j.1432-0436.1992.tb00776.x; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROY AL, 1993, NATURE, V365, P356; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STACEY G, 1992, CYTOTECHNOLOGY, V9, P211, DOI 10.1007/BF02521748; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	49	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2835	2843		10.1038/sj.onc.1201124	http://dx.doi.org/10.1038/sj.onc.1201124			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190900				2022-12-28	WOS:A1997XD64300012
J	Martinez, JD; Craven, MT; Joseloff, E; Milczarek, G; Bowden, GT				Martinez, JD; Craven, MT; Joseloff, E; Milczarek, G; Bowden, GT			Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation	ONCOGENE			English	Article						p53; DNA binding; nuclear localization; phosphorylation; transactivation	TEMPERATURE-SENSITIVE MUTANT; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; DAMAGING AGENTS; INDUCED TUMORS; 3T3 CELLS; IN-VITRO; PROTEIN	Compelling evidence indicates that p53 acts as a transcription factor and that this activity is regulated by several factors including subcellular localization and phosphorylation status of the protein. To learn more about how these two processes determine whether p53 becomes activated, we studied the temperature sensitive murine p53, p53(val135). At nonpermissive temperatures, p53(val135) remains sequestered in the cytoplasm of cells ,which express it. Electrophoretic mobility shift assays demonstrated that, under these conditions, the protein lacked DNA binding activity. However, by shifting to the permissive temperature, p53(val135) became concentrated in the nucleus, hyperphosphorylated, and had acquired the ability to bind DNA in a sequence specific manner. This was accompanied by the induction of two p53 regulated genes, mdm2 and p21(waf1), which indicated that p53(val135) had become an active transcription factor. Two dimensional gel electrophoresis and tryptic peptide mapping showed that entry into the nucleus resulted in the appearance of new phosphorylated isoforms and that the protein had become extensively phosphorylation at the N-terminus. Notably, phosphorylation at the N-terminus occurred only in the nucleus, whereas phosphorylation at the C-terminus could occur in both the cytoplasm and the nucleus. Based on these observations, we suggest that phosphorylation of p53's N-terminus is compartmentally restricted.			Martinez, JD (corresponding author), UNIV ARIZONA,DEPT RADIAT ONCOL,TUCSON,AZ 85724, USA.				NCI NIH HHS [CA23074, CA40584, R29-CA64842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842, R01CA040584, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Boyle W J, 1991, Methods Enzymol, V201, P110; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hecker D, 1996, ONCOGENE, V12, P953; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO L, 1991, CYANOGEN BROMIDE CLE, P149; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	52	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2511	2520		10.1038/sj.onc.1201095	http://dx.doi.org/10.1038/sj.onc.1201095			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191051				2022-12-28	WOS:A1997XA94900003
J	Pan, BT; Zhang, Y; Brott, B; Chen, DH				Pan, BT; Zhang, Y; Brott, B; Chen, DH			The 96 kDa protein kinase activated by oncogenic Ras in Xenopus egg extracts is also activated by constitutively active Mek: Activation requires serine/threonine phosphorylation	ONCOGENE			English	Article						oncogenic Ras; Mek; Xenopus eggs; protein kinases and phosphatases; signal transduction; p96(h2bk)	SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; OOCYTE MATURATION; MEIOTIC MATURATION; EXTRACELLULAR SIGNALS; P34(CDC2) KINASE; CELL-CYCLE; IN-VITRO; M-PHASE; TYROSINE	In the Xenopus egg and oocyte system, oncogenic Ras protein can induce cell cycle arrest. The effect of oncogenic Ras on the cell cycle seems to be mediated by the Raf-Mek-Erk pathway of Ras signal transduction since constitutively active Raf, Mek, or Erk can mimic the effect of oncogenic Ras protein and since specific inhibition of these kinases can block the effect of oncogenic Ras. Using activated Xenopus egg extracts, we previously reported that the cell cycle arrest induced by oncogenic Ras correlates with the activation of a 96 kDa protein that phosphorylates histone h2b in vitro. This result raised the possibility that the 96 kDa kinase (designated as p96(h2bk)) is a potential target of the Raf-Mek-Erk pathway that links the pathway to the control of the cell cycle. We report here that constitutively active Mek1 could activate p96(h2bk) in the absence of oncogenic Ras. Moreover, inhibition of endogenous Mek by a specific inhibitor, PD 098059, suppressed the activation of p96(h2bk) by oncogenic Ras. These results are consistent with the concept that p96(h2bk) is a component or target of the Raf-Mek-Erk pathway. Furthermore, we have shown that activation of p96(h2bk) requires serine/threonine phosphorylation of p96(h2bk).	UNIV KENTUCKY,CHANDLER MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,CHANDLER MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Kentucky; University of Kentucky; Harvard University	Pan, BT (corresponding author), UNIV KENTUCKY,DEPT SURG,DIV NEUROSURG,CHANDLER MED CTR,800 ROSE ST,LEXINGTON,KY 40536, USA.							ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHEN CT, 1994, J BIOL CHEM, V269, P28034; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Hung W., 1994, P NATL ACAD SCI USA, V91, P8960; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, ONCOGENE, V8, P467; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1994, J BIOL CHEM, V269, P5968; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; ZHANG CF, 1994, EMBO J, V13, P1123	46	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1653	1660		10.1038/sj.onc.1201009	http://dx.doi.org/10.1038/sj.onc.1201009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135066				2022-12-28	WOS:A1997WR89300003
J	Inga, A; Iannone, R; Monti, P; Molina, F; Bolognesi, M; Abbondandolo, A; Iggo, R; Fronza, G				Inga, A; Iannone, R; Monti, P; Molina, F; Bolognesi, M; Abbondandolo, A; Iggo, R; Fronza, G			Determining mutational fingerprints at the human p53 locus with a yeast functional assay: A new tool for molecular epidemiology	ONCOGENE			English	Article						CCNU; mutation spectrum; p53; ADE2	METHYL-N-NITROSOUREA; ALKYLATING-AGENTS; ESCHERICHIA-COLI; BASE SEQUENCE; CROSS-LINKING; DNA-REPAIR; SPECIFICITY; CANCER; CELLS; GENE	In order to isolate experimentally induced p53 mutations, a yeast expression vector harbouring a human wild-type p53 cDNA was treated in vitro with the antineoplastic drug chloroethyl-cyclohexyl-nitroso-urea (CCNU) and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter, p53 mutations were identified in 32 out of 39 plasmids rescued from independent ade- transformants. Ninety-two percent of CCNU induced mutations were CC-targeted single base pair substitutions, and GC>AT transitions represented 73% of all single base pair substitutions, In 70% of the cases the mutated C was preceded 5' by a purine. The distribution of the mutations along the p53 cDNA was not random: positions 734 and 785 appeared as CCNU mutational hotspots (n=3, P<0.0003) and CCNU induced only GC>AT transitions at those positions, The features of these CCNU-induced mutations are consistent with the hypothesis that O6-alkylguanine is the major causative lesion, One third of the CCNU-induced mutants were absent from a huge collection of 4496 p53 mutations in human tumours and cell lines, thus demonstrating that CCNU has a mutational spectrum which is uniquely different from that of naturally selected mutations, This strategy allows direct comparison of observed natural mutation spectra with experimentally induced mutation spectra and opens the way to a more rigorous approach in the field of molecular epidemiology.	NATL INST CANC RES,IST,CSTA,MUTAGENESIS LAB,I-16132 GENOA,ITALY; IST,ADV BIOTECHNOL CTR,BIOSTRUCT UNIT,I-16132 GENOA,ITALY; UNIV GENOA,CHAIR GENET,GENOA,ITALY; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Swiss Institute Experimental Cancer Research			Bolognesi, Martino/B-7924-2017; Iggo, Richard/G-3546-2014; Fronza, Gilberto/AAG-8735-2019; Monti, Paola/Y-1118-2019; Inga, Alberto/AAC-3815-2022	Bolognesi, Martino/0000-0002-9253-5170; Fronza, Gilberto/0000-0003-3722-553X; Monti, Paola/0000-0002-1978-4998; Inga, Alberto/0000-0002-8767-1637; Molina, Francesco Stefano/0000-0003-0171-5297				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BRISCOE WT, 1990, BIOCHEM PHARMACOL, V40, P1201, DOI 10.1016/0006-2952(90)90384-W; BURNS PA, 1988, CANCER RES, V48, P4455; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Cariello NF, 1996, NUCLEIC ACIDS RES, V24, P119, DOI 10.1093/nar/24.1.119; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gerson Stanton L., 1993, Current Opinion in Oncology, V5, P136; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guthrie C, 1991, METHOD ENZYMOL, P194; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTLEY JA, 1986, CANCER RES, V46, P1943; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; INGA A, 1995, CANCER RES, V55, P4658; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jurado J, 1995, MOL CARCINOGEN, V14, P233, DOI 10.1002/mc.2940140403; KUNZ BA, 1989, CANCER RES, V49, P279; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARSELOS M, 1991, CARCINOGENESIS, V12, P1751, DOI 10.1093/carcin/12.10.1751; MINNICK DT, 1992, CANCER RES, V52, P4688; MORIWAKI S, 1991, CANCER RES, V51, P6219; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; POUZAND C, 1993, MUTAT RES, V288, P113; PRAKASH AS, 1992, CARCINOGENESIS, V13, P425, DOI 10.1093/carcin/13.3.425; PUSIEUX A, 1991, CANCER RES, V51, P6185; RICHARDSON KK, 1987, P NATL ACAD SCI USA, V84, P344, DOI 10.1073/pnas.84.2.344; ROLDANARJONA T, 1994, MOL CARCINOGEN, V9, P200, DOI 10.1002/mc.2940090404; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	38	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1307	1313		10.1038/sj.onc.1200952	http://dx.doi.org/10.1038/sj.onc.1200952			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178891				2022-12-28	WOS:A1997WP10900006
J	Somasundaram, K; ElDeiry, WS				Somasundaram, K; ElDeiry, WS			Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region	ONCOGENE			English	Article						E1A; p53; p21(WAF1/CIP1); transformation; checkpoint; cancer	E2F TRANSCRIPTION FACTOR; ADENOVIRUS TYPE-5 E1A; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; GENE-EXPRESSION; P53; TRANSFORMATION; APOPTOSIS; DOMAINS	Cellular transformation by the adenovirus E1A oncoprotein requires its p300/CBP- and Rb-binding domains. We mapped inhibition of p53-mediated transactivation to the p300/CBP-binding region of E1A. An E1A mutant incapable of physically interacting with Rb retained the capacity to inhibit transactivation by p53, whereas E1A mutants of the p300/CBP-interacting domain failed to inhibit p53. The inhibitory effect of the p300/CBP-binding region of E1A on p53 was demonstrated with p53-activated reporters and endogenous p53 targets such as p21(WAF1/CIP1) or MDM2. E1A lacking the capacity to interact with Rb, but capable of p300/CBP interaction, was competent in suppression of a DNA-damage activated p53-dependent cell cycle checkpoint. Exogenous CBP and p300 were able to individually relieve EIA's inhibitory effect on p53-mediated transcription. Mutants of E1A that are not capable of interacting with p300 or CBP were found to efficiently stabilize endogenous p53 but were not competent in repression of p21 expression thus dissociating these two effects of E1A. Our results suggest that the p300/CBP-binding domain of E1A inhibits a p53-dependent cellular response which normally inhibits DNA replication following Adenovirus infection.	UNIV PENN,SCH MED,DEPT MED & GENET,LAB MOL ONCOL & CELL CYCLE REGUL,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; CTR COMPREHENS CANC,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hansen R, 1995, ONCOGENE, V11, P2535; HAYLEY KP, 1984, P NATL ACAD SCI USA, V81, P5734; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LITTLE JW, 1989, NATURE, V338, P39; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MAYR GA, 1995, CANCER RES, V55, P2410; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; TEODORO JG, 1995, ONCOGENE, V11, P467; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Wu GS, 1996, CLIN CANCER RES, V2, P623; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng YX, 1996, ONCOGENE, V12, P1557	54	160	168	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1047	1057		10.1038/sj.onc.1201002	http://dx.doi.org/10.1038/sj.onc.1201002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070653				2022-12-28	WOS:A1997WM07000006
J	Trecca, D; Guerrini, L; Fracchiolla, NS; Pomati, M; Baldini, L; Maiolo, AT; Neri, A				Trecca, D; Guerrini, L; Fracchiolla, NS; Pomati, M; Baldini, L; Maiolo, AT; Neri, A			Identification of a tumor-associated mutant form of the NF-kappa B RelA gene with reduced DNA-binding and transactivating activities	ONCOGENE			English	Article						NF-kappa B; RelA; transcriptional activity; lymphoid malignancies	P65 SUBUNIT; TRANSCRIPTION FACTOR; LYMPHOID MALIGNANCIES; ANTISENSE INHIBITION; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; C-REL; ACTIVATION; EXPRESSION; PROTEINS	Alterations of NF-kappa B family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for kappa B binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Ga14-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of ReLA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-kappa B members, such as p50, cREL and I kappa B alpha. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.	UNIV MILAN,OSPED MAGGIORE,SERV EMATOL,IST SCI MED,IRCCS,LAB EMATOL SPERIMENTALE & GENET MOL,I-20122 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan			Neri, Antonino/I-9690-2014; Fracchiolla, Nicola Stefano/K-1915-2015	Neri, Antonino/0000-0001-9047-5912; Fracchiolla, Nicola Stefano/0000-0002-5356-8690; Critelli, Salvatore/0000-0001-7325-0228; Baldini, Luca/0000-0003-2964-9981; Fracchiolla, Nicola/0000-0002-8982-8079				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHANG CC, 1994, ONCOGENE, V9, P923; DELOUKAS P, 1993, HUM MOL GENET, V2, P1895, DOI 10.1093/hmg/2.11.1895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GRECO A, 1992, ONCOGENE, V7, P237; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1994, ONCOGENE, V9, P2391; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Houldsworth J, 1996, BLOOD, V87, P25; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LAI JL, 1995, BLOOD, V85, P2490, DOI 10.1182/blood.V85.9.2490.bloodjournal8592490; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; LU D, 1991, ONCOGENE, V6, P1235; MATHEW S, 1993, ONCOGENE, V8, P191; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERI A, 1993, BLOOD, V81, P128; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOKOLOSKI JA, 1993, BLOOD, V82, P625; VANDENBERGHE H, 1979, CANCER, V44, P179; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	45	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					791	799		10.1038/sj.onc.1200895	http://dx.doi.org/10.1038/sj.onc.1200895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047386				2022-12-28	WOS:A1997WJ11200005
J	Kelman, Z				Kelman, Z			PCNA: Structure, functions and interactions	ONCOGENE			English	Review						DNA replication; DNA repair; cell cycle; p53; PCNA; protein-DNA interaction	CELL-NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; REPLICATION FACTOR-C; REGULATED GADD45 PROTEIN; SACCHAROMYCES-CEREVISIAE; AUXILIARY PROTEIN; ACCESSORY PROTEINS; MOLECULAR-CLONING	Proliferating cell nuclear antigen (PCNA) plays an essential role in nucleic acid metabolism as a component of the replication and repair machinery. This toroidal-shaped protein encircles DNA and can slide bidirectionally along the duplex. One of the well-established functions for PCNA is its role as the processivity factor for DNA polymerase delta and epsilon. PCNA tethers the polymerase catalytic unit to the DNA template for rapid and processive DNA synthesis. In the last several years it has become apparent that PCNA interacts with proteins involved in cell-cycle progression which are not a part of the DNA polymerase apparatus. Some of these interactions have a direct effect on DNA synthesis while the roles of several other interactions are not fully understood. This review summarizes the structural features of PCNA and describes the diverse functions played by the protein in DNA replication and repair as well as its possible role in chromatin assembly and gene transcription. The PCNA interactions with different cellular proteins and the importance of these interactions are also discussed.			Kelman, Z (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOL BIOL & GENET, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAND SR, 1994, J IMMUNOL, V152, P4120; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BROWN WC, 1993, J BIOL CHEM, V268, P21706; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CELIS JE, 1988, CANCER CELL, V6, P289; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CRAWFORD AM, 1988, J VIROL, V62, P2773, DOI 10.1128/JVI.62.8.2773-2781.1988; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GIBBS E, 1997, IN PRESS J BIOL CHEM; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HATA S, 1992, EUR J BIOCHEM, V203, P367, DOI 10.1111/j.1432-1033.1992.tb16559.x; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JIANG HP, 1995, ONCOGENE, V10, P1855; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; KAZANTSEV A, 1995, SCIENCE, V270, P1003, DOI 10.1126/science.270.5238.1003; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1004; KELMAN Z, 1995, CURR BIOL, V5, P1239, DOI 10.1016/S0960-9822(95)00247-8; Kelman Z, 1995, NUCLEIC ACIDS RES, V23, P4938, DOI 10.1093/nar/23.23.4938; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KELMAN Z, 1995, CURR BIOL, V5, P814, DOI 10.1016/S0960-9822(95)00159-X; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KU DH, 1989, SOMAT CELL MOLEC GEN, V15, P297, DOI 10.1007/BF01534969; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LIN SJ, 1994, J PHYCOL, V30, P449, DOI 10.1111/j.0022-3646.1994.00449.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NICHOSLS AF, 1992, NUCLEIC ACIDS RES, V270, P2441; NISHIDA C, 1988, J BIOL CHEM, V263, P501; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOMURA A, 1994, J CELL SCI, V107, P3291; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OREILLY DR, 1989, NATURE, V337, P606, DOI 10.1038/337606a0; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Roos G, 1996, EXP CELL RES, V226, P208, DOI 10.1006/excr.1996.0220; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIRE EAG, 1995, ANN ONCOL, V6, P589, DOI 10.1093/oxfordjournals.annonc.a059249; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899; TAN CK, 1987, NUCLEIC ACIDS RES, V15, P9299, DOI 10.1093/nar/15.22.9299; TAN CK, 1986, J BIOL CHEM, V261, P2310; TILLMAN B, 1996, DNA REPLICATION EUKA, P435; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988	148	699	736	28	310	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					629	640		10.1038/sj.onc.1200886	http://dx.doi.org/10.1038/sj.onc.1200886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038370				2022-12-28	WOS:A1997WG43000001
J	Koreth, J; Bakkenist, CJ; McGee, JO				Koreth, J; Bakkenist, CJ; McGee, JO			Allelic deletions at chromosome 11q22-q23.1 and 11q25-qterm are frequent in sporadic breast but not colorectal cancers	ONCOGENE			English	Article						LOH; breast; colorectal; cancer; microsatellites; chromosome 11q	ATAXIA-TELANGIECTASIA; GENETIC ALTERATIONS; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; OVARIAN-CANCER; LONG ARM; HETEROZYGOSITY; TUMORS; REGION; 11Q23	We identified the chromosome 11q23 region as containing a putative tumour suppressor gene(s) frequently deleted in nonfamilial breast and other cancers. To define this region(s) further, we performed a systematic genetic analysis at chromosome 11q14-qterm in sporadic breast and colorectal cancer, Tumour and constitutional DNA from a panel of 81 cases (51 breast and 30 colorectal cancers) were analysed with multiple microsatellite markers distal to 11q13. Of 51 breast cancers, 31 of 49 informative cases (63%) showed LOH at the 11q22-q23.1 region (similar to 8 Mb). Furthermore, 23 of 45 informative cases (51%) had a deletion at 11q25 (similar to 2 Mb), Overall, LOH on 11q occurred in 37 of 51 breast cancers (72%). Colorectal cancers had LOH at 11q22 in two of 18 informative cases (11%), LOH at 11q23.3 in two of 17 informative cases (12%) and LOH at 11q25 in three of 20 informative cases (15%). Overall, LOH at 11q occurred in five of 30 colorectal cancers (16%), This data shows that chromosome 11q contains at least two independent regions (one novel) frequently deleted in breast cancers. Contrary to previous reports, LOH at distal 11q is not frequent in colorectal cancer. Chromosome 11q22-q23.1 and 11q25-qterm contain putative tumour suppressor genes with a significant role in breast but not colorectal carcinogenesis.	UNIV OXFORD, NUFFIELD DEPT PATHOL & BACTERIOL, JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Oxford								Baffa R, 1996, CANCER RES, V56, P268; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARTER SL, 1994, CANCER RES, V54, P6270; CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; Coleman A., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P196; Davis M, 1996, CANCER RES, V56, P741; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; LASKEY RA, 1990, RADIOISOTOPES BIOL P, P87; LITT M, 1995, GENOMICS, V27, P101, DOI 10.1006/geno.1995.1011; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; PARSHAD R, 1992, HUM GENET, V88, P524, DOI 10.1007/BF00219338; RASIO D, 1995, CANCER RES, V55, P3988; SATO T, 1990, CANCER RES, V50, P7184; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; STICKLAND JE, 1992, BR J CANCER S17, V66, P3; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Tomlinson IPM, 1996, J CLIN PATHOL, V49, P386, DOI 10.1136/jcp.49.5.386; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; WINQVIST R, 1995, CANCER RES, V55, P2660	36	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					431	437		10.1038/sj.onc.1200847	http://dx.doi.org/10.1038/sj.onc.1200847			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053840				2022-12-28	WOS:A1997WE36400006
J	Iotsova, V; Crepieux, P; Montpellier, C; Laudet, V; Stehelin, D				Iotsova, V; Crepieux, P; Montpellier, C; Laudet, V; Stehelin, D			TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53	ONCOGENE			English	Article						p53; Ets; promoter; repression	TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; REGULATORY ELEMENTS; DNA; EXPRESSION; SEQUENCE; GROWTH; INITIATOR; INVITRO; DOMAIN	p53 has been reported to repress a number of TATA-containing promoters in transient transfection assays, TATA-less promoters are generally believed to be refractive to p53 repression. We report here that the TATA-less promoters of Ets-family genes (Ets-1 and Ets-2) are efficiently repressed by wild-type but not mutant p53 in transient co-transfection assays, Moreover, p53 was immunologically detected in protein complexes formed on oligonucleotides from both the TATA-containing and TATA-less promoters, Our data suggest that p53 is involved in the regulation of the expression of both promoter types, most probably by protein-protein interaction, A model for p53 function in promoter repression is proposed.	INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59018 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Crepieux, Pascale/X-3217-2019	MONTPELLIER, Claire/0000-0002-3112-8491				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P913; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CHEN JH, 1993, ONCOGENE, V8, P133; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Crepieux Pascale, 1993, Gene Expression, V3, P215; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAISST S, 1994, VIROLOGY, V202, P466, DOI 10.1006/viro.1994.1363; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETH A, 1990, ONCOGENE, V5, P1761; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2335	49	20	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2331	2337						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957074				2022-12-28	WOS:A1996VX10800005
J	Li, J; Hu, SX; Perng, GS; Zhou, YL; Xu, K; Zhang, CY; Seigne, J; Benedict, WF; Xu, HJ				Li, J; Hu, SX; Perng, GS; Zhou, YL; Xu, K; Zhang, CY; Seigne, J; Benedict, WF; Xu, HJ			Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro	ONCOGENE			English	Article						tumor suppressor gene; retinoblastoma (RB) gene; p53; tumor invasion; inducible gene expression	QUANTITATIVE ASSAY; BASEMENT-MEMBRANE; PROTEIN; CARCINOMA; MATRIX; TRANSCRIPTION; ASSOCIATION; ACTIVATION; GROWTH; CYCLE	To determine if replacement of the retinoblastoma (RE) tumor suppressor gene could inhibit invasion of RB-defective tumor cells, the capacity of tumor cells to migrate or invade was quantitated by the Boyden chamber assay, The studies were done in a diverse group of stable RE-reconstituted human tumor cell lines, including those derived from the osteosarcoma and carcinomas of the lung, breast and bladder, The expression of the exogenous wildtype RE protein in these tumor cell lines was driven by either a constitutively active promoter or an inducible promoter, It was found that significantly more tumor cells from the parental RE-defective cell lines and the RB(-) revertants than from the RE-reconstituted RB(+) cell lines penetrated through the Matrigel (P < 0.001, two-tailed t-test), although both RB(+) and RB(-) cells migrated at approximately the same rate on uncoated polycarbonate filters in the Boyden chambers, Of note, the inhibition of invasiveness of various RE-defective tumor cells by RE replacement was apparently web correlated with suppression of their tumorigenicity in vivo. In contrast, although either functional RE or p53 re-expression effectively suppressed tumor formation in nude mice of the RB(-)/p53(nuII) osteosarcoma cell line, Saos-2, replacement of the wild-type p53 gene had much less impact on their invasiveness as compared to the RE gene, These studies provided an insight into the broader biological basis of the RE-mediated tumor suppression in RE-defective tumor cells.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL ONCOL,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,THE WOODLANDS,TX 77381; BAYLOR COLL MED,CTR BIOTECHNOL,THE WOODLANDS,TX 77381	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine				Zhou, Yunli/0000-0003-4831-209X	NATIONAL CANCER INSTITUTE [R01CA067274] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67274] Funding Source: Medline; NEI NIH HHS [EY-06195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Dawson D. W., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P88; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; Geng Y, 1996, ONCOGENE, V12, P1173; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P3; HART IR, 1978, CANCER RES, V38, P3218; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KARIKO K, 1993, CANCER RES, V53, P3109; KLEIN G, 1990, BIOESSAYS, V12, P347, DOI 10.1002/bies.950120708; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, CANCER LETT, V11, P141, DOI 10.1016/0304-3835(80)90105-6; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; NEVINS JR, 1992, SCIENCE, V258, P424; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STARKEY JR, 1984, CANCER RES, V44, P1585; TERANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465; XU HJ, 1991, ONCOGENE, V6, P1139; Xu HJ, 1996, CANCER RES, V56, P2245; XU HJ, 1995, ADV ANAT PATHOL, V2, P213; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	30	39	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2379	2386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957079				2022-12-28	WOS:A1996VX10800010
J	Kamada, S; Washida, M; Hasegawa, J; Kusano, H; Funahashi, Y; Tsujimoto, Y				Kamada, S; Washida, M; Hasegawa, J; Kusano, H; Funahashi, Y; Tsujimoto, Y			Involvement of caspase-4(-like) protease in Fas-mediated apoptotic pathway	ONCOGENE			English	Article						apoptosis; cysteine protease; Fas(APO-1/CD95); caspase-4(TX/ICH-2/ICErelII)	INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYSTEINE PROTEASES; CELL-DEATH; FAMILY; CED-3	Proteases of the caspase family, especially caspase-1 (ICE)(-like), caspase-3 (CPP32/Yama/apopain)(-like) and caspase-8 (MACH/FLICE/Mch5) proteases, are implicated in Pas (APO-1/CD95)-mediated apoptosis. Here, we show that the caspase-4 (TX/ICH-2/ICErelII)(-like) protease, another member of the caspase family, is also involved in Pas-mediated apoptosis, based upon the observations: (i) caspase-4 is processed in response to an agonistic anti-Pas antibody treatment, (ii) overexpression of a mutant caspase-4 with active site mutations in both p20 and p10 subunits delays Pas-mediated apoptosis, (iii) microinjected anti-caspase-4 antibodies inhibit Fas-mediated apoptosis. Together with our observations that the mutant caspase-4 inhibits the Pas-mediated activation of caspase-3(-like) proteases and purified caspase-4 cleaves pro-caspase-3 to generate a subunit of active form, these results suggest that Pas-mediated apoptosis is driven by a caspase cascade in which the caspase-4(like) protease transmits a death signal from caspase-8 to caspase-3(-like) proteases probably through directly cleaving pro-caspase-3(-like) proteases.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN	Osaka University								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BEIDLER DR, 1995, J BIOL CHEM, V270, P16527; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Hasegawa J, 1996, CANCER RES, V56, P1713; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMADA S, 1995, CANCER RES, V55, P354; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2251; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	91	94	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					285	290		10.1038/sj.onc.1201192	http://dx.doi.org/10.1038/sj.onc.1201192			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233763				2022-12-28	WOS:A1997XK99900005
J	Wei, MX; deTurenneTessier, M; Decaussin, G; Benet, G; Ooka, T				Wei, MX; deTurenneTessier, M; Decaussin, G; Benet, G; Ooka, T			Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus	ONCOGENE			English	Article						EBV; BARF1; immortalization; epithelial cells	LYMPHOCYTE GROWTH TRANSFORMATION; NASOPHARYNGEAL CARCINOMA; GENE-EXPRESSION; DNA; TRANSCRIPTION; PROTEINS	We previously reported that the BARF1 (BamH1-A right frame 1) gene product from Epstein-Barr Virus (EBV) may have oncogenic properties since injection into new-born rats of transfected cell lines resulted in the development of BARF1 expressing tumors, which were agressive in the case of murine fibroblasts and transient in that of human B lymphocytes. As EBV has been associated with nasopharyngeal carcinoma (NPC) and evidence of BARF1 transcription in this cancer was emerging from our biopsy analyses, we examined the effects of BARF1 transfection into primate primary epithelial cells. The expression of the BARF1 open reading frame in primary monkey kidney epithelial cells led us to the establishment of continuously dividing lines. The BARF1 transfectants showed the major characteristics of immortalized cells: morphological change, short cell doubling time, ability to divide at low cell density and continuous growth over 50 passages. Injection of BARF1 transfectants into nude mice did not induce any tumor. Established subclones were shown to be epithelial cells expressing known keratins as well as the BARF1 coded mRNA and protein. This is the first report indicating that expression of the BARF1 gene product in primary epithelial cells may contribute to the establishment of cell lines.	FAC MED R LAENNEC,UMR 5537 CNRS,MOL VIROL LAB,IVMC,F-69372 LYON 08,FRANCE; RHONE MERIEUX,F-69007 LYON,FRANCE									BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BOUZID M, 1994, INT J CANCER, V56, P468, DOI 10.1002/ijc.2910560403; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NIEDOBITEK G, 1992, VIRCHOWS ARCH B, V62, P55, DOI 10.1007/BF02899665; OOKA T, 1977, EXP CELL RES, V104, P319, DOI 10.1016/0014-4827(77)90097-0; SbihLammali F, 1996, J MED VIROL, V49, P7, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt;7::AID-JMV2&gt;3.0.CO;2-A; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TOOZE J, 1981, MOL BIOL TUMOUR VIRU; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; WEI MX, 1994, CANCER RES, V54, P1843; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988	32	64	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3073	3081		10.1038/sj.onc.1201128	http://dx.doi.org/10.1038/sj.onc.1201128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223671				2022-12-28	WOS:A1997XG10000010
J	Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA				Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA			Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression	ONCOGENE			English	Article						cyclin D1; p21; E2F; cell cycle; transcription; tetracycline	HUMAN BREAST-CARCINOMA; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; DEPENDENT KINASES; MAMMALIAN-CELLS; GROWTH ARREST; IN-VIVO; G(1); E2F	Cyclin D1 plays a key regulatory role during the G(1) phase of the cell cycle and its gene is amplified and overexpressed in many cancers. To address the relationship between cyclin D1 and other cell cycle regulatory proteins, we established human glioma and rodent fibroblast cell lines in which cyclin D1 expression could be regulated ectopically with tetracycline. In both of these cell lines, we found that ectopic expression of cyclin D1 in asynchronously growing cells was accompanied by increased levels of the p53 tumor suppressor protein and the cyclin/cdk inhibitor p21. Despite the induction of these cell cycle inhibitory proteins, cyclin D1-associated cdk kinase remained activated and the cells grew essentially like that of the parent cells. Although growth parameters were unchanged in these cells, morphological changes were clearly identifiable and anchorage independent growth was observed in NIH3T3 cells. In a first step toward elaborating the mechanism for cyclin D1-mediated induction of p21 gene expression we show that co-expression of E2F-1 and DP-1 can specifically transactivate the p21 promoter. In support of these findings and a direct effect of E2F on induction of p21 gene expression a putative E2F binding site was identified within the p21 promoter. In summary, our results demonstrate that ectopic expression of cyclin D1 can induce gene expression of the cdk inhibitor p21 through an E2F mechanism the consequences of which are not to growth arrest tells but possibly to stabilize cyclin D1/cdk function.	MASSACHUSETTS GEN HOSP,CTR NEUROSCI,NEUROSURG SERV,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center								ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bennett JD, 1996, ONCOGENE, V13, P1073; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fueyo J, 1996, ONCOGENE, V12, P103; GomezManzano C, 1996, CANCER RES, V56, P694; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HE J, 1994, CANCER RES, V54, P5804; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JUNG JM, 1995, ONCOGENE, V11, P2021; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAMMIE GA, 1991, ONCOGENE, V6, P439; Liu Y, 1996, CANCER RES, V56, P31; LOVEC H, 1994, ONCOGENE, V9, P323; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marchetti A, 1996, ONCOGENE, V12, P1319; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michieli P, 1996, ONCOGENE, V12, P775; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHUURING E, 1992, ONCOGENE, V7, P355; Sgambato A, 1996, CANCER RES, V56, P1389; SHAO ZH, 1995, ONCOGENE, V10, P221; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	69	88	89	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2533	2542		10.1038/sj.onc.1201080	http://dx.doi.org/10.1038/sj.onc.1201080			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191053				2022-12-28	WOS:A1997XA94900005
J	Sen, S; Zhou, HY; White, RA				Sen, S; Zhou, HY; White, RA			A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines	ONCOGENE			English	Article						breast cancer; gene amplification; protein kinase	COMPARATIVE GENOMIC HYBRIDIZATION; DIRECT SELECTION; SEQUENCES; REGIONS; YEAST	DNA amplification on chromosome 20q13 is commonly detected in breast cancer and correlates with prognosis. Definitive critical target genes on amplicon have however, not yet been identified. We describe in this paper isolation of a novel gene named BTAK, encoding a putative member of protein serine/threonine kinase family localized on chromosome 20q13 that is amplified and overexpressed in breast tumor cell lines. BTAK maps close to the critical region of amplification defined earlier on this amplicon. Deduced amino acid sequence shows conservation of all the subdomains predicted in protein kinase super family. Translated BTAK peptide shows significant homology with previously cloned protein serine/threonine kinase encoding genes Ip11 from S cerevisae and aurora from Drosophila, both shown to be functionally involved in normal chromosome segregation process. Our findings suggest that amplification and overexpression of BTAK may be playing a critical role in oncogenic transformation of breast tumor cells.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Sen, S (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,SECT EXPT LAB MED,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRINKMAN V, 1996, GENOME RES, V6, P187; CHAN CSM, 1993, GENETICS, V135, P677; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Guan XY, 1996, CANCER RES, V56, P3446; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAY R, 1992, CELL LINES HYBRIDOMA; ISOLA JJ, 1995, AM J PATHOL, V147, P905; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LOVETT M, 1994, CURRENT PROTOCOLS HU; MITELMAN F, 1991, CATALOG CHROMOSOME A; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; OSBORNELAWRENCE S, 1995, GENOMICS, V25, P248, DOI 10.1016/0888-7543(95)80132-6; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Sambrook J., 1989, MOL CLONING; SEN S, 1994, GENOMICS, V19, P542, DOI 10.1006/geno.1994.1104; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372	25	410	443	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2195	2200		10.1038/sj.onc.1201065	http://dx.doi.org/10.1038/sj.onc.1201065			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174055				2022-12-28	WOS:A1997WX93800008
J	Abdollahi, A; Roberts, D; Godwin, AK; Schultz, DC; Sonoda, G; Testa, JR; Hamilton, TC				Abdollahi, A; Roberts, D; Godwin, AK; Schultz, DC; Sonoda, G; Testa, JR; Hamilton, TC			Identification of a zinc-finger gene at 6q25: A chromosomal region implicated in development of many solid tumors	ONCOGENE			English	Article						cancer; ovary; transcription factor; zinc-finger	EPITHELIAL OVARIAN-CANCER; POLYMERASE CHAIN-REACTION; EUROPEAN CASE-CONTROL; SINGLE-STEP METHOD; SPONTANEOUS TRANSFORMATION; DIFFERENTIAL DISPLAY; POOLED ANALYSIS; MESSENGER-RNAS; CELLS; CARCINOMAS	We have used a rat model of epithelial ovarian cancer to identify a gene that shows decreased or lost expression in independently transformed rat ovarian surface epithelial cell lines compared to the normal progenitor cells, Hence, we refer to this gene as Lot-1 (Lost on transformation 1, GenBank accession no, U72620). Here, we report the cloning of the likely human homologue and its initial characterization. The deduced amino acid sequences of the cDNAs for rat and human LOT-1 (GenBank accession no. U72621) contain seven zinc finger motifs of the C2H2 type as well as proline and glutamine rich areas. The genes share 76.4% identity at the nucleotide level, 67.7% at the amino acid level and 85.5% within the seven zinc finger motifs. LOT-1 is ubiquitously expressed in normal human tissues but was not expressed in four of 11 (36%) human ovarian cancer cell lines or spontaneously transformed human ovarian surface epithelial cells, The human gene maps to chromosome 6 at band q25. We show that there is a 38% incidence of allelic loss at this chromosomal location in human ovarian cancers, This chromosomal region has also been implicated in the genesis of breast, kidney, and pleural mesothelial cancers, We suggest that this newly identified gene is not only of intrinsic interest as a ubiquitously expressed probable transcription factor but is a plausible candidate for the tumor suppressor gene which likely resides in the region of chromosome 6 defined by band q25.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; LEHIGH UNIV, DEPT CHEM, BETHLEHEM, PA 18015 USA	Fox Chase Cancer Center; Lehigh University					NATIONAL CANCER INSTITUTE [R01CA056916] Funding Source: NIH RePORTER; NCI NIH HHS [CA56916] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1997, UNPUB CANC RES; Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; AUERSPERG N, 1995, AM J OBSTET GYNECOL, V173, P558, DOI 10.1016/0002-9378(95)90282-1; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BELLACOSA A, 1993, ONCOGENE, V8, P745; CAPUT D, 1986, P NATL ACAD SCI USA, V77, P4170; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLIBY W, 1993, CANCER RES, V53, P2393; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; FATHALLA MF, 1971, LANCET, V2, P163; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GODWIN A, 1996, ENDOCRINOLOGY, P107; GODWIN A, 1996, GYNEDOLOGICAL ONCOLO, P107; GODWIN AK, 1995, ENDOCRINOLOGY, V136, P4640, DOI 10.1210/en.136.10.4640; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hamilton T. C., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P623; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; JOHNSON SW, 1994, CANCER RES, V54, P5911; Johnson SW, 1996, ANAL BIOCHEM, V236, P348, DOI 10.1006/abio.1996.0178; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LICHTER P, 1992, GENOMICS, V13, P999, DOI 10.1016/0888-7543(92)90013-I; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOK S, 1996, J SOC GYNECOL INVEST, V3, pA375; NEGRI E, 1991, INT J CANCER, V49, P50, DOI 10.1002/ijc.2910490110; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; Ozols R. F., 1992, GYNECOL ONCOL, P731; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Saito S, 1996, CANCER RES, V56, P5586; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; SATO T, 1991, CANCER RES, V51, P5118; Schultz DC, 1996, CANCER RES, V56, P1997; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TAGUCHI T, 1993, CANCER RES, V53, P4349; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; TESTA JR, 1994, CANCER RES, V54, P2778; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; Theile M, 1996, ONCOGENE, V13, P677; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Tibiletti MG, 1996, CANCER RES, V56, P4493; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WAN MH, 1994, INT J ONCOL, V5, P1043; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; ZHENG JP, 1991, CANCER RES, V51, P4045	58	92	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1973	1979		10.1038/sj.onc.1201034	http://dx.doi.org/10.1038/sj.onc.1201034			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150364				2022-12-28	WOS:A1997WV80400010
J	Adachi, M; Ishino, M; Torigoe, T; Minami, Y; Matozaki, T; Miyazaki, T; Taniguchi, T; Hinoda, Y; Imai, K				Adachi, M; Ishino, M; Torigoe, T; Minami, Y; Matozaki, T; Miyazaki, T; Taniguchi, T; Hinoda, Y; Imai, K			Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor beta chain	ONCOGENE			English	Article						SHP-2; IL-2; tyrosine phosphorylation; signal transduction	GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; CYTOLYTIC EFFECTOR FUNCTION; C-MYC; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; GAMMA-CHAIN; T-CELL; PROTEIN	Coupling of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) induces rapid increase in tyrosine phosphorylation of cellular substrates through activation of non-receptor protein tyrosine kinases, Here, we report that stimulation through the IL-2R induced tyrosine phosphorylation of the SH2-containing protein-tyrosine phosphatase SHP-2 in F7, a hematopoietic BAF-B03 transfectant clone expressing the IL-2R beta chain. The tyrosine phosphorylation of SHP-2 was specific since another protein-tyrosine phosphatase SHP-1, which is structurally homologous to SHP-2, was not tyrosine phosphorylated, The IL-2-induced tyrosine phosphorylation of SHP-2 required the acidic region within the IL-2R beta chain where Src-family PTKs interact. Though the serine-rich region within IL-2R beta chain was also required for the phosphorylation of SHP-2, Jak3 activation was dispensable, In COS-7 cells, co-expression of SHP-2 with Lyn resulted in increased tyrosine phosphorylation levels of SHP-2, whereas coexpression of SHP-2 with Fyn failed to alter the levels significantly. Considering that Lyn and Fyn are major Src-family PTKs expressed in BAF-B03 cells, our data suggest that Lyn may be principally responsible for the tyrosine phosphorylation of SHP-2 in F7 cells. Furthermore, the IL-2 stimulation also induced tyrosine phosphorylation of SHP-2 in the human IL-2-dependent T-cell line ILT-Mat. Taken together, these studies demonstrate an involvement of SHP-2 in the IL-2-mediated signaling events through the activation of specific PTKs.	HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,CANC RES INST,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PATHOL,SAPPORO,HOKKAIDO 060,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM 1,CHUO KU,KOBE 650,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Hokkaido University; Hokkaido University; Kobe University; Kobe University; University of Tokyo	Adachi, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,HOKKAIDO 060,JAPAN.		Miyazaki, Tadaaki/D-9368-2012					ADACHI M, 1995, FEBS LETT, V372, P113, DOI 10.1016/0014-5793(95)00952-6; Adachi M, 1996, CELL, V85, P15; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CASE RD, 1994, J BIOL CHEM, V269, P10467; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; Ishino M, 1995, ONCOGENE, V11, P2331; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PENG ZY, 1995, ONCOGENE, V11, P1955; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TORIGOE T, 1994, J EXP MED, V180, P1115, DOI 10.1084/jem.180.3.1115; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	36	37	37	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1629	1633		10.1038/sj.onc.1200981	http://dx.doi.org/10.1038/sj.onc.1200981			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129156				2022-12-28	WOS:A1997WQ54800016
J	Voitenleitner, C; Fanning, E; Nasheuer, HP				Voitenleitner, C; Fanning, E; Nasheuer, HP			Phosphorylation of DNA polymerase alpha-primase by cyclin A-dependent kinases regulates initiation of DNA replication in vitro	ONCOGENE			English	Article						DNA replication; cyclins; cyclin-dependent kinases; DNA polymerase alpha primase	P34CDC2 PROTEIN-KINASE; SV40 ORIGIN DNA; CELL-CYCLE; IN-VITRO; INVITRO; ANTIGEN; SUBUNIT	DNA polymerase alpha-primase is the only known eukaryotic enzyme that can start DNA replication de novo. In this study, we investigated the regulation of DNA replication by phosphorylation of DNA polymerase alpha-primase. The p180 and the p68 submits of DNA polymerase alpha-primase were phosphorylated using Cyclin A-, B- and E- dependent kinases. This phosphorylation did not influence its DNA polymerase activity on activated DNA, but slightly stimulated primase activity using poly(dT) single-stranded DNA (ssDNA) without changing the product length of primers. In contrast, site-specific initiation of replication on plasmid DNA containing the SV40 origin is affected: Cyclin A-Cdk2 and Cyclin A-Cdc2 inhibited initiation of SV40 DNA replication in vitro, Cyclin B-Cdc2 had no effect and Cyclin E-Cdk2 stimulated the initation reaction. DNA polymerase alpha-primase that was pre-phosphorylated by Cyclin A-Cdk2 was completely unable to initiate the SV40 DNA replication in vitro; Cyclin B-Cdc2-phosphorylated enzyme was moderately inhibited, while Cyclin E-Cdk2-treated DNA polymerase alpha-primase remained fully active in the initiation reaction.	UNIV MUNICH, INST BIOCHEM, D-81375 MUNICH, GERMANY; VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; INST MOL BIOTECHNOL, BIOCHEM ABT, D-07745 JENA, GERMANY	University of Munich; Vanderbilt University			Nasheuer, Heinz P./B-9025-2008	Nasheuer, Heinz Peter/0000-0002-9218-9079				BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; Ferrari M, 1996, J BIOL CHEM, V271, P8661, DOI 10.1074/jbc.271.15.8661; FOIANI M, 1995, MOL CELL BIOL, V15, P883; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PODUST V, 1990, EUR J BIOCHEM, V193, P189, DOI 10.1111/j.1432-1033.1990.tb19322.x; PRUSSAK CE, 1989, BIOCHEM BIOPH RES CO, V159, P1397, DOI 10.1016/0006-291X(89)92265-1; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	30	60	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1611	1615		10.1038/sj.onc.1200975	http://dx.doi.org/10.1038/sj.onc.1200975			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129153				2022-12-28	WOS:A1997WQ54800013
J	Lallemand, D; Spyrou, G; Yaniv, M; Pfarr, CM				Lallemand, D; Spyrou, G; Yaniv, M; Pfarr, CM			Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts	ONCOGENE			English	Article						Jun; Fos; AP-1; NIH3T3; cell cycle	TRANSCRIPTION FACTOR AP-1; PROGRAMMED CELL-DEATH; LACKING C-FOS; DNA-BINDING; MOUSE FIBROBLASTS; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; G0-TO-G1 TRANSITION; EMBRYO FIBROBLASTS; NEGATIVE REGULATOR	We have analysed the different Jun and Fos proteins as NIH3T3 fibroblasts pass from exponential growth to quiescence and during the first 24 h after their re-entry into the cell cycle following serum stimulation, We show that these proteins can be divided into 3 subgroups based on their pattern of expression. The first contains c-Jun, Jun-D and Fra-2 which are expressed at high level in cycling cells and are only mildly induced by serum. The second contains Jun-B, c-Fos, Fos-B and Delta Fos-B whose levels are low in cycling cells but increase strongly and rapidly after stimulation by serum. The third group contains only Fra-1, which is absent from cycling cells and behaves as a delayed early response protein after serum stimulation, AP-I binding activity is low both in cycling and quiescent fibroblasts but increases after stimulation by serum with kinetics matching the induction of the various Jun and Fos proteins. Antibody supershift analyses demonstrate that the composition of AP-I binding activity reflects the relative abundance of each Jun and Fos protein. Furthermore, the state of post-translational modification varies continuously for all of the AP-1 proteins as growth conditions change. These data indicate that AP-1 activity during the G(0)-G(1) transition is finely regulated and complex, involving changes both in protein expression and in posttranslational modification.	INST PASTEUR, UNITE VIRUS ONCOGENES, UA 1149 CNRS, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE; KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Karolinska Institutet			Pfarr, Curt/HHD-1410-2022; lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CARILLO S, 1996, BIOCHEM J, V270, P623; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHATTON B, 1994, ONCOGENE, V9, P375; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HERBER, 1994, ONCOGENE, V9, P2105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	73	132	133	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					819	830		10.1038/sj.onc.1200901	http://dx.doi.org/10.1038/sj.onc.1200901			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047389				2022-12-28	WOS:A1997WJ11200008
J	Savelieva, E; Belair, CD; Newton, MA; DeVries, S; Gray, JW; Waldman, F; Reznikoff, CA				Savelieva, E; Belair, CD; Newton, MA; DeVries, S; Gray, JW; Waldman, F; Reznikoff, CA			20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells	ONCOGENE			English	Article						HPV16 E7; human uroepithelial cells; immortalization; 20q amplification; genome instability	RETINOBLASTOMA GENE-PRODUCT; BREAST CARCINOMAS; BLADDER-CANCER; DNA-SEQUENCES; SOLID TUMORS; COPY NUMBER; HPV16 E7; HYBRIDIZATION; KINASE; LOSSES	Breast, bladder, colon, and ovarian carcinomas show frequent low level 20q gain and less frequently high level 20q13.2 amplification, but the significance of these 20q amplifications in transformation has not been defined, Using karyotypic and comparative genomic hybridization (CGH) analyses, chromosome losses and gains were analysed in six newly immortalized human uroepithelial cell (HUC) lines transformed by Human Papillomavirus 16 (HPV16) E7. Results showed clonal chromosomes with 20q11->qter gain in all six lines. CGH revealed a peak of 20q13.2 amplification in two cell lines. FISH with whole chromosome 20 paint showed expanded chromosome regions (ECRs) and double minute chromosomes (DMs) that contained chromosome 20 material in cell lines with 20q13.2 amplification. FISH with probes from the center of the 20q13.2 human breast cancer amplicon showed as many as 24 signals in cells with 20q13.2 amplification. The acquisition of genome instability in these E7-HUCs did not correlate with TP53 mutation, as all E7-HUCs contained only wildtype TP53. These results suggest that low level 20q gain is associated with overcoming cellular senescence in E7 transformed cells (P-value=2x10(-7)), but does not confer genome instability, while high level 20q13.2 amplification is associated with chromosome instability. Loss of 10p (P-value=3x10(-5) was also important in immortalization of E7-transformed HUCs. Thus, these results have profound implications for interpreting the significance of high versus low level 20q gains in human cancers.	UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,CTR ENVIRONM TOXICOL,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,COMPREHENS CLIN CANC CTR,MADISON,WI 53792; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC GENET LAB,SAN FRANCISCO,CA 94143; DIV MOL CYTOMETRY,SAN FRANCISCO,CA 94143	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA029525] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA29525-16, R01 CA7158-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELAIR CD, 1996, RADIAT ONCOL INVEST, V3, P368; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EYFJORD JE, 1995, CANCER RES, V55, P646; GRAY JW, 1992, CANCER, V69, P1536, DOI 10.1002/1097-0142(19920315)69:6+<1536::AID-CNCR2820691306>3.0.CO;2-J; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Holt SE, 1996, MOL CELL BIOL, V16, P2932; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; Reznikoff CA, 1996, CANCER RES, V56, P2886; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Scherf U, 1996, P NATL ACAD SCI USA, V93, P2670, DOI 10.1073/pnas.93.7.2670; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHLEGEL J, 1995, CANCER RES, V55, P6002; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; TOMMASINO M, 1993, ONCOGENE, V8, P195; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YEAGER T, 1995, CANCER RES, V55, P493; YUNIS JJ, 1982, GENE AMPLIFICATION, P297	36	120	130	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					551	560		10.1038/sj.onc.1200868	http://dx.doi.org/10.1038/sj.onc.1200868			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053853				2022-12-28	WOS:A1997WF52400006
J	Poirel, H; Oury, C; Carron, C; Duprez, E; Laabi, Y; Tsapis, A; Romana, SP; Mauchauffe, M; LeConiat, M; Berger, R; Ghysdael, J; Bernard, OA				Poirel, H; Oury, C; Carron, C; Duprez, E; Laabi, Y; Tsapis, A; Romana, SP; Mauchauffe, M; LeConiat, M; Berger, R; Ghysdael, J; Bernard, OA			The TEL gene products: Nuclear phosphoproteins with DNA binding properties	ONCOGENE			English	Article						TEL; ETS; translocation; transcription factor; leukemia; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTIONAL ACTIVATION; ETS-FAMILY; CHROMOSOMAL TRANSLOCATION; C-ETS-1 PROTOONCOGENE; EWS GENE; FUSION; DOMAIN; CHILDHOOD	The human TEL gene is involved in several 12p13 chromosomal abnormalities present in various human hematological malignancies, the most frequent being the t(12;21)(p13;q22), specific for childhood acute lymphoblastic leukemia, The predicted product of TEL harbours an amino acid region similar to the ETS DNA binding domain. We now report the isolation of the murine TEL cDNA and the characterization of the human TEL proteins. Human and murine TEL proteins are particularly homologous within their aminoterminal regions and their ETS domains. TEL proteins are nuclear and display specific DNA binding activity toward classical ETS binding sites. In addition, we show that TEL mRNAs initiate translation at either of the two first in-frame ATGs (codon 1 and 43) to encode 50 kDa and 57 kDa TEL proteins. In vivo, each of these primary translational products is modified by multiple phosphorylation events.	INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE; INST GENET MOL,SD 401 301 CNRS,F-75010 PARIS,FRANCE; CTR UNIV ORSAY,INST CURIE,SECT RECH,F-91405 ORSAY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			duprez, estelle a/R-2357-2016; Carron, Clémence/AAG-6304-2021; GHYSDAEL, Jacques/F-3377-2013; Bernard, Olivier A./E-5721-2016	Carron, Clemence/0000-0002-8776-7380; Oury, Cecile/0000-0002-7561-0132; Bernard, Olivier/0000-0002-0463-9747; Romana, Serge Pierrick/0000-0003-3435-239X				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BERNARD OA, 1996, IN PRESS LEUKEMIA LY; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GHYSDAEL J, 1995, PATHOL BIOL, V43, P202; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCLEAN TW, 1996, IN PRESS BLOOD; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; SETH A, 1990, ONCOGENE, V5, P1761; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; VENAUT AM, 1981, CANC GENET CYTOGENET, V3, P327; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	45	94	95	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					349	357		10.1038/sj.onc.1200829	http://dx.doi.org/10.1038/sj.onc.1200829			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018121				2022-12-28	WOS:A1997WD51600011
J	Joy, A; Moffett, J; Neary, K; Mordechai, E; Stachowiak, EK; Coons, S; RankinShapiro, J; Florkiewicz, RZ; Stachowiak, MK				Joy, A; Moffett, J; Neary, K; Mordechai, E; Stachowiak, EK; Coons, S; RankinShapiro, J; Florkiewicz, RZ; Stachowiak, MK			Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells	ONCOGENE			English	Article						growth factor; nuclear localization; astrocytes; glioma; cell proliferation	FIBROBLAST GROWTH-FACTOR; MOLECULAR-WEIGHT FORMS; MESSENGER-RNA LEVELS; HUMAN-BRAIN TUMORS; GENE-EXPRESSION; FACTOR RECEPTOR; FACTOR BFGF; IMMUNOHISTOCHEMICAL LOCALIZATION; PROGENITOR CELLS; BASIC FGF	FGF-2 has been implicated in the neoplastic transformation of glioma cells and in the transition of normal quiescent astrocytes to a proliferating, reactive state. In the present study we have observed that in human glial cells, levels and subcellular localization of FGF-2 are different in quiescent and proliferating cells. FGF-2 was detected in the cytoplasm of non-reactive astrocytes in human brain sections. In contrast FGF-2 was located within the cytoplasm and nuclei of reactive astrocytes in gliotic brain tissue and in neoplastic cells of glioma tumors. In vitro, FGF-2 was found predominantly in the nucleus of subconfluent proliferating astrocytes, but was detected only in the cytoplasm of density arrested quiescent astrocytes. Our results suggest that reduced cell contact stimulates nuclear accumulation of FGF-2, accompanying mitotic activation of reactive human astrocytes. FGF-2 was constitutively localized to the nucleus of continuously proliferating glioma cells independent of cell density. A role for intracellular FGF-2 was further suggested by the observation that glioma cells that are not stimulated to proliferate by extracellular FGF-2 proliferated faster when transfected with FGF-2 expressing vectors. This increased proliferation correlated with nuclear accumulation of FGF-2. Cell proliferation was attenuated by 5'-deoxy-5'-methylthioadenosine, a FGF-2 receptor tyrosine kinase inhibitor that acts within the cell, but was unaffected by myo-inositol hexakis [dihydrogen phosphate] that disrupts FGF-2 binding to plasma membrane receptors. Our results indicate that FGF-2 serves as a nuclear regulator of proliferation in astrocytic cells. In glioma cells, the constitutive presence of FGF-2 in the nucleus may promote proliferation that is insensitive to cell contact inhibition.	BARROW NEUROL INST, PHOENIX, AZ 85013 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Barrow Neurological Institute; Scripps Research Institute					NHLBI NIH HHS [HL49376-01A1] Funding Source: Medline; NIDDK NIH HHS [DK-18811] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; ASCH AS, 1986, P NATL ACAD SCI USA, V83, P2904, DOI 10.1073/pnas.83.9.2904; BERENS M E, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P46; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BINGER DD, 1981, J NEUROPATHOL EXP NE, V40, P201; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOYLE WT, 1985, MOL CELL BIOL, V11, P3017; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; BRIDSTOCK DR, 1991, GROWTH FACTORS, V4, P189; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COURDEC B, 1991, CELL REGUL, V2, P709; ENG LF, 1992, PROG BRAIN RES, V94, P353; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; Latham KE, 1996, ONCOGENE, V12, P827; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; MAHER PA, 1993, J BIOL CHEM, V268, P4244; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MOFFETT J, 1994, J INT DEV NEUROSC S1, V12, P77; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MORRISON RS, 1994, IN VITRO CELL DEV-AN, V30A, P783; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; RAY J, 1995, J NEUROCHEM, V64, P503; ROSENBLUM ML, 1978, CANCER, V41, P2305, DOI 10.1002/1097-0142(197806)41:6<2305::AID-CNCR2820410632>3.0.CO;2-U; SCHECHTER JE, 1992, TISSUE CELL, V24, P791, DOI 10.1016/0040-8166(92)90015-Y; SHERMAN L, 1993, DEVELOPMENT, V118, P131; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WOODWARD WR, 1992, J NEUROSCI, V12, P142; ZAGZAG D, 1990, CANCER RES, V50, P7393	57	126	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					171	183		10.1038/sj.onc.1200823	http://dx.doi.org/10.1038/sj.onc.1200823			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010219				2022-12-28	WOS:A1997WC81800005
J	Simons, A; MelamedBessudo, C; Wolkowicz, R; Sperling, J; Sperling, R; Eisenbach, L; Rotter, V				Simons, A; MelamedBessudo, C; Wolkowicz, R; Sperling, J; Sperling, R; Eisenbach, L; Rotter, V			PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb	ONCOGENE			English	Article						p53; Rb; SR proteins; splicing	RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; LARGE-T-ANTIGEN; LARGE TUMOR-ANTIGEN; RNA SPLICING FACTORS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; SUSCEPTIBILITY GENE; SV40-TRANSFORMED CELLS; EMBRYONIC LETHALITY	Cellular functions of tumor suppressor proteins can be mediated by protein-protein interactions. Using p53 as a probe to screen an expression library, a cDNA encoding a 250 kDa protein was isolated. Recombinant forms of this protein, designated PACT, bind to wild type p53 while two different mutations abolish this interaction. PACT protein can also interfere with p53 specific DNA binding. PACT contains a serine/arginine (SR) rich region and a C' terminal lysine rich domain. The 250 kDa PACT protein can be precipitated from cell lysates by a method specific for SR proteins. snRNPs can be co-immunoprecipitated from cells with anti-PACT antibodies. These antibodies stain cell nuclei in a speckled pattern reminiscent of the distribution of known splicing factors. Recently, RBQ1, a truncated human homologue of PACT was identified by virtue of Rb binding. We show that RBQ1 is truncated as a result of a possible mutational event. PACT can interact with both cellular Rb and p53.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem				Eisenbach, Lea R/0000-0002-4816-1968				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLENCOWE BJ, 1995, RNA, V1, P852; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FU XD, 1995, RNA, V1, P663; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Harlow E., ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUNA RMD, 1995, NATURE, V378, P203; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MANIATIS T, MOL CLONING; MARSTON NJ, 1994, ONCOGENE, V9, P2523; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOORE MJ, SPLICING PRECURSORS, P303; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SAKAI Y, 1995, GENOMICS, V30, P98, DOI 10.1006/geno.1995.0017; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; STEITZ JA, FUNCTIONS ABUNDANT U, P115; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; ZHANG W, 1994, ONCOGENE, V9, P2513	74	63	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					145	155		10.1038/sj.onc.1200825	http://dx.doi.org/10.1038/sj.onc.1200825			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010216				2022-12-28	WOS:A1997WC81800002
J	Ciossek, T; Ullrich, A				Ciossek, T; Ullrich, A			Identification of Elf-1 and B61 as high affinity ligands for the receptor tyrosine kinase MDK1	ONCOGENE			English	Article						MDK1; Elf-1; B61; RAP in situ; organogenesis; midbrain	GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; EPH FAMILY; GENE; EXPRESSION; HINDBRAIN; CLONING; CELLS; PHOSPHATASES; PROTEINS	Mouse Developmental Kinase 1 (MDK1) is a receptor tyrosine kinase of the eck/eph subfamily expressed in a variety of tissues during early mouse embryogenesis. To obtain further insight into the function of MDK1, we determined identity and localisation of its physiological ligand(s). Staining whole embryos,vith fusion proteins between the extracellular domain of MDK1 and human secreted alkaline phosphatase revealed areas of high receptor binding in the caudal mesencephalon, the frontal neocortex and the limb buds. This staining was sensitive to treatment with phosphatidylinositol-specific phospholipase C. Using Scatchard analysis, high affinity binding of Elf-1 (1.7 x 10(-10) M) and B61 (2.2 x 10(-10) M) towards MDK1 could be demonstrated. However, the transmembrane ligand Lerk2 displayed no measurable affinity for MDK1. Elf-1 and B61 bind to the three full-length MDK1 isoforms with similar dissociation constants. Slightly lower affinities were observed for the two truncated receptors MDK1-T1 and MDK1-T2. The activation of MDK1 with Elf-1 or B61 leads to the rapid autophosphorylation of MDK1 as well as tyrosine phosphorylation of an unknown 62 kDa phosphoprotein in Rat1 cells. These findings implicate MDK1 in patterning processes during early mouse embryogenesis and suggest MDK1 involvement in early organogenesis and midbrain development.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V10, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ELLIS J, 1995, MECH DEVELOP, V52, P319, DOI 10.1016/0925-4773(95)00411-S; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; FRIEDRICH R, 1991, VIROLOGY, V183, P343, DOI 10.1016/0042-6822(91)90147-4; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORI T, 1995, MOL BRAIN RES, V34, P154, DOI 10.1016/0169-328X(95)00154-K; Orike N, 1996, CURR BIOL, V6, P108, DOI 10.1016/S0960-9822(02)00435-9; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Patel K, 1996, DEVELOPMENT, V122, P1147; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; TAKAHASHI H, 1995, ONCOGENE, V11, P879; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	49	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					35	43		10.1038/sj.onc.1200800	http://dx.doi.org/10.1038/sj.onc.1200800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010230				2022-12-28	WOS:A1997WB76000003
J	DeCesare, D; Palazzolo, M; Blasi, F				DeCesare, D; Palazzolo, M; Blasi, F			Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription	ONCOGENE			English	Article						urokinase; enhancer; transcription	PLASMINOGEN-ACTIVATOR GENE; COLONY-STIMULATING FACTOR; REGULATORY ELEMENT; PHORBOL-ESTER; HMG DOMAIN; ENHANCER; INDUCTION; CELLS; INTERLEUKIN-3; EXPRESSION	The inducible uPA enhancer contains two phorbol ester responsive elements: the combined PEA3/AP-1(A) and a downstream AP-1(A) site. The integrity of all three sites is essential for enhancer activity, The interposed 74 bp long DNA region (COM, Cooperation Mediator) is in turn required for the synergistic action of the PEA3/AP-1 and AP-1 sites, Here we present a characterization of the COM sequence: our results show that COM and COM-binding proteins (UEF, Urokinase Enhancer Factors) may play a structural role in the induction of the uPA enhancer by phorbol-myristate-acetate (TPA), (1) COM has a bipartite structure (uCOM and dCOM) and each half contributes by about 50% to the COM-mediated TPA induction, (2) COM function is strictly dependent on its position, but not on its orientation and neither the entire COM nor individual UEF-binding sites can directly transactivate a test promoter, (3) The requirement for COM in TPA-induction is partly eliminated by the deletion of COM sequence, However, also in the COM-deleted enhancer, integrity of the PEA3/AP-1, and AP-1, sites is essential for enhancer function, We conclude that COM and COM-binding proteins provide a structural surface which facilitates the cooperation between the transactivator proteins bound at the PEA3/AP-1, and AP-1, sites, Sequences homologous to uCOM are found in the promoters of other inducible genes, coding for proteases, cytokines and chemokines: for example, in the promoter of the MIP1 alpha/LD78 chemokine gene, a 15/18 nucleotides identity is found in a region mediating positive and negative functions in TPA induction. Thus, COM-like elements represent a general enhancer function which, although lacking an intrinsic transactivating capacity, modulates the synergism between transcription factors bound to distant sites.	UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGAN,I-20133 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY	University of Milan				Blasi, Francesco/0000-0001-9406-1784				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERTHELSEN J, 1996, J BIOL CHEM, V272, P3822; BESSER D, 1996, IN PRESS FIBRINOLYSI; Blasi F, 1990, Semin Cancer Biol, V1, P117; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECESARE D, 1995, ONCOGENE, V11, P365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J., 2002, MOL CLONING LAB MANU; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TIJAN R, 1994, CELL, V77, P5; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	34	31	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2551	2562						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000129				2022-12-28	WOS:A1996VZ65400005
J	Kitsberg, DI; Leder, P				Kitsberg, DI; Leder, P			Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice	ONCOGENE			English	Article						keratinocyte growth factor; int-2; transformation; MMTV; transgenic mice; fgf	PROTO-ONCOGENE INT-2; HUMAN-BREAST CANCER; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; FACTOR RECEPTORS; NEU ONCOGENE; TUMOR VIRUS; INNER-EAR; IN-VIVO; C-MYC	The kinetics of solitary mammary tumor formation in transgenic mice bearing the MMTV-int-2 (fgf3) fusion gene suggest that several genetic events are required for tumorigenesis, In an effort to identify elements that could contribute to this oncogenic process, we used differential display PCR to identify gene products that are strongly and specifically induced in int-2 mammary tumors, Using this approach we identified a member of the FGF family, kgf (fgf7), as a gene that is strongly upregulated in an int-2-containing mammary tumor, Since int-2 and kgf strongly bind the same receptor, the IIIb isoform of FGFR2, it is possible that their joint expression, one as a transgene, the other as an activated gene, might reinforce the same mitogenic pathway, To test this possibility, we created transgenic mice that carry kgf as a transgene gene under the control of the MMTV promoter/enhancer, Female mice carrying this transgene develop a very dramatic mammary epithelial hyperplasia and go on to develop solitary, metastatic adenocarcinomas of the mammary gland, Consistent with a common signalling pathway, the MMTV-kgf-induced hyperplasia has the morphologic characteristics of that seen in the MMTV-int-2 mice, Male mice also develop hyperplasia of the male genital tract, including the seminal vesicle, the vas deferens and the prostate, Thus KGF can act as a potent proliferative inducer in mammary and specific urogenital tissue and can contribute to the development of adenocarcinoma of the mammary gland in a manner strongly reminiscent of receptor-related ligand, int-2.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; CARDIFF RD, 1993, CANCER SURV, V16, P97; CUNHA GR, 1994, BIOMED PHARMACOTHER, V48, pS9, DOI 10.1016/S0753-3322(09)80003-6; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Krane IM, 1996, ONCOGENE, V12, P1781; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIDEREAU R, 1988, BIOCHIMIE, V70, P951, DOI 10.1016/0300-9084(88)90237-4; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSOUR SL, 1994, MOL REPROD DEV, V39, P62, DOI 10.1002/mrd.1080390111; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J., 2002, MOL CLONING LAB MANU; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; ULICH TR, 1994, AM J PATHOL, V144, P862; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILSON SE, 1994, CELL MOL BIOL RES, V40, P337; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YI ES, 1994, AM J PATHOL, V145, P1015	43	92	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2507	2515						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000125				2022-12-28	WOS:A1996VZ65400001
J	Novak, U; Nice, E; Hamilton, JA; Paradiso, L				Novak, U; Nice, E; Hamilton, JA; Paradiso, L			Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1	ONCOGENE			English	Article						CSF-1; STAT proteins; CSF-1 receptor	STIMULATING FACTOR-I; PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; GROWTH-FACTOR RECEPTORS; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINE RECEPTORS; FDC-P1 CELLS	Using FDC-P1 derived cell lines which ectopically express either the wild type or mutant forms of the murine CSF-1 receptor in which individual tyrosine residues have been replaced with phenylalanine, we analysed the requirement for tyrosine residues of the receptor for the activation of STAT proteins in response to CSF-1, We found Y706 to be required for efficient activation of STAT1. The activation of STAT3 was not affected by the mutation of Y706 to phenylalanine. The addition of phosphopeptides spanning Y708 of the human CSF-1 receptor (identical with the sequence surrounding Y706 of the murine receptor) to electrophoretic mobility shift assays led to competition of the formation of STAT1 containing complexes, SIF-B and SIF-C with the DNA probe, These phosphopeptides did, however, not affect the formation of the STAT3 containing complex, SIF-A, with the probe. Replacement of Y807 with phenylalanine led to a complete block of activation of all STAT proteins in response to CSF-1, however, this phosphotyrosine does not appear to represent a STAT binding site of the receptor as a phosphopeptide spanning Y809 of the human CSF-1 receptor could not compete any STAT/DNA complex formation in electrophoretic mobility shift assays.	ROYAL MELBOURNE HOSP,TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Novak, U (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.		Nice, Edouard C/B-1026-2011	Hamilton, John A/0000-0002-9493-9224				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SA, 1996, IN PRESS J BIOL CHEM; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROSNET O, 1991, ONCOGENE, V6, P1641; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	46	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2607	2613						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000134				2022-12-28	WOS:A1996VZ65400010
J	Parker, GA; Crook, T; Bain, M; Sara, EA; Farrell, PJ; Allday, MJ				Parker, GA; Crook, T; Bain, M; Sara, EA; Farrell, PJ; Allday, MJ			Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus EIA and papillomavirus E7	ONCOGENE			English	Article						growth transformation; EBV; EBNA3C; pRb; p16(INK4A)	CELL-CYCLE REGULATION; B-MYB TRANSCRIPTION; TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; BINDING PROTEIN; DNA-DAMAGE; P53; TRANSFORMATION; EXPRESSION	Epstein-Barr virus (EBV) requires six genes to efficiently immortalize human B cells, We have shown that one of these, EBNA3C, can cooperate with activated (Ha-)ras in co-transfection assays to immortalize and transform rat embryo fibroblasts (REFs), EBNA3C also augmented transformation by (Ha-)ras and a mutant p53 to a similar extent as human papilloma virus E7, As with E7 this effect was not inhibited by cotransfection with the cyclin-dependent kinase inhibitor (CDKI), a p16(INK4A), which can normally activate the retinoblastoma protein (pRb) and induce growth arrest, Also like E7/ras and E1A/ras transformed cells the EBNA3C/ras transformants are very susceptible to apoptotic cell death. In vitro EBNA3C binds to pRb in a manner which is dependent on the integrity of the pocket domain; this suggests that EBNA3C, even though it lacks the LXCXE pRb binding motif found in E7 and E1A, may interact with pRb in vivo. We conclude that EBNA3C functions as an oncoprotein which directs cell cycle progression through the G(1) phase restriction point when conditions might signal arrest. For the first time this demonstrates that EBV encodes a protein, functionally but not necessarily mechanistically, similar to the pRb-neutralizing nuclear antigens encoded by the 'small' DNA tumor viruses.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK			Fraser, Elizabeth/M-7049-2015	Fraser, Elizabeth/0000-0001-8420-3208; Farrell, Paul/0000-0002-6754-9351	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLDAY MJ, 1988, NUCLEIC ACIDS RES, V16, P4353, DOI 10.1093/nar/16.10.4353; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUTHU A, 1992, ONCOGENE, V7, P2161; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KIEFF E, 1996, FIELDS VIROLOGY; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER G, 1990, VIROLOGY; NEVINS JR, 1992, SCIENCE, V258, P424; Nevins JR, 1996, FIELDS VIROLOGY, P301; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; THOMAS JA, 1991, ADV CANCER RES, V57, P329; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0	39	111	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2541	2549						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000128				2022-12-28	WOS:A1996VZ65400004
J	Taglienti, CA; Wysk, M; Davis, RJ				Taglienti, CA; Wysk, M; Davis, RJ			Molecular cloning of the epidermal growth factor-stimulated protein kinase p56 KKIAMRE	ONCOGENE			English	Article						EGF; MAP kinase; signal transduction	SIGNAL-TRANSDUCTION PATHWAY; CELL-CYCLE CONTROL; MAP KINASE; C-MYC; CAENORHABDITIS-ELEGANS; PHOSPHORYLATION SITES; ACTIVATION DOMAIN; ESCHERICHIA-COLI; XENOPUS-OOCYTES; HUMAN HOMOLOG	A 56 kDa protein kinase was molecularly cloned from human fetal brain. This protein kinase (p56 KKIAMRE) shares homology with p42 KKIALRE (Meyerson et al., 1992) and is related to the proline-directed protein kinase group of signal transducing enzymes. The p56 KKIAMRE and p42 KKIALRE protein kinases exhibit mutually exclusive expression in reproductive tissues; p56 KKIAMRE in testis and p42 KKIALRE in ovary. p56 KKIAMRE and p42 KKIALRE may therefore contribute to signal transduction within these highly differentiated tissues. p56 KKIAMRE and p42 KKIALRE are activated by treatment of cells with epidermal growth factor (EGF). Although p56 KKIAMRE and p42 KKIALRE contain the MAP kinase dual phosphorylation motif Thr-Xaa-Tyr (Thr-Asp-Tyr), phosphorylation on Thr and Tyr within this motif is not required for EGF-stimulated protein kinase activity.	UNIV MASSACHUSETTS, SCH MED, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MOL GENET & MICROBIOL, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA65861, CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHOI KY, 1994, CELL, V78, P499; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GASKINS C, 1994, MOL CELL BIOL, V14, P6996, DOI 10.1128/MCB.14.10.6996; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1994, J CELL SCI, P115; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	63	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2563	2574						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000130				2022-12-28	WOS:A1996VZ65400006
J	Braunger, J; Schleithoff, L; Schulz, AS; Kessler, H; Lammers, R; Ullrich, A; Bartram, CR; Janssen, JWG				Braunger, J; Schleithoff, L; Schulz, AS; Kessler, H; Lammers, R; Ullrich, A; Bartram, CR; Janssen, JWG			Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site	ONCOGENE			English	Article						Ufo/Ax1; receptor tyrosine kinase; CORT; SH2 domain; multi-substrate docking-site	GROWTH-FACTOR RECEPTOR; SCATTER FACTOR-RECEPTOR; ARREST-SPECIFIC GENE-6; PHOSPHOLIPASE-C-GAMMA; MOLECULAR-CLONING; SH2 DOMAINS; PROTEIN-S; PHOSPHATIDYLINOSITOL 3'-KINASE; EXPRESSION CLONING; ADAPTER PROTEIN	Ufo/Axl belongs to a new family of receptor tyrosine kinases with an extracellular structure similar to that of neural cell adhesion molecules, In order to elucidate intracellular signaling, the cytoplasmic moiety of Ufo/Axl was used to screen an expression library according to the CORT (cloning of receptor targets) method, Three putative Ufo substrates were identified: phospholipase C gamma 1 (PLC gamma), as well as p85 alpha and p85 beta subunits of phosphatidylinositol 3'-kinase (PI3-kinase), Subsequently, chimeric EGFR/Ufo receptors consisting of the extracellular domains of the epidermal growth factor receptor (EGFR) and the transmembrane and intracellular moiety of Ufo were engineered, Using different far-Western blot analyses and coimmunoprecipitation assays, receptor binding of PLC gamma and p85 proteins as well as GRB2, c-src and lck was examined in vitro and in vivo, Competitive inhibition of substrate binding and mutagenesis experiments with EGFR/Ufo constructs revealed C-terminal tyrosine 821 (EILpYVNMDEG) as a docking site for multiple effecters, namely PLC gamma, p85 proteins, GRB2, c-src and Ick, Tyrosine 779 (DGLpYALMSRC) demonstrated an additional, but lower binding affinity for the p85 proteins in vitro, In addition, binding of PLC gamma occurred through tyrosine 866 (AGRpYVLCPST), Moreover, our in vivo data indicate that further direct or indirect binding sites for PLC gamma, GRB2, c-src and lck on the human Ufo receptor may exist.	UNIV HEIDELBERG, INST HUMANGENET, D-69120 HEIDELBERG, GERMANY; UNIV ULM, ABT KINDERHEILKUNDE 2, D-89075 ULM, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Ruprecht Karls University Heidelberg; Ulm University; Max Planck Society								ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1993, J BIOL CHEM, V268, P9478; CAO Y, 1990, Technique (Philadelphia), V2, P109; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSIER KE, 1994, GROWTH FACTORS, V11, P137, DOI 10.3109/08977199409001055; DAI W, 1994, ONCOGENE, V9, P975; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HERBST R, 1991, J BIOL CHEM, V266, P19908; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAROSE L, 1993, ONCOGENE, V8, P2493; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARK MR, 1994, J BIOL CHEM, V269, P10720; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OOI J, 1995, ONCOGENE, V10, P1621; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PONTKINGDON G, 1994, BIOTECHNIQUES, V16, P1010; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	73	122	143	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2619	2631		10.1038/sj.onc.1201123	http://dx.doi.org/10.1038/sj.onc.1201123			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178760				2022-12-28	WOS:A1997XB97800001
J	Colley, SM; Tilbrook, PA; Klinken, SP				Colley, SM; Tilbrook, PA; Klinken, SP			Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein	ONCOGENE			English	Article						E mu-myc transgene; mRNA stabilisation; transcription; Myc protein	MESSENGER-RNA STABILITY; 5' NONCODING REGION; C-MYC; CHROMOSOME-TRANSLOCATION; IMMUNOGLOBULIN ENHANCER; MURINE PLASMACYTOMA; NEOPLASTIC-CELLS; GENE-EXPRESSION; ONCOGENE; TRANSLATION	Mice bearing the E mu-myc transgene, which Links the immunoglobulin heavy chain enhancer (E mu) with c-myc, are predisposed to developing B cell lymphomas, Several B lineage cell lines have been isolated from these animals, and some have been converted to macrophages following infection with v-raf. In this study we compared the regulation of myc expression in E mu-myc B lymphoma lines, their macrophage counterparts and other non-myc transformed B cell lines, Nuclear run-on analyses demonstrated that transcription of the transgene was elevated in E mu-myc B cell lines, Moreover, the presence of a 600 bp phi X174 marker in the 3' end of the transgene produced a marked stabilisation of this RNA species, Consequently, steady state myc mRNA levels in the E mu-myc B lymphoma cells were tenfold higher than the macrophage derivatives and non-myc transformed B Lineage lines, Despite the considerable difference in myc RNA levels, the E mu-myc B cell Lines contained only 30-50% more Myc protein than the other cell lines, This discrepancy between RNA and protein content was not due to increased degradation of the protein as the half life was normal in the transgenic cell lines, These results indicate that both E mu and phi X174 sequences influence transgenic myc expression and that protein levels do not correlate with RNA content in E mu-myc cell lines.	UNIV WESTERN AUSTRALIA, DEPT BIOCHEM, LAB CANC MED, ROYAL PERTH HOSP, NEDLANDS, WA 6001, AUSTRALIA	Royal Perth Hospital; University of Western Australia				Colley, Shane/0000-0002-5792-7005				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AGHIB DF, 1990, ONCOGENE, V5, P707; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BAUER SR, 1989, ONCOGENE, V4, P615; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1990, ENZYME, V44, P167, DOI 10.1159/000468755; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOUGH NM, 1980, P NATL ACAD SCI-BIOL, V77, P554, DOI 10.1073/pnas.77.1.554; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAZARUS P, 1988, ONCOGENE, V3, P517; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, P NATL ACAD SCI-BIOL, V81, P829, DOI 10.1073/pnas.81.3.829; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; WINGROVE TG, 1988, J BIOL CHEM, V263, P8918	39	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2735	2739		10.1038/sj.onc.1201113	http://dx.doi.org/10.1038/sj.onc.1201113			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178772				2022-12-28	WOS:A1997XB97800013
J	Enholm, B; Paavonen, K; Ristimaki, A; Kumar, V; Gunji, Y; Klefstrom, J; Kivinen, L; Laiho, M; Olofsson, B; Joukov, V; Eriksson, U; Alitalo, K				Enholm, B; Paavonen, K; Ristimaki, A; Kumar, V; Gunji, Y; Klefstrom, J; Kivinen, L; Laiho, M; Olofsson, B; Joukov, V; Eriksson, U; Alitalo, K			Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia	ONCOGENE			English	Article						VEGF; VEGF-B; VEGF-C; angiopoietin; angiogenesis	VASCULAR-PERMEABILITY FACTOR; FACTOR GENE-EXPRESSION; PROTEIN-KINASE-C; INDUCED TRANSCRIPTION; EPITHELIAL-CELLS; TYROSINE KINASE; MESSENGER-RNA; HA-RAS; P53; ANGIOGENESIS	The vascular endothelial growth factor (VEGF) family has recently been expanded by the isolation of two additional growth factors, VEGF-B and VEGF-C, Here we compare the regulation of steady-state levels of VEGF, VEGF-B and VEGF-C mRNAs in cultured cells by a variety of stimuli implicated in angiogenesis and endothelial cell physiology, Hypoxia, Ras oncoprotein and mutant p53 tumor suppressor, which are potent inducers of VEGF mRNA did not increase VEGF-B or VEGF-C mRNA levels. Serum and its component growth factors, platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) as well as transforming growth factor-beta (TGF-beta) and the tumor promoter phorbol myristate 12,13-acetate (PMA) stimulated VEGF-C, but not VEGF-B mRNA expression, Interestingly, these growth factors and hypoxia simultaneously downregulated the mRNA of another endothelial cell specific ligand, angiopoietin-1. Serum induction of VEGF-C mRNA occurred independently of protein synthesis; with an increase of the mRNA half-life from 3.5 h to 5.5-6 h, whereas VEGF-B mRNA was very stable (T-1/2>8h). Our results reveal that the three VEGF genes are regulated in a strikingly different manner, suggesting that they serve distinct, although perhaps overlapping functions in vivo.	UNIV HELSINKI,HAARTMAN INST,MOL CANC BIOL LAB,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,HAARTMAN INST,DEPT VIROL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT CLIN CHEM,HELSINKI 00290,FINLAND; UNIV HELSINKI,DEPT OBSTET & GYNECOL,HELSINKI 00290,FINLAND; LUDWIG INST CANC RES,S-17177 STOCKHOLM,SWEDEN	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014; Joukov, Vladimir/K-3525-2019	Alitalo, Kari K/0000-0002-7331-0902; 				BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KIESER A, 1994, ONCOGENE, V9, P963; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V220, P147, DOI 10.1006/bbrc.1996.0372; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LIU HS, 1992, CANCER RES, V52, P983; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Paavonen K, 1996, CIRCULATION, V93, P1079, DOI 10.1161/01.CIR.93.6.1079; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493	50	377	399	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2475	2483		10.1038/sj.onc.1201090	http://dx.doi.org/10.1038/sj.onc.1201090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188862				2022-12-28	WOS:A1997WZ68000011
J	Fan, SJ; Chang, JK; Smith, ML; Duba, D; Fornace, AJ; OConnor, PM				Fan, SJ; Chang, JK; Smith, ML; Duba, D; Fornace, AJ; OConnor, PM			Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard	ONCOGENE			English	Article						cell cycle checkpoints; chemosensitivity; p53; CIP1/WAF1; radiation; DNA repair	NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; P53 TUMOR-SUPPRESSOR; DNA-REPLICATION; CROSS-LINKS; P21; INHIBITOR; PROTEIN; LINES	We have previously shown that p53 disruption sensitizes certain cancer cell types to cisplatin (CDDP) (Fan et al., 1995). In the present study we investigated the role of the p53 downstream effector, p21(CIP1/WAF1) (p21), in this sensitization, Studies were performed in human colon cancer HCT-116 cells and murine embryonic fibroblasts (MEF) with intact versus disrupted p21 genes, For comparison, HCT-116 cells lacking p53 function were also prepared through stable transfection with the human papillomavirus type-16 E6 gene. HCT-116/E6 cells were found to be more sensitive than control transfectants to CDDP and another DNA crosslinking agent, nitrogen mustard (HN2). HCT-116 cells with disrupted p21 genes also exhibited greater CDDP and HN2-sensitivity than parental HCT-116 cells. In contrast, the clonogenic survival of HCT-116 cells exposed to ionizing radiation, adriamycin, taxol or vincristine was not affected by p53 or p21 disruption. Sensitization of HCT-116/p21(-/-) cells to CDDP and HN2 was not limited to the HCT-116 cell background since MEF from p21 knockout mice were also more sensitive to these DNA crosslinking agents. Investigations into a possible cause of this enhanced sensitivity revealed that HCT-116 cells lacking p53 or p21 function exhibited a reduced ability to repair cisplatin-damaged CAT-reporter plasmids transfected into the cells. In addition, we found that HCT-116/p21(-/-) cells were much more susceptible to HN2-induced cell cycle delay than parental cells. Our results suggest that p21 disruption preferentially sensitizes at least some cell types to DNA crosslinking agents.	NCI,NIH,MOL PHARMACOL LAB,BETHESDA,MD 20892; NCI,NIH,DIV BASIC SCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN IT, 1995, ONCOGENE, V11, P1931; CROOK T, 1991, ONCOGENE, V6, P873; DABHOLKAR M, 1990, CARCINOGENESIS, V11, P1761, DOI 10.1093/carcin/11.10.1761; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; KASTAN MB, 1991, CANCER RES, V51, P6304; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McDonald E, 1996, CANCER RES, V56, P2250; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OCONNOR PM, IN PRESS PROGR CELL; OCONNOR PM, 1996, ANTI-CANCER DRUG, V7, P135; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; SHEIKH MS, 1997, IN PRESS ONCOGENE; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	40	156	159	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2127	2136		10.1038/sj.onc.1201052	http://dx.doi.org/10.1038/sj.onc.1201052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174048				2022-12-28	WOS:A1997WX93800001
J	Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Logothetis, C; vonEschenbach, AC; Batsakis, JG; Czerniak, B				Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Logothetis, C; vonEschenbach, AC; Batsakis, JG; Czerniak, B			Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia	ONCOGENE			English	Article						bladder cancer; chromosome 17; microsatellites; multistep carcinogenesis; superimposed histologic and genetic mapping	MICROSATELLITE INSTABILITY; POSITIONAL CLONING; SUPPRESSOR LOCI; HUMAN GENOME; LINKAGE MAP; CANCER; CARCINOMAS; MUTATIONS; HETEROZYGOSITY; DELETION	Multistep alterations of chromosome 17 in the progression of human urinary bladder neoplasia were studied by superimposed histologic and genetic mapping. The p53 gene was included in the analysis as a model tumor suppressor gene that is frequently involved in urothelial carcinogenesis. The strategy provided a systematic approach to the study of multistep genomic alterations that occur as neoplasia progresses from precursor intraurothelial conditions to invasive cancer. This was accomplished by sampling the entire mucosa of the organ and displaying microscopically identified invasive cancer and precursor conditions in the form of a histologic map. Subsequent isolation of DNA provided a set of samples in which the search for genetic alterations was performed and superimposed on the histologic map. This approach disclosed multifocal allelic losses of chromosome 17 in the early preinvasive phases of urothelial neoplasia. The alterations were predominantly confined to the p12-13, q22-11 and q24-25 regions. Mutations and allelic losses of the p53 gene were mapped to early preinvasive phases of urothelial neoplasia. The data provide detailed analysis of chromosome 17 allelic losses that occur in the development and progression of urothelial neoplasia and represent the first step for genome-wide modeling of multistep human urothelial carcinogenesis.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOMATH,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT GENITOURINARY MED ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT UROL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R29CA066723, R01CA066723] Funding Source: NIH RePORTER; NCI NIH HHS [CA66723-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, CANCER RES, V54, P1422; CHANG WYH, 1995, CANCER RES, V55, P3246; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; CROPP CS, 1994, CANCER RES, V54, P2548; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Czerniak B, 1995, DIAGNOSTIC CYTOLOGY, P345; DALBAGNI G, 1993, DIAGN MOL PATHOL, V2, P4, DOI 10.1097/00019606-199300020-00002; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; ELDER PA, 1994, ONCOGENE, V9, P3433; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOLBERG R, 1993, J NIH RES, V5, P32; KOSS L G, 1977, Urology, V9, P442, DOI 10.1016/0090-4295(77)90227-8; KOSS LG, 1991, NEW ENGL J MED, V324, P125; KOSS LG, 1974, JAMA-J AM MED ASSOC, V227, P281; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; KOSS LG, 1995, DIAGNOSTIC CYTOLOGY; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; METZ CE, 1989, INVEST RADIOL, V24, P234, DOI 10.1097/00004424-198903000-00012; MIYAO N, 1993, CANCER RES, V53, P4066; OLUMI AF, 1990, CANCER RES, V50, P7081; Ott J., 1991, ANAL HUMAN GENETIC L; PRESTI JC, 1991, CANCER RES, V51, P5405; RUPPERT JM, 1993, CANCER RES, V53, P5093; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SPRUCK CH, 1994, CANCER RES, V54, P784; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; Swets J., 1982, EVALUATION DIAGNOSTI; SWIFT A, 1995, BRIT J CANCER, V71, P995, DOI 10.1038/bjc.1995.191; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAI YC, 1990, CANCER RES, V50, P44; UCHIDA T, 1995, ONCOGENE, V10, P1019; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641; Zar J. H., 1996, BIOSTATISTICAL ANAL	42	42	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2059	2070		10.1038/sj.onc.1201044	http://dx.doi.org/10.1038/sj.onc.1201044			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160886				2022-12-28	WOS:A1997WW80900008
J	Watters, D; Khanna, KK; Beamish, H; Birrell, G; Spring, K; Kedar, P; Gatei, M; Stenzel, D; Hobson, K; Kozlov, S; Zhang, N; Farrell, A; Ramsay, J; Gatti, R; Lavin, M				Watters, D; Khanna, KK; Beamish, H; Birrell, G; Spring, K; Kedar, P; Gatei, M; Stenzel, D; Hobson, K; Kozlov, S; Zhang, N; Farrell, A; Ramsay, J; Gatti, R; Lavin, M			Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms	ONCOGENE			English	Article						ataxia-telangiectasia; cellular localisation; mutations; radiation; p53	CYCLE CHECKPOINT PATHWAY; FLOW CYTOMETRIC ANALYSIS; IONIZING-RADIATION; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN PROTEIN; CELLS; PROGRESSION; RAPAMYCIN	The recently cloned gene (ATM) mutated in the human genetic disorder ataxia-telangiectasia (A-T) is involved in DNA damage response at different cell cycle checkpoints and also appears to have a wider role in signal transduction. Antibodies prepared against peptides from the predicted protein sequence detected a similar to 350 kDa protein corresponding to the open reading frame, which was absent in 13/23 A-T homozygotes. Subcellular fractionation, immunoelectronmicroscopy and immunofluorescence showed that the ATM protein is present in the nucleus and cytoplasmic vesicles. This distribution did not change after irradiation, We also provide evidence that ATM protein binds to p53 and this association is defective in A-T cells compatible with the defective p53 response in these cells. These results provide further support for a role for the ATM protein as a sensor of DNA damage and in a more general role in cell signalling, compatible with the broader phenotype of the syndrome.	PO ROYAL BRISBANE HOSP, QUEENSLAND CANC FUND RES UNIT, QUEENSLAND INST MED RES, HERSTON, QLD 4029, AUSTRALIA; QUEENSLAND UNIV TECHNOL, ANALYT ELECTRON MICROSCOPE FACIL, BRISBANE, QLD 4000, AUSTRALIA; ROYAL BRISBANE HOSP, QUEENSLAND RADIUM INST, BRISBANE, QLD 4029, AUSTRALIA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL, CTR HLTH SCI, LOS ANGELES, CA USA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT SURG, BRISBANE, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Queensland University of Technology (QUT); Royal Brisbane & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010; Hobson, Keith/Q-9306-2019; Kozlov, Sergei/T-9779-2019; Kozlov, Sergei/M-2067-2014; Ramsay, Jonathan/F-7009-2013; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Kozlov, Sergei/0000-0001-6183-7339; Khanna, Kum Kum/0000-0001-8650-5381; Spring, Kevin/0000-0003-0601-924X; Birrell, Geoff/0000-0002-6593-1514				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Beamish H, 1996, ONCOGENE, V13, P963; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; IMRAY FP, 1983, MUTAT RES, V112, P369; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LAVIN MF, 1997, IN PRESS ANN REV IMM; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MEYN MS, 1995, CANCER RES, V55, P5991; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P66, DOI 10.1016/0090-1229(80)90021-5; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; ROTMAN G, 1996, J CLIN IMMUNOL, V16, P254; RUDOLPH NS, 1989, MUTAT RES, V211, P19, DOI 10.1016/0027-5107(89)90103-6; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCHNITT S, 1996, SCIENCE, V272, P123; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SiddooAtwal C, 1996, CANCER RES, V56, P443; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; TEALE B, 1992, J BIOL CHEM, V267, P10295; TEALE B, 1993, J BIOL CHEM, V268, P22450; Telatar M, 1996, AM J HUM GENET, V59, P40; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; XU Y, 1996, GENE DEV, V10, P2389; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	64	168	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1911	1921		10.1038/sj.onc.1201037	http://dx.doi.org/10.1038/sj.onc.1201037			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150358				2022-12-28	WOS:A1997WV80400004
J	Mann, DJ; Higgins, T; Jones, NC; Rozengurt, E				Mann, DJ; Higgins, T; Jones, NC; Rozengurt, E			Differential control of cyclins D1 and D3 and the cdk inhibitor p27(Kip1) by diverse signalling pathways in Swiss 3T3 cells	ONCOGENE			English	Article						cyclin D1; cyclin D3; p27(Kip1); Swiss 3T3 cells; pRb	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; TRANSDUCTION PATHWAYS; REGULATED EXPRESSION; G(1); PROTEIN; P21; FIBROBLASTS; PHASE; ACCELERATION	Quiescent Swiss 3T3 cells can be induced to re-enter the cell cycle by stimulation of a variety of growth factor-dependent signal transduction cascades. We have utilised this cell system to investigate the point of convergence of mitogenic signalling by analysing the changes that distinct mitogens induce in the components of the cell cycle regulatory machinery (the G(1) cyclins, cdks and their inhibitors). In the presence of insulin, activation of cAMP-dependent protein kinase caused a dramatic post-transcriptional down-regulation of p27(Kip1), increase in cyclin D3 but had little effect on cyclin D1 levels, whilst activation of protein kinase C had a more modest effect on cyclin D3 and p27(Kip1) but caused a striking elevation in the expression of cyclin D1, The neuropeptide bombesin, when combined with insulin, caused increased expression of cyclin D1 and down-regulation of p27(Kip1) mRNA and protein. Thus each combination of mitogenic agents had different effects on the components responsible for regulating the orderly progression of the cell cycle. This outcome is incompatible with a single route to mitogenesis and demonstrates that different mitogens remain distinct in the signalling responses they initiate, only converging at the levels of the expression of the D-type cyclins and the inhibitor p27(Kip1).	IMPERIAL CANC RES FUND,GENE REGULAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,GROWTH REGULAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK								Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBERT DA, 1992, P NATL ACAD SCI USA, V89, P1597, DOI 10.1073/pnas.89.5.1597; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BATES S, 1994, ONCOGENE, V9, P71; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI Y, 1994, ONCOGENE, V9, P2261; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MASSUSHIME H, 1992, CELL, V71, P323; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	48	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1759	1766		10.1038/sj.onc.1201134	http://dx.doi.org/10.1038/sj.onc.1201134			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150381				2022-12-28	WOS:A1997WW16600001
J	ONeill, FJ; Hu, Y; Chen, T; Carney, H				ONeill, FJ; Hu, Y; Chen, T; Carney, H			Identification of p53 unbound to T-antigen in human cells transformed by simian virus 40 T-antigen	ONCOGENE			English	Article						p53; T-antigen; human cells; transformation; immortalization	TUMOR-SUPPRESSOR P53; MOUSE EMBRYO FIBROBLASTS; MONOCLONAL-ANTIBODIES; CELLULAR-TRANSFORMATION; IMMUNOCHEMICAL ANALYSIS; SV40-TRANSFORMED CELLS; PROTEIN P53; SV40; MUTATIONS; EXPRESSION	In several clones of SV40-transformed human cells, we investigated the relative amounts of large T-Antigen (T-Ag) and p53 proteins, both unbound and associated within complexes, with the goal of identifying changes associated with transformation and immortalization, Cells were transformed by wild type (wt) T-Ag, a functionally temperature sensitive T-Ag (tsA58) and other T-Ag variants, Western analysis showed that while most of the T-Ag was ultimately bound by p53, most of the p53 remained unbound to T-Ag, Unbound p53 remained in the supernatant after a T-Ag immunoprecipitation and p53 was present in two to fourfold excess of T-Ag, In one transformant there was five to tenfold more p53 than T-Ag, p53 was present in transformants in amounts at least 200-fold greater than in untransformed human cells, In wt and variant T-Ag transformants, including those generated with tsA58 T-Ag, large amounts of unbound p53 were present in both pre-crisis and immortal cells and when the cells were grown at permissive or non-permissive temperatures, We also found that in transformants produced by tsA58, an SV40/JCV chimeric T-Ag and other variants, T-Ag appeared to form a complex with p53 slowly perhaps because one or both proteins matured slowly, The presence in transformed human cells of large amounts of unbound p53 and in excesss of T-Ag suggests that sequestration of p53 by T-Ag, resulting from complex formation, is required neither for morphological transformation nor immortalization of human cells, Rather, these results support the proposal that high levels of p53, the T-Ag/p53 complexes, or other biochemical event(s), lead to transformation and immortalization of human cells by T-Ag.	UNIV UTAH, HUNTSMAN CANC INST, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA; VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84148 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ONeill, FJ (corresponding author), UNIV UTAH, HUNTSMAN CANC INST, DEPT ONCOL SCI, DIV MOL BIOL & GENET, SALT LAKE CITY, UT 84132 USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARTEK J, 1990, ONCOGENE, V5, P893; BENCHIMOL S, 1982, EMBO J, V1, P1053; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1989, NATO ASI SERIES; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEE AP, 1981, ANAL BIOCHEM, V116, P524, DOI 10.1016/0003-2697(81)90397-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Hansen R, 1995, ONCOGENE, V11, P2535; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P5304; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1980, PROC R SOC SER B-BIO, V210, P451, DOI 10.1098/rspb.1980.0146; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; ONEILL FJ, 1990, INTERVIROLOGY, V31, P175, DOI 10.1159/000150152; ONEILL FJ, 1988, VIRUS RES, V11, P109, DOI 10.1016/0168-1702(88)90037-8; ONEILL FJ, 1993, VIRUS RES, V30, P171, DOI 10.1016/0168-1702(93)90005-8; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1994, VIRUS RES, V34, P237, DOI 10.1016/0168-1702(94)90126-0; ONEILL FJ, 1982, J VIROL, V43, P18, DOI 10.1128/JVI.43.1.18-25.1982; ONEILL FJ, 1995, ONCOGENE, V90, P1131; PRIVES C, 1991, COLD SPRING HARB SYM, V56, P227; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TIEMANN F, 1994, ONCOGENE, V9, P1907; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOLKEN RH, 1981, J IMMUNOL METHODS, V54, P209; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZERRAHN J, 1993, J VIROL, V67, P1555, DOI 10.1128/JVI.67.3.1555-1563.1993; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	59	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					955	965		10.1038/sj.onc.1200913	http://dx.doi.org/10.1038/sj.onc.1200913			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050995				2022-12-28	WOS:A1997WK34400009
J	Park, WM; Mosteller, RD; Broek, D				Park, WM; Mosteller, RD; Broek, D			Identification of a dominant-negative mutation in the yeast CDC25 guanine nucleotide exchange factor for Ras	ONCOGENE			English	Article						Ras; CDC25 dominant-negative mutant; yeast; signal transduction	ADENYLYL CYCLASE GENE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; PROTEINS; ACTIVATION; MUTANT; RESIDUES; TRANSFORMATION; COMPLEX; CELLS	In previous studies we changed five conserved amino acid residues in the catalytic domain of the yeast Ras-specific guanine nucleotide exchange factor CDC25(GEF) (Park et al., 1994). One of the substitutions (R1489E) resulted in a molecule which could bind Ras but was catalytically inactive. These observations suggested that CDC25(R1489E) might be a dominant-negative mutant. Here we report further experiments which confirm the dominant-negative phenotype of CDC25(R1489E). Two lines of evidence indicate that the CDC25(R1489E) mutant exhibits Ras-specific binding in vivo. First, expression of CDC25(R1489E) in a wild-type yeast strain caused a partial inhibition of growth which was reversed by overexpression of the wildtype yeast RAS2 protein. Second, expression of CDC25(R1489E) in yeast strain containing a temperature-sensitive, dominant-negative RAS2 mutation (RAS2(vall9ala22)) suppressed the temperature-sensitive phenotype. The latter findings suggest that the CDC25(R1489E) protein bound the mutant RAS2 protein thereby releasing the wild-type CDC25 protein for activation of the wild-type RAS1 protein. Further, using a protein-protein binding assay and guanine nucleotide exchange assay (release of [H-3]-GDP) in vitro, we demonstrate that the CDC25(R1489E) protein can bind wild-type Ras protein but is unable to catalyze GDP-GTP exchange. Thus, the results of genetic and biochemical experiments demonstrate that CDC25(R1489E) encodes a dominant-negative GEF which blocks the Ras signaling pathway by binding wild-type Ras in a catalytically inactive complex.	UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, DEPT BIOCHEM & MOL BIOL, LOS ANGELES, CA 90033 USA	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHEN SY, 1994, ONCOGENE, V9, P2691; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; HANEY SA, 1994, J BIOL CHEM, V269, P16541; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MACARA IG, 1996, FASEB J, V10, P624; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sherman F, 1986, LAB COURSE MANUAL ME; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	26	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					831	836		10.1038/sj.onc.1200893	http://dx.doi.org/10.1038/sj.onc.1200893			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047390				2022-12-28	WOS:A1997WJ11200009
J	Chao, JR; Chen, CS; Wang, TF; Tseng, LH; Tsai, JJ; Kuo, ML; Yen, JJY; Yen, HFY				Chao, JR; Chen, CS; Wang, TF; Tseng, LH; Tsai, JJ; Kuo, ML; Yen, JJY; Yen, HFY			Characterization of factor-independent variants derived from TF-1 hematopoietic progenitor cells: The role of the Raf/MAP kinase pathway in the anti-apoptotic effect of GM-CSF	ONCOGENE			English	Article						apoptosis; GM-CSF signalling; Raf-1; MAP; kinase	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; RAPID PHOSPHORYLATION; PROTOONCOGENE RAF-1; MYELOID-LEUKEMIA; GROWTH-FACTORS; ACTIVATION; INTERLEUKIN-3	Human hematopoietic progenitor cells (TF-I) undergo apoptosis upon deprivation of their dependent cytokine, In this report, we have isolated and characterized some spontaneously derived cytokine-independent variants from TF-1 cells, Analysis of several signaling molecules known to be activated by the GM-CSF pathway revealed that two non-autocrine variants were still responsive to GM-CSF stimulation, However, both variants, without ligand stimulation, already had some activated forms of Raf and MAP kinases, Given current knowledge, the activated Raf/MAP kinase pathway was likely to be responsible for the survival of both variants in the cytokine-free medium, However, the growth of hybrids between wild type and either variant was unexpectedly dependent on GM-CSF, Both variants like the wild type cells were still susceptible to apoptosis induced by other stimuli, These results suggest that either the activated Raf/MAP kinase pathway in both variants fs not sufficient to repress the 'two-fold' death signals generated from the hybrids or that there is another mechanism that is responsible for the factor-independent growth of both variants.	ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; CATHAY GEN HOSP,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,TAIPEI,TAIWAN; NATL TAIWAN UNIV HOSP,DEPT MED GENET,TAIPEI,TAIWAN; CHINESE CULTURE UNIV,INST BIOTECHNOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,SCH MED,INST TOXICOL,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; Cathay General Hospital; National Taiwan University; National Taiwan University Hospital; Chinese Culture University; National Taiwan University			Yen, Jeffrey Jong-Young/Q-5134-2018; Kuo, Min-Liang/C-4872-2009	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; KUO, MIN-LIANG/0000-0002-7139-0144; TSENG, LI-HUI/0000-0002-8308-6772				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; KANAKURA Y, 1991, BLOOD, V77, P243; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKUDA K, 1994, EXP HEMATOL, V22, P1111; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TOMPSON CB, 1995, SCIENCE, V267, P1456, DOI DOI 10.1126/SCIENCE.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; YEN JJY, 1995, J IMMUNOL, V154, P2144	29	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					721	728		10.1038/sj.onc.1200884	http://dx.doi.org/10.1038/sj.onc.1200884			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038380	Bronze			2022-12-28	WOS:A1997WG43000011
J	Pershouse, MA; ElNaggar, AK; Hurr, K; Lin, H; Yung, WKA; Steck, PA				Pershouse, MA; ElNaggar, AK; Hurr, K; Lin, H; Yung, WKA; Steck, PA			Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma	ONCOGENE			English	Article						chromosome 4; loss of heterozygosity; carcinoma	CANCER; ALLELOTYPE; HETEROZYGOSITY; MARKERS	Genomic deletions involving chromosome 4 have recently been implicated in several human cancers. To identify and characterize genetic events associated with the development of head and neck squamous cell carinoma (HNSCC), a fine mapping of allelic losses associated with chromosome 4 was performed on DNA isolated from 27 matched primary tumor specimens and normal tissues. Loss of heterozygosity (LOH) of at least one chromosome 4 polymorphic allele was seen in the majority of tumors (92%). Alleic deletions were confined to short arm loci in four tumors and to the long arm loci in 12 tumors, suggesting the presence of two regions of common deletion. One region of frequent deletion was centered at D4S405 on 4p and included the loci D4S1546 to D4S428 in similar to 41% of the tumors. The common region of deletion on 4q was more complex and extended from D4S1571 to D4S1573, Frequent genetic alterations were observed within this region (4q25) and one marker, D4S407, exhibited a high frequency of LOH (>75%). These results indicate that alterations of chromosome 4 regions are associated with HNSCC tumorigenesis and further localizes the regions that may harbor tumor suppressor genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BRAIN TUMOR CTR,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA056041, R01CA051148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51148, R01 CA 56041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; FAN JB, 1994, HUM MOL GENET, V3, P243, DOI 10.1093/hmg/3.2.243; FUJIMOTO Y, 1994, CANCER RES, V54, P281; GRANDIS JR, 1993, CANCER RES, V53, P3579; GYAPAY G, 1994, NAT GENET, V7, P268; Hong WK, 1995, CLIN CANCER RES, V1, P677; JIN YS, 1993, CANCER RES, V53, P2140; MCGOWANJORDAN IJ, 1994, CANCER RES, V54, P2568; MITRA AB, 1994, CANCER RES, V54, P4481; MURRAY JC, 1992, NAT GENET, V2, P46, DOI 10.1038/ng0992-46; NAWROZ H, 1994, CANCER RES, V54, P1152; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; POLASCIK TJ, 1995, CANCER RES, V55, P5396; SATO T, 1991, CANCER RES, V51, P5118; SHIN DM, 1994, CANCER RES, V54, P321; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SPITZ MR, 1993, CANCER EPIDEM BIOMAR, V2, P329; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P706	27	66	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					369	373		10.1038/sj.onc.1200836	http://dx.doi.org/10.1038/sj.onc.1200836			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018123				2022-12-28	WOS:A1997WD51600013
J	Lu, QA; Kamps, MP				Lu, QA; Kamps, MP			Heterodimerization of Hox proteins with Pbx1 and oncoprotein E2a-Pbx1 generates unique DNA-binding specificities at nucleotides predicted to contact the N-terminal arm of the Hox homeodomain-demonstration of Hox-dependent targeting of E2a-Pbx1 in vivo	ONCOGENE			English	Article						E2a-Pbx1; oncoprotein; homeodomain; Hox	HOMEOBOX GENES; EXPRESSION; LEUKEMIA; EXTRADENTICLE; MOTIF; HOX-4.2; ELEMENT; FUSION; MICE; E2A	Hox proteins control genetic programs that orchestrate development, and a large subset of Hox proteins can bind DNA elements as heterodimers with the Pbx family of homeodomain proteins. A transcriptionally activated version of Phx1, E2a-Pbx1, is an oncoprotein in human pre-B cell leukemia that strongly suppresses differentiation and retains its ability to heterodimerize with Hox proteins. Because monomeric Hox proteins bind very similar DNA motifs, it is unclear how they activate diverse developmental programs. Here we demonstrate that heterodimers containing different Hox proteins and a common Pbx1 or E2a-Pbx1 partner bind different DNA motifs, Structural models suggest that the specificity of the Hox protein is altered by a conformation change involving residues in the N-terminal arm of the Hox homeodomain. Mutational analysis also supported the hypothesis that unique sequences in the N-terminal arm of the Hox homeodomain are at least partially responsible for mediating this specificity. lit vivo, Hox proteins directed E2a-Pbx1-mediated transactivation with moderate specificity to cognate Hox-Pbx motifs. Thus, the development specificity of individual Hox proteins may be mediated, in part, by differential targeting of cellular genes by Pbx1-Hox complexes. Likewise, through its function as a common heterodimer partner, oncoprotein E2a-Pbx1 may be able to interfere with multiple programs of development that are induced by the sequential or simultaneous expression of Hox proteins during hematopoiesis.	UNIV CALIF SAN DIEGO,DEPT PATHOL,SCH MED,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of California System; University of California San Diego; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA056876, P01CA050528] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876-05, 2 PO1 CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CARROLL AJ, 1984, BLOOD, V63, P721; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAWRENCE HJ, 1993, CELL GROWTH DIFFER, V4, P665; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MATHEWS CHE, 1991, BLOOD, V78, P2248; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETRINI M, 1992, BLOOD, V80, P185; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; ZENG WL, 1993, DEVELOPMENT, V118, P339	39	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					75	83		10.1038/sj.onc.1200799	http://dx.doi.org/10.1038/sj.onc.1200799			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010234	Bronze			2022-12-28	WOS:A1997WB76000007
J	Bell, B; Sadowski, I				Bell, B; Sadowski, I			Ras-responsiveness of the HIV-1 LTR requires RBF-1 and RBF-2 binding sites	ONCOGENE			English	Article						HIV-1 LTR; Ras; transcription; RBF-1; RBF-2	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PROTEIN-KINASE-C; ETS DOMAIN PROTEIN; GENE-EXPRESSION; T-CELLS; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; FAMILY PROTEINS	Lentiviruses characteristically form latent integrated proviruses whose transcription can be induced by cell regulatory signals. The HIV-1 LTR responds to multiple signals, including the Ras pathway. We report here that Ras-responsive HIV-1 transcription requires two previously undescribed factors, RBF-1 and RBF-2 in Jurkat T cells. RBF-1 binds to Ets-like motifs located between nucleotides -151 and -142, and within the NF-kappa B binding sites, but is distinct from Ets-l or Elf-1. RBF-2 binds the HIV-1 LTR at nucleotides -131 and -121 and immediately 3' of the TATA box. Both RBF-1 and RBF-2 contain DNA binding subunits of relative molecular weight 100 kilodaltons. Mutation of the RBF-1 and RBF-2 binding elements (RBEs) prevents Ras stimulation of HIV-1 LTR-directed transcription. These data define a mechanism for Ras responsiveness of HIV-1 transcription that involves the previously uncharacterized factors RBF-1 and RBF-2.	UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia								ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DEHBI M, 1994, ONCOGENE, V9, P2399; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EICHER DM, 1994, J IMMUNOL, V152, P2710; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; GARCIA JA, 1994, AIDS, V8, pS3; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB EI, 1990, J VIROL, V64, P3654, DOI 10.1128/JVI.64.8.3654-3660.1990; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hodge DR, 1996, ONCOGENE, V12, P11; HOHASHI N, 1995, INT IMMUNOL, V7, P1851, DOI 10.1093/intimm/7.11.1851; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KELLER A, 1992, J VIROL, V66, P3946, DOI 10.1128/JVI.66.6.3946-3949.1992; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; KINTER AL, 1990, J VIROL, V64, P4306, DOI 10.1128/JVI.64.9.4306-4312.1990; KOKEN SEC, 1992, VIROLOGY, V191, P968, DOI 10.1016/0042-6822(92)90274-S; LEE AH, 1992, J VIROL, V66, P3236, DOI 10.1128/JVI.66.5.3236-3240.1992; LEYS RD, 1990, J VIROL, V64, P1207; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MOSES AV, 1994, J VIROL, V68, P298, DOI 10.1128/JVI.68.1.298-307.1994; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL G, 1990, NATURE, V344, P178, DOI 10.1038/344178b0; Nabel Gary J., 1993, P49; NAKANISHI Y, 1991, J VIROL, V65, P6334, DOI 10.1128/JVI.65.11.6334-6338.1991; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WILLIAMS DH, 1995, EUR J IMMUNOL, V25, P42, DOI 10.1002/eji.1830250109; Yang BS, 1996, MOL CELL BIOL, V16, P538; YI Z, 1992, J VIROL, V66, P5631, DOI 10.1128/JVI.66.9.5631-5634.1992; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991	65	26	26	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2687	2697						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000143				2022-12-28	WOS:A1996VZ65400019
J	Soloway, PD; Alexander, CM; Werb, Z; Jaenisch, R				Soloway, PD; Alexander, CM; Werb, Z; Jaenisch, R			Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host	ONCOGENE			English	Article						Timp-1; metastasis; proteinase inhibitor; targeted mutant	B16-F10 MELANOMA-CELLS; EMBRYONIC STEM-CELLS; TISSUE INHIBITOR; MATRIX METALLOPROTEINASE; EXPRESSION; COLLAGENASE; LOCALIZATION; PROTEINASES; GELATINASES; SECRETION	Timp-1 has been implicated as a suppressor of tumor metastasis, To study the relative importance of Timp-1 expression by tumor vs host during tumor invasion, three pairs of co-isogenic, tumorigenic cells containing wildtype or mutant Timp-1 alleles were generated, These were used in experimental metastasis assays in wild-type or Timp-1-deficient mice, Timp-1 expression in tumorigenic cells could either increase or decrease tumor invasion of lungs in a tumor cell-specific manner, This suggests that depending on the tumor, Timp-1 can either suppress or potentiate metastasis. Mice deficient for Timp-1 were indistinguishable from wild-type mice in metastasis assays with all tumorigenic cells tested, Although Timp-1 is a secreted protein, and lung produces other Timps, the influence of Timp-1 on lung invasion by the tumorigenic cells tested is cell-autonomous, depending only on Timp-1 genotype of tumor and not that of host.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,DEPT ANAT,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437	NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015325] Funding Source: NIH RePORTER; NCI NIH HHS [CA57621] Funding Source: Medline; NEI NIH HHS [EY11279] Funding Source: Medline; NIGMS NIH HHS [GM15325] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CLAVEL C, 1992, B CANCER, V79, P261; DOCHERTY AJ, 1995, NATURE, V318, P66; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HICKS NJ, 1984, INT J CANCER, V33, P835, DOI 10.1002/ijc.2910330620; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MAQUAT LE, 1995, RNA, V1, P453; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PONTON A, 1991, CANCER RES, V51, P2138; Sambrook J., 2002, MOL CLONING LAB MANU; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHULTZ RM, 1988, CANCER RES, V48, P5539; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WANG X, 1994, CANCER RES, V54, P4726; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307	34	109	113	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2307	2314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957071				2022-12-28	WOS:A1996VX10800002
J	Choubey, D; Gutterman, JU				Choubey, D; Gutterman, JU			Inhibition of E2F-4/DP-1-stimulated transcription by p202	ONCOGENE			English	Article						E2F-4-mediated transcription; interferon inducible p202; cell growth inhibition; p107; p130	CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; FACTOR E2F; INTERFERON ACTION; FACTOR DRTF1/E2F; FAMILY MEMBERS; DP FAMILY; GENE; BINDING; P107	The interferon (IFN)-inducible proteins mediate activities of the interferons including the cell growth-regulatory activity. We have shown that p202, an IFN-inducible 52kDa primarily nuclear phosphoprotein whose expression in transfected cells inhibits cell proliferation, interacts with the retinoblastoma tumor suppressor protein (pRb) and the transcription factor E2F (E2F-1/DP-1) in vitro and in vivo. p202 was shown to inhibit E2F-1/DP-1-stimulated transcription of a reporter gene and of endogenous genes. Here we report that expression of p202 inhibited E2F-4/DP-1-stimulated transcription of a reporter gene in transfected cells. Furthermore, this inhibition was associated with the inhibition of the sequence-specific DNA-binding of E2F-4 both in complex with the pocket proteins p107 or p130 and in its 'free' form in vitro. p202 bound to p107 and p130 in vitro and in vivo and also associated with E2F-4, supporting the notion that complexes containing p107/E2F-4 or p130/E2F-4 and p202 exist in vivo. Moreover, cotransfection of E2F-4-encoding plasmid in AKR-2B cells overcame p202-mediated inhibition of cell growth, raising the possibility that p202 contributes to cell growth inhibition by the interferons, at least in part, by modulating E2F-4-mediated transcription.			Choubey, D (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MED ONCOL,BOX 41,HOUSTON,TX 77030, USA.		Choubey, Divaker/A-4771-2008		NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER; NCI NIH HHS [CA69031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMAEYER EM, 1988, INTERFERONS REGULATO; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOOSS K, 1995, ONCOGENE, V10, P1529; JORDAN KL, 1994, ONCOGENE, V9, P1177; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Min W, 1996, MOL CELL BIOL, V16, P359; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZHU L, 1993, GENE DEV, V7, P111; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	59	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					291	301		10.1038/sj.onc.1201184	http://dx.doi.org/10.1038/sj.onc.1201184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233764				2022-12-28	WOS:A1997XK99900006
J	Tsuneoka, M; Nakano, F; Ohgusu, H; Mekada, E				Tsuneoka, M; Nakano, F; Ohgusu, H; Mekada, E			c-myc activates RCC1 gene expression through E-box elements	ONCOGENE			English	Article						c-myc; RCC1; E box element; gene expression	PREMATURE CHROMOSOME CONDENSATION; ORNITHINE DECARBOXYLASE GENE; NUCLEAR-PROTEIN IMPORT; LOOP-HELIX PROTEIN; CELL-CYCLE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSFORMATION; BETA-GALACTOSIDASE; REPRESSOR SIN3	Proto-oncogene c-myc is implicated in proliferation of Although c-Myc protein has been function as a transcription factor recognizing an E-box (CACGTG) element, few c-myc-regulated genes have been identified and the specific role of c-myc is still unclear, RCC1 is necessary for mammalian cells to proliferate, Four CACGTG elements exist within 1.3 kb downstream of the major transcription start site for the human RCC1 gene in HeLa cells, Stimulation of HeLa cells with serum increased c-myc expression and RCC1 expression, Therefore the relationship between the expression of RCC1 and c-myc was investigated, Rat 3Y1 cells overexpressing c-myc contained about tw ice as much RCC1 mRNA as control cells, When a chimeric protein comprised of c-myc and the estrogen binding domain of estrogen receptor was activated by addition of 4-hydroxytamoxifen (OHT), expression of RCC1 mRNA increased twofold, To examine whether c-MSc functions through the CACGTG elements, a DNA fragment of RCC1 intron 4, exon 5 and part of intron 5 was joined to firefly luciferase cDNA to construct a reporter plasmid, In transient expression experiments using HeLa cells, co-transfection with c-myc stimulated the luciferase activity up to 2.5-fold in a dose-dependent manner, When the CACGTG elements in the reporter plasmid were destroyed, stimulation by c-myc was not observed, The four CACGTG elements did not contribute equally to the stimulation by c-myc. Gel retardation experiments suggest that c-Myc with Max binds to the CACGTG elements in the context of the RCC1 gene sequence in vitro. These results indicate that c-Myc can regulate expression of RCC1 through the E-box elements.			Tsuneoka, M (corresponding author), KURUME UNIV, INST LIFE SCI, 2432-3 AIKAWA MACHI, KURUME, FUKUOKA 839, JAPAN.			Mekada, Eisuke/0000-0001-8858-4781				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; ECKERT RL, 1982, CANCER RES, V42, P139; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FURUNO N, 1991, GENOMICS, V11, P459, DOI 10.1016/0888-7543(91)90156-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TOBIAS KE, 1995, ONCOGENE, V11, P1721; TSUNEOKA M, 1992, J BIOL CHEM, V267, P9107; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WEN L, 1989, J BIOL CHEM, V264, P9016; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408; YOSHIMORI T, 1988, CELL STRUCT FUNCT, V13, P311, DOI 10.1247/csf1975.13.311; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	65	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2301	2311		10.1038/sj.onc.1201067	http://dx.doi.org/10.1038/sj.onc.1201067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178906				2022-12-28	WOS:A1997WY88300007
J	Grammer, TC; Blenis, J				Grammer, TC; Blenis, J			Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases	ONCOGENE			English	Article						MAPK; MEK; phosphatidylinositol-3 kinase; protein kinase C	GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; CYCLIC-AMP; INSULIN; PHOSPHORYLATION; TYROSINE; WORTMANNIN; PP90RSK; CELLS; IDENTIFICATION	The mitogen-activated protein kinases (MAPKs) ERK-1 and ERK-2 are activated by a wide variety of oncogenes and extracellular stimuli. The MAPKs participate in a signalling cascade downstream of growth factor/cytokine receptors, Ras, Raf, and MEK. However, MAPK activation is more complicated than a simple linear pathway, and the evidence presented here supports a model of multiple, temporally distinct pathways converging on MAPK which are differentially utilized by various stimuli and cell types. In addition to MEK-dependent MAPK activation, we provide evidence for MEK-independent regulation of the MAPKs. Our results suggest that phosphatidylinositol-3-kinases (PI(3)K) or conventional protein kinase C isoforms (cPKCs) partially contribute to MEK-dependent activation. Importantly, we also find that PI3K and cPKCs play a major role in the MEK-independent, prolonged MAPK activation by platelet-derived growth factor signalling. This finding is of interest as the maintained activation of MAPK has been correlated by others to the regulation of cell proliferation and differentiation.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERBY IM, 1994, J BIOL CHEM, V269, P30485; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H	26	178	179	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	1997	14	14					1635	1642		10.1038/sj.onc.1201000	http://dx.doi.org/10.1038/sj.onc.1201000			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135064				2022-12-28	WOS:A1997WR89300001
J	Jay, P; BergeLefranc, JL; Marsollier, C; Mejean, C; Taviaux, S; Berta, P				Jay, P; BergeLefranc, JL; Marsollier, C; Mejean, C; Taviaux, S; Berta, P			The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p	ONCOGENE			English	Article						CYR61; immediate early gene; CCN family; mosaic protein	IDENTIFICATION; EXPRESSION; PROTEIN; CELLS; HYBRIDIZATION; DELETION; PRODUCT; FAMILY; BETA; NOV	Complementary DNA encoding the human CYR61 protein was isolated from human embryonic tissues and mapped to chromosome 1p22-p31. We show that CYR61 encodes a 381 amino acid protein rich in cysteine and proline residues that is strongly conserved with the mouse homologue. Sequence analysis reveals the presence of several distinct protein domains which confer a mosaic structure to this protein and makes human CYR61 a member of a recently described growth regulator family that includes several proto-oncogene products. From our results we hypothesize that this new immediate early gene may play a role in cell commitment during embryogenesis and more generally in the control of cell proliferation.	CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,INSERM U249,F-34033 MONTPELLIER,FRANCE; FAC MED MARSEILLE,INSERM U406,F-13385 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Jay, Philippe/I-7116-2016; Jay, Philippe/ABD-9223-2020	Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700				BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHEN ZY, 1993, GENOMICS, V16, P533, DOI 10.1006/geno.1993.1224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GEHRING M, 1995, CANCER RES, V55, P5366; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JAY P, 1996, IN PRESS GENOMICS; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SIMON D, 1991, ONCOGENE, V6, P765; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P121; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; ZABEL BU, 1985, P NATL ACAD SCI USA, V82, P469, DOI 10.1073/pnas.82.2.469	33	61	80	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1753	1757		10.1038/sj.onc.1200986	http://dx.doi.org/10.1038/sj.onc.1200986			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135077				2022-12-28	WOS:A1997WR89300014
J	Chen, HJ; Ke, YQ; Oates, AJ; Barraclough, R; Rudland, PS				Chen, HJ; Ke, YQ; Oates, AJ; Barraclough, R; Rudland, PS			Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line	ONCOGENE			English	Article						human metastasis-inducing DNAs; rat mammary cells; osteopontin regulation	CALCIUM-BINDING PROTEIN; HUMAN-BREAST-CANCER; TRANSFECTION; OSTEOPONTIN; BENIGN; TUMOR; ONCOGENES; SEQUENCE; GENE; FIBROBLASTS	Benign rat mammary epithelial cells transfected with restriction enzyme-fragmented DNA from a human malignant metastatic cell line (Ca2-83) produces transfectants that yield metastatic tumours in syngeneic rats. The six metastasis-inducing DNAs (Met-DNAs) that have been isolated from such transfectants are subgene in size and do not code for any expressed mRNAs, but correspond to potential regulatory regions of human DNA from malignant, metastatic cells. In pilot studies the one Met-DNA tested is detectable in some human breast tumours but not in normal tissue. Transfection of all six Met-DNAs singly into the benign mammary epithelial cells causes enhanced expression of osteopontin, whilst transfection of cDNA for osteopontin also induces the metastatic state. These results show that short regulatory DNAs exist in human cancer cells that can induce metastatic spread via a common effector gene, osteopontin, in model rat mammary cell lines.	UNIV LIVERPOOL, SCH BIOL SCI, CANC & POLIO RES FUND LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ANATHAWASWAMY HN, 1988, J CELL BIOCHEM, V36, P137; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BEHREND EI, 1994, CANCER RES, V54, P832; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 1996, INT J CANCER, V65, P104; DAVIES BR, 1994, CANCER RES, V54, P2785; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; ENGEL LW, 1978, CANCER RES, V38, P3352; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FISHER MS, 1981, CANCER RES, V41, P3018; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GIBBINS JR, 1991, ANTICANCER RES, V11, P129; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; KAMBY C, 1990, CANCER TREAT REV, V17, P37, DOI 10.1016/0305-7372(90)90075-Q; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oates AJ, 1996, ONCOGENE, V13, P97; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; RADLERPOHL A, 1988, INT J CANCER, V41, P840, DOI 10.1002/ijc.2910410611; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RUDLAND PS, 1985, CANCER RES, V45, P3864; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TARIN D, 1988, CIBA F SYMP, V141, P149; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0	43	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1581	1588		10.1038/sj.onc.1200993	http://dx.doi.org/10.1038/sj.onc.1200993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129149				2022-12-28	WOS:A1997WQ54800009
J	Atanasoski, S; Schreiber, E; Fontana, A; Herr, W				Atanasoski, S; Schreiber, E; Fontana, A; Herr, W			N-Oct 5 is generated by in vitro proteolysis of the neural POU-domain protein N-Oct 3	ONCOGENE			English	Article						EMSA; transcription; DNA-binding; protease inhibitors	OCTAMER BINDING-PROTEINS; DNA-BINDING; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; MOTIF; ACTIVATION; PROMOTER; EXPRESSION; ELEMENTS; CELLS	The neural POU-domain proteins N-Oct 3 and N-Oct 5 were first identified in electrophoretic mobility retardation assays through their ability to bind to the octamer sequence ATGCAAAT. These two N-Oct factors are detected in extracts from tumor-derived and normal neural cells. They are present differentially, however, in extracts from melanocytes and melanoma cells: N-Oct 3 is present in extracts from both melanocytes and melanoma cells, whereas N-Oct 5 is more evident in extracts from metastatic melanoma cells. We show here that a cDNA encoding N-Oct 3 directs synthesis of both the N-Oct 3 and N-Oct 5 proteins and that the N-Oct 5 protein in neural and melanoma-cell extracts is also related to N-Oct 3. N-Oct 5, however, is apparently not expressed in vivo: It is not detected if cells are rapidly lysed in SDS or if extracts are prepared with a cocktail of protease inhibitors that includes the serine-protease inhibitor 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF). These data suggest that N-Oct 5 is a specific in vitro proteolytic cleavage product of N-Oct 3 and is not directly related to melanocyte malignancy.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV ZURICH HOSP, DEPT INTERNAL MED, DIV CLIN IMMUNOL, CH-8044 ZURICH, SWITZERLAND; CALYDON INC, MENLO PK, CA 94025 USA	Cold Spring Harbor Laboratory; University of Zurich; University Zurich Hospital			Herr, Winship/E-6491-2012; Atanasoski, Suzana/A-3275-2011	Herr, Winship/0000-0002-3606-4546; Atanasoski, Suzana/0000-0001-7340-0775	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGUS J, 1995, ONCOGENE, V11, P691; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; DAS G, 1993, J BIOL CHEM, V268, P25026; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; Harlow E., 1988, ANTIBODIES LAB MANUA; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; SCHREIBER E, 1992, CANCER RES, V52, P6121; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	31	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1287	1294		10.1038/sj.onc.1200953	http://dx.doi.org/10.1038/sj.onc.1200953			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178889				2022-12-28	WOS:A1997WP10900004
J	Asimakopoulos, FA; Hinshelwood, S; Gilbert, JGR; Delibrias, CC; Gottgens, B; Fearon, DT; Green, AR				Asimakopoulos, FA; Hinshelwood, S; Gilbert, JGR; Delibrias, CC; Gottgens, B; Fearon, DT; Green, AR			The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera	ONCOGENE			English	Article						polycythemia vera; SHP-1; myeloproliferative disorders	ERYTHROPOIETIN RECEPTOR GENE; PROTEIN-TYROSINE-PHOSPHATASE; VIRUS GP55 GLYCOPROTEIN; ERYTHROID PROGENITORS; MYELOPROLIFERATIVE DISORDERS; MOLECULAR ANALYSIS; DNA METHYLATION; MOTH-EATEN; C-KIT; INTERLEUKIN-3	Polycythemia vera (PV) is an acquired clonal disorder characterized by increased production of mature red cells and growth of erythroid colonies in the absence of erythropoietin. Mutation of the erythropoietin receptor has been demonstrated to cause familial polycythemia, but no mutations have been found in PV, Moreover, both erythroid and myeloid progenitors from patients with PV have been reported to be hypersensitive to a number of different growth factors. Attention has therefore focused on post-receptor signal transduction pathways, The SHP-1 gene is an especially attractive candidate gene. Firstly, SHP-1 binds to and negatively regulates signalling from the erythropoietin receptor and is likely to regulate other cytokine receptors in a similar manner, Secondly, absence of SHP-1 protein in the motheaten mouse is accompanied by increased sensitivity of hematopoietic progenitors to a number of cytokines including erythropoietin, Thirdly, familial or sporadic polycythemia in man may result from mutations of the SHP-1 binding domain of the erythropoietin receptor. We have therefore searched for mutations of the SHP-1 gene in genomic DNA from patients with PV. In this disease the majority of peripheral blood lymphocytes are not part of the malignant clone and a variable proportion of myeloid cells may arise from normal progenitors. We have therefore chosen to study DNA from purified peripheral blood granulocytes obtained from nine women in whom the granulocytes were clonally derived. Southern analysis was used to show that the gene was not rearranged and densitometry confirmed the presence of two copies of the gene in each DNA sample. Sequencing of the entire coding region and all splice junctions revealed no mutations, Hematopoietic transcription factor binding sites in the SHP-1 promoter region were intact and the methylation status of the two SHP-1 promoters in PV patients was identical to that in three normal controls, Finally, we showed that levels of SHP-1 protein in granulocytes from patients was similar to those from normal controls. These results demonstrate that the SHP-1 gene is structurally and transcriptionally intact in patients with PV.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; UNIV CAMBRIDGE, DEPT MED, WELLCOME TRUST IMMUNOL UNIT, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge				Gottgens, Berthold/0000-0001-6302-5705; Gilbert, James/0000-0001-8079-3159; Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CHRETIEN S, 1994, BLOOD, V83, P1813; Cooper D. N., 1993, HUMAN GENE MUTATION; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1994, BRIT J HAEMATOL, V86, P12, DOI 10.1111/j.1365-2141.1994.tb03246.x; DAI CH, 1992, BLOOD, V80, P891; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DUDLEY JM, 1990, BRIT J HAEMATOL, V75, P188, DOI 10.1111/j.1365-2141.1990.tb02647.x; EAVES CJ, 1978, BLOOD, V52, P1196; ERIDANI S, 1987, BRIT J HAEMATOL, V67, P387, DOI 10.1111/j.1365-2141.1987.tb06158.x; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; Green AR, 1996, LANCET, V347, P844, DOI 10.1016/S0140-6736(96)91338-0; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOBAYASHI S, 1993, BRIT J HAEMATOL, V83, P539, DOI 10.1111/j.1365-2141.1993.tb04688.x; KRANTZ SB, 1991, BLOOD, V77, P419; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; PRCHAL JT, 1994, BLOOD, V83, P1; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SOKOL L, 1994, EXP HEMATOL, V22, P447; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; WARD JC, 1992, EXP HEMATOL, V20, P371; WASSERMAN LR, 1995, POLYCYTHEMIA VERA MY; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	48	40	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1215	1222		10.1038/sj.onc.1200942	http://dx.doi.org/10.1038/sj.onc.1200942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121771				2022-12-28	WOS:A1997WM78200011
J	Gorospe, M; Cirielli, C; Wang, XT; Seth, P; Capogrossi, MC; Holbrook, NJ				Gorospe, M; Cirielli, C; Wang, XT; Seth, P; Capogrossi, MC; Holbrook, NJ			p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells	ONCOGENE			English	Article						melanoma; p53; p21; apoptosis	CYCLE CONTROL; G(1) ARREST; P53; EXPRESSION; ADENOVIRUS; CANCER; P21	The tumor suppressive effect of p53 is believed to be rooted in its two primary functions: the implementation of cellular growth arrest and the execution of apoptotic cell death, While p53-regulated expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) appears to be central for the implementation of G(1) arrest, the participation of p21(Waf1/Cip1) in p53-triggered cell death remains controversial, In the present study, overexpression of p53 in human melanoma SK-MEL-110 cells through use of an adenoviral expression vector (AdCMV,p53) was found to result in apoptosis, while similar infection of primary vascular smooth muscle cells (VSMC) instead resulted in a moderate inhibition of growth, Expression of p21(Waf1/Cip1) was strongly elevated in VSMC, but showed little change in SK-MEL-110 cells, although expression of another p53-regulated gene (GADD45) was comparable in both AdCMV.p53-infected cell types, Evidence that p21(Waf1/Cip1) expression may be required for surviving p53-induced cell death was further supported by the finding that p53 overexpression was highly toxic for p21-deficient mouse embryonal fibroblasts (p21(-/-) MEFs), In both SK-MEL-110 and p21(-/-) MEFs, adenovirus-driven ectopic expression of p21(Waf1/Cip1) resulted in a substantial protection against p53-induced apoptosis, indicating that p21(Waf1/Cip1) rescued cells from a path of programmed cell death to one of enhanced survival.	NIA,NIH,CELLULAR & MOL BIOL LAB,BALTIMORE,MD 21224; NIA,NIH,CARDIOVASC SCI LAB,BALTIMORE,MD 21224; NCI,MED BRANCH,MED BREAST CANC SECT,NIH,BETHESDA,MD 20892; IST DERMOPAT IMMACOLATA,LAB PATOL VASCOLARE,I-00167 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Istituto Dermopatico dell'Immacolata (IDI)				Cirielli, Corrado/0000-0003-2524-7889				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIRIELLI C, 1995, INT J CANCER, V63, P1; CLAYMAN GL, 1995, CANCER RES, V55, P1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DRAZAN KE, 1994, SURGERY, V116, P197; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; GOROSPE M, 1996, IN PRESS MOL CELL BI; GOROSPE M, 1996, CANCER RES, V56, P457; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KIM YH, 1992, J IMMUNOL, V149, P17; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210	35	292	298	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					929	935		10.1038/sj.onc.1200897	http://dx.doi.org/10.1038/sj.onc.1200897			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050992				2022-12-28	WOS:A1997WK34400006
J	Lorenzo, MJ; Gish, GD; Houghton, C; Stonehouse, TJ; Pawson, T; Ponder, BAJ; Smith, DP				Lorenzo, MJ; Gish, GD; Houghton, C; Stonehouse, TJ; Pawson, T; Ponder, BAJ; Smith, DP			RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2	ONCOGENE			English	Article						RET; multiple endocrine neoplasia type 2; Hirschsprung disease; Shc; Grb2	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; SIGNAL-TRANSDUCTION; HIRSCHSPRUNG DISEASE; NUCLEOTIDE EXCHANGE; POINT MUTATION; PROTOONCOGENE; RECEPTOR; PROTEIN	Activating germline mutations of the RET receptor tyrosine kinase are found in the majority of cases of inherited cancer syndrome MEN 2, and inactivating mutations in some cases of dominantly inherited Hirschsprung disease. Using RET activated by a MEN 2 mutation, we show that both the SH2 and PTB domains of the adaptor protein Shc interact with RET, and we identify the PTB domain interaction site. Interaction with both the SH2 and PTB domains of She contributes to the transcriptional activation of a serum response element. RET alternate splicing affects the strength of interaction with both the She SH2 and PTB domains. In addition, a splice isoform-specific HSCR missense mutation, which does not inactivate the RET kinase activity, decreases the strength of the PTB domain interaction and the level of RET-dependent She phosphorylation.	UNIV CAMBRIDGE, ADDENBROOKES HOSP,DEPT PATHOL,CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1TN, ENGLAND; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Lorenzo, Maria Jesus/0000-0003-4416-0615				ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CROWE AJ, 1994, ONCOGENE, V9, P537; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gotoh N, 1995, ONCOGENE, V11, P2525; GUITON M, 1994, J BIOL CHEM, V269, P30370; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JOHANSEN FE, 1996, BIOCHIM BIOPHYS ACTA, V1242, P1; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PONDER BAJ, 1996, IN PRESS ADV CAN RES; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	111	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					763	771		10.1038/sj.onc.1200894	http://dx.doi.org/10.1038/sj.onc.1200894			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047383	Bronze			2022-12-28	WOS:A1997WJ11200002
J	MacCallum, DE; Hupp, TR; Midgley, CA; Stuart, D; Campbell, SJ; Harper, A; Walsh, FS; Wright, EG; Balmain, A; Lane, DP; Hall, PA				MacCallum, DE; Hupp, TR; Midgley, CA; Stuart, D; Campbell, SJ; Harper, A; Walsh, FS; Wright, EG; Balmain, A; Lane, DP; Hall, PA			The p53 response to ionising radiation in adult and developing murine tissues	ONCOGENE			English	Article						p53; radiation; apoptosis; development; heterogeneity; immunochemistry; teratogenesis; transgenesis	CELLULAR TUMOR-ANTIGEN; P53-DEFICIENT MICE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; GASTROINTESTINAL-TRACT; P53-MEDIATED APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GAMMA-IRRADIATION; HELA-CELLS	The induction of the p53 response to ionising radiation has been studied during murine development and in the adult animal. The response has been assessed by precise quantitative assay of p53 protein levels in tissues and by immunohistochemistry. Newly developed transgenic mice in which a lacZ transgene is driven by a p53 response element have also been used to directly assess the transcriptional activity of the induced protein, There is striking developmental control of the p53 response so that in early development all tissues accumulate high levels of p53 following radiation and indeed p53 is present at elevated levels in some unirradiated tissues, Later in development clear heterogeneity of the p53 response becomes apparent, both in terms of the responses of individual tissues and of cell populations, within those tissues, The study of lacZ transgene expression and the occurrence of apoptosis in different tissues that accumulate p53 protein point to a further level of control regulating the nature and degree of the downstream response to elevated levels of p53 in cells, These findings have important implications for the susceptibility of different tissue types to carcinogenic and other insults, The early expression of the p53 response is consistent with novel models of p53 function that suggest it may have evolved principally as a defense against teratogenic insult that permits plasticity of development.	UNIV DUNDEE, DEPT MOL & CELLULAR PATHOL, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, CRC, CELL TRANSFORMAT GRP, DEPT BIOCHEM, DUNDEE DD1 9SY, SCOTLAND; BEATSON INST CANC RES, CRC, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND; UNITED MED & DENT SCH, TRANSGEN UNIT, LONDON SE1 9RT, ENGLAND; UNITED MED & DENT SCH, DEPT EXPT PATHOL, LONDON SE1 9RT, ENGLAND; MRC, RADIAT & GENOME STABIL UNIT, DIDCOT OX11 0RD, OXON, ENGLAND; UNIV DUNDEE, CTR BIOMED RES, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; Beatson Institute; University of London; King's College London; University of London; King's College London; MRC Harwell; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BELLAMY COC, 1996, UNPUB; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAMPBELL SF, IN PRESS J CELL SCI; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ferreira A, 1996, J CELL SCI, V109, P1509; FORBES RM, 1953, J BIOL CHEM, V203, P359; FREBOURG T, 1992, CANCER RES, V52, P6976; GOTTLIEB ER, UNPUB; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL PA, 1994, J CELL SCI, V107, P3569; Hall PA, 1996, J PATHOL, V180, P1; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, EUR J CANCER, V30A, P2001, DOI 10.1016/0959-8049(94)00394-K; HANSEN S, 1996, IN PRESS J BIOL CHEM; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOEVER M, 1994, ONCOGENE, V9, P109; Hogan B, 1994, MANIPULATING MOUSE E; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kitada S, 1996, ONCOGENE, V12, P187; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOMAROVA EA, UNPUB; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P543, DOI 10.1111/j.1365-2559.1993.tb00174.x; MCKEE PH, 1993, HISTOPATHOLOGY, V23, P377, DOI 10.1111/j.1365-2559.1993.tb01223.x; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MERRICK BA, 1995, BIOTECHNIQUES, V18, P292; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RUGH R, 1963, AMER J ROENTGENOL RA, V89, P182; RUSSELL LB, 1957, P SOC EXP BIOL MED, V95, P174; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WEINBERG WC, 1995, ONCOGENE, V10, P2271; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIRNITZER U, 1995, CARCINOGENESIS, V16, P697, DOI 10.1093/carcin/16.4.697; Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0	66	187	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2575	2587						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000131				2022-12-28	WOS:A1996VZ65400007
J	Bottger, V; Bottger, A; Howard, SF; Picksley, SM; Chene, P; GarciaEcheverria, C; Hochkeppel, HK; Lane, DP				Bottger, V; Bottger, A; Howard, SF; Picksley, SM; Chene, P; GarciaEcheverria, C; Hochkeppel, HK; Lane, DP			Identification of novel mdm2 binding peptides by phage display	ONCOGENE			English	Article						mdm2; hdm2; p53; phage display library; peptide inhibitors	TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; SYNTHETIC PEPTIDES; EPITOPE LIBRARY; P53; LIGANDS; PROTEIN	The oncogene mdm2 and its human homologue hdm2 bind to the tumour suppressor protein p53 and inactivate its function as a transcription factor. This has been implied as a possible mechanism for cancer development in several tumours including human sarcomas. The mdm2-p53 interaction is therefore a much persued target for the development of anti-cancer drugs. In order to find novel high affinity ligands for hdm2 which would interfere with its binding to p53 we screened phage display peptide libraries for mdm2 binding phage. We found a series of 12 and 15mer peptides which interact strongly with hdm2. The peptide sequences show striking homology with the previously established mdm2 binding site on p53, confirming that the peptide defined (18)TFSDLW(23) region is crucial for the interaction but that contact between the two molecules extends to position L(26) On p53. Free synthetic peptides derived from the phage selected sequences proved to be up to 100 times stronger inhibitors of the p53-mdm2 interaction than the p53 derived wt-peptide in several ELISA-assays. This illustrates the potency of phage display libraries in the search for new peptide based lead structures designed to mimic or inhibit therapeutically important protein-protein interactions.	UNIV DUNDEE, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND	University of Dundee; Novartis			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545; Bottger, Angelika/0000-0003-3273-9558				BOTTGER V, 1995, J MOL BIOL, V247, P932, DOI 10.1006/jmbi.1995.0191; BOTTGER V, 1994, J MOL BIOL, V235, P61, DOI 10.1016/S0022-2836(05)80013-0; CHAN S, 1987, MOL CELL PROBE, V1, P73, DOI 10.1016/0890-8508(87)90008-9; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SNYDER LC, 1987, SOMAT CELL MOLEC GEN, V13, P235; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	28	178	196	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2141	2147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950981				2022-12-28	WOS:A1996VV14500011
J	Taki, T; Hayashi, Y; Taniwaki, M; Seto, M; Ueda, R; Hanada, R; Suzukawa, K; Yokota, J; Morishita, K				Taki, T; Hayashi, Y; Taniwaki, M; Seto, M; Ueda, R; Hanada, R; Suzukawa, K; Yokota, J; Morishita, K			Fusion of the MLL gene with two different genes, AF-6 and AF-5 alpha, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia	ONCOGENE			English	Article						AF-5 alpha; complex chromosomal translocation; infant leukemia; topoisomerase II recognition site-like sequence	ACUTE LYMPHOBLASTIC-LEUKEMIA; YEAST ARTIFICIAL CHROMOSOME; BREAKPOINT CLUSTER REGION; TUMOR-SUPPRESSOR PROTEIN; ACUTE MYELOID LEUKEMIAS; IN-SITU HYBRIDIZATION; DNA TOPOISOMERASE-II; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; SEPTATE JUNCTIONS	We analysed a complex translocation involving chromosomes 5, 6, 8 and 11 in a case of infant leukemia. Molecular analysis of the MLL gene revealed that MLL was fused with two different genes, AF-6 on chromosome 6q27 and AF-5 alpha. AF-5 alpha, the 11th partner gene fused with MLL, is a novel gene mapped to chromosome 5q12, which encodes a 31 kDa protein of 269 amino acids and contains possible nuclear targeting sequence, potential leucine zipper dimerization motif and an alpha-helical coiled-coil domain. In situ hybridization and molecular cloning analyses demonstrated that two different types of chromosomal recombination had occurred in the cells. One was a three-way translocation among chromosomes 6, 8 and 11, and the other was an insertion of a chromosome 5-derived segment into the breakpoint of chromosomes 8 and 11. Accordingly, the karyotype was defined as del(5)(q11.2q12), der(6)t(6;8) (q27;q11.2), der(8)(8pter-->8q11.2::5q11.2-->5q12::11q23-->11qter), der(11)t(6;11) (q27;q23). Thus, the MLL gene created two different fusion mRNAs, since the chromosome 11 split into two different chromosomes 5 and 6. This is the first report demonstrating fusion of the MLL gene with two different genes by a complex translocation.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, FAC MED, DEPT PEDIAT, BUNKYO KU, TOKYO 113, JAPAN; HAMAMATSU UNIV SCH MED, DEPT PEDIAT, HAMAMATSU, SHIZUOKA 43131, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT INTERNAL MED 3, KAMIGYO KU, KYOTO 602, JAPAN; AICHI CANC CTR, RES INST, LAB CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; SAITAMA CHILDRENS MED CTR, DIV HEMATOL ONCOL, IWATSUKI, SAITAMA 339, JAPAN	National Cancer Center - Japan; University of Tokyo; Hamamatsu University School of Medicine; Kyoto Prefectural University of Medicine; Aichi Cancer Center; Saitama Children's Medical Center				Suzukawa, Kazumi/0000-0001-9904-3905				BEVERLOO HB, 1995, CANCER RES, V55, P4220; CHEN CS, 1993, BLOOD, V81, P2386; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1995, CANCER RES, V55, P4287; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUNGER SP, 1993, BLOOD, V81, P3197; IIDA S, 1993, ONCOGENE, V8, P3085; KEARNEY L, 1992, BLOOD, V80, P1659; KODURU PRK, 1993, ONCOGENE, V8, P3239; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCKEITHAN TW, 1992, P NATL ACAD SCI USA, V89, P4923, DOI 10.1073/pnas.89.11.4923; MORISHITA K, 1990, ONCOGENE, V5, P963; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEGRINI M, 1993, CANCER RES, V53, P4489; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PRASAD R, 1993, CANCER RES, V53, P5624; PUI CH, 1995, LEUKEMIA, V9, P762; RUBNITZ JE, 1994, BLOOD, V84, P570; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	40	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2121	2130						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950979				2022-12-28	WOS:A1996VV14500009
J	Simms, LA; Zou, TT; Young, J; Shi, YQ; Lei, JY; Appel, R; Rhyu, MG; Sugimura, H; ChenevixTrench, G; Souza, RF; Meltzer, SJ; Leggett, BA				Simms, LA; Zou, TT; Young, J; Shi, YQ; Lei, JY; Appel, R; Rhyu, MG; Sugimura, H; ChenevixTrench, G; Souza, RF; Meltzer, SJ; Leggett, BA			Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers	ONCOGENE			English	Article						microsatellite instability; repeats; colorectal cancer; gastric cancer	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; COLON-CANCER; RETINOIC ACID; MISMATCH REPAIR; II RECEPTOR; LUNG-CANCER	Genomic instability at simple repeated sequences has been observed in various types of human cancers and is considered an important mechanism in tumorigenesis. Alterations at microsatellite loci have been reported scattered throughout the genome. Recently, the transforming growth factor-beta receptor type II (TGF-beta RII) and the insulin-like growth factor II receptor (IGF-IIR) genes were shown to have inactivating mutations within coding microsatellite sequences. The demonstration of mutations in two growth regulatory genes supports the idea that other regulatory genes with repeat sequences may also be targets in tumours with defective mismatch repair. We examined genes involved in tumour suppression, cell adhesion and cell cycle regulation for mutations at small repeat sequences in replication error positive gastrointestinal cancers. Several polymorphisms were found which exhibited instability, but no other instability was present in the regions examined.	UNIV MARYLAND, SCH MED, DEPT MED, GI DIV, BALTIMORE, MD 21201 USA; BALTIMORE VA HOSP, BALTIMORE, MD 21201 USA; CATHOLIC UNIV, COLL MED, DEPT MICROBIOL, SEOUL 137701, SOUTH KOREA; HAMAMATSU UNIV SCH MED, DEPT PATHOL 1, HAMAMATSU, SHIZUOKA 43131, JAPAN; QUEENSLAND INST MED RES, BRISBANE, QLD 4029, AUSTRALIA	University System of Maryland; University of Maryland Baltimore; Catholic University of Korea; Hamamatsu University School of Medicine; QIMR Berghofer Medical Research Institute	Simms, LA (corresponding author), ROYAL BRISBANE HOSP FDN, CLIN RES CTR, GLAXO CONJOINT GASTROENTEROL LAB, BRISBANE, QLD 4029, AUSTRALIA.		Chenevix-Trench, Georgia/AAV-2014-2020; Leggett, Barbara A/D-3579-2011; Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011	Chenevix-Trench, Georgia/0000-0002-1878-2587; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONTANA JA, 1990, CANCER RES, V50, P1977; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Greenblatt MS, 1996, CANCER RES, V56, P2130; HAN HJ, 1993, CANCER RES, V53, P5087; HEINEN CD, 1995, CANCER RES, V55, P4797; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JEGO N, 1993, ONCOGENE, V8, P209; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; KRAHE R, 1995, AM J HUM GENET, V56, P1067; KRUYER H, 1994, AM J HUM GENET, V54, P437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOTAN R, 1993, J CELL BIOCHEM, P167; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MYEROFF LL, 1995, CANCER RES, V55, P5545; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; PATEL U, 1994, ONCOGENE, V9, P3695; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; UCHIDA T, 1995, ONCOGENE, V10, P1019; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	57	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2613	2618		10.1038/sj.onc.1201094	http://dx.doi.org/10.1038/sj.onc.1201094			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191061				2022-12-28	WOS:A1997XA94900013
J	Morris, SW; Naeve, C; Mathew, P; James, PL; Kirstein, MN; Cui, XL; Witte, DP				Morris, SW; Naeve, C; Mathew, P; James, PL; Kirstein, MN; Cui, XL; Witte, DP			ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); receptor tyrosine kinase; neural-specific; leukocyte tyrosine kinase (LTK); chromosome 2	HEPATOCYTE GROWTH-FACTOR; AMINO-ACID-SEQUENCES; NERVOUS-SYSTEM; SIGNAL-TRANSDUCTION; MESSENGER-RNAS; SCATTER FACTOR; MET RECEPTOR; SH3 DOMAINS; PROTEIN; EXPRESSION	Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement associated with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking. Here, we characterize a full-length normal human ALK cDNA and its product, and determine the pattern of expression of its murine homologue in embryonic and adult tissues as a first step toward the functional assessment of the receptor, Analysis of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass similar to 177kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap. Biochemical analysis demonstrated that the similar to 177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor. Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s). In situ hybridization studies revealed Alk expression beginning on embryonic day II and persisting into the neonatal and adult periods of development. Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut, Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; MED COLL OHIO, DEPT PEDIAT, TOLEDO, OH 43699 USA; UNIV CINCINNATI, COLL MED, DEPT PATHOL, CINCINNATI, OH 45229 USA; CHILDRENS HOSP RES FDN, DIV PATHOL, CINCINNATI, OH 45229 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Morris, SW (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.				NATIONAL CANCER INSTITUTE [K08CA001702, R01CA069129, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-01702, CA-69129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbacid Mariano, 1993, P123; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BISHOF D, 1997, IN PRES MOL CELL BIO; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CONDIT CM, 1986, NATURE, V323, P178, DOI 10.1038/323178a0; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; ESCANDON E, 1994, J NEUROSCI, V14, P2054; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GRECO A, 1992, ONCOGENE, V7, P237; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOHL D, 1991, J BIOL CHEM, V266, P6626; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KLEIN R, 1990, DEVELOPMENT, V109, P845; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; LAMBALLE F, 1994, J NEUROSCI, V14, P14; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MARU Y, 1990, ONCOGENE RES, V5, P199; MATHEW P, 1995, CYTOGENET CELL GENET, V70, P143, DOI 10.1159/000134080; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MEUNKE M, 1994, NAT GENET, V8, P269; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WITTE DP, 1993, AM J PATHOL, V143, P763; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	65	387	414	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2175	2188		10.1038/sj.onc.1201062	http://dx.doi.org/10.1038/sj.onc.1201062			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174053	Bronze			2022-12-28	WOS:A1997WX93800006
J	Ciana, P; Neri, A; Cappellini, C; Cavallo, F; Pomati, M; Chang, CC; Maiolo, AT; Lombardi, L				Ciana, P; Neri, A; Cappellini, C; Cavallo, F; Pomati, M; Chang, CC; Maiolo, AT; Lombardi, L			Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts	ONCOGENE			English	Article						NF-kappa B; NFKB-2; transcription factor; transformation	NF-KAPPA-B; V-REL; TYROSINE KINASE; GENE-PRODUCT; P65 SUBUNIT; NUCLEAR; ONCOGENE; CLONING; CELLS; BCL-3	The NFKB-2 (Lyt-10) gene codes for an NF-kappa B-related transcription factor containing rel-polyG-ankyrin domains. Rearrangements of the NFKB-2 locus leading to the production of 3' truncated NFKB-2 proteins are recurrently found in lymphoid neoplasms, particularly cutaneous lymphomas, Such mutant NFKB-2 proteins have lost the ability to repress transcription that is typical of NFKB-2 subunit p52, and function as constitutive transcriptional activators. To verify whether the expression of abnormal NFKB-2 proteins can lead to malignant transformations in mammalian cells, we transfected human lymphoblastoid cell lines and murine fibroblasts (Balb/3T3) with expression vectors carrying the cDNAs coding far normal NFKB-2p52, Lyt-10C alpha or LB40 proteins, which are representative of the abnormal types found in lymphoma cases. The expression of both normal and mutant NFKB-2 proteins has a lethal effect on lymphoblastoid cells and a cytotoxic effect was also observed in murine fibroblasts. The fibroblast cell lines expressing Lyt-10C alpha or LB40, but not those expressing normal MFKB-2p52, were capable of forming colonies in soft agar. The analysis of individual clones revealed that cloning efficiency correlated with the expression levels of the abnormal proteins, Injection of the Lyt-10C alpha-transfected Balb cells in SCID mice led to tumor formation in all of the animals, whereas no tumors were observed in the mice injected with control or NFKB-2p52-transfected cells, thus indicating that abnormal NFKB-2 protein expression is tumorigenic in vivo. Our results show that mutant NFKB-2 proteins can lead to the transformed phenotype, and support the hypothesis that alterations in NFKB-2 genes may play a role in lymphomagenesis.	UNIV MILAN,OSPED MAGGIORE IRCCS,IST SCI MED,SERV EMATOL,LAB EMATOL SPERIMENTALE & GENET MOL,MILAN,ITALY; UNIV TURIN,DIPARTIMENTO SCI CLIN BIOL,TURIN,ITALY; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY	University of Milan; University of Turin; Columbia University			Neri, Antonino/I-9690-2014; Ciana, Paolo/F-9224-2012; Cavallo, Federica/C-5666-2011	Neri, Antonino/0000-0001-9047-5912; Cavallo, Federica/0000-0003-4571-1060; CIANA, PAOLO/0000-0001-5771-5638; Critelli, Salvatore/0000-0001-7325-0228				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHANG CC, 1994, ONCOGENE, V9, P923; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRILLI M, 1992, INT REV CYTOL, V143, P1; GRIMM S, 1994, ONCOGENE, V9, P2391; GU W, 1993, P NATL ACAD SCI USA, V90, P2913; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; TARPLEY WG, 1984, MOL CELL BIOL, V4, P2653, DOI 10.1128/MCB.4.12.2653; ZHANG JD, 1994, ONCOGENE, V9, P1931; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	33	41	42	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1805	1810		10.1038/sj.onc.1201015	http://dx.doi.org/10.1038/sj.onc.1201015			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150386	Green Published			2022-12-28	WOS:A1997WW16600006
J	Sheikh, MS; Chen, YQ; Smith, ML; Fornace, AJ				Sheikh, MS; Chen, YQ; Smith, ML; Fornace, AJ			Role of p21(Waf1/Cip1/Sd1) in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells	ONCOGENE			English	Article						excision repair; cell death; adriamycin; uv-irradiation; p53 deficient cells	NUCLEOTIDE EXCISION-REPAIR; P53-MEDIATED G(1) ARREST; CYCLIN-DEPENDENT KINASES; HUMAN BREAST-CARCINOMA; TUMOR SUPPRESSION; GENE-EXPRESSION; GROWTH ARREST; CANCER-CELLS; P21; INDUCTION	Postulated roles for p21(Waf1/Cip1/Sdi1) (p21) in DNA repair and apoptosis remain controversial. Studies suggest both stimulatory and inhibitory effects of p21 in DNA repair. p21 has also been implicated in induction or protection from apoptosis. Using the tetracycline inducible expression system, we studied the role of p21 in DNA repair and apoptosis in wild-type p53 deficient DLD1 colorectal carcinoma cells. These cells displayed marked heterogeneity in their ability to tolerate higher levels of exogenous p21, The majority of the p21 overexpressing cells grew slower and did not exhibit apoptotic phenotype, some cells underwent apoptotic death within 5-8 days following p21 induction while other became giant cells prior to undergoing cell death. Induction of p21 transgene neither sensitized to nor protected from adriamycin-induced acute cell death. p21 also did not alter the clonogenic survival following adriamycin treatment. Clonogenic survival u.v.-irradiation was, however, increased when p21 expression was transiently induced a few hours before and after u.v.-irradiation. Consistent with its effect on clonogenic survival, p21 also enhanced the cellular capacity to repair three different exogenously introduced u.v.-damaged reporter plasmids. Taken together our results demonstrate that p21 may modulate the nucleotide excision repair process to facilitate the repair of u.v.-type DNA damage even in the absence of wild-type p53.	WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48201 USA	Wayne State University	Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA.		Chen, Yong Q/AAI-9864-2021; Fornace, Albert J/A-7407-2008	Chen, Yong Q/0000-0003-4747-4708; Fornace, Albert J/0000-0001-9695-085X				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; CHEN YQ, 1995, CANCER RES, V55, P4536; DIGIUSEPPE JA, 1995, AM J PATHOL, V147, P884; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDBERG EC, 1995, DNA REPAIR; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HUANG YN, UNPUB; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; Johnson E. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P569; JUNG JM, 1995, ONCOGENE, V11, P2021; KLOCKER H, 1986, EUR J CELL BIOL, V39, P346; Kobayashi T, 1995, ONCOGENE, V11, P2311; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin J. K., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P29; McDonald E, 1996, CANCER RES, V56, P2250; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; REED SI, 1994, J CELL SCI, P69; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SHAO ZM, 1995, ONCOGENE, V11, P493; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1996, IN PRESS ONCOGENE; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang J.-L., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P593; ZHANG W, 1995, CANCER RES, V55, P668; Zhang W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P5	42	113	122	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1875	1882		10.1038/sj.onc.1201004	http://dx.doi.org/10.1038/sj.onc.1201004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150394				2022-12-28	WOS:A1997WW16600014
J	Felts, SJ; Stang, MT; Getz, MJ				Felts, SJ; Stang, MT; Getz, MJ			A c-Fos- and E1A-interacting component of the tissue factor basal promoter complex mediates synergistic activation of transcription by transforming growth factor-beta 1	ONCOGENE			English	Article						tissue factor; TGF-beta 1; c-Fos; transcriptional coactivators	NUCLEAR-PROTEIN CBP; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; E1A; COACTIVATOR; FAMILY; CREB; STIMULATION; COAGULATION	Stimulation of quiescent mouse fibroblasts with TGF-beta 1 and certain other growth factors result in cooperative activation of tissue factor (TF) gene transcription, an event accompanied by the rapid entry of c-Fos into specific AP-1 DNA-binding complexes (Felts et al, (1995) Biochemistry 34, 12355-12362), Here, we demonstrate that the ability of TGF-beta 1 to synergistically activate TF transcription in serum-stimulated fibroblasts is dependent upon both c-Fos and a promoter-specific factor with functional properties characteristic of transcriptional coactivators. Inhibition of TF promoter activity by an adenovirus E1A mutant deleted in an essential CREB binding protein (CBP) interaction domain suggests that this factor is distinct from the CBP/p300 family of transcriptional coactivators. Importantly, the ability of this factor to mediate molecular interactions with c-Fos required for transcriptional synergism is directly linked to TGF-beta 1 signaling. These data suggest a model in which a component of the TF basal transcription complex functions to integrate multiple signaling pathways required for full transcriptional activation of TF in fibroblasts.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,PROGRAM TUMOR BIOL,ROCHESTER,MN 55905	Mayo Clinic					NCI NIH HHS [CA65800-01E] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACKMAN N, 1992, ARTERIOSCLER THROMB, V12, P474, DOI 10.1161/01.ATV.12.4.474; Martin ML, 1996, MOL CELL BIOL, V16, P2110; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RANGANATHAN G, 1990, J BIOL CHEM, V265, P3001; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; RAO LVM, 1992, CANCER METAST REV, V11, P249; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Vrana JA, 1996, CANCER RES, V56, P5063; WARR TA, 1990, BLOOD, V75, P1481; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	45	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1679	1685		10.1038/sj.onc.1201006	http://dx.doi.org/10.1038/sj.onc.1201006			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135069				2022-12-28	WOS:A1997WR89300006
J	Servillo, G; Penna, L; Foulkes, NS; Magni, MV; DellaFazia, MA; SassoneCorsi, P				Servillo, G; Penna, L; Foulkes, NS; Magni, MV; DellaFazia, MA; SassoneCorsi, P			Cyclic AMP signalling pathway and cellular proliferation: Induction of CREM during liver regeneration	ONCOGENE			English	Article						cAMP; CREM; CREB; liver regeneration; proliferation; early response	PROTO-ONCOGENE EXPRESSION; LONG-TERM DESENSITIZATION; GENE-TRANSCRIPTION; TYROSINE AMINOTRANSFERASE; PARTIAL-HEPATECTOMY; GROWTH-FACTOR; RAT-LIVER; BINDING; CAMP; PHOSPHORYLATION	The CREM gene encodes both activators and repressors of cAMP-induced gene expression, An isoform of CREM encodes the powerful transcriptional repressor ICER (Inducible cAMP Early Repressor), which has been shown to be inducible by virtue of an alternative, intronic promoter, The CREM gene belongs to the early response class and displays a characteristic neuroendocrine cell- and tissue-specific expression, To date ICER inducibility has in non-replicating, terminally differentiated In this paper we document a robust induction of CREM expression in the regenerating rat liver after partial hepatectomy. This represents the first link of inducible CREM expression to the phenomenon of cellular proliferation, Furthermore, it represents the first example of transcriptional activation of a cAMP-responsive factor in the regenerating liver, This has significant physiological relevance since the adenylate cyclase signalling pathway is strongly implicated in liver regeneration, Finally, we show that the repressor ICER is inducible in the hepatoma cell line H35 upon activation of the adenylate cyclase and phosphorylation of the activator CREB.	INST GENET & BIOL MOL & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV PERUGIA, MONTELUCE POLICLIN, INST PATOL GEN, I-06100 PERUGIA, ITALY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Perugia			Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Servillo, Giuseppe/0000-0001-7960-7689; Della Fazia, Maria Agnese/0000-0002-5373-8477				BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELLAFAZIA MA, 1992, BIOCHEM BIOPH RES CO, V182, P753, DOI 10.1016/0006-291X(92)91796-S; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; EKANGER R, 1989, J BIOL CHEM, V264, P4374; Fausto Nelson, 1994, P1059; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; GARCIASAINZ JA, 1989, AM J PHYSIOL, V256, pC384, DOI 10.1152/ajpcell.1989.256.2.C384; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOUSLAY MD, 1986, BIOCHEM SOC T, V14, P183, DOI 10.1042/bst0140183; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LALLI E, 1994, J BIOL CHEM, V269, P17359; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEFFERT HL, 1988, LIVER BIOL PATHOBIOL, P833; MACMANUS JP, 1972, BIOCHEM BIOPH RES CO, V49, P1201, DOI 10.1016/0006-291X(72)90596-7; Maniatis T, 1989, MOL CLONING; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; TAUB R, 1987, J BIOL CHEM, V262, P10893; TOMLINSON S, 1985, CLIN ENDOCRINOL, V23, P595, DOI 10.1111/j.1365-2265.1985.tb01120.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1601	1606		10.1038/sj.onc.1200996	http://dx.doi.org/10.1038/sj.onc.1200996			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129151				2022-12-28	WOS:A1997WQ54800011
J	Li, Y; Mangasarian, K; Mansukhani, A; Basilico, C				Li, Y; Mangasarian, K; Mansukhani, A; Basilico, C			Activation of FGF receptors by mutations in the transmembrane domain	ONCOGENE			English	Article						achondroplasia; differentiation; cell transformation; receptor phosphorylation	FIBROBLAST-GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MYOGENIC DIFFERENTIATION; TARGETED EXPRESSION; POINT MUTATION; ACHONDROPLASIA; FAMILY; GENE; PHOSPHORYLATION; PROLIFERATION	Signaling through FGF receptors, which constitute a family of membrane-spanning tyrosine kinases, can stimulate cell proliferation, induce or inhibit cell differentiation and plays an important role in development. Recently, mutations in FGF receptors have been shown to be associated with a number of genetically dominant human skeletal disorders. A remarkably conserved mutation (Gly 380-->Arg) in the transmembrane region of FGFR-3 has been shown to be responsible for achondroplasia (ACH) but it was not clear whether such mutations result in loss of receptor function or constitutive activation. We have therefore made mutations in the transmembrane regions of murine FGFR-2 and FGFR-3 and studied their effect on receptor activity. We show here that the ACH mutation in FGFR-3 as well as two similar mutations in FGFR-2 result in constitutive activation of these receptors. This is manifested in their ability to become autophosphorylated in the absence of ligand in L6 cells, transforming activity on NIH3T3 fibroblasts, and the ability to inhibit myogenic differentiation in the absence of growth factor. Thus the transmembrane region of FGFR-2 and FGFR-3 plays a regulatory role in receptor function and the ACH mutation produces a dominant oversignaling receptor which is no longer regulated by FGF binding. These findings also support the newly identified role of FGF signaling as a negative regulator of bone growth.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA42568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Campochiaro PA, 1996, J NEUROSCI, V16, P1679; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FOX JC, 1994, MOL CELL BIOL, V14, P4244, DOI 10.1128/MCB.14.6.4244; IANNOTTI JP, 1994, GROWTH PLATE BONE DE, P185; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO Y, 1990, J BIOL CHEM, V265, P5903; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LONARDO F, 1990, New Biologist, V2, P992; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MIMA T, 1995, P NATL ACAD SCI USA, V92, P467, DOI 10.1073/pnas.92.2.467; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	45	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1397	1406		10.1038/sj.onc.1200983	http://dx.doi.org/10.1038/sj.onc.1200983			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136983				2022-12-28	WOS:A1997WT58400002
J	Vedrenne, J; Assier, E; Pereno, R; BouzinbaSegard, H; Azzarone, B; Jasmin, C; Charron, D; Krief, P				Vedrenne, J; Assier, E; Pereno, R; BouzinbaSegard, H; Azzarone, B; Jasmin, C; Charron, D; Krief, P			Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line	ONCOGENE			English	Article						MHC class II; IK; CIITA; IFN-gamma	BARE LYMPHOCYTE SYNDROME; DEFICIENT COMBINED IMMUNODEFICIENCY; TRANSACTIVATOR GENE CIITA; MONOCLONAL-ANTIBODIES; TRANSCRIPTION; SEQUENCES; CLONING	The expression of major histocompatibility complex (MHC) class II antigens is constitutive in professional antigen presenting cells (APCs) but can also be induced by interferon-gamma (IFN-gamma) on the majority of the non professional APCs (e.g. fibroblasts). We have recently characterised a new factor called IK which is an efficient inhibitor of IFN-gamma induction of MHC class II antigens expression. Here, we demonstrate a novel role for IK in MHC class II expression since over-expression of this protein by stable transfection into human B cells led to a total disappearance of constitutive MHC class II mRNA expression. The class II transactivator (CIITA) is necessary for both constitutive and IFN-gamma induced MHC class II expressions. Examination of CIITA mRNA in IK stably transfected clones revealed a marked reduction of CIITA mRNA transcription. Taken together these results demonstrate that the IK protein plays a keg role in the constitutive expression of MHC class II antigens and that inhibition induced by IK is upstream of CIITA in this regulatory pathway.	HOP PAUL BROUSSE,INSERM U268,F-94807 VILLEJUIF,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vedrenne, J (corresponding author), INSERM U396,INST BIOMED CORDELIERS,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.		Azzarone, Bruno/AAH-9251-2019; Krief, Patricia/M-6073-2014	Azzarone, Bruno/0000-0002-5962-3849; Krief, Patricia/0000-0001-5106-466X; Assier, Eric/0000-0001-8366-1645				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BROWN JA, 1995, IMMUNOGENETICS, V43, P88; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEPREVAL C, 1988, NEW ENGL J MED, V318, P1295, DOI 10.1056/NEJM198805193182003; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Griscelli C, 1989, Immunodefic Rev, V1, P135; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KRIEF P, 1994, ONCOGENE, V9, P3449; KRIEF P, 1987, EUR J IMMUNOL, V17, P1021, DOI 10.1002/eji.1830170719; MACH B, 1994, IMMUNOL REV, V138, P207, DOI 10.1111/j.1600-065X.1994.tb00853.x; PERROT JY, 1986, SCAND J IMMUNOL, V23, P623, DOI 10.1111/j.1365-3083.1986.tb01997.x; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEED JL, 1987, P NATL ACAD SCI USA, V84, P3305; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P410; TOURAINE JL, 1985, EXP HEMATOL, V13, P86; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	26	13	15	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1453	1461		10.1038/sj.onc.1200971	http://dx.doi.org/10.1038/sj.onc.1200971			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136989				2022-12-28	WOS:A1997WT58400008
J	Zatsepina, O; Braspenning, J; Robberson, D; Hajibagheri, MAN; Blight, KJ; Ely, S; Hibma, M; Spitkovsky, D; Trendelenburg, M; Crawford, L; Tommasino, M				Zatsepina, O; Braspenning, J; Robberson, D; Hajibagheri, MAN; Blight, KJ; Ely, S; Hibma, M; Spitkovsky, D; Trendelenburg, M; Crawford, L; Tommasino, M			The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells	ONCOGENE			English	Article						HPV; E7 protein; cellular localisation; nucleolus; mammalian and yeast cells	RETINOBLASTOMA GENE-PRODUCT; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; NUCLEAR; E2F; LOCALIZATION; E7-PROTEIN; SEQUENCES; THIAMINE	In this study we show, by immunofluorescence and electron microscopy immune-gold labelling, that the major transforming protein of Human Papillomavirus type 16 E7 is associated with the nucleolus of cells derived from the HPV16-positive cervical carcinoma line CaSki. The E7 nucleolar staining appeared to be cell cycle dependent, being considerably reduced in the G(2) phase. The total level of the protein in the cell, however, remained constant during all phases, We also show that the cellular protein Rb1, which is targeted by E7, is localised in the nucleus and nucleolus in CaSki cells. Thus, it is possible that the presence of E7 in the nucleolus correlates with a hypothetical function(s) of Rb1 in this particular intranuclear compartment. The nucleolar localisation of HPV16 E7 protein was also observed in the fission yeast Schizosaccharomyces pombe, suggesting that a targeting mechanism of HPV16 E7 protein into the nucleolus is common to both mammalian and yeast systems, Nucleolar localisation of HPV16 E7 protein may be independent from Rb1 since no Rb1 related proteins have been identified in fission yeast.	DEUTSCH KREBSFORSCHUNGSZENTRUM, ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; DEUTSCH KREBSFORSCHUNGSZENTRUM, BIOMED STRUKTURFORSCH, D-69120 HEIDELBERG, GERMANY; ST MARYS HOSP, SCH MED, WRIGHT FLEMING INST, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; UNIV OTAGO, DEPT MICROBIOL, HRC VIRUS RES UNIT, DUNEDIN, NEW ZEALAND	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK; Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; University of Otago			Zatsepina, Olga/O-8753-2015; Spitkovsky, Dimitry/ABA-1605-2020	Zatsepina, Olga/0000-0001-5114-1127; 				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CICCOLINI F, 1994, ONCOGENE, V9, P2633; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HU TH, 1995, INT J ONCOL, V6, P167; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TOMMASINO M, 1990, GENE, V93, P265, DOI 10.1016/0378-1119(90)90234-I; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q	34	25	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1137	1145		10.1038/sj.onc.1200946	http://dx.doi.org/10.1038/sj.onc.1200946			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121762				2022-12-28	WOS:A1997WM78200002
J	Soder, AI; Hoare, SF; Muir, S; Going, JJ; Parkinson, EK; Keith, WN				Soder, AI; Hoare, SF; Muir, S; Going, JJ; Parkinson, EK; Keith, WN			Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer	ONCOGENE			English	Article						telomerase; gene amplification; in situ hybridisation; gene expression; hTR	SQUAMOUS-CELL CARCINOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; IMMORTAL CELLS; IN-SITU; HEAD; NECK; TUMORS; IDENTIFICATION; PROGRESSION	Telomere length is maintained by the enzyme, telomerase, which has been linked to cellular immortality and tumour progression, However, the reasons for the high levels of telomerase found in human tumours are unknown, We have mapped the human telomerase RNA gene, (hTR), to chromosome 3q26.3 and show the hTR gene to be amplified in four carcinomas, (2/33 cervix, 1/31 head and neck, 1/9 lung), In addition, increased copy numbers of the hTR locus was also observed in 97% of tumours, By in situ hybridisation, the histological distribution of high levels of hTR expression could be demonstrated in a lung tumour and its metastasis with hTR amplification, These results are the first report of genetic alterations involving a known component of telomerase in human cancer, Indeed, it is also the first report of the amplification of a specific locus within the chromosome 3q region frequently subject to copy number gains in human tumours, In addition, we also show for the first time the histological distribution of the RNA component of telomerase in human tumours.	UNIV GLASGOW,CRC DEPT MED ONCOL,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW G4 0SF,LANARK,SCOTLAND; BEATSON INST CANC RES,CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute; University of Glasgow; University of Glasgow; Beatson Institute			Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Going, James/0000-0001-9120-919X				Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Avilion AA, 1996, CANCER RES, V56, P645; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Collins K, 1996, CURR OPIN CELL BIOL, V8, P374, DOI 10.1016/S0955-0674(96)80013-5; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUTTS J, 1993, BRIT J CANCER, V68, P793, DOI 10.1038/bjc.1993.430; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FITZPATRICK DR, 1990, DEVELOPMENT, V109, P585; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Hoare SF, 1997, BRIT J CANCER, V75, P275, DOI 10.1038/bjc.1997.45; IWABUCHI H, 1995, CANCER RES, V55, P6172; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, NAT GENET, V9, P104, DOI 10.1038/ng0295-104; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; McLeod HL, 1996, BRIT J CANCER, V74, P508, DOI 10.1038/bjc.1996.394; MURPHY DS, 1995, INT J CANCER, V64, P18, DOI 10.1002/ijc.2910640106; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Parkinson EK, 1996, BRIT J CANCER, V73, P1, DOI 10.1038/bjc.1996.1; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; RIED T, 1994, CANCER RES, V54, P1801; RIED T, 1995, CANCER RES, V55, P5414; Robertson KW, 1996, CANCER RES, V56, P3823; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SODER AI, 1995, CANCER RES, V55, P5030; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; WARD PB, 1996, GENOMICS, V32, P1; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3	46	159	167	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1013	1021		10.1038/sj.onc.1201066	http://dx.doi.org/10.1038/sj.onc.1201066			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070649				2022-12-28	WOS:A1997WM07000002
J	Araujo, JC; Doniger, J; Stoppler, H; Sadie, MR; Rosenthal, LJ				Araujo, JC; Doniger, J; Stoppler, H; Sadie, MR; Rosenthal, LJ			Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation	ONCOGENE			English	Article						transformation suppression; cellular oncogene promoter suppressor; viral oncogene promoter suppressor; retroviral mediated gene transfer	IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; BOVINE PAPILLOMAVIRUS; BINDING PROTEIN; REGION; DNA; INHIBITION; ELEMENTS; RNA; REPLICATION	Human herpesvirus 6A (HHV-6A) strain U1102 was previously shown to contain a 1473 bp transformation suppressor gene (ts) (Araujo et al,, 1995), Ts inhibited transformation of NIH3T3 cells by H-vas and transcription of the H-uas and human immunodeficiency type 1 (HIV-1) promoters in transient transfection experiments. In the current study, stable NIH3T3 cell lines expressing ts protein were established by transfection with pRc-ts containing the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and a neomycin selectable marker. Selected cell lines contained approximately one to two copies per cell of intact ts sequences, expressed ts protein and grew at approximately the same rate as parental NIH3T3 cells. These cell lines were protected from H-ras transformation while parental and NIH3T3 cells containing the ts gene cloned in the antisense orientation were not. Expression of the chloramphenicol acetyl transferase (CAT) gene under the control of the EJ-H-ras promoter was also suppressed in the ts cell lines but not when the CAT gene was under the control of the murine osteosarcoma virus LTR or human cytomegalovirus immediate early promoter. When NIH3T3 cell lines expressing ts protein were established by infection with the retrovirus, LNCts, the cells expressed ts protein and were protected from H-ras transformation, Furthermore, bovine papillomavirus type 1 (BPV-1) transformation was also suppressed in cells cotransfected with BPV-1 plus ts and in ts expressing cell lines transfected with BPV-1. The BPV-1 p89 and p2443 promoters were down-regulated in 3T3-ts lines. Because the human papillomavirus type 16 (HPV-16) p97 promoter has similarity to the BPV-1 p89 promoter, the ability of ts to suppress p97 was also tested. Like the H-ras and BPV-1 promoters, HPV-16 p97 was downregulated in 3T3-ts lines. The data indicate the utility of ts against H-ras, BPV-1 and HPV-16 promoters and their respective oncogenes.	GEORGETOWN UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PATHOL, WASHINGTON, DC 20007 USA; US FDA, CTR BIOL EVALUAT & RES, DIV TRANSFUS TRANSMITTED DIS, ROCKVILLE, MD 20852 USA	Georgetown University; Georgetown University; Georgetown University; US Food & Drug Administration (FDA)								ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; ARAUJO JC, 1995, J VIROL, V69, P4933, DOI 10.1128/JVI.69.8.4933-4940.1995; BATCHU RB, 1994, CANCER LETT, V86, P23, DOI 10.1016/0304-3835(94)90176-7; BATCHU RB, 1995, FEBS LETT, V367, P267, DOI 10.1016/0014-5793(95)00584-V; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIORINI JA, 1994, J VIROL, V68, P797, DOI 10.1128/JVI.68.2.797-804.1994; DONIGER J, 1987, J BIOL CHEM, V262, P3813; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; HERMONAT PL, 1991, CANCER RES, V51, P3373; HERMONAT PL, 1989, VIROLOGY, V172, P253, DOI 10.1016/0042-6822(89)90127-X; HERMONAT PL, 1994, CANCER RES, V54, P2278; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LANS MS, 1994, J BIOL CHEM, V269, P14170; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OELZE I, 1994, J VIROL, V68, P1229, DOI 10.1128/JVI.68.2.1229-1233.1994; RITTNER K, 1992, J GEN VIROL, V73, P2977, DOI 10.1099/0022-1317-73-11-2977; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; THOMSON BJ, 1994, VIROLOGY, V204, P304, DOI 10.1006/viro.1994.1535; THOMSON BJ, 1991, NATURE, V351, P78, DOI 10.1038/351078a0; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	28	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					937	943		10.1038/sj.onc.1200899	http://dx.doi.org/10.1038/sj.onc.1200899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050993				2022-12-28	WOS:A1997WK34400007
J	Frank, S; Munz, B; Werner, S				Frank, S; Munz, B; Werner, S			The human homologue of a bovine non-selenium glutathione peroxidase is a novel keratinocyte growth factor-regulated gene	ONCOGENE			English	Article						KGF; keratinocyte; skin; oxidative stress; peroxidase; psoriasis	FACTOR EXPRESSION; MESSENGER-RNA; TRANSFERASE; INDUCTION; CLONING; SKIN; PURIFICATION; SEQUENCE; FAMILY; CELLS	Keratinocyte growth factor is a potent and specific mitogen for different types of epithelial cells, including keratinocytes of the skin. Furthermore, it has been implicated in morphogenetic processes of several organs. To further define the mechanisms of KGF action in the skin, we attempted to identify genes which are regulated by KGF in keratinocytes. Using the differential display RT-PCR technology, a gene was identified which was strongly induced in these cells by treatment with KGF but not with serum growth factors or pro-inflammatory cytokines. Molecular cloning of the full-length cDNA revealed a strong homology of the corresponding gene product with a bovine non-selenium glutathione peroxidase. Upon transfection of COS cells with the full-length cDNA, a 27 kD cytoplasmic protein was obtained which had the expected size of glutathione peroxidase. Expression of the novel gene was detected in normal human skin and at particularly high levels in psoriatic skin, indicating a possible in vivo function of the protein in this tissue. Identification of a peroxidase as a KGF-regulated gene suggests that prevention from oxygen toxicity is a novel and specific mechanism of KGF action.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ACETO A, 1992, BIOCHEM MED METAB B, V48, P212, DOI 10.1016/0885-4505(92)90067-9; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Ames B.N., 1993, DNA FREE RADICALS, P1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUER D, 1994, PCR METH APPL, V4, P97; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOPHERS E, 1987, DERMATOLOGY GENERAL, P461; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; CUNHA GR, 1994, INT CONGR SER, V1064, P45; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; KANO T, 1987, CANCER RES, V47, P5626; LONTZ W, 1995, FREE RADICAL BIO MED, V18, P349, DOI 10.1016/0891-5849(94)E0124-2; Maniatis T., 1982, MOL CLONING; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MATHIEU M, 1996, BIOL CHEM, V270, P24197; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PENTLAND AP, 1994, ADV EXP MED BIOL, V366, P87; PETERS K, 1994, EMBO J, V13, P3269; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHOPF RE, 1992, MOLECULAR BASIS OF OXIDATIVE DAMAGE BY LEUKOCYTES, P333; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Wendel A, 1981, Methods Enzymol, V77, P325; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	39	108	112	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					915	921		10.1038/sj.onc.1200905	http://dx.doi.org/10.1038/sj.onc.1200905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050990	Bronze			2022-12-28	WOS:A1997WK34400004
J	Weyman, CM; Ramocki, MB; Taparowsky, EJ; Wolfman, A				Weyman, CM; Ramocki, MB; Taparowsky, EJ; Wolfman, A			Distinct signaling pathways regulate transformation and inhibition of skeletal muscle differentiation by oncogenic Ras	ONCOGENE			English	Article						skeletal muscle; differentiation; oncogenic Ras; MAP kinase	FIBROBLAST GROWTH-FACTOR; NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE CASCADE; MYOGENIC DIFFERENTIATION; H-RAS; B-RAF; TERMINAL DIFFERENTIATION; MYOBLAST DIFFERENTIATION; FACTOR-BETA; CELL-CYCLE	Expression of oncogenic Ras in 23A2 skeletal myoblasts is sufficient to induce both a transformed phenotype and a differentiation-defective phenotype, but the signaling pathways activated by oncogenic Ras in these cells and their respective contribution to each phenotype have not been explored, In this study, we investigated MAP kinase activity in control 23A2 myoblasts and in 23A2 myoblasts rendered differentiation-defective by the stable expression of an oncogenic (G12V)Ha-ras gene (Ras9 cells), The MAP kinase immunoprecipitated from Ras9 cells was 30-40% more active than that from control 23A2 cells, To establish if this elevated MAP kinase activity is essential to the maintenance of the onccogenic Ras-induced phenotype, we utilized the selective MAP kinase kinase 1 (MEK1) inhibitor, PD 098059. PD 098059 decreased the MAP kinase activity in Ras9 cells to the level found in 23A2 cells. PD 098059 did not affect the ability of 23A2 myoblasts to differentiate, PD 098059 reverted the transformed morphology of Ras9 cells but did not restore the ability of these cells to express the muscle-specific myosin heavy chain gene or to form muscle fibers, Treatment with PD 098059 also did not affect the ability of oncogenic Ha-Ras to establish a non-myogenic phenotype in C3H10T1/2 cells co-expressing MyoD. These results demonstrate that the activation of MAP kinase is necessary for the transformed morphology of Ras9 cells but is not required by oncogenic Ras to establish or to maintain a differentiation-defective phenotype. While these data do not rule out the possibility that constitutive signaling by MEK1 or MAP kinase could inhibit myoblast differentiation, they clearly demonstrate that other pathways activated by oncogenic Ras are sufficient to inhibit differentiation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weyman, CM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195, USA.				NCI NIH HHS [T32 CA09634] Funding Source: Medline; NIGMS NIH HHS [GM 49652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049652, R55GM049652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FOX PL, 1994, ONCOGENE, V9, P3519; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	54	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					697	704		10.1038/sj.onc.1200874	http://dx.doi.org/10.1038/sj.onc.1200874			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038377				2022-12-28	WOS:A1997WG43000008
J	Bourdon, JC; DeguinChambon, V; Lelong, JC; Dessen, P; May, P; Debuire, B; May, E				Bourdon, JC; DeguinChambon, V; Lelong, JC; Dessen, P; May, P; Debuire, B; May, E			Further characterisation of the p53 responsive element - Identification of new candidate genes for trans-activation by p53	ONCOGENE			English	Article						consensus sequence; computer search; transactivation; MCK; IGF-BP3	WILD-TYPE P53; DNA-BINDING; PROMOTER; PROTEIN; TRANSACTIVATION; EXPRESSION; PATHWAY; SITE	The p53 protein is known to trans-activate a number of genes by specific binding to a consensus sequence containing two decamers of the type: PuPuPuCA/TT/AGPyPyPy. In order to identify new p53 trans-activated genes, we defined a set of criteria for computer search of p53-responsive elements, Based on experimental data, we proposed an extended consensus sequence composed of the two decamers of the El-Deiry consensus sequence flanked by two additional ones, A maximum of 3 bp substitutions was accepted for the two decamers of the El-Deiry consensus sequence, as well as for each additional decamer, except when the two decamers of the El-Deiry consensus sequence are contiguous, In this case, each additional decamer is allowed to bear one base insertion or deletion between the median C and G, This set of criteria was validated by identifying within the promoter region of the IGF-BP3 gene the existence of a novel p53-responsive element whose functional significance was verified, By limiting our computer search to Vertebrate genes involved in cell cycle regulation, cellular adhesion or metastatic processes and to gene families most often found in HOVERGEN database, 7785 gene sequences were first analysed, Among the oncogenes, kinases, proteases and structural proteins, 55 new genes were selected; six of them were retrieved in more than one species	UNITE CNRS UMS 825,INSERM SC13,SERV BIOINFORMAT VILLEJUIF,F-94801 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bourdon, JC (corresponding author), CNRS,CEA,UMR 217,LAB CANCEROGENESE MOL,FONTENAY ROSES,FRANCE.		JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COOK JL, 1995, ONCOGENE, V11, P723; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVRERO M, 1991, GENE, V101, P195, DOI 10.1016/0378-1119(91)90411-4; MAY E, 1992, J VIROL, V66, P3347, DOI 10.1128/JVI.66.6.3347-3354.1992; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1996, BEHRING I MITT, V97, P1; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	27	128	135	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					85	94		10.1038/sj.onc.1200804	http://dx.doi.org/10.1038/sj.onc.1200804			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010235				2022-12-28	WOS:A1997WB76000008
J	Lakin, ND; Weber, P; Stankovic, T; Rottinghaus, ST; Taylor, AMR; Jackson, SP				Lakin, ND; Weber, P; Stankovic, T; Rottinghaus, ST; Taylor, AMR; Jackson, SP			Analysis of the ATM protein in wild-type and ataxia telangiectasia cells	ONCOGENE			English	Article						ataxia telangiectasia; ATM; DNA; repair; PI 3-kinase; p53	STRAND BREAK REPAIR; V(D)J RECOMBINATION; DNA-REPAIR; MAMMALIAN PROTEIN; KINASE-ACTIVITY; KU AUTOANTIGEN; GENE; COMPLEX; PRODUCT; PK	Ataxia telangiectasia (A-T) is a human disorder that results in a number of clinical symptoms, including cerebellar degeneration and increased cancer predisposition. Recently the gene that is defective in A-T has been cloned and designated ATM. Here, we describe the production of antisera raised against the similar to 350 kDa ATM protein, Antisera specificity is confirmed by them recognising a similar to 350 kDa polypeptide in wild-type cells but not in A-T cells containing mutations that truncate ATM upstream of the antibody binding sites, We show that ATM is almost exclusively nuclear and is expressed in all cell lines and tissues analysed, However, ATM levels are not regulated in response to u.v. or ionising radiation, These data are consistent with ATM being a component of the DNA damage detection apparatus rather than being an inducible downstream effector of the DNA damage response. In addition, we analyse ATM protein expression in a variety of A-T patients, Strikingly, ATM expression is reduced drastically or absent in all patients analysed, including those predicted to express proteins that should be detected by our antisera, Thus, the A-T phenotype may result not only from mutations that disrupt functional domains of ATM, but also from mutations that destabilise the ATM mRNA or protein, Finally, we report that a group of patients displaying an intermediate A-T phenotype express low levels of apparently full-length ATM, This suggests that the ATM pathway is partially active in these individuals and that there is a correlation between Levels of residual ATM expression and disease severity.	CANC RES CAMPAIGN INST,WELLCOME TRUST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1TN,ENGLAND; UNIV BIRMINGHAM,SCH MED,CANC RES CAMPAIGN,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	CRUK Cambridge Institute; Wellcome Trust Sanger Institute; University of Cambridge; University of Birmingham			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Stankovic, Tatjana/0000-0002-3780-274X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, P130; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; Jackson S. P., 1993, Gene transcription: a practical approach., P189; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAPPELLER R, 1994, BIOESSAYS, V16, P565; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; McConville CM, 1996, AM J HUM GENET, V59, P320; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TELETAR M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	48	136	142	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2707	2716						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000145				2022-12-28	WOS:A1996VZ65400021
J	Chiappetta, G; Avantaggiato, V; Visconti, R; Fedele, M; Battista, S; Trapasso, F; Merciai, BM; Fidanza, V; Giancotti, V; Santoro, M; Simeone, A; Fusco, A				Chiappetta, G; Avantaggiato, V; Visconti, R; Fedele, M; Battista, S; Trapasso, F; Merciai, BM; Fidanza, V; Giancotti, V; Santoro, M; Simeone, A; Fusco, A			High level expression of the HMGI (Y) gene during embryonic development	ONCOGENE			English	Article						HMGI proteins; in situ hybridization; development; embryo	GROUP PROTEIN HMG-I(Y); NUCLEAR PROTEINS; THYROID-CELLS; TRANSFORMATION; CDNA; ELEMENTS; SEQUENCE; DNA; RNA	The HMGI protein family includes three proteins, named HMG-I, HMG-Y and HMGI-C, The first two proteins are coded for by the same gene, HMGI (Y), through an alternative splicing mechanism, Their expression is elevated in neoplastic tissues and cells and this overexpression has a causal role in the process of cellular neoplastic transformation, We demonstrate that the HMGI (Y) gene is expressed at very tow levels in normal adult tissues, whereas in embryonic tissues it is expressed at high levels comparable to those detected in neoplastic tissues, Specifically, a very high expression of the HMGI (Y) gene was detected in all embryonic tissues at 8.5 dpc, Then in the following days, even though the gene is expressed essentially in all tissues, an abundant gene expression was restricted to some tissues, These results indicate an important role of the HMGI (Y) gene in development.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; IST NAZL TUMORI,FDN SENATORE PASCALE,I-80131 NAPLES,ITALY; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; UNIV NAPLES,FAC MED & CHIRURG NAPOLI,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,THOMAS JEFFERSON CANC INST,PHILADELPHIA,PA 19107; UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOL,I-34127 TRIESTE,ITALY	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; University of Trieste			Fedele, Monica/C-1417-2015; Simeone, Antonio/ABG-5269-2020; Visconti, Roberta/C-5299-2009	Fedele, Monica/0000-0002-9171-1312; Simeone, Antonio/0000-0003-2693-9836; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Fedele M, 1996, CANCER RES, V56, P1896; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8576; REEVES R, 1991, P NATL ACAD SCI USA, V88, P4005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THEILER K, 1989, HOUSE MOUSE; TMIMI Y, 1993, CANCER RES, V53, P5512; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	30	283	289	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2439	2446						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957086				2022-12-28	WOS:A1996VX10800017
J	Nakamura, T; Jenkins, NA; Copeland, NG				Nakamura, T; Jenkins, NA; Copeland, NG			Identification of a new family of Pbx-related homeobox genes	ONCOGENE			English	Article						Meis; Pbx; Hox; homeobox; transcription	HUMAN PROTOONCOGENE PBX1; DNA-BINDING SPECIFICITY; TRANSLOCATION PROTEIN; MYELOID-LEUKEMIA; LINKAGE MAP; PRE-B; EXTRADENTICLE; MOUSE; MICE; ARABIDOPSIS	The expression of Meis1 (a novel Pbx-related homeobox gene) and either Hoxa7 or Hoxa9 are coactivated by retroviral integration in BXH2 murine myeloid leukemias (T Nakamura, DA Largaespada, JD Shaughnessy Jr, NA Jenkins and NG Copeland (1996) Nature Genet. 12: 149-153). As Pbx proteins are Hox cofactors, which cooperatively bind DNA with Hox proteins to modulate the otherwise similar DNA bind specificities of Hox proteins, these results suggested that Meis1 may function as a cofactor for Hoxa7 and Hoxa9 in the induction of murine myeloid leukemias. By DNA cross-hybridization we have identified two Meis1-related genes, Meis2 and Meis3. Sequence analysis revealed extensive amino acid similarity among the three Meis proteins both within and outside of the homeodomain. Phylogenetic analysis showed that the Meis genes belong to a distinct family of Pbx-related genes. Chromosome mapping studies indicated that Meis2 and Meis3 are unlinked to Meis1 and map to mouse chromosome 2 and 7, respectively. The Meis genes displayed distinct but overlapping patterns of expression in normal tissues and were expressed in some cases of murine myeloid leukemia. The identification of two additional Meis genes identifies a new family of potential Hox cofactors as well as two new potential disease genes.	NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								Beckler G S, 1995, Methods Mol Biol, V37, P215; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; DOCKX J, 1995, PLANT MOL BIOL, V28, P723, DOI 10.1007/BF00021196; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Green EL, 1981, GENETICS PROBABILITY, P77; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HURST HC, 1995, PROTEIN PROFILE, V2, P131; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANAK JR, 1994, DEVELOPMENT, P61; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1994, CATALOG CHROMOSOME A; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSCOW JJ, 1995, MOL CELL BIOL, V15, P5434; MUELLER KJ, 1995, NATURE, V347, P727; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PHELAN ML, 1995, MOL CELL BIOL, V15, P3786; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REISER L, 1995, CELL, V83, P735, DOI 10.1016/0092-8674(95)90186-8; SIRACUSA LD, 1991, GENETICS, V127, P169; SIRACUSA LD, 1991, GENETICS, V128, P813; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153	52	95	97	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2235	2242						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950991				2022-12-28	WOS:A1996VV14500021
J	Arai, K; Morishita, K; Shinmura, K; Kohno, T; Kim, SR; Nohmi, T; Taniwaki, M; Ohwada, S; Yokota, J				Arai, K; Morishita, K; Shinmura, K; Kohno, T; Kim, SR; Nohmi, T; Taniwaki, M; Ohwada, S; Yokota, J			Cloning of a human homolog of the yeast OGG1 gene that is involved in the repair of oxidative DNA damage	ONCOGENE			English	Article						oxidative DNA damage; 8-hydroxyguanine; DNA repair; mutagenesis; DNA glycosylase; endonuclease	ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; 8-HYDROXYGUANINE; MUTAGENESIS; 8-HYDROXYDEOXYGUANOSINE; 8-OXOGUANINE; GLYCOSYLASE; EXCISION; CANCER	We report the cloning of a human homolog of the yeast OGG1 gene, which encodes a DNA glycosylase that excises an oxidatively damaged form of guanine, 8-hydroxyguanine (also known as 7,8-dihydro-8-oxoguanine), Since the deduced amino acid sequence (68 amino acids) of a human expressed sequence tag, N55394, matched a short stretch of yeast OGG1 protein with greater than 40% amino acid identity, a full Length cDNA clone was isolated from a HeLa cell cDNA Library with the N55394 clone as a probe, The cDNA clone encodes a predicted protein of 345 amino acids which is homologous to yeast OGG1 protein throughout the entire polypeptide sequence and shares 38% amino acid identity with yeast OGG1 protein, Moreover, we found that both a human homolog and yeast OGG1 protein possess two distinct DNA binding motifs, a helix-hairpin-helix (HhH) motif and a C2H2 zinc finger like motif, and a domain homologous to human and E. coli MutY proteins. Expression of a human homolog suppressed spontaneous mutagenesis of an E. coli (mutM mutY) mutant as in the case of yeast OGG1 protein. The gene mas ubiquitously expressed in a variety of human organs and mapped to chromosome 3p26.2. These results strongly suggest that the gene isolated here is a human counterpart of the yeast OGG1 gene and is involved in the repair of oxidative DNA damage in human cells.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; GUNMA UNIV,SCH MED,DEPT SURG 2,MAEBASHI,GUMMA 371,JAPAN; NATL INST HLTH SCI,DIV GENET & MUTAGENESIS,SETAGAYA KU,TOKYO 158,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT INTERNAL MED 3,KAMIGYO KU,KYOTO 602,JAPAN	National Cancer Center - Japan; Gunma University; National Institute of Health Sciences - Japan; Kyoto Prefectural University of Medicine			Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AU KG, 1989, P NATL ACAD SCI USA, V86, P8771; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHENG KC, 1992, J BIOL CHEM, V267, P166; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GAZDAR AF, 1994, ANTICANCER RES, V13, P261; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KASAI H, 1984, JPN J CANCER RES, V75, P565; KASAI H, 1984, JPN J CANCER RES, V75, P841; KOHNO T, 1995, HUM MOL GENET, V4, P667, DOI 10.1093/hmg/4.4.667; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAGASHIMA M, 1995, CARCINOGENESIS, V16, P1441, DOI 10.1093/carcin/16.6.1441; Nagashima M, 1997, MUTAT RES-DNA REPAIR, V383, P49, DOI 10.1016/S0921-8777(96)00045-6; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIMODA R, 1994, CANCER RES, V54, P3171; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TOTTER JR, 1980, P NATL ACAD SCI-BIOL, V77, P1763, DOI 10.1073/pnas.77.4.1763; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	35	249	259	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2857	2861		10.1038/sj.onc.1201139	http://dx.doi.org/10.1038/sj.onc.1201139			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190902				2022-12-28	WOS:A1997XD64300014
J	Plummer, SJ; Adams, L; Simmons, JA; Casey, G				Plummer, SJ; Adams, L; Simmons, JA; Casey, G			Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25	ONCOGENE			English	Article						breast cancer; growth suppression; MCF7; microcell mediated chromosome transfer; senescence	CELLULAR SENESCENCE; PROTEIN EXPRESSION; GENETIC-ANALYSIS; OVARIAN-CANCER; P53 GENE; TUMOR; CARCINOMAS; MUTATIONS; REGIONS; TUMORIGENICITY	Chromosome 17 is one of the most frequently altered chromosomes in malignant breast cancer, At least four genes implicated in breast cancer reside on chromosome 17 (p53, 17p13; Her-2/neu/ERBB2, 17q12; BRCA1, 17q21; and nm23, 17q22). In addition, allelic imbalance has been described for at least five regions of chromosome 17, We have previously shown that the introduction of a normal human chromosome 17 into the breast cancer cell line MCF7 by microcell mediated chromosome transfer (MMCT) results in the in vitro growth arrest of these cells within 8 weeks, suggesting the presence of a growth suppressor on chromosome 17, Additionally, we have shown that the tumor suppressor gene p53 is not responsible for this phenotype, as it is wild type in MCF7 cells, and overexpression has no effect on either the in vitro or in vivo growth of these cells, We have further localized this growth suppressor gene to 17q24-q25 by transfer of chromosome 17 hybrids containing defined deletions, Whereas transfer of hybrids that contained an intact 17q (delta 43/A9 and delta 26/A9) resulted in growth arrest, two hybrids with overlapping deletions at 17q24-q25, had no effect on growth of MCF7 cells, Molecular analyses revealed that 50/70 (71%) of the resulting delta 2/MCF7 or delta 624/MCF7 MMCT clones retained an intact introduced chromosome 17, In contrast, only 8/34 (24%) of delta 43/MCF7 revertants (deleted for 17p13.1-pter) which escaped growth arrest showed no breakage of the introduced chromosome 17, We did not observe a preferential loss of an intragenic BRCA1 marker in the MMCT hybrids, excluding BRCA1 as the gene responsible for this growth arrest phenotype, These data therefore implicate a new growth suppressor gene involved in breast cancer that is localized to chromosome 17q24-q25.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA58860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058860, U01CA058860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Casey G, 1996, ONCOGENE, V13, P1971; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PC, 1995, ONCOGENE, V10, P577; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; COUNTER C, 1992, EMBO J, V11, P1919; CROPP CS, 1994, JNCI-J NATL CANCER I, V86, P1167, DOI 10.1093/jnci/86.15.1167; CROPP CS, 1993, CANCER RES, V53, P5617; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; EASTON DF, 1993, AM J HUM GENET, V52, P678; Foster JW, 1996, GENOMICS, V33, P185, DOI 10.1006/geno.1996.0182; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTUREAL PA, 1994, SCIENCE, V266, P120; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GREENBLATT MS, 1994, CANCER RES, V54, P4855; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEONE A, 1993, ONCOGENE, V8, P2325; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MURAKAMI YS, 1995, CANCER RES, V55, P3389; NAGAI MA, 1994, GENE CHROMOSOME CANC, V11, P58, DOI 10.1002/gcc.2870110109; NEGRINI M, 1994, CANCER RES, V54, P1818; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; SAITOH S, 1994, ONCOGENE, V9, P2869; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; THIELE M, 1995, ONCOGENE, V10, P439; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	49	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2339	2345		10.1038/sj.onc.1201073	http://dx.doi.org/10.1038/sj.onc.1201073			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178910				2022-12-28	WOS:A1997WY88300011
J	Harvat, BL; Seth, P; Jetten, AM				Harvat, BL; Seth, P; Jetten, AM			The role of p27(Kip1) in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells	ONCOGENE			English	Article						p27(Kip1); growth inhibition; mammary epithelial cells; cdk2; cyclin E; mammary carcinoma	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; TGF-BETA; DNA-REPLICATION; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; POTENTIAL MEDIATOR; GENE-EXPRESSION; MAMMALIAN-CELLS	Interferon gamma (IFN gamma) induces growth arrest in normal human mammary epithelial cells by establishing a block during mid-G(1) corresponding to the time when the retinoblastoma protein (Rb) would normally be inactivated by hyperphosphorylation. IFN gamma inhibits the kinase activities of cdk2, cdk4 and cdk6 within 24 h of treatment, Protein levels of the cdks and G(1) cyclins do not change within this time period, although cdk4 levels are significantly reduced by 48 h. IFN gamma treatment induces p27(Kip1) protein levels, presumably by a posttranscriptional mechanism as no change was observed in the mRNA levels. In addition, IFN gamma-induced inhibition of cdk2 and cyclin E-associated kinase activities is accompanied by a 4.5-fold or greater increase of p27(Kip1) in cdk2 complexes, p27 may also have a role in the inhibition of cdk4/6 kinase activities, as p27 protein associated with these complexes was increase by 55-70% after IFN gamma. In mammary carcinoma cell Lines which are resistant to growth inhibition by IFN gamma, p27 levels are not induced by IFN gamma nor is cdk2 kinase activity inhibited, despite high baseline levels of p27 in cdk2 complexes, However, exogenous expression of p27 in these cells induces growth arrest, In addition, purified p27 protein added to cdk2 complexes immunoprecipitated from carcinoma cells is able to inhibit the kinase activity in a dose dependent manner, Our results suggest that p27(Kip1) has a role in mediating IFN gamma-induced terminal growth arrest. Resistance of mammary carcinomas to growth inhibition by IFN gamma does not appear to involve resistance of cdk2 complexes to the action of p27, but rather an inability to appropriately regulate the balance of cdk2, cyclin E and p27 levels.	NIEHS,CELL BIOL SECT,PULM PATHOBIOL LAB,NIH,RES TRIANGLE PK,NC 27709; NCI,MED BREAST CANC SECT,MED BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445				ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BATES S, 1994, ONCOGENE, V9, P71; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EBLEN ST, 1995, CELL GROWTH DIFFER, V6, P915; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferrando AA, 1996, HUM GENET, V97, P91; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERZINGER T, 1995, ONCOGENE, V10, P2079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sgambato A, 1996, CANCER RES, V56, P1389; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	81	72	74	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2111	2122		10.1038/sj.onc.1201055	http://dx.doi.org/10.1038/sj.onc.1201055			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160891				2022-12-28	WOS:A1997WW80900013
J	Allouche, M; Bettaieb, A; Vindis, C; Rousse, A; Grignon, C; Laurent, G				Allouche, M; Bettaieb, A; Vindis, C; Rousse, A; Grignon, C; Laurent, G			Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells	ONCOGENE			English	Article						Bcl-2; apoptosis; anticancer agents; anthracyclins; ceramide; leukemic cells	DNA FRAGMENTATION; B-CELLS; INTERNUCLEOSOMAL FRAGMENTATION; CHEMOTHERAPEUTIC DRUGS; ANTICANCER DRUGS; DEATH; EXPRESSION; RESISTANCE; PROTEIN; PREVENTION	We have previously demonstrated that daunorubicin (DNR) induces apoptosis in some leukemic myeloid cell lines. We investigated a potential protective role for Bcl-2 in apoptosis induced by DNR in two leukemic cell lines, one myeloid and one lymphoid, overexpressing the anti-apoptotic gene Bcl-2. Parental cells treated with DNR exhibited classical features of apoptosis 6 h after drug exposure, all the cells being dead after 30-48 h. In contrast, overexpression of Bcl-2 significantly delayed, but did not prevent the occurrence of DNR-induced apoptosis, with no surviving cells 96 h after drug exposure. To elucidate the mechanism of the protection mediated by Bcl-2, we explored the signaling pathway which initiates DNR-induced apoptosis. In this report, we show that, in both the myeloid and lymphoid parental cell lines, DNR triggered a sphingomyelin (SM) hydrolysis after 10-15 min with a concomitant ceramide generation. Moreover, exogenous ceramide induced DNA fragmentation in these cells, with levels similar to those observed with DNR treatment. In contrast, Bcl-2 overexpression protected the cells against apoptosis induced by ceramide treatment, without preventing the early SM hydrolysis nor the ceramide generation in these cells. Our results strongly suggest that Bcl-2-mediated protection of DNR-induced apoptosis is effected downstream of the SM-ceramide signaling pathway.			Allouche, M (corresponding author), CJF INSERM 9503,CTR CLAUDIUS REGAUD,20-24 RUE PONT ST PIERRE,F-31052 TOULOUSE,FRANCE.		Vindis, Cécile/AAH-2708-2019	Vindis, Cécile/0000-0003-2421-1155; Bettaieb, Ali/0000-0002-6018-9592				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CAMPOS L, 1993, BLOOD, V81, P3091; CATCHPOOLE DR, 1993, CANCER RES, V53, P4287; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FANG W, 1995, J IMMUNOL, V155, P66; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FISHER TC, 1993, CANCER RES, V53, P3321; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROMOVA II, 1995, P NATL ACAD SCI USA, V92, P102, DOI 10.1073/pnas.92.1.102; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 1995, CLIN CANCER RES, V1, P1005; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levade T, 1996, M S-MED SCI, V12, P1219, DOI 10.4267/10608/654; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; NAUMOVSKI L, 1994, BLOOD, V83, P2261; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; QuilletMary A, 1996, LEUKEMIA, V10, P417; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALKER PR, 1991, CANCER RES, V51, P1078; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YIN DX, 1995, CANCER RES, V55, P4922; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	51	63	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1837	1845		10.1038/sj.onc.1201023	http://dx.doi.org/10.1038/sj.onc.1201023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150390				2022-12-28	WOS:A1997WW16600010
J	Xian, WJ; Rosenberg, MP; DiGiovanni, J				Xian, WJ; Rosenberg, MP; DiGiovanni, J			Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: Possible role in mouse skin tumor promotion	ONCOGENE			English	Article						erbB2; c-src; phosphorylation; tumor promotion	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU-ONCOGENE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HUMAN-BREAST; MOLECULAR-CLONING; CARCINOMA-CELLS; MAMMARY-TUMORS; PROTO-ONCOGENE	In recent work eve showed that the EGF receptor (EGFr) was activated in tumor promoter treated mouse epidermis (Cell Growth & Differentiation, 6: 1447-1455, 1995). In the present study, we have investigated the possible role of other erbB family members in the process of tumor promotion. Both erbB2 and erbB3, but not erbB4, were expressed in cultured mouse keratinocytes and in mouse epidermis in vivo. In cultured mouse keratinocytes, EGF stimulated rapid tyrosine phosphorylation of erbB2 followed by a time-dependent degradation of erbB2 protein. Furthermore, an increase in erbB2:EGFr heterodimer formation was also induced by EGF. In contrast to the results with erbB2, EGF did not induce tyrosine phosphorylation, the degradation of erbB3, or erbB3:EGFr heterodimer formation in cultured keratinocytes. Further analyses revealed that c-src kinase activity was dramatically elevated in cultured mouse keratinocytes exposed to EGF. In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was significantly elevated in a dose-dependent manner. Concomittantly, erbB2:EGFr heterodimer formation and c-src kinase activity were also elevated in TPA-treated epidermis. Structure-activity relationships with several phorbol ester analogs showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor promoting ability. Activation of erbB2 and c-src kinase were also observed in the epidermis of TGF alpha transgenic mice where expression of human TGF alpha was targeted to basal keratinocytes with the human K14 promoter. Collectively, the current data suggest that the activation of erbB2 in phorbol ester treated skin can be explained solely by a mechanism involving elevation of EGFr ligands and activation of the EGFr. In addition, activation of c-spe may be an important downstream effector in mouse keratinocytes both in vivo and in vitro, following activation of the EGFr, erbB2, or both.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline				DiGiovanni, John/0000-0003-4233-6728	NCI NIH HHS [CA57596, CA16672] Funding Source: Medline; NIEHS NIH HHS [ES 07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA057596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALDAZ CM, 1985, CANCER RES, V45, P2753; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOUTWELL RK, 1976, CANCER RES, V36, P2631; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EWING MW, 1988, CARCINOGENESIS, V9, P405, DOI 10.1093/carcin/9.3.405; EWING MW, 1988, CANCER RES, V48, P7048; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; Kiguchi K., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P149; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V301, P621; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASON S, 1995, BREAST, V4, P11, DOI 10.1016/0960-9776(95)90022-5; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAICK AN, 1972, CANCER RES, V32, P1562; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLAGA T J, 1989, P1; SLAGA TJ, 1983, ENVIRON HEALTH PERSP, V50, P3, DOI 10.2307/3429529; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; YUSPA SH, 1994, CANCER RES, V54, P1178	61	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1435	1444		10.1038/sj.onc.1200980	http://dx.doi.org/10.1038/sj.onc.1200980			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136987				2022-12-28	WOS:A1997WT58400006
J	Paulson, R; Jackson, J; Immergluck, K; Bishop, JM				Paulson, R; Jackson, J; Immergluck, K; Bishop, JM			The DFer gene of Drosophila melanogaster encodes two membrane associated proteins that can both transform vertebrate cells	ONCOGENE			English	Article						tyrosine kinase; Drosophila melanogaster; oncogenes; cell transformation; FPS/FES	FUJINAMI SARCOMA-VIRUS; TYROSINE KINASE FER; FPS-GENE; C-FPS; CELLULAR-LOCALIZATION; MYRISTYLATION SIGNAL; NUCLEOTIDE-SEQUENCE; RETROVIRAL VECTORS; TRANSCRIPT FERT; AMINO-ACIDS	The vertebrate gene FER encodes two protein-tyrosine kinases with molecular weights of 51 000 and 94 000 and distinctive aminotermini, The larger kinase is expressed ubiquitously among vertebrate tissues, whereas expression of the smaller kinase appears to be limited to spermatogenic cells in the testes, Here we show that Drosophila melanogaster contains an apparent ortholog of FER (DFer) that also produces two mRNAs by separate initiation of transcription, and two proteins with molecular weights of 45 000 and 92 000, Both proteins are in part loosely associated with cytoplasmic membranes, Both can transform avian and rodent cells with roughly equal potency, when expressed from retroviral vectors, Fusing the myristoylation signal from the SRC protein-tyrosine kinase to the aminoterminus of the DFer protein increased the strength of attachment to membranes but augmented transformation only marginally, The results provide the first demonstration of neoplastic transformation by a protein-tyrosine kinase of Drosophila and by FER from any species, The products of Drosophila and vertebrate FER may be part of similar signaling pathways in the two species.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, GW HOOPER FDN, SAN FRANCISCO, CA 94143 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute					NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [(CA44338)] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FA, 1990, CURRENT PROTOCOLS MO; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1970, CELL, V42, P182; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GARAPIN AC, 1970, J VIROL, V6, P589, DOI 10.1128/JVI.6.5.589-598.1970; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATZEN AL, 1991, MOL CELL BIOL, V11, P226, DOI 10.1128/MCB.11.1.226; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KIM L, 1995, MOL CELL BIOL, V15, P4553; LETWIN K, 1988, ONCOGENE, V3, P621; MCMAHON M, 1991, MOL CELL BIOL, V11, P4760, DOI 10.1128/MCB.11.9.4760; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pawson T, 1988, Adv Exp Med Biol, V234, P55; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; WILKS AF, 1988, ONCOGENE, V3, P289; WOOLFORD J, 1984, VIROLOGY, V135, P168, DOI 10.1016/0042-6822(84)90127-2; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	44	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					641	652		10.1038/sj.onc.1200875	http://dx.doi.org/10.1038/sj.onc.1200875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038371				2022-12-28	WOS:A1997WG43000002
J	Ogretmen, B; Safa, AR				Ogretmen, B; Safa, AR			Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells	ONCOGENE			English	Article						deleted p53; multidrug resistance; MCF-7/Adr	ADRIAMYCIN-RESISTANT; GROWTH SUPPRESSION; P-GLYCOPROTEIN; GENE; MUTATIONS; BCL-2; TRANSACTIVATION; MECHANISMS; PROMOTER; MUTANTS	Multidrug resistance in MCF-7/Adr human breast cancer cells is mediated by several mechanisms including overexpression of the MDR1 gene product, P-glycoprotein and glutathion-related detoxifying enzymes. Mutations in the p53 tumor suppressor protein have been reported to play a role in the development of resistance to DNA damaging agents in several human cancer cells, In the present study we have assessed the mutational status of the p53 protein and its expression levels, degree of stability and cellular localization to investigate whether it is involved in modulating multidrug resistance in MCF-7/Adr cells compared to sensitive MCF-7 cells, As revealed by immunofluorescence microscopy using the anti-p53 mouse monoclonal antibody DO-1, wild-type p53 is sequestered in the cytoplasm of MCF-7 cells, whereas in MCF-7/Adr cells, the protein is localized in the nucleus, The sequencing of full-length p53 cDNA revealed a 21 bp deletion in its one of the four conserved regions within the conformational domain, spanning codons 126-133 at exon five, in MCF-7/Adr cells, Moreover, detection of ThaI polymorphism of codon 72 showed that MCF-7 cells predominantly express wild-type p53 with proline, while mutated p53 in MCF-7/Adr cells contains an arginine residue at codon 72, In addition, we demonstrate that the half-life of p53 in MCF-7 cells is less than 30 min while the mutated protein is more stable; its half-life is about 4 h in MCF-7/Adr cells, Thus, this study demonstrates that the deletion of codons 126-133 in p53 causes increased stability, overexpression and nuclear localization of the protein in multidrug resistant MCF-7/Adr cells, and further suggests that mutated p53 might be involved in the development of multidrug resistance in this cell line.	MED UNIV S CAROLINA,HOLLINGS CANC CTR,DEPT EXPT ONCOL,CHARLESTON,SC 29424	Medical University of South Carolina					NATIONAL CANCER INSTITUTE [R01CA056078] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FUCHS B, 1995, ONCOGENE, V10, P789; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; HALDAR S, 1994, CANCER RES, V54, P2095; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANDESMAN Y, 1994, ONCOGENE, V9, P1241; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NEGRINI M, 1994, CANCER RES, V54, P1818; NGUYEN KT, 1994, ONCOL RES, V6, P71; OCONNOR PM, 1993, CANCER RES, V53, P4776; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; OGRETMEN B, 1996, INT J CANCER, V67, P1; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROUBY SE, 1993, BLOOD, V82, P3452; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAFA AR, 1994, BIOCHEMISTRY-US, V33, P256, DOI 10.1021/bi00167a034; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; TAKAHASHI T, 1991, BIOTECHNIQUES, V11, P166; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	39	86	88	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					499	506		10.1038/sj.onc.1200855	http://dx.doi.org/10.1038/sj.onc.1200855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053847				2022-12-28	WOS:A1997WE36400013
J	Uren, A; Yu, JC; Karcaaltincaba, M; Pierce, JH; Heidaran, MA				Uren, A; Yu, JC; Karcaaltincaba, M; Pierce, JH; Heidaran, MA			Oncogenic activation of the alpha PDGFR defines a domain that negatively regulates receptor dimerization	ONCOGENE			English	Article						PDGFR; dimerization; tyrosine kinase; transformation	GROWTH-FACTOR RECEPTORS; FMS PROTO-ONCOGENE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; LIGAND-BINDING; MONOCLONAL-ANTIBODY; POINT MUTATION; BB BINDING; AA; EXPRESSION	The alpha platelet derived growth factor receptor (alpha PDGFR) extracellular Immunoglobulin (Ig) like domains 1-3 contain major determinants for ligand interaction. We now report that a deletion of Ig-like loop 3, but not Ig-like loop 1 or 2, of the alpha PDGFR causes ligandindependent transformation in NIH3T3 cells. Biochemical analyses of alpha PDGFR mutants lacking Ig-like loop 3 indicate that cellular transformation is mediated by ligand-independent activation of the alpha PDGFR tyrosine kinase activity as determined by receptor autophosphorylation both in vivo and in vitro. Moreover, crosslinking analysis of alpha PDGFR mutants expressed ectopically in NIH3T3 cells indicate that deletion within extracellular domain 3 leads to ligand-independent receptor dimerization. All of these findings suggest that the Ig-like loop 3 of the alpha PDGFR contains the major determinants which inhibit receptor dimerization in the quiescent cells and that the ligand binding induces receptor activation by neutralizing the inhibitory effect of this domain.	NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Karcaaltincaba, Musturay/A-3866-2016	Karcaaltincaba, Musturay/0000-0002-3384-0909				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; FLEMING TP, 1992, ONCOGENE, V7, P1355; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	25	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					157	162		10.1038/sj.onc.1200810	http://dx.doi.org/10.1038/sj.onc.1200810			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010217				2022-12-28	WOS:A1997WC81800003
J	Rahman, N; Arbour, L; Tonin, P; Baruchel, S; PritchardJones, K; Narod, SA; Stratton, MR				Rahman, N; Arbour, L; Tonin, P; Baruchel, S; PritchardJones, K; Narod, SA; Stratton, MR			The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene	ONCOGENE			English	Article						Wilms' tumour; loss of heterozygosity; dominant oncogene; tumour suppressor gene	MEDULLARY-THYROID CARCINOMA; ENDOCRINE NEOPLASIA TYPE-2A; RET PROTOONCOGENE; MUTATIONS; NEUROFIBROMATOSIS; PREDISPOSITION; ALLELES; CANCER; HETEROZYGOSITY; CHROMOSOME-11	A familial Wilms' tumour susceptibility gene, known as FWT1, has recently been localised to chromosome 17q12-q21 by genetic linkage analysis, Four Wilms' tumours from a family showing strong evidence of linkage to FWT1 were examined for allele loss using polymorphic microsatellite markers on chromosome 17q, In three tumours no loss of heterozygosity was observed, In the remaining case, loss of heterozygosity was detected at all markers analysed, However, the alleles lost in this Wilms' tumour were those segregating with the disease in the family, This is in contrast to the usual pattern observed in familial cancer syndromes, where the allele lost in tumours arising in gene carriers is the wild type inherited from the non mutation carrying parent, Taken together with previous data indicating that LOH on chromosome 17q is rare in sporadic Wilms' tumour, the results suggest that FWT1 is not a tumour suppressor gene, Moreover, loss of alleles linked to the disease and the implied absence of the mutated susceptibility gene in one tumour, suggests that a mutation in FWT1 may be necessary for the initiation of some familial Wilms' tumours but subsequently the maintenance of the neoplastic phenotype becomes independent of the FWT1 mutation.	INST CANC RES,PAEDIAT SECT,SUTTON SM2 5NG,SURREY,ENGLAND; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT HUMAN GENET,DIV MED GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PEDIAT ONCOL,MONTREAL,PQ,CANADA; MONTREAL CHILDRENS HOSP,RES INST,MONTREAL,PQ H3H 1P3,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA	University of London; Institute of Cancer Research - UK; McGill University; McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Womens College Hospital	Rahman, N (corresponding author), INST CANC RES,SECT MOL CARCINOGENESIS,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Narod, Steven A/AAA-6112-2022; Rahman, Nazneen/B-8890-2012; Pritchard-Jones, Kathy/F-4286-2014; Rahman, Nazneen/D-2802-2013	Pritchard-Jones, Kathy/0000-0002-2384-9475; Rahman, Nazneen/0000-0003-4376-0440; Arbour, Laura/0000-0002-9589-0880				BIGGS PJ, 1995, NAT GENET, V12, P441; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COLLINS N, 1995, ONCOGENE, V10, P1673; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KELLER HD, 1993, HUM MOL GENET, V2, P851; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEVY DB, 1994, CANCER RES, V54, P5953; MAW MA, 1992, CANCER RES, V52, P3094; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; NELKIN BD, 1989, CANCER RES, V49, P4114; PAL N, 1990, ONCOGENE, V5, P1665; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SHUIN T, 1994, CANCER RES, V54, P2852; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WADEY RB, 1990, ONCOGENE, V5, P901; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	31	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3099	3102		10.1038/sj.onc.1201107	http://dx.doi.org/10.1038/sj.onc.1201107			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223674				2022-12-28	WOS:A1997XG10000013
J	Smith, KS; Jacobs, Y; Chang, CP; Cleary, ML				Smith, KS; Jacobs, Y; Chang, CP; Cleary, ML			Chimeric oncoprotein E2a-Pbx1 induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2	ONCOGENE			English	Article						apoptosis; inducible oncoprotein; translocation; homeodomain	LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; WILD-TYPE P53; DNA-BINDING; PRE-B; FUSION; E2A; TRANSCRIPTION; EXPRESSION	The chimeric oncoprotein E2a-Pbx1 results from fusion of the E2A and PBX1 genes following t(1;19) chromosomal translocations in B cell precursor acute leukemias. Experimentally B cell progenitors do not tolerate constitutive expression of E2a-Pbx1 which contrasts with transformation of several other cell types following its stable expression both in vitro and in vivo, To further investigate the effects of E2a-Pbx1 on the B cell progenitors, we conditionally expressed E2a-Pbx1 under control of a metal response element in hematopoietic precursor cell lines in vitro, Inducible expression of E2a-Pbx1 resulted in cell death with the morphologic and molecular features of apoptosis, A structure-function analysis demonstrated that induction of apoptosis was not a dominant-negative effect of the E2a moiety but, rather, required the DNA-binding homeodomain of Pbx1, E2a-Pbx1-induced apoptosis proceeded through a BCL2-responsive checkpoint eventuating in PARP inactivation but did require p53, Constitutive expression of E2a-Pbx1 did not induce apoptosis or continued cycling of Rat-1 fibroblasts in low serum conditions, These studies demonstrate that E2a-Pbx1 initiates programmed cell death of hematopoietic precursers by a mechanism that requires its chimeric transcriptional properties, but, unlike other nuclear oncoproteins, is independent of p53.			Smith, KS (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,EXPT ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971, CA09151, CA66284] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971, F32CA066284] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHANG CP, 1997, IN RPESS MOL CELL BI; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZHOU H, 1996, SCIENCE, V272, P738	44	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2917	2926		10.1038/sj.onc.1201249	http://dx.doi.org/10.1038/sj.onc.1201249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205098				2022-12-28	WOS:A1997XF55500005
J	Yanai, A; Arama, E; Kilfin, G; Motro, B				Yanai, A; Arama, E; Kilfin, G; Motro, B			ayk1, a novel mammalian gene related to Drosophila aurora centrosome separation kinase, is specifically expressed during meiosis	ONCOGENE			English	Article						serine/threonine protein kinase; centrosome separation; meiosis	KINESIN-LIKE PROTEIN; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; MESSENGER-RNAS; MUTATIONS; SEQUENCES; IDENTIFICATION; CLASSIFICATION; MITOSIS; MEMBERS	A novel murine gene, designated ayk1, which encodes a putative serine/threonine kinase has been cloned and characterized, The predicted catalytic domain of the protein is highly similar to that of Drosophila aurora (62.9% identity), and to that of Saccharomyces Ipl1 (49.4% identity), All three proteins also have very basic calculated isoelectric points (higher than 10), aurora has been recently shown to be crucial for centrosome separation and chromosome segregation, while Ipl1 is essential for yeast viability and accurate chromosome segregation, The results of Northern analysis and in situ RNA localization support a similar role for ayk1. The gene is specifically expressed in meiotically active cells, and during spermatogenesis, ayk1 transcripts accumulate just before the first meiotic division, Much lower levels are found in mitotically active cells, We propose that Ayk1, aurora and Ipl1 belong to a distinct new subfamily of kinases, These results suggest that the pathways controlling chromosome segregation are evolutionary conserved, and that similar control mechanisms operate in mitosis and meiosis.	BAR ILAN UNIV, DEPT LIFE SCI, IL-52900 RAMAT GAN, ISRAEL	Bar Ilan University			Arama, Eli/GYJ-0491-2022; /ABF-8487-2022					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASSOLD T, 1984, ANNU REV GENET, V6, P555; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; Kimura M., 1983, NEUTRAL THEORY MOL E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MOTRO B, 1991, DEVELOPMENT, V113, P1207; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 1988, MOL CLONIGN LAB MANU; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	34	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2943	2950		10.1038/sj.onc.1201144	http://dx.doi.org/10.1038/sj.onc.1201144			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205101				2022-12-28	WOS:A1997XF55500008
J	Merritt, AJ; Allen, TD; Potten, CS; Hickman, JA				Merritt, AJ; Allen, TD; Potten, CS; Hickman, JA			Apoptosis in small intestinal epithelia from p53-null mice: Evidence for a delayed, p53-indepdendent G2/M-associated cell death after gamma-irradiation	ONCOGENE			English	Article						p53; apoptosis; p53-independent apoptosis; radiation; small intestine; G2/M checkpoint	RADIATION-INDUCED APOPTOSIS; DNA-DAMAGE; GASTROINTESTINAL-TRACT; P53; CRYPTS; CYCLE; PROGRESSION; CHECKPOINT; TUMORS; CANCER	The death of small intestinal epithelial cells has been characterized and quantitated after irradiation of mice rendered homozygously null for the p53 gene, In wild-type animals homozygous for p53 a rapid (4.5 h) elevation of p53 protein was observed in the proliferative compartment of the crypts after 8 Gy of irradiation, Cells underwent cell death by apoptosis in this region, We had reported previously a total repression of apoptosis in small intestinal crypt epithelia 4.5 h after the gamma-irradiation (8 Gy) of p53 homozygously null animals, Thus, while 400 apoptotic cells mere observed in 200 half crypts taken from mild-type animals at 4.5 h, this fell to background levels (10-30) in the p53 null animals (Merritt et al., 1994) and did not increase by 12 h, However, we have nom found a delayed initiation of a p53-independent apoptosis after 8 Gy of gamma-radiation: at 24 h, approximately 100 apoptotic cells were observed in 200 half crypts, This late wave of apoptosis was not observed after 1 Gy of gamma-radiation. The morphological appearance of this p53-independent apoptosis suggested that death may have arisen as the result of aberrant mitosis, Analysis of the regeneration of crypts 3 days after irradiation of mice with between 11 and 17 Gy showed that there was no significant increase (P=0.135) in the potential of clonogenic cells from the p53 nub animals to repopulate the crypts, The data support the idea that a p53-independent apoptotic mechanism permits the engagement of apoptosis, probably by a mitotic catastrophe, after 8 Gy of gamma-irradiation in,live and that a loss of p53 does not make these epithelial cells radioresistant lit vivo to doses of 8 Gy and above, In contrast, irradiation with 1 GS failed to induce a p53-independent apoptosis in vivo, suggesting that the p53 'sensor' of damage was more sensitive than that engaging the p53-independent mechanism of cell death.	CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT EPITHELIAL BIOL, CANC RES CAMPAIGN, MANCHESTER M20 4BX, LANCS, ENGLAND; CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT ULTRASTRUCT, MANCHESTER M20 4BX, LANCS, ENGLAND; UNIV MANCHESTER, SCH BIOL SCI, MOL & CELLULAR PHARMACOL GRP, MANCHESTER M13 9PT, LANCS, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fishel R, 1996, J NATL CANCER I, V88, P1608, DOI 10.1093/jnci/88.22.1608; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARMON BV, 1992, CELL PROLIFERAT, V25, P523, DOI 10.1111/j.1365-2184.1992.tb01457.x; HENDRY JH, 1979, RADIAT RES, V78, P404, DOI 10.2307/3574968; Kahlenberg MS, 1996, J NATL CANCER I, V88, P1665, DOI 10.1093/jnci/88.22.1665; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LESHER S, 1969, NATL CANCER I MONOGR, P185; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; Potten C. S., 1995, P45; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; POTTEN CS, 1981, INT J RADIAT BIOL, V40, P321, DOI 10.1080/09553008114551251; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; ROBERTS SA, 1990, INT J RADIAT BIOL, V57, P1243, DOI 10.1080/09553009014551321; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	183	192	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2759	2766		10.1038/sj.onc.1201126	http://dx.doi.org/10.1038/sj.onc.1201126			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190891				2022-12-28	WOS:A1997XD64300003
J	Shinagawa, T; Ishiguro, N; Horiuchi, M; Matsui, T; Okada, K; Shinagawa, M				Shinagawa, T; Ishiguro, N; Horiuchi, M; Matsui, T; Okada, K; Shinagawa, M			Deletion of c-myb exon 9 induced by insertion of repeats	ONCOGENE			English	Article						12-nucleotide repeat; c-myb; exon skipping; transcription; T lymphoma	DNA-BINDING DOMAIN; T-LYMPHOMA-CELLS; V-MYB; TRANSCRIPTIONAL ACTIVATION; PROVIRAL INTEGRATION; CELLULAR PROGENITOR; ONCOGENE PRODUCT; GENE-EXPRESSION; LEUKEMIA-VIRUS; PROTEIN	A simple repeat was found to be inserted into exon 9 of the c-myb gene in three out of 20 bovine T lymphomas. The repeat was composed of multiple copies of a 12-nucleotide motif and had no significant homology to the sequences reported so far. Tumor cells containing the repeat expressed two kinds of c-myb mRNA: (1) are that included the repetitive sequence in exon 9, and (2) are that lacked the whole sequence of exon 9. Transfection of an expression vector containing exon and intron sequences and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the mRNA demonstrated that the insertion of the repeat enhanced exon skipping of the transfected minigene. These observations imply that the insertion of the repeat may enhance exon skipping of the c-myb pre-mRNA. Although the transcription-activating activity by the c-Myb with the repeat was low, that by the c-Myb without exon 9 was three- to eightfold higher than the wild-type c-Myb. These data suggest that insertion of the 12-nucleotide repeat in codon 359 may result in c-Myb proteins having high- and low-transcription-activating activity.	OBIHIRO UNIV AGR & VET MED,DEPT VET PUBL HLTH,OBIHIRO,HOKKAIDO 080,JAPAN; OBIHIRO UNIV AGR & VET MED,DEPT VET PATHOL,OBIHIRO,HOKKAIDO 080,JAPAN; IWATE UNIV,DEPT VET PATHOL,MORIOKA,IWATE 020,JAPAN	Obihiro University of Agriculture & Veterinary Medicine; Obihiro University of Agriculture & Veterinary Medicine; Iwate University								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAVIER D, 1994, ONCOGENE, V9, P305; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; ISHIGURO N, 1994, J BIOL CHEM, V269, P26822; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1995, ONCOGENE, V11, P2113; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHINAGAWA T, 1994, J VET MED SCI, V56, P957, DOI 10.1292/jvms.56.957; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	47	2	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2775	2783		10.1038/sj.onc.1201130	http://dx.doi.org/10.1038/sj.onc.1201130			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190893				2022-12-28	WOS:A1997XD64300005
J	Ceccherini, I; Pasini, B; Pacini, F; Gullo, M; Bongarzone, I; Romei, C; Santamasia, G; Matera, I; Mondellini, P; Scopsi, L; Pinchera, A; Pierotti, MA; Romeo, G				Ceccherini, I; Pasini, B; Pacini, F; Gullo, M; Bongarzone, I; Romei, C; Santamasia, G; Matera, I; Mondellini, P; Scopsi, L; Pinchera, A; Pierotti, MA; Romeo, G			Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene	ONCOGENE			English	Article						RET proto-oncogene; MTC patients; somatic mutations; in frame deletions; transformation assay	TYROSINE KINASE DOMAIN; MUTATIONS; PROTOONCOGENE; DISEASE; FMTC; 2A	Somatic RET mutations have been identified in a variable proportion (about 30-70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few different MTC somatic mutations have been reported so far whose biological activity has still to be tested, In this paper we report the identification, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.	IST NAZL TUMORI,DIREZ SCI,I-20133 MILAN,ITALY; UNIV PISA,IST ENDOCRINOL,I-56018 TIRRENIA,PISA,ITALY; IST GIANNINA GASLINI,LAB GENET MOL,I-16148 GENOA,ITALY; IST NAZL TUMORI,DIV ANAT PATOL,I-20133 MILAN,ITALY; IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY; INT AGCY RES CANC,GENET CANC SUSCEPTIBIL UNIT,F-69372 LYON,FRANCE	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; World Health Organization; International Agency for Research on Cancer (IARC)			Santamaria, Giuseppe/AAB-4185-2021; Pasini, Barbara/AHI-2004-2022; Ceccherini, Isabella/P-8195-2014; Pierotti, Marco Alessandro/AAC-4728-2022; Bongarzone, Italia/B-9544-2017	Santamaria, Giuseppe/0000-0002-7686-6703; Pasini, Barbara/0000-0002-4373-1212; Ceccherini, Isabella/0000-0001-8732-1955; Pierotti, Marco Alessandro/0000-0002-7431-8332; Bongarzone, Italia/0000-0003-2530-9170				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1995, ONCOGENE, V10, P509; Massague J, 1996, NATURE, V382, P29, DOI 10.1038/382029a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Romei C, 1996, J CLIN ENDOCR METAB, V81, P1619, DOI 10.1210/jc.81.4.1619; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SERI M, IN PRESS HUMAN MUTAT; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0	16	27	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2609	2612		10.1038/sj.onc.1201079	http://dx.doi.org/10.1038/sj.onc.1201079			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191060				2022-12-28	WOS:A1997XA94900012
J	Murakami, M; Sonobe, MH; Ui, M; Kabuyama, Y; Watanabe, H; Wada, T; Handa, H; Iba, H				Murakami, M; Sonobe, MH; Ui, M; Kabuyama, Y; Watanabe, H; Wada, T; Handa, H; Iba, H			Phosphorylation and high level expression of Fra-2 in v-src transformed cells: A pathway of activation of endogenous AP-1	ONCOGENE			English	Article						AP-1; Fra-2; phosphorylation; transformation; v-src; ERK2	DNA-BINDING ACTIVITY; GROWTH-STIMULATING ACTIVITY; AFFINITY LATEX-PARTICLES; PROTEIN-KINASE; C-JUN; MAP KINASE; FOS GENE; SIGNAL-TRANSDUCTION; CELLULAR-TRANSFORMATION; TRANSCRIPTION FACTOR	Chicken embryo fibroblasts (CEF) transformed with v-src were previously reported to revert to normal phenotype after the introduction of dominant-negative mutants of Fos or Jun, indicating that endogenous AP-1 activity is essential for the cellular transformation, The major changes in the expression levels of fos and jun family genes induced by v-src were the elevation of fra-2 and c-jun transcripts. We show here that extensive phosphorylation of the AP-1 component Fra-2 is a major qualitative change in v-src transformed CEF and that several Ser and Thr residues in a C-terminal region of Fra-2 (amino acids 266-323) are phosphorylated specifically. The induced kinase activity was detected at the position of 42 kDa by in gel kinase assay using the Fra-2 C-terminal region as a substrate, and it was identified as chicken ERK2. JNK1 and JNK2, other members of the MAP kinase family, were not significantly activated in v-src transformed CEF and Fra-2 was not a good substrate for JNKs. fra-2 promoter analysis indicated that this promoter activity is elevated in v-src transformed CEP via two AP-1 binding sites and CRE-like sequence. We propose that phosphorylation of Fra-2 by ERK2 converts it from an inefficient transcriptional activator to an active one and further that fra-2 expression is autoregulated in response to the phosphorylation status of its gene product.	UNIV TOKYO,INST MED SCI,DEPT GENE REGULAT,MINATO KU,TOKYO 108,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	University of Tokyo; Tokyo Institute of Technology			Sonobe, Martha/I-2877-2015; Watanabe, Hirotaka/GZA-8002-2022					ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CATLING AD, 1993, ONCOGENE, V8, P1875; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Greulich H, 1996, ONCOGENE, V12, P1689; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARTL M, 1991, ONCOGENE, V6, P1623; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; IBA H, 1988, ONCOGENE RES, V2, P121; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	56	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2435	2444		10.1038/sj.onc.1201077	http://dx.doi.org/10.1038/sj.onc.1201077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188858				2022-12-28	WOS:A1997WZ68000007
J	PerezRoger, I; Solomon, DLC; Sewing, A; Land, H				PerezRoger, I; Solomon, DLC; Sewing, A; Land, H			Myc activation of cyclin E Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes	ONCOGENE			English	Article						cell cycle; Cdk2; cyclin E; Myc; p27; Kip1	C-MYC; DNA-BINDING; DEPENDENT KINASES; PHASE PROGRESSION; PROTEIN; EXPRESSION; G(1); MAX; CELLS; FIBROBLASTS	Induction of the Myc-oestrogen receptor fusion protein (MycER) by 4-OH-tamoxifen (OHT) leads to the activation of Cyclin E/Cyclin-dependent kinase 2 (CycE/Cdk2) complexes followed by the induction of DNA synthesis. As CycE/Cdk2 activity is essential for G1/S transition, we have investigated the mechanism by which Myc can activiate CycE/Cdk2. Our results suggest that this activation may involve at least two Myc-dependent steps: the induction of cyclin E gene transcription followed by accumulation of cyclin E mRNA in a protein synthesis-independent manner and the inhibition of p27(Kip1) association with CycE/Cdk2 complexes containing newly synthesised CycE. As a consequence phosphorylation of CycE-bound Cdk2 by cyclin activating kinase (CAK) is accelerated. We propose a model in which the active newly synthesised CycE/Cdk2 complexes trigger a positive feed-back mechanism to activate preexisting complexes through phosphorylation-dependent p27(Kip1) release.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Pérez Roger, Ignacio/K-1346-2014	Pérez Roger, Ignacio/0000-0002-5564-6912				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WIMMEL A, 1994, ONCOGENE, V9, P995	59	198	203	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2373	2381		10.1038/sj.onc.1201197	http://dx.doi.org/10.1038/sj.onc.1201197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188852				2022-12-28	WOS:A1997WZ68000001
J	Mao, SF; Neale, GAM; Goorha, RM				Mao, SF; Neale, GAM; Goorha, RM			T-cell oncogene rhombotin-2 interacts with retinoblastoma-binding protein 2	ONCOGENE			English	Article						oncogene; rhombotin-2; RBP2; transcription	LIM-DOMAIN PROTEINS; CYSTEINE-RICH MOTIF; LOOP-HELIX PROTEIN; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ACUTE LEUKEMIAS; INSULIN GENE; RBTN2	The LIM domain protein rhombotin-2 (RBTN-2/TTG-2/Lmo2) has distinct functions in erythropoiesis and in T-cell leukemogenesis. Additional functions for RBTN2 are indicated by its expression in non-hematopoietic tissues. These diverse functions of RBTN2 are presumed to be accomplished through physical interaction with different protein partners that bind the LIM domains of RBTN2. To identify these proteins which may modulate the activity of RBTN2, a human cDNA library was screened using the yeast two-hybrid assay. Using the RBTN2 LIM domain region as 'bait', the retinoblastoma-binding protein 2 (RBP2) was identified as a partner for RBTN2. The interaction between RBTN2 and RBP2 was confirmed using in vitro binding assays, and by coimmunoprecipitation of the two proteins. Deletion analysis showed the second LM domain of RBTN2 was necessary and sufficient for binding to the last 69 amino acids of RBP2. The interaction between RBTN2 and RBP2 had a functional consequence: the combination of RBP2 and RBTN2 gave higher transcription in vitro, than RBTN2 alone. The interaction with RBP2 suggests tao additional functions for RBTN2: (i) RBTN2 may directly affect the activity of RBP2, and/or (ii) RBTN2 may indirectly modulate the functions of the retinoblastoma protein by binding to RBP2.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOL BIOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PATHOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CANCER INSTITUTE [R01CA043237, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43237, P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AUSEBEL F, 1993, CURRENT PROTOCOLS MO; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARPER JW, 1993, CELL, V75, P805; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LARSON RC, 1995, ONCOGENE, V11, P853; LARSON RC, 1994, ONCOGENE, V9, P3676; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; NEALE GAM, 1995, CELL GROWTH DIFFER, V6, P587; NEALE GAM, 1995, BLOOD, V86, P3060; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	47	30	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1531	1539		10.1038/sj.onc.1200988	http://dx.doi.org/10.1038/sj.onc.1200988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129143				2022-12-28	WOS:A1997WQ54800003
J	Martin, A; Duffy, PA; Liossis, C; GomezMunoz, A; OBrien, L; Stone, JC; Brindley, DN				Martin, A; Duffy, PA; Liossis, C; GomezMunoz, A; OBrien, L; Stone, JC; Brindley, DN			Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblasts	ONCOGENE			English	Article						ceramides; diacylglycerol kinase; phosphatidate phosphohydrolase; phospholipase D	PHOSPHOLIPASE-D ACTIVITY; GTPASE ACTIVATING PROTEIN; CELL-PERMEABLE CERAMIDES; XENOPUS-LAEVIS OOCYTES; DNA-SYNTHESIS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLCHOLINE METABOLISM; QUANTITATIVE MEASUREMENT; TRANSFORMED FIBROBLASTS; LYSOPHOSPHATIDIC ACID	Concentrations of the bioactive lipids, phosphatidate and diacylglycerol, increased with time in culture in ras- and tyrosine kinase (fps)-transformed fibroblasts but not in control fibroblasts, On Day 3, diacylglycerol and phosphatidate concentrations were about 3.3- and 5.5-fold higher respectively in the Pas-transformed compared to control fibroblasts. These concentrations in fps-transformed fibroblasts were increased about twofold. The changes in phosphatidate and diacylglycerol resulted from enhanced phospholipid turnover rather than from synthesis de novo, The increased ratio of phosphatidate to diacylglycerol is explained by decreased activities of two distinct phosphatidate phosphohydrolases and increased diacylglycerol kinase in Pas-transformed fibroblasts. Ceramide concentrations were about 2.5- and threefold higher in the fps- and ras-transformed cells respectively on Day 3 compared to the controls, Incubating control fibroblasts from Days 1 to 3 with phosphatidylcholine-specific phospholipase C increased diacylglycerol, phosphatidate and ceramide concentrations, and decreased Mg2+-independent-phosphatidate phosphohydrolase activity, 8-(4-chlorophenylthio)-cAMP had a cytostatic effect in Pas-transformed cells, it decreased the concentrations of phosphatidate and diacylglycerol, but increased that of ceramide, The consequences of increased ceramide and phosphatidate concentrations in Pas-transformed cells are discussed in relation to signal transduction, cell division and the transformed phenotype.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, SIGNAL TRANSDUCT LABS, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				ALAM MS, 1995, BIOCHEM BIOPH RES CO, V207, P460, DOI 10.1006/bbrc.1995.1210; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOS JL, 1989, CANCER RES, V49, P4682; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DAVIES SA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P173, DOI 10.1016/0167-4889(89)90046-3; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELDAR H, 1993, J BIOL CHEM, V268, P12560; Fiske CH, 1925, J BIOL CHEM, V66, P375; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUANG C, 1992, BIOCHIM BIOPHYS ACTA, V1127, P242, DOI 10.1016/0005-2760(92)90227-M; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTIN A, 1986, BIOCHIM BIOPHYS ACTA, V876, P581, DOI 10.1016/0005-2760(86)90047-0; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORGAN AR, 1974, BIOCH BIOPHYS RES CO, V61; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; MURPHY SK, 1994, BIOCHEM BIOPH RES CO, V205, P1121, DOI 10.1006/bbrc.1994.2782; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Nakamura Y, 1996, J IMMUNOL, V156, P256; PATERSON A, 1991, BIOCHEM J, V280, P829, DOI 10.1042/bj2800829; PREISS J, 1986, J BIOL CHEM, V261, P8597; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAKELAM MJO, 1991, BIOCH SOC S, V56, P103; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	74	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1571	1580		10.1038/sj.onc.1200987	http://dx.doi.org/10.1038/sj.onc.1200987			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129148				2022-12-28	WOS:A1997WQ54800008
J	Canelles, M; Delgado, MD; Hyland, KM; Lerga, A; Richard, C; Dang, CV; Leon, J				Canelles, M; Delgado, MD; Hyland, KM; Lerga, A; Richard, C; Dang, CV; Leon, J			Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells	ONCOGENE			English	Article						max; c-Myc mutants; K562; erythroid differentiation; apoptosis; okadaic acid	MURINE ERYTHROLEUKEMIA-CELLS; HL-60 PROMYELOCYTIC CELLS; OKADAIC ACID; GENE-EXPRESSION; ACTIVATES TRANSCRIPTION; RAS COTRANSFORMATION; FUNCTIONAL DOMAINS; CYCLE PROGRESSION; DOWN-REGULATION; DNA-BINDING	We have used the human leukemia cell line K562 as a model to study the role of c-myc in differentiation and apoptosis, We have generated stable transfectants of K562 constitutively expressing two c-Myc inhibitory mutants: D106-143, that carries a deletion in the transactivation domain of the protein, and In373, that carries an insertion in the DNA-interacting region, We show here that In373 is able to compete with c-Myc for Max binding and to inhibit the transformation activity of c-Myc, K562 cells can differentiate towards erythroid or myelomonocytic lineages, K562 transfected with c-myc mutants showed a higher expression of erythroid differentiation markers, without any detectable effects in the myelomonocytic differentiation, We also transfected K562 cells with a zinc-inducible max gene, Ectopic Max overexpression resulted in an increased erythroid differentiation, thus reproducing the effects of c-myc inhibitory mutants, We also studied the role of c-myc mutants and max in apoptosis of K562 induced by okadaic acid, a protein phosphatases inhibitor, The expression of D106-143 and In373 c-myc mutants and the overexpression of max reduced the apoptosis mediated by okadaic acid, The common biochemical activity of D106-143 and In373 is to bind Max and hence to titrate out c-Myc to form pen-functional Myc/Max Max diners, Similarly, Max overexpression would decrease the relative levels of c-Myc/Max with respect to Max/Max, The results support a model where a threshold of functional c-Myc/Max is required to maintain K562 cells in an undifferentiated state and to undergo drug-mediated apoptosis.	FAC MED,DEPT BIOL MOL,E-39011 SANTANDER,SPAIN; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205; HOSP UNIV MARQUES DE VALDECILLA,SERV HEMATOL,SANTANDER 39011,SPAIN	Johns Hopkins University; Hospital Universitario Marques de Valdecilla (HUMV)			Dang, Chi/Y-3375-2019; Canelles, Matilde/AAB-1011-2019; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Dang, Chi/0000-0002-4031-2522; Delgado, M. Dolores/0000-0003-4682-4040; Canelles, Matilde/0000-0003-2973-609X; Leon, Javier/0000-0001-5803-0112	NCI NIH HHS [CA51497] Funding Source: Medline; NIGMS NIH HHS [T32GM07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051497, R01CA051497, R37CA051497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER SJ, 1994, LEUKEMIA, V8, P1309; BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BENITO A, 1995, AM J PATHOL, V146, P481; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DELGADO MD, 1995, ONCOGENE, V10, P1659; DELGADO MD, 1992, CANCER RES, V52, P5948; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; GORUPPI S, 1994, ONCOGENE, V9, P1537; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZAV S, 1995, ONCOGENE, V11, P1079; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LERGA A, 1995, BIOCHEM BIOPH RES CO, V215, P889, DOI 10.1006/bbrc.1995.2547; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nguyen HQ, 1995, ONCOGENE, V11, P2439; OHMORI Y, 1993, ONCOGENE, V8, P379; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHENG B, 1994, J BIOL CHEM, V269, P12332	75	50	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1315	1327		10.1038/sj.onc.1200948	http://dx.doi.org/10.1038/sj.onc.1200948			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178892				2022-12-28	WOS:A1997WP10900007
J	Hobeika, AC; Subramaniam, PS; Johnson, HM				Hobeika, AC; Subramaniam, PS; Johnson, HM			IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells	ONCOGENE			English	Article						interferon alpha; prostate cancer; cyclin dependent; kinase 2; cyclin E; p21	RETINOBLASTOMA PROTEIN; INTERFERON-ALPHA; GROWTH; PHOSPHORYLATION; CARCINOMA; GENE; G1; TRANSITION; LINES	Prostate cancer, like other types of cancer, is associated with the loss of cell cycle control, resulting in unregulated growth of cells. We report here on the inhibitory effects of interferon alpha (IFN alpha) on the cell cycle of prostate cancer cells, using the human prostate carcinoma cell line DU145 that has mutations in the tumor suppressor genes pRB, p53 and KAI1. IFN alpha inhibited growth and colony formation of DU145 cells and analysis by flow cytometry suggests that IFN alpha inhibited the progression of these cancer cells from the G(1) through S phase of the cell cycle. IFN alpha treatment of DU145 cells reduced cyclin dependent kinase 2 (cdk2) activity, In particular, cyclin E dependent cdk2 activity was inhibited by IFN alpha treatment. IFN alpha treatment, however, did not affect the amount of cdk2 bound to cyclin E. Consistent with this data, IFN alpha was able to induce expression of the kinase inhibitor p21 in DU145 cells, Furthermore, IFN treatment increased the amounts of p21 complexed with cdk2 in these cells. These data support a role for p21 in mediating the antiproliferative action of IFN alpha. The induction of p21 and its growth inhibitory effects in DU145 cells appears independent of p53, pRB and KAI1 status.			Hobeika, AC (corresponding author), UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611, USA.				NATIONAL CANCER INSTITUTE [R01CA069959] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLALOCK JE, 1980, CELL IMMUNOL, V49, P390, DOI 10.1016/0008-8749(80)90041-6; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; CAVENEE WK, 1995, SCI AM           MAR, P72; CREASEY AA, 1980, P NATL ACAD SCI-BIOL, V77, P1471, DOI 10.1073/pnas.77.3.1471; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Familletti P C, 1981, Methods Enzymol, V78, P387; GARNICK MB, 1994, SCI AM           APR, P72; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; ISAACS WB, 1991, CANCER RES, V51, P4716; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; NAKAJIMA Y, 1994, BIOCHEM BIOPH RES CO, V200, P467, DOI 10.1006/bbrc.1994.1472; NETTO GJ, 1994, AM J CLIN PATHOL, V102, pS57; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PINES J, 1995, CELL CYCLE CONTROL, P144; PONTZER CH, 1991, CANCER RES, V51, P5304; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; ROOS G, 1984, CANCER RES, V44, P2358; SICA G, 1989, UROL RES, V17, P111; SUBRMANIAM PS, IN PRESS J INTERFERO; TAMM I, 1987, MECHANISMS INTERFERO, V2, P25; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSAI LH, 1993, ONCOGENE, V8, P1593	26	89	89	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1165	1170		10.1038/sj.onc.1200939	http://dx.doi.org/10.1038/sj.onc.1200939			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121765				2022-12-28	WOS:A1997WM78200005
J	Jung, YK; Yuan, JY				Jung, YK; Yuan, JY			Suppression of Interleukin-1 beta converting enzyme (ICE)-induced apoptosis by SV40 large T antigen	ONCOGENE			English	Article						ICE; ICH-1; SV40 large T antigen; p53	PROGRAMMED CELL-DEATH; TEMPERATURE-SENSITIVE MUTANT; IN-VIVO; GENE CED-3; C-ELEGANS; IL-1-BETA-CONVERTING ENZYME; TRANSGENIC MICE; CRMA GENE; BAX GENE; P53	The Interleukin-1 beta converting enzyme (ICE) family of proteins, homologs of the C elegans cell death gene product CED-3, play important roles in controlling vertebrate programmed cell death. Because inhibition of apoptosis may be an essential step in tumorigenesis, we investigated the interaction of the simian virus 40 large T antigen (T ag) with the ICE family, COS-1 cells which were transformed by the simian virus 40 do not die when transfected,vith expression constructs of Ice or Ich-1(L). We found that expression of T ag alone significantly prevents the ICE-induced apoptosis. p53, but not pRb or p107, antagonizes the effect of T ag on the suppression of ICE-induced cell death, but not on ICH-1(L)-mediated cell death. Thus, wild type p53 may potentiate ICE-induced apoptosis. Expression of a temperature sensitive mutant p53Val(135) sensitizes COS-1 cells to apoptosis induced by ICE at permissive but not at non-permissive temperature. While induction of bax, p21(WAF1/CIP), Or cyclin DI gene expression is observed in the COS-1 p53Val(135) cells at the permissive temperature, overexpression of bax, but not p2l(WAF1/CIP) Or cyclin D1, potentiates ICE-induced COS-1 cell death. Taken together, these results suggest that Tag may modulate the cells' susceptibility to death by suppressing activity of the ICE family through inhibiting p53.	MASSACHUSETTS GEN HOSP EAST, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jung, Yong-Keun/0000-0002-9686-3120	NIA NIH HHS [AG12859-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012859, R37AG012859] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P39761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU J, 1991, J VIOL, V65, P6972	40	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1207	1214		10.1038/sj.onc.1200943	http://dx.doi.org/10.1038/sj.onc.1200943			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121770				2022-12-28	WOS:A1997WM78200010
J	CassarMalek, I; Marchal, S; Rochard, P; Wrutniak, C; Samarut, J; Cabello, G				CassarMalek, I; Marchal, S; Rochard, P; Wrutniak, C; Samarut, J; Cabello, G			Molecular basis of the cell-specific activity of v-erb A in quail myoblasts	ONCOGENE			English	Article						v-erb A; myoblast; RAR; RXR; T3R; AP1 activity	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; C-ERBA; DNA-BINDING; RESPONSE ELEMENT; DOMAIN; GENE; DIFFERENTIATION; REPRESSION; PROTEINS	We have previously shown that v-erb A expression strongly stimulates quail myoblast proliferation and differentiation without alteration of the triiodothyronine (T3) influence in this cell type, In order to understand the molecular basis of v-erb A action in myoblasts, we have studied the influence of this oncoprotein on c-erb A alpha 1 encoded T3 nuclear receptor (TRu) activity, In transfection experiments, v-erb A did not inhibit the T3-dependent c-erb A alpha 1 transcriptional activity in QM7 myoblasts in contrast to its action in HeLa cells. However, it repressed the retinoic acid receptor RAR alpha activity in both cell-types, indicating that v-erb A interactions with T3 or RA mediated transcription significantly differs, In EMSA experiments using a TRE(pal) probe. T3R alpha binds as three complexes in HeLa cells, We have previously identified the slow migrating complex, undetectable in QM7 myoblasts, as a T3R/RXR heterodimer. Interestingly, v-erb A inhibited binding of this complex in HeLa cells, but did not affect binding of the two other complexes in QM7 myoblasts. Expression of RXR (gamma isoform), the TR alpha dimerization partner absent in proliferating QM7 cells, restored inhibition of c-erb A alpha 1 transcriptional activity in these cells and abrogated the v-erb A myogenic influence, Lastly, v-erb A induced a T3-independent c-erb A alpha 1 activity in QM7 cells when cotransfected in equimolar ratio with the receptor, by inhibiting AP-1 activity and stimulating transcription of a reporter gene driven by a TRE sequence.	INRA,UNITE ENDOCRINOL CELLULAIRE,LAB DIFFERENCIAT CELLULAIRE & CROISSANCE,F-34060 MONTPELLIER 01,FRANCE; ECOLE NORMALE SUPER LYON,INRA,CNRS UMR 40,LAB BIOL MOL & CELLULAIRE,F-69364 LYON 07,FRANCE	INRAE; INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; CASSARMALEK I, 1994, THESIS U MONTPELLIER; CHEN DJ, 1995, NATURE, V377, P454; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FORCE WR, 1994, J BIOL CHEM, V269, P8863; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERMANN T, 1993, ONCOGENE, V8, P55; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; RASCLE A, 1994, ONCOGENE, V9, P2853; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; Snedecor G.W., 1961, STAT METHODS; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YN PM, 1994, J BIOL CHEM, V269, P903; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	46	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1099	1108		10.1038/sj.onc.1200928	http://dx.doi.org/10.1038/sj.onc.1200928			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070659				2022-12-28	WOS:A1997WM07000012
J	Liao, XB; Du, YB; Morse, HC; Jenkins, NA; Copeland, NG				Liao, XB; Du, YB; Morse, HC; Jenkins, NA; Copeland, NG			Proviral integrations at the Evi5 locus disrupt a novel 90 kDa protein with homology to the Tre2 oncogene and cell-cycle regulatory proteins	ONCOGENE			English	Article						Evi5; Gfi1; leukemia; oncogene; Tre2	GENETIC-LINKAGE MAP; ZINC-FINGER PROTEIN; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; MOUSE CHROMOSOME-5; MOLECULAR-CLONING; MESSENGER-RNA; LYMPHOMAS; SEQUENCE; FAMILY	Evi5 is a common site of retroviral integration in T-cell lymphomas of AKXD mice. Mapping studies have localized Evi5 to a region approximately 18 kb upstream of another common viral integration site, Gfi1, on mouse chromosome 5 (Liao X, Jenkins NA and Copeland NG, (1995a). J. Virol., 69, 7132-7137). Gfi1 encodes a zinc finger transcription factor involved in interleukin-2 signaling. To determine if Evi5 encodes a gene separate from Gfi1 that might also be involved in T-cell disease, we have searched within the Evi5 locus for novel transcripts. A 6.0 kb transcript was identified in these studies that spans the Evi5 locus and is disrupted by viral integration at Evi5. This transcript is expressed in all embryonic and adult mouse tissues examined. While blast searches indicated that Evi5 is a novel gene, homologies were detected between Evi5 and a known oncogene, Tre2, as well as mammalian and yeast cell cycle regulatory proteins. Evi5 thus encodes a gene separate from Gfi1 that may also be involved in T-cell disease.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Morse, Herbert/0000-0002-9331-3705				BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; CHANG F, 1993, TRENDS GENET, V9, P333, DOI 10.1016/0168-9525(93)90022-A; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRANKHAUSER C, 1994, EMBO J, V13, P3011; FRANKHAUSER C, 1993, EMBO J, V12, P2697; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HULSEBOS TJM, 1995, GENOMICS, V29, P712, DOI 10.1006/geno.1995.9947; IHLE JN, 1990, PROG CLIN BIOL RES, V352, P329; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; JUSTICE MJ, 1990, GENETICS, V125, P855; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Maniatis T., 1982, MOL CLONING; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MIYATANI S, 1992, P NATL ACAD SCI USA, V89, P8443, DOI 10.1073/pnas.89.18.8443; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WANG YC, 1995, MOL CELL BIOL, V15, P6838; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zornig M, 1996, ONCOGENE, V12, P1789	49	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1023	1029		10.1038/sj.onc.1200929	http://dx.doi.org/10.1038/sj.onc.1200929			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070650				2022-12-28	WOS:A1997WM07000003
J	Dear, TN; Hainzl, T; Follo, M; Nehls, M; Wilmore, H; Matena, K; Boehm, T				Dear, TN; Hainzl, T; Follo, M; Nehls, M; Wilmore, H; Matena, K; Boehm, T			Identification of interaction partners for the basic-helix-loop-helix protein E47	ONCOGENE			English	Article						E47; helix-loop-helix; eip1	REPLICATION FACTOR-C; DNA-BINDING; DROSOPHILA-MELANOGASTER; IMMUNOGLOBULIN ENHANCER; DEVELOPING SOMITES; EXPRESSION VECTOR; HLH PROTEINS; GENE; E2A; CLONING	Helix-loop-helix proteins constitute a family of transcription factors with the potential to form homo- and hetero-dimers mediated by the helix-loop-helix domain, Oncogenic mutations in such genes can disrupt the equilibrium of protein-protein interactions in the affected cell, In order to assess the biological consequences of such mutations, the full complement of interacting proteins must be known, To identify proteins interacting with the basic-helix-loop-helix domain of the ubiquitously expressed E47 protein, a 'sandwich'-screening procedure was developed which distinguishes between homo- and hetero-oligomers, and specifically excludes the detection of complexes which cannot bind DNA, Nine distinct cDNAs were identified which encode proteins with apparent basic-helix-loop-helix domains, including a novel clone termed eip1 which is distantly related in the basic-helix-loop-helix domain to the Drosophila enhancer-of-split m7 protein, Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells, Interaction was also observed in the yeast two-hybrid system, Three cDNAs encoding proteins without basic-helix-loop-helix domains were also found to interact in the sandwich-expression screen, Interactions with human PARP and mouse replication factor la were confirmed using glutathione transferase-tagged cDNAs, A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.	DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; INNERE MED ABT 1,D-79106 FREIBURG,GERMANY; UNIV FRANKFURT,MED KLIN 4,ZENTRUM INNERE MED,D-60590 FRANKFURT,GERMANY; UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); MRC Laboratory Molecular Biology; Goethe University Frankfurt; University of Bath				Follo, Marie/0000-0002-3090-7442				APERLO C, 1996, IN PRESS GENOMICS; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLINE TW, 1976, GENETICS, V84, P723; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HAINZL T, 1994, ONCOGENE, V9, P885; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU JS, 1992, MOL CELL BIOL, V12, P1031; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VASTRIK I, 1993, ONCOGENE, V8, P503; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	39	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					891	898		10.1038/sj.onc.1200912	http://dx.doi.org/10.1038/sj.onc.1200912			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050988				2022-12-28	WOS:A1997WK34400002
J	Zhang, WL; Lu, Q; Xie, ZJ; Mellgren, RL				Zhang, WL; Lu, Q; Xie, ZJ; Mellgren, RL			Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G(1) to S-phase transition	ONCOGENE			English	Article						calpain; p53; cell proliferation; p21Waf1; peptide diazomethyl ketones	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; UBIQUITIN PATHWAY; MU-CALPAIN; C-JUN; PROGRESSION; DEGRADATION; CALPASTATIN; CIP1; G1	The effect of a calpain-selective cell permeant inhibitor, benzyloxycarbonyl Leu-Leu-Tyr diazomethylketone (ZLLY-CHN2), on the serum-stimulated growth of WI-38 human fibroblasts has been investigated, Only cell permeant protease inhibitors with activity against calpains prevented progression into S-phase, Protein blotting experiments indicated that p53 immunoreactivity increased in late G(1) cells treated with ZLLY-CHN2. The content of p21(Waf1/Cip1) CDK inhibitor also increased, providing a mechanism for the observed failure to enter S-phase, Further studies indicated that p53 could be degraded by a ZLLY-CHN2-sensitive protease immediately prior to S-phase, but that proteolysis did not occur after this critical time point, Chelation of extracellular Ca2+ by addition of EGTA inhibited the p53 degradation, Consistent with proteolysis of p53 in late G(1) phase, mu-calpain immunoreactivity transiently accumulated in ceh nuclei at this time, ZLLY-CHN, did not appear to increase p53 mRNA in WI-38 cells, Purified mu-calpain required only 1 to 3 mu M Ca2+ to proteolyze p53 in WI-38 cell lysates. These results indicate that ZLLY-CHN, inhibits progression of WI-38 cells into S-phase by inactivating a calpain-like protease that is responsible for proteolysis of constitutively expressed p53 in late G(1).	MED COLL OHIO,DEPT THERAPEUT & PHARMACOL,TOLEDO,OH 43699						NHLBI NIH HHS [HL36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARTER R, 1991, ONCOGENE, V6, P229; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P236; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANA X, 1995, ONCOGENE, V11, P211; HARPER JW, 1993, CELL, V75, P805; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hsu HL, 1996, J CELL SCI, V109, P277; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LU Q, 1996, IN PRESS ARCH BIOCH; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MINSHULL J, 1989, J CELL SCI S, V12, P77; MURACHI T, 1981, BIOCHEM INT, V2, P651; MURRAY AW, 1989, J CELL SCI S, V12, P65; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; WAHL M, 1993, MOL BIOL CELL, V4, P293, DOI 10.1091/mbc.4.3.293; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825	34	64	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					255	263		10.1038/sj.onc.1200841	http://dx.doi.org/10.1038/sj.onc.1200841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018111				2022-12-28	WOS:A1997WD51600001
J	Rao, G; Rekhtman, N; Cheng, GH; Krasikov, T; Skoultchi, AI				Rao, G; Rekhtman, N; Cheng, GH; Krasikov, T; Skoultchi, AI			Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation	ONCOGENE			English	Article						PU1; Spi-1; MEL cells; c-myc; c-myb; differentiation	C-MYC ONCOGENE; VIRUS-INDUCED ERYTHROLEUKEMIA; MOUSE ERYTHROLEUKEMIA; FRIEND-ERYTHROLEUKEMIA; ERYTHROID-DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; PUTATIVE ONCOGENE; GENE-EXPRESSION; MESSENGER-RNA; P53 GENE	Murine erythroleukemia (MEL) cells are transformed erythroid precursors that are blocked from completing the late stages of erythroid differentiation. A frequent event in the generation of these malignant cells is deregulation of the hematopoietic-specific transcription factor PU.1 (Spi-1) by retroviral insertion of the spleen-focus-forming virus component of Friend virus. During chemically induced reinitiation of MEL cell terminal differentiation, expression of PU.1 is rapidly downregulated, suggesting that PU.1 might interfere with processes required for terminal differentiation of erythroid precursors. To investigate the role of PU.1 in erythroid differentiation we transfected MEL cells with a PU.1 cDNA controlled by the eucaryotic translation elongation factor EF1 alpha promoter. Deregulated expression of PU.1 blocked chemically induced differentiation and terminal cell division. Deregulated expression of two other protooncogenes, c-myc and c-myb, also has been shown to block MEL differentiation, We present evidence that PU.1 inhibits terminal differentiation at an earlier step than c-Myc and c-Myb. Thus reinitiation of MEL cell terminal differentiation appears to be controlled by an ordered program of turning off several protooncogenes. Down-regulation of PU.1 may be a very early step in this program.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330, R37CA016368] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA13330, 5R37CA16368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONG YH, 1995, MOL CELL BIOL, V15, P1889; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRIEDMAN EA, 1978, P NATL ACAD SCI USA, V75, P3813, DOI 10.1073/pnas.75.8.3813; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAMBARI R, 1978, P NATL ACAD SCI USA, V75, P3801, DOI 10.1073/pnas.75.8.3801; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Harlow E., 1988, ANTIBODIES LAB MANUA; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SOEIRO R, 1969, J MOL BIOL, V44, P551, DOI 10.1016/0022-2836(69)90379-9; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	54	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					123	131		10.1038/sj.onc.1200807	http://dx.doi.org/10.1038/sj.onc.1200807			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010239				2022-12-28	WOS:A1997WB76000012
J	Gangopadhyay, SB; Peacock, JW; Benchimol, S				Gangopadhyay, SB; Peacock, JW; Benchimol, S			A transcript exhibiting homology to endogenous rat retroviral-like elements is regulated by p53	ONCOGENE			English	Article						p53; differential display; RAL retroviral-like elements	WILD-TYPE P53; PROTEIN; GENE; EXPRESSION; GROWTH; CELLS; CHECKPOINT; SEQUENCES; APOPTOSIS; BINDING	Rat embryo fibroblasts transformed with HPV-16 E7 and the Ha-ras oncogene (ER clones) fall into two distinct groups based on their endogenous p53 status, wild-type or mutant, We have taken advantage of such clones in order to study the p53 target genes by the differential display method of RNA fingerprinting, We have identified a cDNA clone, clone 16, that recognises a large transcript on Northern blots. The clone 16 transcript is overexpressed in ER cell lines that express wild-type p53 compared with ER cell lines that express mutant p53. Similar to the waf1/p21 gene, which is transcriptionally activated in cells treated with ionizing radiation in a p53-dependent manner, the clone transcript was also induced in response to irradiation, The sequence of clone 16 exhibits a high homology to two members of RAL retroviral-like elements.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				BRISTOW RG, 1994, ONCOGENE, V9, P1527; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P318, DOI 10.1016/S0006-291X(05)80147-0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; HARPER JW, 1993, CELL, V75, P805; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamuta M, 1989, Virus Genes, V3, P69, DOI 10.1007/BF00301988; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUZUKI N, 1986, NUCLEIC ACIDS RES, V14, P9271, DOI 10.1093/nar/14.23.9271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	28	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2731	2735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000148				2022-12-28	WOS:A1996VZ65400024
J	Chung, SW; Chen, H; Wong, PMC				Chung, SW; Chen, H; Wong, PMC			Activation of quiescent ABL-transduced hemopoietic stem cells	ONCOGENE			English	Article						ABL; hematopoietic stem cells	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PRIMITIVE HEMATOPOIETIC PROGENITORS; CHRONIC MYELOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; BCR-ABL; ABELSON VIRUS; V-ABL; PHILADELPHIA-CHROMOSOME; AUTOCRINE MECHANISM	Chronic myelogenous leukemia (CML) is a hemopoietic stem cell disorder in which an activated ABL oncogene is expressed and has been shown to play an important role in disease pathogenesis. A mouse model has been established in which hemopoietic stem cells (HSCs) transduced with a retrovirus vector carrying an activated ABL oncogene can be analysed. Using this model, we now report that abl-transduced HSCs can be quiescent without causing a disease for an extended period of time. Recipient mice were able to survive more than one treatment of 5-fluorouracil (5-FU) at a dose that normally eliminates cycling hemopoietic progenitor cells; subsequently, transduced HSCs could become activated and undergo clonal expansion, resulting in abl-induced leukemic development. The disease developed in these mice was transplantable. Upon engraftment into secondary mice, previously unidentified abl-transduced HSC clones appeared. These data suggest the presence of an abl-suppressive mechanism in HSCs and have important implications to the pathogenesis of stem cell diseases and leukemic clonal evolution.	TEMPLE UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Chung, SW (corresponding author), TEMPLE UNIV,SCH MED,DEPT BIOCHEM,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDI A, 1993, BLOOD, V81, P2898; BRECHER G, 1993, P NATL ACAD SCI USA, V90, P6028, DOI 10.1073/pnas.90.13.6028; BRETCHER G, 1988, EXP HEMATOL, V16, P627; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1995, ONCOGENE, V10, P1261; CHUNG SW, 1994, ONCOGENE, V9, P3527; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; CRONKITE EP, 1987, EXP HEMATOL, V16, P627; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DUBE ID, 1984, BLOOD, V63, P1172; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FIORETOS T, 1994, BLOOD, V83, P3441; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; HADGSON GS, 1979, NATURE, V281, P381; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; KEATING A, 1994, BLOOD, V83, P1744, DOI 10.1182/blood.V83.7.1744.bloodjournal8371744; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEBIEN TW, 1979, NEW ENGL J MED, V301, P144, DOI 10.1056/NEJM197907193010307; LERNER C, 1990, EXP HEMATOL, V18, P114; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; NOWELL PC, 1960, SCIENCE, V132, P1497; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; POIRIER Y, 1989, J VIROL, V63, P2088, DOI 10.1128/JVI.63.5.2088-2098.1989; ROVERA G, 1987, ONCOGENE, V1, P29; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SCOTT M, 1991, P NATL ACAD SCI USA, V88, P6505; SIRARD C, 1994, BLOOD, V83, P1575; SOKAL JE, 1980, BLOOD, V56, P1072; SPOONCER E, 1994, LEUKEMIA, V8, P620; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; VERFAILLIE CM, 1992, BLOOD, V79, P1003; VOGT M, 1987, ONCOGENE RES, V2, P49; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P851	53	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2397	2405						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957081				2022-12-28	WOS:A1996VX10800012
J	Adachi, Y; Matsubara, S; Pedraza, C; Ozawa, M; Tsutsui, J; Takamatsu, H; Noguchi, H; Akiyama, T; Muramatsu, T				Adachi, Y; Matsubara, S; Pedraza, C; Ozawa, M; Tsutsui, J; Takamatsu, H; Noguchi, H; Akiyama, T; Muramatsu, T			Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)	ONCOGENE			English	Article						Wilms' tumor; WT1; midkine	ACID-RESPONSIVE GENE; GROWTH-DIFFERENTIATION FACTOR; EMBRYONAL CARCINOMA-CELLS; ZINC FINGER PROTEIN; FACTOR-II GENE; FACTOR-A-CHAIN; MOUSE EMBRYOGENESIS; KIDNEY DEVELOPMENT; CHLORAMPHENICOL ACETYLTRANSFERASE; TERATOCARCINOMA SYSTEM	Midkine (MK) is a heparin-binding growth factor which is strongly expressed during the midgestation period of mouse embryogenesis. Wilms' tumor is an embryonal kidney malignancy in infants, and WT1 has been identified as its tumor suppressor gene. The high expression level of MK in all Wilms' tumor specimens so far examined and the presence of two WT1 elements (5-GCGGGGGCG-3') in the human MK promoter region led us to examine the possible role of the WT1 gene product in the regulation of MK gene expression. A gel shift assay verified the complex formation between the WT1 gene product and WT1 consensus sequence of MK gene. DNase1 footprint analysis also demonstrated that the downstream WT1 element was protected from DNase1 cleavage by the addition of the WT1 protein. The human MK promoter fused with the chloramphenicol acetyltransferase gene (phMK2.3kCAT) was cotransfected with an effector plasmid containing the WT1 gene into several cell lines. Transient transfection assays showed suppression of the MK promoter by WT1 co-transfection in recipient cells; deletion of the WT1 binding site abolished the suppression. The evidence reported in this study indicates that MK gene is a newly identified WT1 target gene.	KAGOSHIMA UNIV,FAC MED,DEPT PEDIAT SURG,KAGOSHIMA 890,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT BIOCHEM,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Kagoshima University; Osaka University; Nagoya University	Adachi, Y (corresponding author), KAGOSHIMA UNIV,FAC MED,DEPT BIOCHEM,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BRENNER B, 1992, ONCOGENE, V7, P1431; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRAIZER GE, 1987, J CELL PHYSIOL, V133, P169, DOI 10.1002/jcp.1041330122; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; GANSLER T, 1989, AM J PATHOL, V135, P961; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P227; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HARBOMEL P, 1984, CELL, V39, P653; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEISENRING WM, 1994, CANCER RES, V54, P4680; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUBARA S, 1994, J BIOCHEM-TOKYO, V115, P1088, DOI 10.1093/oxfordjournals.jbchem.a124462; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEDRAZA C, 1995, J BIOCHEM-TOKYO, V117, P845; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RYAN G, 1995, DEVELOPMENT, V121, P867; SAWAI S, 1991, NEW BIOL, V3, P861; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1993, CANCER RES, V53, P1281; UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999	53	53	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2197	2203						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950987				2022-12-28	WOS:A1996VV14500017
J	Molinari, M; Okorokov, AL; Milner, J				Molinari, M; Okorokov, AL; Milner, J			Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding	ONCOGENE			English	Article						p53; damaged DNA; DNA binding proteolysis	WILD-TYPE P53; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; SINGLE STRANDS; GROWTH ARREST; NUCLEIC-ACIDS; CELL-CYCLE; CONFORMATION	The p53 protein binds sites of primary DNA damage via its C-terminus. This interaction in some way activates sequence-specific binding (via the central core domain) and transactivation of p53 target genes. We now show that interaction with non-specific DNA, but not specific DNA targets, induces selective proteolysis of p53 to give a 40 kDa fragment, comprising the core plus C-terminus, and a 35 KDa conformationally intact core domain. Proteolytic cleavage was limited and yielded roughly equivalent proportions of full length p53 and the 40 kDa and 35 kDa fragments. Significantly, both 40 kDa and 35 kDa products were activated for sequence-specific DNA binding. Similar p53-related products were induced by exposure of cells to DNA damage. We propose that some functions of p53 can be activated by proteolytic processing and that this may be important in the cellular response to DNA damage.	UNIV YORK,DEPT BIOL,YCRC P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK				Okorokov, Andrei/0000-0003-2477-3254				BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRAIN R, 1994, ONCOGENE, V9, P1775; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FAN SJ, 1995, CANCER RES, V55, P1649; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HESKETH R, 1995, ONCOGENE FACTS BOOK; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUANG L, 1996, IN PRESS P NATL ACAD, V96; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KURIYAN J, 1995, STRUCTURE, V3, P135, DOI 10.1016/S0969-2126(01)00143-5; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MOLINARI M, 1995, ONCOGENE, V10, P1849; MUMMENBRAUER T, 1996, IN PRESS CELL; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAILLARD S, 1993, PROTEINS, V15, P330, DOI 10.1002/prot.340150310; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	54	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2077	2086						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950974				2022-12-28	WOS:A1996VV14500004
J	Zariwala, M; Xiong, Y				Zariwala, M; Xiong, Y			Lack of mutation in the cyclin-dependent kinase inhibitor, p19(INK4d), in tumor-derived cell lines and primary tumors	ONCOGENE			English	Article						p15(INK4b); p16(INK4a); p18(INK4c); p19(INK4d); CDK inhibitors	SUPPRESSOR GENE; MOLECULAR ANALYSIS; HUMAN MALIGNANCIES; FAMILIAL MELANOMA; P15(INK4B) GENE; CDK6 INHIBITOR; P27(KIP1) GENE; HUMAN CANCERS; P18 GENES; EXPRESSION	Inhibitors of cyclin-dependent kinases provide a major mechanism of negative regulation on cell cycle progression, Defects in the function of the CDK inhibitors may lead to uncontrolled cell proliferation and potentially facilitate tumorigenesis. The p16(INK4) family of CDK inhibitors specifically prevent the phosphorylation of the retinoblastoma susceptibility gene product, pRb, by inhibiting the kinase activity of CDK4 and CDK6, thereby keeping pRb in its active form as a growth suppressor, The loss of p16(INK4) inhibitory activity would, therefore, have the same consequence as the loss of pRb growth suppressing activity, The p16(INK4) family currently includes four members, p15(INK4b), p16INK(4a)) p18INK(4c) and p19(INK4d). Two members, p15(INK4b) and p16(INK4a) have been found to be deleted and mutated in a variety of human tumor-derived cell lines and primary tumors, In the present study we have examined the genomic status of the newly isolated p19(INK4d) gene in 75 tumor-derived cell lines; 13 immortalized, transformed or normal cell lines; 19 ovarian tumors and 18 acute myelogenous leukemias, No deletions or point mutations were observed in the p19(INK4d) gene, A genetic polymorphism at codon 30 (CGC-->CGG) in exon 1 of the p19(INK4d) gene was observed in 10% of the samples under investigation, In the same set of samples, p16(INK4a) was found to be homozygously deleted in 32% of the tumor derived cell lines, These results together with our previous data that showed a 22% deletion frequency in p(15INK4b) and rare alterations in the p18(INK4c) gene, indicating that the p16(INK4a) and p15(INK4b), but not the p18(INK4c) and p19(INK4d) genes, are frequently mutated in human tumors, Hence, members of the p16(INK4) CDK inhibitor family, while evolutionary related and biochemically indistinguishable, carry out distinct biological functions.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 65572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1995, CANCER RES, V55, P1431; BULLRICH F, 1995, CANCER RES, V55, P1199; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAO X, 1995, ONCOGENE, V11, P1395; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HE J, 1994, CANCER RES, V54, P5804; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HURET JL, 1993, LEUKEMIA, V7, P152; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIECHLESCHWARZ M, 1994, GYNECOL ONCOL, V55, P198, DOI 10.1006/gyno.1994.1277; KODORU PRK, 1995, BLOOD, V86, P2900; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, CANCER RES, V54, P6078; LOIS AF, 1995, CANCER RES, V55, P4010; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Orlow I, 1996, CANCER RES, V56, P1219; OTSUKI T, 1995, CANCER RES, V55, P1436; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERRANO M, 1996, CELL, V85, P27; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1996, IN PRESS BIOCH BIOPH; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451; ZHANG SY, 1994, CANCER RES, V54, P5050	65	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2033	2038						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934552				2022-12-28	WOS:A1996VR79500025
J	Chin, PL; Momand, J; Pfeifer, GP				Chin, PL; Momand, J; Pfeifer, GP			In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation	ONCOGENE			English	Article						p53; p21; GADD45; MDM2; radiation	LIGATION-MEDIATED PCR; CYCLE CHECKPOINT PATHWAY; DNA-DAMAGING AGENTS; P53-INDEPENDENT PATHWAY; GROWTH ARREST; WAF1/CIP1 EXPRESSION; METHYLATION ANALYSIS; CHROMATIN STRUCTURE; HUMAN FIBROBLASTS; G(1) ARREST	The tumor suppressor protein p53 has a transcriptional activation activity thought to mediate its biologic function including G(1) arrest and perhaps apoptosis, To learn more about p53's transactivator function in vivo, we performed genomic footprinting experiments examining p53-DNA interactions in the regulatory regions of the p53-regulated genes p21, GADD45, and MDM2. Using ionizing radiation to induce DNA damage in human ML-1 myeloblastic leukemia cells, the promoter and intronic regions of these genes containing p53-consensus binding sites were examined for in vivo footprints, There was a uniform and sustained expression of p53 protein as well as a strong induction of p21, GADD45, and MDM2 mRNA following irradiation, At the two p53 consensus binding sites in the p21 promoter, reduced DNaseI cleavage was observed in irradiated cells beginning 1 to 2 h after irradiation, being most checkpoints, pronounced after 2 h and diminishing after 8 h. A partial interest. in vivo footprint was also observed in the third intron of the GADD45 gene beginning 2 h after irradiation, No in vivo footprints were seen at the two p53 binding sites in the MDM2 gene, Our study provides direct evidence that the DNA damage-induced activity of p53 is mediated by its consensus DNA binding sites in the p21 and GADD45 genes, We suggest that the transient nature and relative instability of p53-DNA interactions in vivo may make the p53 protein more accessible to a rapid turnover pathway which might be impaired under conditions when the protein is stably bound to DNA.	CITY HOPE NATL MED CTR, DEPT BIOL, DUARTE, CA 91010 USA; CITY HOPE NATL MED CTR, DEPT CELL & TUMOR BIOL, DUARTE, CA 91010 USA	City of Hope; City of Hope			Momand, Jamil/F-8154-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Bae I, 1996, CANCER RES, V56, P840; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU M, 1995, ONCOGENE, V10, P1955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maxam A M, 1980, Methods Enzymol, V65, P499; Mayo LD, 1996, ONCOGENE, V13, P2315; MICHIELI P, 1994, CANCER RES, V54, P3391; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1994, ONCOGENE, V9, P3321; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pfeifer G P, 1992, PCR Methods Appl, V2, P107; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pfeifer GP, 1996, MOL BIOTECHNOL, V5, P281, DOI 10.1007/BF02900367; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1994, CANCER RES, V54, P896; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TORMANEN VT, 1992, NUCLEIC ACIDS RES, V20, P5487, DOI 10.1093/nar/20.20.5487; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	67	68	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					87	99		10.1038/sj.onc.1201161	http://dx.doi.org/10.1038/sj.onc.1201161			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233781				2022-12-28	WOS:A1997XH58600010
J	Nakamura, T; WilliamsSimons, L; Westphal, H				Nakamura, T; WilliamsSimons, L; Westphal, H			A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis	ONCOGENE			English	Article						lens; transgenic; HPV18; p53	RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; CYCLE REGULATION; E6 PROTEIN; E7 GENES; MICE; P53	We have studied the concerted action of factors that influence the balance between cell proliferation and cell death in the developing lens of transgenic mice. We show that a human papillomavirus type 18 (HPV18) E6/E7 transgene that predominantly expresses the viral E7 gene product triggers apoptosis in a dose dependent manner, and causes retardation of lens growth or microphakia. E7 is known to inactivate pRB, the product of the retinoblastoma gene, and to enhance the action of p53. Our earlier work had demonstrated that over-expression of p53 itself can cause apoptosis of lens cells, and that a mutant p53 allele can interfere with this process. In the present study, we examined lenses that simultaneously express different constellations of the HPV18 E6/E7, wild-type and mutant human p53, and wild-type human PRE transgenes. We observed that lens cells expressing the HPV18 transgene are more sensitive to mild-type human p53 action than normal lens cells. As a result, there is severe microphakia in lenses that express both the HPV18 and the wild-type p53 transgenes. By contrast, apoptosis was reduced in lenses that coexpressed the HPV18 and either the PRE or the mutant p53 transgene. We conclude that levels of wild-type p53 are critical, and that any excess of p53 or suppression of PRE can cause cell death. Our results encourage attempts to counteract the deleterious action of human papillomaviruses in cervical cancer by a combination of measures that decrease cell proliferation and enhance apoptosis.			Nakamura, T (corresponding author), NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892, USA.							ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COMERFORD SA, 1995, ONCOGENE, V10, P587; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NAKAMURA T, 1989, New Biologist, V1, P193; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SASAGAWA T, 1992, CANCER RES, V52, P4420; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VILLA LL, 1991, VIROLOGY, V181, P374; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; Yatsudo M, 1988, VIROLOGY, V166, P594; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	57	10	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					2991	2998		10.1038/sj.onc.1201155	http://dx.doi.org/10.1038/sj.onc.1201155			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223662				2022-12-28	WOS:A1997XG10000001
J	Weissenberger, J; Steinbach, JP; Malin, G; Spada, S; Rulicke, T; Aguzzi, A				Weissenberger, J; Steinbach, JP; Malin, G; Spada, S; Rulicke, T; Aguzzi, A			Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice	ONCOGENE			English	Article						astrocytoma; transgenic mouse model; tumor angiogenesis; tumor progression	ENDOTHELIAL GROWTH-FACTOR; FIBRILLARY ACIDIC PROTEIN; ROUS-SARCOMA VIRUS; BRAIN-TUMORS; GENE-PRODUCT; IN-VIVO; C-SRC; NEURAL TRANSPLANTS; TRANSFORMING GENE; T-ANTIGEN	We have generated a transgenic mouse model for astrocytoma by expressing the v-src kinase under control of the glial fibrillary acidic protein (GFAP) gene regulatory elements in astrocytes, Abnormal astrogliosis was observed in all transgenic animals already at 2 weeks postnatally, frequently followed by the development of dysplastic changes, Later, small proliferative foci arose, and overt astrocytoma developed in the brain and spinal cord in 14.4% of mice after a follow up time of 65 weeks, While early lesions were histologically consistent with low-grade astrocytoma, at later stages most tumors were highly mitotic and frankly malignant, Vascular endothelial growth factor (VEGF) was expressed by tumor cells already at early stages, suggesting induction by v-src, and it was most pronounced in pseudopalisading cells surrounding necrotic areas, implying additional upregulation by hypoxia, In larger lesions, mitotic activity and expression of flk-1, the cognate receptor of VEGF were induced in endothelial cells, Therefore, end-stage tumors mimicked the morphological and molecular characteristics of human glioblastoma multiforme, Time course and stochastic nature of the process indicate that v-src did not suffice for malignant transformation, and that astrocytomas were the result of a multistep process necessitating co-operation of additional genetic events.	UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,CENT BIOL LAB,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital			Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1996, TRANSGENICS, V2, P29; BILZER T, 1989, NEUROTOXICOL TERATOL, V11, P551, DOI 10.1016/0892-0362(89)90036-6; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BURGER PC, 1988, CANCER RES, V48, P2871; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DANKS RA, 1995, CANCER RES, V55, P4302; EIBL RH, 1994, AM J PATHOL, V144, P556; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; HAGUENAU F, 1981, NEUROCHIRURGIE, V27, P251; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hogan B., 1994, MANIPULATING MOUSE E; HOLASH JA, 1993, P NATL ACAD SCI USA, V90, P11069, DOI 10.1073/pnas.90.23.11069; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JEN J, 1994, CANCER RES, V54, P6353; KAWAHARA E, 1988, AM J SURG PATHOL, V12, P115, DOI 10.1097/00000478-198802000-00004; KLEIHUES P, 1989, IARC SCI PUBL, P121; KLEIHUES P, HISTOLOGICAL TYPING; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARINO S, 1995, LAB INVEST, V73, P103; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MUCKE L, 1991, NEW BIOL, V3, P465; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; PLATE KH, 1993, CANCER RES, V53, P5822; SANDS WA, 1994, EUR J IMMUNOL, V24, P2345, DOI 10.1002/eji.1830241013; SARKAR S, 1991, J NEUROCHEM, V57, P675, DOI 10.1111/j.1471-4159.1991.tb03799.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; TAKENAKA N, 1985, BRAIN RES, V337, P201, DOI 10.1016/0006-8993(85)90055-1; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; VONDEIMLING A, 1994, CANCER RES, V54, P1397	50	124	128	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2005	2013		10.1038/sj.onc.1201168	http://dx.doi.org/10.1038/sj.onc.1201168			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160879				2022-12-28	WOS:A1997WW80900001
J	Chang, CH; Scott, GK; Kuo, WL; Xiong, XH; Suzdaltseva, Y; Park, JW; Sayre, P; Erny, K; Collins, C; Gray, JW; Benz, CC				Chang, CH; Scott, GK; Kuo, WL; Xiong, XH; Suzdaltseva, Y; Park, JW; Sayre, P; Erny, K; Collins, C; Gray, JW; Benz, CC			ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis	ONCOGENE			English	Article						Ets; epithelial-restricted; breast cancer; HER2/neu	TRANSCRIPTION FACTORS; GENE FAMILY; PROTEIN; PROMOTER; BINDING; HYBRIDIZATION; ACTIVATOR; EVOLUTION; PATHWAY; CANCER	The >30 known members of the Ets multigene family of transcriptional regulators are increasingly being recognized for their involvement in early embryonic development and late tissue maturation, directing stage-specific and tissue-restricted programs of target gene expression. Identifiable primarily by their 85 amino acid ETS DNA-binding domain and dispersed across all metazoan lineages into distinct subfamilies, Ets genes also produce malignancies in humans and other vertebrates when overexpressed or rearranged into chimeras retaining the ETS domain, suggesting that their oncogenic potential is determined by the program of target genes they regulate. Searching for Ets factors that regulate expression of the HER2/neu (c-erbB2) oncogene in human breast cancer, we identified a new epithelium-restricted Ets encoding an ETS domain homologous to the Drosophila E74/human Elf-1 subfamily, an amino-terminal region (A-region or Pointed domain) homologous to the distantly related Ets-l subfamily, and a serine-rich box homologous to the transactivating domain of the lymphocyte-restricted High Mobility Group (HMG) protein, SOX4. Recombinant protein encoded by ESX (for epithelial-restricted with serine box) exhibits Ets-like DNA binding specificity in electrophoretic mobility shift assays and, in transient transfection assays, transactivates Ets-responsive promoter elements including that found in the HER2/neu oncogene. ESX is located at chromosome 1q32 in a region known to be amplified in 50% of early breast cancers, is heregulin-inducible and overexpressed in HER2/neu activated breast cancer cells. Tissue hybridization suggests that ESX becomes overexpressed at an early stage of human breast cancer development known as ductal carcinoma in situ (DCIS).	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV HEMATOL ONCOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV MOL CYTOMETRY,SAN FRANCISCO,CA 94143; LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory				Erny-Albrecht, Katrina/0000-0003-3538-1475	NCI NIH HHS [CA44768, CA36773, CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, P01CA044768, R01CA036773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAGANTI RSK, 1986, CYTOGENET CELL GENET, V43, P181, DOI 10.1159/000132318; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GIOVANE A, 1995, GENOMICS, V29, P769, DOI 10.1006/geno.1995.9938; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; ISOLA JJ, 1995, AM J PATHOL, V147, P905; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KODANDAPANI R, 1996, NATURE, V380, P457; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li WL, 1996, ONCOGENE, V12, P2473; LIU E, 1992, ONCOGENE, V7, P1027; MORRIS CM, 1991, ONCOGENE, V6, P1093; NOONBERG SB, 1994, GENE, V149, P123, DOI 10.1016/0378-1119(94)90420-0; OHagan RC, 1996, ONCOGENE, V13, P1323; OHAGAN RC, 1996, AM ASS CANC RES, V37, P3575; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHIPLEY J, 1994, GENOMICS, V23, P710, DOI 10.1006/geno.1994.1564; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Yang BS, 1996, MOL CELL BIOL, V16, P538	31	155	166	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1617	1622		10.1038/sj.onc.1200978	http://dx.doi.org/10.1038/sj.onc.1200978			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129154				2022-12-28	WOS:A1997WQ54800014
J	Sitterlin, D; Tiollais, P; Transy, C				Sitterlin, D; Tiollais, P; Transy, C			The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain	ONCOGENE			English	Article						acute promyelocytic leukemia; PLZF; RAR alpha-PLZF chimera; DNA-binding activity; two-hybrid system	ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; TUMOR GENE-PRODUCT; T(15-17) TRANSLOCATION; FUSION PROTEINS; PML; CELLS; TRANSACTIVATION; SYSTEM; FAMILY	In most cases, Acute Promyelocytic Leukemia (APL) is associated with t(15;17) translocation which juxtaposes sequences from PML and retinoic acid receptor alpha (RAR alpha) genes. The generated PML-RAR alpha fusion interferes with wild type RAR alpha-mediated transcription and disrupts subnuclear compartments, known as PML bodies. Both defects are corrected by all trans retinoic acid (ATRA) therapy which induces differentiation of leukemic cells and clinical remission. In a rare APL syndrome associated,vith t(11;17), fusion of the RAR alpha gene with the PLZF gene, encoding a Zinc-finger protein produces two reciprocal RAR alpha chimeras, Although PLZF-RAR alpha and PML-RAR alpha are similar in their apparent dominant negative effects, t(11;17)-associated APL is refractory to ATRA therapy. In a yeast two-hybrid genetic screening, we isolated clones encoding the GAL4 transactivation domain fused to various parts of PLZF. Using these autonomously transactivating hybrids, similar in structure to the RAR alpha-PLZF fusion, we mapped the DNA-binding domain of PLZF to the last five Zinc-fingers, a region retained in RAR alpha-PLZF chimera and characterized a specific PLZF target sequence. Our data support the hypothesis that RAR alpha-PLZF chimera is not an inert product of reciprocal translocation and may thus contribute to ATRA unresponsiveness of t(11;17)-associated APL.	INST PASTEUR,UNITE REGULAT EXPRESS GENET,INSERM,U 163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DREXLER HG, 1995, LEUKEMIA, V9, P480; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; INOUYE C, 1994, DNA CELL BIOL, V13, P731, DOI 10.1089/dna.1994.13.731; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI JY, 1995, BLOOD S1, V86, pA262; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	35	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1067	1074		10.1038/sj.onc.1200916	http://dx.doi.org/10.1038/sj.onc.1200916			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070655				2022-12-28	WOS:A1997WM07000008
J	Chang, JY; Xia, WY; Shao, RP; Sorgi, F; Hortobagyi, GN; Huang, L; Hung, MC				Chang, JY; Xia, WY; Shao, RP; Sorgi, F; Hortobagyi, GN; Huang, L; Hung, MC			The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer	ONCOGENE			English	Article						HER-2/neu; E1A; gene therapy; adenoviral vector; cationic liposome	PROTEINS INDUCE APOPTOSIS; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-PRODUCTS; NONHUMAN-PRIMATES; OVARIAN-CANCER; POOR SURVIVAL; EXPRESSION; METASTASIS; CELLS	The HER-2/neu proto-oncogene is frequently amplified or overexpressed in human breast and ovarian cancers, and is significantly correlated with shorter survival, We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can repress HER-2/neu overexpression by repressing HER-2/neu promoter activity, and suppress the tumorigenic potential of HER-2/neu-overexpressing ovarian cancer cells, To examine E1A tumor suppressor function in breast cancer, we transduced E1A in vitro by adenovirus into both HER-2/neu-overexpressing and low expressing human breast cancer cell lines, In HER-2/neu-overexpressing cells, E1A greatly inhibited tumor cell growth in vitro, However, in HER-2/neu low expressing cancer cell lines, E1A had no significant effect on cell growth in culture medium, To test the therapeutic efficacy of E1A, we used both adenovirus-mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer animal model, An advanced breast cancer model was established by inoculation of HER-2/neu-overexpressing human breast cancer cells in mammary fat pad and treated by local injections of either replication-deficient adenovirus expressing EIA, Ad.E1A(+) or a liposome-E1A DNA complex, As controls, mice bearing tumors were also treated with Ad.E1A(-) which is virtually the same adenovirus as Ad.E1A(+) except that EIA is deleted, a liposome-E1A frame-shift mutant DNA complex, or just PBS, In mice bearing a HER-2/neu-overexpressing breast cancer cell line, EIA delivered either by adenovirus or liposome significantly inhibited tumor growth and prolonged mouse survival compared with the controls, In fact, 60-80% of E1A-treated mice lived longer than 2 years versus only 0-20% of control mice (P<0.05), Western blot analysis showed that E1A protein was expressed in tumor tissue and immunohistochemical analysis showed that HER-2/neu p185 protein expression was suppressed, Taken together, our results indicated that both adenovirus and cationic liposome delivery systems were effective in transfering EIA gene for tumor suppression in a HER-2/neu-overexpressing breast cancer model.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BREAST & GYNECOL MED ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P01CA059327] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, CA59327, R01-CA60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHANG JY, 1996, IN PRESS ONCOGENE; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERN JA, 1990, CANCER RES, V50, P5284; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PARKER SE, 1995, HUM GENE THER, V6, P575, DOI 10.1089/hum.1995.6.5-575; PATERSON MC, 1991, CANCER RES, V51, P556; PRESS MF, 1993, CANCER RES, V53, P5675; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TEODORO JG, 1995, ONCOGENE, V11, P467; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YONEMURA Y, 1991, CANCER RES, V51, P1034; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P1947	38	80	83	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					561	568		10.1038/sj.onc.1200861	http://dx.doi.org/10.1038/sj.onc.1200861			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053854				2022-12-28	WOS:A1997WF52400007
J	Terradillos, O; Billet, O; Renard, CA; Levy, R; Molina, T; Briand, P; Buendia, MA				Terradillos, O; Billet, O; Renard, CA; Levy, R; Molina, T; Briand, P; Buendia, MA			The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice	ONCOGENE			English	Article						hepatitis B virus; hepatocellular carcinoma; transactivation; oncogene; apoptosis	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; HBX GENE; IN-VIVO; PROTEIN; ACTIVATION; EXPRESSION	The hepatitis B virus X protein (HBx) is thought to be implicated in the development of hepatocellular carcinoma, but its exact function remains controversial, Transgenic mice from PEX7 and AX16 lineages that express HBx in the liver under control of different viral regulatory elements develop no liver pathology (Billet ed al., 1995), We have crossed these two mouse lineages with WHV/c-myc oncomice in which liver-specific expression of c-myc driven by woodchuck hepatitis virus (WHV) regulatory sequences causes liver cancer in all animals, The average tumor latency was shortened by 2 to 3 months in bitransgenic animals from all populations compared with simple c-myc transgenic littermates, At preneoplastic stages, adult bitransgenic mice showed four to fivefold enhanced expression of the c-myc transgene, increased hepatocyte proliferation and more extensive liver lesions compared with simple WHV/c-myc transgenics, Thus in this model, HBx alone has no direct pathological effect but it is shown to accelerate tumor development induced by c-myc. The data presented here firmly establish the oncogenic potential of HBx, apparently acting as a tumor promoter, This model offers unique opportunities to investigate the mechanisms by which HBx trans-activates the expression of target genes and deregulates the hepatocyte growth control in vivo.	INST PASTEUR,DEPT RETROVIRUS,INSERM U163,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS 15,FRANCE; INST COCHIN GENET MOL,INSERM U380,UNITE GENET & PATHOL EXPT,F-75014 PARIS,FRANCE; UNIV PARIS,HOTEL DIEU,FAC BROUSSAIS,LAB RECH HISTOPATHOL,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BALSANO C, 1993, ARCH VIROL         S, V8, P63; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DUFLOT A, 1995, HEPATOLOGY, V21, P1483, DOI 10.1016/0270-9139(95)90448-4; ETIEMBLE J, 1994, ONCOGENE, V9, P727; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1990, ONCOGENE, V5, P867; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GU JR, 1986, J CELL PHYSL S, V4, P13; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HIMENO Y, 1988, LIVER, V8, P208; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KAY A, 1991, J MED VIROL, V33, P228, DOI 10.1002/jmv.1890330404; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOSHY R, 1991, ADV AP BIOT, V13, P159; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MURAKAMI H, 1993, CANCER RES, V53, P1719; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1994, ONCOGENE, V9, P2837; OGSTON CW, 1982, CELL, V29, P385, DOI 10.1016/0092-8674(82)90155-6; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PERFUMO S, 1992, J VIROL, V66, P6819, DOI 10.1128/JVI.66.11.6819-6823.1992; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TRUANT R, 1995, J VIROL, V69, P1951; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei Y, 1996, J GEN VIROL, V77, P177, DOI 10.1099/0022-1317-77-2-177; WEI Y, 1995, J MED VIROL, V45, P82, DOI 10.1002/jmv.1890450116; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; Yen BTS, 1996, J BIOMED SCI, V3, P20; ZHANG XK, 1990, ONCOGENE, V5, P909; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	71	239	259	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					395	404		10.1038/sj.onc.1200850	http://dx.doi.org/10.1038/sj.onc.1200850			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053836				2022-12-28	WOS:A1997WE36400002
J	McGuire, TF; Sebti, SM				McGuire, TF; Sebti, SM			Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity	ONCOGENE			English	Article						Ras inhibition; lovastatin; geranylgeraniol	CELL-CYCLE PROGRESSION; POSTTRANSLATIONAL MODIFICATIONS; PROTEIN FARNESYLTRANSFERASE; CDC42 GTPASES; GROWTH; BIOSYNTHESIS; MEVALONATE; SUBUNIT; RHO; ISOPRENYLATION	Oncogenic H-Ras requires farnesylation for its transforming activity. Lovastatin inhibits both protein farnesylation and geranylgeranylation by decreasing cellular pools of farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), respectively. Use of lovastatin as a chemotherapeutic agent has been precluded by its significant cytotoxic effects. In this report, we describe a novel approach utilizing a combination of lovastatin and geranylgeraniol (GGOH) to potentiate the ability of lovastatin to block oncogenic H-Ras signaling and concomitantly rescue lovastatin toxicity. GGOH co-treatment with lovastatin enhances inhibition of oncogenic H-Ras processing and constitutive activation of mitogen-activated protein kinase (MAPK), and preserves the processing of geranylgeranyltransferase (GGTase) I and GGTase II protein substrates. Moreover, co-treatment with GGOH significantly (15-fold) attenuates the cytotoxic effects of lovastatin as well as prevents lovastatin-induced cell rounding. These results demonstrate that GGOH potentiates the anti-oncogenic/anti-signaling activity of lovastatin while antagonizing its cytotoxicity. These opposing effects are due to a GGOH metabolite that serves simultaneously as a potent inhibitor for farneslyltransferase as web as a substrate for GGTases I and II.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; CRICK DC, 1994, BIOCHEM BIOPH RES CO, V205, P955, DOI 10.1006/bbrc.1994.2758; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HORI Y, 1991, ONCOGENE, V6, P515; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, pI121; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REISS Y, 1992, J BIOL CHEM, V267, P6403; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SUN JZ, 1995, CANCER RES, V55, P4243; VIGANO T, 1995, EUR J PHARM-MOLEC PH, V291, P201, DOI 10.1016/0922-4106(95)90143-4	37	29	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					305	312		10.1038/sj.onc.1200819	http://dx.doi.org/10.1038/sj.onc.1200819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018116				2022-12-28	WOS:A1997WD51600006
J	Lawe, DC; Hahn, C; Wong, AJ				Lawe, DC; Hahn, C; Wong, AJ			The Nck SH2/SH3 adaptor protein is present in the nucleus and associates with the nuclear protein SAM68	ONCOGENE			English	Article						Nck; SAM68; SH3 domains; signal transduction; tyrosine kinases	TYROSINE KINASE; SIGNAL-TRANSDUCTION; SH3 DOMAINS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHOLIPASE C-GAMMA-1; BINDING-PROTEIN; SRC; RECEPTOR	SH2/SH3 adaptor proteins are essential components of the signal transduction pathways initiated by tyrosine kinases. Nck is a ubiquitously expressed adaptor protein whose function has been enigmatic. We performed confocal microscopy to localize Nck in NIH3T3 and A431 cells. Surprisingly, Nck was identified in the nucleus as well as the cytoplasm with no visible change in localization due to PDGF or EGF stimulation. Western blot analysis of nuclear and cytosolic fractions confirmed that there was no translocation in response to growth factor and that tyrosine phosphorylation was specific to only cytosolic Nck. Far Western blot analysis with either Nck, the SH2 domain, or the SH3 domains revealed differential binding in nuclear and cytosolic lysates, indicating specific binding partners for each subcellular location. The major target of c-Src during mitosis is SAM68, a RNA-binding protein ordinarily localized to the nucleus. SAM68 was identified as a nuclear specific binding partner of Nck in both nonmitotic and mitotic cells. Several tyrosine kinases can be found in the nucleus but their signal transduction remains undefined. The discovery of an adaptor protein in the nucleus suggests there are signal transduction mechanisms within the nucleus that recapitulate those found in the cytoplasm.	KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; KIMMEL CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [T32CA009678, R01CA053149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53149, T32-CA09678] Funding Source: Medline; NINDS NIH HHS [NS-31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FELLER SM, 1995, ONCOGENE, V10, P1465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU G, 1995, MOL CELL BIOL, V15, P1169; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NERI LM, 1994, CELL MOL BIOL, V40, P619; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAINE PL, 1983, J CELL BIOL, V97, P1240, DOI 10.1083/jcb.97.4.1240; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Romero F, 1996, MOL CELL BIOL, V16, P37; RON D, 1992, BIOTECHNIQUES, V13, P866; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1995, ONCOGENE, V10, P1977; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	54	60	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					223	231		10.1038/sj.onc.1200821	http://dx.doi.org/10.1038/sj.onc.1200821			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010224	Bronze			2022-12-28	WOS:A1997WC81800010
J	Abarzua, P; LoSardo, JE; Gubler, ML; Spathis, R; Lu, YA; Felix, A; Neri, A				Abarzua, P; LoSardo, JE; Gubler, ML; Spathis, R; Lu, YA; Felix, A; Neri, A			Restoration of the transcription activation function to mutant p53 in human cancer cells	ONCOGENE			English	Article						mutant p53; DNA binding; pegylated peptide; transcription activation; SW480 cells	WILD-TYPE P53; DNA-BINDING FUNCTION; P53-MEDIATED G(1) ARREST; SOLID-PHASE SYNTHESIS; INDUCED APOPTOSIS; GENE-EXPRESSION; GROWTH ARREST; PROTEIN; SEQUENCE; MUTATIONS	The p53 tumor suppressor gene product is a sequence-specific transcription activator frequently mutated in a variety of human malignancies. Typically, tumor-derived p53 missense mutants are defective in DNA binding and this is likely to result in a failure to active p53-regulated genes. Hence, restoring function to mutant p53 represents an attractive target to develop a novel cancer chemotherapeutic agent. We now show that a small chemically modified peptide derived from p53 restores sequence-specific DNA binding to a subset of p53 mutants. Moreover, when microinjected into human colon carcinoma cells this peptide restores the transcription activation function to endogenous mutant p53 protein. This is the first example showing that a small peptide molecule can reverse the effect of several inactivating missense mutations and restore protein function.			Abarzua, P (corresponding author), HOFFMANN LA ROCHE INC,ROCHE RES CTR,NUTLEY,NJ 07110, USA.							ABARZUA P, 1995, CANCER RES, V55, P3490; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LU YA, 1994, INT J PEPT PROT RES, V43, P127; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	68	71	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2477	2482						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957091				2022-12-28	WOS:A1996VX10800022
J	Mumberg, D; Haas, K; Moroy, T; Niedenthal, R; Hegemann, JH; Funk, M; Muller, R				Mumberg, D; Haas, K; Moroy, T; Niedenthal, R; Hegemann, JH; Funk, M; Muller, R			Uncoupling of DNA replication and cell cycle progression by human cyclin E	ONCOGENE			English	Article						cyclin E; DNA-replication; Saccharomyces cerevisiae; oncogene co-operation; ras oncogene	SACCHAROMYCES-CEREVISIAE; G1 CYCLIN; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; POTENTIAL MEDIATOR; DEPENDENT KINASES; DIVISION CYCLE; BUDDING YEAST	The G(1)-specific D- and E-type cyclins are among the most crucial factors controlling cell cycle progression in mammalian cells and are therefore thought to play an important role in tumorigenisis, D-type cyclins have indeed been shown to be endowed with an oncogenic potential, Here, we report that the ectopic expression of human cyclin E, but not cyclin D1, deregulates DNA synthesis in both yeast and mammalian cells, In yeast, induction of DNA synthesis by cyclin E occurs even under conditions of cell cycle arrest in G(1) or G(2)/M, indicating an uncoupling of DNA replication from cell cycle progression, In rat embryo fibroblasts, the cooperative action of Ras and cyclin E induces transformation, These cells, in contrast to those transformed by Ras and cyclin D1, show aberrant levels of DNA synthesis, Since cyclin E is commonly overexpressed in a variety of human tumors, these findings may point to a link between the uncontrolled proliferation and the genomic instability typically seen in malignant tumors, Furthermore they reveal significant differences in the functional properties of cyclin E and D1.	UNIV MARBURG, INST MOL BIOL & TUMORFORSCH, D-35033 MARBURG, GERMANY; UNIV GIESSEN, INST MIKROBIOL & MOL BIOL, D-35392 GIESSEN, GERMANY	Philipps University Marburg; Justus Liebig University Giessen			Müller, Rolf/L-4997-2016; Moroy, Tarik/D-9923-2011	Müller, Rolf/0000-0003-3339-4248; Funk, Martin/0000-0003-2721-4036				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOVEC H, 1994, ONCOGENE, V9, P323; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEWING A, 1993, J CELL SCI, V104, P545; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	48	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2493	2497						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957094				2022-12-28	WOS:A1996VX10800025
J	Rosenberg, JE; Lisle, DK; Burwick, JA; Ueki, K; vonDeimling, A; Mohrenweiser, HW; Louis, DN				Rosenberg, JE; Lisle, DK; Burwick, JA; Ueki, K; vonDeimling, A; Mohrenweiser, HW; Louis, DN			Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval	ONCOGENE			English	Article						chromosome 19; D19S745; glioma; tumor suppressor gene	REGION; ASTROCYTOMAS; CANDIDATE; 19Q13.3; MAP	Allelic loss of chromsome 19q occurs frequently in malignant gliomas, suggesting the presence of a chromosome 19q glioma tumor suppressor gene, Deletion mapping studies have delineated a 3.5 Mb candidate region between D19S219 and HRC, Cloned sequences from the proximal 425 kb of this interval, however, have not shown tumor-specific alterations, To refine the location of the tumor suppressor gene further, we conducted loss of heterozygosity studies on 191 malignant gliomas using nine PCR-based polymorphisms, These included the previously identified and physically mapped markers D19S219, DM, D19S112, HRC and the recently physically mapped polymorphisms at D19S412, STD, D19S596 and GYS. In addition, we isolated a novel microsatellite polymorphism that maps 400 kb telomeric to D19S112, Oligodendroglial tumors showed frequent loss of heterozygosity in all grades, and typically displayed allelic loss at all studied markers, Astrocytomas, however, showed frequent loss primarily in anaplastic astrocytomas and displayed deletion breakpoints within the candidate region, Deletion mapping revealed a minimal region of overlap between D19S412 and STD, a distance of 900 kb, These data suggest that the D19S412-STD interval represents the most likely location for a chromsome 19q glioma tumor suppressor gene involved in astrocytoma, and perhaps oligodendroglioma, tumorigenesis.	MASSACHUSETTS GEN HOSP,DEPT PATHOL NEUROPATHOL,NEUROSURG SERV,MOL NEUROONCOL LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV HOSP,INST NEUROPATHOL,BONN,GERMANY; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Bonn; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X	NATIONAL CANCER INSTITUTE [R01CA057683, R01CA069285] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69285, CA 57683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; DUROCHER F, 1995, GENOMICS, V29, P781, DOI 10.1006/geno.1995.9935; ELBEIN SC, 1994, DIABETES, V43, P1061, DOI 10.2337/diabetes.43.8.1061; GORDON LA, 1995, GENOMICS, V30, P187, DOI 10.1006/geno.1995.9886; Kleihues P, 1993, HISTOLOGICAL TYPING; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LOUIS DN, 1992, AM J PATHOL, V141, P777; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RUBIO MP, 1994, CANCER RES, V54, P4760; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002; YONG WH, 1995, GENOMICS, V29, P533, DOI 10.1006/geno.1995.9972	16	78	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2483	2485						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957092				2022-12-28	WOS:A1996VX10800023
J	Eliopoulos, AG; Dawson, CW; Mosialos, G; Floettmann, JE; Rowe, M; Armitage, RJ; Dawson, J; Zapata, JM; Kerr, DJ; Wakelam, MJO; Reed, JC; Kieff, E; Young, LS				Eliopoulos, AG; Dawson, CW; Mosialos, G; Floettmann, JE; Rowe, M; Armitage, RJ; Dawson, J; Zapata, JM; Kerr, DJ; Wakelam, MJO; Reed, JC; Kieff, E; Young, LS			CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator	ONCOGENE			English	Article						CD40; TNF alpha; Fas; LMP1; TRAF3; epithelial	LATENT MEMBRANE-PROTEIN; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; BCL-2 HOMOLOG BAK; CD40 LIGAND; ACTIVATION MOLECULE; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; IMMUNE-RESPONSES; DRUG-RESISTANCE	CD40, a member of the tumour necrosis factor receptor family, is expressed on the surface of B lymphocytes where its ligation provides a potent survival signal. CD40 is also expressed in basal epithelial cells and in a number of different carcinomas where its function remains unknown. We observed that contrary to the studies in normal B cells, CD40 Ligation in carcinoma cell lines and in normal primary epithelial cells resulted in growth inhibition and enhanced susceptibility to apoptosis induced by anti-neoplastic drugs, TNF-alpha, Fas and ceramide. This effect was also observed in CD40-transfected Rat-1 fibroblasts. The expression of Bcl-2 did not affect growth inhibition induced by CD40 ligation in epithelial cells but the Epstein - Barr Virus-encoded latent membrane protein 1 (LMP1) blocked the effect. Whilst transient expression of LMP-1 resulted in the inhibition of epithelial cell growth, this effect was not observed with a LMP1 mutant lacking the binding domain for TRAF3, a protein which may mediate signal transduction by interacting with the cytoplasmic domains of both CD40 and LMP1. Transient expression of TRAF3 also inhibited epithelial cell growth, whilst expression of a dominant-negative TRAF3 partially blocked the inhibitory effect of CD40 ligation and of transient LMP1 expression. These results suggest that CD40 regulates epithelial cell growth in a manner mimicked by LMP1 and implicate TRAF3 as a common mediator in the transduction of the growth inhibitory signals generated via the CD40 and LMP1 pathways.	UNIV BIRMINGHAM,SCH MED,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,AL,ENGLAND; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101; BURNHAM INST,CANC RES CTR,LA JOLLA,CA 92037	University of Birmingham; Harvard University; Harvard Medical School; Cardiff University; Sanford Burnham Prebys Medical Discovery Institute			ELIOPOULOS, ARISTIDES/ABI-6632-2020; Zapata, Juan M/J-6304-2014; ELIOPOULOS, ARISTIDES/R-9449-2018; Rowe, Martin/B-2880-2009; Young, Lawrence S/B-7213-2009	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Zapata, Juan M/0000-0002-0110-0009; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; Wakelam, Michael/0000-0003-4059-9276	NCI NIH HHS [CA-69381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FLOETTMANN JE, IN PRESS VIROLOGY; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2366; HORNER AA, 1995, J EXP MED, V181, P1239, DOI 10.1084/jem.181.3.1239; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KATIRA A, 1995, LEUKOCYTE TYPING, V5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MORIMOTO H, 1993, CANCER RES, V53, P2591; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PENG M, 1992, ONCOGENE, V7, P1775; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUBY J, 1995, NAT MED, V1, P437, DOI 10.1038/nm0595-437; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	58	190	199	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2243	2254						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950992				2022-12-28	WOS:A1996VV14500022
J	Rhodes, N; Innes, CL; Propst, F; Paules, RS				Rhodes, N; Innes, CL; Propst, F; Paules, RS			Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs	ONCOGENE			English	Article						v-mos-transformed cells; cdk; cyclin; quiescence; cell cycle control; cancer	MAP KINASE-KINASE; CDC2 PROTEIN-KINASE; MURINE SARCOMA-VIRUS; HUMAN BREAST-CANCER; S-PHASE; XENOPUS-OOCYTES; PROTOONCOGENE EXPRESSION; DEVELOPMENTAL REGULATION; MAMMALIAN FIBROBLASTS; DEPENDENT KINASES	Serum deprived v-mos-transformed NIH3T3 cells are unable to enter a true quiescent state, but instead, arrest in the early G1 phase of the cell cycle, We have analysed several cell cycle regulatory proteins in these G1 arrested cells and show altered regulation in the expression and activity of certain cyclins and cyclin-dependent kinases, In particular, p34(cdc2), cyclin A, cyclin D and cyclin E are not appropriately down-regulated in serum starved, G1 arrested, v-mos-transformed cells as compared with quiescent NIH3T3 cells, Furthermore, serum starved v-mos-transformed cells have elevated histone H1 kinase activity associated with cyclin A, cyclin E, p33(cdk2), and p34(cdc2), Using a metallothionein-inducible c-mos(mu) expression system, we show that c-mos(mu) induction in quiescent NIH3T3 cells causes elevated expression of p34(cdc2). However, this induction of c-mos(mu) and subsequent expression of p34(cdc2) was not sufficient to promote significant entry of cells into S phase, Analysis of extracts from serum starved v-H-ras, v-src, and tpr-met transformed NIH3T3 cells demonstrates that these oncogene-transformed cells also contain elevated levels of p34(cdc2). We propose that the altered regulation of these critical cell cycle regulatory molecules, and specifically the inability to fully downregulate their activity, contributes significantly to neoplastic transformation and subsequent unregulated growth of tumor cells.	NIEHS, GROWTH CONTROL & CANC GRP, RES TRIANGLE PK, NC 27709 USA; UNIV VIENNA, INST BIOCHEM & MOL CELL BIOL, VIENNA BIOCTR, A-1030 VIENNA, AUSTRIA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Vienna; Vienna Biocenter (VBC)				Paules, Richard S/0000-0001-9106-7486				ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CANAANI E, 1979, NATURE, V282, P378, DOI 10.1038/282378a0; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DONOGHUE DJ, 1983, J VIROL, V45, P607, DOI 10.1128/JVI.45.2.607-617.1983; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FAUST JB, 1992, CANCER RES, V52, P2460; FILMUS J, 1994, ONCOGENE, V9, P3627; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KESHET E, 1988, ONCOGENE, V2, P235; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEACH FS, 1993, CANCER RES, V53, P1986; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI CCH, 1993, ONCOGENE, V8, P1685; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RHODES N, 1994, EXP CELL RES, V213, P210, DOI 10.1006/excr.1994.1192; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOURAY M, 1991, ONCOGENE, V6, P211; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUI LV, 1993, INT J ONCOL, V2, P493; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	89	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	1997	14	25					3017	3027		10.1038/sj.onc.1201158	http://dx.doi.org/10.1038/sj.onc.1201158			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223665				2022-12-28	WOS:A1997XG10000004
J	Bosse, P; Bernex, F; DeSepulveda, P; Salaun, P; Panthier, JJ				Bosse, P; Bernex, F; DeSepulveda, P; Salaun, P; Panthier, JJ			Multiple neuroendocrine tumours in transgenic mice induced by c-kit-SV40 T antigen fusion genes	ONCOGENE			English	Article						receptor tyrosine kinase; c-kit; stem cell factor; SV40 T antigen; neuroendocrine system; neoplasia	STEM-CELL FACTOR; NEURON-SPECIFIC ENOLASE; C-KIT RECEPTOR; PROOPIOMELANOCORTIN GENE; EXPRESSION; MOUSE; LINES; PROMOTER; PROTOONCOGENE; ENDOCRINE	Transgenic mice carrying either a 1.008 or a 4.225 kb of the mouse c-kit 5'-flanking sequences linked to the oncogenic large T antigen (TAg) region of the sinian virus 40 (SV40) genome were generated to test if the c-kit promoter could be used to develop useful mouse models. Both constructs promote tumourigenesis in the pituitary and the thyroid with high efficiency. The cell types from which each of these tumours derives were identified. Tumours of the pituitary derive from alpha-MSH-expressing cells located in the intermediate lobe, Transformed cells of the thyroid were calcitonin-positive, implying that the tumours derive from C cells or their precursors, Chromogranin A and neuron-specific enolase, general neuroendocrine cell markers, were expressed in both tumour types. Furthermore a variety of tumours appeared in the transgenic mice. Several of them stained positively for chromogranin A and/or neuron-specific enolase, This suggests a previously unsuspected tissue-specificity of the c-kit 5' flanking sequences for neuroendocrine cells. The Kit-TAg transgenic mouse Lines may represent a valuable model for the study of the development and the biology of neuroendocrine tumours.	ECOLE NATL VET,URA,INRA GENET MOL,F-94704 MAISONS ALFORT,FRANCE	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE			PANTHIER, Jean-Jacques/I-4366-2014; De sepulveda, paulo/K-6043-2015	PANTHIER, Jean-Jacques/0000-0002-7966-0663; De sepulveda, paulo/0000-0001-8295-5414; Bosse, Philippe/0000-0001-5701-6415				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bernex F, 1996, DEVELOPMENT, V122, P3023; BISHOP AE, 1988, PATHOL RES PRACT, V183, P119, DOI 10.1016/S0344-0338(88)80040-2; BISHOP AE, 1982, GASTROENTEROLOGY, V83, P902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN PS, 1994, BLOOD, V84, P3465; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; DESEPULVEDA P, 1995, BIOCHEM BIOPH RES CO, V211, P735, DOI 10.1006/bbrc.1995.1874; GEPTS W, 1984, EVOLUTION TUMOUR PAT, P343; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P97, DOI 10.1210/endo-79-1-97; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HIBI K, 1991, ONCOGENE, V6, P2291; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; HOGAN B, 1994, MANIPULATING MOUSE E, P217; HU NP, 1994, ONCOGENE, V9, P1021; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KLOPPEL G, 1994, ANN NY ACAD SCI, V733, P18, DOI 10.1111/j.1749-6632.1994.tb17252.x; KRYSZKE M, 1990, CHROMOSOMES EUCARYOT, V3, P113; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LASSAM N, 1992, ONCOGENE, V7, P51; LAUNAY JM, 1983, BIOMED PHARMACOTHER, V37, P322; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; LIU B, 1992, MOL CELL BIOL, V12, P3978, DOI 10.1128/MCB.12.9.3978; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; LOW MJ, 1993, J BIOL CHEM, V268, P24967; LYON M, 1989, GENETICS VARIANTS ST; MAEDA H, 1992, DEVELOPMENT, V116, P369; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; Motro B, 1996, P NATL ACAD SCI USA, V93, P1808, DOI 10.1073/pnas.93.5.1808; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1995, CANCER RES, V55, P1787; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OGAWA M, 1993, DEVELOPMENT, V117, P1089; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PANTHIER JJ, 1984, P NATL ACAD SCI-BIOL, V81, P5489, DOI 10.1073/pnas.81.17.5489; ROBERTS JL, 1980, BIOCHEM, V17, P3609; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; TAPIA FJ, 1981, LANCET, V1, P808; TEITZ T, 1993, P NATL ACAD SCI USA, V90, P2910, DOI 10.1073/pnas.90.7.2910; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TURNER AM, 1992, BLOOD, V80, P374; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; VICART P, 1994, EXP CELL RES, V214, P35, DOI 10.1006/excr.1994.1231; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILSON BS, 1984, AM J PATHOL, V115, P458; YASUDA H, 1993, BIOCHEM BIOPH RES CO, V191, P893, DOI 10.1006/bbrc.1993.1301	53	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2661	2670		10.1038/sj.onc.1201122	http://dx.doi.org/10.1038/sj.onc.1201122			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178764				2022-12-28	WOS:A1997XB97800005
J	Guerra, B; Gotz, C; Wagner, P; Montenarh, M; Issinger, OG				Guerra, B; Gotz, C; Wagner, P; Montenarh, M; Issinger, OG			The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation	ONCOGENE			English	Article						p53; protein kinase CK2; MDM2; p21(WAF1/CIP1); phosphorylation	TUMOR-SUPPRESSOR PROTEIN; AUTOREGULATORY FEEDBACK LOOP; SOFT-TISSUE SARCOMAS; CASEIN KINASE-2; DNA-BINDING; CELLULAR-REGULATION; BETA-SUBUNIT; WILD-TYPE; DOMAIN; GENE	The oncogene product MDM2 can be phosphorylated by protein kinase CK2 in vitro 0.5-1 mol of phosphate were incorporated per mol MDM2 protein, The catalytic subunit of protein kinase CK2 (alpha-subunit) catalyzed the incorporation of twice as much phosphate into the MDM2 protein as it was obtained with the holoenzyme, Polylysine stimulated MDM2 phosphorylation by CK2 holoenzyme threefold in contrast to the alpha-subunit-catalyzed MDM2 phosphorylation which was reduced by about 66% when polylysine was added, Full length p53, but also a peptide representing a C-terminal fragment of the tumor suppressor gene product p53 (amino acids 264-393 which also harbors the CK2 beta interaction site at amino acids 287-340) mimicked the polylysine effect in all respects, ie, stimulation of phosphate incorporation by CK2 holoenzyme and inhibition in the presence of the catalytic CK2 alpha-subunit. Stimulation by p53(264-393) was on the average close to twofold and inhibition in the case of the alpha-subunit-catalyzed MDM2 phosphorylation was about 40%, Phosphorylation of MDM2 by CK2 holoenzyme in the presence of the p21(WAF1/CIP1), known to be a potent inhibitor of cyclin-dependent protein kinases, also led to a significant reduction of phosphate incorporation into MDM2 indicating that p21(WAF1/CIP1) does not exclusively inhibit cell cycle kinases, Furthermore, these data add new insight into the autoregulatory loop which include p21(WAF1/CIP1), MDM2 protein, CK2 and p53.	ODENSE UNIV,BIOKEMISK INST,DK-5230 ODENSE,DENMARK; UNIV SAARLAND,FR MED BIOCHEM,D-66424 HOMBURG,GERMANY	University of Southern Denmark; Saarland University			Montenarh, Mathias/AAB-6689-2020	Guerra, Barbara/0000-0003-1136-2413				ADDISON C, 1990, ONCOGENE, V5, P423; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BOLDYREFF B, 1995, 20 EUR S HORM CELL R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Filhol O, 1996, BIOCHEM J, V316, P331, DOI 10.1042/bj3160331; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gotz C, 1996, ONCOGENE, V13, P391; GOTZ C, 1995, REV PHYSL BIOCH PHAR, V127, P65; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HERRMANN CPE, 1991, ONCOGENE, V6, P877; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; ISSINGER OG, 1992, RECENT ADV CELLULAR, V4, P17; KRAISS S, 1990, ONCOGENE, V5, P845; LEACH FS, 1993, CANCER RES, V53, P2231; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MEED DW, 1990, J VIROL, V64, P1734; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Tuazon PT, 1990, ADV 2 MESSENGER PHOS, V23, P123; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WAGNER P, 1994, INT J ONCOL, V4, P491; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	59	60	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2683	2688		10.1038/sj.onc.1201112	http://dx.doi.org/10.1038/sj.onc.1201112			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178766				2022-12-28	WOS:A1997XB97800007
J	Baldin, V; Cans, C; SupertiFurga, G; Ducommun, B				Baldin, V; Cans, C; SupertiFurga, G; Ducommun, B			Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?	ONCOGENE			English	Article						cdc25B; cell cycle; protein phosphatase; splicing	FISSION YEAST CDC25; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; MITOTIC INDUCER; M-PHASE; PHOSPHORYLATION; ACTIVATION; MITOSIS; HOMOLOG	CDC25B2, a protein tyrosine phosphatase closely related to the putative CDC25B oncogene, was identified in a Burkitt lymphoma cDNA library, CDC25B2 differs from CDC25B by a 14 residue insertion and a 41 residue deletion, which are both located in the amino-terminal region of the protein, upstream of the catalytic domain. Examination of the genomic sequence revealed that CDC25B1 (formerly B) and CDC25B2 are splice variants of the same gene, A third variant, CDC25B3, that carries both the 14 and the 41 residue sequences was also identified in the same cDNA library. All three variants were detected in a panel of human primary culture and cell lines, although at different levels. In primary fibroblasts and in HeLa cells the CDC25B expression is cell cycle regulated, reaching a maximum in G(2)-phase. In vitro, CDC25B1 phosphatase is slightly more active than CDC25B2 and B3. However, episomal overexpression of the three CDC25B variants in fission yeast reveals that in vivo, CDC25B2 is largely more active than either B1 or B3 (B2>B3>B1) both to complement a thermosensitive S pombe CDC25 activity and to act as a mitotic inducer, Alternative splicing of CDC25B may therefore contribute to the control of cell proliferation.	UNIV TOULOUSE 2, INST PHARMACOL & BIOL STRUCT, CNRS, F-31077 TOULOUSE, FRANCE; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	Universite de Toulouse; Universite de Toulouse - Jean Jaures; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)			BALDIN, Véronique/Y-8397-2019; DUCOMMUN, Bernard/B-3208-2008; Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	BALDIN, Véronique/0000-0001-8523-0494; Superti-Furga, Giulio/0000-0002-0570-1768; DUCOMMUN, Bernard/0000-0002-7126-8368				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DEMETRICK DJ, 1993, GENOMICS, V18, P144, DOI 10.1006/geno.1993.1440; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRANA X, 1994, ONCOGENE, V9, P2097; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LANE SA, 1993, GENOMICS, V15, P693, DOI 10.1006/geno.1993.1129; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGATA A, 1991, NEW BIOL, V3, P959; NARGI JL, 1994, IMMUNOGENETICS, V39, P99, DOI 10.1007/BF00188612; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEWING A, 1994, J CELL SCI, V107, P581; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1996, IN PRESS NATURE BIOT; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Xu X, 1996, J BIOL CHEM, V271, P5118; YUSHERMAN M, 1992, EMBO J, V11, P71	48	92	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2485	2495		10.1038/sj.onc.1201063	http://dx.doi.org/10.1038/sj.onc.1201063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188863				2022-12-28	WOS:A1997WZ68000012
J	Defilippi, P; Olivo, C; Tarone, G; Mancini, P; Torrisi, MR; Eva, A				Defilippi, P; Olivo, C; Tarone, G; Mancini, P; Torrisi, MR; Eva, A			Actin cytoskeleton polymerization in Dbl-transformed NIH3T3 fibroblasts is dependent on cell adhesion to specific extracellular matrix proteins	ONCOGENE			English	Article						Dbl; integrins; stress fibers	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEIN; RHO GENE-PRODUCT; ONCOGENE PRODUCT; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; ESCHERICHIA-COLI; LAMININ RECEPTOR; STRESS FIBERS; INTEGRIN	The Dbl oncogene is the putative exchange factor for two small GTP-binding proteins, RhoA and CDC42 which are involved in the polymerization of actin to produce stress fibers and filopodia, respectively. We report here that Dbl oncogene-transformed NIH3T3 cells show actin stress fibers only when cells are plated on fibronectin, Plating of cells on collagen I and IV as well as on poly-D-lysine and gelatin induces polymerization of actin to form filopodia, lamellipodia and membrane ruffles but not stress fibers, The putative collagen receptors, alpha 1/beta 1 and alpha 2/beta 1 integrins are expressed at reduced level in Dbl-transformed cells compared to untransformed NIH3T3 fibroblasts, Nevertheless, adhesion to collagens is not altered, Inhibitory monoclonal antibody to mouse integrin beta 1 subunit blocked adhesion of both Dbl-transformed and untransformed NIH3T3 cells, demonstrating that adhesion to collagen I and TV is mediated by the beta 1 family of integrins. Dbl product rapidly induces the depolymerization of actin stress fibers, rounding up of the cells, and formation of filopodia and lamellipodia when microinjected in NIH3T3 cells plated on gelatin, Thus, Dbl may exert its effect on actin cytoskeleton organization in response to extracellular proteins by altering integrin-mediated signalling pathways.	IST GIANNINA GASLINI,MOL BIOL LAB,I-16148 GENOA,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENT MED SPERIMENTALE & PATOL,I-00161 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,I-00161 ROME,ITALY; UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,I-10126 TURIN,ITALY	University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome; Sapienza University Rome; University of Turin			Eva, Alessandra/J-8268-2016; DEFILIPPI, Paola/L-2232-2014	Eva, Alessandra/0000-0003-2949-078X; Tarone, Guido/0000-0003-4805-086X; Defilippi, Paola/0000-0001-6427-4906; mancini, patrizia/0000-0003-0556-2056	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRAZIANI G, 1989, ONCOGENE, V4, P823; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1988, NEURON, V1, P713, DOI 10.1016/0896-6273(88)90170-5; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRAMER RH, 1989, J BIOL CHEM, V264, P4686; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TARONE G, 1982, J CELL BIOL, V94, P179, DOI 10.1083/jcb.94.1.179; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; ZANGRILLI D, 1995, METHOD ENZYMOL, V256, P347; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	40	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1933	1943		10.1038/sj.onc.1201027	http://dx.doi.org/10.1038/sj.onc.1201027			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150360				2022-12-28	WOS:A1997WV80400006
J	Mekeel, KL; Tang, W; Kachnic, LA; Luo, CM; DeFrank, JS; Powell, SN				Mekeel, KL; Tang, W; Kachnic, LA; Luo, CM; DeFrank, JS; Powell, SN			Inactivation of p53 results in high rates of homologous recombination	ONCOGENE			English	Article						p53; genetic stability; homologous recombination; plasmid	CELL-CYCLE CONTROL; C-TERMINAL DOMAIN; WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; INDUCED MUTATION; HAMSTER-CELLS; COLON-CANCER; GENE; APOPTOSIS	Using a plasmid substrate which integrates into the genome, we determined that the rate of homologous recombination was suppressed by p53, Human tumor cell lines, mutant or null for p53 had recombination rates 10 000-times greater than primary fibroblasts. When isogenic cell pairs from tumor cells or primary fibroblasts were compared, differing only in one genetic change which inactivated p53, the recombination rate increased >100-fold. Functional inactivation of p53 by dominant mutant p53, by large T antigen of SV40 virus, by E6 protein of human papilloma virus, or by genetic deletion led to the same result. Our results suggest that p53 suppresses spontaneous homologous recombination, and that p53 is not required for recombination to proceed, The mechanism of recombination suppression may be related to the reported association of p53 with Rad 51, but the functional consequences of this association are not yet established. It is suggested that suppression of homologous recombination is the means by which p53 maintains genetic stability.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [CA58985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLE J, 1976, MUTAT RES, V41, P377, DOI 10.1016/0027-5107(76)90110-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FAN SJ, 1995, CANCER RES, V55, P1649; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; KIM HG, 1994, AM J PATHOL, V145, P148; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luo CM, 1996, J BIOL CHEM, V271, P4497; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MICHIELI P, 1994, CANCER RES, V54, P3391; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; POWELL SN, 1995, CANCER RES, V55, P1643; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SMITHRAVIN J, 1989, INT J RADIAT BIOL, V56, P951, DOI 10.1080/09553008914552411; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; TLSTY TD, 1993, COLD SPRING HARB SYM, V58, P645, DOI 10.1101/SQB.1993.058.01.072; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12	45	193	198	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1847	1857		10.1038/sj.onc.1201143	http://dx.doi.org/10.1038/sj.onc.1201143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150391				2022-12-28	WOS:A1997WW16600011
J	Mils, V; Piette, J; Barette, C; Veyrune, JL; Tesniere, A; Escot, C; Guilhou, JJ; BassetSeguin, N				Mils, V; Piette, J; Barette, C; Veyrune, JL; Tesniere, A; Escot, C; Guilhou, JJ; BassetSeguin, N			The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis	ONCOGENE			English	Article						c-fos; c-jun; keratinocytes; apoptosis; differentiation	CELL-DEATH; PROTOONCOGENE EXPRESSION; CARCINOMA-CELLS; AP-1 ELEMENT; JUN; DIFFERENTIATION; GENE; PHOSPHORYLATION; PROLIFERATION; TRANSLATION	In human skin, most studies have suggested a role of c-fos or c-fos related genes in keratinocyte differentiation. The aim of our work was to more directly address this question by transfecting more or less differentiated keratinocyte cell lines (A431 and HaCaT) with constitutive expression vectors for c-Fos or c-Fos+c-Jun. Our results showed that c-Fos expression decreased keratinocyte growth, yet addition of c-Jun seemed to revert this c-Fos induced growth inhibition. Whereas no obvious differentiation program was turned on by c-Fos or c-Fos+c-Jun expression in our tissular model, apoptotic figures were observed and confirmed by in situ DNA fragmentation studies. These results do not rule out a role of c-Fos in keratinocyte differentiation but may indicate that the cell lines we used have reached an irreversible state of transformation so that they no longer respond to differentiation signals and rather die from apoptosis. These data add further evidence in favor of a role of c-Fos in epidermal homeostasis.	IURC,LAB DERMATOL MOL,F-34093 MONTPELLIER 5,FRANCE; INST MOL GENET,UMR5535,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier				BARETTE, Caroline/0000-0003-0999-7751				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1992, ONCOGENE, V7, P2271; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEN SL, 1994, CANCER LETT, V85, P119, DOI 10.1016/0304-3835(94)90247-X; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ESCOT C, 1991, ANAL CELL PATHOL, V3, P215; FISHER C, 1991, DEVELOPMENT, V111, P253; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORCZYCA W, 1993, CANCER RES, V53, P1945; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; KERR JFK, 1991, CURRENT COMMUNICATIO; MARTI A, 1994, ONCOGENE, V9, P1213; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Polakowska R R, 1994, Cell Death Differ, V1, P19; Preston GA, 1996, MOL CELL BIOL, V16, P211; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	40	34	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1555	1561		10.1038/sj.onc.1200991	http://dx.doi.org/10.1038/sj.onc.1200991			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129146				2022-12-28	WOS:A1997WQ54800006
J	Zhang, R; Zhang, H; Zhu, WM; Pardee, AB; Coffey, RJ; Liang, P				Zhang, R; Zhang, H; Zhu, WM; Pardee, AB; Coffey, RJ; Liang, P			Mob-1, a Ras target gene, is overexpressed in colorectal cancer	ONCOGENE			English	Article						ras oncogene; chemokines; colorectal cancer; cell transformation	DIFFERENTIAL DISPLAY; MESSENGER-RNA; EXPRESSION; CELLS; INDUCTION; PROTEINS	Mutations in the ras oncogenes have been linked to many different cancers, In contrast to the extensive body of knowledge related to the genetics of ras activation, relatively little is known of the transcriptional events triggered by ras, In previous work we have used differential display to identify Mob-1, a member of alpha-chemokine family, as one of the immediate transcriptional targets following Ras activation, Here, we provide additional experimental evidence to support this finding by the use of an inducible H-ras expression system, the treatment of Ras farnesyl transferase inhibitor and activation of endogenous Ras by serum growth factors, We further demonstrate that IP-10, the human homolog of Mob-1, is overexpressed in the majority of colorectal cancers.	VANDERBILT UNIV,DEPT CELL BIOL,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED & CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,VET AFFAIRS MED CTR,NASHVILLE,TN 37232; DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute					NCI NIH HHS [R01 CA46413, R01 CA61232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413, R01CA061232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; GODWIN AK, 1990, ONCOGENE, V5, P1231; KIARIS H, 1995, INT J ONCOL, V7, P413; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MARTINEZ J, 1991, GENE DEV, V5, P152; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; OLDHAM S, 1996, IN PRESS P NATL ACAD; STOECKLE M Y, 1990, New Biologist, V2, P313; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANGURI P, 1990, J BIOL CHEM, V265, P15049	17	28	28	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1607	1610		10.1038/sj.onc.1200957	http://dx.doi.org/10.1038/sj.onc.1200957			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129152				2022-12-28	WOS:A1997WQ54800012
J	Urich, M; Senften, M; Shaw, PE; BallmerHofer, K				Urich, M; Senften, M; Shaw, PE; BallmerHofer, K			A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation	ONCOGENE			English	Article						polyomavirus; middle-T; cell transformation; serum response element; transcription; fos	ACTIN STRESS FIBERS; MAP KINASE KINASE; C-FOS PROMOTER; TUMOR-ANTIGEN; PROTEIN-KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; PLASMA-MEMBRANE	The oncogenic proteins encoded by papovaviruses, the tumor antigens, have been extensively used as model systems to study mitogenic signaling and cell transformation, These proteins stimulate cell growth in cultured cells and induce tumors in virus infected or transgenic animals, One of these proteins, polyomavirus middle-T, acts like a constitutively activated tyrosine growth factor receptor, Middle-T recruits several cellular enzymes into a multifunctional complex located at cellular membranes, This results in the activation of cellular enzymes involved in the regulation of cell signaling, like tyrosine kinases of the Src family, a phosphatidylinositol 3-kinase and a GDP/GTP exchange factor for Ras, These activities are all required for stimulation of cell growth by middle-T and activate members of the MAP kinase family, Here we investigate the role of T antigen-activated pathways in the stimulation of transcription of immediate early genes, These genes are essential for progression of resting cells into S phase, Our data show that Rho family GTPases play an essential role in cell transformation by middle-T. Furthermore, we demonstrate that the c-fos promoter is activated by two Pas-initiated signaling cascades, One is Raf-dependent and requires binding of SHC and PI 3-kinase to the middle-T complex, This pathway signals via ternary complex factor (TCF) to the serum response element (SRE) of the c-fos promoter, Signaling to TCF by Raf also depends on functional Pac, but not CDC42, as demonstrated in luciferase reporter assays with an ETS domain-containing promoter, The second pathway is Raf-independent, does not require SHC but functional PI 3-kinase, and transduces signals via Pac to serum response factor (SRF), Microinjection of dominant negative Rad blocks nuclear translocation of ERK1 in middle-T-expressing cells, This lends support to the idea that the two signaling cascades initiated by Pas show crosstalk at the level of MAP kinase-mediated signaling to nuclear transcription factors.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT BIOCHEM,NOTTINGHAM NG7 2UH,ENGLAND	Friedrich Miescher Institute for Biomedical Research; University of Nottingham				Ballmer-Hofer, Kurt/0000-0002-3800-9129; SHAW, Peter/0000-0002-2598-4283				Besser D, 1995, ONCOGENE, V11, P2383; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JELINEK MA, 1992, ONCOGENE, V7, P1687; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Tooze J, 1980, DNA TUMOR VIRUSES; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	54	32	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1235	1241		10.1038/sj.onc.1200982	http://dx.doi.org/10.1038/sj.onc.1200982			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121774				2022-12-28	WOS:A1997WM78200014
J	James, LA; Mitchell, ELD; Menasce, L; Varley, JM				James, LA; Mitchell, ELD; Menasce, L; Varley, JM			Comparative genomic hybridisation of ductal carcinoma in situ of the breast: Identification of regions of DNA amplification and deletion in common with invasive breast carcinoma	ONCOGENE			English	Article						CGH; DCIS; breast cancer	MOLECULAR CYTOGENETIC ANALYSIS; TERM FOLLOW-UP; IN-SITU; SOLID TUMORS; COPY NUMBER; HYBRIDIZATION; CANCER; HETEROZYGOSITY	Comparative genomic hybridisation has been used to map copy number changes in nine cases of ductal carcinoma in situ of the breast obtained from wax-embedded archive material. A wide variety of abnormalities were detected including gain of regions of 1q, 17q, 19q, 20p and 20q and loss on 13q, 14q, 17p, 16q and 22q. Amplification of areas on 10p, 8q and 20q were also observed, Chromosomal alterations were more frequent in higher grade DCIS and closely resemble those previously detected in invasive breast cancer using the same technique. These data provide strong molecular support for the view that DCIS is a precursor lesion of invasive breast carcinoma.	CHRISTIE HOSP NHS TRUST,DEPT PATHOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital	James, LA (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; COX DW, 1995, CYTOGENET CELL GENET, V69, P160; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frykberg E R, 1993, Adv Surg, V26, P29; ISOLA J, 1994, AM J PATHOL, V145, P1301; James L, 1996, CHROMOSOME RES, V4, P163, DOI 10.1007/BF02259711; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; LUI E, 1992, ONCOGENE, V7, P1027; MITCHELL ELD, 1995, CYTOGENET CELL GENET, V70, P183, DOI 10.1159/000134028; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Munn KE, 1996, BRIT J CANCER, V74, P1578, DOI 10.1038/bjc.1996.592; MUNN KE, 1995, ONCOGENE, V10, P1653; Munn KE, 1996, BRIT J CANCER, V73, P636, DOI 10.1038/bjc.1996.110; *NHS BREAST SCREEN, 1995, NHSBSP PUBL, V3; NIELSEN KV, 1989, ACTA ONCOL, V28, P919, DOI 10.3109/02841868909092332; OMALLEY FP, 1994, LAB INVEST, V71, P67; PAGE DL, 1982, CANCER, V49, P715; RADFORD DM, 1993, CANCER RES, V53, P2947; RIED T, 1995, CANCER RES, V55, P5415; ROSNER D, 1980, ANN SURG, V192, P193; SPEICHER MR, 1995, AM J PATHOL, V146, P1332; SPEICHER MR, 1993, HUM MOL GENET, V2, P1907; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; TANNER MM, 1994, CANCER RES, V54, P4257; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; TEYSSIER JR, 1989, CANCER GENET CYTOGEN, V37, P103, DOI 10.1016/0165-4608(89)90080-0; WILTSHIRE RN, 1995, CANCER RES, V55, P3954	33	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1059	1065		10.1038/sj.onc.1200923	http://dx.doi.org/10.1038/sj.onc.1200923			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070654				2022-12-28	WOS:A1997WM07000007
J	Kenck, C; Bugert, P; Wilhelm, M; Kovacs, G				Kenck, C; Bugert, P; Wilhelm, M; Kovacs, G			Duplication of an approximately 1.5 Mb DNA segment at chromosome 5q22 indicates the locus of a new tumour gene in nonpapillary renal cell carcinomas	ONCOGENE			English	Article						kidney cancer; chromosome 5q22; duplication	LUNG-CANCER; ALLELE LOSS; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR-GENE; LINDAU DISEASE; HETEROZYGOSITY; MUTATIONS; MCC; APC; IDENTIFICATION	Previous karyotyping showed an unbalanced translocation between chromosome 3p11.2-p13 and chromosome 5q22 leading to duplication of chromosome 5q22-qter region in nonpapillary renal cell carcinomas. In order to determine the breakpoint at chromosome 5q22 at the molecular level, we have investigated 50 sporadic nonpapillary renal cell carcinomas from consecutive nephrectomies and 24 renal cell carcinomas obtained from two patients with von Hippel-Lindau disease. We used seven DNA markers mapped to and around the APC and MCC genes to detect allelic imbalance. We observed a duplication of chromosome 5q sequences in 11 of 23 informative sporadic tumours and in 18 of 24 hereditary tumours. We determined a breakpoint cluster between the APC and MCC genes at chromosome 5q22. In addition we have found a partial duplication of the smallest overlapping region of about 1.5 Mb sequences including the MCC gene in seven tumours without visible alteration of chromosome 5q in the karyotype. We suggest that this DNA segment harbours a gene or gene cluster, the altered dosage of which is important for the growth of nonpapillary renal cell carcinomas.	UNIV HEIDELBERG, DEPT UROL, CLIN RES GRP MOL ONCOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								AMLER LC, 1995, ONCOGENE, V10, P1095; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; CORVI R, 1995, CANCER RES, V55, P3471; CROSSEY PA, 1994, HUM GENET, V93, P53; DAMICO D, 1992, CANCER RES, V52, P1996; FONG KM, 1995, CANCER RES, V55, P220; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; FUJIMORI M, 1991, CANCER RES, V51, P89; FUJIWARA Y, 1993, CANCER RES, V53, P857; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HORII A, 1992, CANCER RES, V52, P6696; HOSOE S, 1994, CANCER RES, V54, P1787; Kenck C, 1996, J PATHOL, V179, P157, DOI 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P256, DOI 10.1002/gcc.2870030404; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; Moch H, 1996, CANCER RES, V56, P27; MORITA R, 1991, CANCER RES, V51, P5817; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PRESTI JC, 1991, CANCER RES, V51, P1544; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TIAINEN M, 1992, GENE CHROMOSOME CANC, V4, P176, DOI 10.1002/gcc.2870040212; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	27	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	1997	14	9					1093	1098		10.1038/sj.onc.1200915	http://dx.doi.org/10.1038/sj.onc.1200915			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070658				2022-12-28	WOS:A1997WM07000011
J	Xu, YQ; Grundy, P; Polychronakos, C				Xu, YQ; Grundy, P; Polychronakos, C			Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor	ONCOGENE			English	Article						imprinting; Wilms' tumor; insulin-like growth factor II; receptor; gene dosage	MATERNAL-SPECIFIC METHYLATION; IGF2R LOCUS; EXPRESSION; MOUSE; HETEROZYGOSITY; RELAXATION; CANCER; SIGNAL; WT1	Wilms' tumor (WT) is an embryonal renal malignancy, which overexpresses insulin-like growth factor II (IGF-II a fetal mitogen. Relaxation of parental imprinting of IGF2, the gene encoding IGF-II, is found in Wilms' tumors, suggesting an important role for IGF2 dosage in tumorigenesis. The IGF2R gene encodes a nonmitogenic receptor which targets IGF-II to the lysosomes for degradation and, therefore, inhibits the mitogenic function of IGF-II. The human IGF2R is imprinted in a proportion of normal individuals. To test the hypothesis that IGF2R imprinting predisposes to Wilms' tumor through the effect of decreased IGF2R dosage on IGF-II inactivation, we examined IGF2R imprinting in Wilms' tumors. Two transcribed CA repeat polymorphisms were used to distinguish the two alleles in the RT-PCR product. We observed that in 7/16 of Wilms' tumor patients, the paternal IGF2R was markedly but not completely repressed in both tumor and normal kidney. In one additional case, IGF2R was likewise imprinted in the tumor but not in the normal kidney. A similar imprinting was observed in fetal tissues and placenta prior to 20 weeks fetal age but not in term placenta or postnatal blood cells, indicating abnormal persistence of a fetal pattern in the kidneys of Wilms' patients, Genetic analysis showed association of the imprinting with a cis-acting locus. The high frequency of aberrant persistence of IGF2R imprinting in the kidneys of Wilms' tumor patients, which may be an embryonic feature, suggests that it is a predisposing factor in tumorigenesis. This is in accordance with evidence that IGF2R is a tumour suppressor in other types of malignancies.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT PEDIAT,DIV ENDOCRINOL,MONTREAL,PQ H3H 1P3,CANADA; CROSS CANC INST,EDMONTON,AB T6G 1Z2,CANADA	McGill University; University of Alberta			Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635				ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARLOW DP, 1991, NATURE, V349, P8487; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Ellis MJC, 1996, MOL ENDOCRINOL, V10, P286, DOI 10.1210/me.10.3.286; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOTO J, 1992, NUCLEIC ACIDS RES, V20, P923, DOI 10.1093/nar/20.4.923; HAIG D, 1991, CELL, V64, P1045; Hankins GR, 1996, ONCOGENE, V12, P2003; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KIESS W, 1987, J BIOL CHEM, V262, P12745; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OKA Y, 1985, J BIOL CHEM, V260, P9435; POLYCHRONAKOS C, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P369; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIS A, 1994, AM J HUM GENET, V54, P741; Riesewijk AM, 1996, GENOMICS, V31, P158, DOI 10.1006/geno.1996.0027; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542	34	59	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1041	1046		10.1038/sj.onc.1200926	http://dx.doi.org/10.1038/sj.onc.1200926			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070652				2022-12-28	WOS:A1997WM07000005
J	Stiegler, P; Schuchner, S; Lestou, V; Wintersberger, E				Stiegler, P; Schuchner, S; Lestou, V; Wintersberger, E			Polyomavirus large T antigen-dependent DNA amplification	ONCOGENE			English	Article						DNA amplification; tumor viruses; cell cycle; checkpoint; tumorsuppressors	CELL-CYCLE CONTROL; SV40-TRANSFORMED HUMAN-CELLS; CHINESE-HAMSTER CELLS; WILD-TYPE P53; GENE AMPLIFICATION; GROWTH ARREST; RETINOBLASTOMA PROTEIN; GENOMIC INSTABILITY; HUMAN FIBROBLASTS; ADENOVIRUS E1A	DNA amplification is a readily measurable indicator for genome destabilization. Contrary to normal senescing cells, those of most immortal or transformed cell lines are karyotypically unstable and permissive for amplification. Permissivity for amplification can be generated by gene products of several DNA tumor viruses whereby their interaction with the tumorsuppressor protein p53 is important. p53 is the major protein involved in check point control of DNA damage. Polyomavirus large T antigen is also involved in immortalization and transformation of cells but it does not interact with p53. We, therefore, examined whether this protein could still make the non-permissive cell line REF52 permissive for gene amplification. To this end REF52 cell lines were constructed which conditionally expressed the wild type polyomavirus large T antigen or a mutant form unable to bind the retinoblastoma protein. Using the inhibitor of de novo pyrimidine biosynthesis, phosphonoacetyl-L-aspartate (PALA), as selective agent we found that PALA resistant cells arise with a frequency of about 5x10(-5) and that the interaction of polyomavirus large T protein with the retinoblastoma protein or another related pocket protein is important for this to occur. PALA resistant cells have an increased number of chromosomes and dicentric chromosomes which are considered as starting point for DNA structures characteristic for amplified DNA. Such structures were indeed found with the help of fluorescence in situ hybridization. PALA resistant cells appear normal with respect to p53. Our data indicate that PALA induces a G(1) block which can be partially overcome by polyomavirus large T protein by its interaction with E2F-pocket protein complexes providing further evidence that these complexes are downstream targets of p53.	UNIV VIENNA, VIENNA BIOCTR, INST MOL BIOL, VIENNA, AUSTRIA; ST ANNA CHILDRENS HOSP, A-1090 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Saint Anna Children's Hospital								ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; GANNON JV, 1991, NATURE, V349, P802; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HICKMAN ES, 1994, ONCOGENE, V9, P2177; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; OTTO E, 1989, J BIOL CHEM, V264, P3390; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; SZEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320; Thomas RC, 1996, EXP CELL RES, V223, P227, DOI 10.1006/excr.1996.0076; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINTERSBERGER E, 1994, CHROMOSOMA, V103, P73, DOI 10.1007/BF00352315; WOODS C, 1994, ONCOGENE, V9, P2943; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZERFASS K, 1995, J GEN VIROL, V76, P1815, DOI 10.1099/0022-1317-76-7-1815; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	59	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					987	995		10.1038/sj.onc.1200904	http://dx.doi.org/10.1038/sj.onc.1200904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050998				2022-12-28	WOS:A1997WK34400012
J	Fujitani, Y; Hibi, M; Fukada, T; TakahashiTezuka, M; Yoshida, H; Yamaguchi, T; Sugiyama, K; Yamanaka, Y; Nakajima, K; Hirano, T				Fujitani, Y; Hibi, M; Fukada, T; TakahashiTezuka, M; Yoshida, H; Yamaguchi, T; Sugiyama, K; Yamanaka, Y; Nakajima, K; Hirano, T			An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT	ONCOGENE			English	Article						JAK; STAT; yeast two-hybrid system; JH2 domain	PROTEIN-TYROSINE KINASES; CILIARY NEUROTROPHIC FACTOR; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; RESPONSE ELEMENTS; GROWTH-FACTOR	JAK is believed to be an essential tyrosine kinase that mediates signals from the cytokine receptor to its downstream events. JAK associates with the cytoplasmic domain of the type I cytokine receptor superfamily and upon the ligand stimulation it can be activated, resulting in the receptor phosphorylation. In signaling from gp130, a common signal transducer for the IL-6 family cytokines, STAT3, a transcription factor that contains an SH2 domain, is recruited by phosphotyrosines on gp130 and is subsequently phosphorylated by gp130-associated JAKs. In this study, we attempted to find a new target for JAK that is directly activated by JAK, independent of gp130 tyrosine phosphorylation, by using a yeast two-hybrid system. Tn the process we found that the JH2 domain of JAK1, JAK2 or JAK3 could specifically associate with the carboxy-terminal portion of STAT5, but not with STAT3 or STAT1. The interaction was confirmed using both a transient expression system in a cell line and a GST-fusion protein binding assay. Furthermore, we showed that the activation of STAT5 via gp130 did not need any phosphotyrosines on gp130 while that of STAT3 strictly depended on phosphotyrosines on gp130. Mutations of STAT5 that eliminated the interaction with JAK1 reduced the activation of STAT5 upon the gp130 stimulation, although such mutants could be still activated through erythropoietin receptor. These results indicate that STAT5 are activated through cytokine receptors by two distinct mechanisms, one dependent on receptor tyrosine phosphorylation and the other mediated by the JAK-STAT direct interaction.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MOL ONCOL,SUITA,OSAKA 565,JAPAN; NIPPON BOEHRINGER INGELHEIM CO LTD,KAWANISHI,HYOGO 66601,JAPAN	Osaka University; Boehringer Ingelheim			Hirano, Toshio/C-8194-2009; Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444; Yamanaka, Yojiro/0000-0003-1483-8691				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; FREDERIC WQ, 1996, MOL CELL BIOL, V16, P1622; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; FUKADA T, 1996, IN PRESS IMMUNITY; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER JW, 1993, CELL, V75, P805; HARPUR AG, 1992, ONCOGENE, V7, P1347; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1994, CYTOKINE HDB, P145; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1996, CELL, V84, P311; IKEDA EI, 1993, P NATL AACAD SCI US, V90, P123; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; MACKIEWICZ A, 1995, ANN NY ACAD SCI, V762, P1; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMSON AW, 1994, CYTOKINE HDB; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	80	130	137	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					751	761		10.1038/sj.onc.1200907	http://dx.doi.org/10.1038/sj.onc.1200907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047382				2022-12-28	WOS:A1997WJ11200001
J	Arap, W; Knudsen, ES; Wang, JYJ; Cavenee, WK; Huang, HJS				Arap, W; Knudsen, ES; Wang, JYJ; Cavenee, WK; Huang, HJS			Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma	ONCOGENE			English	Article						tumor suppressor gene; CDKN2A; p16(INK4a); RB; mutation; glioma	CELL-CYCLE INHIBITION; HOMOZYGOUS DELETIONS; CDK4 AMPLIFICATION; HUMAN ASTROCYTOMAS; GENE-MUTATIONS; P16; RETINOBLASTOMA; P16(INK4); PROTEIN; LINES	Deletions of chromosomal region 9p21 are among the most common genetic alterations observed during the clonal evolution of high grade malignant gliomas. Structural and functional evidence has suggested that homozygous deletion involving CDKN2A (the genetic locus encoding the cyclin-dependent kinase inhibitor p16(INK4a)) is mechanism of inactivation of this gene and that it can be a growth suppressor in human gliomas. However, the presence of other potential suppressor genes in the 9p21 region and the relatively large sizes of the deletions has made it difficult to be certain that the CDKN2A gene is their actual target. Here, we tested this hypothesis by determining the growth suppressive effects, cell cycle inhibitions, and the activities of seven naturally occurring glioma-derived CDKN2A alleles carrying point mutations and found that two of them were functionally compromised. To resolve discrepancies among the different existing functional assays, we developed an assay for p16(INK4a) function that allowed us to demonstrate that the expression of wild-type CDKN2A, but not alleles with inactivating mutations, prevents pRB phosphorylation in vivo in human glioma cells. These data suggest that CDKN2A is a critical target for mutational inactivation in human malignant gliomas.	UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; STANFORD UNIV,CAN BIOL PROGRAM,STANFORD,CA 94305	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Costello JF, 1996, CANCER RES, V56, P2405; DURO D, 1995, ONCOGENE, V11, P21; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GIANI C, 1994, CANCER RES, V54, P6338; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GURNARI GB, 1995, CANCER SURV, V25, P233; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JAMES CD, 1993, CANCER RES, V53, P3674; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kyritsis A. P., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P582; Kyritsis AP, 1996, ONCOGENE, V12, P63; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOULTON T, 1995, AM J PATHOL, V146, P613; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLOPADE OI, 1992, CANCER RES, V52, P2523; Parry D, 1996, MOL CELL BIOL, V16, P3844; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STONE S, 1995, CANCER RES, V55, P2988; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DG, 1995, CANCER RES, V55, P20; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YANG R, 1995, CANCER RES, V55, P2503	45	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					603	609		10.1038/sj.onc.1200870	http://dx.doi.org/10.1038/sj.onc.1200870			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053859				2022-12-28	WOS:A1997WF52400012
J	deRooij, J; Bos, JL				deRooij, J; Bos, JL			Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras	ONCOGENE			English	Article						Ras; small GTPases; activation-specific probes	KINASE; IDENTIFICATION; STIMULATION; ONCOGENES; P21(RAS); COMPLEX; P21RAS; CELLS	Ras is a small GTPase that cycles between an inactive GDP-bound and an active GTP-bound form. A large variety of ligands that stimulate cell surface receptors induce the activation of Ras. Thus far, this activation could only be measured by the increase of GTP bound to Ras, which was precipitated from radio-labelled cell extract. We have used the minimal Ras-binding domain (RED) of Ran (aa 51-131) to identify in vivo activated Ras. This novel method is based on the observation that RED binds RasGTP in vitro with a Kd of 20 nM whereas the affinity between RED and RasGDP is three orders of magnitude lower. Here we show that the Gst-RBD fusion protein precipitates transfected RasL61 (RasGTP) but not RasN17 (RasGDP) from cell lysates. In addition, we demonstrate for two different cell lines that the increase in RasGTP is reflected by an increase in Ras bound to Gst-RBD. From these results we conclude that the minimal Ras-binding domain of Raf1 is an excellent activation specific-probe for Ras.	UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3584 CG UTRECHT,NETHERLANDS	Utrecht University			de rooij, johan/C-1325-2019					BOS JL, 1989, CANCER RES, V49, P4682; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FRANKE B, 1997, IN PRESS EMBO J; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOODIE SA, 1993, SCIENCE, V260; PONTING CP, 1996, TRENDS BIOCHEM SCI, V21, P423; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; VANWEERING DHJ, 1997, IN RPESS J BIOL CHEM; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wolthuis RMF, 1996, ONCOGENE, V13, P353; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	22	405	408	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					623	625		10.1038/sj.onc.1201005	http://dx.doi.org/10.1038/sj.onc.1201005			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053862				2022-12-28	WOS:A1997WF52400015
J	Sun, Y; Bian, JH; Wang, YL; Jacobs, C				Sun, Y; Bian, JH; Wang, YL; Jacobs, C			Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound	ONCOGENE			English	Article						phenanthroline; p53; transcriptional activation; apoptosis; redox regulation	WILD-TYPE P53; CELL-CYCLE CHECKPOINT; DNA-BINDING; ANTICANCER AGENTS; APOPTOSIS; SEQUENCE; CONFORMATION; INDUCTION; PROTEIN; GENE	p53, a tumor suppressor gene, functioning as transcription factor, has been recently shown in a cell free system to be subject to redox (reduction/oxidation) regulation. Oxidants or metal chelating reagents disrupt wildtype p53 conformation and decrease or abolish its DNA binding activity, while reductants restore wildtype conformation and increase DNA binding. We have extended these observations to intact cell systems by using luciferase transactivation assay in two murine tumor cell lines, both harboring endogenous wildtype p53. The results showed that none of these in vitro active reagents, except 1,10-phenanthroline (OF) has a significant effect on p53 transactivation activity. OF, a metal chelator and p53 inactivator in cell free systems, however, induces p53 transactivation activity as well as sequence-specific DNA binding in a dose dependent manner. OP also differentially induces endogenous expression of several known p53 target genes such as Waf-1 and Mdm-2, but not Bar, Gadd45, and PCNA. Increased p53 activity induced by OP is not due to elevated p53 mRNA nor to protein levels. Furthermore, the OP-induced p53 transcriptional activation is not due to its potential DNA intercalating activity, but mainly due to its metal chelating activity. OF was also found to induce dramatically apoptotic cell death in these tumor cells harboring wildtype p53, to a less extent in MEF cells from p53 knockout mice and not at all in Saos-2 cells without p53 or Rb. We concluded from this study that (a) unlike what has been seen in vitro, OP induces p53 activity in intact cells (b) OP activates p53 transcriptional activity without increasing p53 protein; and (c) activation of p53 may contribute to apoptosis, but is not required.			Sun, Y (corresponding author), WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT MOL BIOL, 2800 PLYMOUTH RD, ANN ARBOR, MI 48105 USA.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ADEBODUN F, 1995, J CELL PHYSIOL, V163, P80, DOI 10.1002/jcp.1041630109; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRY DW, 1985, BIOCHEM PHARMACOL, V34, P3499, DOI 10.1016/0006-2952(85)90724-5; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUGHES FM, 1994, J STEROID BIOCHEM, V49, P303, DOI 10.1016/0960-0760(94)90272-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; SEBOLT JS, 1987, CANCER RES, V47, P4299; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SRINIVASAN R, 1993, CANCER RES, V53, P5361; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; SUN Y, 1995, INT J ONCOL, V6, P465; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; WHITACRE CM, 1995, CANCER RES, V55, P3697; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YI S, 1993, INT J CANCER, V55, P952, DOI 10.1002/ijc.2910550613; ZALEWSKI PD, 1991, BIOCHEM INT, V24, P1093; ZHAN QM, 1994, ONCOGENE, V9, P3743	55	75	79	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					385	393		10.1038/sj.onc.1200834	http://dx.doi.org/10.1038/sj.onc.1200834			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053835				2022-12-28	WOS:A1997WE36400001
J	Banga, SS; Kim, S; Hubbard, K; Dasgupta, T; Jha, KK; Patsalis, P; Hauptschein, R; Gamberi, B; DallaFavera, R; Kraemer, P; Ozer, HL				Banga, SS; Kim, S; Hubbard, K; Dasgupta, T; Jha, KK; Patsalis, P; Hauptschein, R; Gamberi, B; DallaFavera, R; Kraemer, P; Ozer, HL			SEN6, a locus for SV40-mediated immortalization of human cells, maps to 6q26-27	ONCOGENE			English	Article						immortalization; growth suppressor; SV40, SEN6; senescence	DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN-DIPLOID FIBROBLASTS; NON-HODGKINS-LYMPHOMA; LARGE T-ANTIGEN; INDEFINITE DIVISION; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; DISTINCT REGIONS; GENETIC-ANALYSIS; SIMIAN VIRUS-40	Normal cells show a Limited lifespan in culture and the phenotype of cellular senescence, Tumors and tumor cell lines have typically overcome this form of growth suppression and grow continuously as immortal cell lines in culture, We have exploited the DNA virus SV40 to study the mechanism by which human fibroblasts overcome senescence and become immortal, Multiple steps have now been identified, including inactivation of cellular growth suppressors through direct interaction with SV40 large T antigen and through mutation of a gene on chromosome 6 (designated SEN6), In this study, we sublocalize the site of SEN6 to 6q26-27 based on molecular genetic analysis, Twelve SV40-immortalized fibroblast cell lines share a deletion in this area based on assessment for loss of heterozygostiy (LOH) for seven informative markers on 6q, Two immortal cell lines (AR5 and HALneo) appeared to have retained separate single copies of chromosome 6 despite the fact that they are both derived from the same preimmortal SV40-transformant and should share the same mutated allele of SEN6 (Hubbard-Smith et al., 1992), Detailed analysis by polymerase chain reaction, restriction fragment length polymorphism and fluorescence in situ hybridization shows, however, that although they differ for 17 markers from the centromere to 6q26, they share AR5 derived sequences (eight markers) distal to 6q26 including the minimal deletion region, further supporting the assignment of SEN6 to this region, Since human tumors including non-Hodgkins lymphoma, mammary carcinoma and ovarian carcinoma show LOH in 6q26-27, inactivation of SEN6 may be responsible for immortalization of these tumors as well.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; CYPRUS INST NEUROL & GENET,DEPT CYTOGENET,NICOSIA,CYPRUS; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; LOS ALAMOS NATL LAB,CELLULAR & MOL BIOL GRP,LOS ALAMOS,NM	Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; United States Department of Energy (DOE); Los Alamos National Laboratory			Kim, Soo Hyun/ABG-8773-2020; Gamberi, Barbara/AAA-7508-2019	Kim, Soo Hyun/0000-0002-9394-1437; Gamberi, Barbara/0000-0003-3616-5838	NIA NIH HHS [AG04821, AG00378] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004821, P01AG000378] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banga SS, 1996, CYTOGENET CELL GENET, V73, P295, DOI 10.1159/000134359; BANGA SS, 1996, AM J HUM GENET; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BRAVARD A, 1992, INT J CANCER, V52, P797, DOI 10.1002/ijc.2910520521; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CASSON AG, 1991, CANCER RES, V51, P4495; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Del Senno L., 1992, Human Molecular Genetics, V1, P354; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FUJII M, 1995, ONCOGENE, V11, P627; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HOFFSCHIR F, 1992, INT J CANCER, V52, P130, DOI 10.1002/ijc.2910520123; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAI S, 1994, MOL CELL BIOL, V14, P7182, DOI 10.1128/MCB.14.11.7182; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MITELMAN F, 1991, CATALOG CHROMOSOME A, V1, P393; NEGRINI M, 1994, CANCER RES, V54, P1331; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OFFIT K, 1993, BLOOD, V82, P2157; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; Patsalis PC, 1995, CLIN GENET, V48, P275; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PURRELLO M, 1994, GENOMICS, V22, P94, DOI 10.1006/geno.1994.1349; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; RAY FA, 1992, CANCER GENET CYTOGEN, V59, P39, DOI 10.1016/0165-4608(92)90155-2; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROSEN DR, 1995, CYTOGENET CELL GENET, V69, P279, DOI 10.1159/000133979; SAGAWARA O, 1990, SCIENCE, V247, P707; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Small MB, 1996, J CELL PHYSIOL, V168, P727, DOI 10.1002/(SICI)1097-4652(199609)168:3<727::AID-JCP26>3.0.CO;2-U; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; TEYSSIER JR, 1992, ANTICANCER RES, V12, P997; TRASK BJ, 1992, METHOD CELL BIOL, V35, P3; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WAN MH, 1994, INT J ONCOL, V5, P1043; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; Wiesmuller L, 1996, J VIROL, V70, P737; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	68	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					313	321		10.1038/sj.onc.1200842	http://dx.doi.org/10.1038/sj.onc.1200842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018117				2022-12-28	WOS:A1997WD51600007
J	Salvucci, M; Lemoine, A; Azoulay, D; Sebagh, M; Bismuth, H; Reynes, M; May, E; Debuire, B				Salvucci, M; Lemoine, A; Azoulay, D; Sebagh, M; Bismuth, H; Reynes, M; May, E; Debuire, B			Frequent microsatellite instability in post hepatitis B viral cirrhosis	ONCOGENE			English	Article						microsatellite; liver; cirrhosis; HBV; PCR	LIVER-TRANSPLANTATION; GENETIC INSTABILITY; CANCER; POLYMORPHISMS; NEOPLASMS; CARCINOMA; VIRUS	The molecular basis of cirrhosis, the most frequent underlying liver disease in hepatocellular carcinoma, remains unclear, We investigated microsatellite instability at six different loci on chromosomes 2p, 3p, 5q, 9p, 13q and 17p, in DNA from 38 cirrhotic livers of viral (n = 28) and nonviral (n = 10) origin. Sixty percent of the patients exhibited microsatellite alterations in at least one chromosome locus, A striking feature was the close association between genomic instability and cirrhosis linked to hepatitis B viral infection (P<0.01), This high instability may be a clue to the etiology of cancer induced by the hepatitis B virus.	HOP PAUL BROUSSE,SERV BIOCHIM,F-94804 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,CTR HEPATOBILIAIRE,F-94804 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,SERV ANAT PATHOL,F-94804 VILLEJUIF,FRANCE; FAC MED PARIS SUD,FONTENAY ROSES,FRANCE; CEA,UMR 217 CNRS,FONTENAY ROSES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; CEA			SEBAGH, Mylène/T-7464-2018; Azoulay, Daniel/Q-7887-2018					BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; CHONG JM, 1994, CANCER RES, V54, P4595; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; HAN HJ, 1993, CANCER RES, V53, P5087; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; MARTINSSON T, 1995, CANCER RES, V55, P5681; MERLO A, 1994, CANCER RES, V54, P2098; RISINGER JI, 1995, CANCER RES, V55, P5664; SAMUEL D, 1995, HEPATOLOGY, V21, P333, DOI 10.1016/0270-9139(95)90089-6; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; TAMURA G, 1995, CANCER RES, V55, P1933; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; UCHIDA T, 1995, ONCOGENE, V10, P1019; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YEE CJ, 1994, CANCER RES, V54, P1641	19	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2681	2685						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000142				2022-12-28	WOS:A1996VZ65400018
J	Ma, GZ; Lu, D; Wu, Y; Liu, JX; Arlinghaus, RB				Ma, GZ; Lu, D; Wu, Y; Liu, JX; Arlinghaus, RB			Bcr phosphorylated on tyrosine 177 binds Grb2	ONCOGENE			English	Article						Bcr; Bcr-Abl; tyrosine phosphorylation; Grb2; Ras pathway; Philadelphia chromosome	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; GENE ENCODES; ABL PROTEIN; CELL LINE; P160 BCR; K562; ASSOCIATION	We and others have shown that the Bcr-Abl oncoprotein binds activators of the Ras pathway such as Grb2 and She, Grb2 binding is mediated through a phosphorylated tyrosine residue (Y177) located within a consensus Grb2 binding site encoded by the first exon of the BCR gene, Our results indicate that P160 BCR is tyrosine phosphorylated at the same site by Bcr-Abl in kinase assays (Pull ef al., 1994), We performed experiments to determine whether Bcr, which was tyrosine phosphorylated within cells by activated c-Abl, could also bind Grb2, and whether phosphotyrosine 177 was the major binding site. Complexes between Bcr and Abl were detected in a hemopoietic cell line lacking Bcr-Abl and in COS1 cells coexpressing both Bcr and Abl proteins, P160 BCR was tyrosine phosphorylated in COS1 cells coexpressing Abl and Bcr proteins, Similarly, various deletion mutants of Bcr including BCRN553, BCRN413 and BCRN221 were tyrosine phosphorylated by activated c-Abl whereas BCRN159 was not, Wild-type Bcr and Bcr Y177F were examined under these conditions for their ability to co-precipitate with Grb2. The results showed that while wild-type tyrosine phosphorylated Bcr efficiently bound Grb2, tyrosine phosphorylated Bcr Y177F had greatly reduced Grb2-binding ability, Studies with GST-SH2 (Grb2) revealed that tyrosine phosphorylated Bcr was able to bind to GST SH2 (Grb2) but tyrosine phosphorylated Bcr Y177F was deficient in binding, These results indicate that the Bcr protein when phosphorylated at tyrosine 177 binds Grb2, thereby implicating Bcr as a potantial activator of the Ras pathway.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA065611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEIKMANN D, 1991, NATURE, V351, P400; DRUKER B, 1992, BLOOD, V79, P2215; GUO JQ, 1994, BLOOD, V83, P3629; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, MOL CELL BIOL, V7, P446; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1995, MOL CELL BIOL, V15, P835; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRIEST JR, 1980, BLOOD, V56, P15; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RON D, 1991, NEW BIOL, V3, P372; Sattler M, 1996, ONCOGENE, V12, P839; SHTIVELMAN E, 1987, BLOOD, V69, P971; SHTIVELMAN E, 1986, CELL, V47, P27; SMITH RG, 1981, J IMMUNOL, V126, P596; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TAUCHI T, 1994, J EXP MED, V179, P165; TENHOEVE J, 1994, MOL CELL BIOL, V9, P1263; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	35	40	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2367	2372		10.1038/sj.onc.1201053	http://dx.doi.org/10.1038/sj.onc.1201053			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178913				2022-12-28	WOS:A1997WY88300014
J	Simpson, S; Woodworth, CD; DiPaolo, JA				Simpson, S; Woodworth, CD; DiPaolo, JA			Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines	ONCOGENE			English	Article						ets and erg; pulsed field gel electrophoresis; papillomavirus HPV-16; cervical carcinoma	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; HUMAN KERATINOCYTES; HUMAN CHROMOSOME-21; NEOPLASTIC TRANSFORMATION; PHYSICAL MAP; TEL GENE; DNA; RAS; TRANSLOCATION	Human Papillomavirus (HPV) type 16 is the most frequently detected HPV in cervical cancer. Although epidemiologic and experimental evidence indicates a prominent role for HPV infection in the development of this disease, other factors are also involved, Altered expression of the sts family transcription factors erg and ets-2 was found associated with the development of cervical carcinoma. Overexpression also occurred in a HPV-16-immortalized cervical cell line, CX16-2, which has HPV integrated at a translocation breakpoint t(19;21) involving 21q22.2-22.3, where these genes have been mapped. Six of 10 cervical carcinoma cell lines overexpressed ets-2 RNA suggesting an association of overexpression with cervical cell neoplasia. A clonally related pair of cervical carcinoma cell lines, C-4I and C-4II, showed differential expression of erg and ets-2. C-4I overexpressed ets-2 RNA compared to normal cervical cells and C-4II, C-4II expressed a 5.3 kb erg transcript not seen in C-4I, ectocervical cells or other cervical carcinoma cell lines examined. Pulsed field gel electrophoresis was used to analyse changes in DNA fragments related to structural changes and to construct a physical map encompassing erg and ets-2. Alterations in erg and ets-2 RNA expression in each of three different cell lines examined were associated,vith translocations. Association between altered expression of erg and ets-2 and altered regional structural suggests that these genes are important targets in cervical carcinogenesis.	NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAYLIN SB, 1991, ABNORMAL PATTERNS DN; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BUIJS A, 1995, ONCOGENE, V10, P1511; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHOMCZYNSKI P, 1992, ONE HOUR DOWNWARD AL; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; Crete N., 1993, European Journal of Human Genetics, V1, P51; DEBRAEKELEER M, 1992, CANCER GENET CYTOGEN, V59, P135, DOI 10.1016/0165-4608(92)90207-O; DENDUNNEN JT, 1991, APPL PULSED FIELD GE, P313; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DIPAOLO JA, 1993, CRIT REV ONCOGENESIS, V4, P337; DOERFLER W, 1992, MALIGNANT TRANSFORMA, P143; DOERFLER W, 1983, DNA METHYLATION GENE, P93; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FREEDMAN RS, 1982, IN VITRO CELL DEV B, V18, P719, DOI 10.1007/BF02796428; GARDINER K, 1988, SOMAT CELL MOLEC GEN, V14, P623, DOI 10.1007/BF01535316; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRAVELL M, 1976, JNCI-J NATL CANCER I, V56, P701, DOI 10.1093/jnci/56.4.701; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HART AH, 1995, ONCOGENE, V10, P1423; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; JEON IS, 1995, ONCOGENE, V10, P1229; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MUNGER K, 1989, J VIROL, V63, P4417; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; OCHMAN H, 1995, MAMM GENOME, V6, P84, DOI 10.1007/BF00303249; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; PATIL N, 1994, HUM MOL GENET, V3, P1811, DOI 10.1093/hmg/3.10.1811; PAULIEN S, 1990, CANCER RES, V50, P7902; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; POPESCU NC, 1990, CANCER RES, V50, P1316; POPESCU NC, 1990, HUM GENET, V84, P383; POPESCU NC, 1995, INT J ONCOL, V7, P279; POPESCU NC, 1990, ONCOGENE RES, V5, P295; POUSTKA A, 1990, Methods (Orlando), V1, P204, DOI 10.1016/S1046-2023(05)80136-7; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RIOU G, 1988, ONCOGENE, V3, P329; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; Sambrook J., 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIRASAWA H, 1987, J GEN VIROL, V68, P583, DOI 10.1099/0022-1317-68-2-583; TANZI RE, 1992, GENOMICS, V14, P498, DOI 10.1016/S0888-7543(05)80251-4; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATKINS PC, 1985, NUCLEIC ACIDS RES, V13, P6075, DOI 10.1093/nar/13.17.6075; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1993, AM J PATHOL, V142, P1544; WOODWORTH CD, 1988, CANCER RES, V48, P4620; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	63	24	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2149	2157		10.1038/sj.onc.1201058	http://dx.doi.org/10.1038/sj.onc.1201058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174050				2022-12-28	WOS:A1997WX93800003
J	Himelstein, BP; Lee, EJ; Sato, H; Seiki, M; Muschel, RJ				Himelstein, BP; Lee, EJ; Sato, H; Seiki, M; Muschel, RJ			Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line	ONCOGENE			English	Article						MMP-9; ras; transcription; purine-pyrimidine repeat	IV COLLAGENASE GENE; 5' FLANKING REGION; MESSENGER-RNA; COLON CANCER; EXPRESSION; LOCALIZATION; PROMOTER; HYBRIDIZATION; INHIBITORS; LYMPHOMAS	The 92 kd type IV collagenase/gelatinase (MMP-9) is important in mediating basement membrane and extracellular matrix degradation in metastasis. Because MMP-9 is made in tumor cells, but not in quiescent normal cells, we wished to identify the transcriptional elements responsible for its synthesis in tumor cells. We chose to characterize transcriptional regulation of the MMP-9 gene in a highly metastatic H-ras and v-myc transformed rat embryo cell line which overexpresses MMP-9. Using transient transfection of reporter gene constructs containing either 5'-deleted or mutated MMP-9 promoter fragments, as well as electrophoretic mobility shift assays, we have demonstrated that multiple transcription factor consensus binding motifs in the promoter, including those for NF kappa B, SP-1, Ets, AP-1, and a retinoblastoma binding element, participate in transcriptional regulation of MMP-9 expression in this cell line. Also, deletion of an alternating purine-pyrimidine tract in the downstream promoter was found to decrease transcriptional activity, suggesting that promoter conformation may be important in MMP-9 regulation. Thus multiple pathways leading to activation of NF kappa B, SP-1, Ets, AP-1, and retinoblastoma binding factors in tumor cells all may contribute to MMP-9 transcription and hence to metastasis.	KANAZAWA UNIV,CANC RES INST,DEPT MOL ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	Kanazawa University; University of Pennsylvania	Himelstein, BP (corresponding author), CHILDRENS HOSP,DIV ONCOL,ABRAMSON 902C,324 S 34TH ST,PHILADELPHIA,PA 19104, USA.		Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015		NCI NIH HHS [CA64805, CA63312, CA46830] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046830, K08CA063312, R01CA064805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CANETESOLER R, 1994, AM J PATHOL, V144, P518; COTTAM DW, 1992, INVEST OPHTH VIS SCI, V33, P1923; DAVIES B, 1993, CANCER RES, V53, P5365; FINI ME, 1994, J BIOL CHEM, V269, P28620; GOLDBERG GI, 1991, REGULATORY MECHANISM, P421; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HERRICK KR, 1993, GENE, V126, P203, DOI 10.1016/0378-1119(93)90368-D; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIMELSTEIN BP, 1995, INVAS METAST, V14, P246; Hua J, 1996, CANCER RES, V56, P5279; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; KARELINA T, 1992, J INVEST DERMATOL, V100, P159; KOSSAKOWSKA AE, 1993, ONCOL RES, V5, P19; KOSSAKOWSKA AE, 1992, ONCOL RES, V4, P233; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; NERLOV C, 1991, ONCOGENE, V6, P1538; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1992, CANCER RES, V52, P1336; RAO JS, 1993, CANCER RES, V53, P2208; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Xia YY, 1996, FEBS LETT, V382, P285, DOI 10.1016/0014-5793(96)00185-8; YU M, 1995, ARCH BIOCHEM BIOPHYS, V316, P407, DOI 10.1006/abbi.1995.1054; ZUCKER S, 1993, CANCER RES, V53, P140	38	98	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1995	1998		10.1038/sj.onc.1201012	http://dx.doi.org/10.1038/sj.onc.1201012			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150367				2022-12-28	WOS:A1997WV80400013
J	Lomax, ME; Barnes, DM; Gilchrist, R; Picksley, SM; Varley, JM; Camplejohn, RS				Lomax, ME; Barnes, DM; Gilchrist, R; Picksley, SM; Varley, JM; Camplejohn, RS			Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family	ONCOGENE			English	Article						p53; Li-Fraumeni syndrome; oligomerisation domain; functional assays	SV40-TRANSFORMED CELLS; CANCER; APOPTOSIS; CARCINOMA; PROTEIN; ANTIGEN; BLOOD	Previous investigations of a Li-Fraumeni like family (Barnes et al., 1992) demonstrated that both the proband and her mother had elevated p53 protein levels in both tumour tissue and normal tissue at sites distant from the tumour, although no mutation was found in the p53 gene, In the present study two recently described functional assays for p53, an apoptotic assay and the functional assay for the separation of alleles in yeast (FASAY), have been employed to study the functional activity of p53 from this patient, The results of the apoptotic assay demonstrated that this patient had a p53 functional defect and the FASAY result suggested that this defect was in fact a germline mutation of the p53 gene, A point mutation of codon 337, which results in an amino acid substitution of a cysteine for an arginine, was demonstrated initially in cDNA and was confirmed by sequencing of genomic DNA, This is an unusual mutation as it is in the oligomerisation domain of p53, in contrast to the majority of p53 mutations which are in the core DNA binding domain, This mutation results in a protein which still retains partial transactivational activity in the FASAY, The mutation of codon 337 is only the second reported case of a germline missense mutation occurring in the oligomerisation domain of p53.	ST THOMAS HOSP,UMDS,RICHARD DIMBLEBY DEPT CANC RES,LONDON SE1 7EH,ENGLAND; GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,CRC,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; PATERSON INST CANC RES,CRC,DEPT CANC GENET,MANCHESTER M20 9BX,LANCS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of Dundee; Paterson Institute for Cancer Research								BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BIRCH JM, 1994, CANCER RES, V54, P1298; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Eeles RA, 1995, CANCER SURV, V25, P101; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HAINAUT P, 1994, ONCOGENE, V9, P299; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182	21	59	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1869	1874		10.1038/sj.onc.1201133	http://dx.doi.org/10.1038/sj.onc.1201133			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150393				2022-12-28	WOS:A1997WW16600013
J	Papadimitrakopoulou, V; Izzo, J; Lippman, SM; Lee, JS; Fan, YH; Clayman, G; Ro, JY; Hittelman, WN; Lotan, R; Hong, WK; Mao, L				Papadimitrakopoulou, V; Izzo, J; Lippman, SM; Lee, JS; Fan, YH; Clayman, G; Ro, JY; Hittelman, WN; Lotan, R; Hong, WK; Mao, L			Frequent inactivation of p16(INK4a) in oral premalignant lesions	ONCOGENE			English	Article						p16(INK4a); head and neck cancer; oral premalignant lesions; immunohistochemistry	CARCINOMA CELL-LINES; PRIMARY TUMORS; CYCLE ARREST; P16 MTS1; EXPRESSION; CANCERS; GENE; MUTATIONS; P16/CDKN2; HEAD	Head and neck carcinogenesis is believed to be a multistep process, whereby genetic events accumulate in the carcinogen-exposed field at risk, resulting in distinct phenotypic premalignant changes that eventually evolve into invasive cancer, Frequent loss of heterozygosity (LOH) at the chromosome 9p21 region and inactivation of p16(INK4a) by different mechanisms have been described in head and neck squamous cell carcinoma (HNSCC), Recently, we reported that loss of 9p21 is also frequent in oral premalignant lesions. To investigate potential inactivation of p16(INK4a) in these premalignant lesions, we analysed 74 biopsies from 36 patients by immunohistochemistry (MC) for expression of the p16 protein. Loss of p16 expression was found in 28 (38%) of the lesion biopsies from 17 patients (47%). LOH at the D9s171, a marker in the 9p21 region, was observed in 19 lesion biopsies from 12 cases and correlated with absence of p16 by IHC in 11 (92%) of the 12 comparable cases and 15 (79%) of 19 lesion biopsies, By direct sequencing of ten lesion biopsies from ten individuals with LOH at D9s171 for p16(INK4a) exon 2, one non-sense mutation at codon 88 (GGA-->TGA) was identified, Our data suggest that inactivation of p16(INK4a) may play an important role in early head and neck cancer development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC HEAD & NECK MED ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL & TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NCI NIH HHS [CA-52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Califano J, 1996, CANCER RES, V56, P2488; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; GERADTS J, 1995, CANCER RES, V55, P6006; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IZZO J, 1996, P AM ASSOC CANC RES, V37, P3687; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KUSHIMOTO Y, 1995, J NATL CANCER I, V87, P1224; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; LUKAS J, 1995, CANCER RES, V55, P4818; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NOBORI T, 1994, NATURE, V368, P735; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARKER SL, 1996, CA CANC J CLIN, V46, P8; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; STONE S, 1995, CANCER RES, V55, P2988; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG SY, 1994, CANCER RES, V54, P5050	30	141	141	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1799	1803		10.1038/sj.onc.1201010	http://dx.doi.org/10.1038/sj.onc.1201010			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150385				2022-12-28	WOS:A1997WW16600005
J	Marechal, V; Elenbaas, B; Taneyhill, L; Piette, J; Mechali, M; Nicolas, JC; Levine, AJ; Moreau, J				Marechal, V; Elenbaas, B; Taneyhill, L; Piette, J; Mechali, M; Nicolas, JC; Levine, AJ; Moreau, J			Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis	ONCOGENE			English	Article						MDM2; p53; ribosomal L5 protein; RING finger	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; RING FINGER; TRANSCRIPTIONAL ACTIVATION; P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOGENE PRODUCT; ONCOPROTEIN MDM2; BINDING DOMAIN	The Mdn2 gene is the best known cellular regulator of p53 tumor suppressor activity. We report here the cloning and characterization of Xdm2, its homolog in Xenopus laevis. Human, mouse and Xenopus MDM2 proteins are more than 65% identical in several regions which are likely to be important for the biological activities of MDM2. Region I is sufficient for binding p53 and inhibiting its G(I) arrest and apoptosis functions. Region II contains most of a central acidic region required for interaction with the L5 ribosomal protein and a putative C4 zinc finger. Region III is nearly identical from Xenopus to human and comprises the RING finger domain. We show that this structural conservation is associated with the conservation of three biochemical activities of MDM2; binding to the p53 and L5 proteins and specifically to RNA. Lastly, Xdm2 expression during early development is mainly restricted from the oocyte stage I/II to the blastula stage and is possibly independent of transcriptional activation by p53. These data as web as the utilization of Xenopus laevis to investigate the roles of MDM2 and p53 during early embryogenesis are discussed.	PRINCETON UNIV, DEPT MOL BIOL, PRINCETON, NJ 08544 USA; INST MOL GENET, UMR 5535, F-34033 MONTPELLIER, FRANCE; INST JACQUES MONOD, DEPT DEV BIOL, F-75251 PARIS, FRANCE	Princeton University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UDICE-French Research Universities; Universite Paris Cite	Marechal, V (corresponding author), HOP ROTHSCHILD, MICROBIOL SERV, F-75571 PARIS, FRANCE.		marechal, vincent/P-7719-2017; Taneyhill, Lisa/K-1815-2013					Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AUGIAS D, 1966, IN PRESS; BAE I, 1995, EXP CELL RES, V217, P541, DOI 10.1006/excr.1995.1120; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1994, ONCOGENE, V9, P2951; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FREEDMAN D, 1996, UNPUB; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOEVER M, 1994, ONCOGENE, V9, P109; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LADANYI M, 1993, CANCER RES, V53, P16; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LENG P, 1995, ONCOGENE, V10, P1275; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOUSSI T, 1987, ONCOGENE, V1, P71; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG Y, 1995, ONCOGENE, V10, P779; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	61	37	38	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1427	1433		10.1038/sj.onc.1200967	http://dx.doi.org/10.1038/sj.onc.1200967			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136986				2022-12-28	WOS:A1997WT58400005
J	Ookawa, K; Tsuchida, S; Adachi, J; Yokota, J				Ookawa, K; Tsuchida, S; Adachi, J; Yokota, J			Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line	ONCOGENE			English	Article						tumor suppressor gene; RB; p53; cell cycle; differentiation; apoptosis	TUMOR-SUPPRESSOR GENES; WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; CYCLE CONTROL; HUMAN BLADDER; HUMAN CANCER; CDK4 AMPLIFICATION; MAMMALIAN-CELLS; CARCINOMA CELLS; LUNG-CARCINOMA	Multiple genetic alterations, including concurrent inactivation of RB and p53, occur frequently in several human cancers. To investigate the biological significance of RB and p53 gene inactivations, a wild-type RB or p53 cDNA expression vector regulated by tetracycline was introduced by stable transfection into an osteosarcoma cell line Saos-2, in which both the RB and p53 genes were inactivated. Induction of introduced RB expression resulted in suppression of cell growth, increased percentage of cells at the G(0)/G(1) phase, and enlargement of the cells. Furthermore, activity of alkaline phosphatase was increased and expression of fibronectin was decreased, suggesting the induction of cell differentiation by RB expression. Induction of p53 expression also resulted in significant suppression of cell growth with slight accumulation of cells at the G(0)/G(1) and G(2)/M phases. The cells mere detached from culture dishes and the dead cell fraction increased. Furthermore, condensation of chromatin and DIVA fragmentation were observed, suggesting the induction of apoptosis by p53. These results suggest that RB and p53 play different roles in carcinogenesis of osteoblast; RB inactivation releases cells from G(0)/G(1) arrest and suppresses cell differentiation while p53 inactivation assists the cells to proliferate by repressing both apoptosis and cell cycle arrest at G(0)/G(1) and G(2)/M.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; HIROSAKI UNIV,SCH MED,DEPT BIOCHEM 2,HIROSAKI,AOMORI 036,JAPAN	National Cancer Center - Japan; Hirosaki University			Tsuchida, Shigeki/L-3382-2013	Tsuchida, Shigeki/0000-0002-4404-5599				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNG YKT, 1993, ONCOGENE, V8, P2659; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIETTING T, 1995, BIOL CHEM HOPPESEYLE, V376, P441; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ISHIKAWA J, 1991, CANCER RES, V51, P5736; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OOKAWA K, 1993, ONCOGENE, V8, P2175; PRESTI JC, 1991, CANCER RES, V51, P5405; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RUGGERI B, 1992, ONCOGENE, V7, P1503; Sambrook J., 2002, MOL CLONING LAB MANU; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STEWART N, 1995, ONCOGENE, V10, P109; STRATTON MR, 1990, ONCOGENE, V5, P1297; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU HJ, 1991, CANCER RES, V51, P2735; YAMATO K, 1995, ONCOGENE, V11, P1; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	67	35	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1389	1396		10.1038/sj.onc.1200976	http://dx.doi.org/10.1038/sj.onc.1200976			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136982				2022-12-28	WOS:A1997WT58400001
J	Ide, H; Katoh, M; Sasaki, H; Yoshida, T; Aoki, K; Nawa, Y; Osada, Y; Sugimura, T; Terada, M				Ide, H; Katoh, M; Sasaki, H; Yoshida, T; Aoki, K; Nawa, Y; Osada, Y; Sugimura, T; Terada, M			Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs	ONCOGENE			English	Article						bone morphogenetic protein receptor; prostate cancer; human BMPR-IB	GROWTH-FACTOR-BETA; II RECEPTOR; MESSENGER-RNAS; IDENTIFICATION; ACTIVIN; FAMILY; CELLS	Bone metastasis is a common event in prostate cancer, and it is known that some of the bone morphogenetic proteins (BMPs) are expressed in prostate cancer cells, while no study on the expression of their receptors, BMPRs, has been reported, Here we report cloning and sequence analysis of the human BMPR-IB cDNA. We also analysed the expression of transcripts of three types of the BMPR genes in human tissues and prostate cancer cell lines, The BMPR-IB mRNA was present in various organs, but the highest level was found in the prostate. Moreover, the amount of BMPR-IB mRNA was significantly low in prostate cancer tissues after androgen withdrawal and was also low in prostate cancer cell lines. RT-PCR analysis showed that the BMPR-IB message was upregulated by androgen stimulation in the LNCaP cell line which expresses the androgen receptor, By contrast, the mRNA levels of BMPR-IA and BMPR-II were not significantly different among non-cancerous and cancerous prostate tissues. It was also suggested that human BMPR-IA and BMPR-IB might have different biological functions in the prostate, although their sequences were 85.3% identical in the serine-threonine kinase domain.	NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TOKYO 104,JAPAN; MIYAZAKI MED COLL,DEPT PARASITOL,MIYAZAKI 88916,JAPAN; MIYAZAKI MED COLL,DEPT UROL,MIYAZAKI 88916,JAPAN	National Cancer Center - Japan; University of Miyazaki; University of Miyazaki			Nawa, Yukifumi/I-1147-2019	Nawa, Yukifumi/0000-0002-0206-5196				BENTLEY H, 1992, BRIT J CANCER, V66, P1159, DOI 10.1038/bjc.1992.427; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Dawson N A, 1993, Oncology (Williston Park), V7, P17; Dawson NA, 1993, ONCOLOGY, V7, P17; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIU F, 1995, MOL CELL BIOL, V15, P3479; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; *STAT INF DEP, 1995, HLTH WELF STAT JAP, P76; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TILLEY WD, 1990, CANCER RES, V50, P5382; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1973, P NATL ACAD SCI USA, V70, P3511, DOI 10.1073/pnas.70.12.3511; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	27	50	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1377	1382		10.1038/sj.onc.1200964	http://dx.doi.org/10.1038/sj.onc.1200964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178898				2022-12-28	WOS:A1997WP10900013
J	Malumbres, M; Perez de Castro, I; Santos, J; Melendez, B; Mangues, R; Serrano, M; Pellicer, A; FernandezPiqueras, J				Malumbres, M; Perez de Castro, I; Santos, J; Melendez, B; Mangues, R; Serrano, M; Pellicer, A; FernandezPiqueras, J			Inactivation of the cyclin-dependent kinase inhibitor p15(INK4b) by deletion and de novo methylation with independence of p16(INK4 alpha) alterations in murine primary T-cell lymphomas	ONCOGENE			English	Article						p15(INK4b); p16(INK4a); CDK inhibitors; T-cell lymphomas; DNA methylation	TUMOR-SUPPRESSOR GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR-BETA; MOUSE SKIN TUMORS; K-RAS; HUMAN CANCERS; ALLELOTYPE ANALYSIS; MTS1 P16(INK4A); GAMMA-RADIATION; DNA METHYLATION	A wide panel of murine induced T-cell lymphomas have been analysed for p16(INK4a) Or p15(INK4b) alterations, Only one gamma-radiation-induced lymphoma showed p16(INK4a) homozygous deletion and no other intragenic mutations were found in these INK4 genes, However, de novo methylation of the 5' CpG islands of the murine p15(INK4b) and p16(INK4a) genes was found to be highly frequent, While p16(INK4a) hypermethylation was found in 36% of the neutron-radiation-induced lymphomas and 15% of the gamma-radiation-induced lymphomas, de novo methylation of p15(INK4b) occurs in 88% and 42% of these tumors respectively, correlating with deficient expression of the corresponding mRNA and allelic losses in the p15(INK4b) and p16(INK4a) chromosome location, These data represent, to our knowledge, the first report on the significant involvement of hypermethylation of these INK4 genes in murine primary tumors, Moreover, they show the importance of allelic losses and CpG island methylation of p15(INK4b) gene inactivation and support a tumor suppressor role for p15(INK4b) in T-cell lymphomas independent of p16(INK4a).	NYU, MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA; UNIV AUTONOMA MADRID, FAC CIENCIAS, DEPT BIOL, LAB GENET MOL HUMANA, E-28049 MADRID, SPAIN; COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	New York University; New York University; Autonomous University of Madrid; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			de Castro, Ignacio Pérez/A-6260-2012; Mangues, Ramon/J-6396-2014; Malumbres, Marcos/E-8834-2011; Serrano, Manuel/H-2634-2015; Holt, Janet E/B-2415-2013; Santos, Javier/ABF-5755-2021; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Melendez, Barbara/E-1216-2017	de Castro, Ignacio Pérez/0000-0002-8822-8274; Mangues, Ramon/0000-0003-2661-9525; Malumbres, Marcos/0000-0002-0829-6315; Serrano, Manuel/0000-0001-7177-9312; Santos, Javier/0000-0002-4168-6251; Melendez, Barbara/0000-0001-5004-8895; Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA50434, 5T32 CA09161, CA36327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009161, R37CA036327, R01CA050434, R01CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; Duro D, 1996, CANCER RES, V56, P848; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLENDENING JM, 1995, CANCER RES, V55, P5531; GOMBART AF, 1995, BLOOD, V86, P1534, DOI 10.1182/blood.V86.4.1534.bloodjournal8641534; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUERRERO I, 1984, SCIENCE, V225, P1159, DOI 10.1126/science.6474169; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEGI ME, 1994, CANCER RES, V54, P6257; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HERZOG CR, 1994, CANCER RES, V54, P4007; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HOOPER WC, 1991, LEUKEMIA RES, V15, P179, DOI 10.1016/0145-2126(91)90118-D; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; JEN J, 1994, CANCER RES, V54, P6353; Jiang P, 1995, J MOL EVOL, V41, P795; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEMP CJ, 1993, CANCER RES, V53, P6022; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; KODURU PRK, 1995, BLOOD, V86, P2900; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Larsen CJ, 1996, ONCOGENE, V12, P2041; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LOIS AF, 1995, CANCER RES, V55, P4010; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2013; OTSUKI T, 1995, CANCER RES, V55, P1436; OTTERSON GA, 1995, ONCOGENE, V11, P1211; POLLOCK PM, 1996, CANCER, V15, P77; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RICHARDSON KK, 1987, P NATL ACAD SCI USA, V84, P344, DOI 10.1073/pnas.84.2.344; Santos J, 1996, ONCOGENE, V12, P669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; STONE S, 1995, ONCOGENE, V11, P987; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; Winston JT, 1996, ONCOGENE, V12, P127; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wu JJ, 1996, CANCER RES, V56, P616; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	71	70	74	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1361	1370		10.1038/sj.onc.1200969	http://dx.doi.org/10.1038/sj.onc.1200969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178896				2022-12-28	WOS:A1997WP10900011
J	Bansal, A; Ramirez, RD; Minna, JD				Bansal, A; Ramirez, RD; Minna, JD			Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines	ONCOGENE			English	Article						MAP kinase pathway; MEK; human lung cancer	MAP KINASE KINASE; PROTEIN-KINASE; MYC GENE; INSULIN; TRANSFORMATION; PHOSPHORYLATES; AMPLIFICATION; EXPRESSION; ACTIVATOR; PATHWAY	Recently, constitutively active mutants of MEK (MAP/ ERI( kinase) were shown to be capable of transforming cells to tumorigenicity suggesting that MEK can function as a dominant oncogene and potentially play a role in human carcinogenesis, Human lung cancer cells exhibit mutations in other components of the MAP kinase signaling pathway such as the Her-2/neu and ras oncogenes. Thus, the coding sequences of both MEK-1 and MEK-2 cDNAs from human lung cancer cell lines were screened by single strand conformation polymorphism analysis and DNA sequencing for alterations in these two genes. In 37 lung cancer cell lines we found: an allelic variant in MEK-1 cDNA, nt 783 G-->A, (no amino acid change); a MEK-2 cDNA change (nt 977 C-->T mutation leading to 298 Pro-->Leu change); a MEK-2 cDNA change nt 537 C-->T (no amino acid change); and a frequent MEK-2 cDNA germline polymorphism nt 744, A-->C (no amino acid change) with an allele frequency of 0.5 for each form. These results suggest that mutations in the MEK-1 and MEK-2 gene occur at a very low frequency in human lung cancer.	UNIV TEXAS,SW MED CTR,HAMON CTR THERAPEUT ONCOL RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNET A, 1994, ONCOGENE, V9, P3379; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINNA J, 1994, LUNG CANC PRINCIPLES, P143; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; MINNA JD, 1997, CANC PRINCIPLES PRAC; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SEKIDO Y, 1995, CANCER RES, V55, P1227; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	26	21	24	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1231	1234		10.1038/sj.onc.1200947	http://dx.doi.org/10.1038/sj.onc.1200947			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121773				2022-12-28	WOS:A1997WM78200013
J	Meyerhardt, JA; Look, AT; Bigner, SH; Fearon, ER				Meyerhardt, JA; Look, AT; Bigner, SH; Fearon, ER			Identification and characterization of neogenin, a DCC-related gene	ONCOGENE			English	Article						tumor suppressor gene; DCC (deleted in colorectal cancer) gene; brain tumor; neuroblastoma; gene expression; chromosome 18q	COLORECTAL-CANCER; PANCREATIC ADENOCARCINOMA; ALLELOTYPE ANALYSIS; C-ELEGANS; CARCINOMA; CELL; DIFFERENTIATION; HETEROZYGOSITY; CHROMOSOME; EXPRESSION	DCC (deleted in colorectal cancer), a candidate tumor suppressor gene located in chromosome band 18q21.2, encodes a transmembrane protein of 1447 amino acids. Neogenin, a protein with nearly 50% amino acid identity to DCC, was recently identified because of its dynamic expression in the developing nervous system and gastrointestinal tract of the chicken. To explore a role for the human neogenin (NGN) gene in cancer, we have isolated cDNAs for two alternatively spliced forms of NGN, encoding proteins of 1461 and 1408 amino acids. Fluorescence in situ hybridization studies (FISH) localized NGN in chromosome band 15q22, a region infrequently affected by alterations in cancer. NGN transcripts of about 7.5 and 5.5 kb were detected in all adult tissues studied. In contrast to the frequent loss of DCC expression, no alterations in NGN expression were observed in more than 50 cancers studied, including glioblastoma, medulloblastoma, neuroblastoma, colorectal, breast, cervical and pancreatic cancer cell lines and xenografts. Based on their sequence conservation and similar expression during development, DCC and NGN may have related functions. However, the chromosomal location and ubiquitous expression of NGN in various human tumors suggest it is infrequently altered in cancer.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV MED & MOL GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; St Jude Children's Research Hospital; Duke University					NATIONAL CANCER INSTITUTE [R01CA070097, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA70097, CA23009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHAN S, 1995, WORM BREEDERS GAZETT, V13, P48; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CLIBY W, 1993, CANCER RES, V53, P2393; Cooper HM, 1995, ONCOGENE, V11, P2243; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1995, CLIN ONCOLOGY, P11; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FUJINO T, 1994, CANCER RES, V54, P4294; HAHN SA, 1995, CANCER RES, V55, P4670; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KNOWLES MA, 1994, CANCER RES, V54, P531; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; MITRA AB, 1994, CANCER RES, V54, P4481; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; REALE MA, 1994, CANCER RES, V54, P4493; Reale MA, 1996, CLIN CANCER RES, V2, P1097; SATO T, 1990, CANCER RES, V50, P7184; Schold S C Jr, 1983, J Neurooncol, V1, P5; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SEYMOUR AB, 1994, CANCER RES, V54, P2761; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; Wick W, 1996, ONCOGENE, V12, P973; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	40	72	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1129	1136		10.1038/sj.onc.1200935	http://dx.doi.org/10.1038/sj.onc.1200935			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121761				2022-12-28	WOS:A1997WM78200001
J	Okumura, K; Kaneko, Y; Nonoguchi, K; Nishiyama, H; Yokoi, H; Higuchi, T; Itoh, K; Yoshida, O; Miki, T; Fujita, J				Okumura, K; Kaneko, Y; Nonoguchi, K; Nishiyama, H; Yokoi, H; Higuchi, T; Itoh, K; Yoshida, O; Miki, T; Fujita, J			Expression of a novel isoform of Vav, Vav-T, containing a single Src homology 3 domain in murine testicular germ cells	ONCOGENE			English	Article						testis; vav; vav-T; Src homology 3	TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; EXCHANGE FACTOR; STEEL FACTOR; SH2 DOMAIN; B-CELLS; PROTEIN; KINASE; FIBROBLASTS	Vav is a signal transducing molecule containing C-terminal Src homology 3 (SH3)-SH2-SH3 domains, and has been thought to be expressed exclusively in hematopoietic and trophoblastic cells, By Northern blot analysis, vav transcripts of unique sizes, 4.8 kb and 1.0 kb, were detected in the testis among various tissues examined, From a mouse spermatocyte cDNA library, a novel isoform of vav (vav-T) was cloned, which corresponded to a part of the 4.8 kb transcript, Vav-T had an alternative 5' sequence up to the middle of SH2-coding region, and encoded 163 amino acids with a single SH3 domain, Northern blot analysis of fractionated testicular cells and in situ hybridization histochemistry demonstrated that vav-T transcripts were expressed in the differentiating germ cells, especially spermatocytes. A 24 kD protein was detected by anti-Vav antibodies in the testis, but not in the spleen or bone marrow, Transcripts of heterogeneous nuclear ribonucleoprotein K, known to associate with the most C-terminal SH3 domain of Vav, were also detected in the differentiating male germ cells, These results demonstrate expression of previously nondescribed Vav-isoform in the testicular germ cells, and suggest that it interacts with RNA-binding proteins and plays an important role in spermatogenesis.	KYOTO UNIV,FAC MED,DEPT CLIN MOL BIOL,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT UROL,KYOTO 60601,JAPAN; NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	Kyoto University; Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GOLDBERG E, 1977, ISOZYMES CURRENT TOP, P79; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; HIGUCHI T, 1995, BIOL REPROD, V53, P840, DOI 10.1095/biolreprod53.4.840; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Romero F, 1996, MOL CELL BIOL, V16, P37; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	40	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					713	720		10.1038/sj.onc.1200878	http://dx.doi.org/10.1038/sj.onc.1200878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038379	Green Submitted			2022-12-28	WOS:A1997WG43000010
J	Guerrin, M; Scotet, E; Malecaze, F; Houssaint, E; Plouet, J				Guerrin, M; Scotet, E; Malecaze, F; Houssaint, E; Plouet, J			Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2	ONCOGENE			English	Article						VEGF; FGF-2; retinal pigment epithelial cells; transformation	PIGMENT EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; ANGIOGENESIS; RECEPTOR; MITOGEN; VASCULOTROPIN; EXPRESSION	Vascular endothelial growth factor (VEGF) is a family of homodimeric proteins produced from a single gene by alternative splicing of the VEGF transcript. VEGF induces irt vivo angiogenesis and vascular permeability. We have recently demonstrated that VEGF is an autocrine growth factor for retinal pigment epithelial (RPE) cells. To further understand the role of VEGF, we overexpressed VEGF in rat RPE cells. The transfected cells exhibited a growth advantage in vitro and an increased response to the mitogenic effect of fibroblasts growth factor-2 (FGF-2), and formed colonies in soft agar upon FGF-2 addition. Moreover, analysis of FGF-receptors evidenced a dramatic increase in FGFR-1 mRNA and protein level, supporting the hypothesis that this receptor mediates the transforming effect of FGF-2. These results reveal that the oncogenic role of VEGF is exerted through a cross regulation between VEGF and FGF signal transduction pathways.	UPR 9006 CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE; INST BIOL, INSERM U211, F-44035 NANTES, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			SCOTET, Emmanuel/AAC-9971-2019; SCOTET, Emmanuel/L-2576-2015	SCOTET, Emmanuel/0000-0001-8010-9556; SCOTET, Emmanuel/0000-0001-8010-9556				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; Ferrara N, 1991, NEUROENDOCRINE PERSP, P127; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GOTO F, 1993, LAB INVEST, V69, P508; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Lachgar S, 1996, J INVEST DERMATOL, V106, P17, DOI 10.1111/1523-1747.ep12326964; LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MOUKADIRI H, 1992, GROWTH FACTORS OF THE VASCULAR AND NERVOUS SYSTEMS, P123; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOUET J, 1992, GENETIC HYPERTENSION, V218, P207; PRALORAN V, 1991, CR ACAD SCI III-VIE, V313, P21; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P934, DOI 10.1016/0006-291X(87)90340-8; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816	58	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					463	471		10.1038/sj.onc.1200846	http://dx.doi.org/10.1038/sj.onc.1200846			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053843				2022-12-28	WOS:A1997WE36400009
J	Merchant, AK; Loney, TL; Maybaum, J				Merchant, AK; Loney, TL; Maybaum, J			Expression of wild-type p53 stimulates an increase in both Bax and Bcl-x(L) protein content in HT29 cells	ONCOGENE			English	Article						p53; Bax; Bcl-x; programmed cell death; HT29	CHEMOTHERAPY-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; IN-VIVO; DNA FRAGMENTATION; BCL-2 EXPRESSION; CANCER-CELLS; C-MYC; CYCLE; DEATH; GENE	It has been shown previously that wild-type p53 activity can simultaneously up-regulate Bax, a protein which predisposes cells to programmed cell death (PCD), and down-regulate Bcl-2, a protein which antagonizes PCD. These findings have been interpreted to suggest that correction of the mutant p53 status of some tumor cells may be a means of increasing their sensitivity to chemotherapeutic agents, by increasing their likelihood of undergoing PCD. We show here that when wild-type p53 activity is expressed in HT29 human colon cancer cells by use of a temperature sensitive p53 mutant, Bax levels rise, but so do levels of Bcl-x(L) protein. These observations indicate that Bcl-2 and Bcl-x(L) are regulated differently in response to wild-type p53 activity and that, while correction of mutant p53 phenotype may effectively kill cells having Bcl-2 as their major defense against PCD, this is not necessarily the case in cells using Bcl-x(L) as their primary defense	UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [P01CA042761, R01CA056663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42761, R01-CA56663] Funding Source: Medline; NIGMS NIH HHS [2T32 GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAGWELL CB, 1979, J HISTOCHEM CYTOCHEM, V27, P293, DOI 10.1177/27.1.374589; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DOLE MG, 1995, CANCER RES, V55, P2576; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORGUELAFITTE ME, 1989, CANCER RES, V49, P6566; HAGUE A, 1994, ONCOGENE, V9, P3367; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PARK JR, 1994, BLOOD, V84, P440; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SINICROPE FA, 1995, CANCER RES, V55, P237; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; STEWART N, 1995, ONCOGENE, V10, P109; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tang HYK, 1996, CANCER CHEMOTH PHARM, V37, P486, DOI 10.1007/s002800050416; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILLINGHAM MC, 1994, J HISTOCHEM CYTOCHEM, V42, P441, DOI 10.1177/42.4.7907352; Wu GS, 1996, CLIN CANCER RES, V2, P623; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHAN QM, 1994, ONCOGENE, V9, P3743	39	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2631	2637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000137				2022-12-28	WOS:A1996VZ65400013
J	Brown, R; Hirst, GL; Gallagher, WM; McIlwrath, AJ; Margison, GP; vanderZee, AGJ; Anthoney, DA				Brown, R; Hirst, GL; Gallagher, WM; McIlwrath, AJ; Margison, GP; vanderZee, AGJ; Anthoney, DA			hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.	ONCOGENE			English	Article						cisplatin; drug resistance; mismatch repair; ovarian cancer	MISMATCH REPAIR; MICROSATELLITE INSTABILITY; MOLECULAR ANALYSIS; CISPLATIN; DNA; CANCER; TOLERANCE; ADDUCTS; LINES; ACCUMULATION	Loss of expression of the hMLH1 and hPMS2 subunits of the MutL alpha-mismatch repair complex is a frequent event (9/10) in independent cisplatin resistant derivatives of a human ovarian carcinoma cell line, However, only hMLH1 mRNA is decreased in these MutL alpha-deficient lines, No alterations in the levels of the hMSH2 and hMSH6 (GTBP) subunits of the MutS alpha-comples are observed, An increase in the proportion of ovarian tumours negative for the hMLH1 subunit is observed in samples taken at second look laporotomy after chemotherapy (36%: 4/11), compared to untreated tumours (10%: 4/39), No significant difference is observed for hMSH2, hMSH6 or hPMS2. Furthermore, cisplatin and doxorubicin-resistant ovarian lines deficient in hMLH1 expression are cross-resistant to 6-thioguanine and the methylating agent N-methyl-N-nitrosourea (MNU). Depletion of O-6-alkylguanine-DNA-alkyltransferase (ATase) activity confers only limited increased sensitivity to MNU. Thus the mismatch repair deficient lines retain DNA damage tolerance even after ATase depletion, The hMLH1 deficient lines also lose ability to engage G1 and G2 cell cycle arrest after cisplatin damage, Together these data suggest that loss of hMLH1 expression may be a high frequency event following exposure of ovarian tumour cells to cisplatin and may be critically involved in the development of drug resistance, Thus, the hMLH1 status of these cells appears to be highly correlated with the ability to engage cell death and cell cycle arrest after DNA damage induced by cisplatin.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV GRONINGEN HOSP,DEPT GYNAECOL ONCOL,GRONINGEN,NETHERLANDS	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Groningen	Brown, R (corresponding author), UNIV GLASGOW,CRC,BEATSON LABS,DEPT MED ONCOL,SWITCHBACK RD,GLASGOW G61 1BD,LANARK,SCOTLAND.		Margison, Geoff/E-4146-2019	Gallagher, William/0000-0002-4307-5999; Hirst, Gillian/0000-0002-4502-0035				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1990, CANCER RES, V50, P4248; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bubb VJ, 1996, ONCOGENE, V12, P2641; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; DOLAN ME, 1990, CANCER COMMUN, V2, P371, DOI 10.3727/095535490820873985; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EVANS DL, 1994, CANCER RES, V54, P1596; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fink D, 1996, CANCER RES, V56, P4881; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; Gallagher WM, 1997, ONCOGENE, V14, P185; HAWN MT, 1995, CANCER RES, V55, P3721; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kaye SB, 1996, ANN ONCOL, V7, P9; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; KOI M, 1994, CANCER RES, V54, P4308; MAMENTA EL, 1994, CANCER RES, V54, P3500; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; ORMEROD MG, 1994, EXP CELL RES, V211, P231, DOI 10.1006/excr.1994.1082; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Paulson TG, 1996, CANCER RES, V56, P4021; REED E, 1995, SEMIN ONCOL, V22, P90; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; UMAR A, 1994, J BIOL CHEM, V269, P14367; VANDERZEE AGJ, 1995, J CLIN ONCOL, V13, P70, DOI 10.1200/JCO.1995.13.1.70; VANDERZEE AGJ, 1994, ANN ONCOL, V5, P75, DOI 10.1093/oxfordjournals.annonc.a058700; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZAMPLE DB, 1995, TIBS, V20, P435	41	224	224	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					45	52		10.1038/sj.onc.1201167	http://dx.doi.org/10.1038/sj.onc.1201167			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233776				2022-12-28	WOS:A1997XH58600005
J	Nehyba, J; Hrdlickova, R; Bose, HR				Nehyba, J; Hrdlickova, R; Bose, HR			Differences in kappa B DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein	ONCOGENE			English	Article						v-Rel; c-Rel; DNA binding; oncogene; NF-kappa B	CHICKEN SPLEEN-CELLS; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATION; CYTOPLASMIC RETENTION; EMBRYO FIBROBLASTS; AMINO-ACIDS; RECOGNITION SEQUENCE; GENE-EXPRESSION; HOMOLOGY DOMAIN	The oncogene v-rel of Reticuloendotheliosis virus, strain T, is derived from an avian c-rel proto-oncogene, c-rel encodes a member of the Rel/NF-kappa B family of transcription factors, The highly oncogenic v-Rel differs from c-Rel which has low transforming potential by the acquisition of numerous mutations, In this manuscript, we demonstrate that the oncogenic mutations in v-Rel directly alter the ability of this protein to bind to DNA, Electrophoretic mobility shift analysis with Rel proteins synthesized in vitro as well as isolated from nuclei of Rel expressing cells showed that three mutation clusters, present in the N-terminus, the center and the C-terminus of v-Rel, altered three different aspects of DNA binding, In contrast, the oncogenic C-terminal deletion of 118 amino acids present in v-Rel had almost no influence on its DNA binding. The N-terminal mutation cluster altered the kappa B DNA-binding specificity of the v-Rel oncoprotein relative to c-Rel. The mutation Met-20-->Thr was found to be principally responsible for this alteration, The second mutation cluster was responsible for increased binding of v-Rel to all the KB sites examined presumably because it stabilized v-Rel homodimers, This alteration in DNA binding was mapped to the group of two mutations within the cluster, In contrast, the third mutation cluster in the C-terminus of v-Rel destabilized the binding of v-Rel to all of the kappa B sites examined, This is the first indication that regions outside the Rel Homology Region can participate in the control of binding of the c-Rel protein to DNA, The three mutation clusters examined contributed to the tumorigenic potential of v-Rel with the relative strength decreasing with their position from the N-terminus to the C-terminus, These results suggest that the oncogenic mutations in v-Rel cooperate and enable v-Rel to form nuclear complexes with aberrant DNA-binding properties that may directly alter gene expression and DNA replication resulting in the transformation of the cell.	UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, CELL RES INST, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA33192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALTIMORE D, 1995, NATURE, V373, P287, DOI 10.1038/373287a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BREITMAN ML, 1980, VIROLOGY, V100, P450, DOI 10.1016/0042-6822(80)90535-8; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FILARDO EJ, 1994, VIROLOGY, V202, P116, DOI 10.1006/viro.1994.1328; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P1204; GILMORE TD, 1995, DNA PROVIRUS H TEMIN, P105; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1992, ONCOGENE, V7, P567; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KROEMER G, 1990, IMMUNOGENETICS, V31, P405, DOI 10.1007/BF02115020; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LU D, 1991, ONCOGENE, V6, P1235; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STOKER AW, 1987, J GEN VIROL, V68, P2481, DOI 10.1099/0022-1317-68-9-2481; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TONY Y, 1995, CURR BIOL, V5, P1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	93	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2881	2897		10.1038/sj.onc.1201150	http://dx.doi.org/10.1038/sj.onc.1201150			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205096				2022-12-28	WOS:A1997XF55500003
J	Thatikunta, P; Raj, GV; Kundu, M; Khalili, K; Amini, S				Thatikunta, P; Raj, GV; Kundu, M; Khalili, K; Amini, S			The transcription factor E2F-1 modulates TGF-beta 1 RNA expression in glial cells	ONCOGENE			English	Article						E2F1; TGF-beta 1; gene expression; oncoproteins; central nervous system	RETINOBLASTOMA GENE-PRODUCT; GROWTH FACTOR-BETA-1 GENE; TGF-BETA; TUMOR-ANTIGEN; S-PHASE; PROTEIN; CYCLE; PROMOTER; BINDING; INHIBITION	The cell type specificity of the regulation of expression of the potent growth inhibitory cytokine transforming growth factor-beta (TGF-beta), prompted our analyses of the regulation of TGF-beta 1 gene expression in glial cells by viral and cellular oncoproteins. We have shown that SV40 T-antigen diminished TGF-beta 1 expression in glial cells and this repression was dependent on the ability of T-antigen to interact with the tumor suppressor protein, pRb, and two structurally related proteins, p107 and p130. The cellular transcription factor E2F-1, which is a downstream effector of T-antigen, was unable to influence expression from the TGF-beta 1 promoter by itself. Interestingly, E2F-1 could overcome viral T-antigen-mediated repression of the TGF-beta 1 promoter, suggesting potential feedback loop between TGF-beta and E2F in virally transformed glial cells. Using deletion analyses, we have mapped two E2F-1-responsive regions on the TGF-beta 1 promoter: a T-antigen-dependent negative regulatory sequence (TdNRS) between - 323 and - 175, and a T-antigen-independent positive regulatory sequence (TiPRS) between - 34 and + 10 on the TGF-beta 1 promoter, Further examination of TiPRS revealed the presence of a functional E2F binding site. Interestingly, the amino terminus of E2F-1 was required for its activation of TGF-beta 1 expression, as mutations in that domain abolished the ability of E2F-1 to increase TGF-beta 1 expression. These data suggest that yet-uncharacterized interaction between the amino terminus of E2F-1 and cellular proteins regulates TGF-beta 1 expression, The mechanism for E2F-1-mediated Tantigen-dependent regulation of TGF-beta 1 expression from TdNRS awaits further characterization.	ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL,PHILADELPHIA,PA 19107; ALLEGHENY UNIV HLTH SCI,DEPT NEUROL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Drexel University; Drexel University; Jefferson University			Kundu, Mondira/N-8139-2018	Kundu, Mondira/0000-0001-9946-2472				BENZAKOUR O, 1994, B CANCER, V81, P1014; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DATTA PK, 1994, J BIOL CHEM, V269, P25392; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; Raj GV, 1996, ONCOGENE, V12, P1279; ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19; ROBERTS AB, 1990, ANN NY ACAD SCI, V593, P43, DOI 10.1111/j.1749-6632.1990.tb16098.x; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SALA A, 1994, CANCER RES, V54, P1402; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; VERITY AN, 1993, J NEUROCHEM, V60, P577, DOI 10.1111/j.1471-4159.1993.tb03188.x; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	42	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2959	2969		10.1038/sj.onc.1201129	http://dx.doi.org/10.1038/sj.onc.1201129			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205103				2022-12-28	WOS:A1997XF55500010
J	Thomas, RS; Tymms, MJ; McKinlay, LH; Shannon, MF; Seth, A; Kola, I				Thomas, RS; Tymms, MJ; McKinlay, LH; Shannon, MF; Seth, A; Kola, I			ETS1, NF kappa B and AP1 synergistically transactivate the human GM-CSF promoter	ONCOGENE			English	Article						GM-CSF; transcription; ETS1; NF kappa B; API	COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; AP-1 TRANSCRIPTION FACTORS; DNA-BINDING ACTIVITY; T-CELLS; MESSENGER-RNA; MICE LACKING; INFLAMMATORY RESPONSES; COSTIMULATORY SIGNALS; COOPERATIVE BINDING	Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system, Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription, Cis-acting elements with NF kappa B, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation, ETS1 is a transcription factor of the ETS family that is expressed in T cells, We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation, Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors, Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NF kappa B or AP1 transcription factors are supplied by co-transfection, We confirm that binding of endogenous NF kappa B and AP1 is induced following PMA/ionomycin treatment of T cells, Transactivation by ETS1, NF kappa B and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent, Our results suggest that constitutive ETS1, and inducible NF kappa B and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.	MONASH UNIV, MOL GENET & DEV GRP, INST REPROD & DEV, MELBOURNE, VIC 3168, AUSTRALIA; INST MED & VET SCI, DIV HUMAN IMMUNOL, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA; UNIV TORONTO, WOMENS COLL HOSP, DEPT PATHOL, TORONTO, ON, CANADA	Monash University; Institute Medical & Veterinary Science Australia; University of Toronto; Womens College Hospital			Kola, Ismail/C-5254-2013; Thomas, Ross/C-6434-2008					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRORSON KA, 1991, J IMMUNOL, V147, P3601; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FISHER CL, 1991, J IMMUNOL, V146, P1743; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; IWAI Y, 1993, J IMMUNOL, V150, P4386; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOIZUMI S, 1990, ONCOGENE, V5, P675; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI CCH, 1994, J BIOL CHEM, V269, P30089; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MAKOVER D, 1991, ONCOGENE, V6, P455; MASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518, DOI 10.1006/bbrc.1994.2839; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; OSBORNE CS, 1995, J IMMUNOL, V155, P226; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; THOMAS RS, 1995, ONCOGENE, V11, P2135; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ye JP, 1996, MOL CELL BIOL, V16, P157; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672	77	134	136	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2845	2855		10.1038/sj.onc.1201125	http://dx.doi.org/10.1038/sj.onc.1201125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190901				2022-12-28	WOS:A1997XD64300013
J	Whitesell, L; Sutphin, P; An, WG; Schulte, T; Blagosklonny, MV; Neckers, L				Whitesell, L; Sutphin, P; An, WG; Schulte, T; Blagosklonny, MV; Neckers, L			Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo	ONCOGENE			English	Article						ubiquitin; lactacystin; benzoquinone ansamycins; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE; MULTICATALYTIC PROTEINASE; ACTIVATING MUTATIONS; PROTEOLYTIC SYSTEM; TRANSFORMED-CELLS; E6 ONCOPROTEIN; MUTANT P53; DEGRADATION; COMPLEX	Mutation of the tumor suppressor gene p53 is the most common genetic abnormality detected in human cancers, Wild type p53 is a short-lived protein with very low basal intracellular levels, Most mutated forms of the protein, however, display markedly increased intracellular levels as an essential feature of their positive transforming activity, In this report, we have used selective inhibitors of the 20S proteasome to demonstrate that processing of p53 by ubiquitination and proteasome-mediated degradation is impaired by commonly occurring mutations of the protein, We found that this impairment of p53 turnover can be reversed by treatment of tumor cells with the benzoquinone ansamycin, geldanamycin, leading to a marked reduction in intracellular p53 levels. Finally, using cells which over-express a mutant p53 protein, we were able to demonstrate that restoration of proteasome-mediated degradation by geldanamycin is accompanied by p53 polyubiquitination, Although much remains to be learned about the mechanisms involved, our data demonstrate that selective de-stabilization of mutant transforming proteins such as p53 can be achieved pharmacologically with agents such as geldanamycin which modify the function of molecular chaperone proteins within tumor cells.	UNIV ARIZONA,DEPT PEDIAT,STEELE MEM CHILDRENS RES CTR,TUCSON,AZ 85724; NCI,CLIN PHARMACOL BRANCH,NIH,BETHESDA,MD 20892	University of Arizona; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [R29 CA-69537-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HADARI T, 1992, J BIOL CHEM, V267, P719; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Maki CG, 1996, CANCER RES, V56, P2649; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	36	115	117	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2809	2816		10.1038/sj.onc.1201120	http://dx.doi.org/10.1038/sj.onc.1201120			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190897				2022-12-28	WOS:A1997XD64300009
J	Yen, L; ZengRong, N; You, XL; Richard, S; LangtonWebster, BC; AlaouiJamali, MA				Yen, L; ZengRong, N; You, XL; Richard, S; LangtonWebster, BC; AlaouiJamali, MA			Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway	ONCOGENE			English	Article						p185(erbB-2); drug resistance; TAb-250 antibody; tyrosine kinase inhibitors; DNA repair, ras signaling pathway	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; GENE-PRODUCT P185; TYROSINE KINASE; FACTOR RECEPTOR; NEU-ONCOGENE; BENZOQUINOID ANSAMYCINS; MONOCLONAL-ANTIBODIES; CARCINOMA CELLS; LUNG-CANCER	We have examined the role of erbB-2 expression in the modulation of cellular toxicity to cisplatin. We have demonstrated that treatment of NIH3T3-erbB-2 cells, which overexpress the p185(erbB-2) product of the human erbB-2 gene, with a monoclonal antibody directed against the extracellular domain (TAb-250), results in enhanced cisplatin cytotoxicity. A similar enhancement was obtained when cells were exposed to herbimycin A and its analogue CP127 374, both of which inhibit tyrosine kinase activity. Using the host cell. reactivation (HCR) of reporter gene expression from cisplatin-damaged plasmid and unscheduled DNA synthesis (UDS) following cisplatin treatment of cells, we have found that modulation of erbB-2 by TAb-250 was associated with inhibition of DNA repair. TAb-250 alone, under conditions which modulate DNA repair, slightly reduces the S-phase of the cell cycle, while cisplatin induced arrest at S and G(2) phases. Combination of TAb-250 and cisplatin only slightly prevented cisplatin-induced S and G(2) blocks. Since the ras pathway is one of the major signaling components coupled to erbB-2, we have examined the role of ras in DNA repair regulation. Transient expression of a ras dominant negative mutant, Asn-17-ras(H), prevents DNA repair modulation by TAb-250, suggesting that the erbB-2 receptor regulates DNA repair mechanism(s), at least in part, through ras-coupled pathway(s).	MCGILL UNIV, DEPT MED, SIR MORTIMER B DAVIS JEWISH GEN HOSP, LADY DAVIS INST, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, MCGILL TRANSLAT CTR CANC, MONTREAL, PQ H3T 1E2, CANADA; BERLEX BIO SCI INC, DEPT ONCOL RES, STRATEG RES UNIT 1, RICHMOND, CA 94804 USA	Lady Davis Institute; McGill University; McGill University; McGill University								Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSTEIN BM, 1995, MOL CELL ENDOCRINOL, V110, P205, DOI 10.1016/0303-7207(95)03535-F; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JOHNSON RT, 1987, J CELL SCI, P263; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Kuzumaki T, 1996, BBA-MOL CELL RES, V1310, P185, DOI 10.1016/0167-4889(95)00166-2; Liu Y, 1996, CANCER RES, V56, P31; LOCK RB, 1990, CANCER RES, V50, P3761; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER P, 1994, CANCER RES, V54, P2724; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NIE ZR, 1995, CANCER RES, V55, P4760; NISHIKAWA K, 1992, CANCER RES, V52, P4758; Paterson J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P363; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Shearer MC, 1996, FASEB J, V10, pP64; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VICHI P, 1992, CANCER RES, V52, P4135; WEINER DB, 1990, CANCER RES, V50, P421; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; YEN L, 1995, MUTAT RES-DNA REPAIR, V337, P179, DOI 10.1016/0921-8777(95)00022-C; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHANG LS, 1995, CANCER RES, V55, P3890	58	37	39	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1827	1835		10.1038/sj.onc.1201019	http://dx.doi.org/10.1038/sj.onc.1201019			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150389				2022-12-28	WOS:A1997WW16600009
J	Luo, WP; Wood, CG; Earley, K; Hung, MC; Lin, SH				Luo, WP; Wood, CG; Earley, K; Hung, MC; Lin, SH			Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): The adhesion and growth suppression are mediated by different domains	ONCOGENE			English	Article						cell adhesion molecule; breast cancer; tumor suppression	BILIARY GLYCOPROTEIN-I; TUMOR-SUPPRESSOR; C-CAM; CARCINOEMBRYONIC ANTIGEN; SECONDARY-STRUCTURE; CYTOPLASMIC DOMAIN; LIVER DEVELOPMENT; PROSTATE-CANCER; RAT-TISSUES; ECTO-ATPASE	C-CAM1 is an epithelial adhesion molecule of immunoglobulin supergene family and has been implicated in the growth suppression of prostate cancer cells. Here we show that C-CAM1 can also suppress the tumorigenicity of breast cancer cells. These observations suggest that C-CAM1 may be a general growth suppressor in epithelial cells. In addition, we have identified the cytoplasmic domain, but not the extracellular adhesion domain, of C-CAM1 as critical for the growth suppression. Thus, the adhesion and the growth suppression functions of C-CAM1 are independent of each other. Furthermore, mutation at the tyrosine phosphorylation site in the cytoplasmic domain of C-CAM1 did not obliterate C-CAM1's growth suppression function, suggesting that tyrosine phosphorylation is not involved in the signal transduction pathway leading to cell growth suppression. These studies provide the structural basis for future development of therapeutics that may selectively activate C-CAM1's growth suppression function.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; ROSENBERG M, 1993, CANCER RES, V53, P4938; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257	27	82	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1697	1704		10.1038/sj.onc.1200999	http://dx.doi.org/10.1038/sj.onc.1200999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135071				2022-12-28	WOS:A1997WR89300008
J	David, G; Terris, B; Marchio, A; Lavau, C; Dejean, A				David, G; Terris, B; Marchio, A; Lavau, C; Dejean, A			The acute promyelocytic leukemia PML-RAR alpha protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice	ONCOGENE			English	Article						PML-RAR alpha; APL; translocation; hepatocarcinoma; transgenic mice	RETINOIC ACID RECEPTOR; ZINC FINGER GENE; T(1517) TRANSLOCATION; CELL-PROLIFERATION; NUCLEAR RECEPTORS; GROWTH-SUPPRESSOR; FUSION PROTEIN; TGF-ALPHA; HEPATOCARCINOGENESIS; DIFFERENTIATION	The PML-RAR alpha hybrid protein generated by the t(15;17) translocation in acute promyelocytic leukemia (APL) is thought to play a central role in the oncogenic process. However, analysis of the oncogenic activity of the fusion protein in tissue culture assays or in mice has been hampered by its apparent toxicity in multiple murine cells. To circumvent this problem, we generated an inducible line of transgenic mice, MT135, in which the expression of PML-RAR alpha is driven by the metallothionein promoter. After 5 days zinc stimulation, 27 out of 54 mice developed hepatic preneoplasia and neoplasia including foci of basophilic hepatocytes, dysplasia and carcinoma with a significantly higher incidence of lesions in females than in males. The rapid onset of liver pathologies was dependent on overexpression of the transgene since it was not detected in noninduced transgenic animals of the same age. The PML-RAR alpha protein was always present in altered tissues at much higher levels than in the surrounding normal liver tissues. In addition, overexpression of PML-RAR alpha resulted in a strong proliferative response in the hepatocytes. We conclude that overexpression of PML-RAR alpha deregulates cell proliferation and can induce tumorigenic changes in vivo.	INST PASTEUR,UA CNRS,INSERM U163,UNITE RECOMBINAISON & EXPRESS GENET,PARIS,FRANCE; HOP BEAUJON,LAB ANATOMOPATHOL,CLICHY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite			Dejean, Anne/L-5145-2018; Lavau, Catherine/Q-2928-2019; Terris, Benoit/P-1497-2017	Lavau, Catherine/0000-0003-4800-1320; , gregory/0000-0002-3371-4558				ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; BENNOUN M, 1993, AM J PATHOL, V143, P1326; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FACTOR VM, 1993, EXP TOXICOL PATHOL, V45, P239, DOI 10.1016/S0940-2993(11)80399-4; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; Lavau C, 1996, EXP HEMATOL, V24, P544; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TERRIS B, 1995, CANCER RES, V55, P1590; TOSHKOV I, 1990, J CANCER RES CLIN, V116, P581, DOI 10.1007/BF01637078; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEBER E, 1994, CARCINOGENESIS, V15, P1235, DOI 10.1093/carcin/15.6.1235; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	56	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1547	1554		10.1038/sj.onc.1200989	http://dx.doi.org/10.1038/sj.onc.1200989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129145				2022-12-28	WOS:A1997WQ54800005
J	Lohman, FP; Gibbs, S; Fischer, DF; Borgstein, AMB; vandePutte, P; Backendorf, C				Lohman, FP; Gibbs, S; Fischer, DF; Borgstein, AMB; vandePutte, P; Backendorf, C			Involvement of c-JUN in the regulation of terminal differentiation genes in normal and malignant keratinocytes	ONCOGENE			English	Article						keratinocytes; terminal differentiation; c-JUN; SPRR2; involucrin	CORNIFIED CELL-ENVELOPE; PROLINE-RICH PROTEINS; DELETION MUTANT; FOS; CULTURE; TRANSFORMATION; PROTOONCOGENE; EXPRESSION; EVOLUTION; PROMOTER	In stratifying cultures of human keratinocytes, expression of the proto-oncoprotein c-JUN and the small proline rich 2 (SPRR2) protein, a precursor of the cornified cell envelope, are inversely related. Whereas c-JUN is typically found in basal proliferating cells, SPRR2 is restricted to suprabasal differentiating layers. Malignant keratinocytes (derived from squamous cell carcinoma, SCC) have reduced sprr2 expression, consistent with their low potential to differentiate, and express c-jun at higher levels than normal keratinocytes. A direct relation between c-jun and sprr2 expression was shown in several ways: transient ectopic expression of c-jun inhibits sprr2a promoter activity in normal differentiating cells, whereas in malignant keratinocytes a dominant negative c-jun mutant restored at least partially both the low promoter activity and the expression of endogenous sprr2. These effects are mediated via a 134 bp promoter fragment which does not include the sprr2a AP-1 binding site. Interestingly, in an SCC cell line, constitutively expressing the dominant c-jun mutant, expression of the terminal differentiation marker involucrin is also strongly increased, suggesting that c-JUN is a general modulator of keratinocyte terminal differentiation rather than only affecting the expression of sprr2.	LEIDEN INST CHEM, GENET MOL LAB, NL-2300 RA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT DERMATOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University; Leiden University Medical Center (LUMC)				Fischer, David/0000-0002-6690-0197				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HILBERG F, 1992, ONCOGENE, V7, P2371; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LICHTENAUERKALIGIS EGR, 1993, HUM MOL GENET, V2, P173, DOI 10.1093/hmg/2.2.173; PONEC M, 1989, IN VITRO CELL DEV B, V25, P689, DOI 10.1007/BF02623721; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; WATT FM, 1991, J CELL SCI, V99, P397	30	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1623	1627		10.1038/sj.onc.1200974	http://dx.doi.org/10.1038/sj.onc.1200974			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129155				2022-12-28	WOS:A1997WQ54800015
J	Butzler, C; Zou, XG; Popov, AV; Bruggemann, M				Butzler, C; Zou, XG; Popov, AV; Bruggemann, M			Rapid induction of B-cell lymphomas in mice carrying a human IgH/c-mycYAC	ONCOGENE			English	Article						c-myc deregulation; chromosomal translocation; Burkitt's lymphoma; translocus control; immunoglobulin intron enhancer	YEAST ARTIFICIAL CHROMOSOME; HEAVY-CHAIN LOCUS; C-MYC; TRANSGENIC MICE; BURKITT-LYMPHOMA; GENE; ENHANCER; TUMORS; TRANSLOCATION; EXPRESSION	Activation of the c-myc proto-oncogene by one of the imnunoglobulin (Ig) loci after chromosomal translocation is a consistent feature of Burkitt's lymphoma. Different subtypes of this tumor vary in the molecular architecture of the translocation region. In most cases there are no known regulatory elements of the Ig locus neighboring the oncogene and this considerably obscures the mechanism of its deregulation. In order to assess possible oncogene activation signals, we produced an experimental translocation region by insertion of a c-myc gene about 50 kb from the IgH intron enhancer in a yeast artificial chromosome (YAC) containing a 220 kb region of the human Ig heavy chain (IgH) locus. Single copy integration of this YAC into the genome of mouse embryonic stem (ES) cells was achieved by spheroplast fusion. Chimeric mice derived from these ES cells developed monoclonal B-cell lymphomas expressing surface IgM by 8-16 weeks of age. The IgH/c-myc translocus showed different V(H)DJ(H) rearrangement in almost all tumors without any alterations of the distance between c-myc and the IgH intron enhancer. This mouse model can be used for the in vivo analysis of c-myc deregulation and the tumor formation capacity of the IgH locus in aberrant rearrangements.	BABRAHAM INST, DEPT DEV & GENET, CAMBRIDGE CB2 4AT, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Bruggemann M, 1996, IMMUNOL TODAY, V17, P391, DOI 10.1016/0167-5699(96)10025-6; BULUWELA L, 1988, EUR J IMMUNOL, V18, P1843, DOI 10.1002/eji.1830181130; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; CROCE CM, 1993, SEMIN ONCOL, V20, P31; DAVIES NP, 1993, BIO-TECHNOL, V11, P911, DOI 10.1038/nbt0893-911; DAVIES NP, 1992, NUCLEIC ACIDS RES, V20, P2693, DOI 10.1093/nar/20.11.2693; DAVIES NP, 1996, ANTIBODY ENG PRACTIC, P59; GERSTER T, 1986, CELL, V45, P45, DOI 10.1016/0092-8674(86)90536-2; GUNVEN P, 1980, INT J CANCER, V25, P711, DOI 10.1002/ijc.2910250605; GUTIERREZ MI, 1992, BLOOD, V79, P3261; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; LAVENU A, 1994, ONCOGENE, V9, P527; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARKIE D, 1996, METHODS MOL BIOL, V54; Mautner J, 1996, ONCOGENE, V12, P1299; MILSTEIN CP, 1984, NUCLEIC ACIDS RES, V12, P6523, DOI 10.1093/nar/12.16.6523; MORELLO D, 1993, ONCOGENE, V8, P1921; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schedl A, 1996, Methods Mol Biol, V54, P293; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Wagner SD, 1996, GENOMICS, V35, P405, DOI 10.1006/geno.1996.0379; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; Zou XG, 1996, FASEB J, V10, P1227, DOI 10.1096/fasebj.10.10.8751726	40	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1383	1388		10.1038/sj.onc.1200968	http://dx.doi.org/10.1038/sj.onc.1200968			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178899				2022-12-28	WOS:A1997WP10900014
J	Bernardin, F; CollyndHooghe, M; Quief, S; Bastard, C; Leprince, D; Kerckaert, JP				Bernardin, F; CollyndHooghe, M; Quief, S; Bastard, C; Leprince, D; Kerckaert, JP			Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation	ONCOGENE			English	Article						LAZ3/BCL6; lymphoma; major translocation cluster	PROTEIN INTERACTION MOTIF; FINGER ENCODING GENE; CENTER B-CELLS; PROMOTER REGION; DNA-BINDING; BCL-6 GENE; CHROMOSOMAL TRANSLOCATIONS; BTB/POZ DOMAIN; SEQUENCE; MOUSE	The LAZ3/BCL6 gene encoding a Zinc-finger nuclear protein is altered in Non-Hodgkin's Lymphomas (NHLs) by translocations, mutations and/or deletions clustered in its 5' non coding region, in a 3.3 Kbp EcoRI fragment which thus defines the Major Translocation Cluster (MTC). In the present study, we describe at the molecular level the deletions found in the MTC of two (NHL) cases using, (i) DNA obtained from a patient (GUI) with a monosomy 3 and three microdeletions of 101, 22, 25 bp in its unique untranslocated 3q27 allele; (ii) a cell line derived from a patient (VAL) carrying a t(3;4) (q27;pll) translocation and a 2.4 Kbp deletion in the untranslocated allele. As the MTC is recurrently subject to alterations, me have cloned and sequenced the murine equivalent of the human MTC and promoter region in an attempt to identify sequences well conserved in mammals that may be thus important for the LAZ3/BCL6 gene regulation. We show that the human and mouse 5' upstream regions of the LAZ3/BCL6 gene although mainly intronic share a particularly high homology of 79% on the overall sequence. Strikingly, the small sequences which are deleted in patient (GUI) are highly conserved (81%, 100% and 92% respectively). Furthermore, they may play a role in the pathogenesis since proteins prepared from B cell lines and HeLa nuclear extracts bind to these sequences in gel retardation assays. Although a large part of this region is intronic, the high conservation of its sequence and the frequency of alterations in NHLs suggest that they are likely to be significant for the regulation of the LAZ3/BCL6 gene.	INST RECH CANC LILLE,U124 INSERM,F-59045 LILLE,FRANCE; CTR TRANSFUS SANGUINE,DEPT CYTOGENET,F-76232 BOIS GUILLAUME,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Leprince, Dominique/0000-0002-1999-0775				Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DALLERY E, 1995, ONCOGENE, V10, P2171; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FLENGHI L, 1995, AM J PATHOL, V147, P405; FOLEY J, 1994, GENOMICS, V22, P456, DOI 10.1006/geno.1994.1410; FUKUDA T, 1995, ONCOGENE, V11, P1657; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; GALSON DL, 1993, BLOOD, V82, P3321; GWYNN B, 1990, MOL CELL BIOL, V10, P5244, DOI 10.1128/MCB.10.10.5244; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1996, LEUKEMIA, V10, P658; NAKAMURA Y, 1995, BRIT J HAEMATOL, V90, P404, DOI 10.1111/j.1365-2141.1995.tb05166.x; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	39	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					849	855		10.1038/sj.onc.1200903	http://dx.doi.org/10.1038/sj.onc.1200903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047392				2022-12-28	WOS:A1997WJ11200011
J	Alvaro, V; Prevostel, C; Joubert, D; Slosberg, E; Weinstein, BI				Alvaro, V; Prevostel, C; Joubert, D; Slosberg, E; Weinstein, BI			Ectopic expression of a mutant form of PKC alpha originally found in human tumors: Aberrant subcellular translocation and effects on growth control	ONCOGENE			English	Article						protein kinase c; somatic mutation; transformation; fibroblast	PROTEIN-KINASE-C; RAT FIBROBLASTS; EPSILON ISOFORM; DOWN-REGULATION; PHORBOL ESTERS; FOCAL CONTACTS; GENE-TRANSFER; CELL-LINES; RECEPTOR; OVEREXPRESSION	A point mutation in PKC alpha was originally discovered in a subpopulation of human pituitary tumors characterized by their invasive phenotype, and the same mutation was also seen in some thyroid neoplasms, To investigate the role of this mutation in tumorigenesis, normal and mutant human PKC alpha cDNAs were overexpressed in Rat6 embryo fibroblasts (R6), When extracts of R6 cells that expressed either the normal or mutant PKC alpha were assayed in the presence of calcium, phosphatidylserine and the phorbol ester TPA, for phosphorylation of either histone IIIS or the EGF-receptor peptide, both extracts gave similar results, However, the subcellular localization of the two proteins differed. Immunohistochemistry studies indicated that after treatment with TPA normal PKC alpha mainly translocated to the plasma membrane, but mutant PKC alpha translocated mainly to the perinuclear region and slightly to the nucleus, Furthermore, the cells that expressed the mutant PKC alpha displayed a decreased requirement for serum when compared to the cells expressing the normal human PKC alpha, and they formed small colonies in soft agar, By contrast, the cells expressing the normal human PKC alpha failed to form colonies in soft-agar, Thus, ectopic expression in rat fibroblasts of this mutant human PKC alpha sequence alters the growth properties of these cells and, when activated, the mutant PKC alpha displays aberrant intracellular translocation, Therefore, this mutation in PKC alpha could contribute to the process of tumor progression in certain human tumors.	CCIPE,INSERM U401,F-34094 MONTPELLIER 5,FRANCE; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CANC RES INST,NEW YORK,NY 10032	Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Columbia University			Prevostel, Corinne/AAO-1433-2020	PREVOSTEL, Corinne/0000-0002-7553-087X				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; AHMAD S, 1993, MOL PHARMACOL, V43, P858; ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; BENZIL DL, 1992, CANCER RES, V52, P2951; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CACACE AM, 1993, ONCOGENE, V8, P2095; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DONG LQ, 1993, CELL GROWTH DIFFER, V4, P793; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES CLA, 1994, PKC M TAOS NEW MEX; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LELI U, 1992, FEBS LETT, V297, P91, DOI 10.1016/0014-5793(92)80334-D; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; LIU B, 1994, J NATL CANCER I, V86, P1145, DOI 10.1093/jnci/86.15.1145; MAPPELI E, 1994, INT J CANCER, V57, P281; MARKOWITZ D, 1990, ANN NY ACAD SCI, V612, P407; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PREVOSTEL C, 1995, ONCOGENE, V11, P669; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	47	26	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					677	685		10.1038/sj.onc.1200880	http://dx.doi.org/10.1038/sj.onc.1200880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038375				2022-12-28	WOS:A1997WG43000006
J	Sakai, M; Imaki, J; Yoshida, K; Ogata, A; MatsushimaHibiya, Y; Kuboki, Y; Nishizawa, M; Nishi, S				Sakai, M; Imaki, J; Yoshida, K; Ogata, A; MatsushimaHibiya, Y; Kuboki, Y; Nishizawa, M; Nishi, S			Rat maf related genes: Specific expression in chondrocytes, lens and spinal cord	ONCOGENE			English	Article						maf; transcription factor; chondrocyte; lens; spinal cord	TRANSFERASE-P EXPRESSION; TRANSCRIPTION FACTOR; FACTOR NF-E2; V-MAF; FOS; JUN; ONCOGENE; PROTEINS; ENCODES; DOMAIN	maf is a family of oncogenes originally identified from avian oncogenic retrovirus, AS42, encoding a nuclear bZip transcription factor, We have isolated two maf related cDNA clones, maf-1 and maf-2, from a rat liver cDNA library, Comparison of the sequence homologies of the proteins encoded by maf-1 and maf-2 with those of c-maf and chicken mafB indicated that maf-1 and maf-2 are the rat homologues of mafB and c-maf, respectively, Both genes are expressed at low levels in a wide variety of rat tissues, including spleen, kidney, muscle and liver. Immunohistochemical studies and ill situ hybridization analyses show that maf-2 and maf-2 are strongly expressed in the late stages of chondrocyte development in the femur epiphysis and the rib and limb cartilage of 15 day old (E15) embryo in rat, Cartilage cells, induced by subcutaneous implantation of bone morphogenic protein, also expressed maf-1 and maf-2. In situ hybridization analyses of E15 embryos show that both genes are expressed in the eye lens and the spinal cord as well as the cartilage, However, the expression patterns of maf-1 and maf-2 in lens and spinal cord are different.	HOKKAIDO UNIV,SCH DENT,DEPT BIOCHEM,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; NIPPON MED COLL,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC MED,DEPT MOL ONCOL,SAKYO KU,KYOTO 606,JAPAN	Hokkaido University; Nippon Medical School; Kyoto University	Sakai, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,KITA KU,N15 W7,SAPPORO,HOKKAIDO 060,JAPAN.		Sakai, Masaharu/A-4773-2012					ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KUBOKI Y, 1995, CONNECTIVE TISSUE RE, V12, P207; Liu Q, 1996, ONCOGENE, V12, P207; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SAKAI M, 1992, BIOCHEM BIOPH RES CO, V187, P976, DOI 10.1016/0006-291X(92)91293-Y; SAKAI M, 1995, CANCER RES, V55, P5370; SENBA E, 1982, J COMP NEUROL, V208, P54, DOI 10.1002/cne.902080105; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371	21	83	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					745	750		10.1038/sj.onc.1200869	http://dx.doi.org/10.1038/sj.onc.1200869			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038383				2022-12-28	WOS:A1997WG43000014
J	Sangfelt, O; Erickson, S; Einhorn, S; Grander, D				Sangfelt, O; Erickson, S; Einhorn, S; Grander, D			Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines	ONCOGENE			English	Article						interferon; cell cycle; cyclin-dependent kinase; cyclin-dependent kinase inhibitors	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; MUTANT P53; TGF-BETA; ARREST; EXPRESSION; LYMPHOMA; PROTEIN; P21; E2F	One prominent effect of IFNs is their cell growth inhibitory activity. The exact molecular mechanism behind this inhibition of proliferation remains to be elucidated. Possible effecters for IFN-induced growth inhibition are the recently discovered cyclin-dependent kinase inhibitors. The effect of IFN-alpha treatment on the members of the Ink4 and Cip/Kip families of Cdk inhibitors was investigated in three hematopoietic cell lines Daudi, U-266 and H9. Two of these cell lines, Daudi and U-266, respond to IFN-alpha by G(1) arrest, whereas the H9 cell line is not growth arrested by IFN-alpha. We show that a p53-independent upregulation of p21 mRNA occurs following IFN-alpha treatment in all three cell lines. In Daudi and U-266 cells, the mRNA induction is accompanied by an increase in p21 protein, followed by an increased binding of p21 to Cdk2 and a subsequent decrease in Cdk2 activity, temporally coinciding with G(1) arrest. In both these cell lines, there was also an increased binding of p21 to Cdk4. In contrast, p21 protein was not expressed in H9 cells, despite high levels of p21 mRNA following IFN-alpha treatment. In U-266 cells, IFN-alpha increased not only p21 but also p15 mRNA and protein levels, followed by an increased association of p15 with Cdk4, Furthermore, IFN-alpha treatment caused a four- to sixfold induction of the p16 E1 beta transcript in U-266 cells. Expression levels of the other Ink4 and Cip/Kip Cdk inhibitors mere not induced by IFN treatment in any of the cell lines. We conclude that IFN-alpha can act as a potent regulator of Cdk-inhibitor expression, correlating with decreased Cdk activity and cell growth inhibition, One mechanism for resistance to IFN may be loss of the ability of cells to upregulate these proteins.	KAROLINSKA HOSP & INST,RADIUMHEMMET,DEPT ONCOL PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital								Brandter LB, 1996, EUR J HAEMATOL, V56, P313; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CORRADINI P, 1994, LEUKEMIA, V8, P758; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMAYER EM, 1988, INTERFERONS OTHER RE; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; GRANA X, 1995, ONCOGENE, V11, P211; GRANDER D, 1990, LANCET, V336, P337, DOI 10.1016/0140-6736(90)91879-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, CANCER RES, V56, P722; HEYMAN M, 1994, LEUKEMIA, V8, P425; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KUNLIANG G, 1994, GENE DEV, V8, P2939; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA MKJ, 1994, CELL, V79, P487; MAZARS GR, 1992, ONCOGENE, V7, P1015; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1995, CELL, V83, P993; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROOS G, 1984, CANCER RES, V44, P5358; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIYANOV P, 1996, MOL CELL BIOL, V16, P734; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; TAYLORPAPADIMIT.J, 1985, INTERFERONS THEIR IM, P81; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	49	98	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					415	423		10.1038/sj.onc.1200832	http://dx.doi.org/10.1038/sj.onc.1200832			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053838				2022-12-28	WOS:A1997WE36400004
J	Takenaga, K; Nakamura, Y; Sakiyama, S				Takenaga, K; Nakamura, Y; Sakiyama, S			Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells	ONCOGENE			English	Article						S100A4; metastasis; invasion; motility; Lewis lung carcinoma	NONMUSCLE MYOSIN; PEL98 PROTEIN; MTS1; MOTILITY; INVASION; P9KA; ADENOCARCINOMA; IDENTIFICATION; TRANSFECTION; INDUCTION	S100A4 (also known as pEL98/mts1/p9Ka/18A2/42A/calvasculin/FSP1/CAPL), a member of S100-related calcium-binding proteins, has been implicated to play a role in metastasis. In the present study, we examined the effect of antisense S100A4 RNA on metastatic potential of Lewis lung carcinoma (LLC) cells. High-metastatic All cells were transfected with the expression vector containing S100A4 cDNA in an inverted (antisense) orientation under the transcriptional control of the mouse metallothionein promoter. Treatment of a stably transfected clone (AS10 cells) with Zn2+ resulted in the suppression of the experimental metastatic ability, which was accompanied with the expression of antisense S100A4 RNA and the suppression of the S100A4 expression at both the mRNA and the protein levels. To further confirm the effect of antisense S100A4 RNA, we established several clones after retroviral transduction with an antisense S100A4 construct. Notably, reduced metastatic potential was also evident in these clones. In the antisense S100A4 RNA-expressing cells, cell motility and in vitro invasiveness were found to be suppressed.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center	Takenaga, K (corresponding author), CHIBA CANC CTR,RES INST,DIV CHEMOTHERAPY,CHUOH KU,666-2 NITONA,CHIBA 260,JAPAN.							AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES BR, 1993, ONCOGENE, V8, P999; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; EPNER DE, 1993, CANCER RES, V53, P1995; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KANTOR JD, 1993, CANCER RES, V53, P1971; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIOTTA LA, 1991, CANCER RES, V51, pS5054; PARKER C, 1994, DNA CELL BIOL, V13, P1021, DOI 10.1089/dna.1994.13.1021; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; YAMADA KM, 1990, CANCER RES, V50, P4485	29	135	144	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					331	337		10.1038/sj.onc.1200820	http://dx.doi.org/10.1038/sj.onc.1200820			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018119				2022-12-28	WOS:A1997WD51600009
J	Tomida, A; Suzuki, H; Kim, HD; Tsuruo, T				Tomida, A; Suzuki, H; Kim, HD; Tsuruo, T			Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells	ONCOGENE			English	Article						glucose-regulated response; growth arrest; retinoblastoma protein; cyclin D1; p21(WAF1)	MAMMALIAN-CELLS; DEPENDENT KINASES; TUMOR-SUPPRESSOR; P53 PROTEIN; G1 PHASE; GROWTH; INDUCTION; ARREST; P21; ACCUMULATION	Glucose-regulated stress response of cancer cells occurs during the growth of solid tumors and is induced in culture by treatments with various agents, including 2-deoxyglucose, glucosamine, and calcium ionophore A23187. We previously reported that the three stressors commonly induced cell-cycle arrest in the G(1) phase and resistance to antitumor drugs in human cancer A2780 and HT-29 cells. In this study, we investigated the mechanisms of stress-induced G(1) arrest by determining the expression of cell-cycle-regulating proteins. Among G(1) cyclins and cyclin-dependent kinases (cdk) examined, the expression levels of cyclin D1 preferentially decreased in the stressed cells. A time-course study showed that the decrease in cyclin D1 coincided with the appearance of hypophosphorylated retinoblastoma protein (pRb), which is the growth suppressive form. These findings suggest that the stress-induced G(1) arrest is mediated through the down-regulation of cyclin D1-associated kinases (cdk4/6), pRb kinases during G(1) phase. This was also supported by decreased cdk4 expression in stressed HT-29 cells, In addition, p21(WAF1), a cdk inhibitor, was induced in the stressed cells, particularly A23187-treated cells. A23187, compared with the other stressors, caused extreme pRb hypophosphorylation, suggesting that p21(WAf1) is involved in the regulation of pRb phosphorylation in the stressed cells. Our present findings could explain a molecular-based mechanism of a growth-arrested quiescent state and also resistance to chemotherapy of solid tumor cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CAI JW, 1993, J CELL PHYSIOL, V154, P229, DOI 10.1002/jcp.1041540204; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TOMIDA A, 1996, IN PRESS INT J CANC; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yun J, 1995, ONCOL RES, V7, P583	40	29	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2699	2705						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000144				2022-12-28	WOS:A1996VZ65400020
J	Calogero, A; Cuomo, L; DOnofrio, M; deGrazia, U; Spinsanti, P; Mercola, D; Faggioni, A; Frati, L; Adamson, ED; Ragona, G				Calogero, A; Cuomo, L; DOnofrio, M; deGrazia, U; Spinsanti, P; Mercola, D; Faggioni, A; Frati, L; Adamson, ED; Ragona, G			Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines	ONCOGENE			English	Article						Egr-1; EBV; lymphoid cell lines	EPSTEIN-BARR-VIRUS; ZINC FINGER GENE; TRANSCRIPTION FACTOR; BURKITTS-LYMPHOMA; B-LYMPHOCYTES; INVITRO INFECTION; RESPONSE GENES; CROSS-LINKING; WILMS-TUMOR; LUNG-CANCER	In this paper we have investigated the role of Egr-1 in B cell growth regulation by examining the gene expression in a panel of B cell lines, including both EBV genome negative and EBV carrying cell lines. Egr-1 expression correlates with the cellular phenotype and the specific pattern of viral latency established within the individual cell lines. Thus, constitutive activation of Egr-1 gene is invariably associated with unrestricted expression of viral latent genes in all group III EBV genome carrying cell lines. In contrast, Egr-1 expression is abrogated in group I Burkitt tumor cells, irrespective of the EBV genome carrying status. Activated viral gene expression associated with phenotypic conversion of group I cell lines in to group II or III restores the Egr-1 gene expression. Several forms of EGR-1 protein are found within the different groups of cell lines, and the binding activity to DNA consensus sequences was investigated. Finally, time course analysis of Egr-1 expression during the early steps of EBV infection in vitro demonstrated that Egr-1 is upregulated within minutes from the initial interaction with the B lymphocyte.	IRCCS, IST NEUROL MEDITERRANEO, POZZILLI, ITALY; UNIV ROMA LA SAPIENZA, DIPARTIMENTO MED SPERIMENTALE & PATOL, I-00185 ROME, ITALY; SIDNEY KIMMEL CANC CTR, SAN DIEGO, CA USA; BURNHAM INST, SAN DIEGO, CA USA	IRCCS Neuromed; Sapienza University Rome			de Grazia, Ugo/K-1307-2016; Frati, Luigi/ABI-7437-2020; mercola, dan/L-4182-2013; calogero, antonella/U-5418-2019	de Grazia, Ugo/0000-0001-8648-0372; mercola, dan/0000-0002-0281-9840; calogero, antonella/0000-0002-3322-2916				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CIRONE M, 1995, CANCER LETT, V89, P125, DOI 10.1016/0304-3835(94)03663-4; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; GREGORY CD, 1992, REV MED VIROL, V2, P205, DOI 10.1002/rmv.1980020405; GUALANDI G, 1992, J VIROL, V66, P5677, DOI 10.1128/JVI.66.9.5677-5681.1992; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUANG RP, 1995, CANCER RES, V55, P5054; KLAUS SJ, 1993, MOL IMMUNOL, V30, P1553, DOI 10.1016/0161-5890(93)90463-L; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lenoir G M, 1985, IARC Sci Publ, P309; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LEVIN WJ, 1994, CHEST, V106, pS372, DOI 10.1378/chest.106.6.372S; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mitchell R L, 1986, Symp Fundam Cancer Res, V39, P99; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; MONROE JG, 1993, ADV MOL CELL IMMUN B, V1, P1; MURRAY RJ, 1988, J VIROL, V62, P894, DOI 10.1128/JVI.62.3.894-901.1988; Nemerow G R, 1990, Adv Cancer Res, V54, P273, DOI 10.1016/S0065-230X(08)60814-3; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RAGONA G, 1986, CELL BIOL INT REP, V10, P315, DOI 10.1016/0309-1651(86)90002-0; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROONEY CM, 1984, INT J CANCER, V34, P339, DOI 10.1002/ijc.2910340310; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIVEDI P, 1995, ONCOGENE, V11, P505; WILSON RE, 1993, ONCOGENE, V8, P3229; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; ZALANI S, 1995, J VIROL, V69, P3816, DOI 10.1128/JVI.69.6.3816-3823.1995	52	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950977				2022-12-28	WOS:A1996VV14500007
J	McCormack, SJ; Brazinski, SE; Moore, JL; Werness, BA; Goldstein, DJ				McCormack, SJ; Brazinski, SE; Moore, JL; Werness, BA; Goldstein, DJ			Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18	ONCOGENE			English	Article						cell adhesion molecules; focal adhesion kinase; papillomaviruses; protein-tyrosine kinases; signal transduction	PAXILLIN TYROSINE PHOSPHORYLATION; RETINOBLASTOMA GENE-PRODUCT; GROWTH-FACTOR; HUMAN KERATINOCYTES; EXTRACELLULAR-MATRIX; PROTEIN; TRANSFORMATION; BINDING; DOMAIN; DNA	The inappropriate activation of protein-tyrosine kinases (PTKs) has been associated with initiation and progression of several types of human cancers. We therefore postulated that immortalization by DNA tumor viruses results in the induction of PTKs fundamental to these processes. An RT-PCR-based screen was thus used to identify PTKs that were abundantly expressed in HPV-18-immortalized epithelial cells and HPV-containing carcinoma cell lines. One of the genes isolated in this screen was the focal adhesion kinase (FAK; pp125(FAK)), a cytoplasmic protein kinase that is activated in v-src transformed cells or by stimulation with mitogenic polypeptides. FAK also becomes catalytically active upon integrin engagement with extracellular matrix proteins, such as fibronectin. We found that FAK expression and activity were significantly elevated in HPV-18 E6/E7-immortalized human genital epithelial cells relative to their primary cell counterparts. Protein expression and tyrosine phosphorylation of the putative FAK substrate, paxillin, were also notably increased upon HPV-18 immortalization of genital epithelial cells and in HPV-containing cervical carcinoma cell lines. Most significantly, these cells expressed markedly higher levels of both intracellular and extracellular fibronectin, thus providing a mechanism for activation of FAK and increased tyrosine phosphorylation of paxillin. These findings suggest a role for the integrin/FAK-mediated signaling pathway in cervical carcinogenesis and represent one of the first demonstrations of a tyrosine kinase whose activity is elevated following viral immortalization.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; UNIV MISSISSIPPI, MED CTR, DEPT OB GYN, JACKSON, MS 39216 USA; ROSWELL PK CANC INST, DEPT PATHOL, BUFFALO, NY USA	Georgetown University; University of Mississippi; University of Mississippi Medical Center; Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [R29CA063044, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA-63044, IP50CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FERENCZY A, 1987, CERVIVAL INTRAEPITHE, P177; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OWENS LV, 1995, CANCER RES, V55, P2752; PARSONS JT, 1994, J CELL SCI, P109; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RANKIN S, 1994, J BIOL CHEM, V269, P704; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SHEIBANI N, 1991, CANCER RES, V51, P5967; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WOODWORTH CD, 1988, CANCER RES, V48, P4620; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	54	86	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					265	274		10.1038/sj.onc.1201186	http://dx.doi.org/10.1038/sj.onc.1201186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233761				2022-12-28	WOS:A1997XK99900003
J	Kurtz, A; Wang, HL; Darwiche, N; Harris, V; Wellstein, A				Kurtz, A; Wang, HL; Darwiche, N; Harris, V; Wellstein, A			Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis	ONCOGENE			English	Article						FGF-binding protein; gene; skin; carcinogenesis; development; expression	FIBROBLAST GROWTH-FACTOR; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; CELL-GROWTH; MALIGNANT CONVERSION; TARGETED EXPRESSION; WOUND REPAIR; TUMOR-GROWTH; ONCOGENE; DIFFERENTIATION; ANGIOGENESIS	Fibroblast growth factors (FGF)-1 and -2 are found in most embryonic and adult normal and tumor tissues, where they are immobilized in the extracellular matrix (EM), Mobilization of these FGFs is part of a tightly controlled process resulting in the activation of high-affinity receptors, Recently, we have shown that a novel human FGF-binding protein (FGF-BP) mediates the release of immobilized FGF-2 from the EM. Here we isolated genomic and cDNA clones of the mouse FGF-BP homologue and studied its expression during embryonic development and skin carcinogenesis, The murine gene contains two exons that generate a 1.2 kb mRNA and predicts an 18 kDa secreted protein that is 63% identical to its human homologue, FGF-BP mRNA expression during embryogenesis is restricted to skin, intestine and lung. In the developing skin, FGF-BP expression starts at embryonic day 9, reaches peak levels perinatally and is downregulated during postnatal development. Develepment regulation in the intestine is similar, but in lungs and ovaries high expression was also observed in the adult, FGF-BP mRNA expression in the adult skin is dramatically increased during early stages of carcinogen-induced transformation in vivo and by rasactivation in vitro, Finally, mouse FGF-BP binds to FGF-2 and can function as a modulator of FGF in FGF-responsive cells, Our results suggest a potential function of FGF-BP during development and tumorigenesis.	GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT NEUROSURG,WASHINGTON,DC 20007; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kurtz, A (corresponding author), GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,3970 RESERVOIR RD,WASHINGTON,DC 20007, USA.			Kurtz, Andreas/0000-0003-3301-6546; Darwiche, Nadine/0000-0002-1862-5426; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA-58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Brem H., 1993, ONCOGENES TUMOR SUPP, P211; BROADLEY KN, 1989, LAB INVEST, V61, P571; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; DAVIDSON JM, 1985, J CELL BIOL, V100, P1219, DOI 10.1083/jcb.100.4.1219; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; DUCROS DL, 1993, J INVEST DERMATOL, V101, pS106, DOI 10.1111/1523-1747.ep12363020; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0; HENNINGS H, 1988, TUMOR PROMOTERS BIOL, P31; HORI A, 1991, CANCER RES, V51, P6180; HUANG YQ, 1993, J CLIN INVEST, V91, P1191, DOI 10.1172/JCI116279; JANOT F, 1995, INT J CANCER, V64, P117, DOI 10.1002/ijc.2910640208; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STRICKLAND JE, 1988, CANCER RES, V48, P165; VELLUCCI VF, 1995, GENE, V9, P213; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; Vlodavsky I, 1988, Adv Exp Med Biol, V233, P201; WANAKA A, 1991, DEVELOPMENT, V111, P455; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WU DQ, 1991, J BIOL CHEM, V266, P16778	41	55	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2671	2681		10.1038/sj.onc.1201117	http://dx.doi.org/10.1038/sj.onc.1201117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178765				2022-12-28	WOS:A1997XB97800006
J	Nelson, DA; Ludlow, JW				Nelson, DA; Ludlow, JW			Characterization of the mitotic phase pRb-directed protein phosphatase activity	ONCOGENE			English	Article						serine/threonine phosphatase; PP1; cell cycle; retinoblastoma protein; dephosphorylation	SERINE THREONINE PHOSPHATASES; CELL-CYCLE REGULATION; SV40 LARGE-T; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; SKELETAL-MUSCLE; GENE-PRODUCT; PHOSPHOPROTEIN PHOSPHATASE; TYPE-1; PHOSPHORYLATION	We have previously reported on the M-phase specific dephosphorylation of pRb and identified a type 1 serine/ threonine protein phosphatase (PPI) as the enzyme mediating pRb dephosphorylation. In this report, we have characterized the pRb-directed phosphatase activity found in mitotic cells with respect to dose dependence and demonstrate that the pRb isoform conversion detected in vitro mirrors the pRb isoform conversion which occurs during mitosis of intact cells. Cell fractionation and PP1 catalytic subunit isolation studies support the notion that the pRb-directed phosphatase activity involves subpopulations of PP1 catalytic subunits. Coprecipitation studies revealed that PPI can form a complex with hypophosphorylated pRb which was converted from the hyperphosphorylated form in mitotic cell extracts. Taken together with data from previous reports in the literature, a model for the regulation of PP1 activity towards pRb during mitotic exit is proposed.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, CTR CANC, DIV DEV THERAPEUT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Nelson, Deirdre/0000-0001-5527-2570	NATIONAL CANCER INSTITUTE [R29CA056940, P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198, CA56940] Funding Source: Medline; NIDCR NIH HHS [DE07202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRAUTIGAN DL, 1982, BIOCHEMISTRY-US, V21, P1977, DOI 10.1021/bi00538a001; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHATRA BS, 1986, J BIOL CHEM, V261, P8944; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WOODFORD TA, 1986, J BIOL CHEM, V261, P4669; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x	37	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2407	2415		10.1038/sj.onc.1201081	http://dx.doi.org/10.1038/sj.onc.1201081			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188855				2022-12-28	WOS:A1997WZ68000004
J	Husson, H; Mograbi, B; SchmidAntomarchi, H; Fischer, S; Rossi, B				Husson, H; Mograbi, B; SchmidAntomarchi, H; Fischer, S; Rossi, B			CSF-1 stimulation induces the formation of a multiprotein complex including CSF-1 receptor, c-Cbl, PI 3-kinase, Crk-II and Grb2	ONCOGENE			English	Article						Colony Stimulating Factor-1; c-Cbl; c-Crk-II; phosphatidylinositol 3-kinase; Grb2; multimolecular complex	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; INSULIN-RECEPTOR; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; 2-HYBRID SYSTEM; JURKAT CELLS; V-CRK	Recently c-Cbl has been reported to be phosphorylated upon CSF-1 stimulation. The product of the c-cbl protooncogene (c-Cbl) is a 120 kDa protein harboring several docking sites for Src homology 2 (SH2) domain containing proteins and proline-rich regions that have been shown to allow its constitutive association with the SH3 domains of Grb2, We demonstrate here that CSF-1 exposure of stable transfectant CHO cells expressing the CSF-1 receptor induced the sustained tyrosine phosphorylation of c-Cbl and its subsequent association with Crk-II and the p85 kDa subunit of the PI 3-kinase, while it constitutively associates with Grb2, We demonstrate by in vitro experiments that these associations require the SH2 domain of Crk-II and both the C- and N-terminal SH2 domains of the p85 subunit of the PI 3-kinase, c-Cbl is the major PI 3-kinase-containing protein in c-Fms expressing CHO cells upon CSF-1 stimulation, Thus c-Cbl behaves as a core protein, allowing the formation of a quaternary complex including, Crk-II, PI 3-kinase and Grb2, We provide evidence that this multiprotein complex can interact with the tyrosine phosphorylated CSF-1 receptor through the unoccupied SH2 domain of Grb2.	FAC MED,INSERM U364,F-06107 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Mograbi, Baharia/N-5531-2018; Mograbi, Baharia/Q-7953-2019	Mograbi, Baharia/0000-0002-1025-3429				BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FAUX MC, 1986, CELL, V85, P9; FELLER SM, 1995, ONCOGENE, V10, P1465; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Sambrook J., 2002, MOL CLONING LAB MANU; Sattler M, 1996, ONCOGENE, V12, P839; SCHMIDANTOMARCH.H, 1995, EUR J IMMUNOL, V26, P717; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SHERR CJ, 1990, LYMPHOKINE RES, V9, P543; Smit L, 1996, ONCOGENE, V13, P381; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STANLEY ER, 1994, CYTOKINE HDB, P387; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	50	31	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2331	2338		10.1038/sj.onc.1201074	http://dx.doi.org/10.1038/sj.onc.1201074			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178909				2022-12-28	WOS:A1997WY88300010
J	LAllemain, G; Lavoie, JN; Rivard, N; Baldin, V; Pouyssegur, J				LAllemain, G; Lavoie, JN; Rivard, N; Baldin, V; Pouyssegur, J			Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts	ONCOGENE			English	Article						cyclin D1; cAMP; cyclin-CDK complexes; p27(KIP1); DNA synthesis	DEPENDENT KINASE; HAMSTER FIBROBLASTS; NUCLEAR-PROTEIN; RETINOBLASTOMA PROTEIN; PHASE-TRANSITION; GENE-EXPRESSION; MAMMALIAN-CELLS; GROWTH-CONTROL; DNA-SYNTHESIS; S-PHASE	We previously described in the CCL39 hamster fibroblast cell line the inhibition of DNA synthesis reinitiation by agents that elevate cyclic AMP. Here, we show that 8Br-cAMP strongly blocks both the growth factor-induced increase in cyclin D1 protein expression and decrease in p27(KIP1) protein levels, leaving untouched the levels of cyclin D3, cdk2 and cdk4. To assess the role of cyclin D1 in the cAMP-mediated inhibition of DNA synthesis, we overexpressed the cyclin D1 gene in CCL39 and analysed the cAMP response in stable transfectants. We showed that the kinase activities associated to G(1) cyclin-cdk complexes are significantly more resistant to cAMP in cyclin D1 transfectants than in their normal counterparts, although the serum-induced p27(KIP1) disparition is still cAMP sensitive in cyclin D1 overexpressors. Interestingly, the mitogen-induced DNA synthesis reinitiation is also much less inhibited by cAMP in cyclin D1 transfectants than in control cells. These data clearly establish that the cAMP-inducible blockade of the G(1) phase of the cell cycle can be partially alleviated by overexpression of cyclin D1 in hamster fibroblasts, thus strongly suggesting that cyclin D1 protein is one of the major targets for cAMP inhibitory action in fibroblasts.			LAllemain, G (corresponding author), FAC SCI, CTR BIOCHIM, CNRS UMR134, PARC VALROSE, F-06108 NICE 02, FRANCE.		BALDIN, Véronique/Y-8397-2019	BALDIN, Véronique/0000-0001-8523-0494; Lavoie, Josee N/0000-0001-6912-1132				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GRANA X, 1995, ONCOGENE, V11, P211; HAN EKH, 1995, ONCOGENE, V10, P953; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; JIANG W, 1993, ONCOGENE, V8, P3447; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, ONCOGENE, V10, P2125; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Noel J, 1996, J CELL SCI, V109, P929; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1994, J CELL SCI, P69; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAM SW, 1994, ONCOGENE, V9, P2663; Vadiveloo PK, 1996, ONCOGENE, V13, P599; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; ZHOU P, 1995, ONCOGENE, V11, P571; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	59	88	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1981	1990		10.1038/sj.onc.1201038	http://dx.doi.org/10.1038/sj.onc.1201038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150365				2022-12-28	WOS:A1997WV80400011
J	Casola, S; Pedone, PV; Cavazzana, AO; Basso, G; Luksch, R; dAmore, ESG; Carli, M; Bruni, CB; Riccio, A				Casola, S; Pedone, PV; Cavazzana, AO; Basso, G; Luksch, R; dAmore, ESG; Carli, M; Bruni, CB; Riccio, A			Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma	ONCOGENE			English	Article						genomic imprinting; 11p15 LOH; pediatric cancer	GROWTH-FACTOR-II; WILMS-TUMOR; ALVEOLAR RHABDOMYOSARCOMA; MATERNAL ALLELES; RNA; LOCUS; IGF2; HEPATOBLASTOMA; TUMORIGENESIS; METHYLATION	The expression of Insulin-like Growth Factor 2 (IGF-2) and H19, two genes located on human chromosome 11p15 and provided with cell growth modulating activity, is regulated by parental imprinting, in that the activity of their alleles is dependent on the parental origin. Parental bias in the genetic alterations of chromosome 11p15 observed in several pediatric cancers suggests the involvement of imprinted genes in tumor development. We have previously reported that the number of functional IGF-2 alleles is frequently increased in rhabdomyosarcoma (RMS), as a consequence of either relaxation of imprinting (LOI) or gene duplication. Here we show that the expression of the H19 gene is significantly suppressed with respect to normal muscle tissue in 13 out of 15 rhabdomyosarcomas with embryonal histology (ERMS) and in three out of 11 rhabdomyosarcomas classified as alveolar subtype (ARMS). Since a growth-inhibitory activity has been found associated with the H19 gene, the extinction of its expression can contribute to RMS development. Parental imprinting of the H19 gene was found conserved in all informative RMSs, including those whose IGF-2 imprinting was relaxed, indicating that LOI is a gene-specific event. Seven ERMSs and one ARMS displaying low H19 RNA levels showed an underrepresentation of the expressed allele in their genotype. This result is consistent with the paternal imprinting of the H19 gene and with the preferential loss of the maternal 11p15 alleles in these neoplasms. Low H19 expression was also found in four out of eight RMSs retaining the heterozygosity at 11p15, but showing IGF-2 LOI. These findings suggest that the genetic and epigenetic alterations affecting chromosome 11p15 in a high number of RMSs cause deregulation of more than one imprinted gene, possibly affecting tumor growth, including the extinction of H19 expression and an increase in the number of active IGF-2 alleles.	CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY; UNIV NAPLES 2,FAC SCI AMBIENTALI,NAPLES,ITALY; UNIV ROMA TOR VERGATA,IST ANAT PATOL,ROME,ITALY; UNIV PADUA,CLIN PEDIAT 2,DIV ONCOEMATOL,PADUA,ITALY; UNIV PADUA,IST ANAT PATOL,PADUA,ITALY; IST NAZL TUMORI,I-20133 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita della Campania Vanvitelli; University of Rome Tor Vergata; University of Padua; University of Padua; Fondazione IRCCS Istituto Nazionale Tumori Milan			Riccio, Andrea/A-4991-2015; Cerrato, Flavia/O-8315-2015; Luksch, Roberto/K-2206-2016; Casola, Stefano/AAN-8319-2021; Riccio, Andrea/AAY-7571-2020; Casola, Stefano/O-3922-2014	Riccio, Andrea/0000-0001-7990-3576; Cerrato, Flavia/0000-0003-3794-3021; Luksch, Roberto/0000-0002-7203-4176; Casola, Stefano/0000-0001-5580-0986; Riccio, Andrea/0000-0001-7990-3576; Pedone, Paolo Vincenzo/0000-0002-0828-5843; BASSO, GIUSEPPE/0000-0002-2634-9302				ALBRECHT S, 1994, CANCER RES, V54, P5041; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CASOLA S, 1995, ONCOGENE, V11, P711; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS RJ, 1994, CANCER RES, V54, P2869; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELBADRY OM, 1990, CELL GROWTH DIFFER, V84, P829; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Ferracini R, 1996, ONCOGENE, V12, P1697; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kondo M, 1996, ONCOGENE, V12, P1365; LEIBOVITCH MP, 1995, ONCOGENE, V10, P251; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI XR, 1995, ONCOGENE, V11, P221; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NEWTON WA, 1995, CURRENT TOPICS PATHO, V89; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAL N, 1990, ONCOGENE, V5, P1665; Pappo Alberto S., 1995, Current Opinion in Oncology, V7, P361, DOI 10.1097/00001622-199507000-00012; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; Sambrook J., 2002, MOL CLONING LAB MANU; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	51	49	51	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1503	1510		10.1038/sj.onc.1200956	http://dx.doi.org/10.1038/sj.onc.1200956			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136994				2022-12-28	WOS:A1997WT58400013
J	Middeler, G; Zerf, K; Jenovai, S; Thulig, A; TschodrichRotter, M; Kubitscheck, U; Peters, R				Middeler, G; Zerf, K; Jenovai, S; Thulig, A; TschodrichRotter, M; Kubitscheck, U; Peters, R			The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited	ONCOGENE			English	Article						nucleocytoplasmic shuttling; nucleocytoplasmic transport; nuclear import signal; nuclear export signal; subcellular localization	SCANNING MICROPHOTOLYSIS; NUCLEOCYTOPLASMIC FLUX; PROGESTERONE-RECEPTOR; LOCALIZATION SIGNALS; PROTEIN IMPORT; MESSENGER-RNA; GROWTH ARREST; DNA-BINDING; MUTANT P53; IN-VIVO	Human p53 was expressed in E. coli, purified, labeled with fluorescein iodoacetamide (IAF) and characterized for sequence-specific DNA binding and epitope disposition. Injected into the cytoplasm or nuclei of 3T3 cells IAF-p53 was imported into or exported from nuclei within minutes. Import was inhibited by coinjection of the lectin wheat germ agglutinine (WGA). In contrast, the peptide-protein conjugate NLS-HSA carrying the nuclear localization sequence (NLS) of the SV40 T antigen was only imported but not exported. 3T3 polykaryons were injected with IAF-p53 and photobleached by Scanning Microphotolysis in such a manner that only a single nucleus per polykaryon remained non-bleached. IAF-p53 was found to migrate rapidly (halftime similar to 10 min) from non-bleached into bleached nuclei, while NLS-HSA did not. In digitonin permeabilized cells IAF-p53 was imported into nuclei. When removed from the medium after nuclear accumulation IAF-p53 was exported from the nuclei. Nuclear import and export of IAF-p53 both were rapid (halftimes of a few minutes, 22 degrees C) and strongly inhibited by WGA or incubation on ice. NLS-HSA was only imported but not exported. We conclude that the nucleocytoplasmic transport of p53, in contrast to that of NLS-HSA, is bidirectional and that transport in both directions is carrier mediated and energy dependent. These results suggest that p53 contains nuclear export signals (NES) in addition to import signals (NLS) and thus open new views on the potential regulation of p53 cellular fractions.	UNIV MUNSTER,INST MED PHYS & BIOPHYS,D-48149 MUNSTER,GERMANY	University of Munster			Kubitscheck, Ulrich/GPS-8017-2022; Peters, Reiner/E-7352-2011	Kubitscheck, Ulrich/0000-0003-3750-5355				ACKERMANN M, 1991, EXPERIENTIA, V47, pA55; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ADDISON C, 1990, ONCOGENE, V5, P423; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DANG CV, 1989, J BIOL CHEM, V264, P18019; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FRITSCHE M, 1993, ONCOGENE, V8, P3007; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOLDSTEIN L, 1958, EXP CELL RES, V15, P635, DOI 10.1016/0014-4827(58)90118-6; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; GUIOCHONMANTEL A, 1994, BIOCHEM PHARMACOL, V47, P21, DOI 10.1016/0006-2952(94)90433-2; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUBITSCHECK U, 1994, BIOPHYS J, V67, P948, DOI 10.1016/S0006-3495(94)80596-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MEIER UT, 1992, CELL, V70, P127; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MICHAEL WM, 1995, CELL, V83, P415; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; PETERS R, 1974, BIOCHIM BIOPHYS ACTA, V367, P282, DOI 10.1016/0005-2736(74)90085-6; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCHMIDT M, 1994, EUR J CELL BIOL, V65, P70; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; TAKAHASHI K, 1994, ONCOGENE, V9, P183; THULIG A, 1994, MOL BIOL CELL, V5, pA458; TschodrichRotter M, 1996, BIOPHYS J, V70, P723, DOI 10.1016/S0006-3495(96)79612-1; WALASCHEWSKI U, 1995, METHOD MOL CELL BIOL, V5, P87; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEDEKIND P, 1994, J MICROSC-OXFORD, V176, P23, DOI 10.1111/j.1365-2818.1994.tb03496.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	62	78	79	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1407	1417		10.1038/sj.onc.1200949	http://dx.doi.org/10.1038/sj.onc.1200949			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136984				2022-12-28	WOS:A1997WT58400003
J	Carrozza, ML; Jacobs, H; Acton, D; Verma, I; Berns, A				Carrozza, ML; Jacobs, H; Acton, D; Verma, I; Berns, A			Overexpression of the FosB2 gene in thymocytes causes aberrant development of T cells and thymic epithelial cells	ONCOGENE			English	Article						oncogene; thymus; development	C-FOS; TRANSGENIC MICE; PROTO-ONCOGENE; STEM-CELLS; JUN; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; EXPRESSION; INTERACTS	We have examined the role of the AP-1 transcription factor on thymocyte maturation and thymus architecture by overexpressing FosB2 in transgenic mice. FosB2 is a naturally occurring splice variant of the FosB2 gene, encoding a truncated protein which lacks two domains necessary for transcriptional activation. The expression of FosB2 in the thymocytes severely affected their maturation and the structure of the whole thymus: the phenotype developed slowly during the first months of life, resulting in a progressive expansion of the medulla and concomitant reduction of the cortex. CD4(+) thymocytes represented the major thymocyte population, whereas the CD4(+)8(+) thymocytes were virtually absent. This phenotype appeared to be an intrinsic property of bone marrow derived cells, as it could be reproduced in bone marrow chimaeric mice, This pathology was very reminiscent to that observed in mice overexpressing c-Fos in thymic epithelium: also in that case the thymus underwent with age a progressive expansion of the epithelium and major changes in the ratio of thymocyte subsets, but the phenotype appeared to be an intrinsic property of the epithelial cells since it could not be reproduced by transgenic bone marrow transplantation. We speculate that both overexpression of FosB2 in thymocytes and overexpression of c-Fos in thymic epithelium results in aberrant signaling between thymocytes and stroma, that ultimately alters the thymic micromilieu, leading to this severe pathology.	NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Netherlands Cancer Institute; Salk Institute				Jacobs, Heinz/0000-0001-6227-9850				BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; COUTURE C, 1992, EUR J IMMUNOL, V22, P2579, DOI 10.1002/eji.1830221017; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GALY AHM, 1992, J IMMUNOL, V149, P775; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MORGAN JI, 1991, REV NEUROSCI, V14, P421; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAMARLI D, 1987, P NATL ACAD SCI USA, V84, P8598, DOI 10.1073/pnas.84.23.8598; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; WOLF SS, 1992, IMMUNOLOGY, V77, P362; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1991, IMMUNOL TODAY, V12, P65	39	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	1997	14	9					1083	1091		10.1038/sj.onc.1200921	http://dx.doi.org/10.1038/sj.onc.1200921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070657				2022-12-28	WOS:A1997WM07000010
J	Ghosh, AK; Datta, PK; Jacob, ST				Ghosh, AK; Datta, PK; Jacob, ST			The dual role of helix-loop-helix-zipper protein USF in ribosomal RNA gene transcription in vivo	ONCOGENE			English	Article						ribosomal RNA gene; upstream stimulatory factor; repressor; activator; pol I transcription	POLYMERASE-I TRANSCRIPTION; UPSTREAM STIMULATORY FACTOR; KU-RELATED PROTEIN; WILD-TYPE P53; BINDING-FACTOR; MAMMALIAN-CELLS; CORE PROMOTER; FACTOR CPBF; FACTOR E1BF; E-BOX	We have previously demonstrated that the core promoter of rat ribosomal RNA gene (rDNA) contains an E-box-Like sequence to which the core promoter binding factor CPBF binds and that the 44 kDa subunit of this protein is immunologically related to USF1, the helix-loop-helix-zipper DNA binding protein. Further, we showed that RNA polymerase I (pol I) transcription in vitro is competed by oligonucleotides containing USF-binding site, which suggested a key role for USF in rDNA transcription. To prove the potential role of USF in pol I transcription in vivo, USF1 and USF2 homodimers and USF1/USF2 heterodimer were overexpressed in CHO cells by transfection of the respective cDNAs, Co-transfection of a plasmid containing rDNA followed by primer extension analysis showed that overexpression of USF1 and USF2 as homodimers resulted in inhibition of rDNA transcription by as much as 85-90% whereas overexpression of USF1/USF2 in the heterodimeric form activated transcription approximately 3.5-fold. Transfection of mutant USF2 cDNA that is devoid of the basic DNA-binding domain produced only minimal inhibition of rDNA transcription. These data show that USF can modulate transcription of rRNA gene in vivo by functioning as a repressor (homodimer) or activator (heterodimer) of pol I transcription in vivo and suggest that inhibition of rDNA transcription may be responsible for the antiproliferative action of USF homodimers.	FINCH UNIV HLTH SCI CHICAGO MED SCH, DEPT PHARMACOL & MOL BIOL, CHICAGO, IL 60064 USA	Chicago Medical School			Jacob, Samson/H-3135-2011	Datta, Prasun/0000-0001-5133-253X	NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; Ghosh AK, 1996, BIOCHEM BIOPH RES CO, V225, P890, DOI 10.1006/bbrc.1996.1268; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; ISHIKAWA Y, 1991, J MOL BIOL, V218, P55, DOI 10.1016/0022-2836(91)90873-5; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; JOOST CBM, 1994, SCIENCE, V266, P2015; JUVEN T, 1993, ONCOGENE, V8, P3411; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LI JM, 1994, MOL CELL BIOL, V14, P2191, DOI 10.1128/MCB.14.3.2191; LIN Q, 1994, J BIOL CHEM, V269, P23894; LIU ZJ, 1994, J BIOL CHEM, V269, P16618; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; Niu Huifeng, 1995, Gene Expression, V4, P111; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; Paule Marvin R., 1993, Gene Expression, V3, P1; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	44	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					589	594		10.1038/sj.onc.1200866	http://dx.doi.org/10.1038/sj.onc.1200866			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053857				2022-12-28	WOS:A1997WF52400010
J	Park, S; Sanchez, MP				Park, S; Sanchez, MP			The Eek receptor, a member of the Eph family of tyrosine protein kinases, can be activated by three different Eph family ligands	ONCOGENE			English	Article						receptor tyrosine kinase; Eph family; brain	GENE; EXPRESSION; BRAIN; IDENTIFICATION; CLONING; MOUSE; TRKB; ELK; OVEREXPRESSION; HINDBRAIN	The Eph family of receptors, the largest subgroup within the tyrosine protein kinase receptor family, are comprised of at least thirteen members, many of which are predominantly expressed in the developing and adult nervous system. In this study, we have isolated a full-length cDNA, encoding the mouse homologue of a previous partially characterized Eek protein, a member of Eph receptor tyrosine kinase family. In a comparison of the amino acid sequences of various Eph family members, Eek is most similar to Ehk-3/MDK1, Sek/Cek8, Ehk-2, Hek/Mek4/Cek4, and Bsk/Ehk1/Rek7/Cek7, which are predominantly expressed in the nervous system. Additionally, we have used a low-stringency PCR cloning technique to identify ligands, related to B61, that may interact with Eek. Three different GPI-linked ligands, namely Elf-1/Cek7-L, Ehk1-L/Efl-2/Lerk3 and AL-1/RAGS, were isolated from mouse brain. To study the functional interactions between these ligands and the Eek receptors, rye have constructed chimeric ligands consisting of the Fc portion of human IgG fused to their carboxyl-terminus. These chimeric ligands bound to, and activated both the Eek receptors and the Eek-TrkB chimeric receptors expressed in NIH3T3 cells. These findings suggest that Eek receptor can be activated by at least three different GPI-Linked ligands.			Park, S (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Sanchez, Marina P/A-2453-2011	Sanchez, Marina P/0000-0003-1905-3842; Park, Soochul/0000-0002-7029-3414				ANDRES AC, 1994, ONCOGENE, V9, P1461; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V9, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRIAN JP, 1991, MOL CELL BIOL, V11, P5016; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	50	21	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					533	542		10.1038/sj.onc.1200857	http://dx.doi.org/10.1038/sj.onc.1200857			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053851				2022-12-28	WOS:A1997WF52400004
J	Biesova, Z; Piccoli, C; Wong, WT				Biesova, Z; Piccoli, C; Wong, WT			Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth	ONCOGENE			English	Article						epidermal growth factor receptor; eps8; SH3 domain; e3B1; signal transduction	TRANSFORMING ACTIVITY; FACTOR RECEPTOR; SUBSTRATE; KINASE; IDENTIFICATION; PROTOONCOGENE; PRODUCT; CLONING; DOMAIN	Eps8, a substrate of receptor tyrosine kinases, is an SH3 domain containing protein that plays an important role in mitogenic signaling. To determine the cellular function of eps8, we used the SH3 domain of eps8 to screen a human fibroblast M426 expression library and identified, a full-length cDNA clone of 3.2 kb. We designated this clone e3B1 for eps8 SH3 domain binding protein 1. Northern analysis revealed that expression of e3B1 mRNA was ubiquitious in human tissues. The e3B1 gene encodes a SH3 domain containing protein. We show that anti-e3B1 antibodies detect three cytosolic protein species of 65, 68 and 72 kDa in cell lysate isolated from asynchronously growing NIH3T3 cells. E3B1 binds to the SH3 domain of eps8 and Abi in vitro. We also demonstrated that e3B1 associates with eps8 in vivo. Phosphatase digestion and phosphoamino acid analysis revealed that p65(e3B1) is a phosphoserine containing protein and p72(e3B1) and p68(e3B1) are hyperserine-phosphorylated form of p65(e3B1). We further determined that the p65(e3B1) was the most abundant in serum-starved NIH/EGFR cells. Time course studies initiated by the addition of epidermal growth factor (EGF) revealed that the p72(e3B1) started to accumulate at 4 h, peaked at 8 h and remained high until 24 h. Finally, we demonstrate that NIH/EGFR fibroblasts overexpressing e3B1 grow more slowly relative to matched controls.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MIKI T, 1993, PRACT APPROACH SER, P177; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WONG WT, 1994, ONCOGENE, V9, P3057	23	89	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					233	241		10.1038/sj.onc.1200822	http://dx.doi.org/10.1038/sj.onc.1200822			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010225				2022-12-28	WOS:A1997WC81800011
J	Blaszyk, H; Hartmann, A; Tamura, Y; Saitoh, S; Cunningham, JM; McGovern, RM; Schroeder, JJ; Schaid, DJ; Ii, K; Monden, Y; Morimoto, T; Komaki, K; Sasa, M; Hirata, K; Okazaki, M; Kovach, JS; Sommer, SS				Blaszyk, H; Hartmann, A; Tamura, Y; Saitoh, S; Cunningham, JM; McGovern, RM; Schroeder, JJ; Schaid, DJ; Ii, K; Monden, Y; Morimoto, T; Komaki, K; Sasa, M; Hirata, K; Okazaki, M; Kovach, JS; Sommer, SS			Molecular epidemiology of breast cancers in northern and southern Japan: The frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations	ONCOGENE			English	Article						Japan; molecular epidemiology; p53; breast cancer	TUMOR-SUPPRESSOR GENE; FACTOR-IX GENE; CPG DINUCLEOTIDES; CARCINOMAS; WOMEN; ETIOLOGY; PROTEIN; RATES	Comparison of acquired mutations in the p53 tumor suppressor gene can illuminate factors contributing to carcinogenesis among cancer cohorts. Japan has an ethnically homogeneous population with a low incidence of breast cancer. Previously we reported an unusual frequency, allelic status, and clustering of mutations in breast cancers from the northern part of the main Japanese island. To extend these findings, exons 2-11 and adjacent intronic sequences were analysed in tumors of women from northern (Hokkaido) and southern (Tokushima) Japan. The frequency of breast cancers with p53 gene mutations in the Hokkaido group is the highest reported (81%) while that in Tokushima (28%) is similar to most other populations. Thirteen of the 19 mutations (68.4%) in the Hokkaido cohort were heterozygous, an unusually high frequency for p53 mutations in any tumor type. There were three missense mutations at codon 175, a known hotspot for alterations in the p53 gene, and three missense mutations at codon 179, a rare site for p53 changes. In addition, the patterns of p53 gene mutation differed between the two Japanese cohorts (P=0.04). The multiple differences in acquired p53 mutations suggest unsuspected biological differences among breast cancers in northern and southern Japan. In addition, the high frequency of p53 mutations in breast cancers from Hokkaido predicted a poorer prognosis for this population which was confirmed on examination of mortality data.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905; HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT PATHOL 1,TOKUSHIMA 770,JAPAN; SAPPORO MED UNIV,DEPT SURG 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Hirosaki University; Tokushima University; Sapporo Medical University					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA56881, CA15086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BORRESEN AL, 1992, CANCER RES, V52, P3234; BOTTEMA CDK, 1993, HUM GENET, V91, P496; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; CHIBA I, 1990, ONCOGENE, V5, P1603; COLEMAN MP, 1993, IARC SCI PUBL, V121, P1; COLES C, 1992, CANCER RES, V52, P5291; COOPER DN, 1990, HUM GENET, V85, P55; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DeVries EMG, 1996, HUM MUTAT, V7, P202, DOI 10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5; GLEBOV OK, 1994, CANCER RES, V54, P3703; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hartmann A, 1996, BRIT J CANCER, V73, P896, DOI 10.1038/bjc.1996.179; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTMANN A, 1995, J CLIN INVEST, V95, P686, DOI 10.1172/JCI117714; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1991, CANCER RES, V51, P3617; KETTERLING RP, 1994, AM J HUM GENET, V54, P831; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; KUROISHI T, 1994, CANC MORTALITY MORBI, P96; MAZARS R, 1992, CANCER RES, V52, P3918; MOLES JP, 1993, ONCOGENE, V8, P583; SAITOH S, 1994, ONCOGENE, V9, P2869; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SASA M, 1993, BREAST CANCER RES TR, V27, P247, DOI 10.1007/BF00665694; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; SOUSSI T, 1990, ONCOGENE, V5, P945; STEMMERMANN GN, 1991, BREAST CANCER RES TR, V18, pS67, DOI 10.1007/BF02633531; THORLACIUS S, 1993, CANCER RES, V53, P1637; TOMINAGA S, 1995, CANCER LETT, V90, P75, DOI 10.1016/0304-3835(94)03680-H; TOMINAGA S, 1993, GANN TOKEI HAKUSHO R, P86; TOMINAGA S, 1994, CANC MORTALITY MORBI, P120; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TSUDA H, 1993, JPN J CANCER RES, V84, P394, DOI 10.1111/j.1349-7006.1993.tb00149.x; UMEKITA Y, 1994, JPN J CANCER RES, V85, P825, DOI 10.1111/j.1349-7006.1994.tb02954.x	48	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2159	2166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950983				2022-12-28	WOS:A1996VV14500013
J	Marra, G; Chang, CL; Laghi, LA; Chauhan, DP; Young, D; Boland, CR				Marra, G; Chang, CL; Laghi, LA; Chauhan, DP; Young, D; Boland, CR			Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells	ONCOGENE			English	Article						hMSH2; protein expression; cell cycle; DNA mismatch repair	NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MUTATIONS; GENE; YEAST; MSH2; RECOMBINATION	The hMSH2 protein plays an important role in the DNA mismatch repair system. Since this system is involved in the correction of errors that occur during DNA replication, we studied the expression of hMSH2 protein in resting and DNA-replicating cells, as well as through the cell cycle in cell types with different growth characteristics. Using Western blot analysis, we showed that hMSH2 protein was detectable in resting peripheral blood lymphocytes and thymocytes. However, when these cells were induced to proliferate, the protein level increased at least 12-fold. In cell-cycle dependent expression studies we chose two DNA mismatch repair proficient cell lines (HEL and HeLa-S3), and flow cytometry was used to monitor cell-cycle progression. At every phase in the cell cycle, the steady-state level of hMSH2 was higher than in resting lymphocytes or thymocytes, and only minor variations of expression level were observed through the cell cycle. In particular, a two to fourfold decrease in hMSH2 expression occurred at G(1) in HEL and at early S phase in HeLa-S3, but higher expression levels resumed during the replicative and postreplicative phases of the cell cycle. Interestingly, hMSH2 protein expression decreased fourfold when HEL cells were induced to differentiate along the megakaryocyte lineage, when continuous DNA replication occurs without mitosis. These results suggest that a basal level of hMSH2 protein expression is necessary for resting and differentiated cells, and that increased hMSH2 protein expression is required when DNA replication is activated and followed by mitosis.	UNIV CALIF SAN DIEGO, DEPT MED, DIV GASTROENTEROL, LA JOLLA, CA 92093 USA; UNIV MICHIGAN, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV CALIF SAN DIEGO, CTR CANC, CORE FLOW CYTOMETRY FACIL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of California System; University of California San Diego			Chang, Christina/B-9650-2009; Laghi, Luigi/GZM-5831-2022	Laghi, Luigi/0000-0003-4187-1059				ALANI E, 1994, GENETICS, V137, P19; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; CHANG CL, 1988, J BACTERIOL, V170, P4015, DOI 10.1128/jb.170.9.4015-4022.1988; CHI NW, 1994, J BIOL CHEM, V269, P29984; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAWN MT, 1995, CANCER RES, V55, P3721; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Leach FS, 1996, CANCER RES, V56, P235; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOEB LA, 1994, CANCER RES, V54, P5059; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P963; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELVA EM, 1995, GENETICS, V139, P1175; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TANNERGARD P, 1995, CANCER RES, V55, P6092; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TURKA LA, 1991, J IMMUNOL, V146, P1428; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WILSON TM, 1995, CANCER RES, V55, P5146	52	70	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2189	2196						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950986				2022-12-28	WOS:A1996VV14500016
J	Nishii, K; Kabarowski, JHS; Gibbons, DL; Griffiths, SD; Titley, I; Wiedemann, LM; Greaves, MF				Nishii, K; Kabarowski, JHS; Gibbons, DL; Griffiths, SD; Titley, I; Wiedemann, LM; Greaves, MF			ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block	ONCOGENE			English	Article						apoptosis; BCR-ABL; phosphorylation; cdc2; cell cycle; leukaemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN-TYROSINE KINASE; HAMSTER OVARY CELLS; INDUCED APOPTOSIS; DNA-DAMAGE; ANTICANCER AGENTS; P34CDC2 KINASE; G2 ARREST; DEATH; PHOSPHORYLATION	Using a temperature-sensitive mutant of the p210 BCR-ABL gene, transfected into a growth factor-dependent cell line (BaF3), we show that transient BCR-ABL kinase expression increases single cell and clonogenic resistance to apoptosis arising from genotoxic damage induced by ionizing radiation and VP-16/etoposide. This effect is achieved in the absence of any detectable changes in the levels of BCL-2, BAX or BCL-x proteins and is independent of proliferative, MAP kinase-dependent effects of BCR-ABL kinase. In contrast to parental cells that transiently arrest in G(2) and then apoptose, p210 BaF3 cells show a pronounced and sustained G(2) arrest following radiation coupled with enhanced phosphorylation of cdc2. A cell cycle block in early M phase induced by the mitotic spindle poison, nocodazole, does not provide protection from apoptosis. Reversal of G(2) arrest by caffeine abolishes the protective effect of BCR-ABL kinase. These data provide further insight into the transforming properties of BCR-ABL and are relevant to the clinical intransigence of Ph-positive leukaemias.	INST CANC RES, LEUKAEMIA RES FUND CTR, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ALLEN PB, 1992, MOL GENETICS HAEMATO, P897; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CLARK SS, 1989, MOL DIAGNOSTICS HUMA, P15; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CRIST W, 1990, BLOOD, V76, P489; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HERMANS A, 1989, CANCER CEL, V7, P21; HERZINGER T, 1995, ONCOGENE, V11, P2151; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KHARBANDA S, 1994, CANCER RES, V54, P1412; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1990, CANCER RES, V50, P3767; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McKenna WG, 1996, ONCOGENE, V12, P237; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PALUMBO GJ, 1990, CANCER RES, V50, P1917; PALUMBO GJ, 1991, LEUKEMIA RES, V15, P847, DOI 10.1016/0145-2126(91)90469-A; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; POWELL SN, 1995, CANCER RES, V55, P1643; PROCTOR SJ, 1994, BRIT J HAEMATOL, V88, P229, DOI 10.1111/j.1365-2141.1994.tb05011.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; ROBERTS WM, 1994, LANCET, V343, P331, DOI 10.1016/S0140-6736(94)91166-5; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; SECKERWALKER LM, 1991, LEUKEMIA, V5, P196; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843	58	87	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2225	2234						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950990				2022-12-28	WOS:A1996VV14500020
J	DombroskyFerlan, PM; Corey, SJ				DombroskyFerlan, PM; Corey, SJ			Yeast two-hybrid in vivo association of the Src kinase Lyn with the protooncogene product Cbl but not with the p85 subunit of PI 3-kinase	ONCOGENE			English	Article						Lyn; Cbl; PI 3-kinase; yeast two-hybrid	PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; SH3 DOMAIN; C-CBL; SIGNAL-TRANSDUCTION; 2-HYBRID SYSTEM; PROTEIN; BINDING; CELLS; ACTIVATION	Ligand binding of multi-chain antigen receptors and hematopoietin/cytokine receptors results in rapid activation of protein tyrosine kinase (PTK)-dependent signalling molecules such as phosphatidylinositol 3-kinase (PI 3-kinase). Go-precipitation studies have shown that Src-related PTK, such as Lyn, associates with the p85 regulatory subunit of PI 3-kinase via SH2 and SH3 domain binding with their cognate ligands, More recent studies have shown that the proto-oncogene product Cbl co-precipitates with p85 following engagement of cytokine and antigen receptors, As opposed to in vitro co-precipitation studies, the yeast two-hybrid screen reveals lit vivo protein-protein interactions, Using the yeast two-hybrid screen, we demonstrate an in vivo association of Lyn's SH3 and SH2 domains with the proline-rich domain of Cbl, Lyn's SH3 and SH2 domains do not interact with p85 in the yeast two-hybrid screen, as would be predicted from glutathione-S-transferase (GST) fusion protein pull-down or co-immunoprecipitation studies from whole cell lysates, However, the SH3 domain of p85 interacts with the proline-rich domain of Cbl, When yeast were transformed with catalytic Lyn, an interaction between p85's SH2 domain and Cbl occurred, From the data, we propose the following three step process of PI 3-kinase activation: (1) complexes of Lyn-Cbl and Cbl-p85 exist without ligand stimulation, (2) upon ligand binding, Lyn becomes active and phosphorylates Cbl, and (3) Cbl's tyrosine phosphorylated residue serves as a docking site for the SH2 domains of p85 - thereby stabilizing the complex and activating PI 3-kinase, The yeast two-hybrid system can be used to dissect the precise mechanisms of in vivo protein-protein interactions, including those between phosphotyrosine and SH2-containing proteins.	CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; CHILDRENS HOSP PITTSBURGH, DEPT PHARMACOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BARTEL P, 1993, BIOTECHNIQUES, V14, P920; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COREY SJ, 1994, LEUKEMIA, V8, P1914; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DREBIN JA, 1995, ONCOGENE, V10, P477; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOLD MR, 1992, J IMMUNOL, V148, P2012; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	26	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2019	2024		10.1038/sj.onc.1201031	http://dx.doi.org/10.1038/sj.onc.1201031			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160881	Bronze			2022-12-28	WOS:A1997WW80900003
J	Huang, CS; Ma, WY; Dong, ZG				Huang, CS; Ma, WY; Dong, ZG			Signal transduction through atypical PKCs, but not the EGF receptor, is necessary for UVC-induced AP-1 activation in immortal murine cells	ONCOGENE			English	Article						ultraviolet; protein kinase C; AP-1; epidermal growth factor receptor	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; ESTER TUMOR PROMOTERS; PHORBOL ESTER; EPIDERMAL-CELLS; GENE-EXPRESSION; TYROSINE KINASE; INDUCED TRANSFORMATION; ENHANCER ELEMENT; DELETION MUTANT	The exposure of mammalian cells to ultraviolet (u.v.) irradiation leads to activation of transcription factors, such as AP-1 and NF kappa B. It is postulated that the EGF receptor but not protein kinase C (PKC) is the major membrane mediator in UVC-induced signal transduction. We demonstrate here that the antisense oligonucleotides of PKC zeta and the dominant negative mutant of PKC lambda/iota as well as dominant negative PKC zeta markedly blocked UVC-induced AP-1 activity. In contrast, UVC-induced AP-1 activity in cells devoid of the EGF receptor (B82), is not significantly different from that of the stable transfectants with a kinase-deficient EGF receptor (B82M721), or wild-type EGF receptor (B82L). This was found at all UVC irradiation doses and time courses studied, while high levels of EGF-induced AP-1 activity were observed in B82L cells but not in B82 cells. This evidence strongly suggests that atypical PKCs, but not the EGF receptor, is necessary for UVC-induced AP-1 activation in JB6 and B82 cells.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Minnesota System				Huang, Chuanshu/0000-0003-4133-5096				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BROWN PH, 1993, ONCOGENE, V8, P877; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN HX, 1993, J MED CHEM, V36, P4094, DOI 10.1021/jm00077a014; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHIDA K, 1983, CANCER RES, V43, P3638; COLLINS MKL, 1982, J CELL PHYSIOL, V112, P42, DOI 10.1002/jcp.1041120108; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG Z, 1994, EARLY DETECTION CANC, P121; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; EPSTEIN JH, 1983, J AM ACAD DERMATOL, V9, P487, DOI 10.1016/S0190-9622(83)70160-X; FITZPATRICK TB, 1976, RES PHOTOBIOLOGY, P485; FORBES PD, 1976, RES PHOTOBIOLOGY, P469; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1996, INT J ONCOL, V8, P389; HUANG CS, 1996, IN PRESS J BIOL CHEM, V271; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUSEWITT DF, 1993, PHOTOCHEM PHOTOBIOL, V58, P450, DOI 10.1111/j.1751-1097.1993.tb09589.x; Lavrovsky V, 1996, IN VITRO CELL DEV-AN, V32, P234; LEY RD, 1993, P NATL ACAD SCI USA, V90, P4337, DOI 10.1073/pnas.90.10.4337; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO Y, 1989, P NATL ACAD SCI USA, V86, P3099; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; RONAI Z, 1988, J VIROL, V62, P1067; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHAH G, 1993, CANCER RES, V53, P38; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P2549, DOI 10.1073/pnas.78.4.2549; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	78	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1945	1954		10.1038/sj.onc.1201056	http://dx.doi.org/10.1038/sj.onc.1201056			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150361				2022-12-28	WOS:A1997WV80400007
J	Shridhar, V; Wang, L; Rosati, R; Paradee, W; Shridhar, R; Mullins, C; Sakr, W; Grignon, D; Miller, OJ; Sun, QC; Petros, J; Smith, DI				Shridhar, V; Wang, L; Rosati, R; Paradee, W; Shridhar, R; Mullins, C; Sakr, W; Grignon, D; Miller, OJ; Sun, QC; Petros, J; Smith, DI			Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas	ONCOGENE			English	Article						fragile site; breakpoints; renal cell carcinoma	TUMOR-SUPPRESSOR GENE; SHORT ARM; FRAGILE SITE; HETEROZYGOSITY; DELETION; IDENTIFICATION; TRANSLOCATION; CHROMOSOME-3; SEQUENCES; 3P14	The constitutive fragile site at chromosomal band 3p14.2, FRA3B, is the most active common fragile site in the human genome, We have localized aphidicolin-induced breakpoints to two distinct clusters, separated by 200 Kb, in FRA3B (Paradee et al., 1996). Sequence analysis of these regions identified two polymorphic microsatellite markers immediately adjacent to each of these breakpoint clusters. In this report we have used these two new microsatellites and 14 additional 3p microsatellites to analyse chromosome 3p breakage and loss in 94 sporadic RCC samples, including nonpapillary, papillary and oncocytomas, We have found heterozygous loss of 3p14 sequences in >60% of the RCC samples, including both clear cell and papillary renal cell carcinomas, We have found frequent breakage in the region immediately surrounding FRA3B, demonstrating that FRA3B does play a role in chromosome breakage and loss in RCC, In contrast to other reports, >50% of the papillary tumors also showed LOH of 3p markers, We also observed microsatellite instability (MIN) with most of the tested markers in seven of eight oncocytomas and one of 69 clear cell carcinomas, The MIN in some oncocytomas was of the RER + (replication error) type I phenotype, None of the five 3p14.2 markers detected any homozygous deletions in tumor samples, but 69/94 (73%) of the tumors had LOH for the region, which includes the recently identified FHIT gene.	WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT HUMAN GENET,ATLANTA,GA 30322; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT UROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,ATLANTA,GA 30322	Barbara Ann Karmanos Cancer Institute; Wayne State University; Emory University; Wayne State University; Wayne State University; Emory University; Emory University					NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGLEY DH, 1990, COMPREHENSIVE TXB ON, P1055; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DRUCK T, 1995, CANCER RES, V55, P5348; Kastury K, 1996, CANCER RES, V56, P978; KOVACS G, 1989, AM J PATHOL, V134, P27; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MORITA R, 1991, CANCER RES, V51, P820; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PRESTI JC, 1993, CANCER RES, V53, P5780; Schwerdtle RF, 1996, CANCER RES, V56, P2927; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SHUIN T, 1994, CANCER RES, V54, P2852; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; STORKEL SF, 1995, BIOL RENAL CELL CARC, P1; Thiagalingam S, 1996, CANCER RES, V56, P2936; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WILHELM M, 1995, CANCER RES, V55, P5383; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YAMAKAWA K, 1991, CANCER RES, V51, P4707; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	31	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1269	1277		10.1038/sj.onc.1201100	http://dx.doi.org/10.1038/sj.onc.1201100			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178887				2022-12-28	WOS:A1997WP10900002
J	Nakagawa, H; Wang, TC; Zukerberg, L; Odze, R; Togawa, K; May, GHW; Wilson, J; Rustgi, AK				Nakagawa, H; Wang, TC; Zukerberg, L; Odze, R; Togawa, K; May, GHW; Wilson, J; Rustgi, AK			The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach	ONCOGENE			English	Article						cyclin D1; oncogene; squamous epithelial cells; transgenic mice	SQUAMOUS-CELL CARCINOMA; NECK-CANCER; P53 GENE; EXPRESSION; PROGRESSION; OVEREXPRESSION; AMPLIFICATION; FIBROBLASTS; G(1); HEAD	Cyclin D1 in cooperation with its major catalytic partners, cyclin-dependent kinases cdk4 and cdk6, facilitates progression through the G(1) phase of the eukaryotic cell cycle, in part through phosphorylation of the retinoblastoma protein, Cyclin D1's oncogenic properties have been suggested by its cooperation with ras or adenovirus E1a to transform cultured cells, as well its overexpression in transgenic mice that leads to breast cancer. Activated by a number of different mechanisms in human cancers, the cyclin D1 gene is frequently amplified in squamous epithelial cancers derived from the head/neck and esophageal regions. In order to study the functional consequences of cyclin D1 overexpression in these squamous epithelial specific sites, we have linked the Epstein-Barr virus ED-L2 promoter to the human cyclin D1 cDNA and utilized this transgene to generate founder lines. This transgene is transcribed specifically in the tongue, esophagus and forestomach, all sharing a stratified squamous epithelium. The transgene protein product localizes to the basal and suprabasal compartments of these squamous epithelial tissues, and mice from different lines develop dysplasia, a prominent precursor to carcinoma, by 16 months of age in contrast to age-matched wild-type mice, This transgenic model is useful in demonstrating cyclin D1 may be a tumor initiating event in aero-upper digestive squamous epithelial tissues.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV GLASGOW,INST BIOMED & LIFE SCI,ROBERTSON LAB BIOTECHNOL,GLASGOW,LANARK,SCOTLAND	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Glasgow					NATIONAL CANCER INSTITUTE [R01CA067463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561] Funding Source: NIH RePORTER; NCI NIH HHS [CA67463] Funding Source: Medline; NIDDK NIH HHS [DK43351, DK40561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHUNG KY, 1993, CANCER RES, V53, P1676; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; LIU QY, 1995, ONCOGENE, V10, P619; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; VANDERRIET P, 1994, CANCER RES, V54, P1156; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	105	110	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1185	1190		10.1038/sj.onc.1200937	http://dx.doi.org/10.1038/sj.onc.1200937			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121767				2022-12-28	WOS:A1997WM78200007
J	Takenoshita, S; Tani, M; Nagashima, M; Hagiwara, K; Bennett, WP; Yokota, J; Harris, CC				Takenoshita, S; Tani, M; Nagashima, M; Hagiwara, K; Bennett, WP; Yokota, J; Harris, CC			Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and Intron primers	ONCOGENE			English	Article						transforming growth factor beta type II receptor; colon carcinogenesis; tumor biology	MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA-CELLS; TGF-BETA	Mutations in the transforming growth factor beta type II receptor (TGF beta RII) gene have been detected in several human cancers exhibiting microsatellite instability. To extend analyses of this gene, we previously investigated the exon-intron organization of the TGF beta RII. gene and defined seven exons and flanking intron sequences. In this study, we further determined the nucleotide sequences surrounding these seven exons and designed eight sets of intron-based primers to examine the entire coding region of the TGF beta RII gene. Using these primers, we screened genomic DNA sequences from 30 sporadic colorectal cancers for mutations of the TGF beta RII. gene. TGF beta RII mutations were detected in two of 30 tumors and both displayed microsatellite instability. One had a deletion in a polyadenine tract in exon 3 and the other had a point mutation in the kinase domain located in exon 7. There were no mutations in exons 1, 2, 4, 5 and 6. These results further implicate the polyadenine tract and kinase domain as mutational hotspots in the TGF beta RII gene in cells,vith genomic instability and suggest that TGF beta RII gene mutations occur rarely in cells lacking genomic instability.	NCI,HUMAN CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892; NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan								GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIMARU G, 1995, INT J CANCER, V64, P153, DOI 10.1002/ijc.2910640302; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044	12	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1255	1258		10.1038/sj.onc.1200938	http://dx.doi.org/10.1038/sj.onc.1200938			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121777				2022-12-28	WOS:A1997WM78200017
J	deJong, R; tenHoeve, J; Heisterkamp, N; Groffen, J				deJong, R; tenHoeve, J; Heisterkamp, N; Groffen, J			Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site	ONCOGENE			English	Article						SH2-SH3 adaptor protein; tyrosine-phosphorylation; BCR/ABL; leukemia; mutagenesis	CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; SH3 DOMAIN; C-CRK; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; KINASE-ACTIVITY; RAS ACTIVATION; ABL PROTEIN; FACTOR C3G	BCR/ABL has a causal role in Philadelphia (Ph)-chromosome positive leukemia. The SH2/SH3 adapter protein CRKL is a major substrate of the deregulated BCR/ABL tyrosine kinase and is aberrantly tyrosine-phosphorylated in Ph-positive leukemia cells. In this study, experiments were pursued to identify and analyse the CRKL phosphorylation site(s). In an in vitro kinase assay, CRKL phosphorylation by the abl kinase was limited to a small region between the two CRKL SH3 domains. Within this region, mutation of tyrosine residue 207 yielded a mutant CRKL which could not be phosphorylated by BCR/ABL. Stable overexpression of CRKL or CRKL-Y207F did not transform NIH3T3 cells, while the Y207F mutation eliminated tyrosine-phosphorylation of CRKL. These studies indicate that Y207 in CRKL represents the major in vivo phosphorylation site. Phosphorylation of Y207 provides a binding site for the CRKL SH2 domain and potentially for other SH2-containing proteins. The Y207F mutation in CRKL did not enhance or decrease association with various target signalling proteins, including SOS or C3G, which interact specifically with the CRKL N-SH3 domain. These findings suggest that complex formation with cellular targets is not modulated by CRKL tyrosine-phosphorylation.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, SECT MOL CARCINOGENESIS, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA 47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, ONCOGENE, V11, P1469; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Harlow E., 1988, ANTIBODIES LAB MANUA; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LUGO TG, 1990, SCIENCE, V237, P532; MALY FE, 1994, J BIOL CHEM, V269, P18743; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1993, LEUKEMIA ADV RES TRE; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					507	513		10.1038/sj.onc.1200885	http://dx.doi.org/10.1038/sj.onc.1200885			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053848				2022-12-28	WOS:A1997WF52400001
J	Zinszner, H; Immanuel, D; Yin, Y; Liang, FX; Ron, D				Zinszner, H; Immanuel, D; Yin, Y; Liang, FX; Ron, D			A topogenic role for the oncogenic N-terminus of TLS: Nucleolar localization when transcription is inhibited	ONCOGENE			English	Article						hnRNP; gene expression; RNA-binding protein; immunofluorescence	RNA-BINDING PROTEIN; ACUTE MYELOID-LEUKEMIA; EWS/FLI-1 FUSION GENE; ROUND-CELL TUMOR; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MYXOID LIPOSARCOMA; COILED BODIES; SARCOMA; EWS	TLS (FUS) and the related gene EWS encode the N-terminal portion of many fusion oncoproteins involved in human sarcomas and leukemia. TLS is an RNA-binding nuclear protein that is identical to hnRNP P2 and may be implicated in mRNA metabolism. When RNA polymerase II is inhibited, TLS immunostaining in the nucleus is dramatically altered, from its normal diffuse nucleoplasmic pattern to accumulation in dense nuclease-resistant aggregates. Co-immunostaining with antibodies to fibrillarin or p80 coilin and immunoelectron microscopy revealed that the TLS associated with the nucleolus and are other known structures such as the coiled body or the interchromatin granule. Injection of cells with an oligodeoxynucleotide that disrupts splicing does not result in redistribution of TLS, indicating that the event is specific to inhibition of transcription. Oncoproteins that contain the N-terminal domain from either TLS, EWS or their Drosophila homologue, SARFH (CAZ), are also targeted to the same structure. These findings suggest a correlation between the topogenic and transforming activities of TLS and EWS N-termini and imply the existence of cellular targets that are shared by the germ-line encoded proteins and their oncogenic derivatives.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University; New York University; New York University; New York University				Ron, David/0000-0002-3014-5636; Liang, Fengxia/0000-0003-0037-4590	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; BRASCH K, 1992, EXP CELL RES, V202, P2211; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROWN AD, 1995, ONCOGENE, V10, P1749; CALVIO C, 1995, RNA, V1, P724; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Fujimura Y, 1996, ONCOGENE, V12, P159; HARDERS J, 1989, EMBO J, V8, P3941, DOI 10.1002/j.1460-2075.1989.tb08577.x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; KALLAND KH, 1991, NEW BIOL, V3, P389; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LESSNICK SL, 1995, ONCOGENE, V10, P423; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTH J, 1986, J MICROSC-OXFORD, V143, P125, DOI 10.1111/j.1365-2818.1986.tb02771.x; ROTH J, 1998, HISTOCHEMISTRY, V95, P132; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SPECTOR D, 1991, EMBO J, V10, P3476; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	52	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					451	461		10.1038/sj.onc.1200854	http://dx.doi.org/10.1038/sj.onc.1200854			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053842				2022-12-28	WOS:A1997WE36400008
J	Cottu, PH; Muzeau, F; Estreicher, A; Flejou, JF; Iggo, R; Thomas, G; Hamelin, R				Cottu, PH; Muzeau, F; Estreicher, A; Flejou, JF; Iggo, R; Thomas, G; Hamelin, R			Inverse correlation between RER(+) status and p53 mutation in colorectal cancer cell lines	ONCOGENE			English	Article						colon cancer; p53 mutations; mismatch repair	NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; REPEATED SEQUENCES; MISMATCH REPAIR; HOMOLOG; TUMORIGENESIS; GENE; RECEPTOR; TUMORS	The high point mutation rate of replication error-prone (RER(+)) cells could theoretically lead to inactivation of the p53 gene by polyclonal mutations, which might explain the conflicting results that have been published on the p53 status of RER(+) colon cancers, To address this issue, we tested the p53 status of 21 human colorectal cancer cell lines, including four showing microsatellite instability (RER(+) phenotype). Denaturing gradient gel electrophoresis (DGGE) followed by sequencing showed that all four RER(+) cell lines were mild type for p53 while 15 of the 17 RER(-) cell lines contained p53 mutations (P=0.001), Eight cell lines (four RER(+) and four RER(-)) were analysed using three complementary methods to test more rigorously the polyclonal mutation hypothesis, (i) Of 87 single-cell clones (seven to 14 per cell line) examined by DGGE, only those derived from known p53 mutant cell lines showed altered profiles, (ii) Antibody DO-7 stained more than 80% of nuclei from the p53 mutant cell lines, but only 15% of nuclei from the RER(+) cell lines, (iii) A yeast functional assay which can simultaneously detect polyclonal mutations at over 500 different sites in the p53 cDNA scored all four RER(+) cell lines as containing only transcriptionally active p53, These data thus do not support the polyclonal mutation hypothesis and instead suggest that mismatch repair deficiency provides a p53-independent pathway for development of colorectal cancers.	INST CURIE,INSERM U434,F-75005 PARIS,FRANCE; FAC XAVIER BICHAT,INSERM U410,PARIS,FRANCE; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Swiss Institute Experimental Cancer Research			Iggo, Richard/G-3546-2014; Cottu, Paul/ABC-8595-2020	Estreicher, Anne/0000-0001-6828-2508				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HAMELIN R, 1993, ONCOGENE, V8, P2213; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	21	112	113	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2727	2730						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000147				2022-12-28	WOS:A1996VZ65400023
J	Tatematsu, K; Nakayama, J; Danbara, M; Shionoya, S; Sato, H; Omine, M; Ishikawa, F				Tatematsu, K; Nakayama, J; Danbara, M; Shionoya, S; Sato, H; Omine, M; Ishikawa, F			A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias	ONCOGENE			English	Article						telomerase; leukemia; progression; PCR	HUMAN-LYMPHOCYTES; CELLS; IMMORTALITY; TRANSFORMATION; LENGTH; CANCER; EVENT	Telomerase activation is important for carcinogenesis. However, the timing and magnitude of the activation during cancer development are unknown. In this study, a new PCR-based method for measuring telomerase activity was developed and shown to be very useful for quantitative analysis of human telomerase. Using this assay, blood or bone marrow cells from healthy donors, and patients with chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) were examined as to their relative activity. Telomerase activity present in normal peripheral blood cells was generally very low. However, significant activity was detected occasionally in samples derived from younger healthy donors. Striking telomerase activation was observed at the time of the blastic crisis in CML: no samples from chronic phase cases showed significant activity, while all cases with a well established crisis showed strong activity. Most AML cases were telomerase-positive. Quantitative analyses revealed that the relative titer varied among the AML patients, from as low as found in normal cells to as high as found in cell lines. However, a tendency that the activity was higher in relapsed cases than in fresh ones was suggested. In summary, telomerase was activated during the progression of the clinical stages in leukemias. This observation suggests that shortened telomeres and increased telomerase activity might be necessary for cancer cells to undergo clonal evolution towards more malignant phenotypes in advanced stages.	TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; KITASATO UNIV,SCH MED,DEPT INTERNAL MED,SAGAMIHARA,KANAGAWA 228,JAPAN; TEIKYO UNIV,SCH MED,DEPT INTERNAL MED 4,TAKATSU KU,KAWASAKI,KANAGAWA 213,JAPAN; SHOWA UNIV,FUJIGAOKA HOSP,SCH MED,DEPT HEMATOL,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology; Kitasato University; Teikyo University; Showa University			Ishikawa, Fuyuki/AAU-4056-2021; Nakayama, Jun-ichi/C-6003-2011	Ishikawa, Fuyuki/0000-0002-5580-2305; Nakayama, Jun-ichi/0000-0002-5597-8239				ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; BECKERANDRE M, 1993, METHOD ENZYMOL, V218, P420; BEDI A, 1994, BLOOD, V83, P2038; BEDNAREK A, 1995, CANCER RES, V55, P4566; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1995, TELOMERES, P265; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FERRE F, 1994, POLYM CHAIN REACTION, P67; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1993, COLD SPRING HARB SYM, V58, P719, DOI 10.1101/SQB.1993.058.01.079; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HARLEY CB, 1994, COLD SPRING HARB SYM, V64, P1; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OHYASHIKI K, 1994, CANCER GENET CYTOGEN, V78, P64, DOI 10.1016/0165-4608(94)90047-7; PAITYSZEK MA, 1995, METHODS CELL SCI, V17, P1; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; TAKAUCHI K, 1994, JPN J CANCER RES, V85, P127, DOI 10.1111/j.1349-7006.1994.tb02071.x; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	33	127	138	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2265	2274						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950994				2022-12-28	WOS:A1996VV14500024
J	Kitamura, Y; Goodfellow, PJ; Shimizu, K; Nagahama, M; Ito, K; Kitagawa, W; Akasu, H; Takami, H; Tanaka, S; Wells, SA				Kitamura, Y; Goodfellow, PJ; Shimizu, K; Nagahama, M; Ito, K; Kitagawa, W; Akasu, H; Takami, H; Tanaka, S; Wells, SA			Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): Mutation analysis in Japanese patients with MTC	ONCOGENE			English	Article						RET proto-oncogene; medullary thyroid carcinoma; mutations; multiple endocrine neoplasia type 2	TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; MEN 2A; CLINICAL-FEATURES; POINT MUTATION; PROTOONCOGENE; FMTC; FAMILY	Germ-like and somatic mutations in the RET protooncogene are associated with inherited and sporadic medullary thyroid carcinoma (MTC). The majority of patients with multiple endocrine neoplasia type 2A (MEN2A) and familial medullary thyroid carcinoma (FMTC) carry germ-line point mutations that result in the substitution of one of five cysteine residues. We investigated exons 10, 11, 13, 14 and 16 of the RET proto-oncogene in 33 unrelated Japanese patients with MTC. Eleven of the 33 cases (33%) were found to have germ-line mutations. Three previously unreported mutations in exon 10 and 11 were identified: one in codon 620, (TGC-->GGC), resulting in a cysteine to glycine substitution, and two in codon 630, (TGC-->TCC) and (TGC-->TAC), resulting in cysteine to serine and cysteine to tyrosine changes, respectively. The new mutations were present in the germ-line DNA of four unrelated patients for whom a family history of MTC had not been documented. Because the new RET alleles described here involve cysteine residues in a region of protein previously associated with FMTC and MEN2A, it is very likely that they represent mutations that predispose to the development of MTC.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV GEN SURG,ST LOUIS,MO 63110; NIPPON MED COLL,DEPT SURG 2,TOKYO 113,JAPAN; TEIKYO UNIV,SCH MED,DEPT SURG 1,TOKYO 162,JAPAN	Washington University (WUSTL); Nippon Medical School; Teikyo University								BERGHOLM U, 1989, CANCER, V63, P1196, DOI 10.1002/1097-0142(19890315)63:6<1196::AID-CNCR2820630626>3.0.CO;2-O; BOLINO A, 1995, ONCOGENE, V10, P2415; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; DECKER RA, 1995, SURGERY, V118, P257, DOI 10.1016/S0039-6060(05)80332-0; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; FrankRaue K, 1996, J CLIN ENDOCR METAB, V81, P1780, DOI 10.1210/jc.81.5.1780; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KOMMINOTH P, 1995, CANCER, V76, P479; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PONDER BAJ, 1988, Q J MED, V67, P299; RAUE F, 1994, ENDOCRIN METAB CLIN, V23, P137, DOI 10.1016/S0889-8529(18)30121-X; SAAD MF, 1984, MEDICINE, V63, P319, DOI 10.1097/00005792-198411000-00001; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; TAKAHASHI M, 1989, ONCOGENE, V4, P805; WELLS SA, 1994, ANN SURG, V220, P237, DOI 10.1097/00000658-199409000-00002; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZEDENIUS J, 1994, HUM MOL GENET, V3, P1259, DOI 10.1093/hmg/3.8.1259	24	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3103	3106		10.1038/sj.onc.1201102	http://dx.doi.org/10.1038/sj.onc.1201102			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223675				2022-12-28	WOS:A1997XG10000014
J	Cheng, JQ; Altomare, DA; Klein, MA; Lee, WC; Kruh, GD; Lissy, NA; Testa, JR				Cheng, JQ; Altomare, DA; Klein, MA; Lee, WC; Kruh, GD; Lissy, NA; Testa, JR			Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis	ONCOGENE			English	Article						AKT2; transformation; cell cycle; serine/threonine kinase	PROTEIN-KINASE-B; SIGNAL-TRANSDUCTION; C-AKT; MOLECULAR-CLONING; V-AKT; PRODUCT; LOCALIZATION; CARCINOMAS; SUBFAMILY; DOMAINS	The AKT2 oncogene encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling proteins. Recently, it was shown that AKT2 kinase activity can be induced by platelet-derived growth factor through phosphatidylinositol-3-OH kinase, suggesting that AKT2 may be an important signal mediator that contributes to the control of cell proliferation, We previously reported amplification and overexpression of AKT2 in human cancers, To investigate the transforming activity of AKT2, we used a retrovirus-based construct to express AKT2 in NIH3T3 cells. Overexpression of AKT2 was found to transform NIH3T3 cells, as determined by growth in soft agar and tumor formation in nude mice, The oncogenic activity of AKT2 was diminished by truncation of a 70-amino acid proline-rich region at the carboxyl-terminus. To facilitate the characterization of AKT2, we generated monoclonal and polyclonal antibodies against this protein. AKT2 was localized to the cytoplasm by cell fractionation experiments, immunocytochemistry, and immunofluorescence, Protein levels were more abundant in mitotic cells than in interphase cells. Western blot analysis of synchronized pancreatic cancer cells demonstrated that the expression level of AKT2 protein in mitotic cells is three to fivefold higher than in their interphase counterparts, A time-course study of phytohemagglutinin-stimulated lymphocytes revealed that AKT2 mRNA and AKT2 protein levels are highest 48-72h after addition of mitogen, when cells are actively dividing. These data suggest that AKT2 could play a significant role in cell cycle progression and that the oncogenic activity of overexpressed AKT2 may be mediated by aberrant regulation of cellular proliferation.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [R01 CA077429, P30 CA006927, CA-06927, CA 09035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arranz E, 1996, CANCER GENET CYTOGEN, V87, P1, DOI 10.1016/0165-4608(95)00230-8; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; RICHMAN DP, 1980, J CELL BIOL, V85, P459, DOI 10.1083/jcb.85.2.459; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SMITH DB, 1994, CURRENT PROTOCOLS MO; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; WILLINGHAM MC, 1990, FOCUS, V12, P62	32	129	142	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2793	2801		10.1038/sj.onc.1201121	http://dx.doi.org/10.1038/sj.onc.1201121			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190895				2022-12-28	WOS:A1997XD64300007
J	Fan, JG; Bertino, JR				Fan, JG; Bertino, JR			K-ras modulates the cell cycle via both positive and negative regulatory pathways	ONCOGENE			English	Article						ras; cell cycle; gene regulation	BREAST-CANCER CELLS; DNA-BINDING ACTIVITY; GENE-EXPRESSION; E2F FAMILY; IN-VIVO; S-PHASE; P53-REGULATED PROTEIN; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; TUMOR-SUPPRESSOR	The effect of activated human K-ras on cell cycle proteins was studied by use of a stable MCF-7 transfectant expressing inducible activated K-ras under the control of a tetracycline (Tet)-responsive promoter. Induction of activated K-ras by Tet withdrawal accelerated cell growth and entry into S-phase, To understand the mechanism(s) by which activated K-ras exerts its effect on the cell cycle, expression of both cell cycle stimulatory proteins as well as cell cycle inhibitors was examined. Upon induction of activated K-ras, several cell cycle stimulators were up-regulated, including cyclins A, D3, and E, and the E2F family of transcription factors, which was accompanied by increased cyclin A-associated kinase activity and E2F transcriptional activity, respectively. Up-regulation of cyclin A occurred at the transcriptional level and in a serum-dependent manner, Furthermore, induction of activated K-ras down-regulated p27(Kip1) and up-regulated p53. Up-regulation of p53 was correlated with enhanced p53 transactivation and accompanied by up-regulation of p21(Waf1) and Gadd 45, two p53 effecters and negative cell cycle regulators. In addition, activated K-ras upregulates bcl-2 but has no effect on bax or bcl-x expression. Taken together, these data indicate that activated K-ras affects the cell cycle by modulating both positive and negative cell cycle regulatory pathways.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA062948, P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [CA62948-02, P01-CA-47179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrams SI, 1996, SEMIN ONCOL, V23, P118; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAE IS, 1995, CANCER RES, V55, P2387; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLUME E, 1993, J NATL CANCER I, V85, P1542, DOI 10.1093/jnci/85.19.1542; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCK V, 1995, ONCOGENE, V11, P31; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CASEY G, 1991, ONCOGENE, V6, P1791; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN J, 1997, IN PRESS BIOCH PHARM; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; FILMUS J, 1994, ONCOGENE, V9, P3627; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTARDIS MM, 1995, ENDOCRINOLOGY, V136, P5659, DOI 10.1210/en.136.12.5659; Gotz C, 1996, REV PHYSIOL BIOCH P, V127, P65, DOI 10.1007/BFb0048265; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; HALDAR S, 1994, CANCER RES, V54, P2095; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1994, CARCINOGENESIS, V15, P845, DOI 10.1093/carcin/15.5.845; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mangues R, 1992, Semin Cancer Biol, V3, P229; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NEGRINI M, 1994, CANCER RES, V54, P1818; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAN BT, 1994, J BIOL CHEM, V269, P5968; PINES J, 1992, CIBA F SYMP, V170, P187; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG RA, 1996, CELL, V85, P242; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Winston JT, 1996, ONCOGENE, V12, P127; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; WU H, 1993, GENE DEV, V7, P1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YAMATO K, 1995, ONCOGENE, V11, P1; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	84	58	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2595	2607		10.1038/sj.onc.1201105	http://dx.doi.org/10.1038/sj.onc.1201105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191059				2022-12-28	WOS:A1997XA94900011
J	Chang, THT; Ray, FA; Thompson, DA; Schlegel, R				Chang, THT; Ray, FA; Thompson, DA; Schlegel, R			Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells	ONCOGENE			English	Article						mitosis; cell cycle; checkpoints; SV40 T antigen; chromosome aberrations	INDUCED PREMATURE MITOSIS; IRRADIATED HELA-CELLS; SIMIAN VIRUS-40; HUMAN-FIBROBLASTS; TUMOR-ANTIGEN; CYCLIN-B; DNA-REPLICATION; MAMMALIAN-CELLS; FISSION YEAST; TYROSINE PHOSPHORYLATION	SV40 large T antigen (T) inactivates the tumor suppressor proteins p53 and pRb, and can induce cells to enter DNA replication at inappropriate times, We show here that T also compromises three cell cycle checkpoints that regulate the entry into and exit from mitosis, Human diploid fibroblasts infected with a retrovirus expressing T displayed an attenuated radiation-induced mitotic delay, were more susceptible to chemical-induced uncoupling of mitosis from the completion of DNA replication, and were more likely to exit mitosis and rereplicate their DNA when mitotic spindle assembly was inhibited, Consistent with altered mitotic checkpoint control, cells expressing T displayed elevated protein levels and/or associated activities of the mitotic regulatory proteins cyclin A, cyclin B, Cdc25C and p34(cdc2). These changes in mitotic control were evident within 5-10 population doublings after retroviral infection, indicating a direct effect of T expression, Cells acutely infected with the T-expressing retrovirus suffered numerical and structural chromosome aberrations, including increases in aneuploidy, dicentric chromosomes, chromatid exchanges and chromosome breaks and gaps, These findings indicate that T rapidly disrupts mitotic checkpoints that help maintain genomic stability, and suggest mechanisms by which T induces chromosome aberrations and promotes the immortalization and neoplastic transformation of human cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115; ALBANY MED COLL,DEPT MICROBIOL,ALBANY,NY 12208; CHIRON DIAGNOST,E WALPOLE,MA 02032	Harvard University; Harvard T.H. Chan School of Public Health; Albany Medical College								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROWN M, 1991, COLD SPRING HARB SYM, V61, P359; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chang THT, 1996, J CELL BIOCHEM, V60, P161, DOI 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-V; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONAHUE LM, 1988, ONCOGENE, V3, P221; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FAN SJ, 1995, CANCER RES, V55, P1649; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KAUFMANN WK, 1995, CANCER RES, V55, P7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIEBMANN J, 1994, CANCER CHEMOTH PHARM, V33, P331; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NICHOLS WW, 1977, SCIENCE, V196, P60, DOI 10.1126/science.841339; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAULES RS, 1995, CANCER RES, V55, P1763; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POWELL SN, 1995, CANCER RES, V55, P1643; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAY FA, 1992, MUTAT RES, V284, P265, DOI 10.1016/0027-5107(92)90011-P; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAY FA, 1993, CARCINOGENESIS, V14, P1511, DOI 10.1093/carcin/14.8.1511; RICE RH, 1993, MOL BIOL CELL, V4, P185, DOI 10.1091/mbc.4.2.185; ROBERTS JR, 1990, CANCER RES, V50, P710; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL KJ, 1995, CANCER RES, V55, P1639; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SCHLEGEL R, 1990, CELL GROWTH DIFFER, V1, P171; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STEINMANN KE, 1994, ONCOGENE, V9, P387; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; STEWART N, 1995, ONCOGENE, V10, P109; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WOLMAN S. R., 1964, CYTOGENETICS [BASEL], V3, P45, DOI 10.1159/000129797; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	92	81	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2383	2393		10.1038/sj.onc.1201196	http://dx.doi.org/10.1038/sj.onc.1201196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188853				2022-12-28	WOS:A1997WZ68000002
J	Ivan, M; Bond, JA; Prat, M; Comoglio, PM; WynfordThomas, D				Ivan, M; Bond, JA; Prat, M; Comoglio, PM; WynfordThomas, D			Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells	ONCOGENE			English	Article						met; ras; ret; thyroid; epithelium; paracrine	TYROSINE KINASE; HGF RECEPTOR; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; SCATTER FACTOR; DNA-SYNTHESIS; CANCER; OVEREXPRESSION; GENE; PROTOONCOGENE	Hepatocyte Growth Factor (HGF) receptor, encoded by the protooncogene c-met, is overexpressed in many human tumours, including those of thyroid epithelium. The absence in most cases of any primary structural abnormality of the met gene suggests that overexpression is secondary to mutation of other gene(s). To test this hypothesis we investigated the effect on met expression of two activated oncogenes known to play a major role in thyroid oncogenesis, ras and ret. To minimize the possibility of unknown co-operating events, we introduced these genes directly into normal human thyrocytes in primary culture using amphotropic retroviral vectors and assessed met expression as early as possible in the resulting epithelial colonies. Double immunofluorescence revealed expression of met protein, strictly localized to cells expressing the mutant ras and ret vectors, expression in background normal cells being barely detectable. In contrast, colonies induced to proliferate at a comparable rate by a vector expressing SV40 T showed no increase in met expression. To permit quantitation by Western blotting we also extended these findings to a thyroid cell line (R18) containing a zinc-inducible mutant ras gene. Induction of the oncogene led to a fourfold increase in met protein expression. We conclude that overexpression of met is induced by activation of the ras or ret signalling pathway and not simply by deregulation of the cell cycle per se. The data suggest that the proliferative advantage conferred by these oncogenes may be in part due to the resulting sensitization of tumour epithelium to paracrine HGF secreted by stromal cells.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES; UNIV TURIN,DEPT BIOMED SCI & ONCOL,SCH MED,TURIN,ITALY	Cardiff University; University of Turin			Ivan, Mircea/A-8109-2012	Ivan, Mircea/0000-0003-3424-6642; Comoglio, Paolo/0000-0002-7056-5328				BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BOND JA, IN PRESS INT J CANC; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DAWSON TP, 1995, CANCER RES, V55, P915; DAWSON TP, 1991, BRIT J CANCER, V63, P897, DOI 10.1038/bjc.1991.197; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Eccles N, 1996, MOL CELL ENDOCRINOL, V117, P247, DOI 10.1016/0303-7207(95)03757-8; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LIU C, 1992, ONCOGENE, V7, P181; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; NALDINI L, 1991, ONCOGENE, V6, P501; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCARPELLI DG, 1994, PATHOLOGY, P794; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUAREZ HG, 1990, ONCOGENE, V5, P565; Thomas G. A., 1995, Journal of Endocrinology, V144, pRC3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WILLIAMS DW, 1988, THYROID TUMOURS, P57; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115	44	136	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2417	2423		10.1038/sj.onc.1201083	http://dx.doi.org/10.1038/sj.onc.1201083			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188856				2022-12-28	WOS:A1997WZ68000005
J	Stachowiak, EK; Maher, PA; Tucholski, J; Mordechai, E; Joy, A; Moffett, J; Coons, S; Stachowiak, MK				Stachowiak, EK; Maher, PA; Tucholski, J; Mordechai, E; Joy, A; Moffett, J; Coons, S; Stachowiak, MK			Nuclear accumulation of fibroblast growth factor receptors in human glial cells - Association with cell proliferation	ONCOGENE			English	Article						FGF-2; FGF receptor; nuclear localization; cell proliferation; astrocytes; glioma	ENDOTHELIAL-CELLS; GENE-EXPRESSION; BINDING; MODULATION; FAMILY; FLG	In this study we describe the presence of high affinity FGF-2 binding sites in the nuclei of U251MG glioma cells (K-d=7 pM). Immunoprecipitation of total cell extracts with FGF receptor (FGFR) 1-4 antibodies showed that U251MG glioma cells express only FGFR1. [I-125]FGF-2 cross linking to nuclear extracts followed by FGFR1 immunoprecipitation showed that FGFR1 may account for the nuclear FGF-2 binding sites. Western blot analysis demonstrated the presence of 103, 118 kDa and small amounts of 145 kDa FGFR1 isoforms in the nuclei of glioma cells. All isoforms contain both the C-and N-terminal domains. Nuclear FGFR1 retains kinase activity, Immunocytochemistry using confocal microscopy showed specific FGFR1 immunoreactivity within the nuclear interior, In continuously proliferating glioma cells, nuclear FGFR1 is constitutively expressed, independent of cell density. In contrast, in nontransformed human astrocytes, nuclear FGFR1 levels fluctuate with the proliferative state of the cell. In quiescent, confluent astrocytes nuclear FGFR1 protein was depleted. An accumulation of nuclear FGFR1 was observed following the transition to a subconfluent, proliferating state, Transfection of a pcDNA3.1-FGFR1 expression vector into glioma cells that do not express FGFR1 resulted in the nuclear accumulation of FGFR1, increased cell proliferation, and stimulated transition from the G(0)/G(1) to the S-phase of the cell cycle, The increased proliferative rate was resistant to inhibition by the cell-impermeable FGF binding antagonist, myoinositol hexakis [dihydrogen phosphate], Our results suggest that the constitutive nuclear presence of FGFR1 contributes to the increased proliferation of glioma cells while the transient nuclear accumulation of FGFR1 in normal astrocytes may play a role in the transition to a reactive state.	BARROW NEUROL INST, PHOENIX, AZ 85013 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Barrow Neurological Institute; Scripps Research Institute					NHLBI NIH HHS [HL49376-01A1] Funding Source: Medline; NINDS NIH HHS [NS28121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON BJ, 1994, GLIA, V11, P73, DOI 10.1002/glia.440110110; BERENS M E, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P46; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BINGER DD, 1981, J NEUROPATHOL EXP NE, V40, P201; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRAPER NR, 1966, APPLIED REGRESSION A, P263; DUVERGER E, 1995, J CELL SCI, V108, P1325; ENG LF, 1992, PROG BRAIN RES, V94, P353; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Latham KE, 1996, ONCOGENE, V12, P827; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, IN VITRO CELL DEV-AN, V30A, P783; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SHERMAN K, 1993, DEVELOPMENT, V24, P791; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILKIE AOM, 1995, CURR BIOL, V5, P500; XU JM, 1992, J BIOL CHEM, V267, P17792	41	101	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	1997	14	18					2201	2211		10.1038/sj.onc.1201057	http://dx.doi.org/10.1038/sj.onc.1201057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174056				2022-12-28	WOS:A1997WX93800009
J	Osada, S; Izawa, M; Saito, R; Mizuno, K; Suzuki, A; Hirai, S; Ohno, S				Osada, S; Izawa, M; Saito, R; Mizuno, K; Suzuki, A; Hirai, S; Ohno, S			YSK1, a novel mammalian protein kinase structurally related to Ste20 and SPS1, but is not involved in the known MAPK pathways	ONCOGENE			English	Article						MAP kinase; protein kinase; stress; signal transduction	SIGNAL-TRANSDUCTION PATHWAYS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CDC42 GTPASES; ACTIVATION; IDENTIFICATION; YEAST; RAC; HOMOLOG; CASCADE	To clarify the upstream regulatory mechanism of mitogen-activated protein kinase (MAPK), we performed the reverse transcriptase-based polymerase chain reaction (RT-PCR) with degenerate primers synthesized based on sequences conserved among the kinase domains of yeast MAPK kinase kinases (MAPKKKs), Stell, Bck1, and Byr2. We isolated several mammalian cDNA fragments that encode kinase subdomains sharing significant sequence homology with yeast MAPKKKs. Subsequent screening of a HeLa cell cDNA library using one of these cDNA fragments as a probe resulted in the isolation of a full-length cDNA that encodes a novel protein kinase. The catalytic domain sequence of this gene product is closely related to those of budding yeast Sps1 and Ste20 protein kinases, Thus, we call this protein YSK1 (Yeast Sps1/Ste20-related Kinase 1), The transcript of YSK1 was detected in a wide range of tissues and cells, Immunoprecipitated YSK1 shows protein kinase activity, Although YSK1 is significantly similar in its kinase domain to kinases of the yeast and mammalian MAPK pathways, the overexpression of YSK1 did not lead to the activation of the ERK (extracellular signal-regulated kinase) pathway, JNK (c-Jun NH2-terminal kinase)/SAPK (stress-activated protein kinase) pathway, or p38/Mpk2 pathway, These results suggest that YSK1 may be involved in the regulation of a novel intracellular signaling pathway.	YOKOHAMA CITY UNIV, SCH MED, DEPT BIOL MOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAYHOFF MO, 1978, ATLAS PROTEIN SEQ S3, V5, P353; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FISHER SM, 1994, NATURE, V372, P739; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	50	29	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2047	2057		10.1038/sj.onc.1201043	http://dx.doi.org/10.1038/sj.onc.1201043			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160885				2022-12-28	WOS:A1997WW80900007
J	Gum, R; Wang, H; Lengyel, E; Juarez, J; Boyd, D				Gum, R; Wang, H; Lengyel, E; Juarez, J; Boyd, D			Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades	ONCOGENE			English	Article						MMP-9; type IV collagenase; JNK; ERK; AP-1	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; C-JUN; MAP KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; TRANSDUCTION PATHWAYS; 92-KDA GELATINASE	The 92 kDa type IV collagenase (MMP-9), which degrades type IV collagen, has been implicated in tissue remodeling. The purpose of the current study was to determine the role of Jun amino-terminal kinase (JNK)- and extracellular signal-regulated kinase- (ERK)-dependent signaling cascades in the regulation of MMP-9 expression. Towards this end, we first determined the transcriptional requirements for MMP-9 promoter activity in a cell line (UM-SCC-1) which is an avid secretor of this collagenase. Transfection of these cells with a CAT reporter driven by progressive 5' deleted fragments of the MMP-9 promoter indicated the requirement of a region spanning -144 to -73 for optimal promoter activity. DNase I footprinting revealed a protected region of the promoter spanning nucleotides -91 to -68 and containing a consensus AP-1 motif at -79. Mutation of this AP-1 motif practically abolished the activity of the MMP-9 promoter-driven CAT reporter. Mobility shift assays indicated c-Fos and Jun-D bound to this motif and transfection of the cells with a mutated c-Jun, which quenches the function of endogenous Jun and Fos proteins, decreased MMP-9 promoter activity by 80%. UM-SCC-1 cells contained a constitutively activated JNK and the expression of a kinase-deficient JNK1 reduced the activity of a CAT reporter driven either by the MMP-9 promoter or by three tandem AP-1 repeats upstream of a thymidine kinase minimal promoter. Conditioned medium collected from UM-SCC-1 cells transfected with the dominant negative JNK1 expression vector diminished 92 kDa gelatinolysis. Similarly, interfering with MEKK, which lies upstream of JNK1, using a dominant negative expression vector reduced MMP-9 promoter activity over the same concentration range which repressed the AP-l-thymidine kinase CAT reporter construct. UM-SCC-1 cells also contained a constitutively activated ERK1. MMP-9 expression, as determined by CAT assays and by zymography, was reduced by the co-expression of a kinase-deficient ERK1. Interfering with MEK1, which is an upstream activator of ERK1, either with PD 098059, which prevents the activation of MEK1, or with a dominant negative expression construct, reduced 92 kDa gelatinolysis and MMP-9 promoter activity respectively. c-Raf-l is an upstream activator of MEK1 and a kinase-deficient c-Raf-l expression construct decreased the activity of a promoter driven by either the MMP-9 promoter or three tandem AP-1 repeats. Conversely, treatment of UM-SCC-1 cells with PMA, which activates c-Raf-l, increased 92 kDa gelatinolysis. These data suggest that MMP-9 expression in UM-SCC-1 cells, is regulated by JNK- and ERK-dependent signaling pathways.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-8000 MUNICH,GERMANY	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER V, 1994, J BIOL CHEM, V269, P11186; AGARWAL S, 1995, ONCOGENE, V11, P427; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson IC, 1996, CANCER RES, V56, P715; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cha HJ, 1996, CANCER RES, V56, P2281; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DECLERCK YA, 1992, CANCER RES, V52, P701; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIDMAN R, 1995, CANCER RES, V55, P2548; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENGYEL E, 1995, CANCER RES, V55, P963; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKAJIMA M, 1993, CANCER RES, V53, P5802; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1992, CANCER RES, V52, P1336; RAO JS, 1993, CANCER RES, V53, P2208; RAO VN, 1993, CANCER RES, V53, P3449; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SOZERI O, 1992, ONCOGENE, V7, P2259; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	73	220	231	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1481	1493		10.1038/sj.onc.1200973	http://dx.doi.org/10.1038/sj.onc.1200973			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136992				2022-12-28	WOS:A1997WT58400011
J	Fan, JG; Bertino, JR				Fan, JG; Bertino, JR			Functional roles of E2F in cell cycle regulation	ONCOGENE			English	Article						E2F; cell cycle; gene regulation	DEPENDENT KINASE INHIBITORS; RETINOBLASTOMA PROTEIN; S-PHASE; TUMOR-SUPPRESSOR; IN-VIVO; GROWTH SUPPRESSION; GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-REPLICATION; CDK6 INHIBITOR	The E2F family of transcription factors play a key role in G1-S progression. A dominant negative mutant (E2F97) of E2F1 containing the DNA binding domain of E2F1 under the control of a tetracycline-responsive promoter was constructed. Stable transfectants were produced in the pRb-lacking SaOS-2 cell line and SV40-transformed VA-13 cell line, respectively. Induction of E2F97 by tetracycline withdrawal resulted in strong inhibition of the E2F transcriptional activity and a decreased percentage of cells in S-phase, To understand the mechanism(s) by which E2F97 exerts its effect on the cell cycle, the effect of E2F97 on expression of various cell cycle proteins was examined. Upon induction of E2F97, a significant decrease in the levels of both dihydrofolate reductase and thymidylate synthase was observed in transfectants derived from both cell lines. Induction of E2F97 also led to a decrease in cyclin A and D1 protein levels. Regulation of cyclin A by E2F97 occurred at the transcriptional level. In addition, in VA13 cells, induction of E2F97 resulted in downregulation of the tumor suppressor protein p53. These data suggest that E2F regulates both G1 and S-phase cyclins and that there may be a potential positive feedback regulatory loop between E2F and cyclin D1.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA062948, P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-47179, CA62948-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCK V, 1995, ONCOGENE, V11, P31; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Geng Y, 1996, ONCOGENE, V12, P1173; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LI Y, 1994, ONCOGENE, V9, P2261; LOWKVIST B, 1986, DEV BIOL, V116, P291, DOI 10.1016/0012-1606(86)90132-6; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MAYOL X, 1995, ONCOGENE, V11, P801; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; North S, 1996, CELL GROWTH DIFFER, V7, P339; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OSWALD F, 1994, ONCOGENE, V9, P2029; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1994, J CELL SCI, P89; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	86	53	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1191	1200		10.1038/sj.onc.1200940	http://dx.doi.org/10.1038/sj.onc.1200940			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121768				2022-12-28	WOS:A1997WM78200008
J	Puri, PL; Balsano, C; Burgio, VL; Chirillo, P; Natoli, G; Ricci, L; Mattei, E; Graessmann, A; Levrero, M				Puri, PL; Balsano, C; Burgio, VL; Chirillo, P; Natoli, G; Ricci, L; Mattei, E; Graessmann, A; Levrero, M			MyoD prevents cyclin A cdk2 containing E2F complexes formation in terminally differentiated myocytes	ONCOGENE			English	Article						MyoD; E2F; pRb2/p130; p21; cell cycle	TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA GENE FAMILY; DNA-BINDING ACTIVITY; LARGE T-ANTIGEN; S-PHASE ENTRY; MYOGENIC DIFFERENTIATION; CELL-PROLIFERATION; IN-VIVO; MUSCLE DIFFERENTIATION; DEPENDENT KINASE	Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130, Downstream effecters of 'pocket' proteins are the components of the E2F family of transcription factors, which regulate the G(1)/S-phase transition, We analysed by EMSA the composition of E2F complexes in cycling, quiescent undifferentiated and differentiated C2C12 skeletal muscle cells, An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G(0)/G(1) complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G(1)/S complex), Serum stimulation reinduces DNA synthesis and the re-appearance of E2F-G(1)/S complexes in quiescent myoblasts but not in differentiated C2C12 myotubes, In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced, Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis, Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle, Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.	UNIV ROMA LA SAPIENZA,MED CLIN 1,I-00161 ROME,ITALY; UNIV AQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY; CNR,IST TECNOL BIOMED,ROME,ITALY; FREE UNIV BERLIN,INST MOL BIOL & BIOCHEM,D-1000 BERLIN,GERMANY	Sapienza University Rome; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Free University of Berlin	Puri, PL (corresponding author), UNIV ROMA LA SAPIENZA,FDN A CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095	Telethon [A.064] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CARUSO M, 1993, ONCOGENE, V8, P267; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERTZINGER T, 1995, ONCOGENE, V10, P2079; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MAIONE R, 1992, ONCOGENE, V7, P85; MARTELLI F, 1994, ONCOGENE, V9, P3579; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NATOLI G, 1994, ONCOGENE, V9, P2837; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SALA A, 1994, CANCER RES, V54, P1402; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WOLF DA, 1995, ONCOGENE, V10, P2067; YAFFE D, 1977, NATURE, V270, P225; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG YH, 1995, ONCOGENE, V10, P2085	84	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1171	1184		10.1038/sj.onc.1200941	http://dx.doi.org/10.1038/sj.onc.1200941			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121766				2022-12-28	WOS:A1997WM78200006
J	Iwahara, T; Fujimoto, J; Wen, DZ; Cupples, R; Bucay, N; Arakawa, T; Mori, S; Ratzkin, B; Yamamoto, T				Iwahara, T; Fujimoto, J; Wen, DZ; Cupples, R; Bucay, N; Arakawa, T; Mori, S; Ratzkin, B; Yamamoto, T			Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system	ONCOGENE			English	Article						receptor protein tyrosine kinase; anaplastic lymphoma kinase; leukocyte tyrosine kinase; nervous system	MESSENGER-RNAS; HUMAN LTK; PROTEIN; GENE; FUSION; ONCOGENE; SEQUENCES; LEUKEMIA; LIGANDS; SEGMENT	The 2;5 chromosomal translocation is frequently associated with anaplastic large cell lymphomas (ALCLs). The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5, A recent study shows that the product of the npm-alk fusion gene is oncogenic. To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biological function of the alk gene product, ALK. Here, we show molecular cloning of cDNAs for both the human and mouse ALK proteins. The deduced amino acid sequences reveal that ALE is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain. These sequences are absent in the product of the transforming npm-alk gene, ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biological function is presently unknown. RNA blot hybridization analysis of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord. Immunoblotting with anti-ALK antibody shoes that ALK is highly expressed in the neonatal brain. Furthermore, RNA in situ hybridization analysis shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice, These data suggest that ALE plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.	UNIV TOKYO, DEPT ONCOL, INST MED SCI, Tokyo 108, JAPAN; UNIV TOKYO, DEPT PATHOL, INST MED SCI, Tokyo 108, JAPAN; AMGEN CORP, THOUSAND OAKS, CA 91320 USA	University of Tokyo; University of Tokyo; Amgen								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRECO A, 1992, ONCOGENE, V7, P237; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1990, ONCOGENE RES, V5, P199; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PARK M, 1986, CELL, V45, P865; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SHIOTA M, 1994, ONCOGENE, V9, P1564; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	517	547	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					439	449		10.1038/sj.onc.1200849	http://dx.doi.org/10.1038/sj.onc.1200849			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053841				2022-12-28	WOS:A1997WE36400007
J	Gelderloos, JA; Anderson, SM				Gelderloos, JA; Anderson, SM			Over-expression of protein tyrosine phosphatase 1 (PTP1) alters IL-3-dependent growth and tyrosine phosphorylation	ONCOGENE			English	Article						IL-3; signal transduction; protein tyrosine phosphatase; tyrosine kinase	COLONY-STIMULATING FACTOR; RECEPTOR-LIKE PROTEIN; MYELOID CELL-LINES; GM-CSF RECEPTOR; INTERLEUKIN-3 RECEPTOR; SIGNAL-TRANSDUCTION; KINASE PP56LCK; HUMAN-PLACENTA; BETA-SUBUNIT; STEEL FACTOR	Interleukin-3 (IL-3) is a hematopoietic growth factor receptor which stimulates the proliferation of multilineage progenitor cells, It is known that IL-3 stimulates tyrosine phosphorylation while transducing a mitogenic signal. The signal transduction pathways activated by the IL-3 receptor, however, are not fully understood, In this study a protein tyrosine phosphatase has been overexpressed in the IL-3 dependent, murine myeloid progenitor cell line, 32D c13 in order to test whether altering the levels of tyrosine phosphorylation would change IL-3 stimulated proliferation, These cells were transfected with a metal-inducible expression vector containing a rat cDNA encoding PTP1. A low basal level of rat PTP1 message and protein was detected in cells transfected with the PTP1 vector, and zinc treatment resulted in a three- to fourfold increase in the amount of PTP1 message, protein and catalytic activity, Over-expression of PTP1 resulted in a two- to threefold decrease in IL-3 stimulated proliferation, Cells over-expressing PTP1 also exhibited decreased levels of tyrosine phosphorylation; phosphorylation of the IL-3 receptor beta subunit and the She protein were both dramatically decreased, Thus, PTP1 over-expression negatively modulated IL-3 signal transduction. To identify potential substrates of PTP1, 32D c13 cells were transfected with a catalytically inactive PTP1 mutant, PTP1(C/S). Three tyrosine-phosphorylated proteins of MW 140, 79 and 69 k coprecipitated with PTP1(C/S). We believe that the 140 kDa protein represents the beta subunit of the IL-3 receptor, In addition, a GST-fusion protein containing active PTP1 dephosphorylated the beta-subunit in an in vitro assay, By immunofluorescent microscopy over-expressed PTP1(C/S) co-localized largely with calnexin, an endoplasmic reticulum-associated protein, Immunofluorescent microscopy also indicated that PTP1(C/S) and the beta subunit co-localized at discrete sites at the plasma membrane and around a cytoplasmic organelle where most of the beta subunit was located, These observations suggest PTP1 over-expression may downregulate the growth response to IL-3 through dephosphorylation of the IL-3 receptor, perhaps in an intracellular compartment, thereby inhibiting propagation of the IL-3 mitogenic signal.	SUNY STONY BROOK, PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ANDERSON SM, 1995, J IMMUNOL, V155, P1660; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CIRCIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ERWIN JL, 1992, ONCOGENE, V7, P1101; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; IHLE JN, 1982, J IMMUNOL, V129, P1377; IHLE JN, 1982, IMMUNOL REV, V63, P5, DOI 10.1111/j.1600-065X.1982.tb00409.x; ISCOVE NN, 1982, J CELL PHYSIOL, P65; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; OKUDA K, 1992, BLOOD, V79, P2880; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RAINES MA, 1992, BLOOD, V79, P3350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1983, EXP HEMATOL, V11, P667; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOJO A, 1987, EXP CELL RES, V171, P16, DOI 10.1016/0014-4827(87)90247-3; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TORIGOE T, 1992, BLOOD, V80, P617; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	64	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2367	2378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957078				2022-12-28	WOS:A1996VX10800009
J	Badiani, PA; Kioussis, D; Swirsky, DM; Lampert, IA; Weston, K				Badiani, PA; Kioussis, D; Swirsky, DM; Lampert, IA; Weston, K			T-cell lymphomas in v-Myb transgenic mice	ONCOGENE			English	Article						Myb; T cell; lymphoma; transgenic mice	MURINE HEMATOPOIETIC-CELLS; RECEPTOR-DELTA-ENHANCER; C-MYB; LEUKEMIA-VIRUS; PROTO-ONCOGENE; ANTISENSE OLIGODEOXYNUCLEOTIDES; INSERTIONAL MUTAGENESIS; PROMONOCYTIC LEUKEMIAS; GENE-EXPRESSION; RAPID INDUCTION	v-Myb, the transforming protein of avian myeloblastosis virus, causes acute myeloid leukemia in chickens. Similarly, truncation and rearrangement of the c-myb proto-oncogene to yield a v-Myb-like protein leads to myeloid and B cell lymphomas in chickens and mice, and may be a factor in a number of human cancers. To study the effects of deregulation of v-Myb on T cell development, we have generated lines of transgenic mice in which the v-Myb oncoprotein is expressed in a T-cell-specific fashion. Analysis of T cell development in the v-Myb transgenic mice shows that ectopic expression of v-Myb affects the ratio of helper to cytotoxic T cells, by increasing the number of CD4(+) helper cells, and inhibits thymic involution, such that mature animals have elevated numbers of thymocytes and circulating mature T cells. In a significant proportion of older animals, high grade T cell lymphomas develop, demonstrating that v-Myb is oncogenic in T cells.	INST CANC RES, CRC, CTR CELLULAR & MOL BIOL, LONDON SW3 6JB, ENGLAND; NATL INST MED RES, LAB MOL IMMUNOL, LONDON NW7 1AA, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HISTOPATHOL, LONDON W12 0NN, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC National Institute for Medical Research; Imperial College London; Imperial College London								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BERNS A, 1989, INT J CANCER, P22; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; Bies J, 1996, ONCOGENE, V12, P355; BLICK M, 1984, BLOOD, V64, P1234; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BORN W, 1985, P NATL ACAD SCI USA, V82, P2925, DOI 10.1073/pnas.82.9.2925; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CALABRETTA B, 1991, CANCER RES, V51, P4505; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALNAN BJ, 1995, IMMUNITY, V3, P273; CHURILLA AM, 1989, J EXP MED, V170, P105, DOI 10.1084/jem.170.1.105; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRAO P, 1995, ONCOGENE, V11, P1631; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOGAN B, 1986, MANIPULATING MOUSE E; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; JACOBS SM, 1994, CANCER GENET CYTOGEN, V75, P31, DOI 10.1016/0165-4608(94)90212-7; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LAOUAR Y, 1994, J IMMUNOL, V153, P3948; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1995, ONCOGENE, V11, P525; PRUDHOMME GJ, 1991, J IMMUNOL, V147, P3314; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMARDA J, 1994, ONCOGENE, V9, P237; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STRASSER A, 1993, ONCOGENE, V8, P1; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; TESCH H, 1992, LEUKEMIA RES, V16, P265, DOI 10.1016/0145-2126(92)90064-E; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	70	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2205	2212						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950988				2022-12-28	WOS:A1996VV14500018
J	Billon, N; vanGrunsven, LA; Rudkin, BB				Billon, N; vanGrunsven, LA; Rudkin, BB			The CDK inhibitor p21(WAF1/Cip1) is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells	ONCOGENE			English	Article						NGF; PC12; p21(WAF1/Cip1); p300; E1A; cell cycle; differentiation	NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; TERMINAL DIFFERENTIATION; TRANSCRIPTIONAL ADAPTER; REQUIRES BINDING; CYCLE ARREST; P21; PROTEIN; EXPRESSION; INDUCTION	The block of cell proliferation elicited by the addition of nerve growth factor (NGF) to exponentially-growing PC12 cells results, in part, from the inhibition of cyclin D1-associated kinase activity by p2l(WAF1/ClP1). NGF treatment of PC12 cells provokes the accumulation of p21 mRNA, due to transcriptional activation of the p21 promoter in a p53-independent manner. Transient expression of a mutated form of the adenovirus E1A protein (E1A dCR2), which retains its capacity to bind the transcriptional co-activator p300, completely abolishes the NGF-mediated stimulation of p21 promoter activity. This phenomenon can be reversed by ectopic expression of p300, suggesting that p300 is necessary for the induction of p21 by NGF. In addition, stable expression of E1A dCR2 in PC12 cells results in the inhibition of the NGF response, i.e. it prevents activation of the p21 promoter, cell cycle arrest, and neuronal differentiation. The signalling pathway from the TrkA receptor via the MAP kinase pathway is not altered in these cells. Together, these data indicate that p300 could play a pivotal role in the triggering of the anti-mitogenic effect of NGF and of neuronal differentiation.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,DIFFERENTIAT & CELL CYCLE GRP,UMR 49 CNRS,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)			van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BANNISTER AJ, 1995, EMBO J, V14, P4790; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Dubois PM, 1996, J IMMUNOL, V156, P1356; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUNDBLAD JR, 1995, NATURE, V374, P83; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Savatier P, 1996, ONCOGENE, V12, P309; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; SLACK RS, 1995, ONCOGENE, V10, P19; Smits PHM, 1996, ONCOGENE, V12, P1529; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZENG X, 1996, ONCOGENE, V12, P1557	53	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2047	2054						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950971				2022-12-28	WOS:A1996VV14500001
J	Brizzi, MF; Dentelli, P; Lanfrancone, L; Rosso, A; Pelicci, PG; Pegoraro, L				Brizzi, MF; Dentelli, P; Lanfrancone, L; Rosso, A; Pelicci, PG; Pegoraro, L			Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation	ONCOGENE			English	Article						c-Cbl; thrombopoietin; stem cell factor; cell proliferation; signal transduction	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-3 DOMAIN; C-CBL PROTOONCOGENE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; ANTIGEN RECEPTOR; SH3 DOMAINS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	Hemopoietic cell proliferation is mediated by nontyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the Grb2/c-Chl. In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation. By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation. In these cells the adaptor protein Grb2 constitutively binds a substantial fraction of c-Cbl through the N-terminal SH3 domain. In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit. By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2. In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl. Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits She, probably via Grb2. By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes. Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.	UNIV TURIN,DIPARTIMENTO MED INTERNA,I-10126 TURIN,ITALY; IST EUROPEO ONCOL,DIPARTIMENTO ONCOL SPERIMENTALE,I-20141 MILAN,ITALY	University of Turin; IRCCS European Institute of Oncology (IEO)			Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Brizzi, Maria Felice/J-7882-2016	Lanfrancone, Luisa/0000-0002-4523-3815; 				AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEV S, 1992, J BIOL CHEM, V267, P10866; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MIKI H, 1994, J BIOL CHEM, V269, P5489; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; Montrucchio G, 1996, BLOOD, V87, P2762, DOI 10.1182/blood.V87.7.2762.bloodjournal8772762; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MYERS M, 1995, TRENDS BIOCHEM SCI, V19, P289; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG XY, 1995, J BIOL CHEM, V270, P27999; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	55	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2067	2076						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950973				2022-12-28	WOS:A1996VV14500003
J	Cabannes, E; Vives, MF; Bedard, PA				Cabannes, E; Vives, MF; Bedard, PA			Transcriptional and post-transcriptional regulation of kappa B-controlled genes by pp(60v-src)	ONCOGENE			English	Article						gene expression; pp60(v-src); transformation; NF-kappa B	ROUS-SARCOMA VIRUS; CHICKEN SPLEEN-CELLS; SRC-INDUCIBLE GENE; V-REL ONCOPROTEIN; TRANSFORMED-CELLS; PLATELET PROTEIN; TYROSINE KINASES; GROWTH-FACTOR; AVIAN CELLS; T-CELLS	The CEF-4/9E3 gene is expressed aberrantly in chicken embryo fibroblasts transformed by the Rous sarcoma virus, This aberrant expression is dependent on transcriptional activation and on the stabilization of the CEF-4 mRNA, The characterization of the CEF-4 promoter indicated that three distinct regulatory elements corresponding to an AP-1 binding site, a PRDII/kappa-B domain and a CAAT box are involved in the activation by pp60(v-src). Several v-src responsive genes are controlled by AP-1 and members of the Ets family but few appear to be dependent on NF-kappa B. In this study me characterize the expression of genes regulated by NF-kappa B in normal and RSV-transformed CEF, Run-on transcription analysis indicated that pp60(v-src) induces the transcription of several genes controlled by NF-kappa B but at different levels, While the transcription of CEF-4 was strongly stimulated, that of NF-kappa B1, c-rel, p53 or I kappa B-alpha was activated more modestly by pp60(v-src). In addition the CEF-4 mRNA mas the only mRNA species to accumulate significantly in transformed CEF, The ectopic expression of RelA or Rel resulted in the stimulation of the transcription of several known targets of NF-kappa B, However, the mRNA for I kappa B-alpha was the only mRNA species to accumulate considerably in the RelA- or Rel-expressing cells, Hence for most kappa B-controlled genes, transcriptional activation was not sufficient to obtain a significant increase in mRNA expression, Likewise, RelA or Rel enhanced the transcription of the CEF-4 gene without a significant accumulation of the CEF-4 mRNA, However, transformation by v-src caused a massive accumulation of the CEF-4 mRNA but not of other mRNA species in the RelA- and Rel-expressing cells, Transient expression assays, run-on transcription and Northern blotting analyses indicated that the effect of pp60(v-src) on CEF-4 expression was mediated predominantly at the post-transcriptional level in these cells, Therefore transcriptional and post-transcriptional mechanisms determine the restricted pattern of activation of kappa B-controlled genes in RSV-transformed CEF.	YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA	York University - Canada; Universite de Montreal								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEHBI M, 1994, ONCOGENE, V9, P2399; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EICHER DM, 1994, J IMMUNOL, V152, P2710; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; HANNINK M, 1990, ONCOGENE, V5, P1843; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HRDLICKOVA R, 1995, J VIROL, V69, P403; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JAHNER D, 1991, ONCOGENE, V6, P1259; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARONEY AC, 1992, ONCOGENE, V7, P1207; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; VIVES MF, 1995, THESIS U MONTREAL; WASYLYK C, 1994, ONCOGENE, V9, P3665; WELHAM MJ, 1990, ONCOGENE, V5, P161; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	58	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					29	43		10.1038/sj.onc.1201162	http://dx.doi.org/10.1038/sj.onc.1201162			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233775				2022-12-28	WOS:A1997XH58600004
J	Jackson, JH; Vollenweider, M; Hill, J; Rodriguez, H; Schwabacher, AW; Mitra, G; Kuo, CY				Jackson, JH; Vollenweider, M; Hill, J; Rodriguez, H; Schwabacher, AW; Mitra, G; Kuo, CY			Stimulated human leukocytes cause activating mutations in the K-ras protooncogene	ONCOGENE			English	Article						inflammation; carcinogenesis; oxidants; DNA damage; K-ras	POLYMERASE CHAIN-REACTION; SITE-SPECIFIC MUTAGENESIS; C-HA-RAS; MAMMALIAN-CELLS; TUMOR PROMOTER; DNA TEMPLATES; POLYMORPHONUCLEAR LEUKOCYTES; IONIZING-RADIATION; ULCERATIVE-COLITIS; OXIDATIVE DAMAGE	Human tissues which are chronically infiltrated with inflammatory leukocytes are more likely to develop malignancies than non-inflamed tissues, however the mechanism(s) by which leukocytes contribute to carcinogenesis is unknown. Stimulated human leukocytes release superoxide anion and hydrogen peroxide which, in the presence of iron, can be converted into the potent oxidant, hgdroxyl radical (. OH). Previous studies have shown that leukocyte-derived . OH (or a . OH-Like species) can cause DIVA damage, however a relationship between leukocyte-induced DNA damage and carcinogenesis has not been established. The present report demonstrates that leukocyte-derived . OH-induced DNA damage can cause K-ras oncogene activation, and suggests that there may be a characteristic pattern of . OH-induced k-ras oncogene activation. Since activation of the k-ras oncogene is believed to play a crucial role in the pathogenesis of many human malignancies . OH induced K-ras oncogene activation could be an important mechanism by which human leukocytes contribute to carcinogenesis.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PROMEGA CORP, MADISON, WI 53711 USA	Princeton University; Promega Corporation	Jackson, JH (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, BOX 1MM 12, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA-54298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BERKOW RL, 1983, J LAB CLIN MED, V102, P732; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOS JL, 1989, CANCER RES, V49, P4682; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENG KC, 1992, J BIOL CHEM, V267, P166; DEVROEDE GJ, 1971, NEW ENGL J MED, V285, P17, DOI 10.1056/NEJM197107012850103; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRENKEL K, 1986, CANCER RES, V46, P5533; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREENSTEIN AJ, 1979, GASTROENTEROLOGY, V77, P290; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1989, J CLIN INVEST, V84, P1644, DOI 10.1172/JCI114342; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAMIYA H, 1992, CANCER RES, V52, P3483; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LEWIS JG, 1985, CANCER RES, V45, P1270; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NASSICALO L, 1989, CARCINOGENESIS, V10, P1055, DOI 10.1093/carcin/10.6.1055; ORITA S, 1991, VIRUS GENES, V5, P75, DOI 10.1007/BF00571733; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; WEITZMAN SA, 1990, BLOOD, V76, P655; WEITZMAN SA, 1982, J IMMUNOL, V128, P2770; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085	47	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2803	2808		10.1038/sj.onc.1201118	http://dx.doi.org/10.1038/sj.onc.1201118			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190896				2022-12-28	WOS:A1997XD64300008
J	Reddy, TR; Tang, HL; Li, XQ; WongStaal, F				Reddy, TR; Tang, HL; Li, XQ; WongStaal, F			Functional interaction of the HTLV-1 transactivator Tax with activating transcription factor-4 (ATF4)	ONCOGENE			English	Article						human T-cell leukemia virus-1; Tax; ATF-4; transactivation	VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; DNA-BINDING PROTEINS; RESPONSIVE ELEMENT; GENE; ENHANCER; IDENTIFICATION; TRANSFORMATION; LYMPHOCYTES	The Tax protein of the Human T-cell Leukemia Virus (HTLV) activates the expression of viral mRNA through a three 21 bp repeat enhancer located within the HTLV-1 LTR, Since Tax does not bind to the 21bp DNA repeats directly, it has been speculated that Tax interacts with cellular protein(s) which mediate binding to the enhancer, We employed the yeast two hybrid system to identify host proteins that are potentially relevant to Tax transactivation. We identified a Tax binding protein encoded from a cDNA expression library derived from peripheral blood lymphocytes. The corresponding cDNA has sequence identity with a known transcription factor, activating factor-4 (ATF-4). ATF-4 also binds to GST-Tax fusion protein in vitro. Tax mutants that did not transactivate the HTLV-1 LTR also failed to bind ATF-4. The critical domain for Tax binding resides in a 85 amino acid stretch in the C-terminus of ATF-4, which contains the basic domain and leucine zipper, We further demonstrated that both full length and N-terminal truncated ATF-4 were able to enhance Tax transactivation, Thus, ATF-4 may act as an adapter between Tax and the TRE (Tax responsive element), and play an important role in Tax-mediated transactivation.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Tang, Hengli/F-2085-2014		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R01AI031378] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30-AI36214-03, R01 AI31378] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P, 1991, NEW BIOL, V2, P1034; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REDDY TR, 1995, AIDS RES HUM RETROV, V11, P663, DOI 10.1089/aid.1995.11.663; SEEMES OJ, 1992, J VIROL, V66, P7183; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V226, P177; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	37	60	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2785	2792		10.1038/sj.onc.1201119	http://dx.doi.org/10.1038/sj.onc.1201119			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190894				2022-12-28	WOS:A1997XD64300006
J	Charlesworth, A; Rozengurt, E				Charlesworth, A; Rozengurt, E			Bombesin and neuromedin B stimulate the activation of p42(mapk) and p74(raf-1) via a protein kinase C-independent pathway in Rat-1 cells	ONCOGENE			English	Article						p21(ras); G(q); neuropeptide; MAP kinases; signal transduction	SWISS 3T3 CELLS; GASTRIN-RELEASING PEPTIDE; MAP KINASE; LUNG-CANCER; RECEPTOR; GROWTH; RAS; PHOSPHORYLATION; IDENTIFICATION; FIBROBLASTS	The mechanisms by which seven transmembrane receptors activate p42(mapk)/p44(mapk) are not well defined although p21(ras)- and protein kinase C (PKC)-dependent pathways have been implicated, typically for G(i)- and G(q)-coupled receptors, respectively, Here, we demonstrate that in Rat-1 cells transfected with the G(q)-coupled bombesin/gastrin releasing peptide receptor, bombesin stimulated activation of p42(mapk) that was not inhibited by the specific PKC inhibitor GF 109203X or by down regulation of phorbol ester-sensitive PKC isoforms, In addition, bombesin rapidly stimulated p74(raf-1) activity that was also independent of PKC activity and insensitive to inhibition by pertussis toxin, Furthermore, addition of neuromedin B to Rat-l cells transfected with the neuromedin B preferring receptor also activated p42(mapk) and p74(raf-1) in a PKC-independent and pertussis toxin-insensitive manner, Finally we show that addition of bombesin to Rat-1 cells stimulated the GTP loading of p21(ras). Our results reveal a novel PKC-independent pathway in the action of G(q)-coupled receptors and stress the importance of cell context in defining the signal transduction pathway(s) that link specific receptors to the activation of the mitogen-activated protein kinase cascade.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; CARNEY DN, 1987, CANCER RES, V47, P821; Charlesworth A, 1996, ONCOGENE, V12, P1337; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLEY RR, 1995, MOL CELL BIOL, V14, P8623; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLAEPFER DD, 1994, NATURE, V372, P786; SETHI T, 1992, CANCER RES, V52, pS2737; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P1; SOZERI O, 1992, ONCOGENE, V7, P2259; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	46	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2323	2329		10.1038/sj.onc.1201075	http://dx.doi.org/10.1038/sj.onc.1201075			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178908				2022-12-28	WOS:A1997WY88300009
J	TakahashiTezuka, M; Hibi, M; Fujitani, Y; Fukada, T; Yamaguchi, T; Hirano, T				TakahashiTezuka, M; Hibi, M; Fujitani, Y; Fukada, T; Yamaguchi, T; Hirano, T			Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK	ONCOGENE			English	Article						JAK; Btk; Tec; PI-3 kinase; cytokine receptor	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCER; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; BRUTON TYROSINE; SRC-FAMILY; ERYTHROPOIETIN RECEPTOR; REGULATORY SUBUNIT	Tec/Btk tyrosine kinases are members of a subgroup of Src tyrosine kinase family. They are reported to be activated in response to cytokines, such as IL-3 and IL-6. Janus kinases (JAKs) are known to associate with certain cytokine receptors, e.g. gp130, the signal transducing subunit of IL-6 receptor, and the common beta chain of IL-3 receptor, which can be activated upon receptor dimerization in response to cytokines. Here we show the association between Jak1/Jak2 and Tec or Jak1 and Btk. Furthermore, Jak1 but not Jak2 induces tyrosine phosphorylation of Btk, but not Tee. These observations suggest that upon cytokine stimulation JAKs activate Tec/Btk or induce their dimerization resulting in endogenous tyrosine phosphorylation. Furthermore using a yeast two-hybrid system we have identified the target molecules for Tee, the p85 and p55PIK subunits of PI-3 kinase, and Vav. Tec associated with Vav through its SH2 domain independently of its kinase activity. In contrast the p85 and p55PIK subunits of PI-3 kinase associated with the SH2-kinase domain of Tee, dependent on Tec kinase activity. Consistent with these, IL-6 or IL-3 induced the association between Tec and the p85 subunit of PI-3 kinase in mammalian cells. These findings suggest that Tec tyrosine kinase links cytokine receptors to PI-3 kinase probably through JAKs.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MOL ONCOL, SUITA, OSAKA 565, JAPAN	Osaka University			Hirano, Toshio/C-8194-2009; Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARGUMEDO LS, 1995, INT IMMUNOL, V7, P163; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CANTLEY LC, 1994, J CELL SCI, P121; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKADA T, 1996, IN PRESS IMMUNITY; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARPER JW, 1993, CELL, V75, P805; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HE TC, 1993, BLOOD, V82, P3530; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HIRANO T, 1994, CYTOKINE HDB, P145; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACHIDE M, 1995, ONCOGENE, V11, P619; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1995, BLOOD, V85, P343; MANO H, 1994, ONCOGENE, V9, P3205; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MIURA O, 1994, J BIOL CHEM, V269, P614; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OKADA T, 1994, J BIOL CHEM, V269, P3568; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PONS S, 1995, MOL CELL BIOL, V15, P4453; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAITO M, 1992, J IMMUNOL, V148, P4066; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TOKER A, 1994, J BIOL CHEM, V269, P32358; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YIN TG, 1993, J IMMUNOL, V151, P2555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x	92	75	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2273	2282		10.1038/sj.onc.1201071	http://dx.doi.org/10.1038/sj.onc.1201071			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178903				2022-12-28	WOS:A1997WY88300004
J	Clarke, AR; Howard, LA; Harrison, DJ; Winton, DJ				Clarke, AR; Howard, LA; Harrison, DJ; Winton, DJ			p53, mutation frequency and apoptosis in the murine small intestine	ONCOGENE			English	Article						p53; mutation; apoptosis	RADIATION-INDUCED APOPTOSIS; P53-DEFICIENT MICE; TRANSGENIC MICE; GERMLINE MUTATIONS; MYC TRANSGENE; MOUSE; CARCINOGENESIS; ABNORMALITIES; ACCUMULATION; EPITHELIUM	Normal function of the p53 gene is integral to the cellular response to genotoxic stress, One prediction arising from this is that p53 deficiency results in an increased mutation frequency, However, limited evidence has been produced in support of this idea, In order to further investigate the in vivo role of p53 in surveillance against mutation, and particularly to address the significance of p53-dependent apoptosis, we scored mutation frequency at the Dlb-1 locus within cells of the intestinal epithelium of animals which were wild type, heterozygous or null for p53 and heterozygous (a/b) at the Dlb-1 locus, Using this assay we have shown that loss of a p53-dependent apoptotic pathway is associated with the detectable acquisition of mutations, but only at high levels of DNA damage, These results question the significance of the immediate 'wave' of p53-dependent apoptosis seen in this tissue, particularly as there was a delayed p53-independent apoptotic pathway, We conclude that loss of p53 function only becomes relevant to the in vivo acquisition of mutations and thus tumorigenesis in certain circumstances.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge	Clarke, AR (corresponding author), UNIV EDINBURGH,CRC LABS,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BLYTH K, 1995, ONCOGENE, V10, P1717; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELSON A, 1995, ONCOGENE, V11, P181; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LEE JM, 1994, ONCOGENE, V9, P3731; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, CANCER RES, V54, P614; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NISHINO H, 1995, ONCOGENE, V11, P263; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P611, DOI 10.1111/j.1365-2184.1982.tb01067.x; WYLLIE AH, 1994, COLD SPRING HARB SYM, V59, P403, DOI 10.1101/SQB.1994.059.01.045; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295	29	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2015	2018		10.1038/sj.onc.1201040	http://dx.doi.org/10.1038/sj.onc.1201040			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160880				2022-12-28	WOS:A1997WW80900002
J	Klapper, LN; Vaisman, N; Hurwitz, E; PinkasKramarski, R; Yarden, Y; Sela, M				Klapper, LN; Vaisman, N; Hurwitz, E; PinkasKramarski, R; Yarden, Y; Sela, M			A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors	ONCOGENE			English	Article						signal transduction; tyrosine kinase; oncogene; Neu differentiation factor; epidermal growth factor; adenocarcinoma	NEU DIFFERENTIATION FACTOR; HUMAN MAMMARY-CARCINOMA; HUMAN-BREAST-CANCER; EXTRACELLULAR DOMAIN; NEU/ERBB-2 RECEPTOR; SIGNAL-TRANSDUCTION; GENE-PRODUCT; CELLS; ONCOGENE; TRANSFORMATION	ErbB-2 is an orphan receptor that belongs to a family of tyrosine kinase receptors for either epidermal growth factor (EGF) or Neu differentiation factor (NDF/ neuregulin), Because overexpression of the erbB-2 proto-oncogene is frequently associated with an aggressive clinical course of certain human adenocarcinomas, the encoded protein is an attractive target for immunotherapy. Indeed, certain monoclonal antibodies (mAbs) to ErbB-2 effectively inhibit tumor growth in animal models and in clinical trials, but the underlying mechanism is incompletely understood. To study this question, we generated a large battery of mAbs to ErbB-2, that were classified epitopically, Whereas most antibodies stimulated tyrosine phosphorylation of ErbB-2, their anti-tumor effect correlated with its accelerated endocytic degradation, One group of tumor-inhibitory mAbs (Class II mAbs) was elicited by the most antigenic site of ErbB-2, and inhibited in trans binding of NDF and EGF to their direct receptors. The inhibitory effect was due to acceleration of ligand dissociation, and it resulted in the reduction of the ability of ErbB-2 to transactivate the mitogenic signals of NDF and EGF, These results identify two potential mechanisms of antibody-induced therapy: acceleration of ErbB-2 endocytosis by homodimerization and blocking of heterodimerization between ErbB-2 and growth factor receptors.	WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012	Pinkas-Kramarski, Ronit/0000-0002-1000-369X	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1992, CANCER RES, V52, P2580; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; FENDLY BM, 1990, J BIOL RESP MODIF, V9, P449; GOLDENBERG DM, 1993, AM J MED, V94, P297, DOI 10.1016/0002-9343(93)90062-T; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; GULLICK WJ, 1990, INT J CANCER, P55; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HELLSTROM KE, 1989, FASEB J, V3, P1715, DOI 10.1096/fasebj.3.6.2649402; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RUSSO C, 1983, J IMMUNOL METHODS, V65, P269, DOI 10.1016/0022-1759(83)90324-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STANCOVSKI I, 1992, J STEROID BIOCHEM, V43, P95, DOI 10.1016/0960-0760(92)90192-L; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STANCOVSKI I, 1994, REGULATORY MECH BREA, P161; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TREPEL JB, 1990, CANCER RES, V50, P2773; TZAHAR E, 1996, IN PRESS MOL CELL BI; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	54	153	203	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2099	2109		10.1038/sj.onc.1201029	http://dx.doi.org/10.1038/sj.onc.1201029			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160890				2022-12-28	WOS:A1997WW80900012
J	deWinter, JP; Roelen, BAJ; tenDijke, P; vanderBurg, B; vandenEijndenvanRaaij, A				deWinter, JP; Roelen, BAJ; tenDijke, P; vanderBurg, B; vandenEijndenvanRaaij, A			DPC4 (SMAD4) mediates transforming growth factor-beta 1 (TGF-beta 1) induced growth inhibition and transcriptional response in breast tumour cells	ONCOGENE			English	Article						DPC4; Smad; TGF-beta; activin; tumour suppressor	MAMMARY EPITHELIAL-CELLS; FACTOR-BETA; CANCER-CELLS; EXPRESSION; RECEPTOR; ACTIVIN; RESPONSIVENESS; IDENTIFICATION; PROLIFERATION; ESTROGEN	A family of structurally related proteins homologous to the Drosophila mothers against dpp (MAD) gene product have been implicated in signal transduction by members of the TGF-beta superfamily, One of these MAD related proteins (DPC4) has been cloned as a candidate tumour suppressor in pancreas carcinomas, suggesting a role for DPC4 in growth regulation by TGF-beta related proteins, The involvement of DPC4 in TGF-beta 1 induced growth inhibition and transcriptional response is demonstrated here, by the introduction of DPC4 in the TGF-beta and activin insensitive breast tumour cell line MDA-MB-468, from which the DPC4 gene is deleted, Transfection of DPC4 in this cell line restores both growth inhibition and the induction of a TGF-beta sensitive reporter construct (3TPlux) by TGF-beta 1, In contrast, a DPC4 splice variant lacking amino acid residues 223-301 and cloned from another TGF-beta and activin resistant breast tumour cell line (MDA-MB-231), does not restore the induction of the 3TPlux reporter by TGF-beta 1, We also show that in this latter cell line activin resistance is partly due to the absence of a functional activin type IB receptor, These results indicate that DPC4 is part of the TGF-beta signalling cascade and mediates TGF-beta induced growth inhibition, Together with the deletion of DPC4 from pancreas carcinomas these results suggest a role for DPC4 as a tumour suppressor.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deWinter JP, 1996, EXP CELL RES, V224, P323, DOI 10.1006/excr.1996.0142; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Gucev ZS, 1996, CANCER RES, V56, P1545; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705; JENG MH, 1993, MOL CELL ENDOCRINOL, V97, P115, DOI 10.1016/0303-7207(93)90217-8; JI HJ, 1994, J CELL BIOCHEM, V54, P332, DOI 10.1002/jcb.240540309; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; NAKAO A, IN PRESS J BIOL CHEM; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VANDENEIJNDENVANRAAIJ AJM, 1988, BIOCHEM BIOPH RES CO, V157, P16, DOI 10.1016/S0006-291X(88)80004-4; VANDENEIJNDENVANRAAIJ AJM, 1992, DEV BIOL, V154, P356, DOI 10.1016/0012-1606(92)90074-Q; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	42	131	136	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1891	1899		10.1038/sj.onc.1201017	http://dx.doi.org/10.1038/sj.onc.1201017			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150356				2022-12-28	WOS:A1997WV80400002
J	Cosgaya, JM; Recio, JA; Aranda, A				Cosgaya, JM; Recio, JA; Aranda, A			Influence of Ras and retinoic acid on nerve growth factor induction of transin gene expression in PC12 cells	ONCOGENE			English	Article						metalloproteinases; neurite extension; retinoic acid; nerve growth factor	PROTEIN-KINASE; FACTOR RECEPTOR; B-RAF; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NGF-INDUCTION; STROMELYSIN; ONCOGENE; INHIBITION; PROMOTER	Nerve growth factor (NGF)- and ras-induced neuronal differentiation of PC12 cells is accompanied by expression of transin, a secreted metalloproteinase. Retinoic acid (RA) is known to exert important effects on neural cell proliferation and differentiation, In this study we have analysed different PC12 sublines which express either activated Ras or dominant negative p21(N17) Ras, to evaluate the influence of retinoic acid (RA) on the response of the transin gene to NGF and Ras. There was a good correlation between neurite extension and induction of transin mRNA levels in the different subclones. NGF did not induce transin mRNA in cells which do not differentiate in response to this neurotrophin. In addition, incubation with RA did not detectably increase basal transin mRNA levels, but caused a significant increase in the transin response to NGF or Ras in cells in which these factors induce a neuronal morphology. Sequences contained within 750 base pairs of the 5' flanking region of the transin gene confer responsiveness to NGF and Ras, but do not mediate the stimulatory effect of RA. In addition, expression of oncogenic Raf increases transin promoter activity in PC12 cells, but a dominant-negative Raf mutant was unable to block NGF-induced transin activity suggesting the existence of a bifurcation downstream of ras in the signaling mechanism leading to transin expression by NGF.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916; Recio, Juan Angel/0000-0002-7320-3832				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cosgaya JM, 1996, J NEUROCHEM, V66, P89; COSGAYA JM, 1996, IN PRESS ONCOGENE; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1585; GUIGUERE V, 1994, ENDOCR REV, V15, P61; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kerr L D, 1992, Matrix Suppl, V1, P176; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOSARDO JE, 1995, CLIN EXP METASTAS, V13, P236, DOI 10.1007/BF00133479; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	43	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1687	1696		10.1038/sj.onc.1200997	http://dx.doi.org/10.1038/sj.onc.1200997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135070				2022-12-28	WOS:A1997WR89300007
J	Wasylyk, C; Bradford, AP; GutierrezHartmann, A; Wasylyk, B				Wasylyk, C; Bradford, AP; GutierrezHartmann, A; Wasylyk, B			Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2	ONCOGENE			English	Article						MAP kinase; auto-inhibition; DNA-binding; Drosophila; vertebrates	PROTEIN SECONDARY STRUCTURE; TERNARY COMPLEX FACTORS; DNA-BINDING ACTIVITY; GENE FAMILY; V-ETS; DOMAIN PROTEIN; C-FOS; ONCOGENIC CONVERSION; NEURAL NETWORKS; DROSOPHILA EYE	Cell transformation by the Pas oncogene is mediated by members of the ets gene family, To analyse the mechanisms of regulation, we have studied activation of several ets factors by Pas expression, We show that expression of Ha-Pas strongly activates the Ets1 p68 and p54 isoforms and Ets2 in F9 EC cells. We have mapped the Pas responsive elements of Ets1 p68 to two domains, RI+II and RIII. Mutation of threonine 82 to alanine in RI+II abolishes both Pas activation and phosphorylation by MAP kinase. Threonine 82 is part of a sequence that is conserved in Drosophila Pointed P2, an ets protein that has been shown both genetically and biochemically to mediate Pas signalling in Drosophila cells. We extend the comparison of these evolutionary related proteins by showing that Pointed P2 is activated by Pas in mammalian cells and mutation of the homologous threonine abolishes activation. Furthermore, we show that Pointed P2 resembles Ets1, in that it has conserved sequences in a similar position adjacent to the ets DNA binding domain that negatively auto-regulates DNA binding. These results go towards showing that the Drosophila Pointed and vertebrate Ets1 are evolutionary related proteins that have remarkably conserved Pas regulatory mechanisms downstream from MAP kinase.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wasylyk, C (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1, CNRS, INSERM, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.		Wasylyk, Bohdan/ABG-6778-2020; Gutierrez-Hartmann, Arthur/F-1295-2011	Wasylyk, Bohdan/0000-0002-1718-1237; 				ALBAGLI O, 1994, ONCOGENE, V9, P3259; ALBAGLI O, 1992, ONCOGENE, V7, P1435; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COFFER P, 1994, ONCOGENE, V9, P911; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GEGONNE A, 1992, NEW BIOL, V4, P512; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIARIS H, 1995, INT J ONCOL, V7, P413; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QUEVA C, 1993, ONCOGENE, V8, P2511; RABAULT B, 1994, J BIOL CHEM, V269, P28143; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROSS IL, 1994, ONCOGENE, V9, P121; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VALENTINE MA, 1995, J EXP MED, V182, P1943, DOI 10.1084/jem.182.6.1943; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2	78	93	96	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					899	913		10.1038/sj.onc.1200914	http://dx.doi.org/10.1038/sj.onc.1200914			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050989				2022-12-28	WOS:A1997WK34400003
J	Brunton, VG; Ozanne, BW; Paraskeva, C; Frame, MC				Brunton, VG; Ozanne, BW; Paraskeva, C; Frame, MC			A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer	ONCOGENE			English	Article						EGF receptor; c-Src; FAK; colon cancer	PROTEIN-TYROSINE KINASE; CARCINOMA CELL-LINE; FACTOR-ALPHA; FAMILY KINASES; FACTOR EGF; PP60C-SRC; EXPRESSION; ACTIVATION; MIGRATION; PHOSPHORYLATION	We have examined the function of the epidermal growth factor (EGF) receptor, c-Src and focal adhesion kinase (FAK) in the progression of colon cancer using an in vitro progression model. A non-tumorigenic cell line was derived from a premalignant colonic adenoma (PC/AA) from which a clonogenic variant was established (AA/C1). Following sequential treatment with sodium butyrate and the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine an anchorage-independent line was isolated which, with time in culture, became tumorigenic when injected into athymic nude mice (AA/C1/SB10). We have shown that both EGF receptor and FAK protein levels were elevated in the carcinoma cells as compared to the adenoma cells, while the expression and activity of c-Src were unaltered during the adenoma to carcinoma transition. EGP induced the movement of the carcinoma cells into a reconstituted basement membrane which was not seen with the premalignant adenoma cells. This increased motility was accompanied by an EGF-induced increase in c-Src kinase activity, relocalisation of c-Src to the cell periphery and phosphorylation of FAK in the carcinoma cells but not in the adenoma cells. This suggests that c-Src plays a role in the biological behaviour of colonic carcinoma cells induced by migratory factors such as EGF, perhaps acting in conjunction with FAK to regulate focal adhesion turnover and tumour cell motility. Furthermore, although c-Src has been implicated in colonic tumour progression, we demonstrate here that in the adenoma to carcinoma in vitro model c-Src is not the driving force for this progression but co-operates with other molecules in carcinoma development.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	Brunton, VG (corresponding author), BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,LANARK,SCOTLAND.							AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARDIELLO F, 1993, INT J CANCER, V54, P952; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KARAMERIS A, 1993, PATHOL RES PRACT, V189, P133, DOI 10.1016/S0344-0338(11)80082-8; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANNING AM, 1991, ONCOGENE, V6, P1471; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OWENS LV, 1995, CANCER RES, V55, P2752; PLUMB JA, 1989, CANCER RES, V49, P4435; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SUNDARESHAN P, 1991, CANCER COMMUN, V3, P149, DOI 10.3727/095535491820873380; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063	48	106	119	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					283	293		10.1038/sj.onc.1200827	http://dx.doi.org/10.1038/sj.onc.1200827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018114				2022-12-28	WOS:A1997WD51600004
J	Zenklusen, JC; Hodges, LC; Conti, CJ				Zenklusen, JC; Hodges, LC; Conti, CJ			Loss of heterozygosity on murine chromosome 6 in two-stage carcinogenesis: Evidence for a conserved tumor suppressor gene	ONCOGENE			English	Article						human chromosome 7; mitotic recombination; skin tumors; tumor suppressor gene; trisomy	POLYMERASE CHAIN-REACTION; MOUSE SKIN TUMORS; SQUAMOUS-CELL; MICROSATELLITE INSTABILITY; MITOTIC RECOMBINATION; ALLELOTYPE ANALYSIS; MALIGNANT-TUMORS; FREQUENT LOSS; CARCINOMAS; CANCER	We have recently demonstrated that loss of heterozygosity (LOH) at 7q31 is frequent in many kinds of human primary tumors and that introducing a single human chromosome (hchr) 7 into a murine squamous cell carcinoma (SCC)-derived cell line suppresses the malignant phenotype. To investigate whether the putative tumor suppressor gene on hchr 7 is conserved in mice, we studied LOH on mouse chromosome (mchr) 6 in chemically induced SCCs in (C57BL x DBA2) F1 (B6D2F1) females. LOH analysis was performed by polymerase chain reaction amplification of 17 (CA), microsatellite repeats in mchr 6 A1-C3. As expected, all the B6D2F1-derived tumors were informative for all the locus assayed. The highest percentage of LOH in the hchr 7q-homologous segment was found at D6Mit50 (60.0%) and the other markers in this segment had LOH incidences normally distributed around the peak. The high incidence of LOH in the tumors studied suggests that a tumor suppressor gene relevant to the development of epithelial cancers is present on mchr 6 A2. As this segment is homologous with hchr 7q31, these data suggest that the putative tumor suppressor gene is conserved in the two species and explains the suppression of tumorigenicity when a single hchr 7 is introduced to a murine SCC cell line.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA53123] Funding Source: Medline; PHS HHS [PP 57596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; ALDAZ CM, 1986, CANCER GENET CYTOGEN, V20, P223, DOI 10.1016/0165-4608(86)90077-4; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; AN HX, 1995, INT J CANCER, V64, P291, DOI 10.1002/ijc.2910640502; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; ATKIN NB, 1991, CANCER GENET CYTOGEN, V52, P113, DOI 10.1016/0165-4608(91)90061-X; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Boyd J A, 1991, Basic Life Sci, V57, P183; CANZIAN F, 1994, CANCER RES, V54, P6315; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; CONTI CJ, 1992, PROG CLIN BIOL RES, V376, P85; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; EMERIT I, 1989, MUTAT RES, V214, P97, DOI 10.1016/0027-5107(89)90202-9; HEGI ME, 1994, CANCER RES, V54, P6257; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KEMP CJ, 1993, CANCER RES, V53, P6022; KERE J, 1989, BLOOD, V73, P230; KIBBELAAR RE, 1993, BLOOD, V82, P904; LEHMAN TA, 1991, ENVIRON HEALTH PERSP, V93, P133, DOI 10.2307/3431181; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MILLER DR, 1987, CANCER RES, V47, P1935; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; MORI N, 1989, CANCER RES, V49, P5130; NEUBAUER A, 1992, ONCOGENE, V7, P1019; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; SASAKI K, 1995, CANCER RES, V55, P3513; SCHREIBER G, 1990, AM J PATHOL, V137, P653; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; *WHIT I MIT CTR GE, 1994, GEN MAP MOUS; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YUSPA SH, 1994, INVEST DERMATOL S, V103, pS90; ZAR JH, 1991, BIOSTAT ANAL, P102; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					109	114		10.1038/sj.onc.1200806	http://dx.doi.org/10.1038/sj.onc.1200806			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010237				2022-12-28	WOS:A1997WB76000010
J	Kaufmann, AM; Lichtner, RB; Schirrmacher, V; Khazaie, K				Kaufmann, AM; Lichtner, RB; Schirrmacher, V; Khazaie, K			Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis	ONCOGENE			English	Article						EGF receptor; retroviral gene transfer; mammary carcinoma; proliferation; apoptosis; metastasis	EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST-CANCER; CARCINOMA-CELLS; TRANSGENIC MICE; TGF-ALPHA; EXPRESSION; GENES; ACTIVATION; STIMULATION; FIBROBLASTS	The low metastatic MTC (13762NF) rat mammary adenocarcinoma cell line is devoid of epidermal growth factor receptor (EGFR). To test for a link between expression of EGFR and the ability of tumour cells to metastasise from their orthotopic site (spontaneous metastasis), stable subclones of this line (S+) that had been retrovirally transduced to express an ectopic full length HER1 were established and characterised, Proliferation, survival, and response to TGF-alpha were investigated and related to the tumorigenic growth and metastatic properties of the cells, S+ clones responded in vitro to ligand stimulation by growth inhibition and apoptosis, Upon orthotopic inoculation into the mammary fat pad of nude (nu/nu) mice, S+ clones showed retarded growth and apoptosed in situ, while MTC cells or neo(R) control cells showed no signs of apoptosis, Yet, S+ cells exhibited more spontaneous metastasis than the MTC parental cells or neo(R) control cells, Spontaneous metastasis requires cellular detachment (primary site) as well as attachment (secondary site) and growth in target organs, Neither the HER1 mediated increased ECM adhesion nor its negative effect on growth potential explains the observed effect, This is the first direct demonstration of the potential of EGFR to promote spontaneous metastasis of mammary adenocarcinoma cells from their orthotopic site.	GERMAN CANC RES CTR, DIV TUMOR IMMUNOL, D-69120 HEIDELBERG, GERMANY; SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Schering AG				Kaufmann, Andreas/0000-0001-7732-3009				ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; Behrens J, 1992, Semin Cell Biol, V3, P169; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CASTELLANI R, 1994, CANCER, V73, P344, DOI 10.1002/1097-0142(19940115)73:2<344::AID-CNCR2820730218>3.0.CO;2-Y; DEAN C, 1994, INT J CANCER, P103; DELARUE JC, 1988, BREAST CANC RES TREA, V11; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAUFMANN AM, 1994, INT J ONCOL, V4, P1149; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1991, ONCOGENE, V6, P21; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KOENDERS PG, 1991, CANCER RES, V51, P4544; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LICHTNER RB, 1995, ONCOGENE, V10, P1823; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARSHALLHEYMAN H, 1994, ONCOGENE, V9, P3655; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MODJTAHEDI H, 1994, CANCER RES, V54, P1695; MORONI MC, 1992, J BIOL CHEM, V267, P2714; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1984, EXP CELL RES, V150, P3, DOI 10.1016/0014-4827(84)90696-7; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; OZAWA S, 1987, INT J CANCER, V40, P706, DOI 10.1002/ijc.2910400523; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	50	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2349	2358						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957076				2022-12-28	WOS:A1996VX10800007
J	Wang, MH; MonteroJulian, FA; Dauny, I; Leonard, EJ				Wang, MH; MonteroJulian, FA; Dauny, I; Leonard, EJ			Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein	ONCOGENE			English	Article						MSP; RON; PI-3 kinase; migration	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MET PROTOONCOGENE PRODUCT; HA-RAS MUTATION; TYROSINE KINASE; FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; 3-KINASE; FAMILY	Macrophage stimulating protein (MSP) is a ligand for the RON receptor protein tyrosine kinase. Activation of RON in murine resident macrophages results in cell shape change and migration. We studied cell movement induced by MSP in different types of human epithelial cells and the possible role of phosphatidylinositol-3 (PI-3) kinase in RON-mediated signal transduction. We observed specific and saturable binding of I-125-MSP to RON on several epithelial cell lines. In addition to activation and phosphorylation of RON, MSP also induced tyrosine phosphorylation of the PI-3 kinase p85 subunit in a time-dependent manner, with a peak at 15 min. Moreover, phosphorylated RON formed complex with PI-3 kinase in both HK-NOC keratinocyte and RON cDNA-transfected MDCK cells. An in vitro protein interaction assay confirmed that PI-3 kinase from a lysate of MSP-activated cells bound to pure RON protein. MSP, at a concentration range of 1 to 5 nM, induced migration of three epithelial cell lines. This effect was inhibited by wortmannin, a specific inhibitor for PI-3 kinase, with an IC50 of 10 nM. MSP-induced shape change in murine resident peritoneal macrophages was also abolished by wortmannin. These data suggest that activation of PI-3 kinase is required for MSP-induced epithelial cell migration. The stimulation by MSP of epithelial cell movement may have implications for tissue repair, wound healing, and tumor metastasis.	NCI,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,NIH,FREDERICK,MD 21702; IMMUNOTECH SA,ANTIBODY DEPT,MARSEILLE 9,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ANDO Y, 1993, J CELL PHYSIOL, V156, P487, DOI 10.1002/jcp.1041560308; Banu N, 1996, J IMMUNOL, V156, P2933; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROXMEYER HE, 1996, IN PRESS ANN HEMATOL; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1996, IN PRESS EXP CELL RE; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	50	80	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2167	2175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950984				2022-12-28	WOS:A1996VV14500014
J	Pim, D; Massimi, P; Banks, L				Pim, D; Massimi, P; Banks, L			Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth	ONCOGENE			English	Article						HPV; E6; p53; transformation	HUMAN PAPILLOMAVIRUS TYPE-16; FULL-LENGTH E6; MESSENGER-RNA; HUMAN KERATINOCYTES; EARLY GENES; E7; EXPRESSION; DNA; IDENTIFICATION; TRANSCRIPTION	The E6 proteins originating from the tumour-associated Human Papillomavirus (HPV) types 16 and 18 have been shown to bind to and target the tumour suppressor protein, p53, for ubiquitin-mediated degradation. However, in cell lines derived from cervical neoplasias, the predominant early region transcripts are spliced and encode truncated forms of E6, termed E6*. We report here that HPV-18 E6* protein will interact both with the full-length E6 proteins from HPV-16 and HPV-18 and also with E6-AP, and subsequently blocks the association of full length E6 protein with p53. We also show that, as a result of this block, E6* can inhibit E6-mediated degradation of p53 both in vitro and in vivo. The biological consequences of this are increased transcriptional activity on p53-responsive promoters and an inhibition of cell growth in cells transfected with E6*. This is the first report of a potential biological function for this polypeptide and may represent a means by which HPV is able to modulate the activity of the full-length E6 protein with respect to p53 during viral infection.			Pim, D (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BUTZ K, 1995, ONCOGENE, V10, P927; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CHOW LT, 1987, J VIROL, V61, P2581, DOI 10.1128/JVI.61.8.2581-2588.1987; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Massimi P, 1996, ONCOGENE, V12, P2325; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MUNGER K, 1989, J VIROL, V63, P4417; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shally M, 1996, VIRUS RES, V42, P81, DOI 10.1016/0168-1702(96)01301-9; SHIRASAWA H, 1994, VIROLOGY, V203, P36, DOI 10.1006/viro.1994.1452; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Thomas M, 1996, ONCOGENE, V13, P471; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	44	96	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					257	264		10.1038/sj.onc.1201202	http://dx.doi.org/10.1038/sj.onc.1201202			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233760				2022-12-28	WOS:A1997XK99900002
J	Thron, CD				Thron, CD			Bistable biochemical switching and the control of the events of the cell cycle	ONCOGENE			English	Article						biochemical switch; bistability; cell cycle; cyclin-dependent kinase inhibitors; positive feedback	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATION; CDK INHIBITORS; FISSION YEAST; E2F-1 GENE; G1 PHASE; ACTIVATION; TRANSCRIPTION; EXPRESSION	Some of the events of the cell cycle appear to be triggered by a bistable mechanism. A bistable biochemical system can respond to a small, slow signal and is carried by positive feedback from one stable steady state directly to another, in an all-or-none manner. Slow or subthreshold stimuli do not cause accommodation or loss of excitability. Switching is not readily reversible by removing the stimulus, i.e. there is hysteresis: reversal generally requires a stronger, opposite stimulus. Biochemically, bistable biochemical switching requires positive feedback, and mechanisms for stabilizing the system against premature activation and for destabilization in response to a biological signal. Three bistable biochemical models, all suggested by reported experimental observations, are described and analysed. These models suggest that a titratable inhibitor may play an important part in bistable switching, because the end-point of titration can form a natural threshold for enhancement of positive feedback.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755	Dartmouth College								ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; EDELSTEIN BB, 1971, J THEOR BIOL, V32, P191, DOI 10.1016/0022-5193(71)90146-9; Edelstein-Keshet L., 1988, MATH MODELS BIOL; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fotedar R, 1996, ONCOGENE, V12, P2155; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Geng Y, 1996, ONCOGENE, V12, P1173; GRAY P, 1990, CHEM OSCILLATIONS IN; HALL M, 1995, ONCOGENE, V11, P1581; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HIGGINS J, 1967, IND ENG CHEM, V59, P18, DOI 10.1021/ie50689a006; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; Meinhardt H., 1982, MODELS BIOL PATTERN; Murray A, 1993, CELL CYCLE INTRO; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NOVAK B, 1993, J THEOR BIOL, V165, P101, DOI 10.1006/jtbi.1993.1179; NOVAK B, 1995, J THEOR BIOL, V173, P283, DOI 10.1006/jtbi.1995.0063; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OSWALD F, 1994, ONCOGENE, V9, P2029; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1995, MOL CELL BIOL, V15, P742; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roy LM, 1996, ONCOGENE, V12, P2203; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEELIG FF, 1972, FEBS LETT, V24, P283, DOI 10.1016/0014-5793(72)80373-9; SHEER CJ, 1996, SCIENCE, V274, P1672; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Thron CD, 1996, BIOPHYS CHEM, V57, P239, DOI 10.1016/0301-4622(95)00075-5; THRON CD, 1994, BIOSYSTEMS, V32, P97, DOI 10.1016/0303-2647(94)90035-3; THRON CD, 1997, IN PRESS P 2 WORLD C; THRON CD, 1997, ADV MATH POPULATION; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	73	56	56	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					317	325		10.1038/sj.onc.1201190	http://dx.doi.org/10.1038/sj.onc.1201190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233766				2022-12-28	WOS:A1997XK99900008
J	Yokouchi, M; Suzuki, R; Masuhara, M; Komiya, S; Inoue, A; Yoshimura, A				Yokouchi, M; Suzuki, R; Masuhara, M; Komiya, S; Inoue, A; Yoshimura, A			Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation	ONCOGENE			English	Article						B lymphocytes; signal transduction; protein tyrosine kinase; SH2 domain; PH domain	T-CELL; ANTIGEN RECEPTOR; EXPRESSION CLONING; LYMPHOCYTES-B; ZETA-CHAIN; PROTEIN; KINASE; ACTIVATION; FAMILY; SIGNAL	Stimulation of B lymphocytes through their antigen receptor (BCR) results in rapid increases in tyrosine phosphorylation of a number of proteins, which leads to a cascade of biochemical changes that initiates B cell proliferation and differentiation or growth inhibition, A novel cDNA, designed APS, encoding an adaptor protein with a Pleckstrin homology (PH) domain, Src homology 2 (SH2) domain, and a tyrosine phosphorylation site was cloned from a B cell cDNA library using a yeast two hybrid system, APS is structurally similar to SH2-B, an SH2 protein that potentially binds to the immunoreceptor tyrosine-based activation motif (ITAM) as well as Lnk which is postulated to be a signal transducer that Links T-cell receptor to phospholipase C gamma, Grb2 and phosphatidylinositol 3-kinase, APS expressed only in human Burkitt's lymphoma cells among cell Lines me examined and tyrosine phosphorylated in response to BCR stimulation, APS bound to Shc irrespective of stimulation and bound to Grb2 after stimulation, suggesting that it plays a role in Linkage from BCR to Shc/Grb2 pathway, These results indicate that APS, SH2-B and Lnk form a new adaptor family that links immune receptors to signaling pathways involved in tyrosine-phosphorylation.	KURUME UNIV, FAC MED, INST LIFE SCI, KURUME, FUKUOKA 839, JAPAN; KURUME UNIV, FAC MED, DEPT ORTHOPAED SURG, KURUME, FUKUOKA 839, JAPAN	Kurume University; Kurume University			Yoshimura, Akihiko/K-5515-2013					BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Weiner M. P., 1994, STRATEGIES, V7, P41; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	43	108	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					7	15		10.1038/sj.onc.1201163	http://dx.doi.org/10.1038/sj.onc.1201163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233773				2022-12-28	WOS:A1997XH58600002
J	Afshari, CA; Rhodes, N; Paules, RS; Mudryj, M				Afshari, CA; Rhodes, N; Paules, RS; Mudryj, M			Deregulation of specific E2F complexes by the v-mos oncogene	ONCOGENE			English	Article						E2F; mos oncogene; cell cycle	MAP KINASE KINASE; CELL-CYCLE REGULATION; MURINE SARCOMA-VIRUS; TRANSCRIPTION FACTOR; XENOPUS-OOCYTES; PROTO-ONCOGENE; MEIOTIC MATURATION; TRANSFORMED CELLS; THYMIDINE KINASE; MAMMALIAN-CELLS	The product of the c-mos proto-oncogene is a protein kinase that is normally expressed in germ cells and functions during oocyte maturation, It has been shown, however, that inappropriate expression of either the viral or cellular mos gene can induce neoplastic progression in somatic cells. Furthermore, v-mos-transformed NIH3T3 cells will undergo arrest of proliferation in early G1 upon serum withdrawal but are unable to appropriately downregulate cell cycle regulatory proteins, such as cyclin and cdc2 proteins, that normally are down-regulated in quiescent, untransformed NIH3T3 cells. Since the levels of these proteins are partially transcriptionally controlled, me investigated whether there were alterations in the expression of E2F and AP-1 transcription factor complexes. Indeed, the putative G0/G1-specific p130-E2F complex that is normally observed during low serum-induced cell cycle arrest in NIH3T3 cells is not present in serum starved v-mos-transformed cells. instead, G1-phase arrested v-mos-transformed cells stably express two E2F protein complexes that are normally observed only during S-phase in untransformed cells, The elevation of these complexes in arrested v-mos-transformed cells may be the cause of the transcriptional activation of the E2F-regulated genes cdc2, DHFR, Cyclin A, and E2F1 seen in serum starved v-mos-transformed cells. In addition, there are high levels of AP-1 DNA binding activity in serum starved v-mos-transformed cells compared to very low amounts in nontransformed cells. This altered regulation of transcription factor complexes and cell cycle control proteins upon serum withdrawal may provide a mechanism for the uncontrolled cell growth associated with neoplastic transformation induced by certain proto-oncogenes.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27705; DURHAM VA VET ADM MED CTR,GRECC 182,DURHAM,NC 27705; CTR STUDY AGING & HUMAN DEV,DURHAM,NC 27705; NIEHS,GROWTH CONTROL & CANC GRP,RES TRIANGLE PK,NC 27709; UNIV CALIF DAVIS,SCH MED,DEPT MED MICROBIOL & IMMUNOL,DAVIS,CA 95616; MARTINEZ VET ADM,MARTINEZ,CA	Duke University; Geriatric Research Education & Clinical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California Davis				Paules, Richard S/0000-0001-9106-7486	NATIONAL INSTITUTE ON AGING [T32AG000029] Funding Source: NIH RePORTER; NIA NIH HHS [T32AG00029] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CANAANI E, 1979, NATURE, V282, P378, DOI 10.1038/282378a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LAMB EWF, 1993, EMBO J, V12, P2705; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESTER SC, 1980, SOMAT CELL GENET, V6, P241, DOI 10.1007/BF01538799; LIU SH, 1994, CELL GROWTH DIFFER, V5, P447; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V246, P603; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RHODES N, 1994, EXP CELL RES, V213, P210, DOI 10.1006/excr.1994.1192; RICHTER KH, 1991, CANCER RES, V51, P6010; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHONTHAL A, 1990, New Biologist, V2, P143; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SINGH B, 1988, ONCOGENE, V3, P79; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	52	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3029	3038		10.1038/sj.onc.1201157	http://dx.doi.org/10.1038/sj.onc.1201157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223666				2022-12-28	WOS:A1997XG10000005
J	Hime, GR; Dhungat, MP; Ng, A; Bowtell, DDL				Hime, GR; Dhungat, MP; Ng, A; Bowtell, DDL			D-Cbl, the Drosophila homologue of the c-Cbl proto-oncogene, interacts with the Drosophila EGF receptor in vivo, despite lacking C-terminal adaptor binding sites	ONCOGENE			English	Article						cbl; EGF receptor; Drosophila; signal transduction	TYROSINE KINASE; SH3 DOMAIN; V-CBL; PROTOONCOGENE PRODUCT; JURKAT CELLS; STIMULATION; PHOSPHORYLATION; ASSOCIATION; COMPLEXES; ELEGANS	The c-Cbl proto-oncogene encodes a multidomain phosphoprotein that has been demonstrated to interact with a wide range of signalling proteins. The biochemical function of c-Cbl in these complexes is, however, unclear. Recent studies with the C. elegans Cbl homologue, sli-1, have suggested that Cbl proteins may act as negative regulators of EGF receptor (EGFR) signalling. As the EGFR and other protein tyrosine kinase receptor signalling pathways are highly conserved between insects and vertebrates, we sought a Drosophila homologue of c-Cbl for a detailed genetic analysis. We report here that Drosophila melanogaster has a single gene, D-cbl, that is homologous to c-cbl. We find that D-cbl encodes a 52 kDa protein that has a high degree of similarity to c-Cbl and SLI-1 across novel phosphotyrosine-binding (PTB) and RING finger domains. Surprisingly, however, D-Cbl is C-terminally truncated relative to c-Cbl and SLI-1 and consequently is unable to bind SH3-domain containing adaptor proteins, including the Drosophila Grb2 homologue, Drk. Although the D-Cbl protein lacks Drk binding sites it can nevertheless associate with a tyrosine phosphorylated protein, or is itself tyrosine phosphorylated in an DER dependent manner and associates,vith activated Drosophila EGF receptors (DER) in vivo. Consistent with a role for D-Cbl in DER dependent patterning in the embryo and adult, D-Cbl is expressed at a high level in early embryos and throughout the imaginal discs in third instar larvae. This study forms the basis for future genetic analysis of D-Chl, aimed at gaining insights into the role of Cbl proteins in signal transduction.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA	Peter Maccallum Cancer Center			Ng, Ashley/D-3842-2011; Bowtell, David/H-1007-2016; Hime, Gary/B-7162-2015	Ng, Ashley/0000-0001-9690-0879; Bowtell, David/0000-0001-9089-7525; Hime, Gary/0000-0003-4732-3184				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAUMANN P, 1993, DEVELOPMENT, P65; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BOWTELL DDL, 1996, GENETICS RAS SIGNALL; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HIME G, 1992, DEVELOPMENT, V114, P165; Johnson RL, 1995, DEVELOPMENT, V121, P4161; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAROCHELLE S, 1995, GENE, V164, P209; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LINDBLOM A, 1994, AM J HUM GENET, V54, P871; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Matsuo T, 1996, FEBS LETT, V397, P113, DOI 10.1016/S0014-5793(96)01151-9; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PARDUE M, 1994, DROSOPHILA MELANOGAS, V44; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 2002, MOL CLONING LAB MANU; Sattler M, 1996, ONCOGENE, V12, P839; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wisniewski D, 1996, LEUKEMIA, V10, P1436; XU T, 1993, DEVELOPMENT, V117, P1223; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZAK NB, 1990, DEVELOPMENT, V109, P865	64	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2709	2719		10.1038/sj.onc.1201223	http://dx.doi.org/10.1038/sj.onc.1201223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178769				2022-12-28	WOS:A1997XB97800010
J	Sharma, SV; Boyajian, A; Myers, CD; Nakano, H				Sharma, SV; Boyajian, A; Myers, CD; Nakano, H			Specific changes in rasGAP-associated 62 kilodalton protein during integrin mediated cell-substrate interaction	ONCOGENE			English	Article						rasGAP; GAP associated-p62; cell-substrate interaction; integrins; transformation	GTPASE-ACTIVATING PROTEIN; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; SURFACE PROTEIN; TRANSFORMED-CELLS; HUMAN-PLATELETS; NUDE MICE; GENE	A cascade of signal transduction events is initiated when cells make contact with each other or with a substrate. The nature of these signal transduction pathways is beginning to be elucidated. In particular, adhesive interactions between cells and their substrate, mediated by cell-surface integrins and extracellular matrix proteins, appears to activate the MAP kinase pathway. Here we show that in mouse fibroblasts and rat epithelial cells, tyrosine phosphorylation of a 62 kilodalton rasGAP-associated protein (GAPa-p62) is decreased upon cell-substrate interaction. Interaction between fibroblasts and various extracellular matrices such as fibronectin, vitronectin and collagen IV, but not laminin, results in tyrosine dephosphorylation of GAPa-p62. Cell-substrate mediated tyrosine dephosphorylation of GAPa-p62 is defective in transformed cell lines, suggesting a possible role for p62 in tumorigenic transformation. These studies suggest that in fibroblasts, and perhaps even in epithelial cells, the signal transduction pathway(s) triggered by different integrin engagement events converge on the rasGAP protein and alter the tyrosine phosphorylation and/or association of GAPa-p62.	KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN	Kyowa Kirin Ltd	Sharma, SV (corresponding author), UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER; NCI NIH HHS [CA55983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN Q, 1994, J BIOL CHEM, V296, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HEMLER ME, 1993, GUIDEBOOK EXTRACELLU; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER, 1984, CELL CULTURE METHODS; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; TODARO GJ, 1964, P NATL ACAD SCI USA, V51, P66, DOI 10.1073/pnas.51.1.66; TODARO GJ, 1966, VIROLOGY, V28, P756, DOI 10.1016/0042-6822(66)90261-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHAO JF, 1995, ONCOGENE, V11, P161; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	71	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2641	2649		10.1038/sj.onc.1201115	http://dx.doi.org/10.1038/sj.onc.1201115			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178762				2022-12-28	WOS:A1997XB97800003
J	Westermarck, J; Seth, A; Kahari, VM				Westermarck, J; Seth, A; Kahari, VM			Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors	ONCOGENE			English	Article						collagenase; ETS, AP-1; transcription; fibroblast	C-JUN; EXTRACELLULAR-MATRIX; OKADAIC ACID; AP-1; PROMOTER; CELLS; FAMILY; PROTEINS; ONCOGENE; DNA	Expression of interstitial collagenase (MMP-1) has been detected in stromal fibroblasts of various malignant tumors, Here, we have studied the effect of three structurally different ETS transcription factors (ETS-1, ERGB/Fli-1, and PU.1) on MMP-1 promoter activity in NIH3T3 fibroblasts, ETS-1 increased the activity of 3.8 kb MMP-1 promoter construct up to tenfold, while ERGB/FLi-1 or PU.1 alone had no marked effect on basal promoter activity, ETS-1 also markedly potentiated enhancement of MMP-1 promoter by both c-Jun and JunB, whereas ERGB/FLi-1 augmented only the effect of c-Jun, Interestingly, PU.1 abolished induction of MMP-1 promoter by both c-Jun and JunB, Stimulation of MMP-1 promoter by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid was differentially augmented by ETS-1 and ERGB/Fli-1, and abrogated by PU.1, Cotransfection studies with MMP-1 promoter 5'-deletion constructs revealed that AP-1 site was necessary for PU.1-elicited suppression, As compared to control cell lines, PU.1-positive stable cells exhibited clearly weaker binding of c-Jun and JunD containing AP-1 complexes to MMP-1 promoter AP-1 element, as well as marked reduction in basal level and induction of c-jun mRNA by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid, suggesting a novel mechanism for PU.1-mediated inhibition of AP-1 dependent gene expression, These results show that three structurally distinct ETS transcription factors differently modulate AP-1 dependent upregulation of MMP-1 gene expression.	UNIV TURKU,CENT HOSP,DEPT DERMATOL,FIN-20520 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,FIN-20520 TURKU,FINLAND; UNIV TURKU,MEDICITY RES LAB,FIN-20520 TURKU,FINLAND; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5S,CANADA; UNIV TORONTO,MRC,PERIODONTAL PHYSIOL GRP,TORONTO,ON M5S,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S,CANADA	University of Turku; University of Turku; University of Turku; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Westermarck, Jukka/AAL-6464-2020; Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019	Westermarck, Jukka/0000-0001-7478-3018; Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BISWAS C, 1995, CANCER RES, V55, P434; BOLON I, 1995, AM J PATHOL, V147, P1298; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHEN HM, 1995, ONCOGENE, V11, P1549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5924; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY ST, 1992, AM J PATHOL, V141, P301; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Neyns B, 1996, ONCOGENE, V12, P1247; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; POLETTE M, 1991, INVAS METAST, V11, P76; SCHONTHAL A, 1991, NEW BIOL, V3, P977; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1994, ONCOGENE, V9, P469; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205	58	130	133	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2651	2660		10.1038/sj.onc.1201111	http://dx.doi.org/10.1038/sj.onc.1201111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178763				2022-12-28	WOS:A1997XB97800004
J	Persengiev, SP; Kondova, II; Millette, CF; Kilpatrick, DL				Persengiev, SP; Kondova, II; Millette, CF; Kilpatrick, DL			Gli family members are differentially expressed during the mitotic phase of spermatogenesis	ONCOGENE			English	Article						proto-oncogenes; spermatogonia; DNA binding proteins; male germ line	GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GENE CUBITUS-INTERRUPTUS; ZINC-FINGER PROTEIN; EXTRA-TOES XT; CELL-DIFFERENTIATION; KRUPPEL FAMILY; MESSENGER-RNA; MOUSE; RAT; TRANSCRIPTION	The Cli family of DNA binding proteins has been implicated in multiple neoplasias and developmental abnormalities, suggesting a primary involvement in cell development and differentiation, However, to date their specific roles and mechanisms of action remain obscure, and a drawback has been the lack of a model system in which to study their normal function, Here we demonstrate that Gli family members are differentially expressed during spermatogenesis in mice, Specifically, Gli and Gli3 mRNAs were detected in mouse germ cells, while Gli2 was not, Further, both Gli and Gli3 exhibited stage-dependent patterns of expression selectively in type A and B spermatogonia, Gli expression was somewhat higher in type B spermatogonia,while the abundance of Gli3 transcripts was similar in type A and B cells, Gel-shift analyses also demonstrated the enrichment of DNA binding activity specific for the Gli target sequence in spermatogonial cells, These results indicate a selective role for Gli and Gli3 during mitotic stages of male germ cell development, Spermatogenesis may thus provide a unique opportunity to identify downstream targets and explore the normal function of Gli family proteins.	WORCESTER FDN BIOMED RES, NEUROBIOL GRP, SHREWSBURY, MA 01545 USA; UNIV S CAROLINA, SCH MED, DEPT CELL BIOL & NEUROSCI, COLUMBIA, SC 29208 USA	Worcester Foundation for Biomedical Research; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NICHD NIH HHS [HD15269] Funding Source: Medline; NIDDK NIH HHS [DK36468] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCIVAR AA, 1991, MOL REPROD DEV, V30, P187, DOI 10.1002/mrd.1080300304; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; KEW D, 1990, MOL ENDOCRINOL, V4, P337, DOI 10.1210/mend-4-2-337; KEW D, 1989, MOL ENDOCRINOL, V3, P1191, DOI 10.1210/mend-3-8-1191; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROBERTS WM, 1989, CANCER RES, V49, P5407; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; SCHIMMANG T, 1992, DEVELOPMENT, V116, P799; TORRY DS, 1992, AM J REPROD IMMUNOL, V27, P167, DOI 10.1111/j.1600-0897.1992.tb00745.x; VORTKAMP A, 1992, MAMM GENOME, V3, P461, DOI 10.1007/BF00356157; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691	32	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2259	2264		10.1038/sj.onc.1201068	http://dx.doi.org/10.1038/sj.onc.1201068			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178901				2022-12-28	WOS:A1997WY88300002
J	Soucek, T; Pusch, O; HengstschlagerOttnad, E; Adams, PD; Hengstschlager, M				Soucek, T; Pusch, O; HengstschlagerOttnad, E; Adams, PD; Hengstschlager, M			Deregulated expression of E2F-1 induces cyclin A- and E-associated kinase activities independently from cell cycle position	ONCOGENE			English	Article						E2F; cyclin E; cyclin A; CDK; centrifugal elutriation	TUMOR-SUPPRESSOR PROTEIN; S-PHASE ENTRY; TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; DNA-SYNTHESIS; G(1); FIBROBLASTS; APOPTOSIS; GENES	The transcription factor E2F activates genes required for S phase, such as cyclin E and cyclin A, We show that, contrary to long term effects of E2F-1 overexpression, short ectopic overexpression of this transcription factor in logarithmically growing cells does neither affect the cell cycle distribution nor the cell size, but heavily induces cyclin E and A expression as well as cyclin E- and A-dependent kinase activities, We further separated logarithmically growing E2F-1-overexpressing cells according to their different cell cycle phases by centrifugal elutriation, These experiments revealed that deregulated E2F-1 expression triggers high levels of cyclin E and A expression and kinase activities in small early G(1) cells, normally not exhibiting these activities, These effects on the regulation of cyclin E- and A-associated kinases are not accompanied by any detectable alteration in the rate of progression through the cell cycle, suggesting that these changes are independent of any mitogenic properties of E2F-1.	UNIV VIENNA,DEPT PRENATAL DIAGNOSIS & THERAPY,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MOL GENET,A-1030 VIENNA,AUSTRIA; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115	University of Vienna; University of Vienna; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Pusch, Oliver/0000-0001-7166-2800; Adams, Peter/0000-0002-0684-1770				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHEN PL, 1995, CRIT REV EUKAR GENE, V5, P79; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Geng Y, 1996, ONCOGENE, V12, P1173; GRANA X, 1995, ONCOGENE, V11, P211; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; JANSENDURR P, 1995, CELL CYCLE, P243; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LUKAS B, 1996, MOL CELL BIOL, V16, P1047; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	44	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2251	2257		10.1038/sj.onc.1201061	http://dx.doi.org/10.1038/sj.onc.1201061			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178900				2022-12-28	WOS:A1997WY88300001
J	Jain, SK; Langdon, WY; Varticovski, L				Jain, SK; Langdon, WY; Varticovski, L			Tyrosine phosphorylation of p120(cbl) in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase	ONCOGENE			English	Article						BCR/abl tyrosine kinase; c-cbl; GRB2; PI 3-kinase	CHRONIC MYELOGENOUS LEUKEMIA; EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; BCR-ABL ONCOGENE; SIGNAL-TRANSDUCTION; PROTEIN PRODUCT; DOMAIN-BINDING; SH2 DOMAINS; V-CBL; PHOSPHOINOSITIDE 3-KINASE	Increased tyrosine kinase activity of abi oncogene in Philadelphia chromosome positive-leukemic cells leads to activation of p21(ras) and phosphatidylinositol 3'-kinase (PI 3-Kinase). The mechanism of activation of these signaling pathways is not understood, but numerous studies have focused on the identification and characterization of downstream substrates of BCR/abl tyrosine kinase as potential mediators of oncogenic signaling. It was recently found that the 120 kDa protein product of the c-cbl proto-oncogene is highly tyrosine phosphorylated and associates with BCR/abl in transformed hematopoietic cells. We have characterized further cbl's involvement in BCR/abl mediated tumorigenesis using growth factor independent BCR/abl transformed BaF3 cells. Our experiments show that, in contrast to other cell types, the in vivo interaction of cbl with GRB2 and p85 is significantly enhanced in BCR/abl transformed BaF3 cells and that tyrosine phosphorylation of cbl leads to a direct interaction with GRB2, p85 and abl SH2 domains. A 14-fold increase in cbl associated PI 3-kinase activity in BCR/abl transformed cells suggests that the binding of p85 SH2 domains to tyrosine phosphorylated cbl may contribute to PI 3-kinase activation. Domain analysis studies indicate that both SH3 domains of GRB2 bind to the proline rich region of cbl in quiescent BaF3 cells, whereas GRB2 SH2 domain interacts with a non-contiguous sequence of cbl in transformed cells. Although the interaction of cbl with GRB2 in transformed cells was facilitated by binding of GRB2 to BCR/abl, phosphorylation of cbl and its interaction with p190 BCR/abl remained unaltered in BaF3 cells transformed by p190Y177F BCRlabl mutant which is unable to bind GRB2 The current information and the data presented here suggest that, although cbl lacks src homology domains, it represents a novel intermediate protein which, by interaction with key SH-containing adaptor proteins, may participate in regulation of the Ras and PI 3-kinase pathways in BCR/abl transformed hematopoietic cells.	TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, BOSTON, MA 02135 USA; UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA	St. Elizabeth's Medical Center; Tufts University; University of Western Australia				Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [CA-53094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLESSO N, 1994, ONCOGENE, V9, P149; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG SW, 1995, ONCOGENE, V10, P1261; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Frank DA, 1996, LEUKEMIA, V10, P1724; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KIM TJ, 1995, J BIOL CHEM, V271, P1534; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, MOL CELL BIOL, V16, P45; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1996, ONCOGENE, V12, P839; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUSA M, 1992, J BIOL CHEM, V267, P22951; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	74	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	1997	14	18					2217	2228		10.1038/sj.onc.1201049	http://dx.doi.org/10.1038/sj.onc.1201049			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174058				2022-12-28	WOS:A1997WX93800011
J	Watanabe, Y; Lee, SW; Detmar, M; Ajioka, I; Dvorak, HF				Watanabe, Y; Lee, SW; Detmar, M; Ajioka, I; Dvorak, HF			Vascular permeability factor vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells	ONCOGENE			English	Article						VPF/VEGF; senescence; cell cycle; endothelial cells	CYCLIN-DEPENDENT KINASES; DNA-BINDING FUNCTION; HUMAN-FIBROBLASTS; CELLULAR SENESCENCE; MUTANT P53; EXPRESSION; TUMOR; INTERLEUKIN-1-ALPHA; INHIBITOR; INVITRO	Like most other normal cells, human endothelial cells possess a limited replicative life span, and, after multiple passages in vitro, develop an arrest in cell division referred to as replicative senescence, For many cell types senescence can be delayed by oncogenes or tumor suppressor genes or prevented altogether by malignant transformation; however, once developed, senescence has been regarded as irreversible, We now report that a cytokine, vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), significantly delays senescence in human dermal microvascular endothelial cells (HDMEC). Typically, VPF/VEGF-treated HDMEC could be cultured for at least 15-20 more population doublings (PD) than control cells, Protection from senescence was reversible in that subsequent withdrawal of VPF/VEGF returned cells to the senescent phenotype, Expression of several cell cycle-related genes (p21, p16 and p27) was significantly reduced in VPF/VEGF-treated cells but p53 expression was not significantly altered, Of particular importance, VPF/VEGF was able to rescue senescent HDMEC, restoring them to proliferation, to a more normal morphology, and to reduced expression of a senescence marker, neutral beta-galactosidase, Taken together, VPF/VEGF delayed the onset of senescence and also reversed senescence in microvascular endothelial cells without inducing cell transformation.	BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT PATHOL,DIV GERONTOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; TOKYO INST TECHNOL,DEPT BIOMOL ENGN,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tokyo Institute of Technology					NCI NIH HHS [CA-58845, CA-50453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058845, R01CA050453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COMI P, 1995, EXP CELL RES, V219, P304, DOI 10.1006/excr.1995.1232; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DETMAR M, 1990, J INVEST DERMATOL, V95, pS219, DOI 10.1111/1523-1747.ep12875807; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGERMAN RL, 1967, LAB INVEST, V17, P738; GARFINKEL S, 1994, P NATL ACAD SCI USA, V91, P1559, DOI 10.1073/pnas.91.4.1559; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; HITRAYA EG, 1995, LAB INVEST, V73, P393; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IMCKE E, 1991, ARCH DERMATOL RES, V283, P149, DOI 10.1007/BF00372054; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRKLAND JL, 1992, CLIN BIOCHEM, V25, P61, DOI 10.1016/0009-9120(92)80047-K; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RUSZCZAK Z, 1990, J INVEST DERMATOL, V95, P693, DOI 10.1111/1523-1747.ep12514496; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; TAHARA H, 1995, ONCOGENE, V10, P835; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto Y, 1996, CLIN CANCER RES, V2, P821; YEO KT, 1993, CANCER RES, V53, P2912; Zar J., 1994, BIOSTATISTICAL ANAL	46	116	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2025	2032		10.1038/sj.onc.1201033	http://dx.doi.org/10.1038/sj.onc.1201033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160882				2022-12-28	WOS:A1997WW80900004
J	Chen, H; Yu, DH; Chinnadurai, G; Karunagaran, D; Hung, MC				Chen, H; Yu, DH; Chinnadurai, G; Karunagaran, D; Hung, MC			Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu	ONCOGENE			English	Article						adenovirus 5 E1A domains; transcriptional repression; neu protooncogene; suppression; transformation	LUNG-CANCER CELLS; OVARIAN-CANCER; TUMOR-SUPPRESSOR; GENE-PRODUCTS; MUTATIONAL ANALYSIS; FUNCTIONAL DOMAINS; C-ERBB-2 ONCOGENE; POINT MUTATION; EXPRESSION; PROTEIN	Overexpression of nea (also known as c-erbB-2 or HER-2) commonly occurs in human cancer and is also known to enchance tumor metastasis and chemoresistance. Our earlier reports showed that the adenovirus 5 E1A can suppresss the neu-mediated transformation by repression of neu. Thus, E1A has the potential to be used as a therapeutic agent against the neu-overexpressing human cancers. However, a serious concern to this approach is that E1A is also capable of immortalizing primary culture cells and can co-operate with ras or E1B oncogenes to transform them. The E1A CR2 domain (amino acid residues 120 to 140) necessary for binding to RB is believed to be required for this oncogenic function. Here, we report that deletion of CR2 region did not affect E1A's capability to repress neu. Interestingly, deletion of the amino acid residues 4 to 25 or 40 to 80 completely disrupted E1A-mediated neu repression. By deleting the amino acid residues from 81 to 185, we have successfully generated a mini-E1A mutant that was sufficient to inhibit neu promoter activity and suppress neu-mediated transformation. The mini-E1A mutant does not contain the CR2 domain that is crucial for RB binding and immortalization, and hence, may serve as a more selective tumor suppressor, and a safes therapeutic agent. It may also be a useful tool to further investigate the molecular mechanism(s) of neu overexpression and E1A-mediated transcriptional repression in cancer cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,INST MOL VIROL,ST LOUIS,MO 63110	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)			Hung, Mien-Chie/ABD-5911-2021; Karunagaran, Devarajan/A-8148-2010	Hung, Mien-Chie/0000-0003-4317-4740; Karunagaran, Devarajan/0000-0001-9331-8947; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, R01-CA60858] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DEMILIA J, 1989, ONCOGENE, V4, P1233; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORN E, 1986, J VIROL, V57, P765; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Mymryk JS, 1996, ONCOGENE, V13, P1581; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEINER DB, 1990, CANCER RES, V50, P421; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZHANG X, 1989, ONCOGENE, V4, P985; ZHANG YJ, 1995, ONCOGENE, V10, P1947	50	22	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1965	1971		10.1038/sj.onc.1201030	http://dx.doi.org/10.1038/sj.onc.1201030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150363				2022-12-28	WOS:A1997WV80400009
J	Lamphere, L; Fiore, F; Xu, X; Brizuela, L; Keezer, S; Sardet, C; Draetta, GF; Gyuris, J				Lamphere, L; Fiore, F; Xu, X; Brizuela, L; Keezer, S; Sardet, C; Draetta, GF; Gyuris, J			Interaction between Cdc37 and Cdk4 in human cells	ONCOGENE			English	Article						Cdk; cyclin; cdc37; hsp90	SUPPRESSOR GENE-PRODUCT; PROTEIN-KINASE ACTIVITY; DEPENDENT KINASES; DIVISION; COMPLEX; CDC28; G(1); ASSOCIATION; INHIBITORS; CYCLINS	Using the yeast two-hybrid system we have identified novel potential Cdk4 interacting proteins. Here we described the interaction of Cdk4 with a human homologue of the yeast Drosophila CDC37 gene products. Cdc37 protein specifically interacts with Cdk4 and Cdk6, but not with Cdc2, Cdk2, Cdk3, Cdk5 and any of a number of cyclins tested. Cdc37 is not an inhibitor nor an activator of the Cdk4/cyclin D1 kinase, while it appears to facilitate complex assembly between Cdk4 and cyclin D1 in vitro. Cdc37 competes with p16 for binding to Cdk4, suggesting that p16 might exert part of its inhibitory function by affecting the formation of Cdk4/cyclin D1 complexes via Cdc37.	MITOTIX INC,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE CTR 9,CAMBRIDGE,MA 02139; EUROPEAN INST ONCOL,DEPT EXPT ONCOL,I-20141 MILAN,ITALY	Massachusetts Institute of Technology (MIT); Whitehead Institute; IRCCS European Institute of Oncology (IEO)								CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIORE F, 1995, CELL CYCLE MATERIALS, P211; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1980, GENETICS, V95, P561; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WICK ST, 1995, ONCOGENE, V11, P2013	25	82	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1999	2004		10.1038/sj.onc.1201036	http://dx.doi.org/10.1038/sj.onc.1201036			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150368				2022-12-28	WOS:A1997WV80400014
J	Duprez, E; Tong, JH; Derre, J; Chen, SJ; Berger, R; Chen, Z; Lanotte, M				Duprez, E; Tong, JH; Derre, J; Chen, SJ; Berger, R; Chen, Z; Lanotte, M			JEM-1, a novel gene encoding a leucine-zipper nuclear factor upregulated during retinoid-induced maturation of NB4 promyelocytic leukaemia	ONCOGENE			English	Article						leukaemia; differentiation; retinoids; nuclear factors; cloning	LEUKEMIA-CELL LINE; ACID RECEPTORS; TRANSLOCATION; AP-1; PROLIFERATION; TRANSCRIPTION; PROTEASOME; PROMOTER; RNA	Retinoid-induced proliferation causing hyperleukocytosis is a severe complication of retinoid therapy in t(15;17) acute promyelocytic leukaemia. The molecular basis of this phenomenon is unknown. It is possible that the transiently enhanced cell proliferation results from RA-induction of growth regulatory genes. Using Differential Display of cDNAs from NB4 cells we have identified Jem, a novel gene transcript which is upregulated by retinoids during the early proliferative response in maturating cells but not in resistant cells. A 2.7 kb cDNA was cloned and sequenced. The open reading frame contains a 400 amino acid sequence corresponding to a novel 45 kDa basic protein (pI 8.9). The JEM DNA sequence is detected by FISH on human chromosome 1 at q24. The Jem peptide sequence shows a 'leucine-zipper' dimerisation motif with limited homology to Fos/Jun and ATF/CREB proteins and several putative phosphorylation sites. An atypical basic region may correspond to an unknown DNA-binding domain. The C-terminal end of Jem spans a long stretch featuring a PEST motif. After transfection into COS cells, the Jem protein shows a ponctuated nuclear localisation. We hypothesise that this novel nuclear factor may act as a transcription factor, or coregulator, involved in either cell growth control and/or maturation.	HOP ST LOUIS,INSERM U301,CTR G HAYEM,F-75475 PARIS,FRANCE; RUI JIN HOSP,INST HEMATOL,SHANGHAI,PEOPLES R CHINA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			duprez, estelle a/R-2357-2016					BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGNAM JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GRIGNANI F, 1994, BLOOD, V83, P10; Gudas Lorraine J., 1994, P443; Hong Waun Ki, 1994, P597; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES D, 1992, P NATL ACAD SCI USA, V89, P4042, DOI 10.1073/pnas.89.9.4042; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LANOTTE M, 1991, BLOOD, V77, P1080; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Peck Gary L., 1994, P631; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SAKASHITA A, 1993, BLOOD, V81, P1009; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VINSON CR, 1989, SCIENCE, V246, P172; YANGYEN HF, 1991, NEW BIOL, V3, P1206	35	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1563	1570		10.1038/sj.onc.1200995	http://dx.doi.org/10.1038/sj.onc.1200995			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129147				2022-12-28	WOS:A1997WQ54800007
J	Dazard, JE; Augias, D; Neel, H; Mils, V; Marechal, V; BassetSeguin, N; Piette, J				Dazard, JE; Augias, D; Neel, H; Mils, V; Marechal, V; BassetSeguin, N; Piette, J			MDM-2 protein is expressed in different layers of normal human skin	ONCOGENE			English	Article						MDM-2; p53; keratinocyte; skin	SOFT-TISSUE SARCOMAS; WILD-TYPE P53; CELL-LINES; TRANSCRIPTIONAL ACTIVITY; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; SUPPRESSOR GENE; MUTATIONS; ONCOGENE	MDM-2 is one of the target genes of the p53 tumor suppressor protein. Its best characterized function is found in the inhibition of p53's ability to modulate transcription. Deregulated expression of MDM-2 could thus at least partially substitute for p53 mutation in the process of tumorigenesis. We show here that MDM-2 is highly expressed in biopsies of normal human skin or in vitro reconstituted human skin. The protein is detected in the nucleus of keratinocytes throughout the different layers of the epidermis and in reconstituted skin as early as the two to three cell layer stage. The 90 kiloDalton (kD) protein is one of the major forms detected in Western blot experiments. MDM-2 is detected in skin reconstituted from keratinocytes in which p53 is inactivated by mutation or degradation by E6 protein, providing evidence that MDM-2 expression in the skin can occur in the absence of wild type p53. Moreover, we found no correlation between the p53 status and MDM-2 expression levels in a series of basal and squamous cell carcinomas or Bowen diseases. Our data provide first evidence for the expression of MDM-2 in a differentiated adult tissue.	INST GENET MOL,UMR 5535,F-34033 MONTPELLIER 01,FRANCE; IURC,LAB DERMATOL MOL,F-34033 MONTPELLIER 05,FRANCE; HOP ROTHSCHILD,MICROBIOL LAB,F-75571 PARIS 12,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite			marechal, vincent/P-7719-2017					ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALL PA, 1993, ONCOGENE, V8, P203; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOLES JP, 1993, ONCOGENE, V8, P583; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PARK DJ, 1994, ONCOGENE, V9, P1899; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISS M, 1992, ONCOL RES, V4, P349; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SPANDAU DF, 1994, ONCOGENE, V9, P1861; THEILLET C, 1989, ONCOGENE, V4, P915; WABER PG, 1993, CANCER RES, V53, P6028; WATANABE T, 1994, BLOOD, V84, P3158; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	45	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1123	1128		10.1038/sj.onc.1200922	http://dx.doi.org/10.1038/sj.onc.1200922			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070662				2022-12-28	WOS:A1997WM07000015
J	Kenny, JJ; Knobloch, TJ; Augustus, M; Carter, KC; Rosen, CA; Lang, JC				Kenny, JJ; Knobloch, TJ; Augustus, M; Carter, KC; Rosen, CA; Lang, JC			GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes	ONCOGENE			English	Article						apoptosis; Bcl-2 homologue; leukemia; melanoma; FISH analysis	FOLLICULAR LYMPHOMA; SEQUENCE SIMILARITY; HUMAN MELANOCYTES; HOMOLOG BAK; APOPTOSIS; INDUCTION; ANTIGENS; MEMBRANE; PROTEIN; DEATH	Our laboratory previously described the independent isolation of the fibroblast growth factor 4 (FGF-4) gene by NIH3T3 transformation assay using DNA from a patient with CML leukemia (Lucas et al., 1994). The FGF-4 gene was truncated by DNA rearrangement with a novel gene named GRS. In this manuscript we describe isolation of GRS cDNA and show by sequence comparison that GRS is a novel member of the Bcl-2 gene family. Northern analysis shows expression of the gene in normal human tissue to be largely restricted to the hematopoietic compartment. Analysis of the pattern of gene expression in cancer cell lines demonstrates GRS is expressed in hematopoietic malignancies and in melanoma. The chromosomal location of GRS has also been determined. The gene is positioned on chromosome 15 within bands q24-25.	OHIO STATE UNIV HOSP,ARTHUR G JAMES CANC HOSP & RES INST 1248,COLUMBUS,OH 43210; HUMAN GENOME SCI,ROCKVILLE,MD 20850	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; GlaxoSmithKline; Human Genome Sciences Inc					NCI NIH HHS [CA 63134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FRASER JK, 1987, EXP HEMATOL, V15, P406; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOKALJVOKAC N, 1991, CYTOGENET CELL GENET, V57, P11, DOI 10.1159/000133103; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LIN EY, 1993, J IMMUNOL, V151, P1979; LUCAS JM, 1994, ONCOL RES, V6, P139; Morris C, 1996, ONCOGENE, V12, P677; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OTLVAI ZN, 1993, CELL, V74, P609; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	28	27	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					997	1001		10.1038/sj.onc.1200898	http://dx.doi.org/10.1038/sj.onc.1200898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050999				2022-12-28	WOS:A1997WK34400013
J	Arighi, E; Alberti, L; Torriti, F; Ghizzoni, S; Rizzetti, MG; Pelicci, G; Pasini, B; Bongarzone, I; Piutti, C; Pierotti, MA; Borrello, MG				Arighi, E; Alberti, L; Torriti, F; Ghizzoni, S; Rizzetti, MG; Pelicci, G; Pasini, B; Bongarzone, I; Piutti, C; Pierotti, MA; Borrello, MG			Identification of Shc docking site on Ret tyrosine kinase	ONCOGENE			English	Article						Ret; Shc; receptor tyrosine kinase; oncogene	PAPILLARY THYROID CARCINOMAS; SIGNAL-TRANSDUCTION; PROTO-ONCOGENE; INSULIN-RECEPTOR; DOMAIN; PROTEINS; PHOSPHOTYROSINE; PHOSPHORYLATION; PROTOONCOGENE; BINDING	The RET proto-oncogene encodes two isoforms of a receptor type tyrosine kinase which plays a role in neural crest and kidney development, Distinct germ-line mutations of RET have been associated inherited cancer syndromes MEN2A, MEN2B FMTC as well as with the congenital disorder Hirschsprung disease (HSCR), whereas somatic rearrangements (RET/PTCs) have been frequently detected in the papillary thyroid carcinoma, Despite these findings, suggesting a relevant role for RET product in development and neoplastic processes, little is known about the signalling triggered by this receptor, In this study, we have demonstrated that the transducing adaptor molecule She is recruited and activated by both Ret isoforms and by the rearranged cytoplasmatic Ret/ptc2 oncoproteins as well as by the membrane bound receptor activated by MEN2A or by MEN2B associated mutations, Moreover, our analysis has identified the Ret tyrosine residue and the She domains involved in the interaction, In fact, here we show that both the phosphotyrosine binding domains of She, PTB and SH2, interact with Ret/ptc2 in vitro, However, PTB domain binds 20 folds higher amount of Ret/ptc2 than SH2, The putative binding site for either SH2 and PTB domains has been identified as Tyr586 of Ret/ptc2 (Tyr1062 on proto-Ret). In keeping with this finding, by using RET/PTC2-Y586F mutant, we have demonstrated that this tyrosine residue, the last amino acid but one before the divergence of the two Ret isoforms, is the docking site for She.	IST NAZL TUMORI,DIV EXPT ONCOL A,I-20133 MILAN,ITALY; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY; IST NAZL TUMORI,SCI DIRECT,I-20133 MILAN,ITALY; PHARMACIA & UPJOHN RES,ONCOL & IMMUNOL PRECLIN RES,I-20014 NERVIANO,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS European Institute of Oncology (IEO); Fondazione IRCCS Istituto Nazionale Tumori Milan			Bongarzone, Italia/B-9544-2017; Pasini, Barbara/AHI-2004-2022; Pierotti, Marco Alessandro/AAC-4728-2022; Pelicci, Giuliana/AAA-8921-2022; Borrello, Maria Grazia/C-3161-2017	Bongarzone, Italia/0000-0003-2530-9170; Pasini, Barbara/0000-0002-4373-1212; Pierotti, Marco Alessandro/0000-0002-7431-8332; Pelicci, Giuliana/0000-0003-0986-8255; Borrello, Maria Grazia/0000-0002-6854-2848				BALDARI CT, 1995, ONCOGENE, V10, P1141; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH S, 1993, NATURE, V367, P87; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANZI C, 1992, ONCOGENE, V7, P2189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PONDER PAJ, 1995, CANCER SURV, V25, P195; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TRUB T, 1995, J BIOL CHEM, V270, P18205; TRUPP E, 1996, NATURE, V381, P785; TURCK CW, 1994, PEPTIDE RES, V7, P140; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1996, J BIOL CHEM, V271, P31119	46	104	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					773	782		10.1038/sj.onc.1200896	http://dx.doi.org/10.1038/sj.onc.1200896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047384				2022-12-28	WOS:A1997WJ11200003
J	Wilson, CA; Payton, MN; Elliott, GS; Buaas, FW; Cajulis, EE; Grosshans, D; Ramos, L; Reese, DM; Slamon, DJ; Calzone, FJ				Wilson, CA; Payton, MN; Elliott, GS; Buaas, FW; Cajulis, EE; Grosshans, D; Ramos, L; Reese, DM; Slamon, DJ; Calzone, FJ			Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Delta 11b	ONCOGENE			English	Article						BRCA1; subcellular localization; alternative splicing	HUMAN CYTOMEGALO-VIRUS; IMMEDIATE EARLY GENE; BREAST-CANCER; OVARIAN-CANCER; MONOCLONAL-ANTIBODIES; KINETIC-MODEL; MUTATIONS; FAMILIES; PROTEIN; TISSUES	The mechanism of BRCA1 tumor suppression in human breast and ovarian cells is the focus investigation. In this report, full length (230 kDa) introduced into cells with CMV promoter constructs was nuclear when transgene expression was low whereas high expression resulted in cytoplasmic accumulation, aberrant nuclear and cell morphology. A nuclear localization signal (NLS) was mapped to BRCA1 amino acid positions 262-570. We describe a splice variant, BRCA1-Delta 11b, missing the majority of exon 11 including the NLS. Exogenous BRCA1-Delta 11b (110 kDa) was cytoplasmic and, unlike the full-length protein, overexpression of the protein encoded by the variant did not appear to be toxic. RNA probe titrations and RT-PCR demonstrated that BRCA1 and Delta 11b transcripts are coexpressed in a wide variety of cells and tissues. Interestingly, BRCA1-Delta 11b message was greatly reduced or absent in several breast and ovarian tumor lines relative to exon 11 transcripts and a Delta 9,10 splice variant. Taken together our results suggest that full-length BRCA1 and BRCA1-Delta 11b may have distinct roles in cell growth regulation and tumorigenesis.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90095 USA	Amgen; University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA36827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; BAG J, 1991, TRANSLATION EUKARYOT, P71; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; Bienstock RJ, 1996, CANCER RES, V56, P2539; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0; Bradley A, 1996, NAT GENET, V13, P268, DOI 10.1038/ng0796-268b; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNIG D, 1994, PROG GROWTH FACTOR R, V4, P353; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GALAU GA, 1977, ARCH BIOCHEM BIOPHYS, V179, P584, DOI 10.1016/0003-9861(77)90147-3; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GODEFROYCOLBURN T, 1981, J BIOL CHEM, V256, P1762; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Ithier G, 1996, NEW ENGL J MED, V334, P1198; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jensen RA, 1996, NAT GENET, V13, P269, DOI 10.1038/ng0796-269; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Rao VN, 1996, ONCOGENE, V12, P523; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shattuck-Eidens D, 1995, JAMA-J AM MED ASSOC, V273, P535; Slobin L.I., 1991, TRANSLATION EUKARYOT, P149; Sobol A, 1996, CANCER RES, V56, P3216; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264	50	176	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					1	16		10.1038/sj.onc.1200924	http://dx.doi.org/10.1038/sj.onc.1200924			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010228				2022-12-28	WOS:A1997WB76000001
J	Roy, B; Reisman, D				Roy, B; Reisman, D			Positive and negative regulatory elements in the murine p53 promoter	ONCOGENE			English	Article						p53 expression; transcription; promoter	TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; HELIX-LOOP-HELIX; TRANSCRIPTIONAL REPRESSION; PROTEIN; EXPRESSION; ANTIGEN; CELLS; TRANSFORMATION; BINDING	In order to understand the basis for regulated as well as de-regulated expression of the p53 tumor suppressor gene, we have focused on characterizing the transcriptional regulation of the p53 gene. Here we present evidence for the existence of two additional upstream regulatory elements in the murine p53 promoter. One of these sites maps to a region between -296 to -270 and the second one between -255 to -226 relative to the major transcription initiation site. These two sites are referred to as binding sites for PBF I and II, respectively. Nucleotide bases that have been found to be critical for the binding of nuclear factors to these sites are 5'-AGA-3' (-282 to -280) in binding site I and 5'-ACAG-3' (-246 to -243) in binding site II. Mutational analyses in conjunction with transient transfection assays indicated that the factor that binds to the region between -245 to -242 (PBF II) plays a positive regulatory role p53 promoter activity. This was demonstrated by the observation that promoter mutations that abolished binding to this site, showed a decreased level of activity as compared to the wild type promoter. In analogous experiments, mutational anlayses and transient transfection assays indicated that the factor that binds to the region between -282 to -280 (PBF I) plays a negative regulatory role in p53 promoter activity. This was demonstrated by the observation that promoter mutations that abolished binding to this site, showed an increased level of activity as compared to the wild type promoter.	UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL CANCER INSTITUTE [R29CA059986] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA59986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Balint E, 1996, CANCER RES, V56, P1648; BEINZTADMOR B, 1985, EMBO J, V4, P3209; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1990, ONCOGENE, V5, P1285; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLTIVAI ZN, 1993, CELL, V74, P609; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU HY, 1994, J BIOL CHEM, V269, P20067; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2359	2366						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957077				2022-12-28	WOS:A1996VX10800008
J	ZerfassThome, K; Zwerschke, W; Mannhardt, B; Tindle, R; Botz, JW; JansenDurr, P				ZerfassThome, K; Zwerschke, W; Mannhardt, B; Tindle, R; Botz, JW; JansenDurr, P			Inactivation of the cdk inhibitor p27(KIP1) by the human papillomavirus type 16 E7 oncoprotein	ONCOGENE			English	Article						cdk2; cyclin A; cyclin E; HPV-16 E7; p27(KIP1)	HIGH-EFFICIENCY TRANSFORMATION; DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; HUMAN CYCLIN-E; CELL-CYCLE; HUMAN KERATINOCYTES; PHASE-TRANSITION; PROTEIN; GENE; ADENOVIRUS-E1A	Expression of the E7 oncogene of HPV-16 induces S phase entry of mammalian cells in the presence of antiproliferative signals. In particular, E7 can bypass G(0)/G(1) arrest in response to both serum withdrawal and loss of cell adhesion, two experimental conditions in which cell cycle progression is accompanied by elevated levels of the cdk inhibitor p27(KIP1). We show here that E7 can antagonize the ability of p27(KIP1) block cyclin E-associated kinase in vitro and to inhibit transcription from the cyclin A gene in transfection experiments. E7 associates with p27(KIP1) both in a reconstituted in vitro system and in extracts of mammalian cells, and association requires the C-terminal part of E7. The interaction between p27(KIP1) and E7 can also be demonstrated in a yeast two hybrid system. The data suggest that the ability of E7 to override certain forms of G(0)/G(1) arrest is mediated in part by binding to and subsequent inactivation of the cdk inhibitor p27(KIP1).	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCH SCHWERPUNKT ANGEW TUMORVIROL, ABT 620, D-69120 HEIDELBERG, GERMANY; PRINCESS ALEXANDRA HOSP, LIONS HUMAN IMMUNOL LABS, BRISBANE, QLD 4102, AUSTRALIA	Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCOLINI F, 1994, ONCOGENE, V9, P2633; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MIN SY, 1992, ONCOGENE, V7, P1531; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1989, J VIROL, V63, P4417; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schulze A, 1996, MOL CELL BIOL, V16, P4632; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; Zwerschke W, 1996, ONCOGENE, V12, P213	41	276	297	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2323	2330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957073				2022-12-28	WOS:A1996VX10800004
J	Bond, J; Haughton, M; Blaydes, J; Gire, V; WynfordThomas, D; Wyllie, F				Bond, J; Haughton, M; Blaydes, J; Gire, V; WynfordThomas, D; Wyllie, F			Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence	ONCOGENE			English	Article						p53; senescence; immortalisation; transactivation; beta-galactosidase; DNA damage	HUMAN-DIPLOID FIBROBLASTS; DNA-BINDING FUNCTION; EPITHELIAL-CELLS; MUTANT P53; MAMMALIAN-CELLS; HUMAN CANCER; IMMORTALIZATION; EXPRESSION; PROTEIN; DAMAGE	Wild-type p53 is necessary for the growth arrest of human diploid fibroblasts (HDF) (and many other cell types) at the end of their proliferative lifespan. Although p53 may actively mediate senescence, possibly in response to telomere erosion, it is however equally possible that it is merely a permissive factor required for response to some other inducer. To address this question, we have generated stable transfectants of early passage HDF, represented here by clone LacZ21, in which expression of a beta-galactosidase reporter construct reflects p53 transactivation activity. During continuous passage, the proportion of beta-gal positive LacZ21 cells remained below 2% for 25 population doublings (pd), first became significantly increased after 29 pd, and thereafter increased rapidly, reaching a maximum of 88% in fully-senescent cells (32 pd), which exceeded the response observed following an optimum dose (20 J/m(2)) of u.v. radiation. Correspondingly, the proportion of cells incorporating bromodeoxyuridine (BrdU) (initially 45-50%) began to fall at 29 pd and thereafter dropped rapidly to below 1% by pd 32. There was therefore a near-perfect reciprocal relationship between reporter construct expression and DNA synthesis as cells approached senescence. Furthermore, a dominant-negative p53 mutant (introduced by retroviral transduction) rescued LacZ21 cells from senescence and generated colonies with extended lifespan in which beta-gal expression was totally abolished. These data, although not excluding the need for other p53 functions, strongly suggest that p53-mediated transactivation of growth regulatory genes is a direct trigger, rather than a permissive factor, for cellular senescence.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			Blaydes, Jeremy/AAC-6939-2019; Gire, Veronique/N-7553-2017; Gire, Véronique/AAC-2218-2020	Blaydes, Jeremy/0000-0001-8525-0209; Gire, Veronique/0000-0002-9009-2185				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLAYDES JP, 1995, ONCOGENE, V10, P307; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; FRIEDRICH VL, 1993, J NEUROSCI RES, V36, P88, DOI 10.1002/jnr.490360110; GUDAS J, 1995, ONCOGENE, V11, P253; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOPEZLARRAZA D, 1990, MUTAT RES, V232, P57, DOI 10.1016/0027-5107(90)90110-P; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; RENZING J, 1995, ONCOGENE, V10, P1865; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SHAY JW, 1993, ONCOGENE, V8, P1407; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119	37	126	130	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2097	2104						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950976				2022-12-28	WOS:A1996VV14500006
J	Cairns, LA; Crotta, S; Minuzzo, M; RicciardiCastagnoli, P; Pozzi, L; Ottolenghi, S				Cairns, LA; Crotta, S; Minuzzo, M; RicciardiCastagnoli, P; Pozzi, L; Ottolenghi, S			Immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice	ONCOGENE			English	Article						pheochromocytoma; transgenic mice; adrenal medullary tumor; ret	INTENSELY FLUORESCENT CELLS; NERVE GROWTH-FACTOR; RET PROTOONCOGENE; CHROMAFFIN CELLS; CREST DERIVATIVES; EXPRESSION; GENE; DIFFERENTIATION; RAT; GLUCOCORTICOIDS	Pheochromocytomas are adrenal medullary tumors which arise from the transformation of neural crest-derived cells. In the course of studies of mice transgenic for an SV40 T-gene ectopically expressed in the adrenal medulla, we observed the occurrence of large, mainly bilateral tumors in a high proportion of transgenic animals. From these tumors we established immortalized cell lines which grow in vitro at 32 degrees C (the permissive temperature for the tsA58 T-protein encoded by the transgene), but not at 38 degrees C. These cells demonstrate characteristics of both neuronal (160 kd neurofilament) and endocrine (chromogranins) cells. The expression of Mash-1 and ret supports their initial characterization as early bipotential neuro-endocrine progenitors.	CNR,CTR STUDIO FARMACOL CELLULARE & MOL,I-20133 MILAN,ITALY; UNIV ROME,SEZ BIOL CELLULARE,DIP BIOPATHOL UMANA,ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Cairns, LA (corresponding author), UNIV MILAN,DIP GENET & BIOL MICROORGANISMI,MILAN,ITALY.			Crotta, Stefania/0000-0003-4676-8616				Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; ANDERSON DJ, 1989, TRENDS GENET, V5, P74; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAUDE P, 1988, NEURON, V1, P783, DOI 10.1016/0896-6273(88)90126-2; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; EIDEN LE, 1987, NEUROSCIENCE, V21, P1019, DOI 10.1016/0306-4522(87)90056-X; ERANKO O, 1972, HISTOCHEM J, V4, P49, DOI 10.1007/BF01005268; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; IKEDA I, 1990, ONCOGENE, V5, P1291; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; LANDIS SC, 1981, TRENDS NEUROSCI, V4, P172, DOI 10.1016/0166-2236(81)90056-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; SANTORO M, 1990, ONCOGENE, V5, P1595; SHALNIK DG, 1991, MOL CELL BIOL, V11, P4518; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; UNSICKER K, 1989, INT J DEV NEUROSCI, V7, P413, DOI 10.1016/0736-5748(89)90002-6; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WHITE LA, 1994, J NEUROSCI, V14, P6744; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3093	3098		10.1038/sj.onc.1201137	http://dx.doi.org/10.1038/sj.onc.1201137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223673				2022-12-28	WOS:A1997XG10000012
J	Edelson, MI; Scherer, SW; Tsui, LC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Edelson, MI; Scherer, SW; Tsui, LC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas	ONCOGENE			English	Article						ovary; cancer; borderline; LOH; chromosome 7	TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; HUMAN BORDERLINE; SQUAMOUS-CELL; ALLELIC LOSS; CANCER; HETEROZYGOSITY; HUMAN-CHROMOSOME-7; MALIGNANCIES; ALLELOTYPE	We have used polymerase chain reaction (PCR) amplification of tandem repeats to study the pattern of allelic loss on chromosome 7q31 in invasive epithelial ovarian carcinomas and borderline ovarian tumors. Using 13 primer sets spanning loci from 7q31 to 7q32, 16 borderline and 54 invasive ovarian tumor tissue, together with their corresponding normal tissue, were analysed. Invasive epithelial ovarian tumors demonstrated loss of heterozygosity (LOH) at one or more loci on 7q in 32 of 54 cases (59%). The invasive epithelial ovarian tumors demonstrated the highest percentage of LOH at the loci D7S643 (20 of 40 informative cases, 50%) and GATA44F09 (18 of 42 informative cases, 43%). In contrary, only one borderline ovarian tumor showed LOH at one locus (GATA44F09, one of 14 informative cases, 7%). Our results display a sharp contrast in the pattern of LOH between invasive and borderline ovarian tumors suggesting that allelic loss at chromosome 7q31.3 may be involved in the development and progression of invasive epithelial ovarian tumors but not borderline ovarian tumors. Further analysis of the deletion map for the invasive epithelial ovarian tumors showed two regions Likely to harbor ovarian tumor suppressor genes including a novel 1300 kilobase common loss region flanked by GATA44F09 and D7S643.	BRIGHAM & WOMENS HOSP,LAB GYNECOL ONCOL,DIV GYNECOL ONCOL,DEPT OBSTET GYNECOL & REPROD BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999	NATIONAL CANCER INSTITUTE [R01CA063381, R01CA069291, R01CA069453] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69291, R01CA69453, R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; Bryan EJ, 1996, CANCER RES, V56, P719; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CLIBY W, 1993, CANCER RES, V53, P2393; Davis M, 1996, CANCER RES, V56, P741; DODSON MK, 1993, CANCER RES, V53, P4456; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1992, DIS MARKERS, V10, P95; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1990, GYNECOL ONCOL, V38, P473, DOI 10.1016/0090-8258(90)90094-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; Kerr J, 1996, ONCOGENE, V13, P1815; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; LEE JH, 1990, CANCER RES, V50, P2724; Lin JC, 1996, ONCOGENE, V13, P2001; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SATO T, 1991, CANCER RES, V51, P5118; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; Tangir J, 1996, ONCOGENE, V12, P735; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	37	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2979	2984		10.1038/sj.onc.1201271	http://dx.doi.org/10.1038/sj.onc.1201271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205105				2022-12-28	WOS:A1997XF55500012
J	Knoepfler, PS; Kamps, MP				Knoepfler, PS; Kamps, MP			The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-Pbx1 and class I Hox proteins - Evidence for selective targetting of E2a-Pbx1 to a subset of Pbx-recognition elements	ONCOGENE			English	Article						Pbx; E2a-Pbx1; Hox; t(1;19) pre-B ALL	EMBRYONAL CARCINOMA-CELLS; HUMAN PROTOONCOGENE PBX1; HOMEOBOX GENES; RETINOIC ACID; PRE-B; TRANSLOCATION PROTEIN; TRANSCRIPTION FACTOR; HOMEODOMAIN; MOTIF; EXTRADENTICLE	Oncoprotein E2a-Pbx1 contains the N-terminal transactivation domains of E2a and the majority of the homeodomain protein, Pbx1, Using recombinant proteins, both Pbx1 and E2a-Pbx1 heterodimerize with Hox proteins on bipartite elements, Pbx1 binding a 5' TGAT core and Class I Hox proteins binding adjacent 3' TAAT, TTAT, or TGAT cores. In contrast to these in vitro results, nuclear extracts from E2a-Pbx1-transformed cells assemble an abundant Pbx-containing complex on TGATTGAT that excludes E2a-Pbx1, suggesting that an uncharacterized in vivo partner discriminates between E2a-Pbx1 and Pbx proteins, distinguishing it from Hox proteins. Here, we describe the DNA-binding properties of this complex, and identify TGATTGAC (PCE; Pbx Consensus Element) as its optimal recognition motif. In vitro, the PCE fails to bind heterodimers of Class I Hox proteins plus either Pbx1 or E2a-Pbx1. Likewise, in vivo, the PCE fails to mediate cooperative transactivation by E2a-Pbx1 plus Class I Hox proteins. Thus, the PCE binds a Pbx dimer partner that behaves unlike Class I Hox proteins, Competition analysis indicates that the Pbx-containing complex that binds the PCE also binds the TGATTGAT Pbx-Hox element and binds promoter elements required for tissue-specific expression of a number of cellular genes. Thus, different Pbx partners dictate targetting of Pbx heterodimers to related DNA motifs that differ in the sequence of their 3' half-sites, and E2a-Pbx1 heterodimerizes with only a subset of Pbx partners, restricting its potential DNA targets.			Knoepfler, PS (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Knoepfler, Paul/0000-0001-5444-334X	NATIONAL CANCER INSTITUTE [P01CA050528, R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876, 2 PO1 CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1991, GENE DEV, V5, P353; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KNOEPFLER PS, 1997, IN PRESS MECH DEV; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SPOEREL NA, 1993, J MOL BIOL, V230, P151, DOI 10.1006/jmbi.1993.1132; TANG SQ, 1995, NUCLEIC ACIDS RES, V23, P1928, DOI 10.1093/nar/23.11.1928; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	44	38	39	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2521	2531		10.1038/sj.onc.1201097	http://dx.doi.org/10.1038/sj.onc.1201097			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191052				2022-12-28	WOS:A1997XA94900004
J	Lane, S; Farlie, P; Watson, R				Lane, S; Farlie, P; Watson, R			B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation	ONCOGENE			English	Article						B-Myb; cyclin A; transactivation; cell cycle	DNA-BINDING ACTIVITY; C-MYB; TRANSCRIPTIONAL ACTIVATION; CELL-CYCLE; GENE-PRODUCT; ONCOGENE; TRANSACTIVATION; EXPRESSION; DOMAINS; TRANSFORMATION	Transcription of the B-Myb gene is cell cycle regulated by an E2F-dependent mechanism and its product, B-Myb, is itself a transcription factor required for S-phase entry. Previously, rye have shown that B-Myb is specifically phosphorylated during S-phase and that similar modification to a less electrophoretically mobile form could be induced by baculovirus-expressed cyclin A/Cdk2 kinase. We report here that cyclin A-mediated phosphorylation of B-Myb is associated with a marked increase in transactivation function in U-2 OS cells. In contrast to previous studies, transactivation of the luciferase reporter was dependent upon Myb binding sites located upstream of the promoter. Enhancement of B-Myb activation function was also obtained by truncation of the C-terminus just downstream of a domain conserved in evolution. Potentiation of B-Myb activity by phosphorylation was not simply a consequence of overcoming the negative effect of the C-terminus, however, as the truncated protein was to a lesser extent also activated by cyclin A/Cdk2. Whereas wild-type B-Myb transactivation activity could not be potentiated by cyclin A/Cdk2 in NIH3T3 cells, the truncated protein was hyperactive. Finally, we showed that B-Myb synergises with cyclin A to promote U-2 OS cells into S-phase.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,ST MARYS HOSP,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,ST MARYS HOSP,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London								ARSURA M, 1992, BLOOD, V79, P2708; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLAY J, 1994, ONCOGENE, V9, P2469; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MA XP, 1994, CANCER RES, V54, P6512; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Robinson C, 1996, ONCOGENE, V12, P1855; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	70	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2445	2453		10.1038/sj.onc.1201086	http://dx.doi.org/10.1038/sj.onc.1201086			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188859				2022-12-28	WOS:A1997WZ68000008
J	Liu, DR; Pavlopoulos, E; Modi, W; Moschonas, N; Mavrothalassitis, G				Liu, DR; Pavlopoulos, E; Modi, W; Moschonas, N; Mavrothalassitis, G			ERF: Genomic organization, chromosomal localization and promoter analysis of the human and mouse genes	ONCOGENE			English	Article						ets; transcriptional repressor; genomic organization; promoter	ETS DOMAIN PROTEIN; EWINGS-SARCOMA TRANSLOCATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; THYROID ADENOMAS; MYELOID-LEUKEMIA; ONCOGENE FAMILY; DROSOPHILA EYE; TEL GENE	ERF (Ets2 Repressor Factor) is a ubiquitously expressed ets-domain protein that exhibits strong transcriptional repressor activity, has been shown to suppress ets-induced transformation and has been suggested to be regulated by MAPK phosphorylation. We report here the sequence of the mouse gene, the genomic organization of the human and the mouse genes, their chromosomal position and the analysis of the promoter region. Genomic clones encompassing either the human ERI; or the mouse Erf gene were isolated and utilized to define their molecular organization. The gene in both species consists of 4 exons over a 10 kb region. Utilizing FISH, somatic cell hybrids and linkage analysis, we identified the chromosomal position of ERP on human chromosome 19q13.1 and on its syntenic region in the mouse, on chromosome 7. Sequence analysis of the mouse gene indicated a 90% identity to the human gene within the coding and promoter regions. The predicted Erf protein is 98% identical to the human protein and all of the identifiable motifs are conserved between the two proteins. However, the mouse protein is three amino acids longer (551 versus 548 aa). The area surrounding the region that is homologous to the 5' end of the human cDNA can serve as a promoter in transfection into eukaryotic cells. This region is highly conserved between the mouse and the human genes. A number of conserved transcription factor binding sites can be identified in the region including an ets binding site (EBS). Interestingly, removal of a small segment that includes the :EBS, seriously hampers promoter function, suggesting the ERF transcription may be regulated by ets-domain proteins.	NCI,FREDERICK CANC RES & DEV CTR,MOL ONCOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,FREDERICK,MD 21702; FORTH,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,GREECE; UNIV CRETE,DEPT BIOL,IRAKLION 71110,GREECE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Foundation for Research & Technology - Hellas (FORTH); University of Crete				Moschonas, Nicholas/0000-0002-2556-537X				BARTNITZKE S, 1989, CANCER GENET CYTOGEN, V39, P65, DOI 10.1016/0165-4608(89)90230-6; BELGE G, 1992, CANCER GENET CYTOGEN, V60, P23, DOI 10.1016/0165-4608(92)90227-Y; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GILLE H, 1992, NATURE, V358, P415; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHANSSON B, 1994, CANCER GENET CYTOGEN, V74, P62, DOI 10.1016/0165-4608(94)90031-0; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NUNN M, 1984, VIROLOGY, V133, P330; OHNO H, 1993, LEUKEMIA, V7, P2057; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAIETTA E, 1988, CANCER GENET CYTOGEN, V34, P19, DOI 10.1016/0165-4608(88)90162-8; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; RAO VN, 1994, ONCOGENE, V9, P1855; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sambrook J., 2002, MOL CLONING LAB MANU; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TANAKA S, 1990, CANCER GENET CYTOGEN, V49, P219, DOI 10.1016/0165-4608(90)90144-Y; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WLODARSKA I, 1995, BLOOD, V85, P2848, DOI 10.1182/blood.V85.10.2848.bloodjournal85102848; YABUMOTO K, 1994, INT J HEMATOL, V59, P211; Yang BS, 1996, MOL CELL BIOL, V16, P538; 1995, GENOME NEWS, V19, P21	56	17	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1445	1451		10.1038/sj.onc.1200965	http://dx.doi.org/10.1038/sj.onc.1200965			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136988				2022-12-28	WOS:A1997WT58400007
J	Judware, R; Culp, LA				Judware, R; Culp, LA			Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: Differential regulation of alpha 2, alpha 3 and beta 1	ONCOGENE			English	Article						integrin; neuroblastoma; N-myc	GENE-EXPRESSION; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; DNA-BINDING; PROTEIN; ADHESION; MAX; AMPLIFICATION; SEQUENCE; ONCOGENE	Amplification and over-expression of the N-myc oncogene is associated with the progression of neuroblastoma in children and in a nude mouse model system. Neuroblastoma cell lines with widely different levels of N-myc illustrate an inverse relationship between N-myc over-expression and reduced expression of several integrin extracellular matrix receptors. Transfection and over-expression of N-myc in a neuroblastoma cell line not normally expressing the protein resulted in cells that grew loosely associated with tissue culture plates; this correlated with reduced levels of beta 1 integrin subunit. Evidence is now presented that alpha 2 and alpha 3 integrin subunit levels are also reduced in cells that over-express N-myc, with virtually no association of alpha 2 or alpha 3 subunits with beta 1. Consequently, maturation of the beta 1 subunit and cell surface expression of the integrins are greatly reduced in N-myc-transfected cells. A small amount of beta 1 protein does get to the cell surface, however, suggesting that an as yet unidentified alpha subunit is produced by the N-myc-expressing cells. Finally, the observed reductions in integrin protein levels are reflections of greatly reduced levels of integrin alpha 2 and alpha 3 mRNAs, as well as a smaller reduction in beta 1 mRNA (80%, 94% and 52%, respectively). Post-transcriptional mechanisms modulating beta 1 integrin levels are also operative. These results indicate that over-expression of N-myc from a transfected gene in a neuroblastoma cell line that does not normally produce the protein generates cell lines with many of the characteristics of naturally metastatic cells with amplified N-myc genes. Modulation of N-myc and integrin expressions may play a significant role in progression of human neuroblastoma.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University					NCI NIH HHS [IF32CA65068] Funding Source: Medline; NINDS NIH HHS [NS17139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORDOW SB, 1994, CANCER RES, V54, P5036; BRODEUR GM, 1991, BIOCH MOL ASPECTS SE, P251; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHENG NC, 1995, ONCOGENE, V10, P291; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; Ellmeier W, 1996, GENOMICS, V32, P155, DOI 10.1006/geno.1996.0095; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; HEINO J, 1989, J BIOL CHEM, V264, P380; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUDWARE R, 1995, CLIN EXP METASTAS, V13, P123, DOI 10.1007/BF00133617; Judware R, 1995, ONCOGENE, V11, P2599; KLEINMAN NR, 1994, BRIT J CANCER, V69, P670, DOI 10.1038/bjc.1994.129; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA A, 1993, ONCOGENE, V8, P1093; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT ML, 1984, CELL GROWTH DIFFER, V5, P171; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	50	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1341	1350		10.1038/sj.onc.1200955	http://dx.doi.org/10.1038/sj.onc.1200955			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178894				2022-12-28	WOS:A1997WP10900009
J	Bui, TD; Rankin, J; Smith, K; Huguet, EL; Ruben, S; Strachan, T; Harris, AL; Lindsay, S				Bui, TD; Rankin, J; Smith, K; Huguet, EL; Ruben, S; Strachan, T; Harris, AL; Lindsay, S			A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas	ONCOGENE			English	Article						WNT10B; cloning; breast carcinoma	MAMMARY EPITHELIUM; MOLECULAR-CLONING; TRANSGENIC MICE; TUMORS; ONCOGENE; FAMILY; INT-1; HYPERPLASIA; MULTIPLE; SEQUENCE	Several members of the Wnt gene family have been shown to cause mammary tumors in mouse. Using degenerate primer polymerase chain reaction (PCR) on human genomic DNA, and specific PCR of cDNA libraries, we have isolated a WNT gene which has not previously been described in human. The gene is the human homologue of mouse Wnt10b, recently shown to be one of the oncogenes cooperating with FGF3 in the development of mouse mammary tumour virus (MMTV) induced mouse mammary carcinomas. The human WNT10B sequence was 88% and 95% identical to the murine gene at nucleotide and amino acid levels, respectively, YAC FISH mapping localises the gene to 12q13, a chromosomal region frequently rearranged in human tumours and also containing the WNT1 gene. In normal and benign proliferations of human breast tissue, WNT10B expression was not detected by ribonuclease protection assays but was found at low levels in RT-PCR experiments. In contrast, using both methods, WNT10B expression was found to be elevated in 3 of 50 primary breast carcinomas. Southern blot analysis of the carcinoma expressing the highest levels of WNT10B showed no amplification or rearrangement of the gene. The WNT10B gene was also expressed in some cancer and non cancerous breast cell lines. These findings suggest that the WNT10B gene may be involved in human breast cancer, and show that there is differential expression of the WNT10B gene in benign and malignant disease.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,GROWTH FACTORS GRP,OXFORD OX3 9DU,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT HUMAN GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Oxford; Newcastle University - UK; GlaxoSmithKline; Human Genome Sciences Inc			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Lindsay, Susan/0000-0003-2980-4582				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FANTES JA, 1992, AM J HUM GENET, V51, P1286; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HUGUET EL, 1994, CANCER RES, V54, P2615; Lako M, 1996, GENOMICS, V35, P386, DOI 10.1006/geno.1996.0374; LAZO PA, 1992, FEBS LETT, V300, P109, DOI 10.1016/0014-5793(92)80175-G; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; LIN TP, 1992, CANCER RES, V52, P4413; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCMAHON AP, 1992, TIG, V8, P237; MOCK BA, 1993, ENCY MOUSE GENOME, V3; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; TAYLORPAPADIMITRIOU J, 1993, CANCER SURV, V16, P59; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	28	70	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1249	1253		10.1038/sj.onc.1200936	http://dx.doi.org/10.1038/sj.onc.1200936			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121776				2022-12-28	WOS:A1997WM78200016
J	Tortora, G; Damiano, V; Bianco, C; Baldassarre, G; Bianco, AR; Lanfrancone, L; Pelicci, PG; Ciardiello, F				Tortora, G; Damiano, V; Bianco, C; Baldassarre, G; Bianco, AR; Lanfrancone, L; Pelicci, PG; Ciardiello, F			The RI alpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor	ONCOGENE			English	Article						growth factors; signal transduction; breast cells	MAMMARY EPITHELIAL-CELLS; C-HA-RAS; REGULATORY SUBUNIT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DEPENDENT ACTIVATION; NUCLEOTIDE EXCHANGE; HL-60 LEUKEMIA; MESSENGER-RNA; CAMP; DIFFERENTIATION	Functional interactions between protein kinase A (PKA) and epidermal growth factor receptor (EGF-R) signalling pathways have been suggested. Unlike the type II isoform of PKA (PKAII), the type I (PKAI) and/or its regulatory submit RI alpha are generally overexpressed in cancer cells and are induced following transforming growth factor alpha (TGF alpha)/EGF-R-dependent transformation. Downregulation of RI alpha/PKAI inhibits TGF alpha expression and EGF-R-dependent signalling. We have previously shown that addition of EGF to quiescent human normal epithelial MCF-10A cells determines PKAI expression and cell membrane translocation before cells enter S phase, while PKAI inhibition prevents S phase entry. Constitutive overexpression of PKAI confers the ability to grow in serum free medium, bypassing EGF requirement. Here we demonstrate a direct interaction of PKAI, but not of PKAII, with the activated EGF-R, that occurs within 5 min following EGF treatment of MCF-10A cells, Moreover, induction of mitogen-activated protein kinase (MAPK) activity following EGF-R activation is mimicked by PKAI overexpression and inhibited by downregulators of PKAI. Finally, the PKAI-EGF-R association occurs through the binding of RI alpha to the SH3 domain(s) of Grb2 adaptor protein, thus allowing the recruitment of the PKAI holoenzyme to the activated EGF-R. This is the first demonstration of a direct interaction of PKAI with the activated EGF-R macromolecular signalling complex.	EUROPEAN INST ONCOL,DEPT EXPT ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)	Tortora, G (corresponding author), UNIV NAPLES,DIPARTIMENTO ENDOCRINOL & ONCOL MOL & CLIN,CATTEDRA ONCOL MED,VIA PANSINI 5,I-80131 NAPLES,ITALY.		Baldassarre, Gustavo/K-1350-2016; Tortora, Giampaolo/HGB-6261-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Baldassarre, Gustavo/0000-0002-9750-8825; Lanfrancone, Luisa/0000-0002-4523-3815; Ciardiello, Fortunato/0000-0002-3369-4841; Tortora, Giampaolo/0000-0002-1378-4962				BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOCHUNG YS, 1993, PHARMACOL THERAPEUT, V60, P265, DOI 10.1016/0163-7258(93)90010-B; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1993, INT J CANCER, V53, P438, DOI 10.1002/ijc.2910530315; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GRIFFITHS G, 1990, J CELL SCI, V96, P691; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LAXMINARAYANA D, 1993, J CLIN INVEST, V92, P2207, DOI 10.1172/JCI116823; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; TORTORA G, 1994, ONCOGENE, V9, P3233; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	24	94	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					923	928		10.1038/sj.onc.1200906	http://dx.doi.org/10.1038/sj.onc.1200906			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050991				2022-12-28	WOS:A1997WK34400005
J	Okazaki, M; Kishida, S; Hinoi, T; Hasegawa, T; Tamada, M; Kataoka, T; Kikuchi, A				Okazaki, M; Kishida, S; Hinoi, T; Hasegawa, T; Tamada, M; Kataoka, T; Kikuchi, A			Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator	ONCOGENE			English	Article						RalGDS; Raf; Ras; Ral; c-fos promoter	PLASMA-MEMBRANE; PROTEIN-KINASE; EFFECTOR; TRANSFORMATION; GTPASES; RAC1; IDENTIFICATION; PATHWAY; CDC42HS; RHOA	Ral, a member of small GTP-binding protein (G protein) superfamily, has been suggested to act downstream of Ras, since Ral GDP dissociation stimulator (RalGDS) has been found to be an effector protein of Ras. In this study, we examined the effects of RalGDS and Ral on gene expression using c-fos promoter linked to the luciferase reporter gene (c-fos-luciferase). RalGDS interacted with Ras(G12V/E37G) (in which Gly-12 and Glu-37 were changed to Val and Gly, respectively) which failed to bind to Raf in COS cells, RafCAAX is an active Raf kinase targeted to the plasma membranes by virtue of the addition of a C-terminal localization signal from K-Ras. Transfection of either RalGDS or RafCAAX into NIH3T3 cells slightly stimulated c-fos-luciferase expression and cotransfection of both proteins greatly enhanced the expression. RalGDS and an activated Rac (Rac(G12V)) did not act synergistically to stimulate c-fos-luciferase expression. Transfection of an activated Ral (Ral(G23V)) stimulated c-fos-luciferase expression. Furthermore, cotransfection of Ral(G23V) and an activated Ras (Ras(G12V)) enhanced Ras(G12V)-dependent c-fos-luciferase expression. However, Ral(G23V) did not synergize with RafCAAX, Rac(G12V) or RalGDS to stimulate the expression. These results show that RalGDS and Ral regulate c-fos promoter activity and suggest that RalGDS may activate c-fas promoter synergistically with the signal from Raf by transmitting the signal to a target other than Ral.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Hiroshima University; Kobe University			Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177; kishida, shosei/0000-0003-0405-851X				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GORMAN CM, 1985, HIGH EFFICIENCY GENE; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lee T, 1996, DEVELOPMENT, V122, P409; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Okazaki M, 1996, CANCER RES, V56, P2387; Park SH, 1995, ONCOGENE, V11, P2349; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	43	57	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					515	521		10.1038/sj.onc.1200860	http://dx.doi.org/10.1038/sj.onc.1200860			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053849				2022-12-28	WOS:A1997WF52400002
J	Wolf, G; Elez, R; Doermer, A; Holtrich, U; Ackermann, H; Stutte, HJ; Altmannsberger, HM; RubsamenWaigmann, H; Strebhardt, K				Wolf, G; Elez, R; Doermer, A; Holtrich, U; Ackermann, H; Stutte, HJ; Altmannsberger, HM; RubsamenWaigmann, H; Strebhardt, K			Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer	ONCOGENE			English	Article						serine/threonine kinase; mRNA expression; prognosis; non-small cell lung cancer; polo-like kinase	PROTEIN-TYROSINE KINASES; K-RAS ONCOGENE; NUCLEAR ANTIGEN; PARAFFIN SECTIONS; DROSOPHILA POLO; CYCLE ANALYSIS; ADENOCARCINOMA; TUMORS; INDEX; GENE	Our previous data indicate that the expression of the PLK gene which codes for a serine/threonine kinase is restricted to proliferating cells. In Northern blot experiments PLK mRNA expression was at the limit of detection in normal lung tissue but elevated in most samples of non-small cell lung cancer (NSCLC). A very low frequency of PLK transcripts was only found in bronchiolo-alveolar carcinomas. NSCLC patients whose tumors showed moderate PLK expression survived significantly longer (5 year survival rate=51.8%) than those with high levels of PLK transcripts (24.2%, P=0.001). No statistically significant correlation was found between PLK mRNA expression and age, sex, TNM status, histological type or degree of differentiation, Interestingly, the prognosis of patients in postsurgical stages I and II was correlated with PLK expression (5 year survival rates in stage I: 69.1% (moderate PLK) - 43.5% (high PLK), P=0.03 or in stage II: 51.9% (moderate PLK) - 9.9% (high PLK), P=0.006). These results suggest that PLK mRNA expression provides a new independent prognostic indicator for patients with NSCLC.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; KRANKENHAUS NORDSTADT,DEPT THORAC & VASC SURG,FRANKFURT,GERMANY; KRANKENHAUS NW FRANKFURT,DEPT PATHOL,FRANKFURT,GERMANY; UNIV FRANKFURT,SCH MED,DEPT PATHOL,D-60596 FRANKFURT,GERMANY; UNIV FRANKFURT,SCH MED,DEPT BIOMATH,D-60596 FRANKFURT,GERMANY; BAYER AG,PHARMA RES CTR,INST VIROL,D-42096 WUPPERTAL,GERMANY	Krankenhaus Nordwest; Goethe University Frankfurt; Goethe University Frankfurt; Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHME B, 1993, ONCOGENE, V8, P2857; BONGIORNO PF, 1994, J THORAC CARDIOV SUR, V107, P590, DOI 10.1016/S0022-5223(94)70107-5; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYTON F, 1991, CANCER, V68, P1309, DOI 10.1002/1097-0142(19910915)68:6<1309::AID-CNCR2820680621>3.0.CO;2-I; DEAN PN, 1984, CELL TISSUE KINET, V17, P427, DOI 10.1111/j.1365-2184.1984.tb00601.x; FONTANINI G, 1992, CANCER-AM CANCER SOC, V70, P1520, DOI 10.1002/1097-0142(19920915)70:6<1520::AID-CNCR2820700613>3.0.CO;2-K; FUJII M, 1993, ACTA MED OKAYAMA, V47, P103; GERDES J, 1984, J IMMUNOL, V133, P1710; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GOULD VE, 1989, THORACIC ONCOLOGY, P77; Haldane JBS, 1940, BIOMETRIKA, V31, P346, DOI 10.2307/2332614; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS EK, 1991, SURVIVORSHIP ANAL CL; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KARN T, 1993, ONCOGENE, V8, P3433; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Miller R.G., 1981, SIMULTANEOUS STAT IN, Ved 2nd, DOI DOI 10.1007/s11263-015-0816-y; MOORE DF, 1995, LUNG CANC STAGING PR, P481; PENCE JC, 1993, ARCH SURG-CHICAGO, V128, P1382; QUIRKE P, 1986, J PATHOL, V149, P79, DOI 10.1002/path.1711490202; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5737; Sambrook J., 2002, MOL CLONING LAB MANU; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STREBHARDT K, 1994, ONCOL REP, V1, P195; SUNKEL CE, 1988, J CELL SCI, V89, P25; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOLM M, 1993, J CANCER RES CLIN, V119, P507, DOI 10.1007/BF01686458	39	287	306	1	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					543	549		10.1038/sj.onc.1200862	http://dx.doi.org/10.1038/sj.onc.1200862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053852				2022-12-28	WOS:A1997WF52400005
J	Bies, J; Wolff, L				Bies, J; Wolff, L			Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway	ONCOGENE			English	Article						c-Myb; proteolytic stability; 26S proteasome; ubiquitin; PEST sequence	NEGATIVE REGULATORY DOMAIN; LEUKEMIA-CELL-LINE; V-MYB; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; PROTEIN-DEGRADATION; TRANS-ACTIVATION; MESSENGER-RNA; GENE; EXPRESSION	c-myb activation by insertional mutagenesis in murine myeloid leukemias can lead to amino (NH2)-terminal or carboxyl (COOH)-terminal truncation of its protein product, We observed that in these leukemias, the steady state level of the protein truncated at the COOH terminus was remarkably higher than that of the protein truncated at the NH2-terminus or full length wild-type protein, To examine the rate of proteolysis of different forms of Myb in a uniform cellular background, the proteins were constitutively expressed in the myeloblast cell line M1, using the retrovirus vector LXSN. In pulse chase experiments, using metabolically S-35-labeled proteins, it was determined that COOH-terminal truncation of c-Myb by 248 aa (CT-c-Myb) substantially increases protein stability, resulting in a t(1/2) of about 140 min, as compared to 50 min for full length c-Myb (FL-c-Myb). In an investigation of the mechanism involved in the in vivo degradation of this short lived transcription factor, inhibitors of the lysosomal (chloroquine), proteasomal (ALLM, ALLN, iactacystin) and calpains (EGTA, E-64d, BAPTA/AM) pathways were utilized, Results of this experiment identified the 26S proteasome as a major pathway responsible for rapid breakdown of the protein in hematopoietic cells, Further experiments carried out in vitro demonstrated that c-Myb cap be ubiquitinated, suggesting that this process may be involved in the targeting of wild-type c-Myb to degradation by the 26S proteasome. In addition, it was demonstrated that CT-c-Myb was less efficiently ubiquitinated than wild-type protein indicating that defects in modification account for its escape from rapid turnover, We speculate that the increased half-life of c-Myb resulting from truncation could contribute to its transforming potential.	NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; FERRAO P, 1995, ONCOGENE, V11, P1631; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PERRYMAN S, 1991, NUCLEIC ACIDS RES, V19, P6950; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	48	60	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					203	212		10.1038/sj.onc.1200828	http://dx.doi.org/10.1038/sj.onc.1200828			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010222				2022-12-28	WOS:A1997WC81800008
J	Thompson, AD; Braun, BS; Arvand, A; Stewart, SD; May, WA; Chen, E; Korenberg, J; Denny, C				Thompson, AD; Braun, BS; Arvand, A; Stewart, SD; May, WA; Chen, E; Korenberg, J; Denny, C			EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene	ONCOGENE			English	Article						SH2 domain; transcription factor; oncogenes; cellular transformation; sarcoma	RNA-BINDING PROTEIN; ROUND-CELL TUMORS; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; EWS GENE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; TRANSLOCATION; FAMILY	The EWS/FLI1 fusion protein is created by the translocation between chromosomes 11 and 22 that appears in most Ewing's sarcomas, This chimeric protein has been demonstrated to be an aberrant transcription factor. Genes up regulated by EWS/FLI1 but not by full-length FLI1 were identified by representational difference analysis (RDA), We have characterized a novel gene, EWS/FLI1 activated transcript 2 (EAT-2) that was cloned from a murine cDNA library using a differentially expressed RDA fragment. EAT-2 expression is seen within 4-8 h of EWS/FLI1 induction, Its expression correlates with transformation of NIH3T3 cells by chimeric proteins related to EWS/FLI1 but not by unrelated genes, EAT-2 is expressed in normal murine tissues and contains a unique but biochemically functional SH2 domain, An homologous sequence in the human genome has been identified and mapped to chromosome 1q22, Human EAT-2 transcripts were identified by reverse transcriptase-polymerase chain reaction (RT-PCR) in Ewing's sarcoma cell tumour cell lines. EAT-2's unique structure and correlation with transformation make it a candidate for playing a role in the transformation of NIH3T3 cells and the oncogenesis of Ewing's sarcoma.	UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT EXPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INTERCAMPUS MED GENET TRAINING PROGRAM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,AHMANSON DEPT PEDIAT,DIV GENET,CEDARS SINAI MED CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA32737, CA09056] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Gotoh N, 1995, ONCOGENE, V11, P2525; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heim S, 1995, CANC CYTOGENETICS; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JEON IS, 1995, ONCOGENE, V10, P1229; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KORNBERG JR, 1995, CYTOGENET CELL GENET, V69, P196; LESSNICK SL, 1995, ONCOGENE, V10, P429; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, NAT GENET, V6, P146; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	50	99	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2649	2658						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000139				2022-12-28	WOS:A1996VZ65400015
J	Kim, YW; Wang, HY; Sures, I; Lammers, R; Martell, KJ; Ullrich, A				Kim, YW; Wang, HY; Sures, I; Lammers, R; Martell, KJ; Ullrich, A			Characterization of the PEST family protein tyrosine phosphatase BDP1	ONCOGENE			English	Article						protein tyrosine phosphatase; PEST sequence; growth factor receptor phosphatase	CHROMOSOMAL LOCALIZATION; HUMAN-PLACENTA; GENE; CLONING; SEQUENCES; REGION; CELLS; CAP	Using a polymerase chain reaction (PCR) amplication strategy, we identified a novel protein tyrosine phosphatase (PTPase) designated Brain Derived Phosphatase (BDP1). The full length sequence encoded an open reading frame of 459 amino acids with no transmembrane domain and had a calculated molecular weight of 50 kDa. The predicted amino acid sequence contained a PEST motif and accordingly, BDP1 shared the greatest homology with members of the PTP-PEST family. When transiently expressed in 293 cells BDP1 hydrolyzed p-Nitrophenylphosphate, confirming it as a functional protein tyrosine phosphatase. Northern blot analysis indicated that BDP1 was expressed not only in brain, but also in colon and several different tumor-derived cell lines. Furthermore, BDP1 was found to differentially dephosphorylate autophosphorylated tyrosine kinases which are known to be overexpressed in tumor tissues.	MAX PLANCK INST BIOCHEM,DEPT MOL BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Wang, Hongyang/B-1340-2010					BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHLESSINGER J, 1992, CELL, V9, P383; SELICOF A, 1993, J BIOL CHEM, V268, P13448; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TAKEKAWA M, 1994, FEBS LETT, V339, P222, DOI 10.1016/0014-5793(94)80420-6; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILKS M, 1994, J HOSP INFECT, V28, P231, DOI 10.1016/0195-6701(94)90105-8; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	26	25	32	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2275	2279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950995				2022-12-28	WOS:A1996VV14500025
J	Zhan, QM; Alamo, I; Yu, K; Boise, LH; Cherney, B; Tosato, G; OConnor, PM; Fornace, AJ				Zhan, QM; Alamo, I; Yu, K; Boise, LH; Cherney, B; Tosato, G; OConnor, PM; Fornace, AJ			The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function	ONCOGENE			English	Article						BCL-X(L); p53; apoptosis; ionizing radiation	TUMOR-SUPPRESSOR P53; CELL-CYCLE; BCL-X; ATAXIA-TELANGIECTASIA; CANCER-CELLS; DNA-DAMAGE; BAX GENE; IN-VIVO; C-MYC; EXPRESSION	We have investigated the effect of DNA damage on the expression of BCL-X, a member of the BCL-2 family. BCL-X mRNA levels were found to increase upon exposure human cells to ionizing radiation (IR). The Bcl-X(L) protein, but not Bcl-X(S), was identified to be induced by IR. Like BAX, another member of the BCL-2 family and a p53-regulated gene, the induction of BCL-X(L) was dependent on normal p53 function and required that cells have an apoptosis-susceptible phenotype. The induction of BCL-X(L) was rapid, transient and dose-dependent. The mRNA level peaked at 4 h and returned to baseline by 24 h post-irradiation. In agreement with the increased transcript level, Bcl-X(L) protein level was also observed to increase in cells with wild-type p53 where IR triggered apoptosis. In addition, a survey of the BCL-X(L) mRNA basal levels in human cells with known apoptotic responses showed that low basal levels of BCL-X(L) mRNA in cells were highly correlated with a strong ability of cells to undergo IR-induced apoptosis. On the other hand, high levels of basal BCL-X(L) were correlated,vith the resistance of cells to IR-induced apoptosis regardless of p53 status. These results indicate that BCL-2 and BCL-X(L) behave differently in response to DNA damage treatment even though they both are able to protect cells from p53-mediated apoptosis; along with down-regulation of BCL-2, BCL-X(L) was up-regulated by IR in human cells with wild-type p53 and susceptibility to IR-induced apoptosis. We speculate that the physiological function of increased BCL-X(L) protein would be expected to probably limit the severity and length of BAX effect in order to maintain a proper threshold for apoptosis and to complete cell cycle arrest activated by p53.	UNIV CHICAGO,GWEN KNAPP CTR LUPUS & IMMUNOL,CHICAGO,IL 60637; US FDA,CTR BIOL,BETHESDA,MD 20892	University of Chicago; US Food & Drug Administration (FDA)	Zhan, QM (corresponding author), NCI,MOL PHARMACOL LAB,DIV BASIC SCI,ROOM 5C09,BLDG 37,BETHESDA,MD 20892, USA.		Boise, Lawrence/AAD-2314-2019; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Boise, Lawrence/0000-0001-9436-8815; Tosato, Giovanna/0000-0003-1663-3227				BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1996, UNPUB; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1994, CANCER RES, V54, P2095; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SCOTT WL, 1993, CELL, V74, P957; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	35	71	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2287	2293						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950997				2022-12-28	WOS:A1996VV14500027
J	Luan, XD; Shi, GP; Zohouri, M; Paradee, W; Smith, DI; Decker, HJ; Cannizzaro, LA				Luan, XD; Shi, GP; Zohouri, M; Paradee, W; Smith, DI; Decker, HJ; Cannizzaro, LA			The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma	ONCOGENE			English	Article						FHIT; renal cell carcinoma	CHROMOSOME-TRANSLOCATION; TUMOR-CELLS; BREAKPOINT; FRA3B	FHIT (Fragile Histidine Triad), a putative tumor suppressor gene, was cloned from fetal brain and colon cDNA libraries, Portions of this gene are deleted in esophageal, colon, lung and breast tumors, but this gene has not been found altered in sporadic renal cell carcinomas, We report here an alternatively spliced form of this gene cloned from a kidney cDNA library, This cDNA is 1189 bp in length, and contains an additional 94 bp exon, designated exon 2a (E2a), This novel sequence is located between exon 2 and exon 3 of the FHIT gene's untranslated region and exon 2a is present in all normal kidney tissues and cell Lines, Analyses performed on sporadic renal cell carcinoma (RCC) tissues and cell Lines, show consistent loss of exon 8 of the FHIT cDNA in almost 60% of the cases, Interestingly, in a familial, as well as, in a metastatic RCC, derived from a patient with the sporadic form, exon 2a and exon 3 are also deleted, Northern analyses with the exon 2a of the familial and the metastatic RCC demonstrates concurrent loss of expression of a 4.4 kb transcript with the loss of the E2a sequence, suggesting that exon 2a of the FHIT gene may play an important role in the oncogenesis of renal cell carcinoma.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PATHOL, BRONX, NY 10461 USA; WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA; UNIV MAINZ, DEPT MED, DIV HEMATOL ONCOL, D-55313 MAINZ, GERMANY	Yeshiva University; Albert Einstein College of Medicine; Wayne State University; Johannes Gutenberg University of Mainz								ANGLARD P, 1991, CANCER RES, V51, P1071; ATCHISON L, 1995, CYTOGENET CELL GENET, V71, P136, DOI 10.1159/000134092; BOGHOSIANSELL L, 1992, CYTOGENET CELL GENET, V60, P268; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Fallon B, 1989, Semin Urol, V7, P228; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAMZA AW, 1995, BIOTECHNIQUES, V18, P228; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; KOVACS G, 1988, HUM GENET, V78, P148, DOI 10.1007/BF00278186; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P256, DOI 10.1002/gcc.2870030404; KOVACS G, 1989, CANCER RES, V49, P651; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Moch H, 1996, CANCER RES, V56, P27; MORITA R, 1991, CANCER RES, V51, P820; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OLSON S, 1984, TUMORS KIDNEY URINAR, P15; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; Sambrook J, 1989, MOL CLONING; Shi G, 1996, CYTOGENET CELL GENET, V75, P180, DOI 10.1159/000134473; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YAMAKAWA K, 1992, GENOMICS, V14, P412, DOI 10.1016/S0888-7543(05)80234-4	27	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					79	86		10.1038/sj.onc.1201164	http://dx.doi.org/10.1038/sj.onc.1201164			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233780				2022-12-28	WOS:A1997XH58600009
J	BalcerKubiczek, EK; Meltzer, SJ; Han, LH; Zhang, XF; Shi, ZM; Harrison, GH; Abraham, JM				BalcerKubiczek, EK; Meltzer, SJ; Han, LH; Zhang, XF; Shi, ZM; Harrison, GH; Abraham, JM			Csa-19, a radiation-responsive human gene, identified by an unbiased two-gel cDNA library screening method in human cancer cells	ONCOGENE			English	Article						Csa-19; X-ray; fission neutron; gene transcription; DNA damage; signal transduction	PROTEIN-KINASE-C; CARDIAC ACTIN GENE; IONIZING-RADIATION; MESSENGER-RNA; CYCLOSPORINE-A; LEUKEMIA-CELLS; INDUCTION; ACTIVATION; EXPOSURE; APOPTOSIS	A novel polymerase chain reaction (PCR)-based method was used to identify candidate genes whose expression is altered in cancer cells by ionizing radiation, Transcriptional induction of randomly selected genes in control versus irradiated human HL60 cells was compared, Among several complementary DNA (cDNA) clones recovered by this approach, one cDNA clone (CL68-5) was downregulated in X-irradiated HL60 cells but unaffected by 12-O-tetradecanoyl phorbol-13-atetate, forskolin, or cyclosporin-A. DNA sequencing of the CL68-5 cDNA revealed 100% nucleotide sequence homology to the reported human Csa-19 gene, Northern blot analysis of RNA from control and irradiated cells revealed the expression of a single 0.7-kilobase (kb) messenger RNA (mRNA) transcript, This 0.7-kb Csa-19 mRNA transcript was also expressed in a variety of human adult and corresponding fetal normal tissues, Moreover, when the effect of X- or fission neutron-irradiation on Csa-19 mRNA was compared in cultured human cells differing in p53 gene status (p53(-/-) ver sus p53(+/+)), downregulation of Csa-19 by X-rays or fission neutrons was similar in p53-wild type and p53-null cell lines, Our results provide the first known example of a radiation-responsive gene in human cancer cells whose expression is not-associated with p53, adenylate cyclase or protein kinase C.	UNIV MARYLAND,DEPT MED,DIV GASTROENTEROL,SCH MED,BALTIMORE,MD 21201; UNIV MARYLAND,VET AFFAIRS HOSP,BALTIMORE,MD 21201; UNIV MARYLAND,GRAD SCH,PROGRAM MOL & CELL BIOL,BALTIMORE,MD 21201; UNIV MARYLAND,CTR CANC,PROGRAM ONCOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	BalcerKubiczek, EK (corresponding author), UNIV MARYLAND,DEPT RADIAT ONCOL,DIV RADIAT RES,BALTIMORE,MD 21201, USA.				NATIONAL CANCER INSTITUTE [R01CA067497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; NIEHS NIH HHS [ES07120] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABEND M, 1995, INT J RADIAT BIOL, V67, P315, DOI 10.1080/09553009514550371; Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; BAE IS, 1995, CANCER RES, V55, P2387; BalcerKubiczek EK, 1996, ENVIRON HEALTH PERSP, V104, P1188, DOI 10.2307/3432912; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1985, CURR TOP CELL REGUL, V17, P23; COLLEDGE WH, 1990, BIOCHIM BIOPHYS ACTA, V1087, P39, DOI 10.1016/0167-4781(90)90118-L; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; EINAT P, 1990, DIFFERENTIATION, V44, P36, DOI 10.1111/j.1432-0436.1990.tb00534.x; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISICARO N, 1995, MOL IMMUNOL, V32, P565, DOI 10.1016/0161-5890(95)00032-A; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Hall EJ, 1994, RADIOBIOLOGY RADIOLO, V1994, P153; HARRISON GH, 1997, IN PRESS BIOELECTROC; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; Hopcia KL, 1996, RADIAT RES, V145, P315, DOI 10.2307/3578987; HULTSCH T, 1990, J IMMUNOL, V144, P2659; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JUNG M, 1994, CANCER RES, V54, P2541; Kondratyev AD, 1996, CANCER RES, V56, P1498; LEWIN B, 1994, GENES, V5, P271; Makepeace CM, 1996, RADIAT RES, V146, P116, DOI 10.2307/3579405; MANIATIS T, 1982, MOL CLONING LAB MANU, P70; MELTZER SJ, 1994, CANCER RES, V54, P3379; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRICE BD, 1994, CANCER RES, V54, P896; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SHENA M, 1996, P NATL ACAD SCI USA, V93, P10614; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STARZL TE, 1991, TRANSPLANTATION, V51, P67, DOI 10.1097/00007890-199101000-00010; THOMAS MG, 1994, BIOTECHNIQUES, V16, P229; TSANG P, 1995, HUM MOL GENET, V4, P1499, DOI 10.1093/hmg/4.9.1499; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; YADANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437; Yan J, 1996, INT J RADIAT BIOL, V69, P539, DOI 10.1080/095530096145544; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	49	16	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3051	3057		10.1038/sj.onc.1201151	http://dx.doi.org/10.1038/sj.onc.1201151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223668				2022-12-28	WOS:A1997XG10000007
J	Dupressoir, A; Heidmann, T				Dupressoir, A; Heidmann, T			Expression of intracisternal A-particle retrotransposons in primary tumors of oncogene-expressing transgenic mice	ONCOGENE			English	Article						oncogenes; IAP; tumors; transgenic mice	LONG TERMINAL REPEAT; CAMP RESPONSE ELEMENT; HEMATOPOIETIC-CELLS; HA-RAS; C-MYC; GENES; METHYLATION; SEQUENCE; ACTIVATION; PROMOTER	Intracisternal A-Particle (IAP) sequences are endogenous retrovirus-like mobile elements, present at 1000 copies in the mouse genome, These elements transpose in a replicative manner via an RNA intermediate and its reverse transcription, and their transposition should therefore be tightly controlled by their transcription level, The in vi,to pattern of expression of these potentially mutagenic elements had previously been analysed in normal mice, and we have now investigated their expression in transgenic mice carrying different oncogenes (e.g. c-myc, v-Ha-ras, SV40 T-antigen) under tissue-specific promoters and disclosing tumors within the brain, the mammary or salivary glands, or the lymphoid organs, Northern blot analysis of IAP expression within the resulting tumors demonstrates a lack of significant and/or systematic effect of v-Ha-ras and SV40 T-antigen expression, but a systematic IAP induction in the myc-induced tumors, In this case, however, analysis of double transgenic mice obtained by crossing the tumor-prone mice with previously described transgenic mice carrying IAP reporter genes did not provide any evidence for induction of the IAP transgenes, therefore strongly suggesting that c-myc expression had an effect on only a limited number of IAP sequences - most probably depending on their position and/or methylation state, These results strengthen the importance of in vivo studies for a correct appraisal of complex biological processes, and moderate previous conclusions derived from in vitro analyses on the general activation of IAPs by oncogenes and on the role of these transposable elements in tumorigenesis.	INST GUSTAVE ROUSSY,UNITE PHYSICOCHIM & PHARMACOL MACROMOL BIOL,CNRS URA147,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy			Dupressoir, Anne/M-5280-2018	Dupressoir, Anne/0000-0002-3464-8513				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASCH BB, 1990, CANCER RES, V50, P2404; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; AUGENLICHT LH, 1984, J BIOL CHEM, V259, P1842; BEGEMANN M, 1988, MOL CARCINOGEN, V1, P196, DOI 10.1002/mc.2940010308; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; DEOCA FHM, 1984, BIOL CELL, V52, P199; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1986, CANCER RES, V46, P1915; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Dupressoir A, 1995, BBA-GENE STRUCT EXPR, V1264, P397, DOI 10.1016/0167-4781(95)00181-6; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; FEENSTRA A, 1986, NUCLEIC ACIDS RES, V14, P4343, DOI 10.1093/nar/14.10.4343; GALIEN R, 1994, ONCOGENE, V9, P1101; GALIEN R, 1991, ONCOGENE, V6, P849; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; Lamb Bruce T., 1991, Gene Expression, V1, P185; Lueders K K, 1995, Curr Top Microbiol Immunol, V194, P405; LUEDERS KK, 1986, NUCLEIC ACIDS RES, V14, P1495, DOI 10.1093/nar/14.3.1495; LUEDERS KK, 1993, MOL CELL BIOL, V13, P7439, DOI 10.1128/MCB.13.12.7439; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOWAT M, 1990, ONCOGENE, V5, P241; Puech A, 1997, J BIOL CHEM, V272, P5995, DOI 10.1074/jbc.272.9.5995; ROLAND J, 1993, CELL GROWTH DIFFER, V4, P891; RONAI Z, 1992, MOL CARCINOGEN, V5, P81, DOI 10.1002/mc.2940050113; SHENONG GLC, 1984, J VIROL, V49, P171, DOI 10.1128/JVI.49.1.171-177.1984; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901	43	20	22	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2951	2958		10.1038/sj.onc.1201148	http://dx.doi.org/10.1038/sj.onc.1201148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205102				2022-12-28	WOS:A1997XF55500009
J	Chiba, N; Watanabe, T; Nomura, S; Tanaka, Y; Minowa, M; Niki, M; Kanamaru, R; Satake, M				Chiba, N; Watanabe, T; Nomura, S; Tanaka, Y; Minowa, M; Niki, M; Kanamaru, R; Satake, M			Differentiation dependent expression and distinct subcellular localization of the protooncogene product, PEBP2 beta/CBF beta, in muscle development	ONCOGENE			English	Article						PEBP2 beta/CBF beta; transcription factor; acute myeloid leukemia; muscle development; immunohistochemistry	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; SKELETAL-MUSCLE; E-CADHERIN; AML1 GENE; FUSION TRANSCRIPT; DNA-BINDING; PROTEIN; RUNT; DOMAIN	The Pebpb2/Cbfb gene encodes the non-DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF. To examine the expression of the PEBP2 beta/CBF beta protein in vivo, we carried out immunohistochemistry using the tissues from adult mice as well as embryos, Although PEBP2 beta/CBF beta was detected in various tissues to various degrees, interesting features of expression were observed in the skeletal myogenic cells. Here PEBP2 beta/CBF beta was found mainly to occur as cytoplasmic staining and the intensity of this staining increased depending on the differentiation stage of the cells, In the undifferentiated myoblasts PEBP2 beta/CBF beta was undetectable, whereas moderate levels of PEBP2 beta/CBF beta were detected in the elongated and aligned myocytes. PEBP2 beta/CBF beta appeared to accumulate further when the cells fused to each other to become multinucleated myotubes, Once the muscle fibers were established, PEBP2 beta/CBF beta was relocated onto or around the Z-lines. PEBP2 beta/CBF beta was also detected in the cytoplasm of cardiac myocytes and in the smooth muscle cells of the digestive tract. In all the above, the skeletal myotubes were the only case that showed both nuclear and cytoplasmic staining of PEBP2 beta/CBF beta. Thus, we could show differentiation dependent pattern of PEBP2 beta/CBF beta expression in muscle development and establish PEBP2 beta/CBF beta to be a cytoplasmic as well as nuclear protein in vivo.	TOHOKU UNIV,DEPT MOL IMMUNOL,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,DEPT CLIN ONCOL,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Tohoku University; Tohoku University; Osaka University								ABERLE H, 1994, J CELL SCI, V107, P3655; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOBER E, 1994, DEVELOPMENT, V120, P603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; ERICKSON P, 1992, BLOOD, V80, P1825; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRIS EJ, 1994, J CELL SCI, V107, P377; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	42	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2543	2552		10.1038/sj.onc.1201109	http://dx.doi.org/10.1038/sj.onc.1201109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191054				2022-12-28	WOS:A1997XA94900006
J	Blaydes, JP; Gire, V; Rowson, JM; WynfordThomas, D				Blaydes, JP; Gire, V; Rowson, JM; WynfordThomas, D			Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2	ONCOGENE			English	Article						p53; transcriptional activation; mdm-2; microinjection; transformed epithelial cells	DNA-DAMAGING AGENTS; TUMOR-SUPPRESSOR GENE; LARGE-T-ANTIGEN; MUTANT HA-RAS; GROWTH ARREST; BINDING-SITE; TRANSACTIVATION FUNCTION; TRANSCRIPTIONAL ACTIVITY; COLORECTAL-CARCINOMA; PROTEIN ACCUMULATION	A significant proportion of human cancers express high levels of p53 protein in the absence of an underlying mutation in the gene. Using transformed (Vh1) and non-transformed (FRTL-5) rat thyroid epithelial cell lines as a model, we have examined the mechanisms by which high levels of wild-type p53 may be tolerated. Stable transfection with p53-dependent reporter constructs demonstrated that the 'excess' wild-type p53 in Vh1 cells is not associated with a comparable increase in p53-dependent transcription (though the response to u.v. irradiation is retained). Mdm-2, which binds p53 and inhibits its transactivation activity, is overexpressed in Vh1 cells in the absence of gene amplification and in a p53-dependent manner. Furthermore disruption of p53-mdm-2 complex formation in Vh1 cells by microinjection of an antibody to the p53-binding domain of mdm-2 resulted in a dramatic increase in p53-dependent transcription. Since only a small proportion of the p53 in Vh1 cells was found to be in complex with mdm-2 (the majority of unbound protein being in a latent form), this suggests that mdm-2 selectively binds a pool of p53 that would otherwise be active as a sequence-specific activator of transcription. We suggest that, in some types of tumour, the 'sensitivity' of the p53-driven mdm-2 feedback loop may be sufficient to prevent free, active p53 reaching the level required for growth arrest or apoptosis, making them an ideal target for therapies designed to disrupt p53-mdm-2 interactions.	UNIV WALES COLL MED,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			Blaydes, Jeremy/AAC-6939-2019; Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Blaydes, Jeremy/0000-0001-8525-0209; Gire, Veronique/0000-0002-9009-2185				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BLAYDES JP, 1995, ONCOGENE, V10, P307; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; Burden AD, 1996, J CUTAN PATHOL, V23, P25, DOI 10.1111/j.1600-0560.1996.tb00773.x; BURNS JS, 1992, INT J ONCOL, V1, P79; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CARBONE DP, 1994, CHEST S, V106, P377; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORNELIS RS, 1994, CANCER RES, V54, P4200; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DOWELL SP, 1995, J PATHOL, V177, P221, DOI 10.1002/path.1711770302; DUNN JM, 1993, BRIT J SURG, V80, P1410, DOI 10.1002/bjs.1800801118; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FREBOURG T, 1992, CANCER RES, V52, P6976; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUPPI K, 1994, ONCOGENE, V9, P3017; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANG FF, 1994, ONCOGENE, V9, P949; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUTZKER SG, 1996, NAT MED, V2, P802; MACGEOCH C, 1993, DIS MARKERS, V11, P239, DOI 10.1155/1993/480686; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RENZING J, 1995, ONCOGENE, V10, P1865; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; RUBIO MP, 1993, CANCER RES, V53, P3465; Sambrook J., 2002, MOL CLONING LAB MANU; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TISHLER RB, 1993, CANCER RES, V53, P2212; TOP B, 1995, INT J CANCER, V64, P83, DOI 10.1002/ijc.2910640203; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	74	73	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1859	1868		10.1038/sj.onc.1201018	http://dx.doi.org/10.1038/sj.onc.1201018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150392				2022-12-28	WOS:A1997WW16600012
J	Wang, JK; Goldfarb, M				Wang, JK; Goldfarb, M			Amino acid residues which distinguish the mitogenic potentials of two FGF receptors	ONCOGENE			English	Article						FGFR; chimeric; BaF3; proliferation; autophosphorylation	GROWTH-FACTOR RECEPTOR; C-KIT RECEPTOR; DIFFERENT SIGNALING PATHWAYS; TYROSINE KINASE-ACTIVITY; INSULIN-RECEPTOR; POINT MUTATION; BINDING-SITE; MET PROTOONCOGENE; BETA-SUBUNIT; EGF RECEPTOR	Fibroblast growth factors mediate cellular responses by interacting with a family of related receptor tyrosine kinases (FGFRs), We have previously shown that FGFR-1, but not of FGFR-4, ectopically expressed in BaF3 lymphoid cells allows for proliferation in response to FGFs, and that the intracellular signaling halves of these two receptors distinguish their mitogenic potentials (Wang et al., 1994), In order to map the residues which functionally distinguish these receptors, a panel of chimeric receptors whose cytodomains bear different contributions from FGFR-1 and FGFR-4 were constructed and characterized, The behavior of these chimeras implicate amino acids from both the kinase insert and kinase domains in receptor-mediated proliferation, Specifically, two tyrosine residues present in the short kinase insert domain of FGFR-1 and absent from FGFR-4 are a necessary, but not sufficient, component bf a fully mitogenic receptor, suggesting that tyrosine phosphorylation in the kinase insert promotes a mitogenic signaling pathway, A strongly mitogenic receptor also requires one or two FGFR-1-specific residues from either of two regions within the kinase domain, One of these regions is within the kinase domain's activation loop, where FGFR-1, but not FGFR-4, bears a key aspartate residue, The mitogenic potentials of FGFR-1, FGFR-4, and the chimeric receptors strongly correlates with the magnitude of ligand-induced receptor autophosphorylation in BaF3 cells, We discuss mechanisms by which these few key amino acid differences may determine the levels of ligand-induced FGF receptor autophosphorylation and mitogenic potency.	CUNY MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University; Regeneron					NATIONAL CANCER INSTITUTE [R01CA048054] Funding Source: NIH RePORTER; NCI NIH HHS [CA48054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LONGATI P, 1994, ONCOGENE, V9, P49; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SERVE H, 1994, J BIOL CHEM, V269, P6026; SHAOUL E, 1995, ONCOGENE, V10, P1553; STARK KL, 1991, DEVELOPMENT, V113, P641; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHAN X, 1987, ONCOGENE, V1, P369; ZHANG B, 1991, J BIOL CHEM, V266, P990	57	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1767	1778		10.1038/sj.onc.1201021	http://dx.doi.org/10.1038/sj.onc.1201021			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150382				2022-12-28	WOS:A1997WW16600002
J	Yi, HK; Fujimura, Y; Ouchida, M; Prasad, DDK; Rao, VN; Reddy, ESP				Yi, HK; Fujimura, Y; Ouchida, M; Prasad, DDK; Rao, VN; Reddy, ESP			Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias	ONCOGENE			English	Article						Ewing's sarcoma; human myeloid leukemias; EWS- and TLS-fusion proteins; apoptosis; therapy	RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; ETS-RELATED GENE; EWINGS-SARCOMA TRANSLOCATION; ROUND-CELL TUMOR; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; CHROMOSOMAL TRANSLOCATION; EWS GENE; FUSION TRANSCRIPTS	Two ets family members, namely erg and Fli-1 are fused with two EWS familiy members namely EWS and TLS/FUS as a result of chromosome translocation in human solid tumors and leukemias. EWS-erg and EWS-FLi-1, which are involved in greater than 95% of Ewing family of tumors, were shown to function as transcriptional activators. TLS/FUS-erg, which is involved in human myeloid leukemias also functions as a transcriptional activator. Expression of these fusion proteins (EWS-erg and EWS-FLi-1) are shown to be essential for maintaining the oncogenic and tumorigenic properties of tumor cells. Cancer is thought to be caused not only by uncontrolled cell proliferation but also by deregulation of programmed cell death. Therefore, we have studied the role of normal (Fli-1 and erg) and aberrant fusion proteins (EWS-erg, EWS-Fli-1 and TLS/FUS-erg) in apoptosis. We have found that expression of normal (Fli-1 and erg) and aberrant fusion proteins inhibit the apoptosis of NIH3T3 cells induced by either serum deprivation or by treatment with calcium ionophore. We have also observed similar suppression of apoptosis in Ewing's sarcoma cells expressing EWS-Fli-1 and EWS-erg proteins suggesting that these fusionproteins may be responsible for the decreased ability of these tumor cells to undergo apoptosis. Inhibition of the expression of these aberrant fusion proteins by antisense RNA technique resulted in increased susceptibility to apoptosis leading to the death of tumor cells. Therefore, our results suggest that one can use therapeutic agents which can down regulate the expression of fusion proteins in combination with chemotherapeutic agents as an effective treatment for these human solid tumors and leukemias.	ALLEGHENY UNIV HLTH SCI,DEPT HUMAN GENET,DIV CANC GENET,PHILADELPHIA,PA 19102; KIMMEL CANC INST,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Drexel University; Jefferson University					NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [CA51083, CA58642, CA57322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BEDI A, 1994, BLOOD, V83, P2038; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Clark J, 1996, ONCOGENE, V12, P229; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Fujimura Y, 1996, ONCOGENE, V12, P159; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HELM S, 1994, GENES CHROM CANC, V11, P256; HOFFMAN B, 1994, ONCOGENE, V9, P1807; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LADANYI M, 1994, CANCER RES, V54, P2837; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MITELMAN F, 1991, CATALOG CHROMOSOME A; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Shao NS, 1996, ONCOGENE, V13, P1; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRICHE TJ, 1993, CURR TOP PATHOL, V89, P47; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	52	100	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1259	1268		10.1038/sj.onc.1201099	http://dx.doi.org/10.1038/sj.onc.1201099			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178886				2022-12-28	WOS:A1997WP10900001
J	Columbano, A; LeddaColumbano, GM; Pibiri, M; Piga, R; Shinozuka, H; DeLuca, V; Cerignoli, F; Tripodi, M				Columbano, A; LeddaColumbano, GM; Pibiri, M; Piga, R; Shinozuka, H; DeLuca, V; Cerignoli, F; Tripodi, M			Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP	ONCOGENE			English	Article						immediate early genes; liver; priming; cell proliferation; TCPOBOP; CCl4	MYC MESSENGER-RNA; FACTOR KAPPA-B; REGENERATING LIVER; RAT-LIVER; CELL-PROLIFERATION; GROWTH-FACTORS; GENE; 1,4-BIS<2-(3,5-DICHLOROPYRIDYLOXY)>BENZENE; INDUCTION; IDENTIFICATION	The notion that an increased expression of immediate early genes such as c-fos and c-jun is an absolute requirement for the G(0)-G(1) transition of the hepatocytes has recently been challenged by the finding that rat liver cell proliferation induced by primary mitogens may occur in the absence of such changes (Columbano and Shinozuka, 1996). To further investigate the relationship between immediate early genes and hepatocyte proliferation, we have compared the hepatic levels of c-fos, c-jun and LRF-1 transcripts during mouse liver cell proliferation in two conditions: (i) direct hyperplasia induced by the non-genotoxic hepatocarcinogen 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene, and (ii) compensatory regeneration caused by a necrogenic dose of carbon tetrachloride. The results show striking differences in the activation of early genes. In spite of a rapid stimulation of S phase by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (approximately 8% of hepatocytes were BrdU-positive as early as 24 h after mitogen treatment versus 1% of labelled hepatocytes after 2/3 partial hepatectomy), no changes in the expression of c-fos, c-jun and LRF-1 could be observed. Moreover, no change in steady state mRNA hepatic levels of IGFBP-1 (a gene highly expressed in rat liver following partial hepatectomy), and only a slight increase in c-myc and PRL-1, was found after mitogen administration. On the contrary, a rapid, massive and transient increase in the hepatic mRNA levels of all these genes was observed during carbon tetrachloride induced regeneration. The results indicate that increased expression of immediate early genes may be dependent upon the nature of the proliferative stimulus, and it may not be a prerequisite in certain in vivo conditions such as proliferation induced in the absence of liver tissue damage.	UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15260; UNIV ROMA LA SAPIENZA,DIP BIOPATOL UMANA,SEZ BIOL CELLULARE,FDN IST PASTEUR CENCI BOLOGNETTI,ROME,ITALY	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fondazione Cenci Bolognetti; Sapienza University Rome	Columbano, A (corresponding author), UNIV CAGLIARI,IST PATOL SPERIMENTALE,I-09124 CAGLIARI,ITALY.		Tripodi, Marco/F-1143-2011; Tripodi, Marco/ABO-1160-2022; Columbano, Amedeo/C-7463-2011	Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X; Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616	NCI NIH HHS [CA53453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; COLUMBANO A, 1996, P AM ASSOC CANC RES, V37, P1466; CONI P, 1990, CARCINOGENESIS, V11, P835, DOI 10.1093/carcin/11.5.835; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIWAN BA, 1992, CARCINOGENESIS, V13, P1893, DOI 10.1093/carcin/13.10.1893; DRAGANI TA, 1985, CARCINOGENESIS, V6, P225, DOI 10.1093/carcin/6.2.225; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; GARIBOLDI M, 1995, MOL CARCINOGEN, V14, P71, DOI 10.1002/mc.2940140202; GOLDSWORTHY TL, 1994, CELL PROLIFERAT, V27, P269, DOI 10.1111/j.1365-2184.1994.tb01424.x; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; MENEGAZZI M, 1996, IN PRESS HEPATOLOGY; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; Ohmura T, 1996, AM J PATHOL, V148, P815; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCEARCE LM, 1996, CELL DEATH DIFFER, V3, P51; SHINOZUKA H, 1994, LAB INVEST, V71, P35; SHORT J, 1972, J BIOL CHEM, V247, P1757; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0	33	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					857	863		10.1038/sj.onc.1200891	http://dx.doi.org/10.1038/sj.onc.1200891			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047393				2022-12-28	WOS:A1997WJ11200012
J	Menon, AG; Rutter, JL; vonSattel, JP; Synder, H; Murdoch, C; Blumenfeld, A; Martuza, RL; vonDeimling, A; Gusella, JF; Houseal, TW				Menon, AG; Rutter, JL; vonSattel, JP; Synder, H; Murdoch, C; Blumenfeld, A; Martuza, RL; vonDeimling, A; Gusella, JF; Houseal, TW			Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative 'tumor progression' locus	ONCOGENE			English	Article						loss of heterozygosity; chromosome 14; meningioma	CYTOGENETIC ANALYSIS; BRAIN TUMORS; GENES; EVOLUTION; AMPLIFICATION; TUMORIGENESIS; RECOMBINATION; METAPHASE; FRAGMENTS; PROBES	Formation of meningiomas has been associated with the loss of genetic material on chromosome 22. To approach the additional chromosomal events that underlie progression of these tumors to malignancy, we have examined several other chromosomal regions for loss of heterozygosity (LOH) in these tumors. Fifty-eight tumors, comprising 43 benign meningiomas, 11 atypical meningiomas and four malignant meningiomas, were examined. While the loss of chromosome 22 was seen in approximately half of all these tumors, regardless of their malignancy, the most frequent chromosomal losses observed in the malignant and atypical tumors were on the long arm of chromosome 14. Thirty-nine tumors were informative for at least one of the three markers on chromosome 14 that we tested. Of these, 7/14 malignant and atypical tumors showed LOH in contrast to only 1/25 benign tumors. Other loci that showed LOH in malignant tumors, although at a much lower frequency, were on chromosomes 17p and 1p, The high frequency of LOH for loci on chromosome 14q in atypical and malignant tumors suggests the presence of a tumor progression gene at this locus. In one of the malignant meningiomas heterozygosity was lost at D14S13 and D14S16 but retained at the proximal marker D14S43 as well as the more distal marker D14S23. This suggests that an interstitial deletion occurred in this tumor which should be useful for further refining the position of the putative tumor progression locus.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET LAB,CHARLESTOWN,MA 02129; GEORGETOWN UNIV,DEPT NEUROSURG,WASHINGTON,DC 20007; UNIV BONN,INST NEUROPATHOL,D-5300 BONN,GERMANY; GENZYME GENET,FRAMINGHAM,MA 01701	Harvard University; Massachusetts General Hospital; Georgetown University; University of Bonn; Sanofi-Aventis; Genzyme Corporation	Menon, AG (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.		von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; Rutter, Joni/0000-0002-6502-2361	NINDS NIH HHS [NS31145-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031145] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSAADI A, 1987, CANCER GENET CYTOGEN, V26, P127, DOI 10.1016/0165-4608(87)90140-3; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; BELLO MJ, 1989, NEOPLASMA, V36, P71; BIGNER SH, 1986, CANCER GENET CYTOGEN, V22, P121, DOI 10.1016/0165-4608(86)90172-X; BOGHOSIAN L, 1989, CANCER GENET CYTOGEN, V43, P39, DOI 10.1016/0165-4608(89)90125-8; CASALONE R, 1990, CANCER GENET CYTOGEN, V45, P237, DOI 10.1016/0165-4608(90)90088-R; CASARTELLI C, 1989, CANCER GENET CYTOGEN, V40, P33, DOI 10.1016/0165-4608(89)90143-X; CHALLA VR, 1992, NEUROSURGERY, V1, P613; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBHART E, 1986, BREAST CANCER RES TR, V8, P125, DOI 10.1007/BF01807701; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KATSUYAMA J, 1986, CANCER GENET CYTOGEN, V22, P63, DOI 10.1016/0165-4608(86)90138-X; KLINGER K, 1992, AM J HUM GENET, V51, P55; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NAKAMURA Y, 1989, GENOMICS, V4, P76, DOI 10.1016/0888-7543(89)90317-0; *NIH CEPH COLL MAP, 1992, SCIENCE, V258, P67; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RUSSELL DS, 1990, PATHOLOGY TUMORS NER; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1722, DOI 10.1093/nar/19.7.1722; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SUZUKI T, 1989, CANCER RES, V49, P1095; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; ZANKL H, 1972, HUMANGENETIK, V14, P167, DOI 10.1007/BF00273305	34	99	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					611	616		10.1038/sj.onc.1200853	http://dx.doi.org/10.1038/sj.onc.1200853			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053860				2022-12-28	WOS:A1997WF52400013
J	Sood, AK; Buller, RE				Sood, AK; Buller, RE			Genomic instability in ovarian cancer: A reassessment using an arbitrarily primed polymerase chain reaction	ONCOGENE			English	Article						ovarian cancer; genomic instability; replication error	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; GENETIC INSTABILITY; REPEATED SEQUENCES; MISMATCH REPAIR; ALU REPEATS; CELL-LINES; DNA; MUTATIONS; TUMORS	Traditional polymerase chain reaction (PCR) amplification of multiple microsatellite markers to detect microsatellite instability (MI) is labor intensive and may be marker dependent, An arbitrarily primed polymerase chain reaction (AP-PCR) is a modification of PCR that generates a genomic DNA fingerprint using a single, arbitrarily chosen primer which is useful in the detection of somatic genetic alterations, We hypothesize that AP-PCR of an AluI DNA restriction digest, which we term Alu/AP-PCR, identifies genomic instability as well, In order to test this hypothesis, we correlated Alu/AP-PCR fingerprints with analyses of traditional PCR amplified microsatellite markers using paired germline and tumor DNA samples obtained from 68 patients with ovarian cancer, The microsatellite markers tested included dinucleotide, trinucleotide, and tetranucleotide repeats. We found that MI is more common in ovarian cancer than previously thought, We estimate a minimum incidence of MI at 37% based on the 10 traditional markers we tested, to an incidence of 53% based upon our Alu/AP-PCR analysis, All cases of MI were associated with an abnormal Alu/AP-PCR banding pattern, Both MI, detected by polymorphic markers (P=0.03), and an abnormal Alu/MAP-PCR pattern (P=0.01) were significantly associated with the occurrence of a second primary malignancy in the same patient. In addition, abnormal Alu/AP-PCR patterns were associated with higher grade lesions (P=0.02), and family history of cancer (P=0.009), These findings suggest: (1) MI may play an important role in ovarian carcinogenesis, and (2) Alu/AP-PCR is a novel technique for identification of genomic instability.	UNIV IOWA HOSP & CLIN, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARCOT SS, 1995, GENOMICS, V29, P136, DOI 10.1006/geno.1995.1224; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BOYER JC, 1995, CANCER RES, V55, P6063; BULLER RE, 1995, GYNECOL ONCOL, V58, P368, DOI 10.1006/gyno.1995.1244; Cass I., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P544; CHARLIEU JP, 1992, NUCLEIC ACIDS RES, V20, P1333, DOI 10.1093/nar/20.6.1333; DESOUZA AP, 1994, GENOMICS, V19, P391, DOI 10.1006/geno.1994.1079; HAN HJ, 1993, CANCER RES, V53, P5087; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBS IJ, 1993, CANCER RES, V53, P1218; KOLODNER RD, 1995, CANCER RES, V55, P242; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MUTA H, 1990, CANCER, V77, P265; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PEROLAT P, 1994, J CLIN MICROBIOL, V32, P1949, DOI 10.1128/JCM.32.8.1949-1957.1994; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Skilling JS, 1996, ONCOGENE, V13, P117; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WEBER JL, 1989, AM J HUM GENET, V44, P388; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090	35	55	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2499	2504						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957095				2022-12-28	WOS:A1996VX10800026
J	Montano, X				Montano, X			p53 associates with trk tyrosine kinase	ONCOGENE			English	Article						trk and p53 association; PC12 differentiation; phosphorylation	NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; WILD-TYPE P53; DNA-REPLICATION; CELL-CYCLE; NEURONAL DIFFERENTIATION; SV40-TRANSFORMED CELLS; NEUROTROPHIN RECEPTORS; PROTOONCOGENE PRODUCT; TRANSFORMED-CELLS	The p53 tumor suppressor gene encodes a phosphoprotein which when overexpressed can induce growth arrest at the G1 and G2/M phases of the cell cycle, promote differentiation and apoptosis. This paper demonstrates that p53 can associate with trk tyrosine kinase. Expression of a murine temperature-sensitive (ts) p53 mutant in PC12 cells overexpressing trk (a model system to analyse cellular differentiation and signal transduction induced by NGF) induces morphological changes in the absence of NGF stimulation at 32 degrees C but not at 37 degrees C. In cells differentiated by p53, trk, but not EGFr, was hyperphosphorylated on tyrosine. Furthermore trk was not phosphorylated when expressed in Saos-2 cells (human osteosarcoma cells that lack expression of both endogenous trk and p53) at either temperature. However, transfection of ts p53 into these cells induces trk phosphorylation at 32 degrees C in the absence of NGF stimulation. Association of trk and p53 can be detected in NIH3T3 and PC12 cells co-expressing trk and the ts p53 mutant, in NIH3T3 and PC12 cells transfected with trk alone, and in untransfected PC12 cells, showing that overexpressed and/or endogenous trk associates with endogenous, low levels of p53. These data suggest a novel function for p53 which involves the stimulation of signal transduction pathways (mediating morphological properties of cells), possibly through association with and hyperphosphorylation of trk.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARBACID M, 1993, ONCOGENE, V8, P2033; BARBACID M, 1993, TRK FAMILY NEUROTROP; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BASU T, 1994, ONCOGENE, V9, P3483; BERG MM, 1992, J BIOL CHEM, V267, P13; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COFFER AI, 1994, BIOCHIM BIOPHYS ACTA, V1119, P11; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E., 1988, ANTIBODIES LAB MANUA; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Knippschild U, 1996, ONCOGENE, V12, P1755; KNUSEL B, 1992, J NEUROCHEM, V59, P715, DOI 10.1111/j.1471-4159.1992.tb09427.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SATHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1994, NEURON, V1, P1; TAPLEY P, 1992, ONCOGENE, V7, P371; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; YAN GZ, 1995, J NEUROSCI, V15, P6200; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371	78	25	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					245	256		10.1038/sj.onc.1201215	http://dx.doi.org/10.1038/sj.onc.1201215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233759				2022-12-28	WOS:A1997XK99900001
J	Vorechovsky, I; Tingby, O; Hartman, M; Stromberg, B; Nister, M; Collins, VP; Toftgard, R				Vorechovsky, I; Tingby, O; Hartman, M; Stromberg, B; Nister, M; Collins, VP; Toftgard, R			Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours	ONCOGENE			English	Article						medulloblastoma; mutation; nevoid basal cell carcinoma syndrome; chromosome 9; patched; PTCH	CELL CARCINOMA SYNDROME; P53 GENE-MUTATIONS; GORLIN SYNDROME; APC GENE; MEDULLOBLASTOMA; LINE; ESTABLISHMENT; PROTEIN	The naevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple developmental defects and cancer susceptibility, in particular to basal cell carcinomas (BCCs). Medulloblastomas,primitive neuroectodermal tumours (PNETs) arising in childhood, occur in about 3-5% of NBCCS patients and a subset of PNETs was previously found with allelic imbalance at 9q22-q23, the region containing the gene for NBCCS (PTCH). We have analysed tumour DNA samples from 37 unrelated patients with sporadic PNETs and five medulloblastoma cell lines for PTCH mutations using an exon-by-exon single strand conformation polymorphism assay. We found three missense mutations, which affect conserved residues in transmembrane domains of the gene product and in the extracellular loop implicated in binding sonic hedgehog, one 2 bp deletion and an exon skipping splice site mutation. Most mutations were associated with the absence of the wild-type allele and were found in tumours exhibiting loss of heterozygosity (LOH) at loci flanking PTCH. The finding of LOH at 9q22-q23 in most mutated tumours while present in only three out of 26 tumours, in which a mutation was not identified, implicates PTCH as the target gene in PNETs with LOH at 9q22-q23 and deficient PTCH in the development of a subset of these tumours. Since all observed mutations were absent in the germ-line, a sporadic medulloblastoma developing as the first symptom of NBCCS is likely to be a very uncommon event.	UNIV LONDON, ROYAL FREE HOSP, SCH MED, LONDON NW3 2PF, ENGLAND; KAROLINSKA HOSP, GUSTAV V RES INST, DEPT PATHOL & ONCOL, S-17176 STOCKHOLM, SWEDEN; UNIV UPPSALA HOSP, DEPT PATHOL, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, DEPT PAEDIAT, S-75185 UPPSALA, SWEDEN	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Vorechovsky, I (corresponding author), KAROLINSKA INST, NOVUM, DEPT BIOSCI, CTR NUTR & TOXICOL, S-14157 HUDDINGE, SWEDEN.							Acqui M, 1989, J Neurosurg Sci, V33, P263; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004; Beaudet AL, 1996, HUM MUTAT, V8, P197; BELAMARIC J, 1969, J NEUROSURG, V30, P76, DOI 10.3171/jns.1969.30.1.0076; Bhat KM, 1996, DEVELOPMENT, V122, P2921; BICKERSTAFF ER, 1967, ACTA NEUROPATHOL, V8, P104, DOI 10.1007/BF00686656; Blaeker H, 1996, GENE CHROMOSOME CANC, V15, P54, DOI 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.3.CO;2-4; Chidambaram A, 1996, CANCER RES, V56, P4599; COGEN PH, 1992, AM J HUM GENET, V50, P584; David KM, 1997, J NEUROSURG, V86, P13, DOI 10.3171/jns.1997.86.1.0013; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EVANS DGR, 1993, J MED GENET, V30, P460, DOI 10.1136/jmg.30.6.460; EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FRIEDMAN HS, 1985, J NEUROPATH EXP NEUR, V44, P592, DOI 10.1097/00005072-198511000-00005; FRIEDMAN HS, 1988, AM J PATHOL, V130, P472; FULTS D, 1992, J NEUROPATH EXP NEUR, V51, P272, DOI 10.1097/00005072-199205000-00005; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HE XM, 1991, LAB INVEST, V64, P833; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUNG KL, 1990, SURG NEUROL, V33, P341, DOI 10.1016/0090-3019(90)90203-2; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kleihues P, 1993, HISTOLOGICAL TYPING; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LACOMBE D, 1990, Genetic Counseling, V1, P273; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Merchant TE, 1996, INT J RADIAT ONCOL, V36, P29, DOI 10.1016/S0360-3016(96)00274-X; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; REIS A, 1992, LANCET, V339, P617, DOI 10.1016/0140-6736(92)90903-G; SAYLORS RL, 1991, CANCER RES, V51, P4721; Scheurlen W, 1996, EUR J PEDIATR, V155, P880; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; SCHOFIELD D, 1995, AM J PATHOL, V146, P472; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; Simoneau AR, 1996, CANCER RES, V56, P5039; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310; Vorechovsky I, 1996, CANCER RES, V56, P2726; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wicking C, 1997, AM J HUM GENET, V60, P21; WICKING C, 1994, GENOMICS, V22, P505, DOI 10.1006/geno.1994.1423; YAMASHITA J, 1975, Surgical Neurology, V4, P225; YONG WH, 1995, NEW ENGL J MED, V333, P524	55	139	144	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					361	366		10.1038/sj.onc.1201340	http://dx.doi.org/10.1038/sj.onc.1201340			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233770				2022-12-28	WOS:A1997XK99900012
J	Sato, S; Roberts, K; Gambino, G; Cook, A; Kouzarides, T; Goding, CR				Sato, S; Roberts, K; Gambino, G; Cook, A; Kouzarides, T; Goding, CR			CBP/p300 as a co-factor for the Microphthalmia transcription factor	ONCOGENE			English	Article						microphthalmia; transcription activation; E1A; CBP; melanocytes	MELANOCYTE-SPECIFIC TRANSCRIPTION; NUCLEAR-PROTEIN CBP; ACTIVATION DOMAINS; TYROSINASE GENE; E1A; DIFFERENTIATION; MUTATIONS; P300; EXPRESSION; MYOBLASTS	The Microphthalmia basic-Helix-loop-Helix-Leucine Zipper (bHLH-LZ) transcription factor (Mi) plays a crucial role in the genesis of melanocytes; mice deficient for a functional (Microphthalmia) gene product lack all pigment cells, We show here that the Mi activation domain resides N-terminal to the DNA-binding domain and that as little as 18 amino acids are sufficient to mediate transcription activation, The minimal activation region of Mi is highly conserved in the related transcription factor TFE3 and is predicted to adopt an amphipathic alphahelical conformation, This region of Mi is also highly conserved with a region of E1A known to be essential for binding the CBP/p300 transcription cofactor, Consistent with these observations, the Mi activation domain can interact in vitro with CBP specifically through a region of CBP required for complex formation with E1A, P/CAF and c-Fos, and anti p300 antibodies can co-immunoprecipitate Mi from both melanocyte and melanoma cell lines, In addition, co-transfection of a vector expressing CBP2 (aas 1621-1891) fused to the VP16 activation domain potentiated the ability of Mi to activate transcription, confirming the significance of the CBP-Mi interaction observed in vitro. These data suggest that transcription activation by Mi is achieved at least in part by recruitment of CBP, The parallels between transcription regulation by Microphthalmia in melanocytes and MyoD in muscle cells are discussed.	MARIE CURIE RES INST,EUKARYOT TRANSCRIPT LAB,OXTED RH8 0TL,SURREY,ENGLAND; CRC,WELLCOME INST,CAMBRIDGE CB2 1QR,ENGLAND	Wellcome Trust Sanger Institute			Sato, Shigeru/ABE-2090-2020	Kouzarides, Tony/0000-0002-8918-4162; Goding, Colin/0000-0002-1614-3909	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BANERJEE AC, 1994, ONCOGENE, V9, P1733; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BATTACHARYA S, 1996, NATURE, V383, P344; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FITZPATRICK TB, 1979, BIOL MELANIN PIGMENT; GANSS R, 1994, J BIOL CHEM, V269, P29808; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; OELGESCHLAGER M, 1996, EMBO J, V15, P1227; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PERKINS ND, 1997, SCIENCE, V275, P451; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STEEL KP, 1989, DEVELOPMENT, V107, P453; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; YACUIK P, 1991, MOL CELL BIOL, V11, P5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	57	147	151	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3083	3092		10.1038/sj.onc.1201298	http://dx.doi.org/10.1038/sj.onc.1201298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223672				2022-12-28	WOS:A1997XG10000011
J	Thompson, MA; Flegg, R; Westin, EH; Ramsay, RG				Thompson, MA; Flegg, R; Westin, EH; Ramsay, RG			Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines	ONCOGENE			English	Article						c-myb; transcriptional attenuation; colon tumour cells	NONPOLYPOSIS COLORECTAL-CANCER; MESSENGER-RNA; MULTIPLE MECHANISMS; REPLICATION ERRORS; SUPPRESSOR PROTEIN; ADENOMATOUS POLYPS; SODIUM-BUTYRATE; GENE; DIFFERENTIATION; ELONGATION	In the hemopoietic system c-myb expression is required for proliferation of immature cells and its downregulation is required for differentiation. In colonic mucosa c-myb expression occurs at levels comparable to immature hemopoietic cells. Inhibition of c-myb expression in colon cell lines, using anti-sense oligonucleotides, indicates that c-myb expression is required for proliferation. However, the mechanism of c-myb regulation during colon cell differentiation has not been explored. Using the LIM1215 and CaCo-2 colon carcinoma cell lines induced to differentiate with sodium butyrate, we demonstrate that c-myb mRNA is down-regulated as an early event in differentiation by a mechanism involving transcriptional attenuation in intron 1. By analogy with procaryotic and eucaryotic genes, transcriptional attenuation probably occurs in a region containing nineteen consecutive thymidine residues. Computer prediction of the secondary structure of the nascent mRNA chain encoded by this region suggests a strong potential for stem-loop formation. Sequence analysis of several colon tumour cell lines reveals mutations in this region that may disrupt transcriptional attenuation and result in the increased c-myb expression observed in colon tumours and tumour cell lines.	PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Peter Maccallum Cancer Center; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Virginia Commonwealth University			Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; AUGERON C, 1984, CANCER RES, V44, P3961; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BOISE LH, 1992, ONCOGENE, V7, P1817; Bubb VJ, 1996, ONCOGENE, V12, P2641; CHEN JS, 1995, CANCER RES, V55, P174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DENG G, 1992, CANCER RES, V52, P3378; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FERRAO P, 1995, ONCOGENE, V11, P1631; GAMET L, 1992, INT J CANCER, V52, P286, DOI 10.1002/ijc.2910520222; GRECO C, 1994, ANTICANCER RES, V14, P1433; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBS SM, 1994, ONCOGENE, V9, P227; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KIM HG, 1994, AM J PATHOL, V145, P148; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUMM A, 1995, SCIENCE, V269, P1400, DOI 10.1126/science.7660121; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LOTHE RA, 1993, CANCER RES, V53, P5849; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MELANI C, 1991, CANCER RES, V51, P2897; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PATHAK S, 1989, CELL MOL BIOL COLON, P139; PINTO M, 1983, BIOL CELL, V47, P323; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SPENCER CA, 1990, ONCOGENE, V5, P777; STROBL L, 1992, EMBO J, V9, P3307; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weston K M, 1990, Semin Cancer Biol, V1, P371; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; WHITEHEAD RH, 1986, GUT, V27, P1447; WU C, 1994, ONCOGENE, V9, P991; XU L, 1995, ONCOGENE, V11, P1865; XU L, 1991, MOL CELL BIOL, V11, P7006; YOKATA J, 1986, SCIENCE, V231, P261; YOUNG J, 1993, ONCOGENE, V8, P671; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	63	51	54	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1715	1723		10.1038/sj.onc.1201007	http://dx.doi.org/10.1038/sj.onc.1201007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135073				2022-12-28	WOS:A1997WR89300010
J	Avigad, S; Barel, D; Blau, O; Malka, A; Zoldan, M; Mor, C; Fogel, M; Cohen, IJ; Stark, B; Goshen, Y; Stein, J; Zaizov, R				Avigad, S; Barel, D; Blau, O; Malka, A; Zoldan, M; Mor, C; Fogel, M; Cohen, IJ; Stark, B; Goshen, Y; Stein, J; Zaizov, R			A novel germ line p53 mutation in intron 6 in diverse childhood malignancies	ONCOGENE			English	Article						p53; germ line mutation; intron; childhood malignancies	TUMOR-SUPPRESSOR GENE; CANCER-PRONE FAMILY; SPLICING MUTATION; FRAUMENI-SYNDROME; PATIENT; EXPRESSION; PREVALENCE; NEOPLASMS; CHILDREN; PROTEIN	Screening for p53 mutations in exons 5 to 8 in 124 pediatric malignancies identified 18 abnormal shifts using single strand conformation polymorphism: 12 were missense mutations and in 6, no mutation was detected in the exon or in the splice donor acceptor sequences. Sequencing was then performed in the adjacent introns, revealing a G to A base substitution at 39 base pairs upstream to exon 7. This mutation was identified in the germ line of five of the patients, and also in the father of one, whose parents mere available. For comparison, of the 184 normal controls similarly screened, only one had this mutation (P=0.036). Positive staining of p53 protein was observed in three of the paraffin embedded tissues that were available: brain tumor, rhabdomyosarcoma, and lymphocytes from a normal lymph node from the rhabdomyosarcoma patient. All tumors with the identified intron mutation were Li-Fraumeni syndrome tumors. Sequencing of all exons including splice sites was performed and revealed no mutation. We suggest that this mutation in intron 6 of the p53 gene stabilizes the mild type p53 protein, resulting in its abnormal accumulation. Mutations in the noncoding region of p53 should be further studied.	RABIN MED CTR,DEPT PATHOL,PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL; KAPLAN MED CTR,DIV IMMUNOL,REHOVOT,ISRAEL	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Kaplan Medical Center	Avigad, S (corresponding author), FELSENSTEIN RES CTR,SCHNEIDER CHILDRENS MED CTR ISRAEL,PETAH TIQWA,ISRAEL.		Cohen, Ian/H-3358-2013					BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, CANCER RES, V54, P1298; BRUGIERES L, 1993, CANCER RES, V53, P452; FELIX CA, 1993, ONCOGENE, V8, P1203; FOGEL M, 1990, DIFFERENTIATION, V45, P242, DOI 10.1111/j.1432-0436.1990.tb00478.x; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JOLLY KW, 1994, ONCOGENE, V9, P97; LAW JC, 1991, CANCER RES, V51, P6358; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PELLER S, 1995, DNA CELL BIOL, V14, P98; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; Sambrook J., 2002, MOL CLONING LAB MANU; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRAUSS EA, 1995, CANCER RES, V55, P3237; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	25	40	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1541	1545		10.1038/sj.onc.1200990	http://dx.doi.org/10.1038/sj.onc.1200990			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129144				2022-12-28	WOS:A1997WQ54800004
J	Besser, D; Bardelli, A; Didichenko, S; Thelen, M; Comoglio, PM; Ponzetto, C; Nagamine, Y				Besser, D; Bardelli, A; Didichenko, S; Thelen, M; Comoglio, PM; Ponzetto, C; Nagamine, Y			Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2	ONCOGENE			English	Article						GRB2; hepatocyte growth factor; plasminogen activator; signal transduction; Tpr-Met	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; DEPENDENT PROTEIN-KINASE; DOMINANT-NEGATIVE MUTANT; PHOSPHATIDYLINOSITOL 3-KINASE; HGF RECEPTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; SH2 DOMAINS	The oncogene Tpr-Met is a constitutively active form of the hepatocyte growth factor/scatter factor (HGF/SF) receptor Met. It comprises the intracellular moiety of Met linked to the dimerization domain of the nuclear envelope protein Tpr, thus functioning as a constitutively activated Met, HGF/SF is responsible for various biological processes including angiogenesis and wound healing, in which secreted serine protease urokinase-type plasminogen activator (uPA) is implicated, The action of HGF/SF on cells is mediated by the autophosphorylation of Met on two carboxyterminal tyrosine Y(1349)VHVNATVY(1356)VNV. The two tyrosine provide docking sites for various effector molecules, suggesting that multiple signaling pathways are activated to exert biological effects of HGF/SF [Ponzetto et al., Cell (1994) 77: 261], We found that Tpr-Met efficiently activates the uPA gene via a SOS/Ras/extracellular signal regulated kinase (ERK)-dependent signaling pathway, Mutation of Y-1356, which abrogates GRB2 binding, reduced the induction to half of the control level, while mutation of Y-1349 showed little effect on uPA induction, suggesting an important but partly replaceable role for GRB2 in Met-dependent uPA gene induction, Mutation of both (YVHV)-V-1349 and (YVNV)-V-1356 into optimal PI 3-kinase sites resulted in a residual induction of about one quarter of the control level, suggesting a potential role for PI 3-kinase, Dose-response analysis of the Tpr-Met showed a biphasic curve, These results suggest that the interplay among different signaling molecules on the receptor is important for full induction of the pathway leading to the activation of the uPA gene.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; UNIV BERN,THEODOR KOCHER INST,CH-3012 BERN,SWITZERLAND; UNIV TURIN,SCH MED,CANC RES INST,I-10126 TURIN,ITALY	Friedrich Miescher Institute for Biomedical Research; University of Turin; University of Bern; University of Turin			Besser, Daniel/A-8304-2012; BARDELLI, Alberto/J-9721-2018	Besser, Daniel/0000-0002-4958-9624; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				BARDELLI A, 1992, ONCOGENE, V7, P1973; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blasi F, 1990, Semin Cancer Biol, V1, P117; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE JS, 1994, NUCLEIC ACIDS RES, V22, P569, DOI 10.1093/nar/22.4.569; LONGATI P, 1994, ONCOGENE, V9, P49; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1995, FIBRINOLYSIS DIS; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RUSCIANO D, 1995, ONCOGENE, V11, P1979; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1993, CELL, V72, P1; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TIENARI J, 1991, CELL REGUL, V2, P285, DOI 10.1091/mbc.2.4.285; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991	54	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					705	711		10.1038/sj.onc.1200879	http://dx.doi.org/10.1038/sj.onc.1200879			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038378				2022-12-28	WOS:A1997WG43000009
J	Griffiths, SD; Clarke, AR; Healy, LE; Ross, G; Ford, AM; Hooper, ML; Wyllie, AH; Greaves, M				Griffiths, SD; Clarke, AR; Healy, LE; Ross, G; Ford, AM; Hooper, ML; Wyllie, AH; Greaves, M			Absence of p53 permits propagation of mutant cells following genotoxic damage	ONCOGENE			English	Article						ionizing radiation; mutation; p53; apoptosis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENE; IONIZING-RADIATION; P53-DEFICIENT MICE; HEMATOPOIETIC-CELLS; ANTICANCER AGENTS; GAMMA-IRRADIATION; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS	Much evidence has been gathered in support of a critical role for p53 in the cellular response to DNA damage. p53 dysfunction is associated with progression and poor prognosis of many human cancers and with a high incidence of tumours in p53 knockout mice. The absence of a p53-dependent G(1) arrest that facilitates DNA repair or apoptosis might impact critically on clinical cancer in two ways. First, by abrogating the impact on therapy that operates via genotoxic damage and apoptosis; and second, by encouraging progression either by inducing genomic instability and DNA mis-repair or by permitting survival of mutants. However, experiments examining the relationship between p53 deficiency and mutation frequency have so far failed to confirm these predictions. The precise role played by p53 is therefore unclear. We now report use of a short term in vitro approach to assess the influence of p53 on radiation-induced mutations at the hprt locus in murine B cell precursors that are normally radiation ultrasensitive, We find a high number of hprt mutants among X-irradiated p53 null cells, which results from preferential survival as clonogenic mutants rather than from a p53-dependent increase in mutation rate. This result has important implications for genotoxic cancer therapy.	INST CANC RES, LEUKAEMIA RES FUND CTR, LONDON SW3 6JB, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JB, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, SECT RADIOTHERAPY, LONDON SW3 6JB, ENGLAND; UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Edinburgh			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Healy, Lyn/0000-0002-7044-8789				BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BLANDINO G, 1995, ONCOGENE, V10, P731; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BREIMER LH, 1988, BRIT J CANCER, V57, P6, DOI 10.1038/bjc.1988.2; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX R, 1977, NATURE, V267, P425, DOI 10.1038/267425a0; DERUIJTER YCEM, 1980, MUTAT RES, V69, P325, DOI 10.1016/0027-5107(80)90097-4; DIVE C, 1993, FRONTIERS PHARM CANC, P21; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FAN SJ, 1994, CANCER RES, V54, P5824; FURUNOFUKUSHI I, 1993, RADIAT RES, V136, P97, DOI 10.2307/3578645; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; GRIFFITHS SD, 1994, INT J RADIAT BIOL, V66, P197, DOI 10.1080/09553009414551101; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENT, 1994, INT J RADIAT BIOL, V65, P125; KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE G, 1989, J IMMUNOL, V142, P3875; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARUYAMA Y, 1987, ADV RADIAT BIOL, V12, P1; MERRITT AJ, 1994, CANCER RES, V54, P614; MORLEY AA, 1983, NATURE, V302, P155, DOI 10.1038/302155a0; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NICKLAS JA, 1989, MUTAT RES, V215, P147, DOI 10.1016/0027-5107(89)90178-4; NISHINO H, 1995, ONCOGENE, V11, P263; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; PURDIE CA, 1994, ONCOGENE, V9, P603; ROSS GM, 1995, CANCER RES, V55, P1235; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SELLINS KS, 1987, J IMMUNOL, V139, P3199; THACKER J, 1992, ADV RADIAT BIOL, V16, P77; THACKER J, 1979, RAD RES; VIJAYALAXMI, 1984, MUTAT RES, V125, P87, DOI 10.1016/0027-5107(84)90035-6; WALTON MI, 1993, CANCER RES, V53, P1853; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	58	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					523	531		10.1038/sj.onc.1200871	http://dx.doi.org/10.1038/sj.onc.1200871			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053850				2022-12-28	WOS:A1997WF52400003
J	Pasteau, S; Loiseau, L; Brun, G				Pasteau, S; Loiseau, L; Brun, G			Proliferation of chicken neuroretina cells induced by v-src, in vitro, depends on activation of the E2F transcription factor	ONCOGENE			English	Article						neuroretina cells; mitogenesis; v-src; E2F activity; dominant-negative mutants	ROUS-SARCOMA VIRUS; GREEN FLUORESCENT PROTEIN; RETINA-SPECIFIC GENE; S-PHASE ENTRY; GLUCOCORTICOID RECEPTOR; RETINOBLASTOMA PROTEIN; DEVELOPMENTAL CONTROL; EMBRYONIC RETINA; CYCLE CONTROL; C-JUN	Quiescent chicken or quail retina neuroblasts (NR) can be induced to proliferate actively, in culture, by the v-src oncoprotein. The chE2F-1 transcription factor, a physiological partner of the retinoblastoma gene product, is highly expressed in vivo, in dividing chicken neuroretina cells (CNR), It is sharply down-regulated as cells enter the post-mitotic differentiation stage, thus suggesting that E2F activity is a prerequisite for NR cell proliferation. In the present paper, transient expression assays of different forms of chE2F-1 mere used to investigate the function of E2F for switching CNR cells from a quiescent to a proliferative state in vitro. Attempts to substitute the effects of v-src by an ectopic expression of E2F-1 were unsuccessful. However, in the same conditions, E2F-1 supports full growth of CEF in serum-depleted medium, Deletion mutants of E2F-1, with potential dominant-negative properties, mere transfected in RSV infected CNR cells. One of these truncated mutants induces a G1 phase block in RSV-transformed CNR cells indicating that, although E2F-1 overexpression cannot overcome the cell proliferation block of postmitotic CNR cells E2F-1, activity is an important component of the growth signal pathway delivered by v-src in these nervous cells.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)								ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ALTSHULER D, 1993, DEVELOPMENT, V119, P1317; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENDROR I, 1993, P NATL ACAD SCI USA, V90, P1117, DOI 10.1073/pnas.90.3.1117; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLL J, 1988, J VIROL, V62, P2808, DOI 10.1128/JVI.62.8.2808-2816.1988; CRISANTI P, 1995, METHOD ENZYMOL, V254, P77; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOZIER C, 1988, BIOCHIMIE, V70, P885, DOI 10.1016/0300-9084(88)90229-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESPANEL X, 1997, IN PRESS INT J DEV B; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOROVITS R, 1994, P NATL ACAD SCI USA, V91, P4786, DOI 10.1073/pnas.91.11.4786; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JAMAL HH, 1994, ONCOGENE, V9, P417; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI X, 1994, J BIOL CHEM, V269, P6263; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LOISEAU L, 1997, IN PRESS GENE EXPRES; MARTIN P, 1992, ONCOGENE, V7, P1721; MICHEL D, 1989, ONCOGENE RES, V4, P127; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NEVINS JR, 1992, SCIENCE, V258, P424; North S, 1996, CELL GROWTH DIFFER, V7, P339; PASTEAU S, 1995, ONCOGENE, V11, P1475; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIERANI A, 1995, MOL CELL BIOL, V15, P642; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; PLAZA S, 1995, ONCOGENE, V10, P329; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROPP JD, 1995, CYTOMETRY, V21, P309, DOI 10.1002/cyto.990210402; SAMARUT J, 1995, METHOD ENZYMOL, V254, P206; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TCHENG M, 1994, EXP CELL RES, V212, P30, DOI 10.1006/excr.1994.1114; VARDIMON L, 1991, MOL CELL BIOL, V11, P5275, DOI 10.1128/MCB.11.10.5275; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; Yang Xiao-He, 1995, Gene Expression, V4, P195; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; YOON HY, 1994, ONCOGENE, V9, P801; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; Zhou H, 1996, J NEUROSCI, V16, P2261, DOI 10.1523/jneurosci.16-07-02261.1996; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	7	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					17	28		10.1038/sj.onc.1201177	http://dx.doi.org/10.1038/sj.onc.1201177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233774				2022-12-28	WOS:A1997XH58600003
J	Rosa, JL; Barbacid, M				Rosa, JL; Barbacid, M			A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70	ONCOGENE			English	Article						guanine nucleotide exchange factor; Ras-like small GTPases; protein transport; RCC1-like domains	TRANSPORT; RNA; CELLS; NEURONS; HOMOLOG; IMPORT; RCC1	We have recently identified an unusually large human protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins (EMBO J 15: 4262-4273, 1996), This protein, designated p532 based on its predicted molecular weight (EMBO J 15: 5738, 1996), contains multiple structural domains including two regions of seven internal repeats highly related to the cell cycle regulator RCC1, a guanine nucleotide exchange factor for the small GTP-binding protein Ran, seven beta-repeat domains characteristic of the beta subunit of heterotrimeric G proteins, three putative SH3 binding sites, a putative leucine-zipper and a carboxyterminal HECT domain characteristic of E3 ubiquitin-protein Ligases. Some of these domains are known to be involved in protein-protein interactions, suggesting the existence of p532-interacting proteins, To identify some of these proteins, we used the carboxy-terminal RCC1-like domain (RLD) of p532 in the yeast two-hybrid system, We report here the isolation of a clone that encodes the last 654 amino acid residues of the clathrin heavy chain, This interaction involves amino acid residues 1315-1557 of the clathrin heavy chain and the carboxy, but not the amino-terminal RLD of p532, p532 has been located in the cytosolic fraction as well as in the Golgi apparatus, The interaction between p532 and clathrin only occurs in the cytosol and is mediated by the formation of an ATP-dependent ternary complex with the heat shock protein, Hsp70, These observations suggest that p532 is involved in membrane transport processes.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Rosa, Jose Luis/K-6685-2014	Rosa, Jose Luis/0000-0002-6161-5688				BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BLACK MM, 1991, J NEUROSCI, V11, P1163; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NELSON KK, 1993, MOL CELL BIOL, V13, P521, DOI 10.1128/MCB.13.1.521; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; REN MD, 1995, MOL CELL BIOL, V15, P2117; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROSA JL, 1996, EMBO J, V15, P51738; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	27	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					1	6		10.1038/sj.onc.1201170	http://dx.doi.org/10.1038/sj.onc.1201170			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233772				2022-12-28	WOS:A1997XH58600001
J	Jiang, JG; Chen, QY; Bell, A; Zarnegar, R				Jiang, JG; Chen, QY; Bell, A; Zarnegar, R			Transcriptional regulation of the hepatocyte growth factor (HGF) gene by the Sp family of transcription factors	ONCOGENE			English	Article						hepatocyte growth factor (HGF); transcription; promoter; SP1; SP3	FACTOR-SCATTER-FACTOR; C-MET PROTOONCOGENE; FACTOR/SCATTER FACTOR; EPITHELIAL-CELLS; HEPATOPOIETIN-A; MESSENGER-RNA; EXPRESSION; RECEPTOR; PROMOTER; ACTIVATION	In this study, we have localized an enhancer element in the 5'-flanking region of the HGF gene promoter and have identified its functional transcriptional factors. Through transient transfection of NIH3T3 fibroblast cells and gel mobility shift assays, the functional binding site was localized to a short region (-318 to -303 bp from the transcription start site) which has a CTCCC sequence. This motif is also conserved in the human HGF promoter and acts as a binding site for the Sp family of transcription factors. In the presence of NIH3T3 nuclear protein extracts, this enhancer region formed specific DNA-protein complexes which were totally abrogated by excess amounts of consensus Spl oligonucleotide. In gel mobility supershift assays, anti-Sp1 and anti-Sp3 antibodies specifically recognized these complexes as was evident by their slower migration. Site-specific mutation of this binding motif resulted in total loss of Sp1 and Sp3 binding and a concomitant loss of enhancer function within the context of the HGF promoter. Furthermore, in transient cotransfection assays, overexpression of Sp1 and/or Sp3 stimulated HGF promoter activity independently and additively through binding to the Sp1 binding site in the HGF gene promoter region. DNaseI hypersensitive analysis of freshly isolated nuclei from NIH3T3 cells revealed that five hypersensitive sites (HSS) are present within the 2 kb region immediately upstream of the HGF promoter. One of these sites was mapped to position -0.3 kb from the transcription start site. These data show that both Sp1 and Sp3 transcription factors upregulate HGF promoter activity by binding to the Sp1 binding site at position -318 to -303 bp in the HGF gene promoter.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOL PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; BURKOWITZ EA, 1996, ONCOGENE, V12, P1991; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P388; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; EBERT M, 1994, CANCER RES, V54, P5775; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDBERG ID, 1995, EPITHELIAL MESENCHYM; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hino M, 1996, BRIT J CANCER, V73, P119, DOI 10.1038/bjc.1996.22; Jeffers M, 1996, ONCOGENE, V13, P853; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOKER M, 1991, FEBS LETT, V291, P229; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WAGNER S, 1994, CURR OPIN CELL BIOL, V6, P410, DOI 10.1016/0955-0674(94)90034-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zarnegar R., 1995, V74, P33	60	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3039	3049		10.1038/sj.onc.1201152	http://dx.doi.org/10.1038/sj.onc.1201152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223667				2022-12-28	WOS:A1997XG10000006
J	Nagai, H; Pineau, P; Tiollais, P; Buendia, MA; Dejean, A				Nagai, H; Pineau, P; Tiollais, P; Buendia, MA; Dejean, A			Comprehensive allelotyping of human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatitis; loss of heterozygosity; microsatellite markers; tumor suppressor genes	TUMOR-SUPPRESSOR GENE; B VIRUS INTEGRATION; FREQUENT LOSS; P53 GENE; HETEROZYGOSITY; CANCER; RETINOBLASTOMA; PROGRESSION; DNA; IDENTIFICATION	Hepatocellular carcinoma (HCC) is one of the most common cancers in many parts of the world, however the molecular mechanisms underlying liver cell transformation remain obscure. A genome-wide scan of loss of heterozygosity (LOH) in tumors provides a powerful tool to search for genes involved in neoplastic processes, To identify recurrent genetic alterations in liver tumors, we examined DNAs isolated from 120 HCCs and their adjacent non tumorous parts for LOH using a collection of 195 microsatellite markers located roughly every 20cM throughout 39 autosomal arms, The mean heterozygosity was 73%, Our findings provide additional support that LOH for loci on chromosomal arms 1p, 4q, 6q, 8p, 13q and 16p is significantly elevated in HCC. The highest percentage of LOH is found for a locus in 8p23 (42% of informative csaes), This corresponds to one of the most common genetic abnormalities reported to date in these tumors. In addition, high ratio of LOH (greater than or equal to 35%) is observed on chromosome arms which had not been implicated in previous studies, notably on 1q, 2q and 9q, No correlation was found between LOH of specific chromosomal regions and etiologic factors such as chronic infections with hepatitis B or C viruses. This first report of an extensive allelotypic analysis of HCC should help in identifying new genes whose loss of function contributes to the development of liver cancer.	INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,INSERM U163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Dejean, Anne/L-5145-2018; Pineau, Pascal/AAP-5614-2020	Pineau, Pascal/0000-0002-9407-1592				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 1995, DNA TUMOR VIRUSES ON, P171; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COX DW, 1995, CYTOGENET CELL GENET, V69, P160; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUJIWARA Y, 1993, CANCER RES, V53, P857; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEARLY E, 1995, GENE CHROMOSOME CANC, V12, P152; Hermanek P, 1987, TNM CLASSIFICATION M; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAGAI H, 1994, CANCER RES, V54, P1545; RANFORD DM, 1995, CANCER RES, V55, P3399; SLAGLE BL, 1991, CANCER RES, V51, P49; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TAKITA J, 1995, ONCOGENE, V11, P1829; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VIGNAL A, 1993, METHODS MOL GENETICS, V1; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEH SH, 1994, CANCER RES, V54, P4188; ZHANG X, 1994, CANCER RES, V54, P4177	39	270	284	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2927	2933		10.1038/sj.onc.1201136	http://dx.doi.org/10.1038/sj.onc.1201136			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205099				2022-12-28	WOS:A1997XF55500006
J	Acton, D; Jacobs, H; Domen, J; Berns, A				Acton, D; Jacobs, H; Domen, J; Berns, A			Bcl2 reduces lymphomagenesis in Delta V-TCR beta transgenic mice	ONCOGENE			English	Article						Bcl-2; T-cell receptor; T-cell development; lymphomagenesis; tumor suppression	CELLS; INHIBITION; EXPRESSION; CLONING; GROWTH; IL-7	Overexpression of the bcl-2 oncogene in the lymphoid compartment of transgenic mice prolongs the lifespan of lymphocytes and leads to a low incidence of lymphomas at later age. Transgenic mice carrying a mutated T-cell receptor lacking the variable domain (Delta V-TCR beta) suffer from lymphocyte depletion and are highly predisposed to lymphoma development. We intercrossed Bcl-2-Ig and Delta V-TCR beta transgenic mice to assess whether Bcl-2 could synergize with Delta V-TCR beta in tumorigenesis as reported previously for other oncogenes. Surprisingly, bitransgenic Delta V-TCR beta; bcl-2-Ig mice showed a reduction in the incidence of lymphomas. Analyses of prelymphomatous mice showed that Bcl-2 restored some of the phenotypic aberrations caused by the Delta V-TCR beta transgene in the lymphoid compartment. The inhibitory activity of Bcl-2 on Delta VTCR beta-induced lymphomagenesis was not observed when both transgenes were crossed into the RAG-1(-/-) background suggesting an important role for more mature lymphocytes in this phenomenon. These results show that, depending on the specific conditions, overexpression of Bcl-2 can both promote as well as impair lymphoma development.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CARROZZA ML, IN PRESS ONCOGENE; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Jacobs H, 1996, ONCOGENE, V12, P2089; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; LEE G, 1989, J IMMUNOL, V142, P3875; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; SMETS LA, 1994, BLOOD, V84, P1613; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vairo G, 1996, ONCOGENE, V13, P1511	25	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2497	2501		10.1038/sj.onc.1201089	http://dx.doi.org/10.1038/sj.onc.1201089			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191049				2022-12-28	WOS:A1997XA94900001
J	Lacy, S; Whyte, P				Lacy, S; Whyte, P			Identification of a p130 domain mediating interactions with cyclin A cdk2 and cyclin E cdk2 complexes	ONCOGENE			English	Review						cell cycle; p130; cyclins; cdk	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGENS; CELL-CYCLE; SUSCEPTIBILITY GENE; PROTEIN-KINASE; POTENTIAL MEDIATOR; GROWTH SUPPRESSION; TUMOR SUPPRESSION	P130 shares structural and functional homology with pRb and p107. One property common to p107 and p130, but not to pRb, is the ability to stably interact with cyclin A/cdk2 and cyclin E/cdk2 complexes in vitro and in vivo. Using GST-p130 fusion proteins representing various regions of p130, baculovirus-produced cyclin A/ cdk2 and cyclin E/cdk2 complexes were found to interact with residues within a part of p130 known as the spacer region. Cyclin E was able to bind the p130 spacer region in the presence or absence of cdk2 whereas cyclin A binding was dependent upon the presence of cdk2. The smallest p130 fusion protein sufficient to interact with cyclin A/cdk2 or cyclin E/cdk2 complexes contained p130 amino acids 652-698 and deletion of p130 amino acids 680-682 abolished binding to both of the cyclin/cdk2 complexes. When overexpressed in C33A cells, a p130 mutant containing a deletion of amino acids 620-697 was unable to form complexes with either cyclin A or cyclin E. This p130 mutant was at least as active as wild type p130 in suppressing the growth of G418 resistant colonies when overexpressed in C33A or SAOS-2 cells.	MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, HAMILTON, ON L8S 4K1, CANADA	McMaster University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCK V, 1995, ONCOGENE, V11, P31; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1995, ONCOGENE, V11, P801; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WOLF DA, 1995, ONCOGENE, V10, P2067; WU CL, 1995, MOL CELL BIOL, V15, P2536; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZAKUT R, 1995, ONCOGENE, V11, P393; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	105	55	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2395	2406		10.1038/sj.onc.1201085	http://dx.doi.org/10.1038/sj.onc.1201085			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188854				2022-12-28	WOS:A1997WZ68000003
J	Moriyama, M; Yamochi, T; Semba, K; Akiyama, T; Mori, S				Moriyama, M; Yamochi, T; Semba, K; Akiyama, T; Mori, S			BCL-6 is phosphorylated at multiple sites in its serine- and proline-clustered region by mitogen-activated protein kinase (MAPK) in vivo	ONCOGENE			English	Article						BCL-6; MAP kinase; transcription factor; zinc finger; BTB/POZ; phosphorylation	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; DNA-BINDING ACTIVITY; LARGE-CELL LYMPHOMA; C-FOS PROMOTER; CENTER B-CELLS; TRANSCRIPTION FACTOR; GROWTH-FACTOR; ZINC FINGERS; DOMAIN	BCL-6 gene alterations have been observed in 27-45% of diffuse large B-cell lymphomas (DLBs) with chromosomal translocations at 3q27. The deregulated expression of normal BCL-6 protein caused by this chromosomal translocation is believed to be responsible for lymphomagenesis. Recently, we demonstrated that BCL-6 is expressed at high levels in germinal center B-cells as a 92-98 kDa nuclear protein in a constitutively phosphorylated form. In this study, we show that BCL-6 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro at the sites phosphorylated in vivo. These numerous phosphorylation sites were found to be located in its serine- and proline-clustered (SPC) region (amino acids-250-483). BCL-6 phosphorylation significantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6- and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059. Furthermore, we observed that BCL-6 was associated with MAPK in vivo and its SPC region was important for this association. These results suggest that the functions of BCL-6 are regulated by phosphorylation mediated by the MAPK signaling pathway.	UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, TOKYO 108, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, OSAKA 565, JAPAN	University of Tokyo; Osaka University	Moriyama, M (corresponding author), UNIV TOKYO, INST MED SCI, DEPT PATHOL, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhordain P, 1995, ONCOGENE, V11, P2689; DIBELLO PR, 1991, GENETICS, V129, P385; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIKI T, 1994, BLOOD, V83, P26; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO VN, 1994, ONCOGENE, V9, P1855; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1991, J BIOL CHEM, V266, P23521; Seyfert VL, 1996, ONCOGENE, V12, P2331; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; YAMOCHI T, IN PRESS LEUKEMIA; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	55	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2465	2474		10.1038/sj.onc.1201084	http://dx.doi.org/10.1038/sj.onc.1201084			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188861	Bronze			2022-12-28	WOS:A1997WZ68000010
J	Chlichlia, K; Busslinger, M; Peter, ME; Walczak, H; Krammer, PH; Schirrmacher, V; Khazaie, K				Chlichlia, K; Busslinger, M; Peter, ME; Walczak, H; Krammer, PH; Schirrmacher, V; Khazaie, K			ICE-proteases mediate HTLV-I tax-induced apoptotic T-cell death	ONCOGENE			English	Article						HTLV-I; tax; ER; inducible; apoptosis; CD95; APO-1; Fas; CD95 ligand; ICE	VIRUS TYPE-I; TUMOR-NECROSIS-FACTOR; FAS-LIGAND; MONOCLONAL-ANTIBODY; E1A PROTEINS; HIV-1 TAT; LEUKEMIA; ACTIVATION; LYMPHOCYTES; INDUCTION	The Tax protein of Human T-cell leukemia virus type 1 (HTLV-1) is important for the T-cell immortalizing properties of this virus in vitro and is considered to be responsible for the early stages of leukemogenesis in infected hosts, Tax can upregulate expression of TNF-alpha and TNF-beta, as well as potentiate apoptosis in activated T-cells and in serum starved murine fibroblasts. To examine the role of CD95 (APO-1/Fas) and ICE-proteases in Tax-mediated active T-cell death, Jurkat T cells expressing (APO(S)) or lacking (APO(R)) cell surface expression of CD95 (APO-1/Fas) were genetically modified to express hormone-inducible HTLV-1 Tax constructs, Hormone-inducible action of Tax alone was sufficient to promote programmed cell death in CD95-expressing Jurkat T-cell clones, In contrast, clones lacking CD95 surface expression were resistant to the antiproliferative action of Tax, Both APOS and APOR clones exhibited Tax-dependent upregulation of CD95 ligand and TNF-alpha. Blocking experiments suggested that while the apoptotic action of Tax critically required ICE-protease function it was largely independent of cell surface interaction of CD95 Ligand or TNF-alpha with their corresponding receptors, These observations strongly implicate ICE-proteases in Tax-induced T-cell death, and suggest a possible involvement of CD95 in this process.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; UNIV HEIDELBERG,DEPT SURG,SECT MOL DIAGNOST & THERAPY,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Ruprecht Karls University Heidelberg			Chlichlia, Katerina/Q-3948-2019; Walczak, Henning/AAV-2214-2020; Busslinger, Meinrad J./J-1249-2016	Walczak, Henning/0000-0002-6312-4591; Busslinger, Meinrad J./0000-0002-9111-9351; Peter, Marcus Ernst/0000-0003-3216-036X; Chlichlia, Katerina/0000-0003-4952-0675				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7197; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHLICHLIA K, 1995, ONCOGENE, V10, P269; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; DEBATIN KM, 1993, BLOOD, V81, P2972; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FUJITA M, 1995, ONCOGENE, V11, P15; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Guyot DJ, 1996, J ACQ IMMUN DEF SYND, V11, P317, DOI 10.1097/00042560-199604010-00001; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KALDEN JR, 1994, CLIN EXP IMMUNOL, V98, P1, DOI 10.1111/j.1365-2249.1994.tb06597.x; LASTER SM, 1988, J IMMUNOL, V141, P2629; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SETO K, 1995, ACTA NEUROPATHOL, V89, P483; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHACHLER E, 1989, BLOOD, V73, P194; TSCHACHLER E, 1993, BLOOD, V81, P95; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YIP MT, 1990, MOL BIOL MED, V7, P33; YOSHIKI Y, 1995, PHYTOCHEMISTRY, V38, P229, DOI 10.1016/0031-9422(94)00571-A; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	50	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2265	2272		10.1038/sj.onc.1201070	http://dx.doi.org/10.1038/sj.onc.1201070			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178902				2022-12-28	WOS:A1997WY88300003
J	Delia, D; Goi, K; Mizutani, S; Yamada, T; Aiello, A; Fontanella, E; Lamorte, G; Iwata, S; Ishioka, C; Krajewski, S; Reed, JC; Pierotti, MA				Delia, D; Goi, K; Mizutani, S; Yamada, T; Aiello, A; Fontanella, E; Lamorte, G; Iwata, S; Ishioka, C; Krajewski, S; Reed, JC; Pierotti, MA			Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations	ONCOGENE			English	Article						p53; p21(wafl); p34(CDC2); cell cycle; apoptosis	TUMOR-SUPPRESSOR P53; DNA-DAMAGING AGENTS; EPSTEIN-BARR-VIRUS; HUMAN B-CELLS; P53-DEPENDENT APOPTOSIS; THYMOCYTE APOPTOSIS; BCL-2 FAMILY; BINDING-SITE; BAX GENE; IN-VITRO	The radiation response was investigated in two lymphoblastoid cell lines (LBC) derived from families with heterozygous germ-line missense mutations of p53 at codon 282 (LBC282) and 286 (LBC286), and compared to cells with wt/wt p53(LBC-N). By gel retardation assays, we show that p53-containing nuclear extracts from irradiated LBC282 and LBC286 markedly differ in their ability to bind to a p53 DNA consensus sequence, the former generating a shifted band whose intensity is 30-40% that of LBC-N, the latter generating an almost undetectable band. Unlike LBC286, which fail to arrest in G(1) after irradiation, LBC282 have an apparently normal G(1)/S checkpoint, as they arrest in G(1) like LBC-N. While in LBC-N, accumulation of p53 and transactivation of p21(WAF1) increase rapidly and markedly by 3 h after exposure to gamma-radiation, in LBC286 there is only a modest accumulation of p53 and a significantly delayed and quantitatively reduced transactivation of p21(WAF1). Instead, in LBC282 while p53 levels rise little after irradiation, p21(WAF1) levels increase rapidly and significantly as in normal LBC. Apoptotic cells present 48 h after irradiation account for 32% in LBC-N, 8-9% in LBC282 and 5-7% in LBC286, while the dose of gamma-radiation required for killing 50% of cells (LD50) is 400 rads, 1190 rads and 3190 rads, respectively, hence indicating that the heterozygous mutations of p53 at codon 282 affects radioresistance and survival, but not the G(1)/S cell cycle control. In all LBC tested, radiation-induced apoptosis occurs in all phases of the cell cycle and appears not to directly involve changes in the levels of the apoptosis-associated proteins bcl-2, bax and mcl-1. Both basal as well as radiation-induced p53 and p21(WAF1) proteins are detected by Western blotting of FACS-purified G(1), S and G(2)/M fractions from the three cell lines. p34(CDC2-Tyr15), the inactive form of p34(CDC2) kinase phosphorylated on Tyr15, is found in S and G(2)/M fractions, but not in G(1). However, 24 h after irradiation, its levels in these fractions diminish appreciably in LBC-N but not in the radioresistant LBC286 and LBC282. Concomitantly, p34(CDC2) histone H1 kinase activity increases in the former, but not in the latter cell lines, hence suggesting a role for this protein in radiation-induced cell death. Altogether, this study shows that, in cells harbouring heterozygous mutations of p53, the G, checkpoint is not necessarily disrupted, and this may be related to the endogenous p53 heterocomplexes having lost or not the capacity to bind DNA (and therefore transactivate target genes). Radiation-induced cell death is not cell cycle phase specific, does not involve the regulation of bcl-2, bax or mcl-1, but is associated with changes in the phosphorylation state and activation of p34(CDC2) kinase.	NATL CHILDRENS MED RES CTR, DEPT VIROL, SETAGAYA KU, TOKYO 154, JAPAN; FONDAZ MATARELLI, MILAN, ITALY; TOHOKU UNIV, INST DEV AGING & CANC, AOBA KU, SENDAI, MIYAGI 980, JAPAN; BURNHAM INST, CTR CANC RES, LA JOLLA, CA 92037 USA	National Center for Child Health & Development - Japan; Tohoku University; Sanford Burnham Prebys Medical Discovery Institute	Delia, D (corresponding author), IST NAZL TUMORI, DIV OSA, VIA VENEZIAN 1, I-20133 MILAN, ITALY.		Aiello, Antonella/C-3290-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Aiello, Antonella/0000-0002-1932-7113; Pierotti, Marco Alessandro/0000-0002-7431-8332; Lamorte, Giuseppe/0000-0001-9377-7537	NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Davis P, 1996, ONCOGENE, V13, P1315; DELIA D, 1993, CANCER RES, V53, P6036; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; FAN SJ, 1994, CANCER RES, V54, P5824; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FOURNEL S, 1995, FEBS LETT, V367, P188, DOI 10.1016/0014-5793(95)00532-E; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kitada S, 1996, ONCOGENE, V12, P187; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PELLOQUIN F, 1986, IN VITRO CELL DEV B, V22, P689; Pocard M, 1996, ONCOGENE, V12, P875; REYNOLDS JE, 1994, CANCER RES, V54, P6348; ROLLEY N, 1995, ONCOGENE, V11, P763; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; Thomas A, 1996, ONCOGENE, V12, P1055; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WADA H, 1994, LEUKEMIA, V8, P53; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	59	49	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2137	2147		10.1038/sj.onc.1201050	http://dx.doi.org/10.1038/sj.onc.1201050			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174049	Green Published			2022-12-28	WOS:A1997WX93800002
J	Bunone, G; Mariotti, A; Compagni, A; Morandi, E; DellaValle, G				Bunone, G; Mariotti, A; Compagni, A; Morandi, E; DellaValle, G			Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells	ONCOGENE			English	Article						NGF receptors; apoptosis; neuroblastoma; tumor progression	NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; TRK PROTOONCOGENE; N-MYC; NEURONAL DIFFERENTIATION; INVERSE RELATIONSHIP; SIGNAL-TRANSDUCTION; RET PROTOONCOGENE; EXPRESSION; SYSTEM	The low-affinity nerve growth factor receptor p75(NTR) belongs to a membrane receptor superfamily whose members, in certain cell types, are able to transduce an apoptotic signal. To investigate the effect of p75(NTR) expression in neuroblastoma cells, we transfected the p75(NTR) CDNA into SK-N-BE cells, a neuroblastoma cell line that lacks expression of both p75(NTR) and TrkA. Cell clones expressing elevated levels of p75(NTR) showed a high degree of cell death by apoptosis, even in serum-supplemented medium. Moreover, the level of apoptosis correlated directly with the expression lever of the receptor, indicating that p75(NTR) could activate the cell death program by itself. Clones expressing p75(NTR) showed a dramatic increase of cell death when switched into serum-free medium; these cultures rapidly extinguished. This apoptotic effect was greatly inhibited by NGF treatment. Our results support the hypothesis that p75(NTR), when it is not bound by NGF, may play a role in neuronal selection during embryonic development and suggest that neuroblastomas may arise from immature neuroblasts that escape programmed cell death. Therefore, the loss of p75(NTR) expression in developing neural crest cells might be a primary event in the genesis of neuroblastoma.	UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY; UNIV BOLOGNA,DEPT BIOL,I-40126 BOLOGNA,ITALY	University of Pavia; University of Bologna				Mariotti, Agnese/0000-0002-3704-7908; compagni, amelia/0000-0003-1744-3134				AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BIEDLER JL, 1973, CANCER RES, V33, P2643; BONGARZONE I, 1994, CANCER RES, V54, P2979; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1990, ONCOGENE, V5, P437; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Frade JM, 1996, NATURE, V383, P166; GUIN GH, 1969, AM J CLIN PATHOL, V51, P126; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kinnier-Wilson LM, 1974, BRIT MED J, V3, P301; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, DEVELOPMENT, V120, P1027; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Peverali FA, 1996, ONCOGENE, V12, P457; PFLUG BR, 1992, CANCER RES, V52, P5403; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1	46	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1463	1470		10.1038/sj.onc.1200972	http://dx.doi.org/10.1038/sj.onc.1200972			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136990				2022-12-28	WOS:A1997WT58400009
J	Volpert, OV; Dameron, KM; Bouck, N				Volpert, OV; Dameron, KM; Bouck, N			Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity	ONCOGENE			English	Article						neovascularization; fibrosarcoma; VEGF; thrombospondin; tumor progression	ENDOTHELIAL GROWTH-FACTOR; SOFT-TISSUE SARCOMAS; WILD-TYPE P53; N-RAS; MALIGNANT PROGRESSION; EXPRESSION; THROMBOSPONDIN; ABNORMALITIES; INHIBITOR; CELLS	As normal cells progress to malignancy they must acquire an angiogenic phenotype that will enable them to attract the blood vessels necessary to support their progressive growth. Here we define the mechanism by which human fibroblasts cultured from Li Fraumeni patients and progressing to tumorigenicity in vitro become angiogenic. Initially cells were anti-angiogenic due to the secretion of high levels of inhibitory thrombospondin that overrode the modest amounts of the major inducer, vascular endothelial cell growth factor (VEGF), that were also produced. Cells became fully angiogenic in two steps, the first dependent on the loss of both alleles of wild-type p53 which caused a drop of at least 20-fold in secreted thrombospondin and a fourfold increase in secreted VEGF. Angiogenic activity increased again upon transformation by activated ras due to a further twofold increase in VEGF. Changes in relative levels of VEGF mRNA were sufficient to account for changes in secreted protein levels and in overall angiogenic activity. These studies demonstrate that an angiogenic phenotype able to support tumorigenicity can arise in a step-wise fashion in response to both oncogene activation and tumor suppressor gene loss and involve both a decrease in the secretion of inhibitors and the sequential ratcheting up of the secretion of inducers of angiogenesis.	NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center					NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDEOL Y, 1988, INT J CANCER, V41, P732, DOI 10.1002/ijc.2910410516; ANDREASSEN A, 1993, CANCER RES, V53, P468; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P138; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; Folkman J, 1995, MOL BASIS CANC, P206; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEACH FS, 1993, CANCER RES, V53, P2231; MAILLET MW, 1992, MODERN PATHOL, V5, P410; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; POLLOCK RE, 1994, SEMIN SURG ONCOL, V10, P315, DOI 10.1002/ssu.2980100503; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAK J, 1995, CANCER RES, V55, P4575; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEIMEISTER G, 1996, CANCER RES, V56, P2299; STRATTON MR, 1989, CANCER RES, V49, P6324; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; TANAKA T, 1986, CANCER RES, V46, P1465; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	32	170	187	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1495	1502		10.1038/sj.onc.1200977	http://dx.doi.org/10.1038/sj.onc.1200977			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136993				2022-12-28	WOS:A1997WT58400012
J	Moretti, F; Farsetti, A; Soddu, S; Misiti, S; Crescenzi, M; Filetti, S; Andreoli, M; Sacchi, A; Pontecorvi, A				Moretti, F; Farsetti, A; Soddu, S; Misiti, S; Crescenzi, M; Filetti, S; Andreoli, M; Sacchi, A; Pontecorvi, A			p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells	ONCOGENE			English	Article						p53; tumor suppressor gene; differentiation; thyroid carcinoma	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; G(1) ARREST; MUTANT P53; MUTATIONS; GROWTH; PROTEIN; TRANSFORMATION; THYROTROPIN; INDUCTION	Alterations of the tumor suppressor gene p53 are uncommon in differentiated thyroid neoplasia but are detected at high frequency in anaplastic thyroid carcinoma suggesting that impaired p53 function may contribute to the undifferentiated and highly aggressive phenotype of these tumors, Effects of wild type p53 (wt-p53) re-expression were investigated in a human anaplastic thyroid carcinoma cell line (ARO) expressing a mutated p53, ARO cells were stably transfected with the temperature-sensitive p53 Val(135) gene (ts-p53) which exhibits wild type-like activity at 32 degrees C, Exogenous wt-p53 function in ARO-tsp53 clones was assessed by evaluating its transcriptional activity on a CAT reporter vector containing p53 binding sites, At 32 degrees C, a significant reduction in the proliferation rate (congruent to 50%) was observed, with accumulation of cells in the G(0)/G(1) phase of the cell cycle, This effect was accompanied by induction of the expression of the growth inhibitor p21/Waf1 gene, At 32 degrees C, ARO-tsp53 clones also showed a marked impairment of their tumorigenic potential, Furthermore, transfected clones re-acquired the ability to respond to thyrotropin (TSH) stimulation showing an increased expression of thyroid-specific genes (thyroglobulin, thyroperoxidase and TSH receptor), In conclusion, re-expression of wt-p53 activity in ARO cells, inhibits cell proliferation and restores responsiveness to physiological stimuli.	REGINA ELENA INST CANC RES,MOL ONCOGENESIS LAB,ROME,ITALY; CNR,INST EXPT MED,ROME,ITALY; UNIV ROMA LA SAPIENZA,CHAIR ENDOCRINOL 2,ROME,ITALY; UNIV CATANZARO,CHAIR ENDOCRINOL,CATANZARO,ITALY; CATHOLIC UNIV ROME,INST MED PATHOL,ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Magna Graecia University of Catanzaro; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Crescenzi, Marco/J-3603-2018; Soddu, Silvia/K-2467-2018; Farsetti, Antonella/I-8710-2018; Soddu, Silvia/ABH-6774-2020; Moretti, Fabiola/I-5647-2013	Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Farsetti, Antonella/0000-0002-8603-7925; Soddu, Silvia/0000-0001-8526-0044; Moretti, Fabiola/0000-0002-2691-1254				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BATTISTA S, 1995, ONCOGENE, V11, P2029; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Fagin JA, 1996, CANCER RES, V56, P765; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FAGIN JA, 1994, THYROID TODAY, V17, P1; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUBER GK, 1992, ENDOCRINOLOGY, V130, P2858, DOI 10.1210/en.130.5.2858; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INGBAR S H, 1985, P682; ITO T, 1992, CANCER RES, V52, P1369; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIMURA H, 1992, EXP CELL RES, V203, P402, DOI 10.1016/0014-4827(92)90014-Y; LAMPARIELLO F, 1991, CYTOMETRY, V12, P343, DOI 10.1002/cyto.990120409; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; NAMBA H, 1992, ENDOCRINOLOGY, V132, P839; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PROKOCIMER M, 1994, BLOOD, V84, P2391; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WRIGHT PA, 1991, ONCOGENE, V6, P1693; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [No title captured]	51	112	115	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					729	740		10.1038/sj.onc.1200887	http://dx.doi.org/10.1038/sj.onc.1200887			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038381	Green Published, Bronze			2022-12-28	WOS:A1997WG43000012
J	Gartenhaus, RB				Gartenhaus, RB			Allelic loss determination in chronic lymphocytic leukemia by immunomagnetic bead sorting and microsatellite marker analysis	ONCOGENE			English	Article						allelic losses; chronic lymphocytic leukemia; microsatellite markers	CELL LUNG-CANCER; LYMPHOBLASTIC-LEUKEMIA; HOMOZYGOUS DELETION; CHROMOSOME-3; LYMPHOMAS; REGION; GENES; ARM	Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. Details of the molecular mechanisms involved in the pathogenesis of this leukemia are unclear at present. In other malignancies tumorigenesis has been shown to proceed via a multistep progression model with a causal relation between the accumulation of genetic abnormalities and more aggressive clinical behavior. The loss of chromosomal segments in malignant cells has proven useful in mapping regions of DNA that contain candidate tumor suppressor genes. The detection of loss of heterozygosity (LOH) has been greatly facilitated by the analysis of highly polymorphic microsatellite markers enabling the identification of submicroscopic losses. Utilizing immunomagnetic bead sorting to separate leukemic from normal cells we identified at least one allelic losses in 8/29 (28%) of analysed CLL cases with a PCR-based assay. On chromosomal arm 3p we have identified homozygous deletions in 3/29 cases at locus D3S1284 residing in the vicinity of the newly described FHIT gene. Several cases of CLL manifested LOH at a locus telomeric to the p15 and p16 tumor suppressor genes, all being early to intermediate stage disease. Our findings suggest that losses at these loci may contribute to the development and/or progression of CLL in at least a subset of cases.			Gartenhaus, RB (corresponding author), ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL,ONCOL MOL LAB,PHILADELPHIA,PA 19102, USA.							BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Califano J, 1996, CANCER RES, V56, P2488; CHAGANTI SR, 1995, GENE CHROMOSOME CANC, V12, P32, DOI 10.1002/gcc.2870120106; DALY MC, 1993, ONCOGENE, V8, P1721; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENAUX P, 1992, LEUKEMIA, V6, P246; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; Gartenhaus R, 1996, BLOOD, V87, P38; Gartenhaus RB, 1996, J MOL MED-JMM, V74, P143, DOI 10.1007/BF01575446; GIADANO G, 1991, P NATL ACAD SCI USA, V88, P5413; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANNAMHARRIS A, 1984, P AM ASSOC CANC RES, V25, P157; JULIUSSON G, 1990, NEW ENGL J MED, V323, P710; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MERLO A, 1994, CANCER RES, V54, P640; NOWELL PC, 1988, CANCER GENET CYTOGEN, V33, P155, DOI 10.1016/0165-4608(88)90025-8; OBRIEN S, 1995, BLOOD, V85, P307; OFFIT K, 1994, BLOOD, V83, P2608; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OTSUKI T, 1995, CANCER RES, V55, P1436; PARSA NZ, 1994, GENE CHROMOSOME CANC, V9, P8; RAGHOEBIER S, 1991, BLOOD, V77, P1560; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; RUPPERT JM, 1993, CANCER RES, V53, P5093; SCHENA M, 1992, BLOOD, V79, P2981; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Thiagalingam S, 1996, CANCER RES, V56, P2936	32	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					375	378		10.1038/sj.onc.1200867	http://dx.doi.org/10.1038/sj.onc.1200867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018124				2022-12-28	WOS:A1997WD51600014
J	Watson, DK; Robinson, L; Hodge, DR; Kola, I; Papas, TS; Seth, A				Watson, DK; Robinson, L; Hodge, DR; Kola, I; Papas, TS; Seth, A			FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements	ONCOGENE			English	Article						ETS; FLI1; EWS-FLI1; Egr1; ternary complex factor (TCF); quaternary complex factor (QCF); CArG box; SRE	EWS/FLI-1 FUSION GENE; DNA-BINDING MOTIF; ETS DOMAIN; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; SECONDARY STRUCTURE; ONCOGENIC ACTIVITY; REGULATORY FACTOR; MURINE ETS-1	The ETS gene products are a family of transcriptional regulatory proteins that contain a highly conserved and structurally unique DNA binding domain, termed the ETS domain. Several ETS proteins bind to DNA as monomers, however it has been shown that the DNA binding activity is enhanced or modulated in the presence of other factors. By differential display and whole genome PCR techniques, we have recently shown that the Erg1 gene is a target for ETS proteins. The Egr1 promoter contains multiple ETS binding sites, three of which exist as parts of two serum response elements (SREI and SREII). The SRE is a cis-element that regulates the expression of many growth factor responsive genes. ELK1 and SAP1a have been shown to form ternary complexes with SRF on the SRE located in the c-fos promoter. Similarly, we examined whether the ELK1, SAP1a, FLI1, EWS-FLI1, ETS1, ETS2, PEA3 and PU.1 proteins can form ternary complexes with SRF on the Egr1 SREI and II. Our results demonstrate that indeed ELK1, SAP1a, FLI1 and EWS-FLI1 are able to form ternary complexes with SRF on Egr1 SREs. In addition, ELK1 and SAP1a can also form quarternary complexes on the Egr1 SRE1. However, the proteins ETS1, ETS2, PEA3 and PU.1 were unable to form ternary complexes with SRF on either the Egr1 or c-fos SREs. Our data demonstrate that FLI1 and EWS-FLI1 constitute new members of a subgroup of ETS proteins that can function as ternary complex factors and further implicate a novel function for these ETS transcription factors in the regulation of the Egr1 gene. By amino acid sequence comparison we found that, in fact, 50% of the amino acids present in the B-box of SAP1a and ELK1, which are required for interaction with SRF, are identical to those present in both FLI1 (amino acids 231-248) and EWS-FLI1 proteins. This B-box is not present in ETS1, ETS2, PEA3 or PU.1 and these proteins were unable to form ternary complexes with SRF and Egr1-SREs or c-fos SRE. Furthermore, deletion of 194 amino terminal amino acids of FLI1 did not interfere with its ability to interact with SRF, in fact, this truncation increased the stability of the ternary complex. The FLI1 protein has a unique R-domain located next to the DNA binding region. This R-domain may modulate the interaction with SRF, providing a mechanism that would be unique to FLI1 and EWS-FLI1, thus implicating a novel function for these ETS transcription factors in the regulation of the Egr1 gene.	UNIV TORONTO, MRC, GRP PERIODONTAL PHYSIOL, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, LAB MOL PATHOL, TORONTO, ON M5S 1B2, CANADA; MED UNIV S CAROLINA, CTR MOL & STRUCT BIOL, CHARLESTON, SC 29425 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ONCOL MOL LAB, FREDERICK, MD 21702 USA; MONASH UNIV, MOL GENET & DEV GRP, MELBOURNE, VIC 3168, AUSTRALIA	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Monash University			Kola, Ismail/C-5254-2013					ASCIONE R, 1992, INT J ONCOL, V1, P631; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bhat NK, 1996, INT J ONCOL, V8, P841; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHNO T, 1993, CANCER RES, V53, P5859; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qi S., 1992, DNA Sequence, V3, P127, DOI 10.3109/10425179209034008; ROBINSON L, 1995, MIAMI SHORT REPORTS, V6, P76; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Zhang XK, 1995, HYBRIDOMA, V14, P563, DOI 10.1089/hyb.1995.14.563	49	93	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					213	221		10.1038/sj.onc.1200839	http://dx.doi.org/10.1038/sj.onc.1200839			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010223				2022-12-28	WOS:A1997WC81800009
J	Gopalkrishnan, RV; Dolle, P; Mattei, MG; LaThangue, NB; Kedinger, C				Gopalkrishnan, RV; Dolle, P; Mattei, MG; LaThangue, NB; Kedinger, C			Genomic structure and developmental expression of the mouse cell cycle regulatory transcription factor DP1	ONCOGENE			English	Article						DP1; E2F; cell cycle; genomic structure; mouse chromosome; in situ hybridisation	E2F FAMILY; FACTOR DRTF1/E2F; IN-VIVO; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; SUPPRESSOR GENES; MAMMALIAN-CELLS; BINDING PROTEIN; MEMBER; DNA	The E2F/DP family of transcription factors play an important role in the control of cell cycle progression. By direct regulatory interactions with the retinoblastoma family of proteins, they integrate extracellular growth promoting signals impinging on the cyclin and cyclin dependent kinase complex during the G(1) phase, with cell cycle progression. This is accomplished by direct transcriptional activation of genes required for nucleotide biosynthesis and DNA replication in the S phase, In addition, these transcription factors also play a role in the control of genes involved in regulating G(1) and S phase progression including, autoregulatory control, as in the case of E2F1 itself, In this report, we describe the characterisation of the genomic locus encoding DP1, a member of this family, The DP1 gene has a TATA-less promoter and transcription initiates at multiple sites. Using transient transfection assays we have delineated sequences in the upstream region which have promoter or enhancer activity. The DP1 gene was localised to mouse chromosome 8 by metaphase chromosome analysis, We describe a dynamic pattern of DP1 expression using in situ hybridisation on cryostat sections of mouse embryos at various stages of development and a variable level of expression by Northern blot analysis of RNA from various adult tissues.	INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED TIMONE,INSERM U406,F-13385 MARSEILLE,FRANCE; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Glasgow			Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOCCO JL, 1993, ONCOGENE, V8, P2977; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCK V, 1995, ONCOGENE, V11, P31; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Decimo D, 1996, GENE PROBES PRACTICA, P183; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANA X, 1995, ONCOGENE, V11, P211; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MIRONOV VN, 1995, NUCLEIC ACIDS RES, V23, P3359, DOI 10.1093/nar/23.16.3359; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; OSWALD F, 1994, ONCOGENE, V9, P2029; PASTEAU S, 1995, ONCOGENE, V11, P1475; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	69	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2671	2680						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000141				2022-12-28	WOS:A1996VZ65400017
J	Wang, HL; Xie, ZR; Scott, RE				Wang, HL; Xie, ZR; Scott, RE			JunD phosphorylation, and expression of AP-1 DNA binding activity modulated by serum growth factors in quiescent murine 3T3T cells	ONCOGENE			English	Article						JunD; AP-1; cell proliferation; phosphorylation; transcription factors	C-JUN; PROTEINS; TRANSFORMATION; KINASE; GENE; FOS; ACTIVATION; FAMILY; RAS; DIFFERENTIATION	JunD has been implicated as a negative regulator of cell proliferation, If and how JunD is regulated by growth factors however has not been well investigated, We now report that in quiescent murine 3T3T cells, JunD is present in a hypophosphorylated form, but that when quiescent cells are stimulated to proliferate with serum, JunD undergoes a transient increase in its phosphorylation that occurs within 10 min and persists for up to 4 h, The increase in JunD phosphorylation correlates with the induction of cell proliferation since only those growth factors that promote cell proliferation can induce JunD phosphorylation, Treatment of quiescent 3T3T cells with serum also induces significant decreases in JunD/AP-1 DNA binding activity within 2 h and in JunD expression after 8-48 h, However, both hypophosphorylated and hyperphosphorylated forms of JunD can bind AP-1 DNA, These results suggest that serum growth factors can modulate JunD characteristics in a variety of apparently independent ways to overcome its negative regulatory effect in controlling cell proliferation, These include induction of a transient increase in JunD phosphorylation, repression of JunD AP-1 DNA binding activity and downregulation of JunD expression.	UNIV TENNESSEE,COLL MED,DEPT PATHOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; DIAMOND L, 1977, NATURE, V269, P247, DOI 10.1038/269247a0; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOERL BJ, 1989, J CELL PHYSIOL, V139, P68, DOI 10.1002/jcp.1041390111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarrigue S, 1995, BIOCHEM BIOPH RES CO, V217, P501, DOI 10.1006/bbrc.1995.2804; LASKY SR, 1995, J BIOL CHEM, V270, P19676, DOI 10.1074/jbc.270.34.19676; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Neyns B, 1996, ONCOGENE, V12, P1247; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REZZONICO R, 1995, ONCOGENE, V11, P1069; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; WANG HL, 1994, P NATL ACAD SCI USA, V91, P4649, DOI 10.1073/pnas.91.11.4649; WANG HL, 1991, CELL GROWTH DIFFER, V2, P645; WANG HL, 1991, J CELL PHYSIOL, V147, P102, DOI 10.1002/jcp.1041470114; Wang HL, 1995, MOL CELL BIOCHEM, V153, P59, DOI 10.1007/BF01075919; YE ZS, 1987, J BIOL CHEM, V262, P6313	37	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2639	2647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000138				2022-12-28	WOS:A1996VZ65400014
J	Todd, MC; Xiang, RH; Garcia, DK; Kerbacher, KE; Moore, SL; Hensel, CH; Liu, P; Siciliano, MJ; Kok, K; vandenBerg, A; Veldhuis, P; Buys, CHCM; Killary, AM; Naylor, SL				Todd, MC; Xiang, RH; Garcia, DK; Kerbacher, KE; Moore, SL; Hensel, CH; Liu, P; Siciliano, MJ; Kok, K; vandenBerg, A; Veldhuis, P; Buys, CHCM; Killary, AM; Naylor, SL			An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo	ONCOGENE			English	Article						tumor suppressor gene; small cell lung cancer; human chromosome 3; positional cloning; homozygous deletion	CELL LUNG-CANCER; POLYMERASE CHAIN-REACTION; SHORT ARM; HOMOZYGOUS DELETION; DNA-SEQUENCE; ALLELIC LOSS; OVARIAN-CANCER; CARCINOMA; LINE; GENE	High frequencies of allelic loss on the short arm of chromosome 3 in small cell lung cancer (SCLC) and a number of other tumors suggest the existence of a tumor suppressor gene(s) within the deleted regions. Two small cell lung cancer lines, NCI H740 and GLC20, have been described which have homozygous deletions in the region 3p21.3. The deleted region overlaps with a 2 Mb fragment of human DNA present in the interspecies hybrid HA(3)BB9F, that suppresses tumor formation by mouse A9 fibrosarcoma cells. Human sequences from this cell hybrid were isolated using inter Alu PCR. From this starting point, a P1 contig was developed for the region of 450 Kb that is common to the homozygous deletions seen in the SCLC lines NCI H740 and GLC20 and is also present in HA(3)BB9F, the suppressed A9 hybrid. Individual P1 clones were assayed for their ability to suppress the tumorigenicity of the mouse fibrosarcoma cell line A9 as assayed by injection of transfected A9 cells into athymic nude mice. The introduction of one of the P1 clones into A9 cells resulted in suppression of tumor growth whereas two other P1 clones from the contig failed to suppress tumor formation in athymic nude mice. These data functionally delimit a tumor suppressor locus to a region of 80 kb within a P1 clone at 3p21.3.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; MD ANDERSON CANC INST,DEPT MOL GENET,HOUSTON,TX 77030; MD ANDERSON CANC INST,DEPT LAB MED,HOUSTON,TX 77030; UNIV GRONINGEN,DEPT MED GENET,GRONINGEN,NETHERLANDS	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Groningen			van den Berg, Anke/H-1718-2011; Liu, Paul/A-7976-2012; todd, martin/I-4143-2015	van den Berg, Anke/0000-0002-8894-2638; Liu, Paul/0000-0002-6779-025X; Moore, Shanna/0000-0001-5578-8868	NCI NIH HHS [CA54174, CA56626] Funding Source: Medline; PHS HHS [H600470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056626, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; ELNAGGAR AK, 1993, CANCER, V72, P881, DOI 10.1002/1097-0142(19930801)72:3<881::AID-CNCR2820720337>3.0.CO;2-Q; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HANSEN MF, 1987, P NATL ACAD SCI USA, V84, P9059; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; JONES MH, 1992, ONCOGENE, V7, P1631; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KRAUS C, 1994, GENOMICS, V23, P272, DOI 10.1006/geno.1994.1493; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1992, CANCER RES, V52, P1451; LEACH RJ, 1994, GENOMICS, V24, P549, DOI 10.1006/geno.1994.1665; LEDBETTER SA, 1990, GENOMICS, V6, P475, DOI 10.1016/0888-7543(90)90477-C; LIDEREAU R, 1989, J NATL CANCER I, V81, P1815; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LIU P, 1993, CANCER GENET CYTOGEN, V65, P93, DOI 10.1016/0165-4608(93)90213-6; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; POPESCU NC, 1988, CANCER RES, V48, P142; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RIMESSI P, 1994, ONCOGENE, V9, P3467; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIMIZU M, 1990, ONCOGENE, V5, P185; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG A, IN PRESS CYTOGENET C; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOTA J, 1988, ONCOGENE, V3, P471; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	56	52	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2387	2396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957080				2022-12-28	WOS:A1996VX10800011
J	Byrne, JL; Paterson, HF; Marshall, CJ				Byrne, JL; Paterson, HF; Marshall, CJ			p21Ras activation by the guanine nucleotide exchange factor Sos, requires the Sos/Grb2 interaction and a second ligand-dependent signal involving the Sos N-terminus	ONCOGENE			English	Article						hSos; Grb2; p21Ras; signal transduction	NERVE GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; PC12 CELLS; KINASE ACTIVATION; RAS; MEMBRANE; DIFFERENTIATION; MICROINJECTION; TRANSDUCTION; SEVENLESS	It has been suggested that a key event in growth factor-induced p21Ras activation by the guanine nucleotide exchange factor Sos, is the recruitment of Sos to the plasma membrane by its interaction with the adaptor protein Grb2. However, other evidence argues that the sub cellular localisation of Sos is independent of Grb2, and that the Sos/Grb2 interaction can be dispensed with for p21Ras activation. To clarify the role of the Sos/Grb2 interaction in ligand-stimulated p21Ras activation, we have utilised the observation that overexpression of the Sos C-terminal domain can effectively inhibit p21Ras-dependent signalling in three different mammalian systems. We have shown that concurrent expression of Grb2, but not SH2 or SH3 domain mutants of Grb2, or the alternative adaptor protein Nck, can rescue this inhibitory effect: of the C-terminus. This shows that the Grb2/Sos interaction is required to mediate growth factor-dependent activation of p21Ras, and requires the presence of intact SH2 and SH3 domains of Grb2. This approach was also used for a functional analysis of Sos which revealed that growth factor dependent signals are transmitted through both the N-terminal and C-terminal domains.	INST CANC RES,CHESTER BEATTY LABS,CANC RES CAMPAIGN,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Byrne, Jenny/0000-0002-9381-1851				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU Q, 1995, MOL CELL BIOL, V88, P189; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRONK GJ, 1993, J BIOL CHEM, V268; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294	39	38	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2055	2065						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950972				2022-12-28	WOS:A1996VV14500002
J	Linke, SP; Harris, MP; Neugebauer, SE; Clarkin, KC; Shepard, HM; Maneval, DC; Wahl, GM				Linke, SP; Harris, MP; Neugebauer, SE; Clarkin, KC; Shepard, HM; Maneval, DC; Wahl, GM			p53-mediated accumulation of hypophosphorylated pRb after the G(1) restriction point fails to halt cell cycle progression	ONCOGENE			English	Article						p53; pRb; restriction point; DNA damage; Glarrest	RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; DNA-BINDING; G1 PHASE; TRANSCRIPTIONAL ACTIVITY; SV40-TRANSFORMED CELLS; SUSCEPTIBILITY GENE; DEPENDENT KINASES	This study analyses whether the inability of p53 to induce G(1) arrest after the restriction point relates to an inability to modulate pRb phosphorylation. Transient p53 overexpression in normal human diploid fibroblasts and p53-deficient cancer cells led to increased levels of the cyclin-dependent kinase inhibitor p21(Cip1/Waf1/Sdi1) and an accumulation of hypophosphorylated pRb in cells growing asynchronously and in cells synchronized in late G(1) or M. Similarly, gamma-irradiation of asynchronous, late-G(1), or S phase fibroblasts led to an increase in hypophosphorylated pRb. Experiments with fibroblasts expressing the HPV16 E6 protein indicated that accumulation of hypophosphorylated pRb required functional p53. Progression into and through S phase was not altered by the presence of hypophosphorylated pRb in late G(1), consistent with the failure of p53 to mediate G(1) arrest in cells that are past the restriction point. These data indicate that accumulation of hypophosphorylated pRb has significantly different effects on cell cycle progression in early G(1) versus late G(1) or S phase.	SALK INST BIOL STUDIES, GENE EXPRESS LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; CANJI INC, SAN DIEGO, CA 92121 USA	Salk Institute; University of California System; University of California San Diego				Linke, Steven/0000-0001-8584-4947				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harris MP, 1996, CANCER GENE THER, V3, P121; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hecker D, 1996, ONCOGENE, V12, P953; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McMasters KM, 1996, ONCOGENE, V13, P1731; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RIEDER CL, 1992, J CELL SCI, V102, P387; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLS KN, 1995, CANCER GENE THER, V2, P191; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	76	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					337	345		10.1038/sj.onc.1201200	http://dx.doi.org/10.1038/sj.onc.1201200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233768				2022-12-28	WOS:A1997XK99900010
J	Strobel, T; Swanson, L; Korsmeyer, S; Cannistra, SA				Strobel, T; Swanson, L; Korsmeyer, S; Cannistra, SA			Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells	ONCOGENE			English	Article						apoptosis; p53; BAX; radiation; ovarian; cancer	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; IN-VIVO; BCL-2; DEATH; GENE; RADIOSENSITIVITY; CHECKPOINT; INDUCTION	The p53 protein is known to play a central role in mediating G(1) arrest or apoptosis in response to ionizing radiation in some cell types, It has been proposed that the Link between p53 and induction of apoptosis is provided in part by p53-mediated upregulation of BAX. In this study, we used the human SW626 ovarian cancer cell line, which lacks functional p53, to further investigate the relationship between wildtype p53, BAX, and apoptosis, SW626 cells expressing a temperature sensitive (ts) p53 mutant did not undergo G(1) arrest or apoptosis and did not exhibit enhanced sensitivity to radiation at the permissive temperature of 32 degrees C, The tsp53 protein was functional in these cells as evidenced by rapid induction of p21 at 32 degrees C, but not at 37 degrees C, Interestingly, restoration of wildtype p53 function at 32 degrees C was not associated with BAS upregulation. In addition, stable overexpression of BAX in SW626 cells was not capable of enhancing apoptotic cell death in response to radiation, Thus, failure of p53 to upregulate BAS is not the sole reason for its inability to promote radiation-induced apoptosis in SW626 cells, Taken together, our data suggest that neither p53 nor BAX upregulation is sufficient for the induction of apoptosis in response to genotoxic damage in some cell types.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,DIV MOL ONCOL,ST LOUIS,MO	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA060670] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1995, ONCOGENE, V11, P1921; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; HALDAR S, 1994, CANCER RES, V54, P2095; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU TJ, 1994, CANCER RES, V54, P3662; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	22	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2753	2758		10.1038/sj.onc.1201132	http://dx.doi.org/10.1038/sj.onc.1201132			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190890				2022-12-28	WOS:A1997XD64300002
J	Chen, J; Carey, K; Godowski, PJ				Chen, J; Carey, K; Godowski, PJ			Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation	ONCOGENE			English	Article						Gas6; Mer; Rse/Tyro3; Axl	DEPENDENT PROTEIN-S; HORMONE-BINDING GLOBULIN; ARREST-SPECIFIC GENE-6; EXPRESSION; AXL; PROTOONCOGENE; HOMOLOGY; DOMAINS; CLONING; FAMILY	Mer/Nyk/Eyk is an orphan receptor tyrosine kinase expressed at high levels in monocytes and cells derived from epithelial and reproductive tissues. Overexpression of Mer has been associated with lymphoid malignancies. Here we identify Gas6, the product of a growth arrest specific gene, as a ligand for Mer. Gas6 has previously been shown to activate both Axl and Rse/Tyro3, two other receptor tyrosine kinases in the same family as Mer. The apparent relative association and dissociation rate constants of Gas6 for soluble Axl, Rse/Tyro3 and Mer were compared using surface plasmon resonance. Gas6 was shown to induce rapid phosphorylation of Mer expressed in several different types of cells. We also observed a transient activation of p42 MAP kinase following activation of Mer by Gas6. Thus, Gas6 exerts its biological effects through multiple receptor tyrosine kinases.	GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BIESECKER LG, 1995, ONCOGENE, V10, P2239; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAI W, 1994, ONCOGENE, V9, P975; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GERSHAGEN S, 1987, FEBS LETT, V220, P129, DOI 10.1016/0014-5793(87)80890-6; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HAMMOND GL, 1987, FEBS LETT, V215, P101; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; LAI C, 1994, ONCOGENE, V9, P2567; Li RH, 1996, J NEUROSCI, V16, P2012; LING L, 1995, MOL CELL BIOL, V15, P6582; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; OHASHI K, 1994, ONCOGENE, V9, P669; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	37	146	159	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2033	2039		10.1038/sj.onc.1201039	http://dx.doi.org/10.1038/sj.onc.1201039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160883				2022-12-28	WOS:A1997WW80900005
J	Mashima, T; Naito, M; Noguchi, K; Miller, DK; Nicholson, DW; Tsuruo, T				Mashima, T; Naito, M; Noguchi, K; Miller, DK; Nicholson, DW; Tsuruo, T			Actin cleavage by CPP-32/apopain during the development of apoptosis	ONCOGENE			English	Article						CPP-32/apopain; ICE; actin; apoptosis	PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; GENE CED-3; CRMA GENE; ENCODES; TRANSFORMATION; PRODUCT; ICE	Interleukin-1 beta-converting enzyme (ICE)/ced-3 family proteases play key roles in apoptosis, However, cellular substrates for ICE family proteases involved in apoptosis are not well understood, We previously showed that actin is cleaved in vitro by an ICE family protease, distinct from ICE itself, which is activated during VP-16-induced apoptosis, In this report, we demonstrate that the actin-cleaving ICE-family protease in the apoptotic cell extract is the activated CPP-32/apopain. CPP-32 effectively cleaves actin protein to 15 kDa and 31 kDa fragments, Studies with an antibody raised against Gly-Gln-Val-Ile-Thr peptide, the N-terminal sequence of the cleaved 15 kDa actin fragment, showed that actin is also cleaved in vivo during the development of apoptosis, Moreover, Benzyloxycarbonyl-Glu-Val-Asp-CH2OC(O)-2,6,-dichlorobenzene (Z-EVD-CH2-DCB), a selective inhibitor of CPP-32(-like) protease, efficiently inhibited the cleavage of actin and the apoptosis of VP-16-treated U937 cells, Our present results indicate that actin is the substrate of CPP-32/apopain(-like) protease both in vitro and in vivo and suggest the role of actin in the control of cell growth and apoptosis.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BIOMED RES LAB, TOKYO 113, JAPAN; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, INFLAMMAT RES, RAHWAY, NJ 07065 USA; MERCK FROSST CTR THERAPEUT RES, QUEBEC CITY, PQ H9R 4P8, CANADA; JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, TOKYO 170, JAPAN	University of Tokyo; Merck & Company; Merck & Company; Japanese Foundation for Cancer Research								ANTECOL MH, 1986, CANCER RES, V46, P1867; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAKUNAGA T, 1984, FED PROC, V43, P2275; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Noguchi K, 1996, ONCOGENE, V13, P39; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDEKERCKHOVE J, 1980, CELL, V22, P893, DOI 10.1016/0092-8674(80)90566-8; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	218	223	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1007	1012		10.1038/sj.onc.1200919	http://dx.doi.org/10.1038/sj.onc.1200919			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070648				2022-12-28	WOS:A1997WM07000001
J	Mechta, F; Lallemand, D; Pfarr, CM; Yaniv, M				Mechta, F; Lallemand, D; Pfarr, CM; Yaniv, M			Transformation by ras modifies AP1 composition and activity	ONCOGENE			English	Article						AP1; cJun; Fra1; Ras; serum inducibility; transformation	SERUM RESPONSE ELEMENT; NIH 3T3 CELLS; TERNARY COMPLEX-FORMATION; JUN ACTIVATION DOMAIN; IMMEDIATE EARLY GENES; C-FOS EXPRESSION; PROTEIN-KINASE; GROWTH-FACTORS; TRANSCRIPTION FACTOR; CYCLIN D1	The Ras proteins play a central role in regulating cell growth and their mutation can lead to abnormal proliferation. To analyse the potential link betwen AP1 activity, encoded by members of the jun and fos gene families, and Ras-mediated cellular transformation, we have studied several NIH3T3 clones which overexpress the Ha-Ras or Ki-Ras oncogenes. These transformed fibroblasts accumulated higher levels of cJun, JunB, Fra1 and Fra2 proteins relative to their normal counterparts. They also displayed increased AP1 DNA binding activity which was predominantly composed of cJun and Fra1 containing diners. Following serum stimulation of Ras clones, the elevated levels of cJun and Fra1 remained steady,,while the induction of JunB and Fra2 was partially attenuated. Moreover, deregulated Ras signaling resulted in a complete loss of the serum inducibility of cFos and FosB. Ectopic co-expression of cJun and Fra1 in NIH3T3 fibroblasts led to a transformed phenotype, attenuation of cFos serum inducibility, increased AP1 activity and Cyclin D1 accumulation, all characteristics of oncogenic Ras expressing cells. These results demonstrate that cJun and Fra1 are crucial mediators of the Ras-transformation process.	INST PASTEUR, UNITE VIRUS ONCOGENES, URA 1644 CNRS, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			lallemand, dominique/O-7445-2017; Pfarr, Curt/HHD-1410-2022; MECHTA-GRIGORIOU, Fatima/C-5253-2017	lallemand, dominique/0000-0002-0212-7342; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSSLINGER M, 1994, INC, V10, P133; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1994, ONCOGENE, V9, P3627; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERBER, 1994, ONCOGENE, V9, P2105; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MECHTA F, 1989, New Biologist, V1, P297; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHONTHAL A, 1988, NATURE, V354, P325; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SEWING A, 1993, J CELL SCI, V104, P545; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	86	187	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					837	847		10.1038/sj.onc.1200900	http://dx.doi.org/10.1038/sj.onc.1200900			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047391				2022-12-28	WOS:A1997WJ11200010
J	deMedina, SGD; Chopin, D; ElMarjou, A; Delouvee, A; LaRochelle, WJ; Hoznek, A; Abbou, C; Aaronson, SA; Thiery, JP; Radvanyi, F				deMedina, SGD; Chopin, D; ElMarjou, A; Delouvee, A; LaRochelle, WJ; Hoznek, A; Abbou, C; Aaronson, SA; Thiery, JP; Radvanyi, F			Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; human; transitional cell carcinoma; tumor progression	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; LIGAND-BINDING SPECIFICITY; FGF RECEPTOR; K-SAM; TARGETED EXPRESSION; HUMAN KERATIN-18; CANCER; MOUSE; CLONING; FAMILY	Growth factors and growth factor receptors are involved in tumor progression, The fibroblast growth factor receptor 2 gene encodes distinct isoforms, The isoforms which bind KGF (keratinocyte growth factor or FGF-7) are called KGF-R or FGFR2b. KGF-R is expressed in different epithelia and is involved in the control of epithelial-mesenchymal interactions. Expression of KGF-R mRNA was examined in normal human bladder and transitional cell carcinoma of the bladder (TCC) by semi-quantitative RT-PCR using TFIID and GAPDH as internal standards, In normal bladder, the KGF-R mRNA was detected in the urothelium but not in the underlying stroma, In TCCs, the level of KGF-R mRNA was generally either normal or low, Eighteen out of 54 TCCs had a KGF-R mRNA level below 30% of that found in normal urothelium, This decrease in KGF-R mRNA was not accompanied by an increase in BEK (FGFR2c) mRNA, the other major splice variant of the fibroblast growth factor receptor 2 gene, Expression of the KGF-R was also monitored by immunohistochemistry using a functional KGF-immunoglobulin chimera, The receptor was uniformly expressed throughout the normal urothelium except for the umbrella cells, Immunoreactivity for KGF-R was found to be negative in tumors with low levels of KGF-R mRNA, while the peritumoral normal urothelium was positive, Among patients with muscle invasive tumors, those exhibiting a low level of HGF-R mRNA had a significantly higher proportion of cancer deaths, Our results suggest that decreased expression of KGF-R can be considered as a marker of tumor progression in muscle invasive TCCs.	INST CURIE, CNRS, UMR 144, F-75248 PARIS 05, FRANCE; CHU HENRI MONDOR, GRP ETUD TUMEURS UROL, CRCHM, F-94010 CRETEIL, FRANCE; CHU HENRI MONDOR, UROL SERV, F-94010 CRETEIL, FRANCE; NCI, NIH, BETHESDA, MD 20892 USA; MT SINAI SCH MED, RUTTENBERG CANC CTR, NEW YORK, NY USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai			Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DIONNE CA, 1992, CYTOGENET CELL GENET, V60, P34, DOI 10.1159/000133290; EISEMANN A, 1991, ONCOGENE, V6, P1195; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNOWLES MA, 1994, CANCER RES, V54, P531; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LI ZL, 1989, GENE, V78, P243; LORENZI MV, 1995, ONCOGENE, V10, P2051; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Mostofi FK, 1973, INT HISTOLOGICAL CLA; Nakagawara A, 1994, Prog Clin Biol Res, V385, P155; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SPIESSL B, 1992, ILLUSTRATED GUIDE TN, P214; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	55	75	76	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	1997	14	3					323	330		10.1038/sj.onc.1200830	http://dx.doi.org/10.1038/sj.onc.1200830			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018118				2022-12-28	WOS:A1997WD51600008
J	CollFresno, PM; Batoz, M; Tarquin, S; Birnbaum, D; Coulier, F				CollFresno, PM; Batoz, M; Tarquin, S; Birnbaum, D; Coulier, F			Cytotoxic activity of a diphtheria toxin/FGF6 mitotoxin on human tumour cell lines	ONCOGENE			English	Article						mitotoxin; fibroblast growth factor; tumour cell line; diphtheria toxin	FIBROBLAST GROWTH-FACTOR; FACTOR-PSEUDOMONAS EXOTOXIN; HEPARAN-SULFATE PROTEOGLYCANS; FACTOR-SAPORIN MITOTOXIN; BREAST-CARCINOMA CELLS; CYTO-TOXIC ACTIVITY; PHASE-I TRIAL; FUSION PROTEIN; SIGNAL TRANSDUCTION; MYCOSIS-FUNGOIDES	The FGFs constitute a family of, at least, 12 polypeptides (FGF1 to PGF12) implicated in a number of physiological and pathological processes throughout embryogenesis and adult life. They bind to at least three types of cell surface molecules, including four high affinity transmembrane tyrosine kinase receptors (FGFR1 to FGFR4). In addition to important roles during development, FGF involvement in pathological conditions, including tumour formation, has been suspected, and overexpression of FGFR in tumour specimens is well documented. Diphtheria Toxin/FGF6 (DT/FGF6) mitotoxin has been shown to selectively and effectively target FGFR1-expressing cells. We show here that DT/FGF6 targets myoblasts engineered to express either one of the four FGFR, as well as FGFR-expressing tumour cells.	INSERM,U119,MOL ONCOL LAB,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883				ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1991, ONCOGENE, V6, P659; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BATOZ M, 1995, CELL GROWTH DIFFER, V6, P1143; BEITZ JG, 1992, CANCER RES, V52, P227; BIRNBAUM D, 1991, ANN NY ACAD SCI, V638, P409, DOI 10.1111/j.1749-6632.1991.tb49055.x; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COULIER F, 1996, IN PRESS J MOL EVOL; Coulier Francois, 1994, Progress in Growth Factor Research, V5, P1, DOI 10.1016/0955-2235(94)90014-0; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; FOSS FM, 1994, BLOOD, V84, P1765; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; GAWLAK SL, 1993, BIOCONJUGATE CHEM, V4, P483, DOI 10.1021/bc00024a010; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HORLICK RA, 1992, GENE, V120, P291, DOI 10.1016/0378-1119(92)90108-2; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIHARA A, 1995, CANCER RES, V55, P71; KUZEL TM, 1993, LEUKEMIA LYMPHOMA, V11, P369, DOI 10.3109/10428199309067928; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; LUQMANI YA, 1995, INT J CANCER, V64, P274, DOI 10.1002/ijc.2910640411; MCLESKEY SW, 1994, CANCER RES, V54, P523; MERWIN JR, 1992, CANCER RES, V52, P4995; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pai L H, 1994, Important Adv Oncol, P3; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PLATANIAS LC, 1994, LEUKEMIA LYMPHOMA, V14, P257, DOI 10.3109/10428199409049676; QUARTO N, 1994, J CELL SCI, V107, P3201; RHOGANI M, 1994, J BIOL CHEM, V269, P3976; Siegall C B, 1990, Semin Cancer Biol, V1, P345; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1994, CANCER-AM CANCER SOC, V74, P1006, DOI 10.1002/1097-0142(19940801)74:3+<1006::AID-CNCR2820741506>3.0.CO;2-V; SIEGALL CB, 1994, BIOCONJUGATE CHEM, V5, P77, DOI 10.1021/bc00025a010; TEPLER I, 1994, CANCER-AM CANCER SOC, V73, P1276, DOI 10.1002/1097-0142(19940215)73:4<1276::AID-CNCR2820730424>3.0.CO;2-D; THEILLET C, 1989, ONCOGENE, V4, P915; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; XERRI L, 1991, AM J PATHOL, V138, P9; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YING WB, 1994, CANCER, V74, P848, DOI 10.1002/1097-0142(19940801)74:3<848::AID-CNCR2820740310>3.0.CO;2-J; ZHOU DJ, 1988, ONCOGENE, V2, P279	50	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					243	247		10.1038/sj.onc.1200826	http://dx.doi.org/10.1038/sj.onc.1200826			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010226				2022-12-28	WOS:A1997WC81800012
J	Lohrum, M; Scheidtmann, KH				Lohrum, M; Scheidtmann, KH			Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes	ONCOGENE			English	Review						tumor suppressor; p53; okadaic acid; phosphorylation; transactivation	TUMOR-SUPPRESSOR PROTEIN; LARGE-T-ANTIGEN; WILD-TYPE P53; DNA-BINDING FUNCTION; CASEIN KINASE-II; TRANSCRIPTIONAL ACTIVATION; OKADAIC ACID; P53-MEDIATED TRANSACTIVATION; CELLULAR PROTEINS; EXCISION-REPAIR	The tumor suppressor protein p53 is phosphorylated at multiple sites in the amino-terminal transactivation domain and at several sites in the carboxy-terminal region. Phosphorylation appears to modulate its DNA binding activity. Here we demonstrate that phosphorylation of p53 also modulates its transcriptional activity. Okadaic acid treatment of cells resulted in enhanced phosphorylation of p53 and concomitantly in enhanced transactivation of an mdm2 promoter-linked luciferase reporter gene. This effect was cell type specific, however, since transactivation was enhanced in rat and mouse fibroblasts but reduced in the human Saos-2 cell line. Moreover, the effect was dependent on the promoter. In rat cells transcription from the mdm2, waf1 (cip1) and bar gene promoters, and the artificial PG13 promoter was enhanced by okadaic acid treatment whereas that from the cyclin G promoter was reduced. When various phosphorylation site mutants of p53 were tested for transactivation of these promoters, they behaved differently. Amino-terminal mutants exhibited reduced transcriptional activities on mdm2, waf1 and cyclin G promoters but enhanced activities with bar and PG13 promoters. On the other hand, a mutant at the cdk phosphorylation site, A313, showed reduced activity with mdm2 and waf1 promoters but enhanced activity with the cyclin G promoter, and finally, mutant A390 exhibited enhanced activity on waf1 and bar promoters, but reduced activity on the cyclin G promoter. These results suggest that phosphorylation of p53 may have different effects on its transcriptional activity, depending on the cellular environment and the particular response element. Moreover, both, amino- and carboxy-terminal phosphorylation sites seem to be involved in modulating the DNA-binding and the transactivation activities.	UNIV BONN,INST GENET,ABT MOL GENET,D-53117 BONN,GERMANY	University of Bonn								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; APPEL K, 1995, ONCOGENE, V11, P1971; APPEL K, 1994, INT J ONCOL, V5, P667; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1994, ONCOGENE, V9, P3249; FORRESTER K, 1995, ONCOGENE, V10, P2103; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUALBERTO A, 1995, J BIOL CHEM, V270, P16980; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARPER JW, 1993, CELL, V75, P805; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JAMAL S, 1995, ONCOGENE, V10, P2095; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1992, BIOCHEM J, V287, P1; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller BF, 1996, ONCOGENE, V12, P1941; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; OROURKE RW, 1990, ONCOGENE, V5, P1829; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PERREM K, 1995, ONCOGENE, V11, P1299; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SCHONTHAL A, 1991, ONCOGENE, V6, P423; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIIO Y, 1993, ONCOGENE, V8, P2059; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STRUZBECHER HW, 1996, EMBO J, V15, P1992; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WAGNER P, 1994, INT J ONCOL, V4, P987; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YATSUNAMI J, 1993, CANCER RES, V53, P239; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, CANCER RES, V54, P4448; ZHANG W, 1994, ONCOGENE, V9, P2513; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	121	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2527	2539						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000127				2022-12-28	WOS:A1996VZ65400003
J	Mayo, LD; Berberich, SJ				Mayo, LD; Berberich, SJ			Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation	ONCOGENE			English	Article						mdm-2; p53; F9 cellular differentiation	DNA-BINDING; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TUMOR-SUPPRESSOR; EXPRESSION; SEQUENCE; ONCOGENE; CYCLE; CHECKPOINT; GROWTH	In this study, we set out to assess whether the p53 protein affects mdm-2 gene expression as F9 embryonal carcinoma cells differentiate into parietal endoderm cells. It was previously reported that F9 cells possess abundant levels of wild-type p53 and upon induction to differentiate, p53 mRNA and protein levels decrease (Oren et at, 1982; Deny et al., 1985). We demonstrate that while p53 mRNA and protein levels decrease as F9 cells differentiate, mdm-2 mRNA and protein expression remains constitutive. Using RNA primer extension assays, we determined that the mdm-2 mRNA expression is not directed by p53 in either F9 embryonal (undifferentiated) or parietal endoderm (differentiated) cells. However, p53 protein does stimulate mdm-2 mRNA expression in response to u.v. irradiation. The inability of p53 to transactivate mdm-2 in undamaged F9 cells was not the result of latent pools as p53 sequence specific DNA binding activity was observed using electrophoretic mobility shift assays. Our results suggest that, in F9 cells, the p53:Mdm-2 autoregulatory loop is confined to pathways governing DNA damage.	WRIGHT STATE UNIV,DEPT BIOCHEM & MOL BIOL,DAYTON,OH 45435	Wright State University Dayton								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; BERBERICH S, 1992, ONCOGENE, V7, P775; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHUANG SE, 1994, BIOTECHNIQUES, V17, P634; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1994, ONCOGENE, V9, P3321; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Shaw P, 1996, ONCOGENE, V12, P921; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2315	2321						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957072				2022-12-28	WOS:A1996VX10800003
J	Rousseau, D; Gingras, AC; Pause, A; Sonenberg, N				Rousseau, D; Gingras, AC; Pause, A; Sonenberg, N			The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth	ONCOGENE			English	Article						malignant transformation; cap binding protein; translation inhibitors	CAP-BINDING-PROTEIN; EUKARYOTIC INITIATION FACTOR-4E; RAT EMBRYO FIBROBLASTS; 5' NONCODING REGION; TRANSLATION INITIATION; MALIGNANT TRANSFORMATION; SECONDARY STRUCTURE; ADIPOSE-TISSUE; FACTOR 4E; PHOSPHORYLATION	Initiation in eukaryotes is the rate limiting step of translation. The binding of the mRNA to the 40S ribosomal subunit, which is mediated by the mRNA cap structure, is a key target for control of protein synthesis. The cap binding protein, eIF4E, is the most limiting of all initiation factors and its overexpression in NIH3T3 cells causes malignant transformation. 4E-binding protein 1 (BP1) and 4E-BP2 are small proteins that bind to eIF4E and inhibit translation, Here, 4E-BPs were expressed in cells transformed by eIF4E or by v-src to determine the effect of 4E-BPs on cell growth and tumorigenicity. We show that 4E-BPs cause a significant reversion of the transformed phenotype. Thus, we demonstrate that the eIF4E-binding proteins act as negative regulators of cell growth. We propose that 4E-BPs are members of a class of negative regulators of cell growth acting on the translation machinery of the cell.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University			Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEGG AE, 1988, CANCER RES, V48, P759; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245	38	201	214	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2415	2420						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957083				2022-12-28	WOS:A1996VX10800014
J	Cahill, MA; Peter, ME; Kischkel, FC; Chinnaiyan, AM; Dixit, VM; Krammer, PH; Nordheim, A				Cahill, MA; Peter, ME; Kischkel, FC; Chinnaiyan, AM; Dixit, VM; Krammer, PH; Nordheim, A			CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases	ONCOGENE			English	Article						CD95 (APO-1/FAS); DISC; MAP kinase; apoptosis; signal transduction	TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; INTERLEUKIN-1-BETA CONVERTING-ENZYME; FACTOR RECEPTOR SUPERFAMILY; ACTIN STRESS FIBERS; PROTEIN-KINASE; INDUCED APOPTOSIS; FAS ANTIGEN; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS	Triggering of CD95 (APO-1/Pas) on different T- and B-cell lines resulted in the induction of a number of kinases (35 kDa, 38 kDa, 46 kDa and 54 kDa) that phosphorylate c-Jun and to a lesser extent Histone H1. Activation of these kinases was independent of protein biosynthesis and preceded apoptotic DNA degradation. The kinase activation pattern was specific for CD95 triggering since a variety of physical or chemical inducers of T- and B-cell apoptosis activated different kinases. The kinase activities at 46 and 54 kDa contained members of the stress-activated family of protein kinases (JNK/SAPK). Activation of the CD95-specific set of kinases was prevented by treating cells with the ICE-inhibiting peptide N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (zVAD-fmk) or by overexpression of the cow pox virus serpin CrmA. However, despite inhibition of ICE-like proteases the death signal was readily initiated at the cell membrane since a CD95 death-inducing signaling complex (DISC) was formed. Thus, our results demonstrate that ICE-like proteases in the CD95 pathway function downstream of the DISC but upstream of SAP kinases.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY; GERMAN CANC RES CTR,DIV IMMUNOGENET,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	Hannover Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012; CAHILL, Michael/J-8035-2012	dixit, vishva m/0000-0001-6983-0326; CAHILL, Michael/0000-0002-8593-8844; Peter, Marcus Ernst/0000-0003-3216-036X				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIJAWAKI T, 1992, J IMMUNOL, V149, P3753; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; PETER ME, 1995, CELL DEATH DIFFER, P163; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SCHULZEOSTHOFF K, 1996, IN PRESS CELL DEATH, V3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SKOWRONSKI EW, 1996, IN PRESS CELL GROWTH; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	76	123	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2087	2096						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950975				2022-12-28	WOS:A1996VV14500005
J	Lee, SH; Fujita, N; Mashima, T; Tsuruo, T				Lee, SH; Fujita, N; Mashima, T; Tsuruo, T			Interleukin-7 inhibits apoptosis of mouse malignant T-lymphoma cells by both suppressing the CPP32-like protease activation and inducing the Bcl-2 expression	ONCOGENE			English	Article						interleukin-7; Bcl-2; ICE-family proteases; apoptosis; T-lymphoma	NODE STROMAL CELLS; DEATH GENE CED-3; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; IL-1-BETA-CONVERTING ENZYME; MONOCLONAL-ANTIBODIES; MURINE INTERLEUKIN-7; ICE/CED-3 PROTEASE; CONVERTING-ENZYME; MAMMALIAN HOMOLOG	Mouse malignant T-lymphoma CS-21 cells grow in vitro in the presence of CA-12 lymph node stromal cells, but they undergo apoptotic cell death when separated from CA-12 stromal cells. In the course of examining the nursing effects of CA-12 stromal cells, we found that these cells provided some soluble factors that suppressed CS-21 cell apoptosis. We recently found that cysteine was an antiapoptotic soluble factor. In this report, we identify interleukin-7 (IL-7) as another antiapoptotic soluble factor secreted by CA-12 stromal cells. Although the activity of CPP32-like protease was increased in induction of CS-21 cell apoptosis, the addition of IL-7 suppressed the activity. The expression of Bcl-2 protein was down-regulated when CS-21 cells were cultured alone, but the addition of IL-7 recovered the expression of Bcl-2. These results indicate that CA-12 stromal cells inhibit CS-21 cell apoptosis by producing IL-7, which leads to the suppression of CPP32-like protease activation and the expression of Bcl-2 protein.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research			Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; Lee, Sang-Han/0000-0002-2343-7315				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORZILLO GV, 1992, ONCOGENE, V7, P869; Boulakia CA, 1996, ONCOGENE, V12, P529; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FUJITA N, 1993, CANCER RES, V53, P5022; FUJITA N, 1995, CELL GROWTH DIFFER, V6, P355; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HANAOKA K, 1995, CANCER RES, V55, P2186; HERNANDEZCASELLES T, 1995, HUM IMMUNOL, V43, P181, DOI 10.1016/0198-8859(94)00168-P; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KATAOKA S, 1993, EXP CELL RES, V207, P271, DOI 10.1006/excr.1993.1193; KERR JFR, 1974, J CELL SCI, V14, P571; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE SH, 1995, BIOCHEM BIOPH RES CO, V213, P837, DOI 10.1006/bbrc.1995.2205; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NEITO MA, 1989, J IMMUNOL, V143, P4166; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SAKATA T, 1990, J LEUKOCYTE BIOL, V48, P205, DOI 10.1002/jlb.48.3.205; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shimizu S, 1996, ONCOGENE, V12, P2251; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TSURUO T, 1988, CLIN EXP METASTAS, V6, P141, DOI 10.1007/BF01784845; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	58	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2131	2139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950980				2022-12-28	WOS:A1996VV14500010
J	Feitelson, MA; Ranganathan, PN; Clayton, MM; Zhang, SM				Feitelson, MA; Ranganathan, PN; Clayton, MM; Zhang, SM			Partial characterization of the woodchuck tumor suppressor, p53, and its interaction with woodchuck hepatitis virus X antigen in hepatocarcinogenesis	ONCOGENE			English	Article						woodchuck hepatitis virus; p53; X-antigen; hepatocarcinogenesis	HUMAN HEPATOCELLULAR CARCINOMAS; TATA-BINDING PROTEIN; B-VIRUS; C-MYC; TRANSCRIPTIONAL ACTIVITY; CARRIER PATIENTS; DNA INTEGRATION; TRANSGENIC MICE; LIVER-CANCER; HBX PROTEIN	Full length cDNAs for p53 were made by reverse transcription-polymerase chain reaction of total RNA from two normal woodchuck livers. Two randomly chosen clones from each liver were sequenced and shown to be identical. This sequence revealed 80% or more identity with p53 sequences from human, monkey, and mouse. The cDNA was translated into a similar to 55 kD protein in vitro that was immunoprecipitated by antibodies to p53. Cotranslation of woodchuck p53 with woodchuck hepatitis virus X antigen, followed by immunoprecipitation suggested X/p53 complex formation. Similar complexes were also immunoprecipitated from extracts of infected liver, but not from uninfected liver. The finding of X/p53 complexes in vivo and in vitro in the woodchuck hepadnavirus system, combined with analogous data with hepatitis B, suggests a common mechanism by which these viruses contribute to hepatocellular transformation.			Feitelson, MA (corresponding author), THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107, USA.				NCI NIH HHS [CA48656] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048656, R01CA048656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FEITELSON MA, 1990, GASTROENTEROLOGY, V98, P1071, DOI 10.1016/0016-5085(90)90035-Y; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 1993, J HEPATOL, V17, pS24, DOI 10.1016/S0168-8278(05)80420-9; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hansen RS, 1996, ONCOGENE, V13, P995; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; LEE HS, 1988, HEPATOLOGY, V8, P1116, DOI 10.1002/hep.1840080524; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NATOLI G, 1994, ONCOGENE, V9, P2837; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RIVKINA MB, 1994, CANCER RES, V54, P5430; ROBINSON WS, 1994, ANNU REV MED, V45, P297; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SU Q, 1994, HEPATOLOGY, V19, P788; SUMMERS J, 1981, HEPATOLOGY, V1, P179, DOI 10.1002/hep.1840010215; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WANG J, 1992, ONCOGENE, V7, P1653; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZAHM P, 1988, ONCOGENE, V3, P169; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	57	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					327	336		10.1038/sj.onc.1201203	http://dx.doi.org/10.1038/sj.onc.1201203			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233767				2022-12-28	WOS:A1997XK99900009
J	Zhang, YW; Bae, SC; Takahashi, E; Ito, Y				Zhang, YW; Bae, SC; Takahashi, E; Ito, Y			The cDNA cloning of the transcripts of human PEBP2 alpha A/CBFA1 mapped to 6p12.3-p21.1, the locus for cleidocranial dysplasia	ONCOGENE			English	Article						PEBP2 alpha A/CBFAl; 6p21; cleidocranial dysplasia	ACUTE MYELOID-LEUKEMIA; FLUORESCENCE INSITU HYBRIDIZATION; RUNT DOMAIN; AML1 GENE; FAMILY; EXPRESSION; PROTEIN; LOCALIZATION	PEBP2/CBF is a heterodimeric transcription factor composed of alpha and beta subunits. There are at least three closely related genes, PEBP2 alpha A/Cbfa1, AML1/PEBP2 alpha B/Cbfa2 and PEBP2 alpha C/Cbfa3, encoding the alpha subunit and one beta subunit encoding gene. Structural alterations of AML1 and the beta subunit gene by chromosome translocations are frequently associated with several types of human leukemia. Structural changes of any of these gene products would have potential to affect the function of others. In this study, we isolated the human PEBP2 alpha A cDNA by which we mapped the gene to 6p12.3-p21.1. Human chromosome 6p21 is the locus for cleidocranial dysplasia, an autosomal dominant bone disease. Recent gene disruption study revealed that PEBP2 alpha A/Cbfa1 plays an essential role in osteogenesis (Komori et al., Cell, 1997, in press). Therefore, a close relationship between human PEBP2 alpha A/CBFA1 and this bone disease is strongly implicated.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; CHUNGBUK NATL UNIV,COLL MED,CHONJU 360763,SOUTH KOREA; NATL INST RADIOL SCI,DIV GENET,INAGE KU,CHIBA 263,JAPAN	Kyoto University; Chungbuk National University; National Institutes for Quantum Science & Technology								Ahn MY, 1996, GENE, V168, P279, DOI 10.1016/0378-1119(95)00751-2; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; COLLING G, 1996, MOL CELL BIOL, V16, P932; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; ITO Y, IN PRESS ONCOGENES T; JARVIS JL, 1974, AM J ROENTGENOL, V121, P5, DOI 10.2214/ajr.121.1.5; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOMORI T, 1997, IN PRESS CELL; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1996, ANN NY ACAD SCI, V785, P301, DOI 10.1111/j.1749-6632.1996.tb56290.x; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; NIKIK M, 1997, IN PRESS P NATL ACAD; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WIJIMENGA C, 1995, GENOMICS, V26, P611; ZHANG YW, 1997, IN PRESS MOL CELL BI, V17	38	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					367	371		10.1038/sj.onc.1201352	http://dx.doi.org/10.1038/sj.onc.1201352			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233771				2022-12-28	WOS:A1997XK99900013
J	Ueno, H; Honda, H; Nakamoto, T; Yamagata, T; Sasaki, K; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H				Ueno, H; Honda, H; Nakamoto, T; Yamagata, T; Sasaki, K; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H			The phosphatidylinositol 3' kinase pathway is required for the survival signal of leukocyte tyrosine kinase	ONCOGENE			English	Article						leukocyte tyrosine kinase; phosphatydylinositol 3' kinase; c-Cbl; signal transduction	INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR-I; PHOSPHOTYROSINE-DEPENDENT INTERACTION; HEMATOPOIETIC-CELLS; SH2 DOMAINS; NPEY MOTIF; HUMAN LTK; C-CBL; PROTEIN; 3'-KINASE	Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase which belongs to the insulin receptor superfamily and is mainly expressed in pre-B lymphocytes and neuronal tissues, Recently, we demonstrated that LTK utilizes She and IRS-1 as two major substrates and while both equally activate the Ras pathway, only IRS-1 suppresses apoptosis of hematopoietic cells, suggesting the existence of another unidentified signaling pathway downstream of IRS-1, which is relevant to the anti-apoptotic activity, In the present study, we found that wortmannin, a specific inhibitor of phosphatidylinositol 3' (PI3)-kinase, abolished the survival effects of LTK. Although c-Cbl is found to be phosphorylated by LTK and therefore is a second candidate linking LTK with the P13-kinase pathway along with IRS-1, we found that the p85 subunit of PI3 kinase directly binds to tyrosine 753 of LTK, which is located within a YXXM motif, a consensus binding amino acid sequence for the SH2 domain of p85, but fails to bind to IRS-1 or c-Cbl. Ba/F3 cells which stably express the EGF receptor-LTK chimeric receptor carrying a mutation at tyrosine 753 fell into apoptotic death even in the presence of EGF, indicating that the PI3 kinase pathway is required for the survival effects of LTK.	UNIV TOKYO, DEPT INTERNAL MED 3, FAC MED, TOKYO 113, JAPAN	University of Tokyo								BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; MARU Y, 1990, ONCOGENE RES, V5, P199; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	26	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	1997	14	25					3067	3072		10.1038/sj.onc.1201153	http://dx.doi.org/10.1038/sj.onc.1201153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223670				2022-12-28	WOS:A1997XG10000009
J	Kapoun, AM; Shackleford, GM				Kapoun, AM; Shackleford, GM			Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice	ONCOGENE			English	Article						Fgf8; Wnt1; MMTV; oncogene cooperation; Fgf3; Fgf4; multistep tumorigenesis; growth factors	MESSENGER-RNA; GENE FAMILY; VIRUS; INT-2; EXPRESSION; ONCOGENE; CARCINOGENESIS; TUMORIGENESIS; INT-2/FGF-3; OUTGROWTH	Mouse mammary tumor virus (MMTV) is an insertional mutagen that has been demonstrated to transcriptionally activate flanking cellular proto-oncogenes. Previously we have used MMTV infection to accelerate mammary tumorigenesis in Wnt1 transgenic mice in order to identify genes that cooperate with the Wnt1 oncogene, Initial investigations into the resulting tumor collection, screened primarily by Southern analysis, showed that three fibroblast growth factor genes, Fgf8, Fgf3 and Fgf4, sustain activating insertion mutations in 10%, 42% and 6% of the tumors, respectively, Here, in an examination of the tumors from MMTV-infected Wnt1 transgenic mice that emphasizes Northern analysis, we report transcriptional activation of Fgf8 in 30 additional tumors (increasing the percentage of activations to 50%), while no significant changes in the activation frequency of Fgf3 or Fgf4 were found, To determine the frequency of insertional activation in normal mice, we examined tumors from MMTV-infected nontransgenic Littermates of the Wnt1 transgenics and from MMTV-infected BALB/c mice, Fgf8, Fgf3 and Fgf4 were found to be activated in 11%, 80% and 5%, respectively, of the tumors in the combined nontransgenic groups, Thus, there appears to be an increased predisposition for Fgf8 activations in Wnt1 transgenic mice versus normal mice, suggesting that cells expressing Wnt1 are especially sensitized to stimulation by FGF8 compared with FGF3 or FGF4, In contrast, the activation frequency of Fgf3 in tumors from MMTV-infected Wnt1 transgenic mice was approximately one-half that of normal mice, Our results show that this in vivo model of multistep tumorigenesis reveals significant differences in the activation rates of Fgf3 and Fgf8 depending upon the status of Wnt1 expression in the mammary gland, The differential activation of these Fgfs may relate to differences in their signaling pathways.	CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California; University of Southern California					NCI NIH HHS [CA58412, CA65104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065104, R01CA058412] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MACARTHUR CA, 1997, IN PRESS GENOMICS; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARCHETTI A, 1991, J VIROL, V65, P4550, DOI 10.1128/JVI.65.8.4550-4554.1991; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PETERS G, 1989, J VIROL, V63, P1448, DOI 10.1128/JVI.63.3.1448-1450.1989; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	28	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2985	2989		10.1038/sj.onc.1201146	http://dx.doi.org/10.1038/sj.onc.1201146			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205106	Green Published			2022-12-28	WOS:A1997XF55500013
J	Fichter, M; Hinrichs, R; Eissner, G; Scheffer, B; Classen, S; Ueffing, M				Fichter, M; Hinrichs, R; Eissner, G; Scheffer, B; Classen, S; Ueffing, M			Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C	ONCOGENE			English	Article						CD44; PI 3-kinase; PKC	PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR PROGRESSION; VARIANT ISOFORMS; GROWTH-FACTOR; RAS GENE; METASTASIS; DIFFERENTIATION; HYALURONATE; ACTIVATION; BINDING	With respect to a potential role for CD44 in neuronal tumors, we investigated the regulation of variant CD44 exon containing isoforms (CD44V) in the human neuroblastoma cell line SR-N-SH in response to treatment with differentiation-inducing and mitogenic factors, While the standard form of CD44 was expressed at high levels in both treated and untreated cells, variant isoforms were strongly upregulated in response to treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), insulinlike growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as shown by RT-PCR and immunofluorescence. One of the CD44 isoforms contains sequences encoded by variant exon v6 (CD44V6), which was originally described as a metastasis-associated antigen, Using specific inhibitors, me explored the signal transduction pathways involved in the expression of variant CD44, GF-109203X, a specific inhibitor of protein kinase C effectively blocked TPA- and IGF-1-upregulated expression of CD44v6, Wortmannin, a specific inhibitor of phosphoinositide 3-kinase (PI 3-kinase) partly reduced IGF-1 and PDGF induced CD44v6 expression, The induction of CD44V by TPA, IGF-1 or PDGF was correlated with an increased cellular binding to hyaluronic acid, a major counter receptor for CD44. The increased binding caused by TPA or IGF-1 could specifically be blocked by the above inhibitors, Thus, PKC and PI 3-kinase are likely to transduce growth factor induced signals that upregulate specific CD44 splice variants.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GMBH, NATL RES CTR ENVIRONM & HLTH, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich								ALLEN RW, 1987, J BIOL CHEM, V262, P649; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BLOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1995, EUR J CANCER, V31A, P541, DOI 10.1016/0959-8049(95)00030-M; CHRISTIANSEN H, 1995, KLIN PADIATR, V207, P219, DOI 10.1055/s-2008-1046543; COMBARET V, 1995, EUR J CANCER, V31A, P545, DOI 10.1016/0959-8049(95)00027-G; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; GROSS N, 1994, CANCER RES, V54, P4238; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1993, CANCER RES, V53, P1516; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KODAKI T, 1995, BIOCHEM SOC T, V23, pS195, DOI 10.1042/bst023195s; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; PAHLMAN S, 1992, CELL GROWTH DIFFER, V3, P783; PONTA H, 1994, INVAS METAST, V14, P82; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SADEE W, 1987, CANCER RES, V47, P5207; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; Sleeman JP, 1996, CANCER RES, V56, P3134; SOZERI O, 1992, ONCOGENE, V7, P2259; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; STAUDER R, 1995, IMMUNOLOGIST, V3, P78; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P79, DOI 10.1007/BF00269353; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UEFFING M, 1996, 3 HON KONG INT CANC, P80; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Zhu D, 1996, ONCOGENE, V12, P2309	49	40	40	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2817	2824		10.1038/sj.onc.1201127	http://dx.doi.org/10.1038/sj.onc.1201127			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190898				2022-12-28	WOS:A1997XD64300010
J	Takahashi, A; Hirata, H; Yonehara, S; Imai, Y; Lee, KK; Moyer, RW; Turner, PC; Mesner, PW; Okazaki, T; Sawai, H; Kishi, S; Yamamoto, K; Okuma, M; Sasada, M				Takahashi, A; Hirata, H; Yonehara, S; Imai, Y; Lee, KK; Moyer, RW; Turner, PC; Mesner, PW; Okazaki, T; Sawai, H; Kishi, S; Yamamoto, K; Okuma, M; Sasada, M			Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8	ONCOGENE			English	Article						apoptosis; apoptotic cell death; YV(bio)KD-aomk; serpin; Jurkat T cells	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TUMOR NECROSIS FACTOR; POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; MEDIATED APOPTOSIS; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; INHIBITION; CLEAVAGE	The activation of multiple interleukin-1 beta converting enzyme-related proteases (caspases) in apoptotic mammalian cells raises questions as to whether the multiple active caspases have distinct roles in apoptotic execution as well as how these proteases are organized in apoptotic signaling pathways. Here we used an affinity-labeling agent, YV(bio)KD-aomk, to investigate the caspases activated during apoptotic cell death, YV(bio))KD-aomk identified sis distinct polypeptides corresponding to active caspases in Fas-stimulated Jurkat T cells, On staurosporine treatment, four polypeptides were detected, Competition experiments showed that the labelled caspases have distinct substrate preferences, Stepwise appearance of the labelled caspases in each cell death event was consistent with the view that the activated caspases are organized into protease cascades, Moreover, me found that stepwise activation of caspases similar to that induced by Fas ligation is triggered by exposing non-apoptotic Jurkat cell extracts to caspase-8 (MACH/FLICE/Mch5). Conversely, CrmA protein, a viral suppressor of Fas-induced apoptosis, inhibited the protease activity of caspase-8, Overall, these findings provide evidence that caspase-8, a CrmA-sensitive protease, is responsible for initiating the stepwise activation of multiple caspases in Fas-stimulated cells.	KYOTO UNIV,DEPT HEMATOL & ONCOL,GRAD SCH MED,KYOTO 606,JAPAN; KYOTO UNIV,DEPT VIRAL ONCOL,INST VIRUS RES,KYOTO 606,JAPAN; UNIV FLORIDA,COLL MED,DEPT MOL GENET & MICROBIOL,GAINESVILLE,FL 32610; MAYO CLIN & MAYO FDN,DIV ONCOL RES,ROCHESTER,MN 55905; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA,KANAGAWA 236,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University; State University System of Florida; University of Florida; Mayo Clinic; Japan Tobacco Inc.; Kyoto University			Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Turner, Peter/0000-0002-7706-4593; Takahashi, Atsushi/0000-0003-3340-432X				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Henderson Peter J.F., 1993, P277; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KIKUCHI H, 1995, J BIOCHEM-TOKYO, V117, P936, DOI 10.1093/oxfordjournals.jbchem.a124823; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; NETT MA, 1992, J IMMUNOL, V149, P3254; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Takahashi A, 1997, EXP CELL RES, V231, P123, DOI 10.1006/excr.1996.3459; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAHASHI A, 1997, CELL CYCLE REGULATIO; TAKAHASHI A, 1997, APOPTOSIS PHARM THER; Tatsuta T, 1996, J IMMUNOL, V157, P3949; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THORNBERRY NA, 1997, IN PRESS APOPTOSIS P; Turner PC, 1995, VIROCEPTORS VIROKINE, P67; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	76	104	106	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2741	2752		10.1038/sj.onc.1201131	http://dx.doi.org/10.1038/sj.onc.1201131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190889	Bronze			2022-12-28	WOS:A1997XD64300001
J	Plet, A; Huet, X; Algarte, M; Rech, J; Imbert, J; Philips, A; Blanchard, JM				Plet, A; Huet, X; Algarte, M; Rech, J; Imbert, J; Philips, A; Blanchard, JM			Relief of cyclin A gene transcriptional inhibition during activation of human primary T lymphocytes via CD2 and CD28 adhesion molecules	ONCOGENE			English	Article						cyclin A; primary T lymphocytes adhesion	DNA-BINDING ACTIVITY; CELL-CYCLE; A GENE; RETINOBLASTOMA PROTEIN; S-PHASE; EXPRESSION; KINASE; REPLICATION; FAMILY; E2F	Cyclin A transcription is cell cycle regulated and induced by cell proliferative signals. To understand the mechanisms underlined in this regulation in normal human cells, we have analysed in vivo protein-DNA interactions at the Cyclin A locus in primary T lymphocytes. Stimulation of purified T lymphocytes by a combination of monoclonal antibodies directed at CD2 and CD28 adhesion molecules gives rise to a long lasting proliferation in the absence of accessory cells. Cyclin A was observed after 4 days of costimulation with anti CD2+ CD28 whereas stimulation by anti CD2 or anti CD28 alone was not effective. In vivo genomic DMS footprinting revealed upstream of the major transcription initiation sites, the presence of at least three protein binding sites, two of which were constitutively occupied. They bind in vitro respectively ATF-1 and NF-Y proteins. The third site was occupied in quiescent cells or in cells stimulated by anti CD2 or anti CD28 alone. The mitogenic combination of anti CD2+ anti CD28 released the footprint as cells were committed to proliferation. Consistent with theses results, nuclear extracts prepared from quiescent cells formed a specific complex with this element, whereas extracts prepared from cells treated with anti CD2+ anti CD28 failed to do so after cells entered-a proliferative state.	CNRS, UMR 5535, INST GENET MOL MONTPELLIER, F-34033 MONTPELLIER 1, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)			Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; PHILIPS, Alexandre/AAB-6047-2020	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; 				ALGARTE M, 1995, EMBO J, V14, P5060, DOI 10.1002/j.1460-2075.1995.tb00188.x; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CERDAN C, 1991, J IMMUNOL, V146, P560; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HORI T, 1987, BLOOD, V70, P1069; Huet X, 1996, MOL CELL BIOL, V16, P3789; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; NEVINS JR, 1992, SCIENCE, V258, P424; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER RA, 1995, CELL, V354, P314; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	41	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2575	2583		10.1038/sj.onc.1201103	http://dx.doi.org/10.1038/sj.onc.1201103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191057				2022-12-28	WOS:A1997XA94900009
J	Liu, X; Han, S; Baluda, MA; Park, NH				Liu, X; Han, S; Baluda, MA; Park, NH			HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes	ONCOGENE			English	Article						HPV; genomic integrity; p53; Rb; oral cancer	HUMAN PAPILLOMAVIRUS TYPE-16; CELL NUCLEAR ANTIGEN; DNA-DAMAGE; SHUTTLE VECTOR; UV-IRRADIATION; G(1) ARREST; P53 PROTEIN; GADD45; EXPRESSION; REPAIR	The mutation frequency of pS189 shuttle vector plasmids is higher in human oral keratinocytes (NHOK) immortalized with cloned human papillomavirus-16 (HPV-16) genome than in primary normal NHOK OVHOK), To determine whether oncoproteins E6 and E7 of HPV-16 are responsible for the higher mutation frequency of the plasmids, we measured the mutation frequency in NHOK and in NHOK expressing the HPV-16 oncogenes (E6, E7, or E6 plus E7). We also measured the mutation frequency in NHOK expressing the E6 or E7 proteins of the non-oncogenic HPV-6b, The mutation frequency, either background or N-methyl-M-nitro-N-nitrosoguanidine (MNNG)-induced, in NHOK expressing the HPV-16 oncoproteins (E6, E7, or E6 plus E7) was significantly higher than in NHOK, The HPV-16 oncogenes did not alter the nature of the MNNG-induced mutations (G:C-->A:T), but increased the frequency of deletions and insertions with or without MNNG, The background or MNNG-induced mutation frequency in NHOK expressing the HPV-6b E6 or E7 proteins was the same as in NHOK, NHOK and NHOK expressing HPV6b-E6 or E7 were able to arrest the cell cycle and enhance cellular p53, p21(WAF1/ClP1) and Gadd45 levels when exposed to MNNG, whereas NHOK expressing the HPV-16 E6 oncogene did not demonstrate, NHOK expressing HPV-16 E7 were able to enhance cellular p53, p21(WAF1/ClP1), and Gadd45 levels, but failed to arrest cell cycle progression when exposed to MNNG, These data indicate that HPV-16 E6 and E7 oncogenes are mutagenic in human oral keratinocytes and enhance the mutagenic effect of MNNG, However, the E6 and E7 proteins of the 'low risk' HPV-6b did not demonstrate such an ability.	UNIV CALIF LOS ANGELES,INST DENT RES,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH DENT,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIDCR NIH HHS [DE11229, DE10049, DE00371] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000371, R01DE011229, R01DE010049] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAEK JH, 1994, INT J ONCOL, V5, P1023; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAVRE PA, 1995, CANCER RES, V55, P4420; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; PARK NH, 1995, ONCOGENE, V10, P2145; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIDMAN M, 1989, MUTAT RES, V220, P55, DOI 10.1016/0165-1110(89)90010-9; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SHILLITOE EJ, 1993, CANCER RES, V53, P2189; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; Shin KH, 1996, ONCOGENE, V12, P1089; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	34	43	45	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2347	2353		10.1038/sj.onc.1201078	http://dx.doi.org/10.1038/sj.onc.1201078			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178911				2022-12-28	WOS:A1997WY88300012
J	Berkowitz, EA; Hecht, CP; Azizkhan, JC; Chen, XR; Lee, DC				Berkowitz, EA; Hecht, CP; Azizkhan, JC; Chen, XR; Lee, DC			Transcription factor AP2 is required for expression of the rat transforming growth factor-alpha gene	ONCOGENE			English	Article						TGF alpha promoter; AP2; DNase I footprinting; electrophoretic mobility shift assay; TATA binding protein	MAMMARY EPITHELIAL-CELLS; TRANSGENIC MICE; TGF-ALPHA; FACTOR AP-2; C-MYC; MESSENGER-RNA; PHORBOL ESTER; PROMOTER; ACTIVATION; INDUCTION	DNase I footprinting of the rat TGF alpha promoter in the presence of crude cell nuclear extract revealed three sites of protein-DNA interaction (Fp-A, Fp-B, Fp-C) in the region from -222 to +73. Mutation of specific sites within the Fp-A and Fp-B regions reduced expression of a TGF alpha promoter-reporter gene (TGF alpha LUC) from 50-90% in transiently transfected CHO cells, indicating the importance of protein/DNA interactions at these sites. Since Fp-A contained a perfect AP2 consensus sequence (5'-GCCNNNGGC-3') as its center, we investigated the possibility that AP2 binding is important for TGF alpha promoter activity, A double-stranded oligonucleotide spanning Fp-A displayed a distinct mobility shift in the presence of nuclear extract that was inhibited by an excess of known functional AP2-binding sequence. Moreover, a similar mobility shift occurred in the presence of purified AP2 protein, and the further addition of AP2 antibody produced a supershifted complex. More refined DNase I footprinting of a smaller, oligonucleotide probe in the presence of purified AP2 protein revealed a protected region that included the putative AP2 binding site, Additionally, co-transfection of an AP2 expression vector increased TGF alpha LUC expression 25-foId in Drosophila Schneider cells. These various findings corroborate a role for AP2 in TGF alpha promoter activity. The Fp-B region contains a T-5 motif that has been previously suggested to function as an atypical TATA box. An Fp-B oligonucleotide displayed a specific gel mobility shift in the presence of a TATA binding protein (TBP)-TFIIA complex, and the further addition of TBP antibody produced a supershift. These resdts confirm that protein binding within Fp-B is functionally important, and they also indicate that the T-5 motif functions as a TBP binding site.	UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; ROSWELL PK CANC INST,DEPT EXPT THERAPEUT,BUFFALO,NY 14263	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Roswell Park Cancer Institute			Van Dyke, Michael W./AAY-6751-2020; Imhof, Axel/O-8905-2018	Van Dyke, Michael W./0000-0003-0306-4002; Imhof, Axel/0000-0003-2993-8249	NCI NIH HHS [CA 43973] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; Berkowitz EA, 1996, ONCOGENE, V12, P1991; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEN XR, 1994, ONCOGENE, V9, P3179; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; GODWIN AK, 1990, ONCOGENE, V5, P1231; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Johnson AC, 1996, J BIOL CHEM, V271, P3033; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE LW, 1991, CANCER RES, V51, P5238; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIU C, 1988, CANCER RES, V48, P850; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARTINEZ E, 1994, EMBO J, V13, P3155; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1991, GENE DEV, V5, P1212; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHIN TH, 1994, MOL ENDOCRINOL, V8, P704, DOI 10.1210/me.8.6.704; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1983, VIROLOGY, V124, P201, DOI 10.1016/0042-6822(83)90307-0; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5813; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	55	12	12	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2229	2238		10.1038/sj.onc.1201051	http://dx.doi.org/10.1038/sj.onc.1201051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174059				2022-12-28	WOS:A1997WX93800012
J	Pognonec, P; Boulukos, KE; Aperlo, C; Fujimoto, M; Ariga, H; Nomoto, A; Kato, H				Pognonec, P; Boulukos, KE; Aperlo, C; Fujimoto, M; Ariga, H; Nomoto, A; Kato, H			Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity	ONCOGENE			English	Article						USF; Fra1; AP1; bHLHLZ interaction; transcription	HELIX-LOOP-HELIX; TRANSCRIPTION FACTOR USF; FOS-JUN; C-JUN; GLUCOCORTICOID RECEPTOR; LEUCINE-ZIPPER; DNA-BINDING; FUNCTIONAL ANTAGONISM; ANTITUMOR PROMOTION; INTERACTION CLONING	Heterodimerization among the basic-leucine zipper (bZIP) proteins or among the basic-helix-loop-helix-leucine zipper (bHLHZip) proteins confers a multitude of combinational activities to these transcription factors. To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system, A bZip protein, Fra1, was found to efficiently interact with USF. USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun. Both the bHLHZip and the N-terminal regions of Fra1 are required for efficient interaction with USF, In vivo association between USF and Fra1 has been demonstrated by co-immunoprecipitation. Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells. Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner, These data show that USF and Fra1 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOL MOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MICROBIOL,MINATO KU,TOKYO 108,JAPAN	Hokkaido University; University of Tokyo	Pognonec, P (corresponding author), UNIV NICE,CTR BIOCHIM,PARC VALROSE,F-06108 NICE 2,FRANCE.		Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CHANG LA, 1992, NUCLEIC ACIDS RES, V20, P287, DOI 10.1093/nar/20.2.287; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERPPOLA TK, 1994, ONCOGENE, V9, P675; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; YANG-YEN H-F, 1990, New Biologist, V2, P351; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	48	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2091	2098		10.1038/sj.onc.1201046	http://dx.doi.org/10.1038/sj.onc.1201046			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160889				2022-12-28	WOS:A1997WW80900011
J	Charest, A; Wagner, J; Kwan, M; Tremblay, ML				Charest, A; Wagner, J; Kwan, M; Tremblay, ML			Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2	ONCOGENE			English	Article						SH3 domain; Grb2; PTPase; EGF receptor; p120	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; GUANINE-NUCLEOTIDE EXCHANGE; SIGNALING GENE SEM-5; BACULOVIRUS VECTOR; KINASE SUBSTRATE; ADAPTER PROTEIN; BINDING-SITE; RAS; SOS	The involvement of murine protein tyrosine phosphatase-PEST (MPTP-PEST) in signal transduction pathways is suggested by its ability to dephosphorylate phosphotyrosine residues, its interaction with the adaptor protein SHC and by the presence of five proline-rich stretches in its non-catalytic carboxyl terminus, Proline-rich sequences have been identified as binding sites for Src homology 3 (SH3) domains found in proteins associated with signal transduction events. The ability of these sequences to act as SH3 domain recognition motifs was investigated using bacterially expressed SH3 domains derived from several different signalling proteins. In vitro binding assays indicate that four of these proline-rich sequences constitute specific binding sites for both SH3 domains of the adaptor molecule Grb2, Wild type Grb2, but not Grb2 proteins corresponding to loss-of-function mutants in the Caenorhabditis elegans sem-5 protein, associate with MPTP-PEST in vivo. Experiments in EGF receptor expressing cells show that the interaction between MPTP-PEST and Grb2 results in the binding of this complex to activated EGF receptors. In addition, identification of putative substrate(s) of MPTP-PEST have revealed a candidate protein of similar to 120 kDa which is tyrosine phosphorylated upon EGF stimulation. Together, these results describe a novel SH3 domain-dependent recruitment of a protein tyrosine phosphatase to an activated receptor tyrosine kinase and establish a potential role for MPTP-PEST in signalling pathways at the molecular level.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								AMARNEH B, 1995, MOL CELL ENDOCRINOL, V109, pR1, DOI 10.1016/0303-7207(95)03524-B; AUSUBEL FM, 1995, CURR PROTO MOL BIOL; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI X, 1995, GENOMICS, V28, P442, DOI 10.1006/geno.1995.1173; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2369; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook KJ, 1989, MOL CLONING LAB MANU; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YANG SS, 1995, J BIOL CHEM, V270, P18212, DOI 10.1074/jbc.270.31.18212; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	48	49	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1643	1651		10.1038/sj.onc.1201008	http://dx.doi.org/10.1038/sj.onc.1201008			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135065				2022-12-28	WOS:A1997WR89300002
J	Cadoret, A; Bertrand, F; BaronDelage, S; Levy, P; Courtois, G; Gespach, C; Capeau, J; Cherqui, G				Cadoret, A; Bertrand, F; BaronDelage, S; Levy, P; Courtois, G; Gespach, C; Capeau, J; Cherqui, G			Down-regulation of NF-kappa B activity and NF-kappa B p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells	ONCOGENE			English	Article						Ha-ras; polyoma middle T; NF-kappa B; p65 subunit; Caco-2 cells	PROTEIN-KINASE-C; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; P50 SUBUNIT; ADHESION MOLECULE-1; GROWTH-FACTOR; ACTIVATION; GENE; PROMOTER; ALPHA	The products of ras and src proto-oncogenes are frequently activated in a constitutive state in human colorectal cancer, In this study we attempted to establish whether the tumorigenic progression induced by oncogenic activation of p21(ras) or pp60(c-src) in human colonic cells is associated with alterations of the activity and expression of nuclear factor kappa B (NF-kappa B), a transcription factor suspected to participate in the development of cancer, To this end, we used Caco-2 cells made highly tumorigenic by transfection with an activated Val-12 human Ha-ras gene or with the polyoma middle T (PyMT) oncogene, a constitutive activator of pp60(c-src) tyrosine kinase activity, Compared with control vector-transfected Caco-2 cells, both oncogene-transfected cell lines exhibited: (i) decreased constitutive NF-kappa B DNA-binding activity and NF-kappa B-mediated reporter gene expression, without alteration of their response to TNF-alpha for activation of these parameters; (ii) reduced NF-kappa B cytosolic stores along with a decreased p65 expression due, at least in part, to destabilization of p65 mRNA; (iii) a decrease in adhesion to extracellular matrix component-coated substrata which was partially corrected when stimulating NF-kappa B transcriptional activity with TNF-alpha. These results indicate that the tumorigenic progression induced by oncogenic p21(ras) or PyMT/pp60(c-src) in human colonic Caco-2 cells is associated with a down-regulation of p65 expression and NF-kappa B activity which could be responsible for the reduced adhesive properties of these cells after oncogene transfection.	UNIV PARIS 06, BIOL CELLULAIRE LAB, INSERM U402, F-75571 PARIS 12, FRANCE; INST PASTEUR, CNRS URA 1149, UNITE BIOL MOL EXPRESS GEN, F-75724 PARIS, FRANCE; HOP ST ANTOINE, INSERM, U55, F-75571 PARIS 12, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864; COURTOIS, Gilles/0000-0003-3117-9595				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARGON J, 1992, J BIOL CHEM, V267, P16056; BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELAGE S, 1993, CANCER RES, V53, P2762; deWit H, 1996, EXP HEMATOL, V24, P228; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HEMAR A, 1991, J IMMUNOL, V146, P2409; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JELINEK MA, 1992, ONCOGENE, V7, P1687; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOONG AC, 1994, CANCER RES, V54, P5273; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEVY P, 1996, IN PRESS BR J CANC; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; MUNOZ E, 1994, J VIROL, V68, P8035; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; NODA M, 1988, J BIOL CHEM, V263, P18574; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; ROUSSET M, 1980, JNCI-J NATL CANCER I, V65, P885; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIRINIAN MI, 1993, ONCOGENE, V8, P157; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEISER MM, 1990, LAB INVEST, V62, P325; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995	56	28	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1589	1600		10.1038/sj.onc.1200992	http://dx.doi.org/10.1038/sj.onc.1200992			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129150				2022-12-28	WOS:A1997WQ54800010
J	Altabef, M; Garcia, M; VariorKrishnan, G; Samarut, J				Altabef, M; Garcia, M; VariorKrishnan, G; Samarut, J			A truncated RAR alpha co-operates with the v-erbB oncogene to transform early haematopoietic progenitors in vitro and in vivo	ONCOGENE			English	Article						nuclear hormone receptor; leukaemic transformation; haematopoietic differentiation	RETINOIC ACID RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; DOMINANT-NEGATIVE ACTIVITY; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; HORMONE RECEPTORS; CELLS-INVITRO; TARGET-CELLS; VIRUS; GENE	We have shown recently that a retrovirus vector expressing a natural mutant form of the PML-RAR alpha protein characteristic of human acute promyelocytic leukaemia can transform early chicken hematopoietic progenitors (Altabef et al., 1996). Neither truncated PML nor truncated RAR alpha alone could induce transformation which suggest that the two domains should co-operate for the oncogenicity of the fusion product. To further investigate the mechanisms of this co-operation, we have tested whether a truncated RAR alpha could co-operate with the v-erbB oncogene. This oncogene has previously been shown to co-operate with the rearranged thyroid hormone receptor, v-erbA, to transform erythrocytic progenitors. We show that v-erbB and a truncated RAR alpha co-operate when expressed simultaneously as independent products to transform very early chicken haematopoietic cells close to pluripotent stage. In addition, we show that v-erbB alters transcriptional abilities of RAR alpha by both enhancing its effects on RARE and reducing those on AP-1. Therefore, RAR alpha is able to co-operate with different kinds of proteins to induce transformation of early haematopoietic cells. This strongly suggests that RAR alpha are involved in the differentiation commitment of early haematopoietic progenitors during the normal process of haematopoietic differentiation. These data bring new insights in the mechanisms of oncogenic transformation by rearranged RAR alpha.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,UMR49 CNRS,INRA,LAB ASSOCIE 913,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019					ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALTABEF M, 1996, EMBO J, V15, P270; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HERMANN T, 1993, ONCOGENE, V8, P55; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NICOLSON RC, 1990, EMBO J, V9, P4443; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; YANGYEN HF, 1991, NEW BIOL, V3, P1206	43	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1471	1479		10.1038/sj.onc.1200984	http://dx.doi.org/10.1038/sj.onc.1200984			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136991				2022-12-28	WOS:A1997WT58400010
J	Sakai, R; Nakamoto, T; Ozawa, K; Aizawa, S; Hirai, H				Sakai, R; Nakamoto, T; Ozawa, K; Aizawa, S; Hirai, H			Characterization of the kinase activity essential for tyrosine phosphorylation of p130(Cas) in fibroblasts	ONCOGENE			English	Article						p130(Cas); tyrosine phosphorylation; Src homology 2; signal transduction	PHOSPHOTYROSINE-CONTAINING PROTEINS; SRC HOMOLOGY REGION-2; CRK ONCOGENE PRODUCT; V-CRK; TRANSFORMING ACTIVITY; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; GROWTH-FACTOR; SH3 DOMAIN; CELLS	The cellular transformation by v-Src or v-Crk induces tyrosine phosphorylation of a common substrate molecule, p130(Cas) (Cas), which tightly binds these oncoproteins in vivo. From its structure, Cas is deduced to be an ideal substrate for Src family kinases and Abl kinase. The tyrosine kinase activity associated with Cas was analysed using mouse variant fibroblasts lacking at least one of tyrosine kinases. In normal fibroblasts, Cas is associated with a significant level of tyrosine kinase activity which efficiently phosphorylates Cas in vitro. The Cas-associated tyrosine kinase activity was remarkably elevated in Csk(-/-) cells, which resulted in hyperphosphorylation of cellular Cas. The associated kinase activity was slightly increased in Src(-/-) cells whereas not significantly changed in Abl(-/-) nor Fak(-/-) cells. On the contrary, the Cas-associated kinase activity was remarkably decreased in Fyn(-/-) cells. At the same time, association of Cas with Fyn kinase in vitro was most obviously detected in normal fibroblasts as well as Csk(-/-) cells. Transient expression of v-Crk induced elevation of the Cas-associated kinase activity in all of these cell lines except the primary culture of Fyn(-/-) fibroblasts. These results indicate that Fyn kinase plays an essential role in v-Crk-mediated phosphorylation of Cas.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; JICHI MED SCH, DIV MOL BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KUMAMOTO UNIV, SCH MED, INST MOL EMBRYOL & GENET, DEPT MORPHOGENESIS, KUMAMOTO 860, JAPAN	University of Tokyo; Jichi Medical University; Kumamoto University				Sakai, Ryuichi/0000-0001-6833-1103				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; DECUE JE, 1987, P NATL ACAD SCI USA, V84, P9064; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; ILLC D, 1995, NATURE, V377, P539; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; NADA S, 1994, ONCOGENE, V9, P3571; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAGI T, 1994, ONCOGENE, V9, P2433; ZAITSU H, 1988, BIOMED RES-TOKYO, V9, P181; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1419	1426		10.1038/sj.onc.1200954	http://dx.doi.org/10.1038/sj.onc.1200954			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136985				2022-12-28	WOS:A1997WT58400004
J	Sweeney, KJ; Sarcevic, B; Sutherland, RL; Musgrove, EA				Sweeney, KJ; Sarcevic, B; Sutherland, RL; Musgrove, EA			Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells	ONCOGENE			English	Article						cyclin D2; cyclin D1; breast cancer; CDK	G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; DEPENDENT KINASES; GROWTH-FACTOR; CANCER-CELLS; D1 PROTEIN; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS	To investigate the possibility of differing roles for cyclins D1 and D2 in breast epithelial cells, we examined the expression, cell cycle regulation and activity of these two G(1) cyclins in both 184 normal breast epithelial cells and T-47D breast cancer cells. Synchromisation studies in 184 cells demonstrated that cyclin D1 and cyclin D2 were differentially regulated during G(1), with cyclin D2 abundance increasing by 3.7-fold but only small changes in cyclin D1 abundance observed. The functional consequences of increased cyclin D2 expression were examined in T-47D cells, which express no detectable cyclin D2, Induced expression of cyclin D2 resulted in increases in cyclin E expression, pRB phosphorylation and the percentage of cells in S-phase, while constitutive expression resulted in a consistent trend toward reduced dependence on serum for continued proliferation. Thus, cyclin D2 is a positive regulator of G(1) progression in breast cells analogous to the well-documented effects of cyclin D1. Indeed, equimolar concentrations of inducible cyclin D1 and D2 resulted in quantitatively similar cell cycle effects. Marked divergence was found, however, in the CDKs activated by the two cyclins in breast epithelial cells. Cyclin D2 complexes contained a higher Cdk2/Cdk4 ratio than cyclin D1 complexes. The cyclin D2-associated kinase activity was largely inhibited by Cdk2-specific inhibitors and could phosphorylate histone H1, a substrate for Cdk2 but not for Cdk4 and Cdk6. Therefore, cyclin D2 preferentially activated Cdk2 in breast epithelial cells. In contrast, Cdk4 and Cdk6 were predominantly responsible for cyclin D1-associated kinase activity as previously reported. Thus, although cyclins D1 and D2 elicited similar effects on breast epithelial cell cycle progression they appeared to achieve this end via activation of different CDKs. This is the first evidence of cyclin D2 activating Cdk2 in mammalian cells thus providing further evidence that D-type cyclins are not necessarily redundant.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Sutherland, Robert L/A-8378-2008	Sarcevic, Boris/0000-0002-8063-1050				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; Botz J, 1996, MOL CELL BIOL, V16, P3401; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Geng Y, 1996, ONCOGENE, V12, P1173; GILLETT C, 1994, CANCER RES, V54, P1812; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; HARPER JW, 1993, CELL, V75, P805; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; Hui R, 1996, CLIN CANCER RES, V2, P923; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KRANENBURG O, 1995, ONCOGENE, V10, P87; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REDDEL RR, 1984, CANCER RES, V44, P2398; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SWEENEY KJE, 1996, MAMMARY TUMOR CELL C, P141; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; TSAI LH, 1993, ONCOGENE, V8, P1593; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	63	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1329	1340		10.1038/sj.onc.1200951	http://dx.doi.org/10.1038/sj.onc.1200951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178893				2022-12-28	WOS:A1997WP10900008
J	Zhan, QM; Bieszczad, CK; Bae, I; Fornace, AJ; Craig, RW				Zhan, QM; Bieszczad, CK; Bae, I; Fornace, AJ; Craig, RW			Induction of BCL2 family member MCL1 as an early response to DNA damage	ONCOGENE			English	Article						MCL1; BCL2; radiation; DNA damage	CYCLE CHECKPOINT PATHWAY; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; LEUKEMIA ML-1 CELLS; ATAXIA-TELANGIECTASIA; GENOTOXIC STRESS; MDM-2 ONCOGENE; HOMOLOG BAK; GENE FAMILY; IN-VIVO	When ML-1 human myeloid leukemia cells are exposed to DNA damaging agents, they exhibit dramatic changes in the expression of a variety of gene products, This includes an increase in p53 (wild-type), a decrease in BCL2, a p53-dependent increase in the BCL2 family member BAX, and increases in Growth Arrest and DNA Damage-inducible (GADD) genes such as GADD45; these changes occur as early events in a sequence that culminates in DNA damage-induced apoptosis, DNA damaging agents have now been tested for effects on expression of another BCL2 family member, MCL1, a gene expressed during ML-1 cell differentiation, Expression of MCL1 was found to increase upon exposure of ML-1 cells to various types of DNA damaging agents, including ionizing radiation, ultraviolet radiation, and alkylating drugs. The increase in MCL1 occurred rapidly and was transient, levels of the MCL1 mRNA being elevated within 4 h and having returned to near baseline within 24 h. An increase in the Mcl1 protein was also seen, with the maximal increase occurring at an intermediate dose of IR (5 Gray) and lesser increases occurring at either lower or higher doses, The increase in expression of MCL1 was further studied using a panel of human cell lines that includes cells containing or not containing alterations in p53 as well as cells sensitive or insensitive to the apoptosis-inducing effects of DNA damage, The DNA damage-induced increase in MCL1 mRNA did not depend upon p53 as it was seen in cells lacking functional p53, However, the increase did depend upon susceptibility to apoptosis as it was not seen in cells insensitive to apoptosis-induction by DNA damaging agents. These findings demonstrate that cytotoxic DNA damage causes an increase in the expression of MCL1 along with increases in GADD45 and BAX and a decrease in BCL2, Furthermore, while the increase in GADD45 is seen both in cells that undergo growth arrest and in cells that undergo apoptosis in response to DNA damage, alterations in the profile of expression of BCL2 family members occur exclusively in cells that undergo the apoptotic response, with some family members increasing through p53-dependent (BAX) and others through p53-independent (MCL1) pathways, Overall, expression MCL1 can increase during the induction of cell death as well as during the induction of differentiation.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOL PHARMACOL LAB,BETHESDA,MD 20892	Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL CANCER INSTITUTE [R29CA054385] Funding Source: NIH RePORTER; NCI NIH HHS [CA54385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE IS, 1995, CANCER RES, V55, P2387; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; CRAIG RW, 1984, CANCER RES, V44, P442; CRAIG RW, 1984, CANCER RES, V44, P2421; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1671; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kitada S, 1996, ONCOGENE, V12, P187; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STROUD R, 1995, CURR OPIN STRUC BIOL, V5, P514, DOI 10.1016/0959-440X(95)80037-9; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN Q, 1996, IN PRESS ONCOGENE; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHOU P, 1997, IN PRESS BLOOD	59	74	77	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1031	1039		10.1038/sj.onc.1200927	http://dx.doi.org/10.1038/sj.onc.1200927			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070651				2022-12-28	WOS:A1997WM07000004
J	Beauchemin, N; Kunath, T; Robitaille, J; Chow, B; Turbide, C; Daniels, E; Veillette, A				Beauchemin, N; Kunath, T; Robitaille, J; Chow, B; Turbide, C; Daniels, E; Veillette, A			Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells	ONCOGENE			English	Article						biliary glycoprotein; Bgp; C-CAM; colon carcinoma; SHP-1; PTP1C; HCP	ANTIGEN-RELATED GENE; CARCINOEMBRYONIC ANTIGEN; ADHESION MOLECULE; ECTO-ATPASE; C-CAM; PHOSPHOTYROSINE PHOSPHATASE; COLORECTAL CARCINOMAS; ENDOGENOUS SUBSTRATE; MONOCLONAL-ANTIBODY; MURINE CORONAVIRUS	Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation.	MCGILL UNIV,CTR CANC,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), MCGILL UNIV,CTR CANC,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA.			Kunath, Tilo/0000-0002-8805-7356				Adachi M, 1996, CELL, V85, P15; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRUMMER J, 1995, ONCOGENE, V11, P1649; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; HSIEH JT, 1995, CANCER RES, V55, P190; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kunath T, 1995, ONCOGENE, V11, P2375; KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1989, J BIOL CHEM, V264, P14408; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	53	122	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					783	790		10.1038/sj.onc.1200888	http://dx.doi.org/10.1038/sj.onc.1200888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047385				2022-12-28	WOS:A1997WJ11200004
J	Jouanneau, J; Plouet, J; Moens, G; Thiery, JP				Jouanneau, J; Plouet, J; Moens, G; Thiery, JP			FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo	ONCOGENE			English	Article						FGF-2; angiogenesis; tumor proliferation	FIBROBLAST GROWTH-FACTOR; DNA-SYNTHESIS; FACTOR CDNA; 3T3 CELLS; PROGRESSION; SECRETION; FAMILY; FORMS; LINE; TRANSFORMATION	The comparative biological properties of NET-II cells, a rat bladder carcinoma cell line constitutively expressing FGF-1 and FGF-2 were analysed in nude mice, FGF-1 is not secreted by the transfected cells unless the cDNA contains a signal sequence; conversely, NET-II cells transfected with FGF-2 coding sequence produce and secrete the factor in a biologically active form, Bovine brain capillary endothelial cells are stimulated to proliferate upon addition of medium conditioned by the FGF-2-producing cells and this activity can be abrogated by the addition of anti-FGF-2 blocking antibodies, In addition, the FGF-2-containing medium, which cannot stimulate NET-II cells due to absence of appropriate receptors, is able to induce scattering of NET-II cells expressing the FGFR1, It has been reported previously that FGF-1-producing cells are highly tumorigenic in nude mice and induce carcinoma with a period of latency reduced from 6 to 5 weeks when compared to parental NET-II cells, In contrast, NET-II cells producing FGF-2 are no more tumorigenic than parental cells, indicating are no more tumorigenic than parental cells, indicating that FGF-1 and FGF-2 have different oncogenic properties in carcinoma, FGF-1 and FGF-2 are potent antiogenic factors that trigger the host endothelial cells, VEGF, another potent angiogen was found to be expressed in small amounts by NET-II cells and to be expressed in reduced amount in the FGF-producing cells, In the NET-II system in vivo FGF-1 and FGF-2 are highly and comparatively angiogenic in the resultant carcinoma and this occurs in the absence of production of significant amounts of VEGF by the carcinoma cells, Taken together, our results indicate that activated angiogenesis is not sufficient for rapid tumor expansion, FGF-1 behaves as a tumorigenic factor in the NET-II bladder carcinoma cell model, whereas expression and secretion of large amounts of FGF-2 are not sufficient for increasing tumor growth.	UPR 9006 CNRS,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	Jouanneau, J (corresponding author), INST CURIE,UMR 144 CNRS,26 RUE ULM,F-75248 PARIS 05,FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [(NIH, 2RO1 CA 49417-06)] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUSCI S, 1994, J CELL SCI, V107, P1277; BELLUSCI S, 1995, INVAS METAST, V14, P319; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CARUELLE D, 1989, J CELL BIOCHEM, V39, P117, DOI 10.1002/jcb.240390204; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; COLBEREGARAPIN F, 1982, J MOL BIOL, V105, P1; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; TAKAHASHI JB, 1992, BIOCHEM BIOPH RES CO, V189, P398, DOI 10.1016/0006-291X(92)91572-8; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; YAYON A, 1990, CANC METASTASIS REV, V9, P192	40	37	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					671	676		10.1038/sj.onc.1200883	http://dx.doi.org/10.1038/sj.onc.1200883			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038374				2022-12-28	WOS:A1997WG43000005
J	Horton, LE; Templeton, DJ				Horton, LE; Templeton, DJ			The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity	ONCOGENE			English	Article						cell cycle; cyclins; cyclin dependent kinase; lamin B	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE; CELL-CYCLE; DEPENDENT KINASE-2; CRYSTAL-STRUCTURE; S-PHASE; BINDING; CDC2; PHOSPHORYLATION; EXPRESSION	The cyclins and their catalytic partners, the Cyclin Dependent Kinases (CDKs), are essential for progression through the cell cycle. Cyclin/kinase complexes containing cyclins A or E are active primarily in Late G(1) to S phase and both have been shown to phosphorylate histone H1 and the retinoblastoma gene product (pRb) in vitro. Despite these similarities, cyclins A and E display differences in CDK activation and substrate specificity. We find that in vitro, cyclin E/CDK2 and cyclin A/CDK2 phosphorylate histone H1 similarly but only cyclin A/CDK2 phosphorylates lamin B. While both cyclin A and cyclin E bind CDK1 efficiently, only cyclin A activates CDK1 kinase activity. Using chimeric proteins between cyclins A and E we find that both the cyclin box and C-terminus of cyclins A and E are required for CDK binding, activation and targeting of substrate specificity.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CELL BIOL PROGRAM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NCI NIH HHS [CA-55719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; Hunt T, 1991, Semin Cell Biol, V2, P213; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; MARSHALL CJ, 1994, NATURE, V367, P24; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAYSMITH K, 1993, CURR OPIN CELL BIOL, V5, P166; NUGENT JHA, 1991, J CELL SCI, V99, P669; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; TSAI LH, 1993, ONCOGENE, V8, P1593; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	47	32	33	2	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					491	498		10.1038/sj.onc.1200851	http://dx.doi.org/10.1038/sj.onc.1200851			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053846				2022-12-28	WOS:A1997WE36400012
J	Borkhardt, A; Repp, R; Haas, OA; Leis, T; Harbott, J; Kreuder, J; Hammermann, J; Henn, T; Lampert, F				Borkhardt, A; Repp, R; Haas, OA; Leis, T; Harbott, J; Kreuder, J; Hammermann, J; Henn, T; Lampert, F			Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23)	ONCOGENE			English	Article						acute leukemias; MLL-rearrangement; AFX-gene; forkhead domain	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ALL-1 GENE; CHROMOSOMAL TRANSLOCATIONS; T(10-11) TRANSLOCATION; DROSOPHILA-TRITHORAX; B-MYB; PROTEIN; FAMILY; REARRANGEMENTS	We report the cloning and characterization of the entire AFX gene which fuses to MLL in acute leukemias with a t(X;11)(q13;q23). AFX consists of two exons and encodes for a protein of 501 amino acids. We found that normal B- and T-cells contain similar levels of AFX mRNA and that both the MLL/AFX as well as the AFX/MLL fusion transcripts are present in the cell line and the ANLL sample with a t(X;11)(q13;q23), The single intron of the AFX gene consists of 3706 nucleotides, It contains five simple sequence repeats with lengths of at least 12 bps, a chi-like octamer sequence (GCA/TGGA/TGG) and several immunoglobulin heptamer-like sequences (GATAGTG) that are distributed throughout the entire AFX intron sequence. In the KARPAS 45 cell line the breakpoints occur at nucleotides 2913/2914 of the AFX intron and at nucleotides 4900/4901 of the breakpoint cluster region of the MLL gene, The AFX protein belongs to the forkhead protein family. It is highly homologous to the human FKHR protein, the gene of which is disrupted by the t(2;13)(q35;q14), a chromosome rearrangement characteristic of alveolar rhabdomyosarcomas. It is noteworthy that the t(X;11)(q13;q23) in the KARPAS 45 cell line and in one acute nonlymphoblastic leukemia (ANLL) disrupts the forkhead domain of the AFX protein exactly at the same amino acids as does the t(2;13)(q35;q14) in case of the FKHR protein. In addition, the 5'-part of the AFX protein contains a conserved hexapeptide motif (QIYEWM) that is homologous to the functionally important conserved hexapeptide QIYPWM upstream of the homeobox domain in Hox proteins. This motif mediates the co-operative DNA binding of Pbx family members and Hox proteins and, therefore, plays an important role in physiologic and oncogenic processes. In acute leukemias with t(X;11)(q13;q23), this hexapeptide motif is separated from the remaining forkhead domain within the AFX protein. The predicted amino acid sequence of AFX differs significantly from the partial AFX protein sequence published previously (Genes, Chromosomes and Cancer, 1994, 11, 79-84). This discrepancy can be explained by the occurrence of two sequencing errors in the earlier work at nucleotide number 783 and 844 (loss of a cytosine residue or guanosine residue, respectively) that lead to two reading frame shifts.	UNIV GIESSEN,DEPT PEDIAT HEMATOL & ONCOL,D-35392 GIESSEN,GERMANY; ST ANNA CHILDRENS HOSP,CHILDRENS CANC INST,A-1090 VIENNA,AUSTRIA	Justus Liebig University Giessen; Saint Anna Children's Hospital			Haas, Oskar/AAM-5794-2020					BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BARLETTA C, 1991, CANCER RES, V51, P3821; BERNARD OA, 1994, ONCOGENE, V9, P1039; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BORKHARDT A, 1994, LEUKEMIA, V8, P549; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHERVINSKY DS, 1995, GENE CHROMOSOME CANC, V14, P76, DOI 10.1002/gcc.2870140114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; Dreyling M. H., 1995, Blood, V86, p430A; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; HROMAS R, 1993, BLOOD, V81, P2854; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARPAS A, 1977, LEUKEMIA RES, V1, P35, DOI 10.1016/0145-2126(77)90063-7; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; NACHEVA E, 1982, HEREDITAS, V97, P273, DOI 10.1111/j.1601-5223.1982.tb00771.x; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; RIENITZ A, 1989, EMBO J, V8, P2879, DOI 10.1002/j.1460-2075.1989.tb08436.x; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; Sambrock J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	46	198	202	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					195	202		10.1038/sj.onc.1200814	http://dx.doi.org/10.1038/sj.onc.1200814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010221				2022-12-28	WOS:A1997WC81800007
J	Russo, S; Tato, F; Grossi, M				Russo, S; Tato, F; Grossi, M			Transcriptional down-regulation of myogenin expression is associated with v-ras-induced block of differentiation in unestablished quail muscle cells	ONCOGENE			English	Article						v-ras; oncogenes; transformation; myogenesis; myogenin	MYOBLAST DIFFERENTIATION; POSITIVE AUTOREGULATION; GENE-EXPRESSION; UP-REGULATION; DNA-BINDING; ACTIN GENE; MYOD; TRANSFORMATION; MYC; ONCOGENES	Unestablished quail myoblasts were infected with a retroviral vector encoding the oncogenic form of II-Pas in order to investigate the mechanism by which this oncoprotein interferes with terminal differentiation. Primary quail myogenic cells exhibit the simultaneous expression of the muscle regulatory genes myf-5, MyoD and myogenin in proliferative conditions. v-ras-transformed myoblasts displayed an altered growth control and lost the competence for terminal differentiation. When expression of myogenic regulatory genes was analysed, it was immediately apparent that the difference between normal and v-ras-transformed cells was limited to a severely decreased level of myogenin expression. Forced expression of exogenous myogenin in v-ras-transformed quail myoblasts led to a striking recovery of the competence for terminal differentiation. The present data show that: (i) repression of myogenin expression is linked to the differentiation defective phenotype of quail myoblasts transformed by v-ras as well as other retroviral oncogenes; (ii) correction of the differentiation-defective phenotype of v-uas-transformed myoblasts by exogenous myogenin entailed reactivation of endogenous myogenin and of the E-box-dependent transactivating function. These results strongly indicate that myogenin expression plays a central role in regulating the transition into the terminally differentiated state and that its transcriptional down-regulation represents a nodal step in v-ras-induced block of differentiation.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,ROME,ITALY	Sapienza University Rome			Grossi, Milena/D-2955-2009					ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGNAMI M, 1982, EXP CELL RES, V137, P239, DOI 10.1016/0014-4827(82)90024-6; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; CARUSO M, 1993, ONCOGENE, V8, P267; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; ENRIETTO PJ, 1994, SEMIN CANCER BIOL, V5, P91; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GROSSI M, 1991, ONCOGENE, V6, P1767; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P233; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KNIGHT J, 1988, ONCOGENE, V2, P317; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YOON HY, 1994, ONCOGENE, V9, P801; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	56	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					63	73		10.1038/sj.onc.1200805	http://dx.doi.org/10.1038/sj.onc.1200805			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010233				2022-12-28	WOS:A1997WB76000006
J	Cortez, D; Stoica, G; Pierce, JH; Pendergast, AM				Cortez, D; Stoica, G; Pierce, JH; Pendergast, AM			The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway	ONCOGENE			English	Article						BCR-ABL; apoptosis; Ras; tyrosine phosphorylation	HEMATOPOIETIC-CELLS; PC12 CELLS; TRANSFORMATION; DEATH; ONCOGENE; PROLIFERATION; PROTEIN	BCR-ABL is a deregulated tyrosine kinase that is expressed in Philadelphia chromosome (Ph(1)) positive human leukemias, When expressed in hematopoietic cells, BCR-ABL causes cytokine independent proliferation, induces tumorigenic growth and prevents apoptosis in response to cytokine deprivation or DNA damage, One mechanism by which BCR-ABL signals in cells is by activating the small guanine nucleotide binding protein Ras, BCR-ABL-transformed cells have constitutively high levels of active, GTP-bound Ras, Here we use 32D cells that inducibly express a dominant negative Ras protein to define the Ras requirements in BCR-ABL-transformed cells, Dominant negative Ras inhibits BCR-ABL-mediated Ras activation, and induces cell death by an apoptotic mechanism, Therefore, BCR-ABL inhibits apoptosis through activation of a Ras-dependent signaling pathway.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM,WASHINGTON,DC 20007; NIH,CELL & MOL BIOL LAB,BETHESDA,MD 20892	Duke University; Duke University; Georgetown University; National Institutes of Health (NIH) - USA				Pendergast, Ann Marie/0000-0002-1250-6880	NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER; NCI NIH HHS [CA61033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; MANDANAS RA, 1993, BLOOD, V82, P1838; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	23	131	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2589	2594						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000132				2022-12-28	WOS:A1996VZ65400008
J	Greco, A; Villa, R; Pierotti, MA				Greco, A; Villa, R; Pierotti, MA			Genomic organization of the human NTRK1 gem	ONCOGENE			English	Article						NTRK1 gene; tyrosine kinase receptor; intron exon structure	TRK PROTOONCOGENE; GROWTH-FACTOR; KINASE GENE; RECEPTOR; ONCOGENE; FUSION; MUTATIONS; DOMAIN	The NTRK1 gene encodes one of the receptors for the Nerve Growth Factors and it is located at 1q21-22. Rearrangements of NTRK1 are frequently detected in human papillary thyroid carcinoma and lead to the formation of chimeric oncogenes, similarly to what observed for the other neurotrophin receptor RET. In addition, the two receptor genes are target of point mutations associated with different human diseases. RET is affected by germ line and somatic mutations in MEN2A, MEN2B tumor syndromes and in the abnormal developmental Hirschsprung disease, whereas mutations of NTRK1 have been reported very recently in patients with congenital insensitivity to pain with anidrosis (CIPA). With the aim to provide a tool for searching mutations along the whole NTRK1 gene, we have determined its genomic organization. Our results demonstrated that NTRK1 is contained within 25 Kb of DNA and is organized in 17 exons, one of which is alternatively spliced. The sequence of the 5' flanking region indicates a high content in C/G, the absence of TATA box, the presence of several putative binding sites for Sp1, AP1, AP2, AP3, ATF and GCF transcription factors.			Greco, A (corresponding author), IST NAZL TUMORI,DIV EXPT ONCOL A,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Greco, Angela/C-1953-2017	Greco, Angela/0000-0003-2994-0349; Fontecha, Juliana/0000-0002-2215-7362; Pierotti, Marco Alessandro/0000-0002-7431-8332; Villa, Riccardo/0000-0001-8385-800X				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; WEIER HUG, 1995, GENOMICS, V26, P390, DOI 10.1016/0888-7543(95)80226-C	21	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2463	2466						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957089				2022-12-28	WOS:A1996VX10800020
J	Qian, XL; ORourke, DM; Zhao, HZ; Greene, MI				Qian, XL; ORourke, DM; Zhao, HZ; Greene, MI			Inhibition of p185(neu) kinase activity and cellular transformation by co-expression of a truncated neu protein	ONCOGENE			English	Article						ErbB receptors; neu ectodomain; trans inhibition	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; MONOCLONAL-ANTIBODIES; DOWN-MODULATION; ERBB-2 ONCOGENE; POINT MUTATION; DEFICIENT NEU; EGF RECEPTOR; HUMAN-BREAST; 3T3 CELLS	The rat nea oncogene product encodes a 185 kDa receptor tyrosine kinase which is constitutively activated as a result of a single amino acid substitution (Va1664-->Glu) within the transmembrane region. In this study, we show that the transforming activity of oncogenic p185(neu) (also termed Tneu) can be inhibited by co-expression of a truncated nea protein with a large cytoplasmic deletion (termed T691stop) which includes the tyrosine kinase domain. In cell lines co-expressing full-length and truncated nea proteins, we observed codimerization between full-length p185(neu) and truncated T691 stop, resulting in the formation of a kinase-inactive heteromeric complex. Phenotypic analysis of several different clones showed that the degree of inhibition of transformation in vitro and tumorigenicity in vivo was related to the ratio of full-length and truncated p185 proteins co-expressed in cells. These results provide evidence that expression of kinase-deficient nea proteins leads to co-dimerization that results in suppression of kinase activation and oncogenicity of associated p185(neu)-activated receptors. The mutant nea protein mediates inhibition in both transfected fibroblasts expressing oncogenic p185(neu) and mammalian cancer cells derived from a rat primary neuroglioblastoma expressing oncogenic p185(neu). This truncated peptide may be important for the design of future therapies directed against erbB family oncoproteins.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR RECEPTOR BIOL,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BROWN VI, 1994, DNA CELL BIOL, V13, P193, DOI 10.1089/dna.1994.13.193; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; FARNSWORTH C, 1991, MOL CELL BIOL, V11, P4832; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HACK N, 1993, J BIOL CHEM, V268, P26441; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; LEVEA CM, 1993, RECEPTOR, V3, P293; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MYERS JN, 1992, RECEPTOR, V2, P1; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1995, ONCOGENE, V10, P211; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1995, DNA CELL BIOL, V14, P921, DOI 10.1089/dna.1995.14.921; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	48	25	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2149	2157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950982				2022-12-28	WOS:A1996VV14500012
